Global TB Report 2012

GLOBAL
TUBERCULOSIS
REPORT
2012
WHO Library Cataloguing-in-Publication Data

Global tuberculosis report 2012.
1.Tuberculosis epidemiology. 2.Tuberculosis, Pulmonary prevention and control.
3.Tuberculosis economics. 4.Directly observed therapy. 5.Treatment outcome. 6.National health
programs organization and administration. 7.Statistics. I.World Health Organization.
ISBN 978 92 4 156450 2
(NLM classication: WF 300)
World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax:
+41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications whether for
sale or for noncommercial distribution should be addressed to WHO Press through the WHO web site (http://www.who.int/about/
licensing/copyright_form/en/index.html).
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which
there may not yet be full agreement.
The mention of specic companies or of certain manufacturers products does not imply that they are endorsed or recommended by
the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the
names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication.
However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for
the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages
arising from its use.
Cover design by Tom Hiatt, Western Pacic Regional Ofce, WHO. The front cover illustrates the contribution of different sources
of funding to TB care and control in low-income countries, highlighting the importance of international donor funding (coloured
blocks) compared with domestic contributions (grey band) as well as the role of the Global Fund (red line) that is the leading source
of international donor funding globally; see Figure 5.5. The back cover illustrates the impressive reduction in TB prevalence in Cambodia, a low-income and high-burden country, between 2002 (when a baseline national TB prevalence survey was implemented) and
2011 (when a repeat national TB prevalence survey was implemented); see Box 2.7 in Chapter 2.
Designed by minimum graphics
Printed in France
WHO/HTM/TB/2012.6
Contents
Abbreviations
iv
Acknowledgements
Executive summary
Chapter 1. Introduction
Chapter 2. The burden of disease caused by TB
Chapter 3. TB case notications and treatment outcomes
29
Chapter 4. Drug-resistant TB
41
Chapter 5. Financing TB care and control
52
Chapter 6. Diagnostics and laboratory strengthening
66
Chapter 7. Addressing the co-epidemics of TB and HIV
74
Chapter 8. Research and development
82
Annexes
1. Methods used to estimate the global burden of disease caused by TB
91
2. Country pro les
105
3. Regional proles
129
4. Global, regional and country-specic data for key indicators
137
GLOBAL TUBERCULOSIS REPORT 2012
iii
Abbreviations
AFB
acid-fast bacilli
IGRA
interferon-gamma release assay
AFR
WHO African Region
IPT
isoniazid preventive therapy
AIDS
acquired immunodeciency syndrome
IRR
incidence rate ratio
AMR
WHO Region of the Americas
LED
Light-emitting diode
ARI
annual risk of infection
LPA
Line-probe assay
ART
antiretroviral therapy
MDG
Millennium Development Goal
BCG
Bacille-Calmette-Gurin
MDR-TB
BRICS
Brazil, Russian Federation, India,

China, South Africa
multidrug-resistant tuberculosis
(resistance to, at least, isoniazid and
rifampicin)
CDR
case detection rate
NGO
nongovernmental organization
CPT
co-trimoxazole preventive therapy
NTP
national tuberculosis control programme

or equivalent
CBC
community-based TB care
PEPFAR
DOT
directly observed treatment
US Presidents Emergency Plan for AIDS

Relief
DOTS
the basic package that underpins the

Stop TB Strategy
POC
point-of-care
PPM
PublicPrivate Mix
DR-TB
drug-resistant tuberculosis
SEAR
WHO South-East Asia Region
DRS
drug resistance surveillance or survey
SRL
supranational reference laboratory
DST
drug susceptibility testing
TB
tuberculosis
ECDC
European Centre for Disease Prevention

and Control
TB-TEAM
Tuberculosis Technical Assistance

Mechanism
EMR
WHO Eastern Mediterranean Region
TST
tuberculin skin test
EQA
External quality assurance
UNAIDS
ERR
Electronic recording and reporting
Joint United Nations Programme on HIV/

AIDS
EU
European Union
UNITAID
EUR
WHO European Region
FIND
Foundation for Innovative New

Diagnostics
international facility for the purchase of

diagnostics and drugs for diagnosis and
treatment of HIV/AIDS, malaria and TB
USAID
United States Agency for International

Development
VR
Vital registration
WHA
World Health Assembly
WHO
World Health Organization

WHO Western Pacic Region
GDP
gross domestic product
GLI
Global Laboratory Initiative
Global Fund The Global Fund to ght AIDS,

Tuberculosis and Malaria
Global Plan
Global Plan to Stop TB, 20112015
WPR
GNI
gross national income
XDR-TB
HBC
high-burden country of which there are

22 that account for approximately 80%
of all new TB cases arising each year
Extensively drug-resistant TB, de ned

as MDR-TB plus resistance to a
uoroquinolone and at least one of three
injectable second-line drugs (amikacin,
kanamycin or capreomycin)
HIV
human immunodeciency virus
ZN
Ziehl Neelsen
ICD-10
International Classication of Diseases

(tenth revision)
iv
Acknowledgements
This report on global tuberculosis care and control was produced by a core team of 13 people: Hannah Monica Dias,
Dennis Falzon, Christopher Fitzpatrick, Katherine Floyd, Philippe Glaziou, Tom Hiatt, Christian Lienhardt, Linh Nguyen, Charalambos Sismanidis, Hazim Timimi, Mukund Uplekar, Wayne van Gemert and Matteo Zignol. The team was
led by Katherine Floyd. Overall guidance was provided by the Director of the Stop TB Department, Mario Raviglione.
The data collection forms (long and short versions) were developed by Philippe Glaziou and Hazim Timimi, with
input from staff throughout the Stop TB Department. Hazim Timimi led and organized all aspects of data management.
Christopher Fitzpatrick, Ins Garcia and Andrea Pantoja conducted all review and follow-up of nancial data. The
review and follow-up of all other data was done by a team of reviewers that included Annabel Baddeley, Annemieke
Brands, Hannah Monica Dias, Dennis Falzon, Linh Nguyen, Hazim Timimi, Wayne van Gemert and Matteo Zignol in
WHO headquarters, Tom Hiatt in the Western Pacic Regional Ofce, and Suman Jain, Sai Pothapregada and Mohammed Yassin from the Global Fund. Data for the European Region were collected and validated jointly by the WHO
Regional Ofce for Europe and the European Centre for Disease Prevention and Control (ECDC), an agency of the
European Union based in Stockholm, Sweden.
Philippe Glaziou and Charalambos Sismanidis analysed surveillance and epidemiological data and prepared the
gures and tables on these topics, with assistance from Tom Hiatt. Tom Hiatt, Linh Nguyen and Annabel Baddeley
analysed TB/HIV data and prepared the associated gures and tables. Dennis Falzon and Matteo Zignol analysed data
and prepared the gures and tables related to drug-resistant TB, with assistance from Shu-Hua Wang. Christopher
Fitzpatrick analysed nancial data, and prepared the associated gures and tables. Tom Hiatt and Wayne van Gemert
prepared gures and tables on laboratory strengthening and the roll-out of new diagnostics. Christian Lienhardt and
Karin Weyer prepared the gures on the pipelines for new TB drugs, diagnostics and vaccines, with input from the
respective Working Groups of the Stop TB Partnership. Tom Hiatt checked and nalized all gures and tables in an
appropriate format, ensuring that they were ready for layout and design according to schedule, and was the focal point
for communications with the graphic designer.
The writing of the main part of the report was led by Katherine Floyd, with contributions from the following people:
Philippe Glaziou, Charalambos Sismanidis and Jinkou Zhao (Chapter 2); Hannah Monica Dias, Haileyesus Getahun,
Thomas Joseph and Mukund Uplekar (Chapter 3); Christopher Fitzpatrick and Christian Gunneberg (Chapter 5); and
Annabel Baddeley, Haileyesus Getahun and Linh Nguyen (Chapter 7). Chapter 4, on drug-resistant TB, was prepared
by Dennis Falzon and Matteo Zignol, with input from Katherine Floyd, Philippe Glaziou, Ernesto Jaramillo and Charalambos Sismanidis. Chapter 6, on diagnostics and laboratory strengthening, was prepared by Wayne van Gemert, with
input from Christopher Gilpin, Fuad Mirzayev and Karin Weyer. Chapter 8, on research and development, was written
by Christian Lienhardt, Karin Weyer and Katherine Floyd, with input and careful review by the chairs and secretariats
of the Working Groups of the Stop TB Partnership: particular thanks are due to Michael Brennan, Uli Fruth and Jennifer Woolley (new vaccines); Daniella Cirillo, Philippe Jacon and Alessandra Varga (new diagnostics); and Cherise Scott
and Mel Spigelman (new TB drugs). Karen Ciceri edited the entire report.
Annex 1, which explains methods used to produce estimates of the burden of disease caused by TB, was written
by Philippe Glaziou, Katherine Floyd and Charalambos Sismanidis; we thank Colin Mathers of WHOs Mortality and
Burden of Disease team for his careful review and helpful suggestions. The country pro les that appear in Annex 2 and
the regional pro les that appear in Annex 3 were prepared by Hazim Timimi. Annex 4, which contains a wealth of
global, regional and country-specic data from the global TB database, was prepared by Tom Hiatt and Hazim Timimi.
We thank Pamela Baillie in the Stop TB Departments TB monitoring and evaluation team for impeccable administrative support, Doris Ma Fat from WHOs Mortality and Burden of Disease team for providing TB mortality data
extracted from the WHO Mortality Database, Michel Beusenberg, Kusha Davar, Chika Hyashi and Yves Souteyrand
of WHOs HIV department for the close collaboration that facilitated joint review and validation of TB/HIV data, and
Diana Weil for reviewing and providing helpful comments on the entire report. We also thank Taavi Erkkola, Luisa
Frescura and Peter Ghys from UNAIDS for providing TB/HIV data collected as part of the joint reporting process on
Universal Access in the Health Sector and Global AIDS Response Progress and for following up TB/HIV-related data
queries with countries, and Peter Ghys and Karen Stanecki (UNAIDS) for providing epidemiological data that were
used to estimate HIV-associated TB mortality.
We thank Sue Hobbs for her excellent work on the design and layout of this report; her contribution, as in previous
years, is greatly appreciated.
The principal source of nancial support for WHOs work on monitoring and evaluation of TB control is the United
States Agency for International Development (USAID), without which it would be impossible to produce this report
on global TB care and control. Data collection, validation, analysis, printing and dissemination were also supported
by funding from the governments of Japan and the Republic of Korea. We acknowledge with gratitude their support.
In addition to the core report team and those mentioned above, the report beneted from the input of many staff
working in WHOs regional and country ofces and hundreds of people working for national TB programmes or within
national surveillance systems who contributed to the reporting of data and to the review of report material prior to publication. These people are listed below, organized by WHO region. We thank them all for their invaluable contribution
and collaboration, without which this report could not have been produced.
Among the WHO staff listed below, we thank in particular Amal Bassili, Andrei Dadu, Tom Hiatt, Khurshid Alam
Hyder, Daniel Kibuga, Rafael Lpez Olarte, Andr Ndongosieme, Wilfred Nkhoma, Nobuyuki Nishikiori, Anglica
Salomo, Ward Schrooten, Marithel Tesoro and Henriette Wembanyama for their major contribution to data collection,
validation and review.
WHO staff in regional and country offices

WHO African Region
Esther Aceng, Harura Adamu, Boubacar Abdel Aziz, Inacio Alvarenga, Balde Amadou, Cornelia Atsyor, Ayodele
Awe, Sanni Babatunde, Nay Bah, Marie Barouan, Abera Bekele, Norbert Bidounga, Franoise Bigirimana, Christine
Chakanyuka, Gal Claquin, Peter Clement, Claudina Cruz, Olusoti Daniel, Noel Djemadji, Louisa Ganda, Boingotlo
Gasennelwe, Joseph Imoko, Michael Jose, Jol Kangangi, Nzuzi Katondi, Samson Kefas, Bah Keita, Daniel Kibuga,
Hillary Kipruto, Mwendaweli Maboshe, Leonard Mbam Mbam, Azmera Molla, Julie Mugabekazi, Andr Ndongosieme,
Denise Nkezimana, Nicolas Nkiere, Wilfred Nkhoma, Ghislaine Nkone, Ishmael Nyasulu, Laurence Nyiramasarabwe,
Samuel Ogiri, Sally Ohene, Amos Omoniyi, Chijioke Osakwe, Philips Patrobas, Anglica Salomo, Neema Simkoko,
Desta Tiruneh, Henriette Wembanyama, Assefash Zehaie.

Roberto del Aguila, Monica Alonso, Arletta Anez, Miguel Aragn, Denise Arakaki, Adriana Bacelar, Eldonna Boisson, Gustavo Bretas, Luis Gerardo Castellanos, Maggie Clay, Rachel Eersel, Gerry Eijkemans, Marcos Espinal, Yitades
Gebre, Mirtha Del Granado, Mnica Guardo, Jorge Hadad, Rosalinda Hernndez, Vidalia Lesmo, Rafael Lpez, Tamara
Mancero, Wilmer Marquio, Mario Martnez, Fatima Marinho, Humberto Montiel, Romeo Montoya, Roberto Montoya, Jos Moya, Kam Mung, Soledad Prez, Jean Rwangabwoba, Hans Salas, Roberto Salvatella, Thais dos Santos,
Ward Schrooten, Alfonso Tenorio, Enrique Vazquez, Jorge Victoria, Anna Volz, Victor Zamora.

Ali Akbar, Mohamed Abdel Aziz, Samiha Baghdadi, Amal Bassili, Najwa ElEmam, Sevil Huseynova, Rhida Jebeniani,
Wasiq Khan, Hamida Khattabi, Nuzhat Leiluma, Aayid Munim, Ali Reza Aloudel, Karam Shah, Ireneaus Sindani,
Bashir Suleiman, Rahim Taghizadeh, Martin Van Den Boom.
WHO European Region

Evgeny Belilovsky, Andreea Cassandra Butu, Silvu Ciobanu, Pierpaolo de Colombani, Andrei Dadu, Irina Danilova,
Masoud Dara, Alain Disu, Jamshid Gadoev, Gayane Ghukasyan, Ogtay Gozalov, Sayohat Hasanova, Saliya Karymbaeva, Kristin Kremer, Mehmet Kontas, Nikoloz Nasidze, Dmitry Pashkevich, Robertas Petkevicius, Valiantsin Rusovich,
Javahir Suleymanova, Vadim Testov, Bogdana Shcherbak-Verlan, Melita Vujnovic.

Iyanthi Abeyewickreme, Mohammad Akhtar, Vikarunnesa Begum, Vineet Bhatia, Erwin Cooreman, Puneet Dewan,
Md Khurshid Alam Hyder, Navaratnasingam Janakan, Rim Kwang Il, Kim Son Il, Franky Loprang, Jorge Luna, Partha
Mandal, La Win Maung, Nigor Muzafarova, Ye Myint, Eva Nathanson, Patanjali Nayar, Rajesh Pandav, Razia Pendse,
Sri Prihatini, K Rezwan, Ray Serrano, Mukta Sharma, Aminath Shenalin, Achuthan Sreenivas, Chawalit Tantinimitkul, Kim Tong Hyok, Namgyel Wangchuk, Supriya Warusavithana, Sidharta Yuwono.
vi
WHO Western Pacific Region

Shalala Ahmadova, Nino Dayanghirang, Cornelia Hennig, Tom Hiatt, Narantuya Jadambaa, Sung Hye Kim, Woo-Jin
Lew, Yuhong Liu, Giampaolo Mezzabotta, Nobuyuki Nishikiori, Khanh Pham, Fabio Scano, Jacques Sebert, Marithel
Tesoro, Xuejing Wang, Catharina van Weezenbeek, Rajendra-Prasad Yadav, Dongbao Yu.
National respondents who contributed to reporting and verification of data

via the online global data collection system
WHO African Region
Oumar Abdelhadi, Abdou-Salam Abderemane, Coulibaly Abdoul Karim, Jean Abena, Felix Afutu, Soane Alihalassa, Arlindo Amaral, Gnevive Angue Nguema, Claudina Augusto da Cruz, Fantch Awokou, Swasilanne Bandeira,
Adama Bangoura, Jorge Barreto, Frank Bonsu, Ball Boubakar, Mahamat Bourhanadine, Miguel Camara, Ernest Cholopray, Nkem Chukwueme, Amadou Ciss, Catherine Cooper, Isaias Dambe, Serge Diagbouga, Aicha Diakit, Awa
Diop, Themba Dlamini, Scelo Dlamini, Pierre-Marie Douzima, Said Egwaga, Juan Eyene, Mugabe Frank, Justin Freminot, Ndayikengurukiye Fulgence, Michel Gasana, Evariste Gasana, Ntahizaniye Grard, Sandile Ginindza, Martin
Gninafon, Nii Hanson-Nortey, Adama Jallow, Nathan Kapata, Aristide Komangoya-Nzonzo, Patrick Konwloh, Jacquemin Kouakou, Egidio Langa, Bernard Langat, Gape Machao, Llang Maama-Maime, Jocelyn Mahoumbou, Angelo
Makpenon, David Mametja, Farai Mavhunga, Frank Mba Bekolo, Adamou Moustapha, Youwaoga Moyenga, James
Mpunga, Clifford Munyandi, Lindiwe Mvusi, Anne Mwenye, Ronald Ncube, Thadde Ndikumana, Biruck Negash,
Antoine Ngoulou, Emmanuel Nkiligi, M Nkou, Joshua Obasanya, Davidson Ogunade, Hermann Ongouo, Jean Okiata,
Maria Palma, Victor Pereira, Martin Rakotonjanahary, Sahondra Randriambeloson, Bakoliarisoa Ranivomahefa, Thato
Raleting, F Rujeedawa, Mohameden Salem, Charles Sandy, Marie Sarr-Diouf, Mineab Sebhatu, Mamie Shoma, Joseph
Sitienei, Nicholas Siziba, Dawda Sowe, Kassim Traore, Abdallahi Traor, Alie Wurie, Assefash Zehaie, Abbas Zezai, Eric
Zoungrana

Christian Acosta, Sarita Aguirre, Shalauddin Ahmed, Valentina Alarcn, Xochil Alemn, Valeria Almanza, Ral Alvarez, Mirian Alvarez, Alister Antoine, Chris Archibald, Carlos Ayala, Wiedjaiprekash Balesar, Draurio Barreira, Patricia
Bartholomay, Mara Bermdez, Jaime Bravo, Lynrod Brooks, Marta Calona, John Cann, Martn Castellanos, Jorge
Castillo, Kenneth Castro, Roxana Cspedes, Gemma Chery, Diana Claxton-Carty, Sonia Copeland, Clara Cruz, Mara
de Lourdes, Dy-Juan De Roza, Richard DMeza, Roger Duncan, Mercedes Espaa, Luis Fernando Fernandez, Hugo Fernandez, Clara Freile, Victor Gallant, Julio Garay, Jennifer George, Izzy Gerstenbluth, Perry Gmez, Silvino Gonzlez,
Lizbeth Guevara, Yaskara Halabi, Dorothea Hazel, Maria Henry, Jose na Heredia, Tania Herrera, Martin Huirse, Alina
Jaime, Carla Jeffries, Kathryn Johnston, Ashok Kumar, Athelene Linton, Mara Llanes, Cecilia Lyons, Eugne Maduro,
Marvin Maldonado, Francisco Maldonado, Andrea Maldonado, Marvin Manzanero, Belkys Marcelino, Ada Martnez,
Celia Martnez de Cuellar, Zeidy Mata, Timothy McLaughlin-Munroe, Mary Mercedes, Jeetendra Mohanlall, Ernesto
Moreno, Alice Neymour, Persaud Nordai, Michael Owen, Gisele Pinto, Tomasa Portillo, Irad Potter, Bob Pratt, Edwin
Quinonez, Dottin Ramoutar, Anna Reyes, Leonarda Reyes, Paul Ricketts, Jorge Rodriguez, Adalberto Rodriguez, Maria
Rodriguez, Mirian Romn, Katia Romero, Wilmer Salazar, Joan Simon, Manohar Singh, Sybil Smith, Jackurlyn Sutton,
Clarita Torres, Maribelle Tromp, Christopher Trujillo, William Turner, Melisa Valdez, Reina Valerio, Daniel Vazquez,
Nestor Vera, Juan Villeda, Asin Virginia, Eva de Weever, Michael Williams, Oritta Zachariah, Elsa Zerbini.

Salama AbouZeid, Naila Abuljadayel, Khaled Abu Rumman, Nadia Abu Sabra, Khadiga Adam, Shahnaz Ahmadi,
Amin Al-Absi, Samia Alagab, Abdulbary AlHammadi, Abdul Latif Al-Khal, Mohamed Al Lawati, Saeed Alsaffar, Fatma
Al Saidi, Kifah Alshaqeldi, Salah Ben Mansour, Kenza Bennani, Kinaz Cheikh, Walid Daoud, Mohamed Elfurjani,
Kamal Elneel, Rachid Fourati, Mohammed Gaafar, Amal Galal, Dhikrayet Gamara, Hawa Guessod, Dhafer Hashim,
Kalthoom Hassan, Basharat Javed, Hiba Kamal, Joseph Lasu, Syed Mahmoudi, Alaa Mokhtar, Alaa Mokhtar, Mahshid
Nasehi, Onwar Otien, Ejaz Qadeer, Mulham Saleh, Mohammad Seddiq, Khaled Sediq, Mohammed Sghiar, Mohemmed
Tabena, Hiam Yaacoub.
WHO European Region

Tleukhan Abildaev, Ibrahim Abubakar, Natavan Alikhanova, Avtandil Alisherov, Ekkehardt Altpeter, Laura Anderson,
Delphine Antoine, Gordana Radosavljevic Asic, Andrei Astrovko, Yana Besstraschnova, Oktam Bobokhojaev, Olivera
Bojovic, Bonita Brodhun, Claire Cameron, Noa Cedar, Daniel Chemtob, Domnica Chiotan, Ana Ciobanu, Nico Cioran,
vii
Andra Cirule, Thierry Comolet, Radmila Curcic, Manfred Danilovit, Edita Davidavicene, Hayk Davtyan, Gerard de
Vries, Mladen Duronjuic, Connie Erkens, Jennifer Fernndez, Viktor Gasimov, Lrus Gumundsson, Walter Haas,
Hasan Ha zi, Eugene Hanyukov, Armen Hayrapetyan, Peter Helbling, Gennady Hurevich, Jahongir Ismoilov, Mamuka
Japaridze, Jerker Jonsson, Maria Korzeniewska-Kosela, Aynura Koshoeva, Mitja Konik, Gabor Kovacs, Rukije Mehmeti, Donika Mema, Vladimir Milanov, Seher Musaonbasioglu, Joan ODonnell, Analita Pace-Asciak, Clara Palma, Elena
Pavlenko, Gilda Popescu, Bozidarka Rakocevic, Vija Riekstina, Jerome Robert, Elena Rodrguez-Valn, Kazimierz Roszkowski, Petri Ruutu, Roland Salmon, Gerard Scheiden, Brian Smyth, Ivan Solovic, Petra Sorli, Stefan Talevski, Odorina Tello-Anchuela, Mirzogolib Tilleashahov, Dilrabo Ulmasova, Gulnoz Uzakova, Piret Viiklepp, Pierre Weicherding,
Aysegul Yildirim, Maja Zakoska, Hasan Zutic.

Imesha Abeysekara, Aminath Aroosha, Si Thu Aung, Tashi Dendup, Nuruzzaman Haque, Emdadul Hoque, Suksont Jittimanee, Jang Yong Hui, Kashi Kant Jha, Badri Nath Jnawali, Niraj Kulshrestha, Ashok Kumar, Dyah Erti Mustikawati,
Costantino Lopes, Thandar Lwin, Chawetsan Namwat, Nirupa Pallewatte, Kiran Rade, Chewang Rinzin, Sudath Samaraweera, Yuwono Sidharta, Choe Kum Song, Asik Surya.
WHO Western Pacific Region

Paul Aia, Cecilia Arciaga, Christina Barry, Iobi Batio, Risa Bukbuk, Nou Chanly, Phonenaly Chittamany, Henry Daiwo,
Jiloris Dony, Jane Dowabobo, Saen Fanai, Rangiau Fariu, Ludovic Floury, Celina Gar n, Shakti Gounder, Xaysangkhom Insisiengmay, Noel Itogo, Nese Conway, Mao Tan Eang, Mayleen Ekiek, Suzana Mohd Hashim, Chou Kuok Hei,
Cho En Hi, Nguyen Binh Hoa, Tom Jack, Seiya Kato, Pengiran Ismail, Daniel Lamar, Morisse Laurent, Wang Lixia, Liza
Lopez, Henri-Pierre Mallet, Khin Mar Kyi Win, Sera Moa, Johana Ngiruchelbad, Batbayar Ochirbat, Connie Olikong,
Sosaia Penitani, Saia Penitani, Faimanifo Peseta, Nukutau Pokura, Waimanu Pulu, Marcelina Rabauliman, Bereka
Reiher, Bernard Rouchon, Temilo Seono, Cheng Shiming, Sang-sook Shin, Tokuaki Shobayashi, Tieng Sivanna, Grant
Storey, Dinh Ngoc Sy, Phannasinh Sylavanh, Kenneth Tabutoa, Markleen Tagaro, Cheuk-ming Tam, Wang Yee Tang,
Faafetai Teo-Yandall, Kyaw Thu, Kazuhiro Uchimura, Rosalind Vianzon, Du Xin, Dai Yoshizawa.
viii
Executive Summary
The World Health Organization (WHO) Global Tuberculosis

Report 2012 provides the latest information and analysis
about the tuberculosis (TB) epidemic and progress in TB
care and control at global, regional and country levels. It
is based primarily on data reported by WHOs Member
States in annual rounds of global TB data collection. In
2012, 182 Member States and a total of 204 countries and
territories that collectively have more than 99% of the
worlds TB cases reported data.
Key findings
Progress towards global targets for reductions in

TB cases and deaths continues. The Millennium
Development Goal (MDG) target to halt and reverse
the TB epidemic by 2015 has already been achieved.
New cases of TB have been falling for several years and
fell at a rate of 2.2% between 2010 and 2011. The TB
mortality rate has decreased 41% since 1990 and the
world is on track to achieve the global target of a 50%
reduction by 2015. Mortality and incidence rates are
also falling in all of WHOs six regions and in most
of the 22 high-burden countries that account for over
80% of the worlds TB cases. At country level, Cambodia demonstrates what can be achieved in a lowincome and high-burden country: new data show a
45% decrease in TB prevalence since 2002.
However, the global burden of TB remains enormous. In 2011, there were an estimated 8.7 million
new cases of TB (13% co-infected with HIV) and 1.4
million people died from TB, including almost one
million deaths among HIV-negative individuals and
430 000 among people who were HIV-positive. TB is
one of the top killers of women, with 300 000 deaths
among HIV-negative women and 200 000 deaths
among HIV-positive women in 2011. Global progress
also conceals regional variations: the African and
European regions are not on track to halve 1990 levels
of mortality by 2015.
Access to TB care has expanded substantially
since the mid-1990s, when WHO launched a new global TB strategy and began systematically monitoring
progress. Between 1995 and 2011, 51 million people
were successfully treated for TB in countries that had
adopted the WHO strategy, saving 20 million lives.
Progress in responding to multidrug-resistant
TB (MDR-TB) remains slow. While the number of
cases of MDR-TB notied in the 27 high MDR-TB burden countries is increasing and reached almost 60 000
worldwide in 2011, this is only one in ve (19%) of the
notied TB patients estimated to have MDR-TB. In the
two countries with the largest number of cases, India
and China, the gure is less than one in ten; scale-up
is expected in these countries in the next three years.
There has been further progress in implementing collaborative TB/HIV activities ( rst recommended by WHO in 2004). These saved an estimated
1.3 million lives between 2005 and the end of 2011.
In 2011, 69% of TB patients were tested for HIV in the
African Region, up from 3% in 2004. Globally, 48% of
the TB patients known to be living with HIV in 2011
were started on antiretroviral therapy (ART); coverage
needs to double to meet WHOs recommendation that
all TB patients living with HIV are promptly started on
ART. Kenya and Rwanda are top performers in HIV
testing and provision of ART.
Innovations in diagnostics are being implemented. The roll-out of Xpert MTB/RIF, a rapid molecular
test that can diagnose TB and rifampicin resistance
within 100 minutes, has been impressive. Between
its endorsement by WHO in December 2010 and the
end of June 2012, 1.1 million tests had been purchased
by 67 low- and middle-income countries; South Africa (37% of purchased tests) is the leading adopter. A
41% price reduction (from US$ 16.86 to US$ 9.98) in
August 2012 should accelerate uptake.
The development of new drugs and new vaccines
is also progressing. New or re-purposed TB drugs
and novel TB regimens to treat drug-sensitive or drugresistant TB are advancing in clinical trials and regulatory review. Eleven vaccines to prevent TB are moving
through development stages.
There are critical funding gaps for TB care and
control. Between 2013 and 2015 up to US$ 8 billion
per year is needed in low- and middle-income countries, with a funding gap of up to US$ 3 billion per
year. International donor funding is especially critical
to sustain recent gains and make further progress in
35 low-income countries (25 in Africa), where donors
provide more than 60% of current funding.
There are also critical funding gaps for research
and development. US$ 2 billion per year is needed;
the funding gap was US$ 1.4 billion in 2010.
Additional highlights by topic

Burden of disease
Geographically, the burden of TB is highest in Asia and
Africa. India and China together account for almost 40%
of the worlds TB cases. About 60% of cases are in the
South-East Asia and Western Pacic regions. The African
Region has 24% of the worlds cases, and the highest rates
of cases and deaths per capita.
Worldwide, 3.7% of new cases and 20% of previously
treated cases were estimated to have MDR-TB.
India, China, the Russian Federation and South Africa
have almost 60% of the worlds cases of MDR-TB. The
highest proportions of TB patients with MDR-TB are in
eastern Europe and central Asia.
Almost 80% of TB cases among people living with HIV
reside in Africa.
Estimating the burden of TB in children (aged less than
15) is difcult; estimates are included in the report for the
rst time. There were an estimated 0.5 million cases and
64 000 deaths among children in 2011.
Case notifications and treatment success

In 2011, 5.8 million newly diagnosed cases were notied
to national TB control programmes (NTPs) and reported
to WHO, up from 3.4 million in 1995 but still only twothirds of the estimated total of 8.7 million people who fell
ill with TB in 2011.
Notications of TB cases have stagnated in recent years.
New policy measures, including mandatory case notication by all care providers via an electronic web-based
system in India, could have a global impact on the number of TB cases notied in future years. Intensied efforts
by NTPs to engage the full range of care providers using
public-private mix (PPM) initiatives are also important;
in most of the 21 countries that provided data, 1040% of
notications were from non-NTP care providers.
Globally, treatment success rates have been maintained at high levels for several years. In 2010 (the latest
year for which treatment outcome data are available), the
treatment success rate among all newly-diagnosed cases
was 85% and 87% among patients with smear-positive
pulmonary TB (the most infectious cases).
Responding to drug-resistant TB
Measurement of drug resistance has improved considerably. Data are available for 135 countries worldwide (70%
of WHOs 194 Member States) and by the end of 2012 will
be available from all 36 countries with a high burden of
TB or MDR-TB.
Extensively drug-resistant TB, or XDR-TB, has been
reported by 84 countries; the average proportion of MDRTB cases with XDR-TB is 9.0%.
The target treatment success rate of 75% or higher for

patients with MDR-TB was reached by only 30 of 107
countries that reported treatment outcomes.
Scaling up TB-HIV collaboration

Globally, 40% of TB patients had a documented HIV test
result and 79% of those living with HIV were provided
with co-trimoxazole preventive therapy in 2011.
Interventions to detect TB promptly and to prevent
TB among people living with HIV, that are usually the
responsibility of HIV programmes and general primary
health-care services, include regular screening for TB
and isoniazid preventive therapy (IPT) for those without
active TB. The number of people in HIV care who were
screened for TB increased 39% (2.3 million to 3.2 million) between 2010 and 2011. Nearly half a million people without active TB were provided with IPT, more than
double the number started in 2010 and mostly the result
of progress in South Africa.
Research and development to accelerate progress

Research to develop a point-of-care diagnostic test for TB
and MDR-TB continues, and other diagnostic tests are in
the pipeline.
Today, standard treatment for TB patients lasts six
months and the regimen for most patients with drugresistant TB takes 20 months. Treatment for MDR-TB is
costly and can have serious side-effects. Of the 11 anti-TB
drugs in clinical trials, two new drugs are being evaluated
to boost the effectiveness of MDR-TB regimens. A novel
regimen that could be used to treat both drug-sensitive
TB and MDR-TB and shorten treatment duration has
shown encouraging results in clinical trials.
There is no effective vaccine to prevent TB in adults.
Progress in the past decade means that it is possible that at
least one new vaccine could be licensed by 2020.
Financing for TB care and control

About US$ 1 billion per year of international donor funding is needed for TB care and control (excluding TB/HIV
interventions) in low and middle-income countries from
2013 to 2015, double existing levels. Up to an additional
US$ 1 billion per year is needed for TB/HIV interventions, mostly for ART for HIV-positive TB patients.
National contributions provide the bulk of nancing
for TB care and control in Brazil, the Russian Federation,
India, China and South Africa (BRICS). However, they
remain insufcient for scaling up the diagnosis and treatment of MDR-TB; BRICS account for about 60% of the
worlds estimated cases of MDR-TB.
The Global Fund provides almost 90% of international
donor funding for TB.
CHAPTER 1
Introduction
BOX 1.1
Basic facts about tuberculosis (TB)
TB is an infectious disease caused by the bacillus
Mycobacterium tuberculosis. It typically affects the
lungs (pulmonary TB) but can affect other sites as well
(extrapulmonary TB). The disease is spread in the air when
people who are sick with pulmonary TB expel bacteria, for
example by coughing. In general, a relatively small proportion
of people infected with Mycobacterium tuberculosis will
develop TB disease; however, the probability of developing
TB is much higher among people infected with the human
immunodeciency virus (HIV). TB is also more common
among men than women, and affects mostly adults in the
economically productive age groups.
Without treatment, mortality rates are high. In studies of the
natural history of the disease among sputum smear-positive
and HIV-negative cases of pulmonary TB, around 70% died
within 10 years; among culture-positive (but smear-negative)
cases, 20% died within 10 years.1
The most common method for diagnosing TB worldwide is
sputum smear microscopy (developed more than 100 years
ago), in which bacteria are observed in sputum samples
examined under a microscope. Following recent developments
in TB diagnostics, the use of rapid molecular tests for the
diagnosis of TB and drug-resistant TB is increasing, as highlighted in Chapter 6 of this report. In countries with more
developed laboratory capacity, cases of TB are also diagnosed
via culture methods (the current reference standard).
Treatment for new cases of drug-susceptible TB consists of a
6-month regimen of four rst-line drugs: isoniazid, rifampicin,
ethambutol and pyrazinamide. Treatment for multidrugresistant TB (MDR-TB), dened as resistance to isoniazid and
rifampicin (the two most powerful anti-TB drugs) is longer, and
requires more expensive and toxic drugs. For most patients
with MDR-TB, the current regimens recommended by WHO last
20 months.
1
Tiemersma EW et al. Natural history of tuberculosis: duration

and fatality of untreated pulmonary tuberculosis in HIV-negative
patients: A systematic review. PLoS ONE 2011 6(4): e17601.
Tuberculosis (TB) remains a major global health problem.

It causes ill-health among millions of people each year
and ranks as the second leading cause of death from an
infectious disease worldwide, after the human immunodeciency virus (HIV). The latest estimates included in
this report are that there were almost 9 million new cases
in 2011 and 1.4 million TB deaths (990 000 among HIVnegative people and 430 000 HIV-associated TB deaths).
This is despite the availability of treatment that will cure
most cases of TB. Short-course regimens of rst-line
drugs that can cure around 90% of cases have been available since the 1980s.
The World Health Organization (WHO) declared TB a
global public health emergency in 1993. Starting in the
mid-1990s, efforts to improve TB care and control intensied at national and international levels. WHO developed
the DOTS strategy, a ve-component package comprising political commitment, diagnosis using sputum smear
microscopy, a regular supply of rst-line anti-TB drugs,
short-course chemotherapy and a standard system for
recording and reporting the number of cases detected
by national TB control programmes (NTPs) and the outcomes of treatment. Within a decade, almost all countries had adopted the strategy and there was considerable
progress towards global targets established for 2005: the
detection of 70% of the estimated number of smear-positive pulmonary cases (the most infectious cases) and the
successful treatment of 85% of these cases. In 2005, the
numbers of cases reported by NTPs grew to over 5 million
and treatment success rates reached 85%.
WHOs currently-recommended approach to TB care
and control is the Stop TB Strategy, launched in 2006 (Box
1.2). This strategy was linked to new global targets for
reductions in TB cases and deaths that were set for 2015
(Box 1.3) as part of the Millennium Development Goals
(MDGs) and by the Stop TB Partnership. The targets are
that TB incidence should be falling by 2015 (MDG Target
6.c) and that prevalence and death rates should be halved
compared with their levels in 1990.
The scale at which interventions included in the Stop
TB Strategy need to be implemented to achieve the
2015 targets for reductions in disease burden has been
described in Global Plans developed by the Stop TB Partnership. The latest plan covers the period 20112015 and
BOX 1.2
The Stop TB Strategy at a glance
THE STOP TB STRATEGY
VISION
A TB-free world
GOAL
To dramatically reduce the global burden of TB by 2015 in line with the Millennium Development Goals (MDGs)
and the Stop TB Partnership targets
OBJECTIVES
Achieve universal access to high-quality care for all people with TB

Reduce the human suffering and socioeconomic burden associated with TB
Protect vulnerable populations from TB, TB/HIV and drug-resistant TB
Support development of new tools and enable their timely and effective use
Protect and promote human rights in TB prevention, care and control
TARGETS
MDG 6, Target 6.c: Halt and begin to reverse the incidence of TB by 2015
Targets linked to the MDGs and endorsed by the Stop TB Partnership:
2015: reduce prevalence of and deaths due to TB by 50% compared with a baseline of 1990
2050: eliminate TB as a public health problem
COMPONENTS
1. Pursue high-quality DOTS expansion and enhancement
a. Secure political commitment, with adequate and sustained nancing
b. Ensure early case detection, and diagnosis through quality-assured bacteriology
c. Provide standardized treatment with supervision, and patient support
d. Ensure effective drug supply and management
e. Monitor and evaluate performance and impact
2. Address TB/HIV, MDR-TB, and the needs of poor and vulnerable populations
a. Scale-up collaborative TB/HIV activities
b. Scale-up prevention and management of multidrug-resistant TB (MDR-TB)
c. Address the needs of TB contacts, and of poor and vulnerable populations
3. Contribute to health system strengthening based on primary health care
a. Help improve health policies, human resource development, nancing, supplies, service delivery and information
b. Strengthen infection control in health services, other congregate settings and households
c. Upgrade laboratory networks, and implement the Practical Approach to Lung Health
d. Adapt successful approaches from other elds and sectors, and foster action on the social determinants of health
4. Engage all care providers
a. Involve all public, voluntary, corporate and private providers through publicprivate mix approaches
b. Promote use of the International Standards for Tuberculosis Care
5. Empower people with TB, and communities through partnership
a. Pursue advocacy, communication and social mobilization
b. Foster community participation in TB care, prevention and health promotion
c. Promote use of the Patients Charter for Tuberculosis Care
6. Enable and promote research
a. Conduct programme-based operational research
b. Advocate for and participate in research to develop new diagnostics, drugs and vaccines
TABLE 1.1 Targets for the scale-up of interventions for TB care and control set in the Global Plan to Stop TB 20112015
PLAN COMPONENT AND INDICATORS
2015 TARGET
Diagnosis and treatment of drug-susceptible TB

Number of cases diagnosed, notied and treated according to the DOTS approach (per year)
6.9 million
Treatment success rate (in annual cohort)
90%
Number of countries with 1 laboratory with sputum-smear microscopy services per 100 000 population
149
Diagnosis and treatment of drug-resistant TB

Percentage of previously treated TB patients tested for MDR-TB
100%
Percentage of new bacteriologically-positive TB patients tested for MDR-TB
20%
Number of countries among the 22 HBCs and 27 high MDR-TB burden countries with 1 culture laboratory per 5 million population
36
Percentage of conrmed cases of MDR-TB enrolled on treatment according to international guidelines

Number of conrmed cases of MDR-TB enrolled on treatment according to international guidelines
100%
270 000
Treatment success rate among conrmed cases of MDR-TB
75%
Collaborative TB/HIV activities

Percentage of TB patients tested for HIV
100%
Percentage of HIV-positive TB patients treated with CPT
100%
Percentage of HIV-positive TB patients treated with ART
100%
Percentage of people living with HIV attending HIV care services who were screened for TB at their last visit
100%
Percentage of people living with HIV attending HIV care services who were enrolled on IPT, among those eligible
100%
Laboratory strengthening (additional to those above)

Percentage of national reference laboratories implementing a quality management system (QMS) according to international standards
50%
ART, antiretroviral therapy; CPT, co-trimoxazole preventive therapy; HBC, high TB burden country; HIV, human immunodeciency virus; IPT, isoniazid preventive therapy;
MDR-TB, multidrug-resistant tuberculosis
comes with a price tag of US$ 47 billion.1 The main indicators and associated targets for 2015 are summarized in
Table 1.1.
WHO has published a global report on TB every year
since 1997 (Figure 1.1). The main aim of the report is to
provide a comprehensive and up-to-date assessment of
the TB epidemic and progress made in prevention, care
and control of the disease at global, regional and country
levels, in the context of global targets and WHOs recommended strategy for achieving these targets. This 2012
edition the 17th in the series continues the tradition.
It is based primarily on data compiled in annual rounds of
global TB data collection in which countries are requested to report a standard set of data to WHO (Box 1.4). In
2012, a total of 204 countries and territories that account
for over 99% of the worlds estimated cases of TB reported
data (Table 1.2).
The report is structured in seven major chapters. Each
chapter is intended to stand alone, but links to other
chapters are highlighted where appropriate.
Chapter 2 contains the latest estimates of the burden of
disease caused by TB and assessment of progress towards
the 2015 targets at global, regional and country levels.
The chapter puts the spotlight on Cambodia as a new success story in TB control at country level and for the rst
1
BOX 1.3
Goals, targets and indicators for TB control
Millennium Development Goals set for 2015
Goal 6: Combat HIV/AIDS, malaria and
other diseases
Target 6c: Halt and begin to reverse the incidence of malaria
and other major diseases
Indicator 6.9: Incidence, prevalence and death rates
associated with TB
Indicator 6.10: Proportion of TB cases detected and cured
under DOTS
Stop TB Partnership targets set for 2015 and 2050

By 2015: Reduce prevalence and death rates by 50%,
compared with their levels in 1990
By 2050: Reduce the global incidence of active TB cases to
<1 case per 1 million population per year
The Global Plan to Stop TB, 20112015. Geneva, World Health

Organization, 2010 (WHO/HTM/STB/2010.2).
www.stoptb.org/global/plan/
FIGURE 1.1
Sixteen annual WHO reports on TB in 15 years, 19972011
1997: First report:

epidemiology and
surveillance
2002: Added nancing and

strategy for 22 high-burden
countries (HBCs)
2003: Financing
and strategy
(all countries)
July 2009: Online data collection introduced

December 2009: Short update to 2009 report in transition
to earlier reporting of data and report publication
BOX 1.4
Data collected in WHOs 2012 round of global TB data collection
Data were requested on the following topics: TB case notications and treatment outcomes, including breakdowns by case type, age, sex,
HIV status and drug resistance status; an overview of services for the diagnosis and treatment of TB; laboratory diagnostic services; drug
management; monitoring and evaluation; surveillance and surveys of drug-resistant TB; management of drug-resistant TB; collaborative
TB/HIV activities; TB infection control; engagement of all care providers in TB control; the budgets of national TB control programmes
(NTPs) in 2012 and 2013; utilization of general health services (hospitalization and outpatient visits) during treatment; and NTP
expenditures in 2011. A shortened version of the online questionnaire was used for high-income countries (that is, countries with a gross
national income per capita of US$ 12 475 in 2011, as dened by the World Bank)1 and/or low-incidence countries (dened as countries
with an incidence rate of <20 cases per 100 000 population or <10 cases in total).
Since 2009, data have been reported using an online web-based system.2 In 2012, the online system was opened for reporting on 16
March, with a deadline of 17 May for all WHO regions except the Region of the Americas (31 May) and the European Region (15 June).
Countries in the European Union submit notication data to a system managed by the European Centre for Disease Prevention and
Control (ECDC). Data from the ECDC system were uploaded into WHOs online system.
Data were reviewed, and followed up with countries where appropriate, by a team of reviewers from WHO (headquarters and regional
ofces) and the Global Fund. Validation of data by respondents was also encouraged via a series of inbuilt and real-time checks of
submitted data as well as a summary report of apparent inconsistencies or inaccuracies that can be generated at any time within the
online system. Following corrections and updates by countries, the data used for the main part of this report were the data available in
July 2012. Annex 4 was produced on 25 September 2012, by which time additional data had been reported by a few European countries.3
Besides the data reported through the standard TB questionnaire, data about screening for TB among people living with HIV and
provision of isoniazid preventive therapy to those without active TB were collected by the HIV department in WHO and UNAIDS. The data
were jointly validated and imported into the global TB database.
1
2
3
http://data.worldbank.org/about/country-classications
www.stoptb.org/tme
For this reason, there may be slight discrepancies between the main part of the report and Annex 4.
time includes estimates of the burden of TB in children.

The latest status of efforts to improve measurement of TB
cases and deaths at country level, with guidance and support from WHOs Global Task Force on TB Impact Measurement, is described.
Chapter 3 presents data on the numbers of cases notied to NTPs and reported to WHO and their treatment
outcomes, including breakdowns of cases by type of TB
disease, sex and age.
Chapter 4 focuses on drug-resistant TB, covering progress in drug resistance surveillance and associated estimates of the proportion of TB patients that have MDR-TB
and extensively drug-resistant TB (XDR-TB), and the latest data on the coverage of testing for MDR-TB among
new and previously treated TB patients, notications
of cases of MDR-TB and enrolments on treatment, and
treatment outcomes.
Chapter 5 assesses nancing for TB care and control.
Trends since 2006 are described by source of funding and
category of expenditure. Important contrasts in the extent
to which different country groups rely upon domestic and
donor nancing are illustrated. Funding gaps, the unit
costs of TB treatment and the cost-effectiveness of TB
interventions are discussed as well.
TABLE 1.2 Reporting of data in the 2012 round of global TB data collection
COUNTRIES AND TERRITORIES
WHO REGION OR SET OF COUNTRIES
NUMBER THAT REPORTED DATA
NUMBER
NUMBER THAT REPORTED DATA
African Region
46
46
46
46
Eastern Mediterranean Region
23
23
22
22
54
42
53
41
Region of the Americas
46
46
35
35
South-East Asia Region
11
11
11
11
European Region
Western Pacic Region
36
36
27
27
High-burden countries (HBCs) b
22
22
22
22
WORLD
216
204
194
182
Countries that did not report by the deadlines were mostly low-incidence countries in Western Europe.
The HBCs are Afghanistan, Bangladesh, Brazil, Cambodia, China, the Democratic Republic of the Congo, Ethiopia, India, Indonesia, Kenya, Mozambique, Myanmar, Nigeria,
Pakistan, the Philippines, the Russian Federation, South Africa, Thailand, Uganda, the United Republic of Tanzania, Viet Nam and Zimbabwe.
Chapter 6, on TB diagnostics and laboratory strengthening, summarizes recent policy development and analyses laboratory capacity in 2011. The development of
laboratory capacity through the EXPAND-TB project and
the latest data on progress in rolling out Xpert MTB/RIF
since endorsement of this rapid molecular test in 2010 are
given particular attention.
Chapter 7 contains the most recent data on progress
in implementing collaborative TB/HIV activities to jointly
address the epidemics of TB and HIV. The lives saved by
these interventions since WHO policy was issued in 2004
and the need to further increase the coverage of antiretroviral therapy for TB patients living with HIV are highlighted.
MEMBER STATES
NUMBER
Chapter 8 discusses research and development for new

TB diagnostics, drugs and vaccines. After years of stagnation, considerable progress has occurred in the last
decade and the development pipelines as of mid-2012 are
described and discussed.
The report also has four annexes. Annex 1 explains
the methods used to produce estimates of the burden of
disease caused by TB. Annex 2 contains country pro les
for the 22 high-burden countries (HBCs) that collectively
account for about 80% of the worlds TB cases (pro les
for all countries are available online1). Annex 3 contains
regional pro les. Annex 4 consists of summary tables that
provide data on key indicators for the world, WHOs six
regions and individual countries.
www.who.int/tb/data
CHAPTER 2
The burden of disease caused by TB
KEY FACTS AND MESSAGES

There has been major progress in reducing TB cases and
deaths in the past two decades.
The 2015 MDG target of halting and reversing TB
incidence has been achieved, with TB incidence falling
globally for several years and declining at a rate of 2.2%
between 2010 and 2011. Globally, the TB mortality rate
has fallen by 41% since 1990 and the world is on track
to reach the global target of a 50% reduction by 2015.
Mortality and incidence rates are falling in all of WHOs
six regions and in most of the 22 HBCs that account for
over 80% of the worlds TB cases.
Cambodia provides an important new success story for
TB control in a HBC: a national population-based survey
completed in 2011 showed that TB prevalence had
fallen 45% since a baseline survey in 2002.
Despite this encouraging progress, the global burden
of TB remains enormous. There were an estimated
8.7 million incident cases of TB in 2011 (13%
co-infected with HIV). There were also 1.4 million
deaths from TB (990 000 deaths among HIV-negative
individuals and 430 000 among people who were
HIV-positive). These deaths included 0.5 million among
women, making TB one of the top killers of women
worldwide.
Geographically, the burden of TB is highest in Asia and
Africa. India and China combined have almost 40% of
the worlds TB cases; the South-East Asia and Western
Pacic Regions of which they are a part account for
60%. The African Region has approximately one quarter
of the worlds cases, and the highest rates of cases and
deaths relative to population.
Globally, 3.7% of new cases and 20% of previously
treated cases are estimated to have MDR-TB.
Estimates of the burden of disease caused by TB are
being continuously improved at country level, supported
by WHOs Global Task Force on TB Impact Measurement.
The burden of disease caused by TB can be measured in

terms of incidence (de ned as the number of new and
relapse cases of TB arising in a given time period, usually
one year), prevalence (de ned as the number of cases of
TB at a given point in time) and mortality (de ned as the
number of deaths caused by TB in a given time period,
usually one year).
This chapter presents estimates of TB incidence,
prevalence and mortality (absolute numbers and rates)
between 1990 and 2011 and (for prevalence and mortality) forecasts up to 2015 (in sections 2.12.3). These data
are used to assess progress towards achieving the global
targets for TB control set for 2015: that incidence should
be falling (MDG Target 6.c) and that prevalence and
death rates should be halved by 2015 compared with 1990
(Box 1.3 in Chapter 1). Key aspects of the methods used
to produce the estimates are provided at the beginning of
each section.1 Section 2.4 contains estimates of the number of prevalent cases of multidrug-resistant TB (MDRTB) in 2011, and estimates of the proportion of MDR-TB
cases globally, regionally and in high TB-burden countries (HBCs).2
In response to increasing demand and global attention,
this 2012 global report is the rst to feature estimates of
the number of TB cases and deaths among children and
the rst to include estimates of TB mortality among women that include HIV-associated TB deaths.3 The chapter
also puts the spotlight on Cambodia, which provides
a new success story for TB control at country level. A
national survey in 2011 showed that TB prevalence had
fallen by 45% in the 9 years since a baseline survey in
2002.
There is uncertainty in all estimates of the burden
of disease caused by TB. Section 2.5 pro les efforts to
improve measurement of the burden of the disease under
the umbrella of the WHO Global Task Force on TB Impact
Measurement. These include efforts to strengthen surveillance of cases and deaths via notication and vital
registration (VR) systems, and national surveys of the
prevalence of TB disease in global focus countries.
1
2
A detailed description is provided in Annex 1.

Chapter 4 includes a much fuller discussion of the MDR-TB
epidemic and the latest data on progress in the diagnosis and
treatment of MDR-TB.
In previous reports, estimates were restricted to the number of
TB deaths among women who were HIV-negative.
BOX 2.1
Uncertainty in estimates of TB incidence, prevalence and mortality
Measuring the incidence of TB at national level has never been done because it would require long-term studies among large cohorts
of people (hundreds of thousands) at high cost and with challenging logistics. In countries with a high burden of TB, prevalence can
be directly measured in nationwide surveys using sample sizes of around 50 000 people; costs range from US$ 1 to US$ 4 million per
survey.1 Between 2009 and 2015, an unprecedented number of national TB prevalence surveys are being conducted in countries where
TB is endemic. In low and medium-burden countries, sample sizes and costs become prohibitively large. TB mortality among HIV-negative
people can be directly measured if national vital registration (VR) systems of high coverage in which causes of death are accurately
coded according to the latest revision of the international classication of diseases (ICD-10) are in place. Sample VR systems covering
representative areas of the country (as in China) provide an interim solution. Mortality surveys can also be used to directly measure deaths
caused by TB. In 2011, most countries with a high burden of TB lacked national or sample VR systems and few had conducted mortality
surveys. TB mortality among HIV-positive people is hard to measure even when VR systems are in place because deaths among HIVpositive people are coded as HIV deaths and contributory causes (such as TB) are often not reliably recorded.
For all these reasons, the estimates of TB incidence, prevalence and mortality included in this chapter are presented with uncertainty
intervals. The methods used to produce best estimates and uncertainty intervals are described in detail in Annex 1.
1
2.1
TB prevalence surveys: a handbook. Geneva, World Health Organization, 2011 (WHO/HTM/TB/2010.17).
Incidence
The incidence of TB cannot be measured directly (Box

2.1). For 96 countries that account for 89% of the worlds
TB cases, estimates were revised between 2009 and 2012
in regional or country workshops (Figure 2.1) using a
framework (Figure 2.2) and associated tools developed
by the WHO Global Task Force on TB Impact Measurement. In-depth analyses of the available surveillance,
survey and programmatic data were undertaken, and
expert opinion about the fraction of cases diagnosed but
not reported, or not diagnosed at all, was documented.
Reliance on expert opinion is one of the reasons why estimates are uncertain (Box 2.1); strengthening surveillance
and better quantifying the extent of under-reporting (i.e.
the number of cases that are missed by surveillance systems) are needed to reduce this uncertainty (efforts to do
so are discussed in Section 2.5). For countries not covered
in workshops, estimates are based on extending previous
time-series or on updates using mortality data from VR
systems combined with evidence about the case fatality
rate (see Annex 1 for details).
In 2011, there were an estimated 8.7 million incident cases of TB (range, 8.3 million9.0 million) globally, equivalent to 125 cases per 100 000 population
(Table 2.1, Table 2.2, Figure 2.3, Figure 2.4, Figure 2.5).
Most of the estimated number of cases in 2011 occurred
in Asia (59%) and Africa (26%);1 smaller proportions
of cases occurred in the Eastern Mediterranean Region
(7.7%), the European Region (4.3%) and the Region of
the Americas (3%). The 22 HBCs that have been given
highest priority at the global level since 2000 (listed in
Table 2.1 and Table 2.2) accounted for 82% of all estimat-
FIGURE 2.1
Progress in applying the Task Force

framework for assessment of TB surveillance
data, as of July 2012a
All countries shown in orange participated in regional workshops held from

April 2009 to June 2010, with the exception of the United Republic of Tanzania
where a country mission was undertaken in October 2009 and India where three
country missions were undertaken between April and July 2011. As follow-up to
the regional workshop held for countries in the Western Pacic Region in June
2010, national workshops were also held in China in June 2011, in India in July
2011 and July 2012, in Cambodia in February 2012 and in Indonesia in March
2012. Further details about these workshops are provided in ANNEX 1.
Asia refers to the WHO regions of South-East Asia and the

Western Pacic. Africa means the WHO African Region.
FIGURE 2.2
Framework for assessment of TB surveillance data (notication and vital registration data)
DATA QUALITY
TRENDS
Do surveillance data
reect trends in incidence
and mortality?
ARE ALL CASES AND
DEATHS CAPTURED IN
SURVEILLANCE DATA?
Completeness
No duplications, no misclassications
Internal and external consistency
IMPROVE surveillance system
Analyse time-changes in notications and deaths

alongside changes in e.g. case-nding, case
denitions, HIV prevalence and other determinants
EVALUATE trends and impact of TB control
UPDATE estimates of TB incidence and mortality
Onion model
Inventory studies
Capture re-capture studies
Prevalence surveys
Innovative operational research
notications incidence
VR mortality data deaths
If appropriate, CERTIFY TB surveillance data as a

direct measure of TB incidence and mortality
TABLE 2.1 Estimated burden of disease caused by TB, 2011. Numbers in thousands.a
MORTALITY b
POPULATION
32 358
13
Bangladesh
150 494
68
Brazil
196 655
5.6
4.6
14 305
9.1
4.2
China
DR Congo
Ethiopia
Indiad
Indonesia
Kenya
BEST
LOW
INCIDENCE
HIGH
BEST
LOW
HIV-POSITIVE INCIDENT TB CASES

HIGH
BEST
LOW
23
110
55
190
61
51
73
0.3
0.2
120
620
300
1 100
340
280
400
0.6
0.3
91
36
170
83
69
97
16
120
99
140
61
52
70
6.8
16
3.1
47
45
49
1 400
1 200
1 600
1 000
890
1 100
13
67 758
36
16
65
350
180
570
220
190
250
34
13
2.6
8.6
27
HIGH
0.4
1.0
19
3.6
17
41
84 734
15
11
20
200
160
240
220
160
280
38
28
49
1 241 492
300
190
430
3 100
2 100
4 300
2 200
2 000
2 500
94
72
120
242 326
65
29
120
680
310
1 200
450
380
540
15
11
20
15
120
63
200
120
110
120
47
45
49
41 610
9.2
4.7
23 930
11
48 337
23
Nigeria
162 471
27
Pakistan
176 745
59
26
94 852
28
25
142 836
22
South Africa
50 460
25
Thailand
69 519
9.8
4.2
Uganda
34 509
5.0
2.1
UR Tanzania
46 218
6.4
3.3
Viet Nam
88 792
Zimbabwe
12 754
High-burden
countries
PREVALENCE
HIGH
1 347 565
Myanmar
Russian Federation
5.3
29
Mozambique
Philippines
LOW
Afghanistan
Cambodia
BESTc
30
6.0
4.0
22
120
56
200
130
91
180
83
58
110
40
240
190
310
180
160
210
18
15
22
64
280
71
620
190
90
330
50
23
86
110
620
280
1 100
410
340
490
1.5
1.0
31
460
400
520
260
210
310
1.1
0.6
22
23
180
72
330
140
120
160
9.3
7.4
11
44
390
200
630
500
410
600
330
270
18
110
51
200
86
71
100
13
10
15
63
33
100
67
54
81
35
28
42
11
82
43
130
78
73
83
30
28
32
55
290
130
500
180
140
220
14
11
18
11
70
37
110
77
59
96
46
36
58
11
6.1
12
2.4
9.0
2.1
1.6
11
390
4 370 719
820
680
980
9 700
8 300
11 000
7 100
6 800
7 500
890
810
970
AFR
857 382
220
180
270
2 500
2 100
3 000
2 300
2 100
2 400
870
800
950
AMR
943 019
21
18
24
330
250
420
260
240
280
37
34
40
EMR
608 628
99
61
150
1 000
660
1 500
660
590
740
EUR
899 500
45
44
46
500
370
650
380
350
400
23
20
25
SEAR
1 830 361
480
350
630
5 000
3 800
6 300
3 500
3 200
3 700
140
120
170
WPR
1 808 797
130
100
150
2 500
2 200
2 800
1 700
1 500
1 800
36
31
Global
6 947 687
990
840
1 100
12 000
10 000
13 000
8 700
8 300
9 000 1 100
8.7
7.6
1 000
9.9
42
1 200
Numbers for mortality, prevalence and incidence shown to two signicant gures. Totals (HBCs, regional and global) are computed prior to rounding.
Mortality excludes deaths among HIV-positive TB cases. Deaths among HIV-positive TB cases are classied as HIV deaths according to ICD-10.
Best, low and high indicate the point estimate and lower and upper bounds of the 95% uncertainty interval.
Estimates for India have not yet been ofcially approved by the Ministry of Health & Family Welfare, Government of India, and should therefore be considered provisional.
10
TABLE 2.2 Estimated burden of disease caused by TB, 2011. Rates per 100 000 population except where indicated.a
MORTALITYa
POPULATION
(THOUSANDS)
LOW
HIGH
32 358
39
16
71
351
169
597
189
156
225
0.5
0.3
0.7
Bangladesh
150 494
45
19
82
411
199
698
225
185
268
0.2
0.1
0.3
Brazil
196 655
China
DR Congo
Ethiopia
Indiac
Indonesia
Kenya
67 758
3.5
2.3
29
3.4
54
24
3.4
HIGH
BEST
LOW
HIGH
BEST
19
HIGH
46
18
87
42
35
50
690
954
424
364
489
5.1
4.8
104
91
119
75
66
85
1.2
0.9
96
512
263
842
327
282
375
15
13
17
17
17
18
3.6
20
LOW
817
111
20
5.3
1.7
84 734
18
14
24
237
191
288
258
191
335
1 241 492
24
15
35
249
168
346
181
163
199
4.2
3.3
5.2
242 326
27
12
48
281
130
489
187
155
222
3.3
2.5
4.2
41 610
22
11
36
291
152
475
288
276
300
39
39
40
63
63
64
23 930
47
17
91
490
235
837
548
380
747
Myanmar
48 337
48
22
84
506
390
637
381
326
439
Nigeria
162 471
17
40
171
44
382
118
56
204
Pakistan
176 745
33
15
60
350
158
618
231
190
276
3.7
9.9
26
0.4
8.8
25
11
26
0.3
0.5
0.6
94 852
29
26
33
484
425
546
270
223
322
0.4
0.3
142 836
16
15
16
124
50
229
97
82
114
6.7
5.7
South Africa
50 460
49
21
87
768
399
1 250
993
819
1 180
65
65
66
Thailand
69 519
14
6.1
25
161
73
282
124
102
147
15
14
15
Uganda
34 509
14
6.2
26
183
95
298
193
156
234
53
52
53
UR Tanzania
46 218
14
7.1
23
177
93
286
169
159
180
38
38
39
Viet Nam
88 792
33
14
62
323
148
563
199
153
250
Zimbabwe
12 754
47
19
88
547
287
889
603
466
757
60
59
60
4 370 719
19
15
22
222
190
255
163
155
171
13
11
14
AFR
857 382
26
21
31
293
243
347
262
242
283
39
37
41
AMR
943 019
35
26
44
28
26
29
14
11
17
170
108
246
109
97
122
1.5
0.9
2.1
56
41
73
42
39
45
6.1
4.4
8.0
271
206
344
189
176
203
4.1
3.3
5.0
138
123
154
92
84
100
2.2
1.4
3.1
170
150
192
125
120
130
Russian Federation
High-burden
countries
1 347 565
2.9
63
LOW
Mozambique
Philippines
14 305
BEST
HIV PREVALENCE IN INCIDENT

TB CASES (%)
INCIDENCE
Afghanistan
Cambodia
BEST b
PREVALENCE
EMR
608 628
EUR
899 500
SEAR
1 830 361
WPR
1 808 797
Global
6 947 687
2.2
16
5.0
26
6.9
14
1.9
10
4.9
19
5.7
12
2.5
24
5.1
34
8.3
17
8.0
13
7.8
12
7.7
8.2
14
Mortality excludes deaths among HIV-positive TB cases. Deaths among HIV-positive TB cases are classied as HIV deaths according to ICD-10.
Best, low and high indicate the point estimate and lower and upper bounds of the 95% uncertainty interval.
Estimates for India have not yet been ofcially approved by the Ministry of Health & Family Welfare, Government of India, and should therefore be considered provisional.
ed incident cases worldwide. Of the 8.7 million incident

cases, an estimated 0.5 million were children (Box 2.2)
and 2.9 million (range, 2.63.2 million) occurred among
women.
The ve countries with the largest number of incident
cases in 2011 were India (2.0 million2.5 million), China
(0.9 million1.1 million), South Africa (0.4 million0.6
million), Indonesia (0.4 million0.5 million) and Pakistan (0.3 million0.5 million). India and China alone
accounted for 26% and 12% of global cases, respectively.
Of the 8.7 million incident cases in 2011, 1.0 million1.2 million (1214%) were among people living
with HIV, with a best estimate of 1.1 million (13%) (Table
2.1). The proportion of TB cases coinfected with HIV was
highest in countries in the African Region (Figure 2.6);
overall, 39% of TB cases were estimated to be coinfected
with HIV in this region, which accounted for 79% of TB

cases among people living with HIV worldwide.
Globally, incidence rates were relatively stable from
1990 up to around 2001, and then started to fall (Figure 2.3). Between 2010 and 2011, the rate of decline was
2.2%; if this trend is sustained, MDG Target 6.c will be
achieved. The absolute number of incident cases is also
falling, albeit slowly (Figure 2.4), as the decline in the
incidence rate (per 100 000 population) exceeds the rate
of growth in the worlds population.
Incidence rates are declining in all of WHOs six regions
(Figure 2.7). The rate of decline between 2010 and 2011
was 0.5% in the Eastern Mediterranean Region, 2.0% in
the South-East Asia Region, 2.3% in the Western Pacic
Region, 3.1% in the African Region, 3.8% in the Region
of the Americas and 8.5% per year in the European
11
FIGURE 2.3
Global trends in estimated rates of TB incidence, prevalence and mortality. Left: Global trends in estimated
incidence rate including HIV-positive TB (green) and estimated incidence rate of HIV-positive TB (red). Centre and
right: Trends in estimated TB prevalence and mortality rates 19902011 and forecast TB prevalence and mortality rates
20122015. The horizontal dashed lines represent the Stop TB Partnership targets of a 50% reduction in prevalence and
mortality rates by 2015 compared with 1990. Shaded areas represent uncertainty bands. Mortality excludes TB deaths
among HIV-positive people.
Incidence
Prevalence
200
Mortality
300
30
250
25
200
20
150
15
100
10
50
Rate per 100 000 population
150
100
50
0
1990
FIGURE 2.4
1995
2000
2005
2011
0
1990
1995
2000
2005
2010
2015
1990
1995
2000
2005
2010
2015
Estimated absolute numbers of TB cases and deaths (in millions), 19902011
TB incidence
TB deaths
2.0
All TB cases
8
1.5
Millions
Millions
TB deaths among
HIV-negative people
1.0
0.5
HIV-associated
TB deathsa
HIV-positive TB cases
0
0
1990
a
1995
2000
2005
2011
1990
1995
2000
2005
2011
HIV-associated TB deaths are classied as HIV deaths according to ICD-10.
Region. Incidence rates have been falling since the mid1990s in the Eastern Mediterranean Region and since
around 2000 in South-East Asia; they peaked at the end
of the 1990s in the European Region and around 2002 in
Africa, and have been falling since 1990 in the Americas
and the Western Pacic Region. The latest assessment for
the 22 HBCs suggests that incidence rates are falling in
most countries (Figure 2.8).
2.2
Prevalence
The prevalence of TB can be directly measured in nationwide population-based surveys, and comprehensive
theoretical and practical guidance on how to design,
implement, analyse and report such surveys is available.1
12
When repeat surveys are conducted, trends in TB prevalence can be directly measured as well. The countries in
which surveys have been implemented or are planned in
the near future are shown in Figure 2.9.
If survey data are not available, prevalence can be indirectly estimated as the product of incidence and the average duration of disease, but with considerable uncertainty
(Annex 1). Although the data available from prevalence
surveys allow for a robust assessment of trends in the
Western Pacic Region (especially in Cambodia, China
and the Philippines) and are becoming more widely avail-
FIGURE 2.5
Estimated TB incidence rates, 2011
Estimated new
TB cases (all forms)
per 100 000 population
024
2549
50149
150299
300
No estimate
Not applicable
FIGURE 2.6
Estimated HIV prevalence in new TB cases, 2011
HIV prevalence
(%), all ages
04
519
2049
50
No estimate
Not applicable
13
BOX 2.2
The burden of TB disease among children
For many years, the prevention, diagnosis and treatment of TB among
children have been relatively neglected. Greatest attention has been
given to the detection and treatment of infectious cases, most of
which occur in adults. The Stop TB Strategy launched by WHO in
2006 includes case-nding in high-risk or vulnerable groups such
as children and prevention of TB in children who live in the same
household as newly detected TB cases. To help to address the burden
of TB in children (dened as those aged <15 years) and monitor
progress, robust data on childhood TB are necessary. This is the rst
WHO report on global TB care and control to include estimates of the
burden of TB disease among children, with best estimates of 490 000
cases and 64 000 deaths per year.1 The reasons why it remains
difcult to estimate the burden of TB disease in children, the methods
used to produce this rst set of estimates and the next steps needed
to improve them are discussed below.
Challenges in assessing the number of TB cases and

deaths among children
There is no easy-to-use and accurate diagnostic test for TB in
children. Most children have paucibacillary TB that is harder to
diagnose with sputum smear microscopy and culture. Many children,
especially younger children, are also not able to expectorate sputum.
Diagnosis is usually made using a combination of clinical (as
opposed to laboratory) criteria and a non-specic test for tuberculous
infection, but there is no universally applied diagnostic algorithm.
The denitive diagnosis of extrapulmonary TB requires specialised
services that are usually available only in referral hospitals, and thus
often not accessible to those in need. Besides diagnostic challenges,
children diagnosed with TB are not always reported to national
surveillance systems because of the lack of linkages among individual
paediatricians, paediatric hospitals and national TB programmes,
and data from national surveys including children are limited. Many
countries lack VR systems in which deaths from TB are disaggregated
and reported by age.
Estimates of TB notifications and TB incidence in

children in 2011 methods and results
The global number of new TB case notications among children
(aged <15 years) is estimated at 327 000 in 2011 (Table B2.2.1).
This includes cases reported among children and an estimate of the
number of cases among children in countries that did not report
notications disaggregated by age. For countries that did not report
age-disaggregated data (Figure B2.2.1), it was assumed that
the child:adult ratio among notied cases was the same (for each
case type) as the ratio in countries that did report notications
disaggregated by age (an alternative method using the assumption
that the child:adult ratio of notication rates was the same gave
similar results). WHO does not request age-disaggregated data for

relapse cases or those reported as of unknown treatment history; the
number of children in these categories was assumed to be zero.
To estimate TB incidence among children, it was assumed that the
ratio of notied to incident cases at the global level in 2011 (best
estimate 66%, range 64%69%) was the same for adults and
children. On this basis, TB incidence among children was estimated at
490 000 (range, 470 000510 000) in 2011, equivalent to about 6%
of the total number of 8.7 million incident cases.
Limitations of the methods used include:
The assumption that the ratio of notied to incident cases is the
same for adults and children, in the absence of any data on levels
of under-reporting of diagnosed cases for children and adults
separately;
The assumption that reported cases were true cases of TB.
Misdiagnosis is possible, especially given the difculties of
diagnosing TB in children; and
The proportion of cases among children may be different in
countries for which age-disaggregated data are not available.
Estimates of TB mortality in children in 2011

methods and results
Mortality data disaggregated by age from VR systems that have
been reported to WHO were analysed. TB death rates per 100 000
population were calculated for children and adults, after adjustment
for incomplete coverage and ill-dened causes (see Annex 1
for further details). For countries without VR data, an ecological
statistical model was used to predict the ratio of childhood to adult
TB mortality rates. The model included a set of risk factors known
to be associated with TB mortality (for example, GDP per capita,
the percentage of new cases with MDR-TB, HIV prevalence in the
general population and the treatment success rate). The total number
of deaths from TB among HIV-negative children was estimated at
64 000 (range, 58 00071 000) in 2011, equivalent to 6% of the
990 000 TB deaths among HIV-negative TB cases in 2011. The main
limitation in the methods is that the countries reporting usable VR
data were all middle or high-income countries. Predictions for lowincome countries had to be extrapolated from these countries.
Besides the direct impact of TB on children themselves, parental
deaths from TB have created large numbers of orphans. In 2009,
there were almost 10 million children who were orphans as a
consequence of losing at least one of their parents to TB.
Estimates of TB prevalence in children
Data on the prevalence of TB in children are limited to a few

nationwide surveys conducted before 2001.
Examples include a survey in India in 1956,
TABLE B2.2.1 Reporting of TB case notications disaggregated by age, 2011
and surveys in China in 1980, 1990, and
2000. The 2007 survey in the Philippines
SMEAR-POSITIVE
SMEAR-NEGATIVE
EXTRAPULMONARY
included children aged 1014 years. These
Total notications
2 621 049
1 872 745
813 636
surveys consistently found a low burden of
Countries disaggregating by age
2 601 032
1 582 235
684 233
bacteriologically-conrmed TB in children
Countries not disaggregating by age
20 017
290 510
129 403
compared with adults.
(% total notications disaggregated)
(99%)
(84%)
(84%)
a
Number of countries that reported notications

disaggregated by age (number of HBCs) b
Total estimated childhood notications
a
b
197 (22)
171 (15)
171 (15)
327 000
This includes reported cases for whom smear results were unknown or smears were not done.
An additional 9 countries reported zero TB cases in 2011 and two countries had not reported data to WHO
by July 2012.
14
There has been impressive progress in the

implementation of nationwide prevalence
surveys to measure bacteriologically-conrmed
TB since 2008 (see Section 2.5.2). These
surveys are focusing on adults (aged 15
years) and the typical sample size is 50 000
WHO REPORT 2012
GLOBAL TUBERCULOSIS CONTROL
FIGURE B2.2.1
Reporting of notication data disaggregated by age, 2011
Age disaggregation
All case types disaggregated
Only smear-positive cases disaggregated
No age disaggregation
Not applicable
70 000 people. The screening strategy includes chest X-rays and

a symptom-based questionnaire for the entire survey population,
followed by collection of sputum samples from all those with TB signs
and symptoms for subsequent smear and culture examination.
After careful weighing of the advantages and disadvantages by
WHOs Global Task Force on TB Impact Measurement (see Section
2.5), the inclusion of children in national prevalence surveys has not
been recommended. Major reasons are:
Inclusion of children in a survey would not lead to a precise
estimate of TB prevalence among children, since only a few
bacteriologically-conrmed cases would be found. Even existing
surveys of adults are not able to provide precise estimates for
different age groups.
There are ethical considerations associated with the mass
screening of all children, most of whom are healthy. While
evidence exists that chest X-ray screening is safe for adults, similar
evidence does not exist for children. Furthermore, there is no
simple and reliable tool that could be used to restrict the number
of children screened by X-ray: for example, there is no reliable test
for tuberculous infection.
Among adults, use of broad criteria for considering an X-ray
abnormal is encouraged to minimize the number of cases
that are missed during screening. Among children, use of tests
for tuberculous infection and broad criteria for considering an
X-ray abnormal would lead to unnecessary efforts to obtain
specimens, which among young children requires invasive and
uncomfortable gastric aspiration.
Referral hospitals are needed for the follow-up and diagnostic
conrmation of TB in children. These are often not available in the
rural areas that account for a large share of the clusters included
in national prevalence surveys.
WHO REPORT 2012
Inclusion of children would approximately double the sample size

and associated costs. The additional logistical complications of
including children could also jeopardise the survey as a whole.
Next steps to improve existing estimates of TB cases

and deaths among children
Next steps to improve the measurement and estimation of TB
incidence among children include:
Systematic literature reviews of existing data on incident
childhood TB, under-reporting of TB in children and misdiagnosis;
A global consultation to further develop analytical methods and
to dene and prioritize actions needed to obtain new data;
Promotion of case-based electronic recording and reporting
systems that would facilitate compilation and analysis of agedisaggregated data (among other advantages see Section
2.5.1); and
Nationwide inventory surveys to measure under-reporting of
childhood TB.
More contact-tracing and the integration of TB activities in maternal,
newborn and child health services would also help to nd children
with TB that might otherwise not be diagnosed.
To improve estimates of TB mortality among children, the main
actions required are:
Collection of age-specic data from sample VR systems and
mortality surveys in high-burden countries including China, India
and Indonesia;
Advocacy for further development of and continued investment in
VR systems.
1
This estimate is for TB deaths among HIV-negative children. TB deaths

among HIV-positive children are classied as HIV deaths in ICD-10.
15
FIGURE 2.7
Estimated TB incidence rates by WHO region, 19902011. Regional trends in estimated TB incidence rates (green)
and estimated incidence rates of HIV-positive TB (red). Shaded areas represent uncertainty bands.
Africa
The Americas
Eastern Mediterranean
80
400
150
60
300
Rate per 100 000 population per year
100
200
40
100
20
Europe
50
SouthEast Asia
Western Pacific
250
80
200
200
150
60
150
100
40
100
20
50
50
0
1990
1995
2000
2005
2011
1990
1995
able for countries with a high burden of TB (see Section

2.5.2), TB prevalence can be estimated only indirectly in
most countries.
There were an estimated 12 million prevalent cases
(range, 10 million13 million) of TB in 2011 (Table 2.1),
equivalent to 170 cases per 100 000 population (Table 2.2).
The prevalence rate has fallen by 36% globally since 1990.
Current forecasts suggest that the Stop TB Partnerships target of halving TB prevalence by 2015 compared
with a baseline of 1990 will not be met worldwide (Figure
2.3). Regionally, prevalence rates are declining in all of
WHOs six regions (Figure 2.10). The Region of the Americas halved the 1990 level of TB prevalence by around
2005, well in advance of the target year of 2015, and
the Western Pacic Region is close to doing so. Achieving the 50% reduction target by 2015 appears feasible in
the European and South-East Asia regions, but not in the
African and Eastern Mediterranean regions.
16
2000
2.3
2005
2011
1990
1995
2000
2005
2011
Mortality
Mortality caused by TB can be directly measured if a

national VR system of high coverage with accurate coding of causes of death according to the latest revision of
the international classication of diseases (ICD-10) is in
place. Sample VR systems can provide an interim solution, and mortality surveys can sometimes be used to
obtain direct measurements of TB deaths in countries
with no VR system. In the absence of VR systems or
mortality surveys, TB mortality can be estimated as the
product of TB incidence and the case fatality rate, or from
ecological modelling based on mortality data from countries with VR systems.
Until 2008, WHO estimates of TB mortality used VR
data for only three countries. This was substantially
improved to 89 countries in 2009, although most of these
countries were in the European Region and the Region of
the Americas, which account for only 8% of the worlds
TB cases. The use of sample VR data from China and survey data from India for the rst time in 2011 enabled a
further major improvement to estimates of TB mortal-
FIGURE 2.8
Estimated TB incidence rates, 22 high-burden countries, 19902011. Trends in estimated TB incidence rates
(green) and estimated incidence rates of HIV-positive TB (red). Shaded areas represent uncertainty bands.
Afghanistan
Bangladesh
Brazil
Cambodia
300
300
200
100
Ethiopia
150
400
100
200
50
Indiaa
250
200
200
400
150
150
100
200
100
100
50
50
Myanmar
Mozambique
600
1000
500
800
400
600
300
400
200
200
100
Nigeria
1000
100
Philippines
300
400
200
200
100
200
Thailand
Uganda
UR Tanzania
1200
300
200
1000
250
150
800
200
600
150
400
100
50
200
50
0
1990 1995 2000 2005
Zimbabwe
Viet Nam
100
600
100
500
50
200
400
250
150
300
Pakistan
600
South Africa
Russian Federation
400
250
200
1200
Kenya
300
600
300
Indonesia
800
400
600
DR Congo
200
50
100
100
200
China
800
2011
0
1990 1995 2000 2005
2011
1990 1995 2000 2005
2011
300
250
1000
200
800
150
600
100
400
50
200
0
1990 1995 2000 2005
2011
1990 1995 2000 2005
2011
Estimates for India have not yet been ofcially approved by the Ministry of Health & Family
Welfare, Government of India and should therefore be considered provisional.
ity, with direct measurements available for 91 countries

in 2010. The estimates of TB mortality presented in this
report are based on even more VR data. Use of VR data
for 119 countries and survey data from India mean that
direct measurements of TB mortality were used for 120
countries (shown in Figure 2.11) that collectively account
for 46% of the estimated number of TB deaths globally.
VR data are most limited in the African Region and parts
of the South-East Asia Region. A current example of a
country that is building a sample VR system is Indonesia
(Box 2.3).
The best estimate of the number of TB deaths worldwide fell just below 1 million among HIV-negative people
in 2011 (TB deaths among HIV-positive people are classied as AIDS deaths in ICD-10).1 The best estimate for
2011 is 990 000 deaths (Table 2.1), with an uncertainty
interval of 0.84 million1.1 million. This was equivalent
to 14 deaths per 100 000 population. There were also an
additional 0.43 million HIV-associated deaths (range,
0.40 million0.46 million) i.e. deaths from TB among
people who were HIV-positive (data not shown). Thus a
total of approximately 1.4 million people (range, 1.3 million1.6 million) died of TB in 2011, of whom 0.5 million
were women (Box 2.4).
The number of TB deaths per 100 000 population
among HIV-negative people plus the estimated number
of TB deaths among HIV-positive people equates to a best
estimate of 20 deaths per 100 000 population in 2011.
Globally, mortality rates (excluding deaths among
HIV-positive people)2 have fallen by 41% since 1990;
the current forecast suggests that the Stop TB Partnerships target of a 50% reduction by 2015 compared with
a baseline of 1990 will be achieved (Figure 2.3). Mortality rates are also declining in all of WHOs six regions
(Figure 2.12). The 2015 target has already been surpassed
in the Region of the Americas and the Western Pacic
1
International statistical classi cation of diseases and related health

problems, 10th revision (ICD-10), 2nd ed. Geneva, World Health
Organization, 2007.
Trends in TB mortality rates are restricted to TB deaths among
HIV-negative people, given that TB deaths among HIV-positive people are classied as HIV deaths in ICD-10.
17
FIGURE 2.9
Countries in which surveys of the prevalence of TB disease have been implemented since 1990
or are planned in the near future
Prevalence survey
No survey planned
Subnational survey
completed
National survey
ongoing or
planned
One national survey
completed
Repeat national survey
planned
1 repeat national survey completed
Not applicable
FIGURE 2.10 Trends in estimated TB prevalence rates 19902011 and forecast TB prevalence rates 20122015, by WHO
region. Shaded areas represent uncertainty bands. The horizontal dashed lines represent the Stop TB Partnership target of
a 50% reduction in the prevalence rate by 2015 compared with 1990. The other dashed lines show projections up to 2015.
Africa
The Americas
600
400
500
100
400
300
300
200
50
200
100
100
0
Europe
South-East Asia
150
100
50
Western Pacific
600
300
500
250
400
200
300
150
200
100
100
50
0
0
1990
18
1995
2000
2005
2010
2015
1990
1995
2000
2005
2010
2015
1990
1995
2000
2005
2010
2015
FIGURE 2.11 Countries (in blue) for which TB mortality is estimated directly using measurements from vital registration
systems and/or mortality surveys
Region, and may have been reached in the Eastern Mediterranean Region. Among the other three regions, the
South-East Asia Region appears best placed to achieve
the target.
In 2012, considerably more VR data (dating back to
1990) became available to estimate TB mortality in European countries with a high burden of TB. The use of these
data means that the regional trend for the European
Region has been updated; it indicates a sharp rise until
about 1998, followed by a sharp fall back to 1990 levels
by 2011. This pattern is consistent across most individual
countries (Figure 2.13), and corresponds to the economic, social and political disruption following the breakup
of the former Soviet Union, and subsequent rebuilding
and economic development. The striking relationship
between TB mortality rates and national income per capita in Latvia is shown in Figure 2.14.
Among the 22 HBCs, mortality rates appear to be falling in most countries (Figure 2.15).
2.4
Multidrug-resistant tuberculosis
This report, as in 2011, focuses on estimates of the number of prevalent cases of MDR-TB. The reasons are that
MDR-TB is a chronic disease and without appropriate
diagnosis and treatment for most of these cases many
more prevalent cases than incident cases are expected;
calculations of the number of prevalent cases of MDR-TB
are more readily understood compared with the complex
BOX 2.3
Building a sample vital registration
system in Indonesia
With support from AusAID and technical assistance from
University of Queensland, the Indonesian National Institute
of Health Research and Development (NIHRD) piloted a
sample vital registration system in selected sites (Central
Java, Lampung, West Kalimantan, Gorontalo and Papua)
covering 2.5 million population from 2006 to 2008. The pilot
was named the Indonesian Mortality Registration System
Strengthening Project (IMRSSP). The IMRSSP tested the verbal
autopsy questionnaires, eld implementation, and procedures
and standards for calibration of causes of deaths. Results
from the IMRSSP demonstrated that the measurement of
cause-specic mortality is feasible by strengthening the death
registration system in Indonesia. The cost was approximately
US$ 0.51 per capita per year (in the areas covered by the
system). After the pilot, the local Indonesian authorities
continued to implement vital registration in the same sites
with their own funding; data quality has yet to be assessed.
With support from a Global Fund round 10 grant on health
system strengthening, a sample vital registration system is
now being introduced. The NIHRD randomly selected 128
sub-districts across the country, covering a population of about
5 million (2% of the countrys total). The 128 sub-districts do
not include any of the IMRSSP pilot sites. By June 2013, all
selected sub-districts will start to collect data on mortality,
with preliminary results expected by December 2013. An
analysis of the cost of implementing a sample vital registration
system with resources that ensure data quality is planned.
19
BOX 2.4
TB mortality among women
This is the rst WHO report on global TB care and control to include estimates of the number of TB deaths among women1 that include
HIV-associated TB deaths (classied as HIV deaths in ICD-10) as well as TB deaths among HIV-negative people. In total, there were an
estimated 0.5 million TB deaths among women. This includes 300 000 (range, 250 000350 000) TB deaths among HIV-negative women
(30% of all TB deaths among HIV-negative people) and 200 000 (range, 185 000215 000) HIV-associated TB deaths (Table 2.4.1).
TB is one of the top killers of women worldwide.
Although globally the numbers of HIV-associated TB deaths were similar among men and women, there were regional variations
(Figure B2.4.1). In the African Region, more deaths occurred among women than men, while in other regions more deaths were estimated
to occur among men. The male:female ratio of HIV-associated TB deaths ranged from 0.83 in the African Region to 3.1 in the Western
Pacic Region.
TABLE B2.4.1
Number of HIV-associated TB deaths among women
in 2011, by WHO region
FIGURE B2.4.1
The male:female ratio for HIV-associated TB deaths
among adults (aged 15 years), globally and for
WHO regions
ESTIMATED NUMBER OF DEATHS

WHO REGION
BEST ESTIMATE
AFR
169 000
155 000184 000
3 130
2 7103 580
AMR
UNCERTAINTY INTERVAL
EMR
1 290
1 1001 500
EUR
2 960
2 4903 460
SEAR
19 800
16 00024 000
WPR
3 680
2 8104 660
200 000
185 000215 000
Global
AFR
AMR
EMR
EUR
SEAR
WPR
Global
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Sex ratio (M:F)

1
Dened as females aged 15 years.
calculations needed to estimate the incidence of MDR-TB;

and the number of prevalent cases of MDR-TB directly
inuences the active transmission of strains of MDR-TB.
The number of prevalent cases of MDR-TB can be estimated as the product of the estimated number of prevalent cases of TB and the best estimate of the proportion
of notied TB patients1 with MDR-TB (and in China a
direct measurement is available from the 2010 national
TB prevalence survey). Globally in 2011, there were an
estimated 630 000 cases of MDR-TB (range, 460 000
1
This includes new and retreatment cases (see Chapter 3 for

de nitions).
Class A continuous surveillance refers to data from ongoing
surveillance of drug resistance that are representative of the
caseload of patients.
Guidelines for the surveillance of drug resistance in tuberculosis, 4th
ed. Geneva, World Health Organization, 2010 (WHO/HTM/
TB/2009.422).
For further details, see Box 2.6 in the 2011 WHO report on
global TB control.
20
790 000) among the worlds 12 million prevalent cases of

TB. Estimates at country level are not presented for reasons explained in Annex 1. However, estimates of the proportion of new and retreatment cases that have MDR-TB
are summarized in Table 2.3.
A recurring and important question is whether the
number of MDR-TB cases is increasing, decreasing or stable. A reliable assessment of trends in MDR-TB requires
data from Class A continuous surveillance2 or data from
periodic surveys of drug resistance that are designed,
implemented and analysed according to WHO guidelines.3 There has been substantial progress in the coverage
of continuous surveillance and surveys of drug resistance
(Figure 2.16). Unfortunately, progress is not yet sufcient
to provide a de nitive assessment of trends in MDR-TB
globally or regionally.4
FIGURE 2.12 Trends in estimated TB mortality rates 19902011 and forecast TB mortality rates 20122015, by WHO
region. Estimated TB mortality excludes TB deaths among HIV-positive people. Shaded areas represent uncertainty
bands.a The horizontal dashed lines represent the Stop TB Partnership target of a 50% reduction in the mortality rate by
2015 compared with 1990. The other dashed lines show projections up to 2015.
Africa
The Americas
60
60
50
6
40
40
4
20
20
30
2
10
0
Europe
South-East Asia
25
Western Pacific
60
20
6
40
15
10
20
5
0
0
1990
a
1995
2000
2005
2010
2015
0
1990
1995
2000
2005
2010
2015
1990
1995
2000
2005
2010
2015
The width of an uncertainty band narrows as the proportion of regional mortality estimated using vital registration data increases or the quality and completeness of the
vital registration data improves.
2.5
Strengthening measurement of the

burden of disease caused by TB: the
WHO Global Task Force on TB Impact
Measurement
The estimates of TB incidence, prevalence and mortality

and their trend presented in sections 2.12.4 are based on
the best available data and analytical methods. In 2009,
methods were fully revised, and since April 2009 consultations have been held with 96 countries accounting for
89% of the worlds TB cases. Nonetheless, there is considerable scope for further improvement. This nal section of the chapter describes the latest status of efforts to
improve measurement of the burden of disease caused by
TB, under the umbrella of the WHO Global Task Force on
TB Impact Measurement.
Established in mid-2006, the mandate of the WHO
Global Task Force on TB Impact Measurement is to ensure
the best possible assessment of whether the 2015 global
targets for reductions in the burden of disease caused by
TB are achieved, to report on progress in the years leading
up to 2015 and to strengthen capacity for monitoring and
evaluation at the country level. The Task Force includes
representatives from leading technical and nancial partners and countries with a high burden of TB.1
At its second meeting in December 2007, the Task
Force de ned three strategic areas of work:2
strengthening surveillance towards the ultimate goal

of direct measurement of incidence and mortality from
notication and VR systems;
conducting surveys of the prevalence of TB disease in
a set of global focus countries that met epidemiological
and other relevant criteria; and
periodic revision of the methods used to translate surveillance and survey data into estimates of TB incidence, prevalence and mortality.
The third area of work is discussed in more detail in

Annex 1. The following sections focus on the rst two
strategic areas of work. Full details of the Task Forces
work are available on its web site.3
1
Partners that are actively participating in the work of the Task

Force include the Centers for Disease Control and Prevention
in the USA, the European Centre for Disease Prevention and
Control, the Global Fund, the Health Protection Agency in the
UK, the KNCV Tuberculosis Foundation, the London School
of Hygiene and Tropical Medicine in the UK, the Research
Institute for Tuberculosis in Japan, the Union and USAID.
Many countries with a high burden of TB are engaged in the
work of the Task Force.
TB impact measurement: policy and recommendations for how to
assess the epidemiological burden of TB and the impact of TB control. Geneva, World Health Organization, 2009 (Stop TB policy
paper no. 2; WHO/HTM/TB/2009.416).
www.who.int/tb/advisory_bodies/impact_
measurement_taskforce
21
FIGURE 2.13 Trends in TB mortality rates in Eastern European countries, 19902011. The solid orange line shows the best
estimate of the TB mortality rate and the orange band represents the uncertainty related to this estimate.a Uncertainty
is due to adjustments made to the mortality data from vital registration systems that were reported by countries (the
reported data are represented by the x symbol). Reported data were adjusted to account for incomplete coverage (deaths
with no reported cause) and ill-dened causes, and the uncertainty range does not account for miscoding of causes of
deaths (such as HIV deaths miscoded as TB deaths); further explanation of methods is provided in Annex 1.
Azerbaijan
Armenia
25
10
6
4
15
10
5
4
3
Kazakhstan
Georgia
9
8
7
6
5
4
3
TB mortality rate per 100 000 population per year
10
20
30
20
10
10
15
10
6
4
12
20
10
15
10
Turkmenistan
15
10
5
1990
1995
2000
2005
2011
10
Uzbekistan
Ukraine
40
35
30
25
20
15
10
20
Russian Federation
Romania
15
Tajikistan
12
20
Republic of Moldova
Lithuania
13
12
11
10
9
8
7
Latvia
Kyrgyzstan
25
40
25
Bulgaria
Belarus
25
20
20
15
15
10
10
1990
1995
2000
2005
1990
2011
1995
2000
2005
2011
1990
1995
2000
2005
2011
The width of an uncertainty band narrows as the quality and completeness of the vital registration data improves.
2.5.1 Strengthening surveillance
TB mortality rate per 100 000 population per year
FIGURE 2.14 Changes in TB mortality and gross national

income (GNI) per capita in Latvia, 1990
2011. The vertical dashed line shows the GNI per
capita in 1990, prior to the economic crisis. The
economy shrank during the early 1990s and the
level of 1990 was only recovered in 1999.
1997 1998
1996
12
1999
1995
2000
2001
1994
10
2002
1993
2003
1992
2004
2005
2006
1991
2007
2008
1990
2010
6000
8000
10000
12000
GNI per capita (US$)
14000
16000
2009
In 2008, the Task Force de ned a conceptual framework to assess surveillance data as a basis for updating
estimates of the burden of disease caused by TB and for
de ning recommendations for how surveillance needs to
be improved to reach the ultimate goal of direct measurement of TB cases and deaths from notication and VR
data (Figure 2.2). Tools to implement the framework were
also developed, and used in the 96 country consultations
illustrated in Figure 2.1. Major challenges in current estimates of TB incidence include reliance on expert opinion about the number of cases that are diagnosed but not
reported to national surveillance systems and the number
of cases that are not diagnosed at all. Major challenges in
estimating TB mortality include the lack of VR systems of
sufcient coverage and quality in many countries, notably in Africa and parts of Asia (Figure 2.11).
Since 2011, the Task Forces three priorities have been:
22
developing and applying standards and benchmarks

for TB surveillance;
preparing a guide on inventory studies to measure TB
under-reporting;
producing and widely disseminating a guide on electronic recording and reporting (ERR) for TB care and
control.
TABLE 2.3 Estimated proportion of TB cases that have

MDR-TB, 27 high MDR-TB burden countries and
WHO regions
These are discussed in more detail below.

ESTIMATED
% OF NEW TB
CASES WITH
MDR-TBa
Standards and benchmarks for TB surveillance

The long-term goal is direct measurement of the burden
of disease caused by TB from routine surveillance data,
using notication data to measure TB incidence and
VR data to measure TB mortality. Achieving this goal
requires strengthened surveillance in most countries.
While the need to strengthen surveillance is difcult to dispute in many countries, putting it into practice
requires a clear understanding of what a model surveillance system should look like and a method for assessing
the current performance of TB surveillance. An assessment of the performance of TB surveillance could then
be used to identify which countries have surveillance
systems that already provide an accurate measure of the
number of TB cases and deaths that occur each year, and
to de ne the actions necessary to strengthen surveillance
in countries in which gaps are identied. Countries in
the former category could be certied or accredited as
having TB surveillance data that provide a direct measure
of TB incidence and/or mortality.
In 2011, the Task Forces subgroup on TB surveillance
began work on a TB surveillance checklist of standards
and benchmarks, the purpose of which is to:
Armenia
Azerbaijan
Bangladesh
Belarus
The standards are general statements about the characteristics that de ne a high-performance TB surveillance
system. For each standard, benchmarks de ne (in quantitative terms wherever possible) the level of performance
that is considered good enough to meet the standard.
A prototype checklist was developed in the rst half of
2011. Progress in piloting and re nement of the checklist accelerated after June 2011 mainly due to intensied
collaboration between WHO and the Centers for Disease
Control and Prevention in the United States of America
(USA). By mid-2012, three rounds of testing had been
completed with the checklist applied in Brazil, China,
Egypt, Estonia, Japan, Kenya, the Netherlands, Thailand, Uganda, the United Kingdom (UK) and the USA;
two global meetings to discuss ndings and re ne the
checklist had been held; and a close-to- nal version of
the checklist was available. The pre- nal version contains
9 standards related to measurement of TB cases and one
standard related to measurement of TB deaths. For standards related to measurement of TB cases, one is specic
to paper-based systems with aggregated data and one
is specic to electronic case-based systems. For a coun-
3849
5260
0.72.5
29
2434
3035
76
7279
26
1933
China
5.7
4.67.1
26
2230
3.1
0.17.1
10
2.118
1729
58
4371
0.92.7
12
5.621
9.612
32
2835
Georgia
23
1.6
11
India
2.1
1.52.7
15
1317
Indonesia
1.9
1.42.5
12
8.117
Kazakhstan
30
2932
51
5053
Kyrgyzstan
26
2331
52
4558
Latvia
13
1016
29
2040
Lithuania
11
9.213
49
4454
Myanmar
4.2
3.15.6
10
6.914
Nigeriab
3.1
0.17.1
10
2.118
2.656
Pakistan
3.4
0.111
29
Philippines
4.0
2.95.5
21
1429
Republic of Moldova
19
1722
64
6067
Russian Federation
20
1822
46
4152
5.58.1
South Africa
43
55
1.13.2
Ethiopia
7.112
1926
2.0
Estonia
identify gaps in national surveillance systems that

need to be addressed.
1.4
32
CONFIDENCE
INTERVAL
Bulgaria
DR Congo
assess a national surveillance systems ability to accurately measure TB cases and deaths; and
9.4
22
CONFIDENCE
INTERVAL
ESTIMATED
% OF
PREVIOUSLY
TREATED
TB CASES
WITH MDR-TBa
1.42.3
6.7
Tajikistan
13
1.8
9.816
54
4859
Ukraine
16
1418
44
4049
Uzbekistan
23
1830
62
5371
Viet Nam
2.7
23.6
19
1425
High MDR-TB
burden countries
4.3
2.16.4
21
1230
3.418
AFR
2.9
0.16.2
11
AMR
2.0
0.83.3
11
4.518
EMR
3.4
0.110
30
6.953
EUR
15.1
1020
44
4049
SEAR
2.1
1.82.5
16
1219
WPR
4.8
3.46.1
22
1826
Global
3.7
2.15.2
20
1326
Best estimates are for the latest available year. Estimates in italics are based on
regional data.
Direct measurements will be available shortly and are expected to be consistent
with the estimates provided in the table.
23
FIGURE 2.15 Trends in estimated TB mortality rates 19902011 and forecast TB mortality rates 20122015, 22 highburden countries. Estimated TB mortality excludes TB deaths among HIV-positive people. Shaded areas represent
uncertainty bands. The horizontal dashed lines represent the Stop TB Partnership target of a 50% reduction in the
mortality rate by 2015 compared with 1990. The other dashed lines show projections up to 2015.
Afghanistan
Bangladesh
120
100
100
80
80
60
40
20
20
DR Congo
Indiaa
120
60
20
40
10
20
Nigeria
150
40
30
20
10
0
Pakistan
Philippines
60
200
200
100
150
100
40
150
100
100
50
50
20
50
50
0
Russian Federation
20
15
10
5
0
South Africa
60
100
50
80
40
60
30
40
20
20
10
100
Zimbabwe
Uganda
UR Tanzania
60
80
40
60
40
20
20
Viet Nam
Thailand
Kenya
50
80
30
Myanmar
Indonesia
100
40
20
250
10
100
50
40
Mozambique
15
150
50
Ethiopia
China
20
200
60
Cambodia
250
100
50
300
60
40
Brazil
6
0
1990 1995 2000 2005 2010 2015
0
1990 1995 2000 2005 2010 2015
1990 1995 2000 2005 2010 2015
100
80
80
60
60
40
40
20
20
0
1990 1995 2000 2005 2010 2015
1990 1995 2000 2005 2010 2015
Estimates for India have not yet been ofcially approved by the Ministry of Health & Family
Welfare, Government of India and should therefore be considered provisional.
trys TB surveillance system to be certied as providing a

direct measurement of TB cases, all of the standards need
to be met. For a countrys surveillance system to provide
a direct measure of TB deaths, both of the two benchmarks (which are related to geographical coverage and
data quality) must be met.
The checklist also includes a supplementary list of
three standards and associated benchmarks that can be
used to assess whether TB surveillance data provide a
direct measure of the number of cases of MDR-TB, the
number of HIV-positive cases of TB and TB in children
specically.
The TB surveillance checklist was discussed at meetings of the Technical Evaluation Reference Group (TERG)
of the Global Fund and the WHO Global Task Force on TB
Impact Measurement held in May 2012. There was consensus that use of the checklist should be integrated within the grant processes of the Global Fund, with results
from the systematic assessments of existing TB surveillance using the checklist then used to develop an investment plan to strengthen surveillance. With more than
24
100 low-income and middle-income countries receiving

grants for TB care and control from the Global Fund, this
approach has great potential to make a real difference to
TB surveillance worldwide. As of July 2012, the aim was
to apply the checklist in three countries before the end
of 2012, and in approximately 15 countries by mid-2014.
Inventory studies to measure TB under-reporting

Inventory studies with record-linkage are used to quantify the number of TB cases that are diagnosed but not
recorded in surveillance (notication) data. They allow
a much better estimation of TB incidence because they
provide concrete evidence of the gap between notied cases and diagnosed cases (which may be especially big in countries with a large private sector). One
of the standards in the TB surveillance checklist is that
underreporting of diagnosed TB cases is minimal, with a
benchmark that in a national investigation less than 10%
of diagnosed cases are missed by TB surveillance. Inventory studies are needed to provide evidence of the level of
under-reporting; if reporting is below acceptable levels,
FIGURE 2.16 Progress in global coverage of data on drug resistance, 19942011
Year of most recent

representative data
on anti-TB drug
surveillance
19951999
20002004
20052009
20102011
Ongoing 2012
No data
Subnational data only
Not applicable
corrective actions need to be identied and implemented.

Inventory studies have been implemented in very few
countries to date. Examples include the UK, the Netherlands and several countries in the Eastern Mediterranean
Region (Egypt, Iraq, Yemen and, most recently, Pakistan).
To facilitate and encourage inventory studies in more
countries, WHO and its partners (notably the Centers for
Disease Control and Prevention in the USA and the UKs
Health Protection Agency) initiated the development of a
guide on how to design, implement, analyse and report
on inventory studies in 2011. As this report went to press,
the guide was due to be published before the end of 2012.
Electronic recording and reporting of data

Assessment of various aspects of data quality is the rst
and most basic of the three major components of the
Task Forces framework for assessing surveillance data
(Figure 2.2) and several of the standards in the TB surveillance checklist are about data quality. In all of the
regional and country workshops held between 2009 and
2012, it was evident that it is much easier to assess the
quality of TB surveillance data in countries with casebased electronic recording and reporting. In 2011, WHO
and its partners produced a guide on electronic recording
and reporting for TB care and control, which was widely
disseminated in April 2012 (Box 2.5).
2.5.2 Surveys of the prevalence of TB disease

Nationwide population-based surveys of the prevalence
of TB disease provide a direct measurement of the number of TB cases; repeat surveys conducted several years
apart can allow direct measurement of trends in disease
burden. Surveys are most relevant in countries where the
burden of TB is high (otherwise sample sizes and associated costs and logistics become prohibitive) and surveillance systems are thought (or known) to miss a large
fraction of cases.
Before 2007, few countries had implemented prevalence surveys (Figure 2.9, Figure 2.17). In the 1990s,
national surveys were con ned to China, Myanmar, the
Philippines and the Republic of Korea. Before 2009 and
with the exception of Eritrea in 2005, the last national
surveys in the African Region were undertaken between
1957 and 1961. From 2002 to 2008, there was typically
one survey per year. In 2007, WHOs Global Task Force
on TB Impact Measurement identied 53 countries that
met epidemiological and other criteria for implementing a
survey. A set of 22 global focus countries were selected to
receive particular support in the years leading up to 2015.
Following ve years of substantial efforts by countries, supported by the Task Force (Box 2.6), enormous
progress has been achieved (Figure 2.17). If surveys are
implemented according to schedule, around 20 surveys
will be implemented during 20112013, with a major
peak in activity in 2012 and 2013. The number of surveys being implemented at the same time in 2012, at ve,
25
BOX 2.5
New guidance on electronic recording and reporting for TB care and control
Surveillance systems depend on countries keeping good records of all TB cases notied to national TB control programmes (NTPs) and of
TB treatment outcomes. This is a data-intensive activity that is increasingly moving away from paper-based to electronic recording and
reporting (ERR).
Advantages of ERR include:
Better management of individual patients, for example by providing fast access to laboratory results;
Better programme and resource management, by encouraging staff to use and act upon live data. This may help to prevent defaulting
from treatment and assist with management of drug supplies (including avoidance of stockouts);
Improved surveillance by making it easier for facilities not traditionally linked to the NTP, such
as hospitals, prisons and the private sector, to report TB cases, and by reducing the burden of
compiling and submitting data through paper-based quarterly reports;
Greater analysis and use of data, since data can be readily imported into statistical packages,
results are available to decision-makers more quickly and it is possible to detect outbreaks
promptly;
Higher quality data, since automated data quality checks can be used and duplicate or
misclassied notications can be identied and removed (which is very difcult or impossible to do
nationally with paper-based systems). It is also easier to introduce new data items.
WHO coordinated the development of a guide on how to design and implement ERR according to bestpractice standards in 2011. The guide was widely disseminated in April 2012 and is available at
www.who.int/tb/publications/electronic_recording_reporting
FIGURE 2.17 Global progress in implementing national surveys of the prevalence of TB disease, actual (20022012)
and expected (20132017)
11
Asia GFC
Africa GFC
Other
Sudan
10
DPR Korea
9
Nepal
Number of surveys
8
Mongolia
South Africa
Global focus
countries (GFC) selected by
WHO Global Task Force on
TB Impact Measurement
6
5
Zambia
4
3
2
1
0
26
Viet Nam
Rwanda
Kenya
Lao PDR
Thailand
Malawi
Pakistan
Nigeria
Uganda
Myanmar
Cambodia
Gambia
Ghana
Viet Nam
Philippines
Cambodia
Malaysia
Indonesia
Eritrea
Thailand
Philippines
Bangladesh
Myanmar
China
Ethiopia
UR Tanzania
Indonesia
Bangladesh
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
20142017
BOX 2.6
Efforts by the Task Force to support TB prevalence surveys and build AA collaboration
The WHO Global Task Force on TB Impact Measurement has strongly recommended national TB prevalence surveys in 22 global focus
countries: 13 in Africa and 9 in Asia. The African countries are Ethiopia, Ghana, Kenya, Malawi, Mali, Mozambique, Nigeria, Rwanda,
Sierra Leone, South Africa, Uganda, the United Republic of Tanzania and Zambia. The Asian countries are Bangladesh, Cambodia, China,
Indonesia, Myanmar, Pakistan, the Philippines, Thailand and Viet Nam.
Since 2008, the Task Force has made substantial efforts to support countries to design, implement, analyse and report on surveys. The
Task Force subgroup on TB prevalence surveys, led by WHO, has been very active and activities have included:
close collaboration with the Global Fund to help secure full funding for surveys through reprogramming of grants (several surveys were
initially under-budgeted);
workshops to develop protocols and expert reviews of protocols by at least two Task Force partners not directly involved in the survey;
production of a second edition of a WHO handbook on TB prevalence surveys (also known as the lime book), which provides
comprehensive theoretical and practical guidance on all aspects of surveys.1 The book was produced as a major collaborative effort
involving 15 agencies and institutions and 50 authors in 2010, and was widely disseminated in 2011;
training courses for survey coordinators without prior experience of survey implementation, including opportunities to observe eld
operations in ongoing surveys;
training courses to build a group of junior international consultants who can provide technical
assistance to countries;
country missions by experts from the Task Force, mostly funded by the US government through the
TB-TEAM mechanism (see Box 5.2 in Chapter 5).
The concept of AsiaAsia, AsiaAfrica and AfricaAfrica (AA) collaboration has been strongly
promoted. This involves building collaboration among countries implementing surveys such that survey
coordinators and other staff can learn from and help each other, with the result that capacity to
implement prevalence surveys is built at country, regional and global levels. Examples of AA collaboration
are survey coordinators from Asian countries providing guidance and support to those leading surveys
in African countries where no recent experience exists; survey staff from Ethiopia providing support to
African countries planning surveys in 2012 and 2013; exchange visits and study tours; workshops to
observe central and eld operations hosted by Cambodia and Thailand; and mid-term reviews in which
survey coordinators visit other countries where survey operations are underway.
Besides WHO, technical partners that are actively engaged in prevalence surveys include the Centers for Disease Control and Prevention,
USA; the KNCV Tuberculosis Foundation in the Netherlands; the London School of Hygiene and Tropical Medicine, UK; and the Research
Institute for Tuberculosis, Japan.
1
www.who.int/tb/advisory_bodies/impact_measurement_taskforce/resources_documents/thelimebook
is already unprecedented. As this report went to press,

surveys were nearing completion in the Gambia, Nigeria,
Rwanda, Thailand and the United Republic of Tanzania,
with results expected in the rst half of 2013.
In late 2011 and early 2012, results from surveys completed in Ethiopia (June 2011) and Cambodia (September
2011) were disseminated. The Ethiopian survey found a
lower prevalence of TB than was previously estimated,
with most cases in young adults. As this report went to
press, dissemination of results from surveys in the Lao
Peoples Democratic Republic and Pakistan was expected

by early 2013.
Cambodia is only the third high-burden country to
implement a repeat national prevalence survey in the
past 20 years (following China and the Philippines).
The results provide an excellent example of the value of
national TB prevalence surveys for measuring disease
burden, evaluating the impact of TB control and identifying ways to improve TB care and control in future
(Box 2.7).
27
BOX 2.7
Reducing the burden of TB disease: a success story from Cambodia
For the last two decades, Cambodia has been known to have one of the highest levels of TB burden (in terms of rates per 100 000
population) in the world. TB control in Cambodia was reinstated in 1994 following decades of civil conict and economic hardship. TB
services were rst limited to provincial and district hospitals. Decentralization of TB control services to the health centre level was initiated
in the early 2000s, with nationwide expansion achieved in 2005, contributing to rapidly increasing case notications (depicted with a
solid black line in Figure B2.7.1).
At the early stage of DOTS expansion to health centres, the National TB Programme decided to directly measure the burden of TB through
a nationwide prevalence survey, completed in 2002. A total of 22 160 people aged 15 years participated in the survey, grouped in 42
geographically determined clusters. The survey identied 81 smear-positive TB cases (63% were symptomatic) and 190 smear-negative
culture-positive cases. After adjustment for unconrmed TB and for
childhood TB, the prevalence rate for all forms of TB was estimated at
FIGURE B2.7.1
1511 (range 12441803) per 100 000 population, one of the highest
Case notication and estimated incidence rates in
prevalence rates observed in the world in recent history.
Cambodia, 19902011
A second nationally representative survey was conducted in 2011. In
total, 39 680 people aged 15 years were sampled from 62 clusters.
95 smear-positive TB cases (46% were symptomatic) and 218 smearnegative culture-positive TB cases were identied. After adjustment
for unconrmed TB and for childhood TB, the prevalence rate for all
forms of TB was estimated at 817 (range 690954) per 100 000
population, showing a statistically signicant reduction since the rst
survey.
700
Estimated incidence rate
600
500
400
300
Case notification rate
200
100
1990
1995
2000
2005
2010
FIGURE B2.7.2
Estimated TB prevalence (all forms) in Cambodia,
19902011
Survey 1
2000
1500
Survey 2
1000
50% reduction target
1990
28
1995
2000
2005
2010
Most bacteriologically-conrmed prevalent cases did not report

symptoms listed in the screening criteria. The proportion of people
reporting TB symptoms listed in the screening criteria among
bacteriologically-conrmed cases declined from 30% in 2002 to 22%
in 2011. This highlights the need to revise criteria for TB screening in
self-reporting patients, in favour of more sensitive criteria than the
traditional but insensitive criteria of a cough of 2weeks. There was
a signicant decline in prevalence rates for all age groups but the
biggest reduction was observed in younger age groups. The 2011
survey also highlighted the need for more sensitive diagnostics than
sputum smear microscopy.
The repeat survey provides robust evidence of a decline in TB
burden in Cambodia, following DOTS expansion in 2002 (Figure
B2.7.2). Results indicate a 45% reduction in the prevalence of
bacteriologically-conrmed cases since the rst national prevalence
survey conducted in 2002, that is, over a period of only 9 years.
The Cambodia results provide a major success story for TB control.
CHAPTER 3
TB case notifications
and treatment outcomes
In 2011, 6.2 million cases of TB were notied by
national TB control programmes and reported to WHO:
5.8 million were individuals newly diagnosed in 2011
and 0.4 million were previously diagnosed TB patients
whose treatment regimen was changed. India and China
accounted for 39% of notied cases of TB worldwide in
2011, Africa for 24% and the 22 HBCs for 81%.
In 2010, the treatment success rate was 85% among
all new TB cases and 87% among new cases of sputum
smear-positive pulmonary TB (the most infectious cases).
Improvement in treatment outcomes is needed in the
European Region, where the treatment success rate in
2010 was 74% and 67% for new cases and new smearpositive cases respectively.
The provision of diagnosis and treatment according
to the DOTS/Stop TB Strategy has resulted in major
achievements in TB care and control. Between 1995
and 2011, 51 million people were successfully treated
for TB in countries that had adopted the DOTS/Stop TB
Strategy, saving 20 million lives.
Notications of TB cases have stabilized in recent
years, and in 2011 represented 66% (range, 6469%)
of estimated incident cases. Major efforts are needed
to ensure that all cases are detected, notied to
national surveillance systems and treated according
to international standards, for example through PPM
initiatives.
In most of the 21 countries that reported data,
PPM initiatives contributed about 10-40% of total
notications.
In countries reporting age-disaggregated data, most
cases (88%) were aged 1564 years. Children (aged
<15 years) accounted for 6% of notied cases. The
male:female ratio was 1.7 globally, ranging from 1.1 to
2.2 among WHOs six regions.
Reporting of cases and treatment outcomes
disaggregated by age and sex needs to be improved in
some parts of the world, including several HBCs.
The total number of TB cases that occur each year can be

estimated globally and for regions and individual countries, but with uncertainty (as explained in Chapter 2).
This uncertainty reects the fact that national surveillance systems do not capture all cases in most countries.
Cases may be missed by routine notication systems
because people with TB do not seek care, seek care but
remain undiagnosed, or are diagnosed by public and private providers that do not report cases to local or national
authorities.
Routine recording and reporting of the numbers of TB
cases diagnosed and treated by national TB control programmes (NTPs) and monitoring the outcomes of treatment is one of the core elements of the Stop TB Strategy
(Chapter 1). The number of people diagnosed and treated
for TB and associated treatment outcomes are routinely
reported by NTPs in almost all countries; these data are
reported in turn to WHO in annual rounds of global TB
data collection. With increasing engagement by NTPs of
the full range of care providers, including those in the
private sector and those in the public sector not previously linked to NTP reporting systems, data are also better reecting the total number of diagnosed cases. The
number of TB cases that are not diagnosed is expected
to be low in countries with readily accessible and highquality health care.
This chapter has four parts. Section 3.1 summarizes the
total number of people diagnosed with TB and notied by
NTPs in 2011, including disaggregations by case type, age
and sex. Section 3.2 highlights the contribution to total
case notications of publicpublic and publicprivate mix
(PPM) initiatives. Section 3.3 presents trends in notications between 1990 and 2011 and compares these with
trends in estimated TB incidence. Estimates of the ratio
of notied:incident cases (an indicator known as the case
detection rate) are provided for selected years. Section 3.4
describes the latest data on treatment outcomes (for cases
registered for treatment in 2010) as well as treatment outcomes achieved in each year since 1995.
3.1
Case notifications in 2011 by type

of disease, age and sex
In 2011, 6.2 million people with TB were notied to NTPs

and reported to WHO. Of these, 5.8 million had a new
episode of TB (shown as the total of new and relapse cases
in Table 3.1). Of these 5.8 million cases, 5.5 million had
29
TABLE 3.1 TB case notications, 2011

NEW
TOTAL
NOTIFIED
SMEAR-POSITIVE
SMEARNEGATIVE
RETREATMENT
SMEAR NOT
DONE
EXTRAPULMONARY
CASE TYPE
UNKNOWN
RELAPSE
RETREATMENT
EXCL. RELAPSE
NEW AND
RELAPSE(A)
HISTORY
UNKNOWN
PERCENT
NEW PULMONARY CASES
SMEARPOSITIVE
Afghanistan
28 167
13 789
4 166
1 989
6 286
623
1 130
184
27 983
Bangladesh
159 023
98 948
21 921
27 329
2 701
4 665
150 899
3 459
82
Brazil
84 137
40 294
12 683
8 278
10 067
15
3 555
6 490
74 892
2 755
66
Cambodia
39 670
15 812
7 686
14 690
367
1 115
38 555
67
China
911 884
377 005
479 486
2 028
6 540
34 610
12 215
899 669
44
DR Congo
114 290
71 321
13 471
3 761
4 158
110 132
Ethiopia
159 017
49 594
52 967
1 515 872
642 321
340 203
Indonesia
321 308
197 797
101 750
Kenya
103 981
37 085
30 394
9 416
0
India
Mozambique
Myanmar
47 452
19 537
18 159
143 140
42 324
62 038
21 579
2 530
69
84
49 305
2 143
2 478
156 539
226 965
1 952
112 508
191 923
1 323 949
5 348
2 359
318 949
3 356
6 661
97 320
48
52
14 054
17 069
5 504
27 769
1 427
2 825
44 627
4 606
6 403
136 737
47
65
66
41
Nigeria
93 050
47 436
33 034
3 793
2 515
6 272
86 778
59
Pakistan
270 394
105 733
103 824
45 537
5 947
5 460
261 041
3 893
50
2 202
49
Philippines
202 033
90 876
95 297
Russian Federation
159 479
29 191
63 917
1 189
10 023
South Africa
389 974
129 770
70 341
77 925
47 285
67 676
33 169
20 726
10 014
Uganda
49 016
25 614
12 830
1 559
5 001
UR Tanzania
61 148
24 115
20 438
13 725
17 934
2 679
6 925
1 714
98 462
5 192
1 444
2 901
38 404
2 155 046 1 600 839 108 783 587 863
5 269
226 813
348 734
Thailand
Viet Nam
100 176
50 719
20 205
Zimbabwe
41 305
12 596
15 303
High-burden
countries
5 062 192
AFR
3 869
3 190
10 468
191 565
8 590
46 569
112 910
18 394
27 521
343 715
18 738
47
1 915
1 852
65 824
62
1 302
2 710
46 306
1 079
1 791
59 357
31
64
0
54
40
4 684 613 28 845
56
56
72
1 460 766
605 929
357 811
109 258
240 843
1 069
52 283
74 622
1 367 193
18 951
AMR
231 880
121 130
36 371
14 254
33 757
1 315
10 004
11 613
216 831
3 436
71
EMR
425 821
170 748
128 182
7 206
93 605
623
11 223
10 102
411 587
4 132
56
EUR
356 670
79 831
121 362
6 896
42 489
3 191
22 838
73 296
275 872
7 502
38
SEAR
2 358 127
1 067 367
598 800
333 993
2 878
135 650
215 554
2 138 688
3 885
64
WPR
1 383 249
576 044
630 219
17 435
68 949
2 708
50 841
33 257
1 346 196
3 796
47
Global
6 216 513
2 621 049 1 872 745
155 049
813 636 11 784 282 839
418 444
5 756 367
41 702
56
Blank cells indicate data not reported.
TB for the rst time and 0.3 million were people who had
a recurrent episode of TB after being previously cured of
the disease. Besides a small number of cases whose history
of treatment was not recorded, the remaining 0.4 million
had already been diagnosed with TB but their treatment
was changed to a retreatment regimen (for de nitions of
each type of case, see Box 3.1).
Among people who were diagnosed with TB for the
rst time (new cases), 2.6 million had sputum smear-positive pulmonary TB, 1.9 million had sputum smear-negative pulmonary TB, 0.2 million did not have a sputum
smear done and 0.8 million had extrapulmonary TB
(Table 3.1). Of the new cases of pulmonary TB, 56% were
sputum smear-positive.
India and China accounted for 39% of the 5.8 million new and relapse cases of TB that were notied in
2011 (23% and 16%, respectively); the South-East Asia
30
and Western Pacic regions of which these countries are

a part accounted for 60% of cases globally. African countries accounted for 24% (one quarter of these cases were
from one country South Africa). The WHO Eastern
Mediterranean and European regions and the Region of
the Americas accounted for 16% of new and relapse cases
notied in 2011 (7%, 5% and 4%, respectively). The 22
HBCs accounted for 81%.
Among the 22 HBCs, the percentage of new cases of
pulmonary TB that were sputum smear-positive was relatively low in the Russian Federation (31%), Zimbabwe
(40%), Myanmar (41%), South Africa (47%), Ethiopia
(47%) and Kenya (48%). A comparatively high proportion of new cases of pulmonary TB were sputum smearpositive in Bangladesh (82%), the Democratic Republic of
the Congo (84%) and Viet Nam (72%).
Almost all (98%) of the notications of new cases of
BOX 3.11
Definitions of TB cases
Denite case of TB A patient with Mycobacterium tuberculosis complex identied from a clinical specimen, either by culture or by
a newer method such as molecular line probe assay. In countries that lack laboratory capacity to routinely identify M. tuberculosis, a
pulmonary case with one or more initial sputum specimens positive for acid-fast bacilli (AFB) is also considered to be a denite case,
provided that there is functional external quality assurance with blind rechecking.
Case of TB A denite case of TB (dened above) or one in which a health worker (clinician or other medical practitioner) has diagnosed
TB and decided to treat the patient with a full course of anti-TB treatment.
Case of pulmonary TB A patient with TB disease involving the lung parenchyma.
Smear-positive pulmonary case of TB A patient with one or more initial sputum smear examinations (direct smear microscopy) AFBpositive; or one sputum examination AFB-positive plus radiographic abnormalities consistent with active pulmonary TB as determined by a
clinician. Smear-positive cases are the most infectious and thus of the highest priority from a public health perspective.
Smear-negative pulmonary case of TB A patient with pulmonary TB who does not meet the above criteria for smear-positive disease.
Diagnostic criteria should include: at least two AFB-negative sputum smear examinations; radiographic abnormalities consistent with
active pulmonary TB; no response to a course of broad-spectrum antibiotics (except in a patient for whom there is laboratory conrmation
or strong clinical evidence of HIV infection); and a decision by a clinician to treat with a full course of anti-TB chemotherapy. A patient
with positive culture but negative AFB sputum examinations is also a smear-negative case of pulmonary TB.
Extrapulmonary case of TB A patient with TB of organs other than the lungs (e.g. pleura, lymph nodes, abdomen, genitourinary tract,
skin, joints and bones, meninges). Diagnosis should be based on one culture-positive specimen, or histological or strong clinical evidence
consistent with active extrapulmonary disease, followed by a decision by a clinician to treat with a full course of anti-TB chemotherapy. A
patient in whom both pulmonary and extrapulmonary TB has been diagnosed should be classied as a pulmonary case.
New case of TB A patient who has never had treatment for TB or who has taken anti-TB drugs for less than one month.
Retreatment case of TB There are three types of retreatment case: (i) a patient previously treated for TB who is started on a
retreatment regimen after previous treatment has failed (treatment after failure); (ii) a patient previously treated for TB who returns to
treatment having previously defaulted; and (iii) a patient who was previously declared cured or treatment completed and is diagnosed
with bacteriologically-positive (sputum smear or culture) TB (relapse).
Case of multidrug-resistant TB (MDR-TB) TB that is resistant to two rst-line drugs: isoniazid and rifampicin. For most patients
diagnosed with MDR-TB, WHO recommends treatment for 20 months with a regimen that includes second-line anti-TB drugs.
Note: New and relapse cases of TB are incident cases. Cases of TB started on a retreatment regimen following treatment failure or treatment
interruption are prevalent cases.
1
See Treatment of tuberculosis guidelines, 4th ed. Geneva, World Health Organization, 2010 (WHO/HTM/STB/2009.420).
BOX 3.2
Achievements in global TB care and control, 19952011
WHO began systematic monitoring of progress in TB control in 1995. Data compiled on an annual basis since then allow achievements in
TB care and control to be assessed.
Between 1995 and 2011, 51 million people were successfully treated for TB in countries that had adopted the DOTS/Stop TB Strategy
(out of a total of 60 million treated). This saved approximately 20 million lives.1
The number of lives saved is based on the estimate that in the absence of treatment, approximately 40% of people with TB would die
of the disease. This estimate allows for differences in the mortality rates for smear-positive compared with other types of TB disease (see
Chapter 1), and for differences in mortality rates between HIV-negative and HIV-positive people.
1
For estimates of the incremental number of lives saved by improvements in TB care associated with implementation of the DOTS and Stop TB Strategy
compared with pre-1995 standards of care, see Glaziou P et al. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for
reducing tuberculosis mortality. Bulletin of the World Health Organization, 2011, 89:573582.
31
TABLE 3.2 Notications of new cases of smear-positive pulmonary TB by age and sex, 2011
014 YEARS
1544 YEARS
4564 YEARS
65 YEARS
% AGED < 15 YEARS
MALE/FEMALE RATIO
Afghanistan
669
8 574
3 319
1 227
Bangladesh
932
53 585
30 877
13 554
<1
1.9
Brazil
692
25 270
11 080
3 211
2.2
73
6 810
6 412
2 581
<1
1.2
China
1 378
173 523
128 585
73 519
<1
2.6
DR Congo
3 379
47 529
17 207
3 206
1.2
Ethiopia
3 830
38 518
6 272
1 074
1.2
12 985
388 447
187 705
53 174
2.2
1 714
115 631
67 378
13 074
<1
1.5
985
29 884
5 207
1 009
1.6
307
23 902
14 198
3 907
<1
1.9
Cambodia
India
Indonesia
Kenya
Mozambique
Myanmar
0.51
Nigeria
1 107
34 559
9 604
2 167
1.6
Pakistan
3 895
64 309
27 495
10 034
1.1
953
51 919
31 069
6 935
2.4
51
18 066
9 477
1 597
<1
2.7
Philippines
Russian Federation
3 404
94 427
27 552
4 387
1.2
Thailand
South Africa
114
14 980
11 862
6 213
<1
2.4
Uganda
695
18 486
4 842
917
1.8
UR Tanzania
411
17 149
5 047
1 508
1.8
Viet Nam
95
23 404
18 271
8 949
<1
3.0
Zimbabwe
326
9 953
1 879
438
1.2
High-burden countries
37 995
1 258 925
625 338
212 681
1.9
AFR
19 183
427 731
114 303
23 574
1.4
AMR
2 337
62 127
27 495
11 311
1.8
EMR
5 763
105 833
42 736
16 303
1.2
EUR
SEAR
WPR
Global
391
46 807
24 197
6 962
<1
2.3
17 144
626 659
329 687
93 857
2.0
2 880
272 434
196 490
104 444
<1
2.4
47 698
1 541 591
734 908
256 451
1.9

indicates values that cannot be calculated.
smear-positive pulmonary TB were disaggregated by age

and sex (Table 3.2); 85% were aged 1564 years and 2%
were children (aged <15 years). The global male:female
sex ratio was 1.9, but among HBCs this varied from 0.5 in
Afghanistan to 3.0 in Viet Nam. Variation among countries may reect real differences in epidemiology as well
as differential access to or use of health-care services
linked to the NTP.
Reporting of cases disaggregated by age and sex was
much less complete for new smear-negative pulmonary
and extrapulmonary cases. For example, data disaggregated by age and sex according to the categories shown in
Table 3.2 were not available for 12 HBCs. When the available data for all new cases were combined, most cases
(88%) were aged 1564 years and 6% were among children (<15 years); the male:female ratio was 1.7, ranging
from 1.1 to 2.2 among WHOs six regions. Further efforts
are needed to improve reporting of all cases disaggregated
by age and sex.
32
3.2
Contribution of publicpublic and

publicprivate mix (PPM) initiatives to
TB case notifications in 2011
In many countries, especially those with a large private

sector, collaboration with the full range of health-care
providers is one of the best ways to ensure that all people
with TB are promptly diagnosed, notied to NTPs and
given standardized care. This is component 4 of the Stop
TB Strategy (Chapter 1); its two subcomponents are:
involving all public, voluntary, corporate and private

providers through PPM approaches; and
promoting the International Standards for Tuberculosis Care through PPM initiatives.
Efforts to engage all health-care providers are being

introduced and scaled up in many countries. Demonstrating this progress is not always possible: it requires
systematic recording of the source of referral and place of
TB treatment locally, and reporting and analysis of aggre-
TABLE 3.3 Contribution of publicprivate and publicpublic mix (PPM) to notications of TB cases in 21 countries, 2011
WHO REGION AND COUNTRY
NUMBER OF NEW TB CASES

NOTIFIED IN 2011
TYPES OF NON-NTP CARE PROVIDERS ENGAGED
CONTRIBUTION TO TOTAL
NOTIFICATIONS OF NEW TB
CASES IN 2011
AFRICAN REGION
Angola
Diverse private and public providers
13 989
Ethiopia
Diverse private providers
15 052
Ghana
1 781
28%
9.5%
11%
Kenya
Private clinics and hospitals and prisons
10 076
Nigeria
Private clinics and hospitals
21 562
23%
9.6%
UR Tanzania
Private facilities and faith-based organizations
13 067
21%
REGION OF THE AMERICAS

El Salvador
Haiti
Private practitioners, NGOs and prison services
581
30%
5 170
36%
3 563
31%
EASTERN MEDITERRANEAN REGION

Iran (Islamic Republic of)
Iraq
Pakistana
5 624
61%
21 117
20%
Egypt
Health insurance organizations, NGOs and other public providers
2 234
24%
Sudan
2 277
11%
Syrian Arab Republic
2 694
73%
12%
SOUTH-EAST ASIA REGION

Bangladesh
Diverse private, public and NGO providers
19 668
Indiab
13 991
2.1%
Indonesia
Public and private hospitals
71 454
22%
Myanmar
31 838
22%
389 112
43%
WESTERN PACIFIC REGION

China
a
b
General public hospitals
Philippines
24 031
12%
Republic of Korea
Diverse private providers
44 684
89%
Data are for smear-positive cases of pulmonary TB only.

Data are for smear-positive cases of pulmonary TB in 14 cities where PPM surveillance is in place.
gated data nationally.1 Nonetheless, a growing number

of countries are systematically recording and reporting
data on the contribution of PPM initiatives to TB notications (Table 3.3). In most of the 21 countries (including
11 HBCs) for which data were reported, PPM initiatives
contributed about 10% to 40% of total notications.
Approaches to engage non-NTP care providers vary
according to the local context. For example, in the Philippines, the national health insurance organization has
designed a special TB package for providers that collaborate with the NTP. India has incentive-based schemes
for individual and institutional providers. China uses
an Internet-based system for mandatory reporting of TB
cases by all providers. It is also noticeable that countries
have prioritized different types of care providers. These
include general public hospitals (in China), private clinics and hospitals (in Nigeria and the Republic of Korea),
1
WHO recommends that the source of referral and the place of

treatment should be routinely recorded and reported.
medical colleges (in India) and health insurance organizations that also provide health services (in Egypt). Social
security organizations and prison health services are the
main non-NTP providers in the Region of the Americas
and in Eastern Europe, respectively.
Comparisons with data reported by countries in previous years show that the contribution of PPM to case notications has grown in some countries, including China,
Indonesia, Myanmar and the Republic of Korea. The
unexplained variations in the data from other countries
indicate that their PPM initiatives, and the recording and
reporting aspects in particular, need to be strengthened.
In most countries, only a small proportion of targeted
care providers collaborate actively with NTPs and contribute to TB case notications. Achieving early TB case
detection to minimize disease transmission will require
greater involvement of front-line health workers such as
community-based informal providers, general practitioners and pharmacists who are often the rst point of
contact for people with symptoms of TB. The need for
33
BOX 3.3
Engaging private providers in countries with a large private sector
Data reported by countries indicate that NTPs mostly engage non-prot and institutional care providers as part of their PPM programmes.
Establishing collaborative links with these providers is relatively less demanding than engaging for-prot private providers and, for a
given amount of effort, may yield a higher number of TB case notications. However, engaging more seriously with for-prot practitioners,
especially in countries with a large private sector, is necessary to increase the number of people with TB who are diagnosed early, treated
according to international standards and reported to national TB control programmes. It is also required to reduce costs to TB patients,
prevent the emergence and spread of drug-resistant TB and protect soon-to-be-available new anti-TB drugs.
The extent of the sale and use of anti-TB drugs in the private sector in 10 countries that account for about 60% of estimated TB cases
globally was assessed in 2011.1 The private markets in four Asian countries (India, Indonesia, Pakistan and the Philippines) had the
largest volumes of sales relative to estimated numbers of TB cases. Annual sales ranged from 65% to 117% of the drugs needed to treat
the estimated number of incident cases occurring each year with a standard 68 month regimen in these countries. The study authors
concluded that expansion of PPM programmes was needed.
Efforts to engage public and private health-care providers in TB care and control have been implemented for several years in India,
Indonesia, Pakistan and the Philippines. Nonetheless, the reported data indicate that there is substantial scope for greater engagement
of the private sector in these and other countries with a large private sector. Disaggregated data on the contribution of providers in the
private sector to TB case notications is not reported by most countries; among those that do report, the contribution of the large forprot private sector is too small to be of any signicance. The recent decision by the Government of India to make notication of TB cases
mandatory by law is a welcome step in the right direction.
1
Wells WA et al. Size and usage patterns of private TB drug markets in the high burden countries. PLoS One, 2011, 6(5):e18964.
FIGURE 3.1
greater attention to collaboration with for-prot private

providers, especially in countries where there is a large
private medical sector and anti-TB drugs are readily available in private pharmacies, is highlighted in Box 3.3.
A new initiative to engage nongovernmental organizations in TB care and control, named ENGAGE-TB, is
described in Box 3.4.
Global trends in case notication (black)

and estimated TB incidence (green) rates,
19902011
200
150
3.3
100
50
0
1990
1995
2000
2005
2011
Globally, the number of TB cases diagnosed and notied per 100 000 population has stabilized since 2008,
following a marked increase between 2001 and 2007
(Figure 3.1). Globally and in all WHO regions, a clear gap
between the numbers of notied cases and the estimated
numbers of incident cases exists, although this is narrowing, particularly in the Western Pacic Region (mostly
driven by trends in China) and the Region of the Americas (Figure 3.2). Trends in the 22 HBCs are shown in Figure 3.3, and for other countries are illustrated in country
pro les that are available online.1
The case detection rate (CDR)2 for TB is an indicator
that is included within the Millennium Development
Goals (Chapter 1). For a given country and year, the CDR
is calculated as the number of new and relapse TB cases
(see Box 3.1 for de nitions) that were notied by NTPs
(Table 3.1), divided by the estimated number of incident
1
2
34
Trends in case notifications since 1990

and estimates of the case detection rate
www.who.int/tb/data
The CDR is actually a ratio rather than a rate, but the term
rate has become standard terminology in the context of this
indicator.
BOX 3.4
Integrating community-based TB activities ENGAGE-TB
During the past ve years, the percentage of estimated cases of incident TB detected and reported to NTPs has stagnated at around
6070%. The missing cases are either diagnosed and treated by providers not reporting to the public health system or are not reached
by the current network of providers of TB care at all. Among notied cases, diagnosis may be delayed. To reach the unreached and to nd
people with TB earlier in the course of their illness, a wider range of stakeholders already involved in community-based activities needs
to be engaged. These include non-governmental organizations (NGOs) and other civil society organizations that are active in communitybased development, particularly in primary health care, maternal and child health and HIV prevention, treatment and care, but which have
not yet included TB in their activities.
The ENGAGE-TB initiative seeks to integrate community-based
activities to control TB in the ongoing work of such NGOs,
aligned with national strategies and plans and supported by
new operational guidance developed by WHO.1 The guidance
recommends the creation or strengthening of NGO coalitions
for TB care and control, regular meetings between the
leadership of such coalitions and NTP staff at various levels,
and streamlining monitoring and evaluation through a single
recording and reporting system. The guidance supports more
explicit measurement of community-based contributions to
case notications and treatment outcomes. The six components
through which integration can be more systematically
undertaken are shown in the gure opposite.
Situation
analysis
Capacity
building
Enabling
environment
ENGAGE-TB
approach
Monitoring
and
evaluation
Community-based activities are conducted outside the premises

of formal health facilities (hospitals, health centres and clinics)
using community-based structures (such as schools, places of
worship and congregate settings) and homesteads. Examples include:
Guidelines
and tools
Task
identication
creating awareness about TB, communication for behavioural change and community mobilization;
efforts to reduce stigma and discrimination;
screening and testing for TB and other TB related co-morbidities (e.g. through HIV counselling and testing, and screening for diabetes),
including through home visits;
facilitating access to diagnostic services, for example by providing transportation to health-care facilities;
initiating and providing interventions to prevent TB, including isoniazid preventive therapy and TB infection control;
referring community members for diagnosis of TB and other co-morbidities;
initiating, providing and observing treatment for TB and other co-morbidities;
supporting adherence to treatment through peer support, education and individual follow-up;
supporting social and livelihood schemes, such as food supplementation and income generation;
providing home-based palliative care for TB and other co-morbidities; and
supporting community-led advocacy.
1
ENGAGE-TB: Integrating community-based TB activities into the work of NGOs and other CSOs (in press).
cases of TB that year. The CDR is expressed as a percentage; it gives an approximate1 indication of the proportion of all incident TB cases that are actually diagnosed,
reported to NTPs and started on treatment.
The best estimate of the CDR for all forms of TB globally in 2011 was 66% (range, 6469%), up from 5359%
in 2005 and 3843% in 1995 the year in which the
DOTS strategy began to be introduced and expanded
(Table 3.4). The highest CDRs in 2011 were estimated
1
It is approximate because of uncertainty in the underlying

incidence of TB and because notied cases are not necessarily
a subset of incident cases that occurred in the same year; see
Chapter 2 for further discussion.
to be in the Region of the Americas (best estimate 84%;

range, 7989%), the Western Pacic Region (best estimate 81%; range, 7589%) and the European Region
(best estimate 73%; range, 6978%). The other regions
had estimated CDRs in the range 5570%, with best estimates of around 60%. All regions have improved their
estimated CDRs since the mid-1990s, with improvements
particularly evident since 2000. Among the 22 HBCs, the
highest rates of case detection in 2011 were estimated to
be in Brazil, China, Kenya, the Russian Federation and
the United Republic of Tanzania; the lowest rates were in
Afghanistan, Bangladesh, Mozambique and Nigeria.
To close the gap between notied cases and estimated
35
FIGURE 3.2
Case notication and estimated TB incidence rates by WHO region, 19902011. Regional trends in case
notication rates (new and relapse cases, all forms) (black) and estimated TB incidence rates (green). Shaded areas
represent uncertainty bands.
Africa
The Americas
80
400
150
60
300
100
200
40
100
20
Europe
50
South-East Asia
Western Pacific
250
80
200
200
150
60
150
100
40
100
20
50
50
0
1990
1995
2000
2005
2011
1990
1995
2000
2005
2011
1990
1995
2000
2005
TB incidence, action is needed in three broad areas:
3.4
3.4.1 New cases of smear-positive pulmonary TB
36
strengthening surveillance, to ensure that all cases

diagnosed with TB are reported and accounted for by
routine notication systems. Establishing links with
the full range of health-care providers through PPM,
as well as stronger enforcement of legislation regarding notication of cases (where this is mandated by
law) can help to minimize the under-reporting of TB
cases. Inventory studies (see Section 2.5.1 in Chapter
2 for further details) can be used to help quantify the
extent to which diagnosed cases are unreported (the
surveillance gap).
improving diagnostic capacity, to ensure that people with TB who seek care are actually diagnosed. It
may require better laboratory capacity as well as more
knowledgeable and better trained staff, especially in
peripheral-level health-care facilities. Details about
current progress in strengthening laboratories and
introducing new rapid diagnostics are provided in
Chapter 6.
increasing access to health care (in nancial and/
or geographical terms), for people with TB who do not
seek care, and improved awareness of how to recognize the signs and symptoms of TB.
2011
Treatment outcomes
Data on treatment outcomes for sputum smear-positive

cases of pulmonary TB are shown in Table 3.5 (de nitions
of the categories used to report treatment outcomes are
provided in Box 3.5). Globally, the rate of treatment success for the 2.7 million new cases of sputum smear-positive pulmonary TB who were treated in the 2010 cohort
was 87%. This was the fourth successive year that the
target of 85% ( rst set by the World Health Assembly in
1991) was met or exceeded globally. It is also impressive
that as the size of the global treatment cohort grew from
1.0 million in 1995 to 2.7 million in 2010, the treatment
success rate progressively improved.
Among WHOs six regions, three met or exceeded
the 85% target: the Eastern Mediterranean Region, the
South-East Asia Region and the Western Pacic Region.
The treatment success rate was 82% in the African Region
(where there has been steady improvement since 1999),
77% in the Region of the Americas (where the rate has
been relatively stable since 2002) and 67% in the European Region (where major efforts to increase treatment
success rates are needed).
Of the 22 HBCs, 15 reached or exceeded the 85% target in 2010. The seven HBCs that reported lower rates of
treatment success were Brazil (74%), Ethiopia (83%),
Nigeria (84%), the Russian Federation (53%), South
Africa (79%), Uganda (71%) and Zimbabwe (81%); all
except Ethiopia and the Russian Federation made prog-
TABLE 3.4 Estimates of the case detection rate for new and relapse cases (%), 19952011a
1995
BEST b
Afghanistan
Bangladesh
LOW
2000
HIGH
21
18
Brazil
79
66
Cambodia
23
18
BEST
2005
LOW
HIGH
BEST
LOW
2010
HIGH
BEST
LOW
2011
HIGH
BEST
LOW
HIGH
16
14
20
42
35
51
47
40
57
46
38
55
26
22
32
39
32
48
46
39
56
45
37
54
97
74
62
91
84
71
100
88
75
110
91
77
110
29
26
21
33
52
44
63
65
57
76
64
55
74
100
26
China
33
28
40
33
28
39
74
65
85
87
77
99
89
79
DR Congo
30
25
36
38
32
45
52
45
61
53
46
61
50
43
58
Ethiopia
11
18
33
22
55
49
32
82
69
52
97
72
55
96
India
58
67
49
44
54
49
44
54
59
54
65
59
54
65
85
Indonesia
8.7
7.2
51
11
19
16
24
56
46
70
66
56
80
70
59
Kenya
61
56
7.0
66
72
67
77
80
76
85
82
79
86
81
78
85
Mozambique
23
11
73
23
13
51
31
20
54
34
25
49
34
25
49
Myanmar
11
8.6
14
17
14
21
57
49
68
71
62
83
74
64
87
160
12
Nigeria
8.8
2.7
Pakistan
4.5
3.7
5.5
3.3
3.9
2.8
170
4.0
190
40
24
83
45
26
96
39
26
32
9.4
47
65
55
79
64
54
78
Philippines
48
40
59
47
39
58
53
44
65
65
54
79
75
63
91
Russian Federation
60
51
70
75
65
89
66
56
78
79
67
93
81
70
96
South Africa
56
47
69
59
49
72
61
51
75
72
61
87
69
58
83
Thailand
59
49
71
32
27
38
56
47
68
75
63
91
76
64
93
Uganda
22
14
41
29
20
48
47
36
66
61
51
76
69
57
86
UR Tanzania
59
51
69
68
60
77
74
69
80
77
72
82
76
71
81
Viet Nam
37
29
49
56
44
73
56
44
74
54
43
70
56
44
73
Zimbabwe
55
40
79
56
45
71
50
41
63
56
44
72
50
40
65
39
36
42
39
36
42
54
51
58
65
62
69
66
63
69
AFR
31
26
38
39
33
47
52
44
61
61
56
66
61
56
66
AMR
68
63
73
70
65
75
75
70
80
80
75
86
84
79
89
EMR
23
21
26
25
22
28
47
42
54
63
56
71
62
55
70
EUR
52
49
54
58
55
62
65
61
70
76
71
81
73
69
78
SEAR
45
41
49
41
38
44
50
46
54
61
57
66
62
58
66
WPR
37
33
43
39
35
43
69
63
76
79
72
86
81
75
89
Global
40
38
43
41
39
44
56
53
59
66
63
68
66
64
69

a
Estimates for all years are recalculated as new information becomes available and techniques are rened, so they may differ from those published previously.
b
Best, low and high indicate best estimates followed by lower and upper bounds. The lower and upper bounds are dened as the 2.5th and 97.5th centiles of outcome
distributions produced in simulations.
ress compared with 2010. In Brazil and Uganda, low rates

reect a relatively high proportion of patients for whom
the outcome of treatment was not evaluated (10% and
13%, respectively) and high default rates (11% in both
countries). In the Russian Federation, treatment failure
rates are high, possibly linked to MDR-TB.
3.4.2 All new cases

Data on treatment outcomes for all new cases of TB are
shown in Table 3.6. Globally, the rate of treatment success
was 85% in 2010. Among WHOs six regions, the highest
rates were in the Eastern Mediterranean (88%), SouthEast Asia (89%) and Western Pacic (92%) regions. The
treatment success rate was 73% in the African Region,
74% in the Region of the Americas and 74% in the
European Region. The data for the African Region were
affected by missing data for South Africa. Once these are

available and reported, the treatment success rate will be
higher.
Of the 22 HBCs, 14 reached or exceeded a treatment
success rate of 85% among all new cases in 2010. The
eight countries that reported lower rates of treatment success were Brazil (72%), Ethiopia (77%), Nigeria (81%),
the Russian Federation (66%), South Africa (53%),1
Thailand (83%), Uganda (68%) and Zimbabwe (76%).
The NTP in South Africa noted that data reported to WHO

were incomplete; the gure of 53% is thus an underestimate.
37
FIGURE 3.3
Case notication and estimated TB incidence rates, 22 high-burden countries, 19902011. Trends in case
notication rates (new and relapse cases, all forms) (black) and estimated TB incidence rates (green). Shaded areas
represent uncertainty bands.
Afghanistan
Bangladesh
Brazil
Cambodia
300
300
200
100
DR Congo
Ethiopia
600
150
400
100
200
50
Indonesia
200
200
400
150
150
100
200
100
100
50
50
Myanmar
1200
600
1000
500
800
400
600
300
400
200
200
100
100
200
200
100
400
200
0
Thailand
Uganda
UR Tanzania
1200
300
200
1000
250
150
800
200
600
150
400
100
50
200
50
100
500
Philippines
300
400
250
1000
Viet Nam
100
600
150
200
Pakistan
600
South Africa
50
300
200
Nigeria
Russian Federation
400
250
600
Mozambique
Kenya
300
250
300
India
800
400
200
50
100
100
200
China
800
1990 1995 2000 2005
Zimbabwe
2011
0
1990 1995 2000 2005
2011
1990 1995 2000 2005
2011
300
1000
250
200
800
150
600
100
400
50
200
0
0
1990 1995 2000 2005
2011
1990 1995 2000 2005
2011
BOX 3.5
Definitions of treatment outcomes for drug-susceptible TB
Cured A patient who was initially sputum smear-positive and who was sputum smear-negative in the last month of treatment and on at
least one previous occasion.
Completed treatment A patient who completed treatment but did not meet the criteria for cure or failure. This denition applies to
sputum smear-positive and sputum smear-negative patients with pulmonary TB and to patients with extrapulmonary disease.
Died A patient who died from any cause during treatment.
Failed A patient who was initially sputum smear-positive and who remained sputum smear-positive at month 5 or later during treatment.
Defaulted A patient whose treatment was interrupted for 2 consecutive months or more.
Not evaluated A patient whose treatment outcome is not known.
Successfully treated A patient who was cured or who completed treatment.
Cohort A group of patients in whom TB has been diagnosed, and who were registered for treatment during a specied time period (e.g.
the cohort of new sputum smear-positive cases registered in the calendar year 2010). This group forms the denominator for calculating
treatment outcomes. The sum of the above treatment outcomes, plus any cases for whom no outcome is recorded (including those still
on treatment in the European Region) and transferred out cases should equal the number of cases registered. Some countries monitor
outcomes among cohorts dened by sputum smear and/or culture, and dene cure and failure according to the best laboratory evidence
available for each patient.
38
TABLE 3.5 Treatment success for new smear-positive cases (%) and cohort size (thousands), 19952010
a. Treatment success (%)
1995
Afghanistan
Bangladesh
Brazil
Cambodia
China
DR Congo
Ethiopia
India
Indonesia
Kenya
Mozambique
Myanmar
Nigeria
Pakistan
Philippines
Russian Federation
South Africa
Thailand
Uganda
UR Tanzania
Viet Nam
Zimbabwe
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
71
17
91
93
74
61
25
91
75
39
67
49
70
60
65
58
64
44
73
89
53
63
20
94
94
48
71
21
81
77
55
79
32
35
57
61
78
33
76
89
32
45
73
27
91
95
64
72
18
54
65
65
82
73
67
78
67
68
58
40
77
85
69
33
77
40
95
95
70
74
27
58
77
82
73
23
71
68
72
68
62
76
92
70
86
79
78
93
95
69
74
21
50
79
71
81
75
70
87
65
57
77
61
78
92
73
85
81
71
91
93
78
80
34
87
80
75
82
79
74
88
68
63
69
63
78
92
69
84
83
55
92
95
77
76
54
86
80
78
81
79
77
88
67
61
75
56
81
93
71
87
84
80
92
92
78
76
60
86
79
78
81
79
78
88
67
68
74
60
80
92
67
86
85
77
93
93
83
70
76
87
80
76
81
78
79
88
61
67
73
68
81
92
66
89
90
76
91
94
85
79
82
90
80
77
84
73
82
87
60
69
74
70
81
93
54
90
91
76
93
94
85
78
86
91
82
79
84
75
83
89
58
71
75
73
82
92
68
84
92
73
93
94
86
84
86
91
85
83
84
76
88
88
58
74
77
70
85
93
60
87
92
72
94
94
87
84
87
91
85
79
85
82
91
89
58
74
83
75
88
92
78
88
91
71
95
94
87
84
87
91
85
84
85
78
90
88
57
76
82
70
88
92
74
86
92
72
95
95
88
84
88
91
86
85
85
83
91
89
55
73
86
67
88
92
78
90
92
74
94
96
90
83
88
90
87
85
86
84
91
91
53
79
85
71
90
92
81
53
50
56
62
60
67
72
75
81
84
86
87
87
87
88
88
AFR
AMR
EMR
EUR
SEAR
WPR
60
50
79
67
33
80
56
51
66
58
31
72
64
58
73
72
29
91
70
67
57
63
40
92
68
79
79
75
34
91
71
76
81
75
50
90
70
69
82
74
63
91
73
81
84
74
68
90
73
80
82
75
79
91
74
79
83
70
84
91
76
79
83
72
87
92
75
76
86
70
87
92
80
79
88
71
88
92
80
77
88
70
88
92
80
76
88
69
89
93
82
77
88
67
88
93
Global
57
54
60
64
64
69
73
76
80
83
85
84
86
86
86
87
b. Cohort size (thousands)

1995
1996
1997
Afghanistan
Bangladesh
Brazil
Cambodia
China
DR Congo
Ethiopia
India
Indonesia
Kenya
Mozambique
Myanmar
Nigeria
Pakistan
Philippines
Russian Federation
South Africa
Thailand
Uganda
UR Tanzania
Viet Nam
Zimbabwe
11
46
4.4
131
16
5.1
265
3.0
6.5
11
7.9
9.5
0.8
90
0.05
28
20
15
20
38
9.7
30
45
9.1
175
25
11
291
12
13
13
9.7
24
126
43
45
0.1
15
21
48
12
2.0
34
43
12
189
26
12
293
21
19
11
9.2
11
2.8
27
0.7
55
3.7
18
22
54
12
739
967
AFR
AMR
EMR
EUR
SEAR
WPR
178
129
46
34
318
296
233
134
51
94
360
372
1 001
1 245
Global
1998
2.9
38
30
13
210
33
15
284
40
22
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
10
13
29
21
0.7
37
8.0
13
24
55
13
2.0
38
27
16
208
35
21
345
46
27
12
12
15
3.0
37
1.5
81
14
14
24
53
13
3.1
38
34
15
214
36
30
349
52
28
13
17
16
4.1
50
3.6
86
23
14
24
53
14
6.3
41
41
14
190
41
32
384
54
31
14
21
17
6.3
55
4.1
101
20
17
24
54
17
7.8
47
29
17
194
45
37
396
76
31
15
24
21
15
59
5.2
99
27
19
24
57
16
6.8
54
38
19
267
54
40
420
93
34
16
27
28
20
68
6.3
114
28
20
25
56
14
10
63
43
19
385
62
41
489
129
41
17
31
34
32
78
26
127
28
21
26
58
15
10
85
42
21
473
65
39
507
159
40
18
37
35
48
81
26
135
30
21
25
55
13
12
102
48
19
470
63
37
553
175
39
18
40
40
66
86
31
140
29
20
25
56
16
13
104
38
19
466
66
38
592
161
38
18
43
44
89
87
32
143
30
21
25
54
11
13
106
41
20
464
66
41
616
166
37
19
41
46
100
85
32
144
33
23
24
53
10
12
109
41
18
449
72
45
625
169
37
20
42
45
102
89
32
139
28
23
25
51
10
13
106
42
17
430
73
47
630
183
36
20
42
45
104
89
30
134
30
23
24
52
12
879
912
1 044
1 119
1 186
1 260
1 450
1 776
1 965
2 087
2 132
2 181
2 184
2 185
268
125
60
24
376
294
235
111
89
48
399
313
323
110
66
22
473
353
365
111
64
41
512
360
409
102
52
50
550
346
452
105
76
54
604
357
491
110
81
60
661
439
552
121
98
75
780
575
564
119
114
81
856
663
566
132
132
98
938
663
577
116
156
108
974
661
591
109
167
114
1 011
657
606
123
167
105
1 022
641
635
123
170
84
1 045
622
1 147
1 195
1 347
1 453
1 510
1 649
1 842
2 200
2 396
2 529
2 591
2 649
2 665
2 680

39
TABLE 3.6 Treatment success for all new cases (%) and cohort size (thousands), 19952010
a. Treatment success (%)
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
Afghanistan
Bangladesh
Brazil
Cambodia
China
DR Congo
Ethiopia
India
Indonesia
Kenya
Mozambique
Myanmar
Nigeria
Pakistan
Philippines
Russian Federation
South Africa
Thailand
Uganda
UR Tanzania
Viet Nam
Zimbabwe
71
17
91
93
74
61
25
91
75
39
67
49
70
60
65
58
64
44
73
89
53
63
20
94
94
48
71
21
81
77
55
79
32
35
57
61
78
33
76
89
32
45
73
27
91
95
64
72
18
54
65
65
82
73
67
78
67
68
58
40
77
85
69
33
77
40
95
95
70
74
27
58
77
82
73
23
71
68
72
68
62
76
92
70
86
79
78
93
95
69
74
21
50
79
71
81
75
70
87
65
57
77
61
78
92
73
85
81
71
91
93
78
80
34
87
80
75
82
79
74
88
68
63
69
63
78
92
69
84
83
55
92
95
77
76
54
86
80
78
81
79
77
88
67
61
75
56
81
93
71
87
84
80
92
92
78
76
60
86
79
78
81
79
78
88
67
68
74
60
80
92
67
86
85
77
93
93
83
70
76
87
80
76
81
78
79
88
61
67
73
68
81
92
66
89
90
72
91
92
85
79
81
87
77
77
82
73
80
78
65
65
71
70
82
92
48
90
90
72
91
92
85
78
87
89
81
79
83
75
82
89
67
69
71
73
83
92
66
84
91
69
92
92
60
84
87
90
83
83
83
76
86
88
69
70
75
68
85
92
67
87
90
72
93
93
86
84
88
90
83
79
84
82
90
88
69
71
81
72
88
91
78
88
91
69
94
93
86
80
88
90
84
84
84
78
89
84
69
73
80
67
88
92
70
86
91
70
94
94
88
81
89
89
84
85
84
84
91
85
68
68
84
64
88
92
75
86
91
72
89
95
89
77
89
89
86
85
88
81
90
90
66
53
83
68
89
92
76
53
50
56
62
60
67
72
75
81
82
85
85
87
87
86
86
AFR
AMR
EMR
EUR
SEAR
WPR
60
50
79
67
33
80
56
51
66
58
31
72
64
58
73
72
29
91
70
67
57
63
40
92
68
79
79
75
34
91
71
76
81
75
50
90
70
69
82
74
63
91
73
81
84
74
68
90
73
80
82
75
79
91
70
76
82
75
83
88
74
75
82
77
87
90
72
73
86
75
87
90
77
78
87
76
88
91
77
73
87
76
88
91
76
73
87
75
89
91
73
74
88
74
89
92
Global
57
54
60
64
64
69
73
76
80
81
84
84
85
85
85
85
b. Cohort size (thousands)

1995
1996
1997
2004
2005
2006
2007
2008
2009
2010
10
13
29
21
0.7
37
8.0
13
24
55
13
2.0
38
27
16
208
35
21
345
46
27
12
12
15
3.0
37
1.5
81
14
14
24
53
13
3.1
38
34
15
214
36
30
349
52
28
13
17
16
4.1
50
3.6
86
23
14
24
53
14
6.3
41
41
14
190
41
32
384
54
31
14
21
17
6.3
55
4.1
101
20
17
24
54
17
7.8
47
29
17
194
45
37
396
76
31
15
24
21
15
59
5.2
99
27
19
24
57
16
6.8
54
38
19
267
54
40
420
93
34
16
27
28
20
68
6.3
114
28
20
25
56
14
10
63
81
30
644
62
41
1 066
206
97
17
66
34
84
126
39
243
47
21
61
92
54
10
119
78
34
788
65
39
1 071
244
98
18
73
35
117
81
74
259
49
21
59
55
43
12
141
81
34
847
92
37
1 137
266
101
18
84
40
149
123
97
271
47
31
58
91
43
13
144
47
35
889
89
38
1 199
263
99
18
85
44
191
136
99
247
47
37
25
91
39
13
106
73
38
932
93
139
1 226
293
99
19
90
46
206
140
103
236
54
39
59
91
40
12
156
75
39
923
106
139
1 244
289
99
20
91
86
212
141
101
367
43
38
60
88
45
26
150
78
40
877
109
152
1 229
296
90
20
127
78
256
162
94
338
48
40
59
88
46
879
912
1 044
1 119
1 186
1 260
1 450
3 183
3 430
3 799
3 872
4 134
4 374
4 403
268
125
60
24
376
294
235
111
89
48
399
313
323
110
66
22
473
353
365
111
64
42
512
360
409
102
52
50
550
346
452
105
76
55
604
357
491
110
81
60
661
439
846
191
178
171
1 530
963
886
187
226
221
1 639
1 030
940
197
259
274
1 758
1 163
930
157
307
276
1 835
1 216
1 087
168
320
279
1 880
1 261
1 297
191
331
248
1 940
1 259
1 251
196
391
220
1 980
1 240
1 147
1 195
1 347
1 453
1 511
1 649
1 843
3 879
4 188
4 592
4 720
4 995
5 267
5 278
Afghanistan
Bangladesh
Brazil
Cambodia
China
DR Congo
Ethiopia
India
Indonesia
Kenya
Mozambique
Myanmar
Nigeria
Pakistan
Philippines
Russian Federation
South Africa
Thailand
Uganda
UR Tanzania
Viet Nam
Zimbabwe
11
46
4.4
131
16
5.1
265
3.0
6.5
11
7.9
9.5
0.8
90
0.05
28
20
15
20
38
9.7
30
45
9.1
175
25
11
291
12
13
13
9.7
24
126
43
45
0.1
15
21
48
12
2.0
34
43
12
189
26
12
293
21
19
11
9.2
11
2.8
27
0.7
55
3.7
18
22
54
12
739
967
AFR
AMR
EMR
EUR
SEAR
WPR
178
129
46
34
318
296
233
134
51
94
360
372
1 001
1 245
Global
1998
2.9
38
30
13
210
33
15
284
40
22
1999
2000
2001
2002
2003

40
CHAPTER 4
Drug-resistant TB

By the end of 2012, representative surveillance data on
levels of MDR-TB will be available from all 27 high MDRTB and 22 high TB burden countries, and from 135 of
194 Member States. Globally, 3.7% (2.15.2%) of new
cases and 20% (1326%) of previously treated cases
are estimated to have MDR-TB.
There were an estimated 310 000 (range, 220 000
400 000) MDR-TB cases among notied TB patients
with pulmonary TB in 2011. Almost 60% of these cases
were in India, China and the Russian Federation.
Extensively drug-resistant TB, or XDR-TB, has been
identied in 84 countries; the average proportion of
MDR-TB cases with XDR-TB is 9.0% (6.711.2%).
Levels of MDR-TB remain worryingly high in some parts
of the world, notably countries in eastern Europe and
central Asia. In several of these countries, 932% of new
cases have MDR-TB and more than 50% of previously
treated cases have MDR-TB.
There has been progress in the detection and treatment
of MDR-TB in the last two years. Globally, almost 60 000
cases of MDR-TB were notied to WHO in 2011, mostly
by European countries and South Africa. The number of
cases reported by the 27 high MDR-TB burden countries
almost doubled between 2009 and 2011.
Despite progress, the number of MDR-TB cases notied
in 2011 represented only 19% of the estimated 310 000
cases of MDR-TB among reported TB patients with
pulmonary TB, and less than 10% in the two countries
with the largest number of cases, China and India.
Achieving universal access to treatment requires a bold
and concerted drive on many fronts of TB care, and
increased nancing.
Major efforts are needed to improve treatment success
rates among patients with MDR-TB. The Global Plan
target of 75% by 2015 was reached by only 30 of 107
countries that reported treatment outcome data for
patients with MDR-TB.
Drug-resistant TB (DR-TB) threatens global TB control

and is a major public health concern in several countries.
The rst part of this chapter summarizes the latest status
of progress in global surveillance of anti-TB drug resistance, using the most recent data on multidrug-resistant
TB (MDR-TB), extensively drug-resistant TB (XDR-TB)
and resistance to uoroquinolones gathered from special
surveys and continuous surveillance (Section 4.1). The
second part of the chapter (Section 4.2) assesses national
progress in diagnosing and treating MDR-TB, using data
on diagnostic testing for DR-TB, enrolment on treatment
with second-line drugs for those found to have MDR-TB
and treatment outcomes.
4.1
Surveillance of drug-resistant TB
4.1.1 Progress in the coverage of drug resistance

surveillance
Since the launch of the Global Project on Anti-tuberculosis Drug Resistance Surveillance in 1994, data on drug
resistance have been systematically collected and analysed from 135 countries worldwide (70% of WHOs 194
Member States). This includes 63 countries that have continuous surveillance systems based on routine diagnostic
drug susceptibility testing (DST) of all TB patients and
72 countries that rely on special surveys of representative
samples of patients.
During the past 4 years, most of the 27 high MDR-TB
and 22 high TB burden countries (a total of 36 countries)
have expanded coverage of surveillance of drug resistance
to obtain more accurate estimates of the burden of MDRTB (Figure 4.1). In 2008, 16 of these 36 countries had no
nationally representative drug resistance surveillance
data (including 8 countries with data only from subnational areas) and only 3 countries (the Baltic States) had
a nationwide routine surveillance system for monitoring
drug resistance. By the end of 2012 when the survey concludes in Pakistan, baseline representative information
about the burden of drug resistance will be available from
all 27 high MDR-TB and 22 high TB burden countries.
Countries such as Afghanistan (Central region), Bangladesh, Belarus, Bulgaria, Nigeria, Uganda and the
central Asian republics of Kyrgyzstan, Tajikistan and
Uzbekistan, which previously had no or very limited
information on drug resistance, concluded surveys in
20102011. Data for Afghanistan could not be disaggregated by history of treatment (% of MDR among all forms
41
FIGURE 4.1
Progress in implementing surveys for

anti-TB drug-resistance in the 27 high
MDR-TB and 22 high-TB burden countries
2008
2012
Afghanistan
No data
Completed in 2010
Bangladesh
No data
Completed in 2011
Belarus
No data
Completed in 2011
Bulgaria
No data
Completed in 2010
Kyrgyzstan
No data
Completed in 2011
Nigeria
No data
Completed in 2011
Pakistan
No data
Ongoing
Tajikistan
No data
Completed in 2011
DR Congo
1999
No more recent data
India
Indonesia
Russian Federation
9 States
1 additional State
2 Provinces
1 additional Province
in 2010
4 Oblasts
17 additional Oblasts
Azerbaijan
2007
Planned for 2013
Uganda
1997
Completed in 2011
Ukraine
2006
Planned for 2013
Uzbekistan
2005
Completed in 2011
Brazil
1996
Ongoing
Cambodia
2007
No more recent data
China
2007
Planned for 2013
Ethiopia
2005
Ongoing
Kenya
1995
Ongoing
Mozambique
2007
No more recent data
Myanmar
2007
Planned for 2013
Philippines
2004
Ongoing
South Africa
2002
Ongoing
Thailand
2006
No more recent data
UR Tanzania
2007
No more recent data
Viet Nam
2006
Ongoing
Zimbabwe
1995
Planned for 2013
Armenia
2007
Moving towards
routine surveillance
Georgia
2007
Routine surveillance
Kazakhstan
2001
Republic of Moldova
2006
Estonia
Latvia
Lithuania
Survey/surveillance at subnational level

Nationwide survey
Nationwide routine surveillance
42
of TB: 6.3%; range 3.710.0). Six countries (Azerbaijan,

the Democratic Republic of the Congo, India, Indonesia,
the Russian Federation and Ukraine) still rely on drug
resistance surveillance data gathered from limited subnational areas. In the Democratic Republic of the Congo,
logistic issues have prevented the implementation of a
nationwide survey. In Indonesia, after two surveys at provincial level, the national TB control programme (NTP)
has opted to work towards establishing a nationwide sentinel system to monitor drug resistance. Concrete plans
exist in Azerbaijan and Ukraine to start nationwide surveys in 2012. Drug resistance surveys are ongoing in
Brazil, Ethiopia, Kenya, Pakistan, the Philippines, South
Africa and Viet Nam.
By the end of 2011, India and the Russian Federation,
which combined with China contribute to almost 60%
of the estimated global burden of MDR-TB, had produced
reliable data only at subnational level. These countries
should consider conducting nationwide drug resistance
surveys in the short term to better understand the burden
of MDR-TB and properly plan diagnostic and treatment
services.
Routine surveillance represents the best approach for
measuring drug resistance and monitoring trends. Among
the 27 high MDR-TB and 22 high TB burden countries,
Georgia, Kazakhstan, the Republic of Moldova and the
Baltic States now have proper routine surveillance systems to monitor drug resistance.
A group of countries Benin, Bolivia, Chile, Colombia,
El Salvador, Lebanon, Sri Lanka, Mongolia, Nicaragua
and Rwanda that relied on special surveys to monitor
drug resistance have established a routine surveillance
system for all previously treated cases. This is the rst
step towards routine drug susceptibility testing for all TB
patients.
Central and Francophone Africa remain the regions
where drug resistance surveillance data are most lacking,
largely as a result of the scarce laboratory infrastructure.
4.1.2 Percentage of new and previously treated TB

cases that have MDR-TB
Globally, 3.7% (2.15.2%) of new cases and 20% (13
26%) of previously treated cases are estimated to have
MDR-TB (Chapter 2).
The proportions of new TB cases with MDR-TB at country level are shown in Figure 4.2. Proportions ranged from
0% to 32.3% and were highest in Belarus (32.3%), Estonia (22.9%), Kazakhstan (30.3%), Kyrgyzstan (26.4%;
preliminary results), the Republic of Moldova (19.4%)
and Uzbekistan (23.2%). Although the average proportion of patients with MDR-TB in the Russian Federation
is lower than in these countries, the proportion is high in
several oblasts (with Arkhangelsk Oblast at the highest
level: 35.1% in 2010).
The proportion of previously treated TB cases with
FIGURE 4.2
Percentage of new TB cases with MDR-TBa
Percentage
of cases
02.9
35.9
611.9
1217.9
18
No data
Not applicable
a
Figures are based on the most recent year for which data have been reported, which varies among countries.
FIGURE 4.3
Percentage of previously treated TB cases with MDR-TBa
Percentage
of cases
05.9
611.9
1229.9
3049.9
50
No data
Not applicable
a
Figures are based on the most recent year for which data have been reported, which varies among countries.
43
FIGURE 4.4
Countries that had notied at least one case of XDR-TB by the end of 2011
At least one case reported

No cases reported
Not applicable
MDR-TB at country level ranged from 0% to 65.1% (Figure 4.3). Countries or subnational areas with the highest
reported proportions were Azerbaijan (Baku city, 55.8%
in 2007), Belarus (75.6% in 2011), Estonia (57.7% in
2011), Kazakhstan (51.3% in 2011), Kyrgyzstan (51.6%
in 2011; preliminary results), the Republic of Moldova
(63.5% in 2011), Tajikistan (53.6% in 2011; preliminary
results) and Uzbekistan (62.0% in 2011). In the Russian
Federation, even if the average proportion of cases with
MDR-TB does not exceed 50%, the proportion is above
50% in several oblasts (with Arkhangelsk Oblast at the
highest level: 58.8% in 2008).
These data con rm that eastern European and central Asian countries continue to represent hot spots for
MDR-TB, with nearly one third of new and two thirds of
previously treated TB cases affected by MDR-TB in some
settings.
4.1.3 XDR-TB and resistance to second-line

anti-TB drugs
Extensively drug-resistant TB (XDR-TB) has been identied in 84 countries globally (Figure 4.4). A total of 65
countries and 3 territories reported representative data
from continuous surveillance or special surveys on the
proportion of XDR-TB among MDR-TB cases. Combining
their data, the proportion of MDR-TB cases with XDR-TB
was 9.0% (95% condence interval, 6.7%11.2%). Since
2007, only 13 out of 68 (19.1%) countries and territories
have reported more than 10 XDR-TB cases in a single
year. Among them, the proportion of MDR-TB cases with
44
XDR-TB was highest in Azerbaijan (Baku city, 12.7%),

Belarus (11.9%), Estonia (18.7%), Latvia (12.6%), Lithuania (16.5%) and Tajikistan (Dushanbe city and Rudaki
district, 21.0%).
The levels of resistance to uoroquinolones in patients
with MDR-TB are described in Box 4.1.
4.2
Management of drug-resistant TB
4.2.1 Coverage of drug susceptibility testing (DST)

The diagnosis of DR-TB requires that TB patients are tested for susceptibility to drugs. The Global Plan to Stop TB
20112015 (Chapter 1) includes targets that by 2015 all
new cases of TB considered at high risk of MDR-TB (estimated at about 20% of all new bacteriologically-positive
cases globally) and all previously treated cases should
undergo DST. Likewise, all patients with MDR-TB need
to be tested for XDR-TB.
With the exception of the European Region, DST for
rst-line drugs was done for a small proportion of cases
in 2011 (Table 4.1); just over 50% of countries reported
data. Coverage of DST in new cases has remained stable
in recent years and is below that envisaged by the Global Plan for 2011 (Figure 4.5). Globally, less than 4% of
new bacteriologically-positive cases and 6% of previously
treated cases were tested for MDR-TB in 2011, with particularly low levels of testing in the African and SouthEast Asia regions. In the European Region, 56% of new
cases and 27% of previously treated cases were tested for
MDR-TB. Among the 27 high MDR-TB burden countries
which account for 86% of estimated MDR-TB cases in
BOX 4.1
Frequencies of resistance to fluoroquinolones among MDR-TB cases
Fluoroquinolones represent the most powerful class of bactericidal second-line drugs for the treatment of MDR-TB. Patients with MDR-TB
and additional resistance to uoroquinolones have a more serious form of disease compared with those with MDR-TB alone. Their disease
is more difcult to treat, and risks evolving into XDR-TB and acquiring resistance to any of the second-line injectable agents.
Monitoring resistance to uoroquinolones in MDR-TB patients is critical to predict the efcacy of second-line treatment and possibly
modify the composition of the treatment regimen. Since 2007, WHO has collected surveillance data on cases of MDR-TB with additional
resistance to uoroquinolones. In most cases, only the compound most commonly used in the country is tested for susceptibility, usually
ooxacin, moxioxacin or levooxacin.
A total of 62 countries and 3 territories reported representative data on the proportion of MDR-TB cases that had additional resistance to
uoroquinolones. Combining their data, the proportion of MDR-TB cases with additional resistance to uoroquinolones was 14.5% (95%
condence interval 11.617.4%), inclusive of cases with XDR-TB.
FIGURE 4.5
DST coverage among new cases and enrolment on MDR-TB treatment, compared with the targets in the
Global Plan to Stop TB, 20112015. Lines indicate the planned targets, blue squares show the situation in 20092011
and green circles the projected enrolments 20122015.
a. DST coverage among new bacteriologically-positive cases
b. Enrolment on MDR-TB treatment

300 000
25
250 000
Number of patients
Percentage of cases
20
15
10
200 000
150 000
100 000
50 000
0
2009
2010
2011
2012
2013
2014
2015
the world the proportion of cases tested was higher than

20% among new cases in 10 of the 12 European countries reporting data, and exceeded 50% among previously
treated cases in six European countries. While data on
DST were not available for new and previously treated
cases separately, overall 13% of TB cases were tested for
drug resistance in South Africa. Among non-European
high MDR-TB burden countries, testing for MDR-TB
among new cases was highest in China (2.6%); among
previously treated cases testing coverage was higher
and reached 17% in the Philippines. India, the country
estimated to have the highest number of MDR-TB cases
among notied TB patients (Figure 4.6), reported no data.
Among TB patients who were notied and con rmed
to have MDR-TB in 2011, 23% were reported to have
second-line DST for both uoroquinolones and secondline injectable drugs, and coverage exceeded 90% in
Armenia, Estonia, Georgia, Lithuania and Pakistan.
South Africa accounted for most of the cases with secondline DST data reported globally, as well as the high level
observed in the African Region, which drops from 67% to
9% when excluding this country. Otherwise, second-line
2009
2010
2011
2012
2013
2014
2015
DST reports were available for 51% of cases in the Eastern

Mediterranean Region, 40% in the Region of the Americas and 810% in the other regions.
Progressive acquisition of drug resistance is a considerable risk if TB patients are inadequately tested and treated
(see Box 4.2). Increasing the coverage of diagnostic DST is
urgently needed to improve the diagnosis of MDR-TB and
XDR-TB, and requires strengthening laboratory capacity
and the introduction of new rapid diagnostics (for further
details, see Chapter 6).
4.2.2 Notification of MDR-TB cases and enrolment on

treatment
The suboptimal levels of coverage of DST in many countries are one of the main reasons why the number of
people who are diagnosed with MDR-TB remains low.
Globally, just under 60 000 cases of MDR-TB were notied to WHO in 2011, mostly by European countries and
South Africa (Table 4.2). This represented 19% of the
310 000 (range, 220 000400 000) cases of MDR-TB estimated to exist among patients with pulmonary TB who
were notied in 2011. An additional 4500 rifampicin-
45
TABLE 4.1 DST coverage among TB and MDRTB cases, 27 high MDR-TB burden countries and WHO regions, 2011
NEW BACTERIOLOGICALLY POSITIVE CASES
NUMBER WITH
DSTa RESULT
Armenia
439
Azerbaijan
Bangladesh
China
DR Congo
Estonia
71
90
0.1
761
588
9 940
22
210
Ethiopia
73
Georgia
2 197
India
Indonesia
96
PREVIOUSLY TREATED CASES

NUMBER WITH
DSTa RESULT
Belarus
Bulgaria
% OF CASES WITH
DST RESULT
62
145
2.6
<0.1
100
0.1
83
160
52
139
675
<0.1
NUMBER WITH
DST b RESULT
% OF CASES WITH
DST RESULT
23
79
100
10
41
46
46
2.0
68
3.0
52
695
CONFIRMED MDRTB CASES
% OF CASES WITH
DST RESULT
9.0
84
2.9
75
96
440
93
88
23
Kazakhstan
5 293
83
4 790
55
Kyrgyzstan
451
29
232
22
357
44
Latvia
Lithuania
562
96
82
85
95
90
1 031
100
369
100
295
100
Myanmar
Nigeria
<0.1
25
<0.1
2 325
Pakistan
Philippines
12
76
14
15
344
100
17
0.9
Republic of Moldova
1 379
74
1 006
68
Russian Federation
34 007
78
13 620
25
8 072
80
415
45
122
20
834
60
South Africa
Tajikistan
161
Ukraine
Uzbekistan
484
Viet Nam
High MDRTB burden countries
AFR
AMR
7.4
11
123
56 950
1 311
13 334
EMR
2 264
EUR
69 467
2.6
0.2
10
1.2
56
6.4
25 755
3 707
4 234
1 466
25 561
4.5
10 907
21
2.9
8 272
67
1 183
40
431
51
20
6.9
27
2 757
8.5
9.7
SEAR
1 200
0.1
1 925
0.5
642
WPR
25 284
4.2
5 131
6.1
336
112 860
3.8
42 024
6.0
13 621
Global
7.7
23

a
DST is for isoniazid and rifampicin.
b
DST is for a uoroquinolone and a secondline injectable drug.
resistant cases were reported to have been detected using

Xpert MTB/RIF; 80% of these were accounted for by the
Philippines and South Africa.1
The proportion of TB patients estimated to have MDRTB that were actually diagnosed was under 20% in almost
all of the high MDR-TB countries outside the European
These are separate from other rifampicin-resistant cases detected by Xpert MTB/RIF, which were included under MDR-TB
notications following subsequent laboratory testing.
46
Region including India (6%) and China (3%). The

notable exception was South Africa where the numbers
reported exceeded the estimated number of cases (Figure 4.7). In the Russian Federation, which ranks third in
terms of estimated numbers of cases of MDR-TB globally,
the proportion of estimated cases that were diagnosed was
31%. Overall, 52/174 countries estimated to have at least
one MDR-TB case among notied TB patients reported
more than 50% of their expected MDR-TB caseload (2015
target: 100%). Nonetheless, there has been an increase
FIGURE 4.6
Number of MDR-TB cases estimated to occur among notied pulmonary TB cases, 2011
MDR-TB cases
0299
3002999
300029 999
30 00059 999
60 000
No data
Not applicable
BOX 4.2
Totally drug-resistant TB and developments in India in 2012
In December 2011, clinicians in Mumbai, India reported TB patients with what was termed total drug resistance.1 As a result of the
intense public interest generated by this episode, in March 2012 WHO convened 40 experts to discuss its implications, whether current
evidence makes it possible to dene patterns of drug resistance beyond extensively drug resistance TB (XDR-TB) and if better guidance
on appropriate treatment options for these patients was possible. While the group acknowledged that patients such as those described in
Mumbai pose a formidable challenge to clinicians and public health authorities, no reliable denition beyond XDR-TB could be proposed.
Without having a better evidence base, no changes to the current guidelines on how to design treatment regimens for patients with broad
patterns of resistance could be recommended. Improvements in the accuracy of drug susceptibility testing to certain drugs and the release
of innovative new drugs will, however, change this position in future.
Since December 2011, several important measures have been taken by the Indian government. In Mumbai, laboratory and hospital
facilities were improved, contact-tracing stepped up and efforts made to train staff on drug-resistant TB and infection control. Medical
staff and funding were increased substantially. Access to second-line drugs was provided to eligible patients. National regulations
governing private sales of anti-TB medication were strengthened. By the end of 2012, all 35 states in the country are expected to provide
programmatic management of drug-resistant TB. In May 2012, India made TB a notiable disease and data collection on TB using a webbased system was initiated.2
1
Udwadia ZF et al. Totally drug-resistant tuberculosis in India. Clinical Infectious Diseases, 2012, 54(4):579581.
Press Information Bureau English Releases (available from: http://pib.nic.in/newsite/erelease.aspx?relid=83486).
in the total number of MDR-TB cases notied between

2010 and 2011 in 19 of the high MDR-TB countries and in
all WHO regions except the Eastern Mediterranean and
European regions.
The ratio of notied MDR-TB cases to numbers of
patients starting treatment with second-line drug regimens for MDR-TB was almost 1:1 globally, but lower in
the African and South-East Asia regions in 2011, possibly reecting the empiric treatment of TB patients at risk
of MDR-TB without a laboratory con rmation or enrol-
ment on treatment of MDR-TB patients detected before

2011 (Table 4.2). Enrolments in the high MDR-TB burden countries nearly doubled between 2009 and 2011 as
a result of steady annual increases in 12 of the countries,
including India, the Philippines, the Russian Federation, South Africa and Ukraine, each of which reported
enrolling more than 2000 patients in 2011. Among 120
countries reporting sex-disaggregated data, the median
male:female ratio was 2. Most countries providing MDRTB enrolment data did not report the inclusion of any
47
TABLE 4.2 Notied cases of MDR-TB and enrolments on MDR-TB treatment 20092011, projected enrolments 20122015
and treatment outcome reporting for 2009 cohort, 27 high MDR-TB burden countries and WHO regions
CASES ENROLLED ON
MDR-TB TREATMENT
NOTIFIED CASES
2009
Armenia
156
Azerbaijan
Bangladesh
Belarus
Bulgaria
1 342
2010
2011
177
79
552
722
339
509
2009
2010
134
352
1 576
CASES EXPECTED TO BE ENROLLED

ON MDR-TB TREATMENT
2011
154
88
286
572
339
390
2012
240
2013
200
2014
134
2 597
1 050
1 300
2 000
55
43
56
42
60
70
1 601
458
1 222
1 155
7 237
3 495
DR Congo
91
87
121
176
191
128
700
800
900
Estonia
86
63
78
86
63
75
80
70
65
Ethiopia
233
140
212
88
120
199
1 071
1 714
Georgia
369
359
475
266
618
737
550
1 660
2 967
4 237
1 136
2 967
3 384
182
383
20
142
260
70
43
100
260
55
1 000
177
195
65
85
99
2 143
2 571
73
31
540
540
530
503
136
15 000
25 000
30 000
32 000
715
43
900
1 800
1 700
Kazakhstan
3 644
7 387
7 408
3 209
5 705
5 261
6 280
7 000
Kyrgyzstan
785
566
806
545
566
492
1 100
1 000
125
125
125
70
7 000
Latvia
131
87
105
124
87
103
Lithuania
322
310
296
322
310
296
Myanmar
815
192
690
64
192
163
400
400
400
400
28
21
95
23
38
220
400
450
550
Pakistan
86
56
Nigeria
167
200
2 792
Indonesia
%a
43
India
2015
200
474
China
MDR-TB CASES
REPORTED WITH
TREATMENT
OUTCOME DATA,
2009 COHORT
125
19
7 579
208
545
69
131
100
322
100
64
7.9
49
444
344
368
424
344
1 115
2 900
5 300
6 360
74
151
Philippines
1 073
522
1 148
501
548
2 397
2 372
2 372
2 237
2 237
394
37
Republic of Moldova
1 069
1 082
1 001
334
791
765
Russian Federation
14 686
13 692
13 785
8 143
13 692
18 902
9 070
7 386
10 085
4 143
5 402
5 643
319
333
604
52
245
380
3 482
5 336
4 298
3 186
3 870
4 950
654
1 023
1 385
464
628
855
601
307
101
578
950
1 100
1 300
1 500
101
47
38 942 48 197
35 712
52 371
55 530
57 208
19 794
49
57
South Africa
Tajikistan
Ukraine
Uzbekistan
Viet Nam
217
101
High MDR-TB burden countries
40 798
47 772
51 123 24 521
4 654
230
1 865
800
800
800
2 155
51
52
16
3 238
93
464
71
AFR
10 741
9 340
12 384
5 994
7 209
7 467
4 409
5 735
6 645
7 539
6 143
AMR
2 884
2 661
2 969
3 153
3 249
3 087
3 435
3 684
3 404
5 551
2 340
81
EMR
496
886
841
707
976
756
3 293
3 937
6 499
7 770
511
103
EUR
28 157
33 863 32 348
17 169
28 336
34 769
4 023
12 262
10 073
8 863
14 158
50
SEAR
2 560
3 937
6 615
2 040
3 901
4 572
20 856
30 217
35 374
36 373
1 140
45
WPR
2 059
4 295
4 392
1 422
2 210
4 946
11 102
7 553
4 167
4 440
1 027
50
47 118 63 388
66 162
70 536
25 319
54
Global
46 897
54 982 59 549 30 485
45 881 55 597

a
The percentage of MDR-TB cases originally notied in 2009 with outcomes reported. Percentage may exceed 100% as a result of updated information about MDR-TB
cases in 2009, absence of linkage between notication systems for TB and MDR-TB, and the inclusion in the treatment cohort of cases of MDR-TB cases from a year prior to
2009.
48
FIGURE 4.7
Notied cases of MDR-TB as a percentage of MDR-TB cases estimated to occur among notied pulmonary
TB cases, 2011a
Percentage notified
of estimated
MDR-TB cases
09.9
1019.9
2049.9
5079.9
80
1 MDR-TB case estimated
No data
Not applicable
a
MDR-TB notications from 2010 are used for 18 countries with missing 2011 data.
children; in the 37 that did, children represented 113%

of total enrolments.
While the absolute numbers of TB cases notied with
MDR-TB and started on second-line treatment remain
low compared with the Global Plans targets, enrolments
increased by 21% globally between 2010 and 2011 (Figure 4.5). Country plans envisage increased enrolments
between 2012 and 2015, although numbers remain well
below targets, partly as a result of incomplete information on forecasts in countries with large burdens, such as
China, the Russian Federation and South Africa. To reach
the targets set out in the Global Plan and advance towards
universal access to treatment, a bold and concerted drive
will be needed on many fronts of TB care, particularly in
the countries where the highest burden is located.
4.2.3 Treatment outcomes for MDR-TB and XDR-TB

Standardized monitoring methods and indicators have
allowed countries to report MDR-TB treatment outcomes
in a comparable manner for several years.1 In most cases, treatment of MDR-TB lasts 20 months or longer, and
requires daily administration of drugs that are more toxic
1
These methods and indicators are de ned in Guidelines for the

programmatic management of drug-resistant tuberculosis, Emergency update 2008. Geneva, World Health Organization, 2008
(WHO/HTM/TB/2008.402). It is anticipated that revised denitions of treatment outcomes will be released in 2013 following piloting in several countries.
and less effective than those used to treat drug-susceptible forms of TB. In a few countries, shorter treatment
regimens are being used to treat patients with MDR-TB
(Box 4.3).
A total of 107 countries reported outcomes for more
than 25 000 MDR-TB cases started on treatment in 2009
(Table 4.2; Figure 4.8). This is equivalent to 54% of the
number of MDR-TB cases notied by countries in the
same year. The Global Plan envisages that by 2015, all
countries will report outcomes for all notied MDR-TB
cases. In contrast, among 117 countries reporting at least
one case of MDR-TB in 2009, 60 overall including 10
high MDR-TB burden countries reported outcomes for a
cohort whose size exceeded 80% of original notications.
The proportion of MDR-TB patients who successfully
completed treatment varied from 44% (Eastern Mediterranean Region) to 58% (South-East Asia Region). Deaths
were highest in the African Region (19%) and the proportion of patients whose treatment failed was highest in
the European Region (12%). Overall, treatment success
was 48%, while 28% of cases were reported as lost to
follow-up or had no outcome information. Among a subset
of 200 XDR-TB patients in 14 countries, treatment success
was 33% overall and 26% died. The Global Plans target
for 2015 of achieving at least 75% treatment success in
MDR-TB patients was only reached by 30/107 countries.
Moving towards the target for treatment success requires
enhancing and scaling up the currently available drug
49
BOX 4.3
Treatment regimens for MDR-TB lasting up to 12 months
WHOs guidelines on treatment of MDR-TB recommend an intensive phase of 8 months and a total duration of 20 months in most
patients.1 While these recommendations are conditional, they are based on >9000 cases treated in observational studies. 2 There is much
less evidence on the effectiveness and safety of regimens of substantially reduced duration and different drug composition, which have
been termed short-regimens. One observational study from Bangladesh using shorter regimens yielded much higher treatment success
than is usually achieved with the longer regimens, and for this reason has generated much interest in the scientic community.3
WHOs position is that regimens which are markedly different from those that make up the current norm should be used only within the
context of research and under close monitoring of the clinical and bacteriological response to treatment for a period of at least 12 months
after treatment is completed. One of the major concerns is that patients who do well after 912 months of treatment with less drugs in
the continuation phase than in the longer regimen may have a higher risk of acquiring resistance in the process and relapsing. Proper
attention to regulatory and ethical issues will be needed to facilitate gathering evidence for use in future updates of policy and standards.
Until sufcient evidence is available to inform a change in policy, WHO is advising countries on a case-by-case basis to introduce short
MDR-TB regimens in projects where:
treatment is delivered under operational research conditions following international standards (including Good Clinical Practice and
safety monitoring), with the objective of assessing the effectiveness and safety of these regimens;
the project is approved by a national ethics review committee, ahead of any patient enrolment; and
the programmatic management of DR-TB and the corresponding research project are monitored by an independent monitoring board
set up by, and reporting to, WHO.
1
Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. (WHO/HTM/TB/2011.6). Geneva, World Health
Organization, 2011.
Ahuja SD et al. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of
9,153 Patients. PLoS Med. 2012, 9(8):e1001300.
Van Deun A et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. American Journal of Respiratory
and Critical Care Medicine, 2010, 182(5): 684692.
BOX 4.4
MDR-TB and mortality
The national surveillance data included in this report show that in all WHO regions a much larger proportion of patients in the MDR-TB
cohorts die compared with the overall TB patient cohorts (Figure 4.8; see also Table 3.5 and Table 3.6 in Chapter 3). MDR-TB has been
described as an independent risk factor for dying even after adjustment for potential confounders.1,2
Data on TB mortality for 2011 from vital registration systems (which exclude deaths attributed to HIV) and data from drug resistance
surveillance on the proportion of TB patients with MDR-TB (among those not previously treated for TB) were analysed to explore the
relationship between these variables. There was no association between TB mortality rates and the proportion of TB patients with MDRTB level in high-income countries (p= 0.3) but there was a positive and signicant association in low and lower middle-income countries
(p<0.001). The positive association remained after adjusting for differences in the age-structure of the population and the prevalence of
HIV-related TB.
Variations in the mortality to total TB notication (M:N) ratio observed in the European region, with high levels in the Russian Federation
(M:N ratio of 20%), lower levels in Estonia, Latvia and Lithuania (11%) and even lower levels in the high-income western European
countries, may reect the impact of differences in the burden of drug-resistant TB and in the effectiveness of efforts to treat MDR-TB.
Analysis of TB mortality data, despite inherent limitations, may help to improve understanding of the different determinants of death in
TB patients, such as MDR-TB. Further exploration of these data is warranted.
50
Low S et al. Mortality among tuberculosis patients on treatment in Singapore. Int J Tuberc Lung Dis, 2009, 13(3):328-34.
Mathew TA et al. Causes of death during tuberculosis treatment in Tomsk Oblast, Russia. Int J Tuberc Lung Dis, 2006, 10(8):857-63.
regimens globally, providing more support that helps

patients adhere to treatment and improving data collection, including TB mortality statistics (Box 4.4).
4.2.4 Other aspects of MDR-TB programme

management
In the course of their illness, patients with MDR-TB
may be cared for as outpatients or in hospitals, usually
secondary or tertiary facilities. WHO recommends that
where possible patients with MDR-TB are treated using
ambulatory care rather than models of care based principally on hospitalization. National policies differ in the
predominant model of care that is employed. Among the
high MDR-TB burden countries, those in Eastern Europe
hospitalize 75100% of patients except for the central
Asian countries (Kazakhstan, Tajikistan and Uzbekistan;
3071%). In the African Region, there is very wide variation in hospitalization, from 10% of patients (Democratic Republic of the Congo) to much higher levels of 70%
(South Africa) and >95% (Ethiopia and Nigeria). The
average duration of hospital stay ranged from 7 to 240
days (median: 90 days). The number of visits to a health
facility after diagnosis of MDR-TB also differed markedly
among countries from less than 25 (Bangladesh, Estonia,
Georgia, Pakistan, South Africa and Viet Nam) to over
600 (Bulgaria, Indonesia and Latvia).
Palliative and end-of-life care delivered through
home-based or institutional services is important for
patients with advanced disease that is not responding to
treatment. Nine of the European high MDR-TB burden
countries plus South Africa reported providing such care
within the scope of the TB control programme.
Among 14 high MDR-TB burden countries providing
information on the quality of second-line drugs in the
public sector, most reported conformity to international
standards in all or some supplies of kanamycin (12/14),
FIGURE 4.8
Treatment outcomes for patients diagnosed

with MDR-TB by WHO region, 2009 cohorts.
The number of countries reporting outcomes for
at least one case, followed by total cases with
outcome data, shown beside each bar.
AFR
(26, 6 143)
AMR
(21, 2 340)
EMR
(14, 511)
EUR
(23, 14 158)
SEAR
(8, 1 140)
WPR
(15, 1 027)
Global
(107, 25 319)
0%
10%
Success
20%
30%
Died
40%
Failed
50%
60%
Defaulted
70%
80%
90%
100%
Unknown
capreomycin (9/11, with 3 other countries not using it),

levooxacin (10/12, with 2 others not using it), ethionamide/prothionamide (12/14) and p-aminosalicylic acid
(9/11, with 3 others not using it). Two countries reported
that all their drugs conformed only to national regulatory
norms.
The information needed to adequately monitor TB
patients, and in particular those on MDR-TB treatment,
is substantial. The use of electronic systems as a tool to
manage data is therefore strongly encouraged (see also
Box 2.5). One of the Global Plans targets is that all 27
high MDR-TB countries manage their data on treatment
of MDR-TB patients electronically by 2015. By 2011, 20
reported that national databases were in place for MDRTB patients, but none were available in Bangladesh, India
(see also Box 4.2), Myanmar, Nigeria, the Russian Federation, Ukraine and Viet Nam.
51
CHAPTER 5
Financing TB care and control

The Global Plan to Stop TB 20112015 sets out the funding
needed for implementation of TB care and control in low
and middle-income countries. From 2013 to 2015, up to
US$ 8 billion per year is required. In 2015, about US$ 5 billion
is needed for the diagnosis and treatment of drug-susceptible
TB, US$ 2 billion for diagnosis and treatment of MDR-TB and
almost US$ 1 billion for TB/HIV interventions.
In 2013 funding is expected to reach US$ 4.8 billion in 104
low- and middle-income countries (94% of global cases) that
reported data to WHO. These amounts generally exclude
funding for TB/HIV interventions, notably ART, that are funded
via HIV programmes. Thus, an extra US$ 23 billion per year is
needed from national and international sources by 2015.
There is capacity to mobilize increased funding from domestic
sources in low and middle-income countries, especially in Brazil,
the Russian Federation, India, China and South Africa (BRICS)
that already rely entirely or mostly on national contributions.
Increased domestic funding in BRICS will be especially critical
for scaling up the diagnosis and treatment of MDR-TB.
International donor funding of up to US$ 1 billion per year is
needed for low and middle-income countries 20132015 to
close funding gaps. This is double the amount of US$ 0.5 billion
expected in 2013 but still much less than the amounts being
mobilized for malaria (US$ 2.0 billion in 2010) and HIV
(US$ 6.9 billion in 2010).
Progress in TB prevention, care and control

requires adequate funding. WHO began monitoring of funding for TB in 2002, and the global TB
database holds data from 2002 up to 2013. This
chapter focuses on the years 20062013, during
which trends can be assessed for 104 low- and middle-income countries that collectively account for
94% of the worlds TB cases.
Trends in total funding are broken down by
country group (Section 5.1), category of expenditure (Section 5.2) and sources of funding (Section
5.3), highlighting striking variations in countries
reliance on donor funding. Section 5.4 compares
funding for TB care and control with total government expenditures on health care. Section 5.5
presents estimates of the cost per patient successfully treated with rst-line drugs, as well as the
total reported funding and unit cost per person for
rst-line and second-line anti-TB drugs. Section 5.6
describes the funding gaps reported by countries.
The nal part of the chapter (Section 5.7) assesses
the gap between projections of potential funding
from domestic sources and the funding requirements specied in the Global Plan.
Further details for each of the 104 countries and
a few additional countries for which trends could
not be assessed for the entire period 20062013
are provided in country
nance pro les that are
available online.1
Brazil
| High TB burden
| High HIV burden
|
WHO TB planning
International donor funding is especially critical to safeguard

recent gains in TB care and control and enable further progress
in low-income countries and in the group of 17 HBCs outside
BRICS. In these country groups, it provides >60% and about
one third of total funding, respectively.
used:
Tuberculosis finance
profile
No
80
Funding by line item
60
Grants (exc Global
80
70
Fund)
Global Fund
40
source
Grants (exc
Global Fund)
Loans
NTP
Government,
150
budget
10
OR/Surveys/Other
PPM/PAL/ACSM/CBC
5
Unknown
MDR-TB
Unknown
100
OR/Surveys/Other
PPM/PAL/ACSM/CBC
40
30
DOTS
her
20
OR/Surveys/Ot
0
M/CBC
10
PPM/PAL/ACS
2006
2007 2008 2009 2010
2011 2012
0
TB/HIV
* ACSM:
Advocacy, Communicat
2007
2008
ion and Social Mobilization;
B
PAL:MDR-T
Practical
Approach to Lung
Health; PPM: Public-Privat CBC: Community-based TB Care;
e Mix; OR: Operational
Per-patien
DOTS t budget
Research
200
(bar)
70
60
50
TB/HIV
150
Global Fund
200
DOTS
2006 2007 2008

2009 2010 2011
2012
Received funding
(dotted line) and actual
expenditure by line
(US$ millions)
item
le
Funding gap
profi
by line item (US$
millions)
ce
sis finan
15
Tuberculo
250
TB/HIV
MDR-TB
10
0
2010 2011 2012
India
Funding by
OR/Surveys/Other
PPM/PAL/ACSM/CBC
30
20
2006 2007 2008 2009
(US$ millions
Unknown
50
40
budget
|
TB burden
High MDRburden |
High HIV
burden |
diture
| High TB
No
g and expen
ng tool used:
millions)
ble fundin
and budgeti
line item (US$
budget, availa
WHO TB planning
Funding by
mme (NTP)
al TB Progra
250
Total Nation
)
(US$ millions)
60
Loans
Government, NTP
20
TB/HIV
MDR-TB
DOTS
2009
2010
50
100
0
2006 2007
Of the international donor funding expected by national TB

control programmes in 2013, 88% is from the Global Fund. In
the absence of any other major streams of international donor
funding for TB, the Global Fund has a crucial role in sustaining
and ensuring further progress in TB care and control worldwide.
DOTS budget required

per TB patient to be
2012(US$ per patient)
treated
2010 2011
(bar)
2008 2009
by line item
1100
2006 2007
expenditure
line) and actual1000
funding (dotted
Received
)
(US$ millions
900
Unknown
80
her
800
70
OR/Surveys/Ot
M/CBC
AL/ACS
60
PPM/P
700
50
2008 2009
Funding gap
2010 2011
by line item
2012
)
(US$ millions
her
OR/Surveys/Ot
M/CBC
PPM/PAL/ACS
1
0.8
TB/HIV
50
600
40
500
2008
30
MDR-TB
0.6
20
MDR-TB budget
required per MDR-TB
patient to be treated
(US$ per patient)
20000
18000
16000
14000
TB/HIV
MDR-TB
DOTS
2009
2010
12000
2011 2012
DOTS
10
2010
0
2009 Use of
2008
general health services
2007
Average length of
hospital stay during
ed TB Care;
treatment (days)
Community-bas Research
2011 2012
30
tion; CBC:
2009 2010
onal
Social Mobiliza rivate Mix; OR: Operati
nication and
Public-P
cy, Commu
to be treated
Health; PPM:
* ACSM: Advoca
ch to Lung
MDR-TB patient
Approa
New smear-positi
l
required per 20
ve
PAL: Practica
MDR-TB budget
New smear-neg/e
budget
xtrap
(US$ per patient)
Per-patient
treated
to be
MDR-TB
TB patient
6000
required per
10
DOTS budget
5000
patient)
(US$ per
10000
2008
0.4
2009
2010
2011
2012
0.2
2008
2006 2007
4000
80
2006 2007 2008

2009 2010 2011
40
2008
2009
2010
2011
2009
2010
care during
Outpatient
2011
New smear-positi
ve
New smear-neg/e
xtrap
40
MDR-TB
Generated: Septembe
r 23, 2012
2012
(typical
treatment
number of
Source: www.who
.int/tb/dat
400
positive
New smeareg/extrap
New smear-n
MDR-TB
visits)
positive
New smeareg/extrap
New smear-n
500
stay
10
The cost per person successfully treated for TB with rstline drugs is in the range US$ 100 to US$ 500 in almost all
countries with a high burden of TB.
number of visits)
60
2012
services
al health
nt (days)
Use of gener
during treatme
of hospital
treatment (typical
2006 2007 2008

2009 2010 2011
1000
0
2008
50
80
2000
60
Outpatient care during
20
3000
70
Average length
MDR-TB
300
200
6
100
4
2
0
52
and budgeting tool
Total National TB
Programme (NTP)
budget, available
funding and expenditur
(US$ millions)
e
Funding by source
2010 2011
2008 2009
2006 2007
2010 2011
2008 2009
2006 2007
Sourc e:
September
Generated:
www. who.i
nt/tb/d ata
23, 2012
w ww.who.int/tb/data
5.2
Funding for TB care and control by

category of expenditure, 20062013
In each year 20062013, the largest share of funding has

been used for the diagnosis of TB and treatment with
rst-line drugs (all categories of expenditure except those
labelled MDR-TB in Figure 5.2 and Figure 5.4). However,
funding for the diagnosis and treatment of MDR-TB has
been increasing and is expected to exceed US$ 0.7 billion
in 2013 (Figure 5.2). Much of the increase is accounted for
by BRICS, but allocations are increasing in other HBCs
and the rest of the world as well (Figure 5.4).
The relatively small amounts of funding reported for
collaborative TB/HIV activities (see Chapter 7 for further
details) reect the fact that funding for most of these
interventions (including the most expensive, antiretroviral treatment) is usually channelled to national HIV
programmes and nongovernmental organizations rather
than to national TB control programmes (NTPs).
5.3

source of funding, 20062013
Domestic funding from national governments is the

single largest source of funding for TB care and control
(Figure 5.3), accounting for 90% of total expected funding in 2013.1 Of the remaining 10% that is expected from
donor sources in 2013, most (88%) is accounted for by
1
Funding for TB care and control in 104

countries reporting 94% of global cases,
by country group, 20062013
5
4.5
US$ billions (constant 2012 US$)
In the 104 countries for which trends in TB funding since

2006 can be assessed and that report 94% of the worlds
TB cases (listed in Table 5.1), funding is expected to reach
US$ 4.8 billion in 2013 (Figure 5.1). This is an increase
in real terms from US$ 3.4 billion in 2006 and a small
increase from US$ 4.6 billion in 2012.
Brazil, the Russian Federation, India, China and South
Africa (BRICS), which report 48% of the worlds TB cases (Chapter 3), account for US$ 3 billion (63%) of the
expected total of US$ 4.8 billion in 2013 (Figure 5.1). The
other 17 high TB burden countries (HBCs) outside BRICS
(listed in Table 5.2), which report 34% of the worlds TB
cases, account for US$ 0.6 billion. A group of 10 European
countries other than the Russian Federation accounts for
a further US$ 0.5 billion (80% of which is accounted for
by three countries: Romania, Turkey and Uzbekistan).
Patterns of funding for multidrug-resistant TB (MDRTB) specically are different, as described in Box 5.1.
FIGURE 5.1
4
3.4
3.6
3.9
4.8
4.0
3.3
Low- and middleincome countries,

excluding HBCs and
Europe
Low- and middleincome countries of
Europe, excluding
the Russian
Federation
HBCs, excluding
BRICS
BRICS
2006 2007 2008 2009 2010 2011
FIGURE 5.2
4.5
4
3.4
2012
2013

by line item, 20062013
3.6
3.9
4.6
4.8
4.0
3.3
General health-care
services: MDR-TB
General health-care
services: DOTS
Other
PPM/PAL/ACSM/
CBC/OR/surveys
TB/HIV
MDR-TB
DOTSa
4.6

country group, 20062013
2006 2007 2008 2009 2010 2011
2012 2013
DOTS includes funding available for rst-line drugs, NTP staff, programme
management and supervision, and laboratory equipment and supplies.
FIGURE 5.3

by source, 20062013
5
5.1
4.5
4
3.4
3.6
3.9
4.6
4.8
4.0
3.3
Global Fund
Grants (excluding
Global Fund)
Government,
general health-care
services
Government, NTP
budget (including
loans)
2006 2007 2008 2009 2010 2011
2012
2013
Domestic funding includes funding for outpatient visits and

inpatient care in hospitals, the costs of which are not usually
included in NTP budgets and expenditures. The amount of
domestic funding for these inputs to TB treatment are estimated by combining data on the average number of outpatient
visits and days in hospital per TB patient reported by countries
with WHO estimates of the unit costs of outpatient visits and
bed-days (see www.who.int/choice).
53
TABLE 5.1 104 countries for which trends in TB funding could be assessed, by income group and WHO region,
20062013a
LOW-INCOME
(GNI PER CAPITA US$ 1025 IN 2011)
LOWER MIDDLE-INCOME
(GNI PER CAPITA US$ 10264035 IN 2011)
UPPER MIDDLE-INCOME
(GNI PER CAPITA US$ 403612 475 IN 2011)
African
Benin, Burkina Faso, Burundi, Central

African Republic, Chad, Democratic
Republic of the Congo, Eritrea,
Ethiopia, Gambia, Guinea-Bissau,
Kenya, Liberia, Madagascar, Malawi,
Mali, Mauritania, Mozambique, Niger,
Rwanda, Sierra Leone, Togo, Uganda,
United Republic of Tanzania, Zimbabwe
Cameroon, Cape Verde, Congo, Cte

dIvoire, Ghana, Lesotho, Nigeria,
Sao Tome and Principe, Senegal,
Swaziland, Zambia
Botswana, Gabon, Namibia, South

Africa
Americas
Haiti
Bolivia (Plurinational State of),

El Salvador, Guatemala, Guyana,
Honduras, Nicaragua, Paraguay
Argentina, Brazil, Colombia, Dominican

Republic, Ecuador, Jamaica, Mexico,
Panama, Suriname, Venezuela
(Bolivarian Republic of)
Afghanistan, Somalia
Djibouti, Egypt, Morocco, Pakistan,

Sudan, Yemen
Iran (Islamic Republic of), Jordan,

Lebanon, Tunisia
Armenia, Georgia, Republic of

Moldova, Uzbekistan
Bulgaria, Latvia, Montenegro, Romania,

Russian Federation, Serbia, Turkey
WHO REGION
European
South-East Asia
Bangladesh, Myanmar, Nepal
Bhutan, India, Indonesia, Sri Lanka,

Timor-Leste
Maldives, Thailand
Western Pacic
Cambodia
Kiribati, Lao Peoples Democratic

Republic, Micronesia (Federated States
of), Mongolia, Papua New Guinea,
Philippines, Solomon Islands, Tonga,
Vanuatu, Viet Nam
China, Malaysia, Tuvalu
Another 11 low- and lower middle-income countries with data available for the years 20112013 were included in the analyses of Figure 5.12: low-income, African:
Guinea; low-income, European: Kyrgyzstan, Tajikistan; low-income, South-East Asia: Democratic Peoples Republic of Korea; lower middle-income, Americas: Belize;
lower middle-income, Eastern Mediterranean: Iraq, Syrian Arab Republic, West Bank and Gaza Strip; lower middle-income, European: Ukraine; lower middle-income,
Western Pacic: Fiji, Marshall Islands.
FIGURE 5.4
Funding for drug-susceptible TBa and MDR-TB,b 20062013, by country group
BRICS
Other HBCs
3000
Other low- and middle-income countries

Drug-susceptible TB,
best estimate and
595th percentiles
600
US$ millions (constant 2012 US$)
1000
2000
400
1000
200
500
0
2006
a
b
MDR-TB, best
estimate and
595th percentiles
2008
2010
2012
2006
0
2008
2010
2012
2006
2008
2010
2012
Costs include rst-line drugs, NTP staff, programme management and supervision, laboratory equipment and supplies, hospital stays and clinic visits.
Costs include second-line drugs, programme management and supervision, hospital stays and clinic visits.
54
TABLE 5.2 NTP budgets, available funding, cost of utilization of general health-care services and total funding required
for TB care and control, 2013 (current US$ millions) a,b
AVAILABLE FUNDING
NTP BUDGET
REQUIRED
GOVERNMENT
(INCLUDING
LOANS)
Afghanistan
11
0.4
Bangladesh
50
1.2
Brazil
86
Cambodia
25
China
70
1.1
GLOBAL FUND
2.2
15
GRANTS
(EXCLUDING
GLOBAL FUND)
1.1
REPORTED
FUNDING
GAP
7.2
COST OF
GENERAL
HEALTH-CARE
SERVICES
(ESTIMATED)
2.8
14
3.2
54
34
0.1
16
2.9
4.8
17
6.8
55
22
108
% OF
DOMESTIC
FUNDING IN
NTP BUDGET
% OF
DOMESTIC
FUNDING
IN TOTAL
AVAILABLEc
10
30
7.1
100
15
100
32
12
31
341
83
83
341
239
Democratic Republic of the Congo
14
Ethiopia
52
India
207
120
Indonesiad
117
2.7
Kenya
51
8.6
Mozambique
35
1.9
3.7
2.5
27
Myanmar
31
0.7
8.3
0.3
22
Nigeria
39
8.7
12
8.3
10
17
57
30
Pakistan
52
17
35
12
63
41
Philippines
78
28
50
98
176
100
100
Russian Federation
South Africa
98
98
Thailand
44
40
48
TOTAL
FUNDING
REQUIRED
8.6
13
0
0
5.2
39
14
12
0.2
64
0
58
81
5.7
93
300
29
85
39
156
3.5
36
3.6
1.0
2.7
9.5
61
55
6.7
42
24
6.6
38
3.5
48
Uganda
United Republic of Tanzania
57
7.6
Viet Nam
63
5.6
Zimbabwe
38
2.8
22 high-burden countries e
4.6
13
7.5
8.5
1.9
59
7.5
1.1
24
71
59
64
41
27
56
51
53
2.8
42
45
49
113
31
81
3.5
24
17
54
20
42
1 390
538
270
33
549
401
1 791
64
73
AFR
821
383
129
38
272
680
1 501
70
85
AMR
177
123
15
1.5
37
170
347
88
95
EMR
126
32
44
1.9
48
65
192
41
66
EUR
1 590
1 547
30
14
522
2 227
98
99
SEA
479
181
145
6.5
146
162
642
54
68
WPR
541
293
69
6.1
173
225
765
80
87
Low income
467
37
125
24
283
85
551
20
32
Lower middle income
831
264
250
27
291
517
1 348
49
74
Upper middle income
2 435
2 257
57
117
1 221
3 774
97
98
Low- and middle-income countries
3 733
2 558
431
691
1 823
5 673
84
89
3.2
54

a
Values in this table may differ from those presented in the gures of this chapter, as they have not been adjusted to constant 2012 US$.
b
Region, income group and global totals include estimates for those countries that did not report data for 2013.
c
Total available is the sum of funding available in the NTP budget plus the cost of general health-care services. In low-income countries, the percentage of general healthcare services cost that is domestically funded is assumed to equal the midpoint between the percentage of NTP funding from domestic sources and 100%. In all other
countries it is assumed to equal 100%. Sensitivity to this assumption is analyzed in Figure 5.5.
d
Indonesia was not able to report funding expected from provincial and district budgets in 2013; these numbers reect only the central governments expected contribution.
e
These totals do not include estimates for countries that did not report data for 2013 (Russian Federation, South Africa and Uganda).
55
BOX 5.1
Funding for diagnosis and treatment of MDR-TB, 20092013
The geographical distribution of MDR-TB cases differs considerably from that of all TB cases. Of the estimated 310 000 MDR-TB cases among
notied pulmonary TB cases in 2011, almost 60% were accounted for by three countries: (in rank order) India, China and the Russian Federation
(Chapter 4). Of the 27 high MDR-TB burden countries that account for about 85% of estimated cases globally, 15 are in the European Region,
where the prevalence of MDR-TB among new and previously treated cases is highest (ranging from 9%32% in new cases and 29%76%
among previously treated cases). The costs of diagnosing and treating MDR-TB are also much higher than the costs of diagnosing and treating
drug-susceptible TB. The regimens recommended in WHO guidelines, which last 20 months for most patients, can cost several thousands of US
dollars. Other costs associated with patient care are also high.1
The funding available for MDR-TB treatment in the 104 countries that reported nancial data, and which have 75% of the worlds estimated
cases of MDR-TB, increased from US$ 0.5 billion in 2009 to US$ 0.6 billion in 2011 (Table B5.1.1).1 This gure is expected to increase to more
than US$ 0.7 billion in 2012 and 2013. NTP spending on second-line drugs and programme management accounts for about three quarters of
the total. Second-line drugs alone now amount to more than US$ 0.3 billion per year. The remaining funding (about US$ 0.2 billion) is channelled
through general health-care services (GHS) for inpatient and outpatient treatment of patients with MDR-TB.
TABLE B5.1.1
Funding available and reported gaps for MDR-TB in 104 low- and middle-income countries, US$ millions
Low- and middle-income
countries
High MDR-TB burden

countries
Upper middle-income
countries
Lower middle-income
countries
Low-income countries
2009
2010
2011
2012
2013
Available fundinga
450
566
615
719
705
Avaliable (NTP only) b
353
445
443
541
523
Avaliable (GHS only)
97
121
172
178
183
% domesticc
89
90
85
71
78
Reported gap
117
58
81
115
84
Available fundinga
384
490
526
610
600
315
409
408
492
472
68
81
118
119
128
% domesticc
90
91
85
70
77
Reported gap
109
42
58
94
61
Available fundinga
387
501
513
533
521
307
400
373
389
374
80
101
140
144
148
% domesticc
95
97
93
86
92
Reported gap
99
11
67
Available fundinga
48
54
82
158
162
33
35
53
128
131
15
19
28
30
31
% domesticc
57
42
46
32
40
Reported gap
11
38
49
26
42
Available fundinga
14
11
20
28
21
13
16
24
18
% domesticc
38
29
34
26
31
Reported gap
15
22
23
33
Avaliable (NTP only)
GHS, general health-care services for hospital stays and clinic visits; MDR-TB, multidrug-resistant TB; NTP, national TB control programme or equivalent
a
Includes funding for second-line drugs, MDR-TB programme management and supervision and estimated cost of GHS for patients with MDR-TB.
b
Includes funding for second-line drugs, MDR-TB programme management and supervision only.
c
Assumes GHS is domestically funded.
About 85% of the funding available is concentrated in the high MDR-TB burden countries, in particular upper middle-income countries. In
absolute terms, China and India have the largest external grants for MDR-TB, at US$ 41 million and US$ 43 million respectively from the Global
Fund in 2013. Meanwhile, low-income and lower middle-income countries report a funding gap of US$ 75 million in 2013, leaving almost one
third of their budgets for MDR-TB unfunded.
1
Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics, 2012,
30:6380.
56
WHO REPORT 2012
FIGURE 5.5
Trends in domestic and donor funding for TB care and control, 20062013, by country groupa
BRICS
Other HBCs
Low--income countries
400
200
300
150
200
100
100
50
Domestic sources
including GHS,
595th percentilesa
3000
2000
Global Fund only,

best estimate
1000
0
2006
Foreign sources
including Global Fund,
595th percentilesa
2008
2010
2012
0
2006
2008
2010
2012
2006
2008
2010
2012
In probabilistic sensitivity analysis, the percentage of GHS costs that is domestically funded in low-income countries is assumed to follow a uniform distribution, ranging
from the percentage of NTP funding from domestic sources up to 100%.
grants from the Global Fund (Table 5.2). Funding reported by NTPs from other donor sources amounts to only
US$ 54 million in 2013, although bilateral and multilateral funds are not always channelled through NTPs. For
example, donors may provide funding directly to nongovernmental organizations and to technical agencies. Recent
data on technical assistance compiled by TB-TEAM (TB
Technical Assistance Mechanism) are provided in Box 5.2.
International donor funding for TB care and control
has increased from US$ 0.2 billion in 2006 to almost
US$ 0.5 billion in 2013, but still falls short of funding for
malaria (US$ 2.0 billion in 2010)1 and HIV (US$ 6.9 billion in 2010).2
Global statistics on sources of funding conceal important variations in the extent to which countries rely on
domestic and donor nancing (Figure 5.5, Figure 5.6, Table
5.2). Differences among BRICS, the other 17 HBCs and
the group of low-income countries are especially striking
(Figure 5.5). In BRICS, domestic funding has consistently
accounted for most of the funding for TB care and control
(for example, >95% in 2012 and 2013), although India is
an outlier at 71% in 2013. In the other 17 HBCs (listed in
Table 5.2), the share of total funding from donor sources
was in the range 2841% between 2006 and 2013. The
group of low-income countries (24 African countries
as well as Afghanistan, Bangladesh, Cambodia, Haiti,
Myanmar, Nepal and Somalia) are most reliant on donor
funding: for example, in 2012, 59% of total funding was
from donor sources. In 2013, *70% of available funding
will be from donor sources in ve HBCs: Afghanistan,
Bangladesh, the Democratic Republic of the Congo, Ethiopia and Myanmar (Table 5.2).
Throughout the period 20062011, donor funding
exceeded domestic funding in low-income countries,
and in 2010 and 2011 nancing from the Global Fund
alone exceeded domestic contributions. The data reported
in 2012 suggest that this pattern will persist in 2012 and

2013. The Global Fund has a crucial role in sustaining and
ensuring further progress in TB care and control.
Of particular concern is the expectation that donor
funding will be lower in 2013 compared with 2012 in
the 17 HBCs outside BRICS and low-income countries
(current data suggest decreases of up to 33% and 18%,
respectively). Donor funding is essential to safeguard
recent gains in TB control in the 17 HBCs outside BRICS
and low-income countries.
5.4
Funding for TB care and control

compared with total government
expenditures on health care
In general, spending on TB control as a proportion of

public sector health expenditures3 is relatively low (Figure 5.7). In most countries, TB control accounts for less
than 3% of public health expenditures. Countries with
higher levels of spending on TB relative to total government expenditures on health are mostly in Africa, eastern Europe (for example, Ukraine) or central Asia. Part
of the explanation for countries in eastern Europe and
central Asia is comparatively high levels of MDR-TB (see
Chapter 4), which is more expensive to treat. Other reasons include continued use of models of care for all forms
of TB that rely extensively on inpatient care. For example,
in Kazakhstan, 84% of smear-negative cases4 and 96%
1
World malaria report 2011. Geneva, World Health Organization,

2011.
Financing the response to AIDS in low- and middle-income countries:
international assistance from donor governments in 2010. UNAIDS
and the Kaiser Family Foundation, 2010 (also available at www.
unaids.org).
Source: World Health Organization National Health Account
database (www.who.int/nha/en) accessed via http://data.
worldbank.org/indicator/SH.XPD.PUBL.ZS in July 2012.
For case de nitions, see Chapter 3.
57
BOX 5.2
Technical assistance for TB care and control
The Global Plan to Stop TB 20112015 highlights the important role of technical assistance to NTPs. The funding required over ve years was
estimated at US$ 2.1 billion, or approximately US$ 400 million per year.
The TB Technical Assistance Mechanism (TB-TEAM) of the Stop TB Partnership was established in 2007 to monitor and coordinate the provision
of technical assistance to NTPs. The secretariat function is carried out by WHOs Stop TB Department. Requests from countries for technical
assistance are matched to appropriate technical partners via the TB-TEAM web site. Technical partners are expected to provide information
about the purpose of the mission, the dates of travel, funding sources and a mission report via the website. All technical partners are invited to
review and comment on quarterly and annual analyses of data.
In 2011, 645 missions were completed and reported to TB-TEAM
(Table B5.2.1). About one third of recorded missions were
organized by WHO, mainly by regional ofces, and one third by the
Union, the KNCV Tuberculosis Foundation and the United States
Centers for Disease Control and Prevention (CDC).
TABLE B5.2.1
Number of missions conducted by technical partners and
reported to TB-TEAM, 2011
PROVIDER OF TECHNICAL ASSISTANCE
NUMBER OF
MISSIONS IN
2011
WHO regional ofces
% OF
TOTAL
126
20
The Union
86
13
KNCV Tuberculosis Foundation
67
10
Centers for Disease Control and Prevention

(CDC), USA
60
WHO headquarters
55
Global Drug Facility
39
WHO country ofces
35
Grant Management Solutions (GMS) project
33
NTP/national TB-TEAM
25
TB-REACH
19
Other
100
16
Total
645
100
In 2011, the main technical areas for which assistance was provided
were MDR-TB and XDR-TB; monitoring and evaluation linked to
impact measurement; the grant processes of the Global Fund;
review missions; and laboratory strengthening (Table B5.2.2). The
data also show that the number of missions fell between 2009 and
2011. This downward trend occurred among most major technical
partners, including WHO, the KNCV Tuberculosis Foundation and
the Union (data not shown), and was especially noticeable for three
topics: MDR and XDR-TB, management of drugs and commodities,
and development of Global Fund proposals.
Information on sources of funding is often not recorded; in the rst
half of 2012, the source of funding was not recorded for 40% of
missions. Of the 389 missions for which information on funding
was provided, 78% was from agencies of the US government,
notably the United States Agency for International Development
(USAID) and OGAC (the Ofce of the Global AIDS Coordinator). The
remaining 22% was from Eli Lilly and the Canadian International
Development Agency (CIDA).
TABLE B5.2.2
Number of missions by topic reported to TB-TEAM, 20092011
% OF
TOTAL IN
2011
TOPIC
2009
2010
2011
MDR-TB and XDR-TB
120
129
91
14
Monitoring and evaluation, supervision and impact

measurement
46
63
73
11
Global Fund grant processes, bottlenecks
34
40
72
11
TB programme planning and review; regional meetings
77
107
64
10
Laboratory strengthening
54
79
57
Drugs and commodities management
89
70
53
Infection control
26
34
36
17
34
Operational and basic science research

TB/HIV
13
17
31
Human resources development
27
39
23
Global Fund proposal development
52
30
19
Advocacy, communication and social mobilization
26
18
12
Childhood TB
Drug resistance surveillance
Other
217
114
62
10
Total
795
769
645
100
58
The regional distribution of missions broadly

correlates to TB burden (data not shown).
An exception is the European Region, which
accounts for 19% of missions but for 5% of TB
cases reported globally. Most of the missions in
this region are related to MDR-TB and laboratory
strengthening. The South-East Asia Region has a
comparatively low share of missions (12%) while
reporting almost 40% of TB cases globally. One
explanation may be that technical assistance
provided from within-country sources in India is
not captured in the database.
WHO REPORT 2012
FIGURE 5.6
Domestic funding as a percentage of total funding available for TB care and control,a
average 20092011
09
1049
5074
7589
90100
No data
Not applicable
a
General health-care services are assumed to be domestically funded in all but the low-income countries, where the share of domestic funding is instead taken to be the
median value obtained through the probabilistic sensitivity analysis described in Figure 5.5.
FIGURE 5.7
Expenditures for TB care and control as a percentage of public sector health expenditures,
average 20072009
<1
12.9%
34.9%
5%
No data
Not applicable
59
of smear-positive cases are hospitalized, with average

lengths of stay of 60 and 100 days respectively; 35% of
MDR-TB cases are hospitalized for 160 days. Nonetheless,
there are signs that countries are reducing their reliance
on hospitalization. For example, Uzbekistan reported a
reduction in the number of dedicated TB beds from more
than 15 000 in 2008 to less than 11 000 in 2012; the
average duration of hospitalization for MDR-TB patients
decreased from 270 to 90 days during the same period.
5.5
Unit costs and cost effectiveness

of TB care
The estimated cost per patient successfully treated for TB

with rst-line drugs is shown for each of the 22 HBCs in
Figure 5.8. The cost generally lies in the range US$ 100
500 per patient successfully treated. The exceptions are
Bangladesh, India and Myanmar (under US$ 100); Brazil
(above US$ 500); and the Russian Federation and South
Africa (both above US$ 1000). From 2006 to 2011, the
cost per patient treated increased in almost all of the
HBCs, as did GDP [gross domestic product] per capita.
It is noticeable that in all of the HBCs, the cost per
patient treated is less than GDP per capita (that is, all
values lie below the solid red line in Figure 5.8). Besides
GDP, a further explanation for variation in costs appears
to be the scale at which treatment is provided. Some of
the countries with relatively low costs for their income
level (for example, China, India, Indonesia and Pakistan)
are countries where the total number of patients treated
each year is comparatively high (as shown by the size of
the circles in Figure 5.8).
As in previous years, the cost of treating TB patients
with rst-line drugs in the Russian Federation is higher
than might be expected for the countrys income level.
The relatively high cost is due in large part to an extensive network of hospitals and sanatoria that are used for
lengthy inpatient care. It should also be highlighted that
the characteristics of the patient population in the Russian Federation (such as high rates of alcohol dependency
and unemployment, and a comparatively high proportion
of ex-prisoners) may also warrant additional investments
in some aspects of TB care. Examples include patient
enablers and incentives to support outpatient care, and
psychosocial support.
The cost per patient successfully treated with rstline drugs at country level is summarized in Figure 5.9.
In most countries in the African, South-East Asia and
Western Pacic regions, the cost per patient successfully
treated is under US$ 1000 (exceptions include Botswana
and South Africa in the African Region, and Malaysia
and Mongolia in the Western Pacic Region). Costs are
higher in the Region of the Americas and the European
Region (notably in Kazakhstan).
Evidence on the cost effectiveness of interventions for
TB care and control is summarized in Box 5.3.
60
Data reported by countries also allow analysis of the

funding available for rst- and second-line anti-TB drugs,
and the unit cost (per patient) for rst- and second-line
regimens (Figure 5.10). The total funding amounts to
about US$ 0.2 billion per year for rst-line drugs, with
a cost per patient of less than US$ 40 in low- and lower
middle-income countries, and around US$ 50 in upper
middle-income countries. The Global Drug Facilitys Stop
TB Patient Kit costs only US$ 22.30 for new cases; freight,
quality control, inspection, agent fees and insurance may
explain why some low-income countries continue to
report unit costs in excess of these prices.
Public spending on second-line drugs is at least
US$ 0.2 billion. Unfortunately, Figure 5.10 does not
include amounts being spent in the Russian Federation and South Africa, which are known to be large but
for which reliable data are not available for the years
20092013; if these were included, spending on secondline drugs would greatly exceed spending on rst-line
drugs. The unit cost for second-line anti-TB drugs is
much higher than that for rst-line drugs. National programmes spent US$ 12003800 per patient treated with
second-line drugs in 2011. They appear to be budgeting
for increases in 2013: from about US$ 2600 per patient in
low-income countries to US$ 4700 per patient in upper
middle-income countries.
5.6
Funding gaps reported by countries,

20062013
Despite increases in funding and 10 completed rounds of

proposals1 to the Global Fund, NTPs continue to report
funding gaps (Figure 5.11). Since 2007, these gaps have
been in the range US$ 0.40.7 billion per year. In 2013,
funding gaps are anticipated for several elements of TB
care and control, including rst-line drugs. It is also evident that while countries have developed budgets for
activities to strengthen and enhance the basics of TB care
and control (such as publicpublic and publicprivate
mix initiatives to increase reporting of cases and improve
treatment outcomes, and advocacy, communication and
social mobilization), gaps relative to available funding for
these activities (shown in Figure 5.2) are comparatively
large.
Funding gaps have persisted and widened during the
past decade.2 Funding gaps reported for 2013 are more
than 20% of the budgets developed by NTPs in 38 countries, including 16 HBCs (Table 5.2).
The rst round was completed in 2003. Round 10 was completed in 2010.
Further details for individual HBCs can be found in Annex 2,
and in nance country pro les for more than 100 countries
that are available online at www.who.int/tb/data.
FIGURE 5.8
Cost per TB patient successfully treated with rst-line drugs,a 22 high TB burden countries,b
2006 and 2011c
The size of the green circle is proportional to the number of
patients treated in 2011.
10000
The green tail attached to each circle depicts the change in

Cost per patient successfully treated (constant 2012 US$), log scale
5000
cost per patient successfully treated and GDP per capita

between 2006 and 2011.
RU
The grey area depicts the 95% condence interval for the
prediction (= white line) of the unweighted loglog regression
of cost per patient successfully treated on GDP per capita
in 2011.
2000
The red line marks where cost per patient successfully treated
equals GDP per capita.
ZA
1000
BR
VN
Costs include rst-line drugs, NTP staff, programme

management and supervision, laboratory equipment and
supplies, collaborative TB/HIV activities, PPM, PAL, ACSM,
CBC, operational research, surveys, hospital stays and clinic
visits.
AF Afghanistan; BD Bangladesh; BR Brazil; CN China; CD

Democratic Republic of the Congo; ET Ethiopia; ID Indonesia;
IN India; KE Kenya; KH Cambodia; MM Myanmar; MZ
Mozambique; NG Nigeria; PK Pakistan; PH Philippines; RU
Russian Federation; TH Thailand; TZ United Republic of
Tanzania; UG Uganda; VN Viet Nam; ZA South Africa; ZW
Zimbabwe.
Costs per patient treated are case-weighted three-year

averages, 20042006 and 20092011, to minimize
distortions associated with non-annual expenses on items
such as buildings, equipment and buffer stocks of drugs. No
time trend is provided for South Africa and Thailand, due to
lack of data.
PH
500
TH
KH
NG
ID
CN
AF
200
TZ
ET
100
ZW
KE
MZ
CD
PK
UG
MM
IN
BD
50
100
200
500
1000
2000
5000
10000
GDP per capita (constant 2012 US$), log scale
FIGURE 5.9
Cost per TB patient successfully treated with rst-line drugsa (US$), average 20092011
< 100
100499
500999
10004999
50009999
10 000
No data
Not applicable
a
Costs include rst-line drugs, NTP staff, programme management and supervision, laboratory equipment and supplies, collaborative TB/HIV activities, PPM, PAL, ACSM,
CBC, operational research, surveys, hospital stays and clinic visits.
61
BOX 5.3
Cost effectiveness of interventions for TB care and control
National TB control programmes have provided good value for the US$ 23 billion they received in the years 20062011. A total of 34
million TB cases were detected and treated over the same period. Treatment success rates have risen (Table 3.5, Table 3.6) while unit
costs have remained low relative to income levels (Figure 5.8). The cost effectiveness of core interventions for TB care and control is
strongly supported by reviews and meta-analyses of economic evaluations, as summarized in Table B5.3.1.
The disability adjusted life year (DALY) is a commonly-used metric for measuring and comparing health outcomes across interventions.
Applied to TB treatment, a DALY averted is approximately equal to a year of life saved. For patients with smear-positive pulmonary TB
that is sensitive to rst-line drugs, a short course of chemotherapy for 6 months costs as little as US$ 550 per year of life saved. Treating
smear-negative forms of drug-sensitive TB costs somewhat more, at US$ 60200 per year of life saved (reecting a lower case fatality rate
in the absence of treatment and less transmission). TB that is resistant to both isoniazid and rifampicin (MDR-TB) requires longer and more
expensive treatment with second-line drugs and costs US$ 200800 per year of life saved.
TABLE B5.3.1
Summary of the available evidence on the cost effectiveness of interventions for TB care and control1,2,3,4
POPULATION
Patients with smear-positive TB

Patients with smear-negative or extrapulmonary TB
Patients with MDR-TB
INTERVENTION
COST PER DALY AVERTED (US$) a
First-line treatment under DOTS
550
First-line treatment under DOTS
60200
1824 months of second-line treatment under WHO guidelines
200800
People living with HIV, infected with TB
Isoniazid preventive therapy
15300
People living with HIV, with TB disease
First-line drugs under DOTS plus ART
100365
Diagnosis of TB using Xpert MTB/RIF as an add-on to smear
40200
People in whom TB is suspected

a
For those unfamiliar with the DALY, this column may be interpreted as the cost per year of life saved.
WHO denes an intervention as highly cost effective if the cost per DALY averted is less than the GDP per capita of the country in which
it is being implemented. According to this benchmark, interventions for TB care and control are highly cost effective even in the lowestincome countries. The high cost effectiveness of TB care and control was recognized by the Disease Control Priorities Project in 2006: TB
treatment was listed as one of the best buys in public health.5 More recently, the Copenhagen Consensus included the expansion of TB
treatment among its top ve investments, out of some 40 proposals designed by experts to address urgent global challenges including
armed conict, climate change, education, hunger and control of infectious diseases. 6
1
Dye C, Floyd K. Tuberculosis. In: Disease control priorities in developing countries, 2nd ed. New York, Oxford University Press, 2006:289312.
Baltussen, R, Floyd K, Dye C. Achieving the millennium development goals for health: cost effectiveness analysis of strategies for tuberculosis control in
developing countries. BMJ, 2005, 331:13641368.
Fitzpatrick C, Floyd K. A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis. Pharmacoeconomics,
2012, 30:6380.
Vassall A et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Medicine,
2011, 8(11):e1001120 (doi:10.1371/journal.pmed.1001120).
www.dcp2.org/main/Home.html
Nobel laureates: more should be spent on hunger, health: top economists identify the smartest investments for policy-makers and philanthropists [press
release dated 14 May 2012]. Denmark, Copenhagen Consensus, 2012 (available at www.copenhagenconsensus.com/Projects/CC12/Outcome.aspx;
accessed July 2012).
5.7
Projections of potential funding from

domestic sources and funding
requirements specified in the Global Plan
The Global Plan to Stop TB 20112015 was published by the

Stop TB Partnership in 2010.1 It sets out what needs to
be done to achieve the global targets for TB control set
for 2015 in 149 low- and middle-income countries,2 and
the associated funding requirements (Table 5.3). The total
1

For a summary of the targets set in the plan, see Chapter 1.
62
requirement over ve years amounts to US$ 47 billion.

Excluding research and development for new TB drugs,
diagnostics and vaccines (Chapter 8), which are not the
responsibility of NTPs, the total is US$ 37 billion.
Funding needs for TB care and control in the Global
Plan (i.e. amounts excluding those for research) were
estimated to grow from around US$ 6 billion in 2011 to
US$ 8 billion in 2015. Diagnosis and treatment with rstline drugs for drug-susceptible TB following the DOTS
approach account for the largest single share of funding
US$ 4 billion in 2011 increasing to around US$ 5 billion
in 2015. The second largest component is diagnosis and
FIGURE 5.10 Total cost and unit cost of rst- and second-line anti-TB drugs in 99 countries,a 20092013,b
by income group
Lower middle-income countries
Upper middle-income countries excluding RSc

100
Total cost, US$ millions

(constant 2012 US$)
First-line,
595th
percentiles
102
81
70
57
54
60
28
27
Second-line,
595th
percentiles
64
46
50
21
22
44
31
34
13
0
2009
2010
2011
2012
2009
2013
2010
2011
2012
2013
Lower middle-income countries
Upper middle-income countries excluding RSc
2009
2010
2011
2012
2013
Unit cost, (constant US$), log scale
20000
10000 7247
4672
4453
2320
100
50
30
47
47
50
2560
1199
36
29
36
23
2010
2011
2012
2009
2013
2010
2011
2012
2013
2009
2010
2011
2012
2013
These 99 countries account for 85% of global drug-susceptible TB cases and 29% of MDR-TB cases receiving treatment. See also note (c).
Values for 2012 and 2013 are based on country plans and budgets, not actual expenditures. Unit costs are case-weighted two-year averages to adjust for purchases of
buffer stock.
The Russian Federation (R) and South Africa (S) were excluded as they did not report expenditures for 2011 or funding expected for 20122013. Together, they account for
about 9% of global drug-susceptible TB cases and 45% of MDR-TB cases receiving treatment.
600
659
602
554
486
400
514
709
567
322
200
Other
ACSM/CBC/
PPM/PAL/OR/
surveys
TB/HIV
MDR-TB
DOTS, excluding
first-line drugs
DOTS, first-line
drugs
Line item surplusa
0
-100
TABLE 5.3 Summary of funding requirements for TB

control during the period 20112015, as set out
in the Global Plan to Stop TB
TOTAL FUNDING REQUIRED
(US$ BILLIONS) [% OF TOTAL]
PLAUSIBLE
RANGE
Implementation
36.9 [79%]
36.137.7
DOTS
22.6 [48%]
22.123.2
PLAN COMPONENT
800
2022
28
26
FIGURE 5.11 Funding gaps for TB care and control

as reported by countries, by line item,
20062013
4396
1000
2009
a
3835
5000
2006 2007 2008 2009 2010 2011 2012
2013
Funding available for a given line item may exceed that required for the same
line item under a countrys plan and budget.
MDR-TB
7.1 [15%]
6.67.7
TB/HIV
2.8 [6%]
2.72.9
Laboratory strengthening
4.0 [8%]
3.74.2
Technical assistance
0.4 [1%]
Research and development
9.8 [21%]
Fundamental research
2.1 [5%]
New diagnostics
1.7 [4%]
New drugs
3.7 [8%]
New vaccines
1.9 [4%]
Operational research
All components
not estimated
0.4 [1%]
46.7 [100%]
45.947.5
63
FIGURE 5.12 Funding required for DOTS and MDR-TB

in the Global Plan 2011-2015 compared
with projections of potential funding from
domestic sources, for six country groups
BRCSa
India
0.5
4.0
0.4
3.0
0.3
2.0
0.2
1.0
0.1
0
Other HBCs
0.6
1.0
Seven other low- and middle-income

European countries with a high burden
of MDR-TBb
US$ billions (current)
0.8
0.4
0.6
0.4
0.2
0.2
0
0
Low-income countries excluding HBCs
0.8
0.3
0.6
0.2
0.4
0.1
0.2
0
2011
0
2012
2013
2014
2015
2011
2012
2013
2014
2015
Funding required for DOTS and MDRTB

Funding required for DOTS
Funding required for MDRTB
Funding forecast to be available from domestic sourcesc
a
b
Brazil, Russian Federation, China and South Africa (BRICS excluding India)
The seven countries included in this group are Armenia, Georgia, Kyrgyzstan,
Republic of Moldova, Tajikistan, Ukraine and Uzbekistan. Of the funding
available in 2012, approximately half is accounted for by Ukraine. The countries
in this group continue to hospitalize TB patients for lengthy periods of time,
while in the Global Plan it was assumed that reliance on inpatient hospital care
in the European Region would be progressively reduced between 2006 and 2015
to an average of 60 days per patient with drug-susceptible TB by 2015. This
explains why the funding amounts estimated to be needed in the Global Plan are
lower than the funding available in this group of countries.
Assumes that: 1) international donor funding received by BRICS in 2011 is
substituted by domestic sources; and 2) domestic funding for TB care and control
in all low and middle-income countries will keep pace with IMF forecasts of
growth in GDP per capita.
treatment of MDR-TB, for which the funding requirement was estimated at US$ 1 billion in 2011, rising to
US$ 1.9 billion in 2015. The funding required for collaborative TB/HIV activities (see Chapter 7) increases to about
US$ 1 billion by 2015, mostly (about 90% of the total) for
antiretroviral therapy for HIV-positive TB patients that
would be funded via HIV programmes (not NTPs).
The funding requirements set out in the Global Plan
are considerably more than the funding amounts reported
by countries. For example, the funding required in 2015
according to the Global Plan is about US$ 2 billion more
than the funding reported to be available in 2013.1 In this
context and with international funding constrained
by economic stagnation or recession in traditional donor
countries assessing the funding that can be mobilized
from domestic sources is of increasing importance.
Figure 5.12 shows estimates of the funding required for
treatment of TB and MDR-TB in the Global Plan, and for
selected groupings of countries de ned by their TB burden and income level. Amounts for collaborative TB/HIV
activities are deliberately excluded because ART, the main
intervention in terms of cost, is not funded through NTPs.
It is therefore not appropriate to compare funding needs
for collaborative TB/HIV activities with funding reported
by NTPs. Also shown in Figure 5.12 are projections of the
funding that could be mobilized from domestic sources in
each country group, on the assumption that: (i) international donor funding received by BRICS in 2011 is substituted by domestic sources; and (ii) domestic allocations
for TB care and control in all low- and middle-income
countries will keep pace with IMF forecasts of growth in
GDP per capita.
The data shown in Figure 5.12 provide insights that
could inform future discussions about investments in TB
care and control, including prioritization of donor funding among countries and interventions and targets for
resource mobilization. For example:
64
There is domestic capacity to fund the investments

needed for basic TB care and control (DOTS) in BRICS.
An increase in domestic allocations for TB care and
control in line with forecast growth in GDP per capita
would be sufcient to mobilize the funding needed for
diagnosis and treatment of MDR-TB in Brazil, the Russian Federation, China and South Africa (all of which
are upper middle-income countries).
In India, without growth in domestic allocations for
TB above forecast growth in GDP per capita, about
US$ 0.1 billion per year is needed from donor sources.
This is excluding amounts for TB/HIV that are mostly for ART
funded through HIV programmes, and allowing for funding
in the 34 countries considered in the Global Plan that are not
in the group of 115 countries for which data were available for
2011 or 2012 (Table 5.1). It is anticipated that most of the funding for TB/HIV interventions will need to come from international donors.
The 14 countries not included in the list of 22 HBCs

but that are part of the list of the 27 high MDR-TB
burden countries are all European countries. Of these
14 countries, six are upper middle-income countries
and one is a high-income country (Estonia). Among
the seven low- and lower middle-income countries,
available funding from domestic sources appears to be
sufcient, although some rationalization in the use of
hospital care may be required.
The 17 HBCs outside BRICS require donor funding of
about US$ 0.30.5 billion per year to reach Global Plan
targets for implementing DOTS and scaling up diagnosis and treatment for MDR-TB. This amount could be
lowered if reductions in the price of second-line antiTB drugs needed for treatment of MDR-TB could be
achieved.
Low-income countries require donor funding of about

US$ 0.20.3 billion per year to reach Global Plan targets for implementing DOTS and scaling up diagnosis
and treatment for MDR-TB, of which US$ 0.10.2 billion per year is in countries outside HBCs.
In addition to the funding needs for DOTS and MDR-TB

set out in the Global Plan, additional investments will be
needed for the scale-up of new rapid molecular diagnostics. Further details about these diagnostics are provided
in Chapter 6.
Overall, these observations suggest that international
donor funding of up to US$ 1 billion per year is needed
for diagnosis and treatment of TB and MDR-TB in lowand middle-income countries 20132015 to close funding
gaps. It is anticipated that most of the funding required
for TB/HIV interventions will also need to come from
international donor sources.
65
CHAPTER 6
Diagnostics and
laboratory strengthening
Conventional technologies have been constraining
diagnosis of TB and drug-resistant TB, but the recent
availability of new rapid tests has the potential to
revolutionize TB care.
The roll-out of Xpert MTB/RIF, a new rapid molecular
test that can diagnose TB and rifampicin-resistant
TB within hours, has been impressive. Between its
endorsement by WHO in December 2010 and the end of
June 2012, 1.1 million test cartridges were procured in
67 (46%) of the 145 countries eligible to purchase them
at concessional prices. Acceleration in uptake is still
needed to realize the full potential of the technology.
Scaling up use of the Xpert MTB/RIF assay is expected
to be greatly accelerated by a 41% drop in the cartridge
price from US$ 16.86 to US$ 9.98 announced in
August 2012. It is essential that expansion in capacity
to diagnose drug-resistant TB is closely aligned with
expansion in capacity to provide treatment.
Laboratory capacity to conduct sputum smear
microscopy still requires strengthening: only 15 of the
22 high TB burden countries met the target of having
1 microscopy centre per 100 000 population in 2011.
Substantial strengthening of laboratory capacity to
detect DR-TB is needed. Among the 36 countries with
a high burden of TB and MDR-TB, 19 did not have the
recommended capacity of 1 laboratory to perform
culture and DST per 5 million population in 2011.
The WHO/GLI Supranational Reference Laboratory
(SRL) Network has assumed a greater role in global
efforts to strengthen TB laboratories. It now comprises
29 laboratories in all WHO regions, with 4 additional
candidate SRLs under development.
WHO has developed more comprehensive policies on
the proper use of TB diagnostics, which now include
guidance on approved tests as well as negative
guidance to dissuade practitioners from using poorly
performing and/or overly costly tests. Countries should
take decisive action to ban poorly-performing and
overly costly tests and introduce WHO-recommended
technologies.
66
A high-quality laboratory system that uses modern diagnostics is a prerequisite for early, rapid and accurate
detection of TB. Of the estimated 8.7 million incident
TB cases in 2011, only 66% were diagnosed and notied to national TB control programmes, due in part to
inadequate laboratory capacity in many low- and middleincome countries. Furthermore, of the notied cases of
pulmonary TB, around one-third were not bacteriologically con rmed using a WHO-recommended laboratory
method, and a proportion of the patients in whom TB
was clinically diagnosed without laboratory con rmation may not have had TB. These numbers do not capture
the signicant delay that many patients experience in
receiving a diagnosis of TB because of poorly functioning laboratory systems, resulting in delays to the start of
their treatment, additional suffering and expenses, and
adverse treatment outcomes.
As described in Chapter 4, diagnosis of drug resistance
remains a particular challenge for laboratory systems in
many low- and middle-income countries. Only 19% of
the 310 000 cases of multidrug-resistant TB (MDR-TB)
estimated to exist among patients with pulmonary TB
received a laboratory-conrmed diagnosis of their disease
and were notied in 2011. Rapid and timely detection of
TB cases and strengthened capacity to diagnose cases of
drug-resistant TB are thus global priorities for TB care
and control.
This chapter has three parts. The rst describes developments in WHOs policies on TB diagnostics during
20112012; the second provides the status of laboratory
capacity globally, regionally and nationally, focusing on
36 countries in the combined list of 22 high TB burden
countries and 27 high MDR-TB burden countries; the
third describes the strengthening of laboratories with a
focus on the EXPAND-TB project, the Supranational Reference Laboratory Network and laboratory accreditation.
6.1
Developments in WHO policies

on TB diagnostics
WHO has established a systematic process for the timely

formulation of policy on new TB diagnostics in response
to the active research and development pipeline in
recent years and resultant new tools (see Chapter 8).
This dynamic process involves synthesizing the available evidence through systematic reviews and metaanalyses, assessing the evidence and its expected impact
on public health by an external Expert Group using the

recommended GRADE approach,1 and preparing policy
guidance2 for dissemination to Member States and other
stakeholders.3 Policy documents are reviewed every 35
years, taking into account new evidence.
In 2011, WHO issued two negative
policy statements on TB diagnostics:
one against the use of commercial,
antibody-based serodiagnostic tests to
diagnose active TB disease; the
other a caution against commercial interferon-gamma release
assays (IGRAs) as a public health
intervention to detect latent TB
infection in low- and middleincome settings.
An Expert Group that reviewed
the evidence on use of commercial, antibody-based serodiagnostic tests found that they
provide inconsistent and imprecise results with highly
variable values for sensitivity and specicity. No evidence was found that existing commercial serological
assays improve outcomes that are important to patients.
As a result of this policy, in June 2012 the Government
of India banned the import, manufacture, distribution
and sale of commercial serodiagnostic tests for TB, which
have been pro igately used in the private sector to diagnose TB. This bold action is expected to greatly reduce the
frequency of false diagnoses of TB and facilitate the introduction of WHO-approved diagnostics into the market.
After reviewing the available evidence on commercial
IGRAs, an Expert Group concluded that:
there are insufcient data and low-quality evidence on

the performance of IGRAs in low- and middle-income
countries, typically those with a high burden of TB
and/or HIV;
IGRAs and the tuberculin skin test (TST) cannot accurately predict the risk of infected individuals developing active TB disease;
neither IGRAs nor the TST should be used to diagnose

active TB disease; and
IGRAs are more costly and technically complex to perform than the TST.
Given their comparable performance but increased cost,

replacing the TST with IGRAs as a public health intervention in resource-constrained settings is not recommended. These guidelines are not intended to apply to
high-income countries or to supersede their national
guidelines.
In 2012, Expert Groups were convened to review the
available evidence on two commercially available diagnostic tests: a manual assay using the loop-mediated
isothermal amplication (LAMP) platform to detect TB
DNA in sputum specimens (TB-LAMP, Eiken Chemi-
cal Co. Ltd., Japan), and a line probe assay for detecting resistance to second-line anti-TB drugs (GenoType
MTBDRsl, Hain Lifescience, Germany).
The Expert Group reviewing the TB-LAMP assay concluded that there was insufcient evidence to proceed
with the development of policy guidance.
For Genotype MTBDRsl, the Expert Group found that
while the tests specicity for detecting resistance to uoroquinolones and second-line injectables was high, its
sensitivity was suboptimal. Therefore, while the test has
the potential to be used as a rule-in test for XDR-TB where
capacity to use line probe assays is available, it cannot be
used as a replacement test for conventional phenotypic
drug susceptibility testing (DST). The Expert Group also
noted that there is incomplete cross-resistance between
the second-line injectables, and that the assay does not
allow for specic resistance to individual second-line
injectables to be determined. Detailed conclusions of the
Expert Group meetings will be described in reports to be
published on the website.4
6.2
Status of laboratory capacity globally,

regionally and nationally
Despite the development in recent years of more sensitive technologies, diagnosis of TB in most low- and middle-income countries continues to rely on sputum smear
microscopy. Maintaining a high level of quality to perform smear microscopy is therefore critical. Of the 144
low- and middle-income countries and territories reporting on numbers of smear microscopy laboratories, only
42% indicated the existence of an external quality assessment programme that encompassed all smear laboratories in the country.
While globally the target of 1 microscopy centre per
100 000 population has been reached, considerable disparities remain at regional and country levels (Table 6.1).
The Western Pacic and Eastern Mediterranean regions
had only 0.5 and 0.8 centres per 100 000 population in
2011, respectively, and 7 of the 22 high TB burden countries also failed to meet the target.
In 2009, WHO recommended the use of the more sensitive uorescent light-emitting diode (LED) microscopy
instead of traditional ZiehlNeelsen (ZN) microscopy.
Roll-out, however, has been slow. As of 2011, only 2% of
microscopy laboratories globally were using LED microscopes, with little variability between regions and no high
TB burden country reporting more than 10% absorption.
The current target for both culture and DST capacity
is 1 laboratory per 5 million population; this target was
1
2
www.gradeworkinggroup.org
WHO handbook for guideline development. Geneva, World Health
Organization, 2012.
WHO policies on TB diagnostics are available at:
www.who.int/tb/laboratory/policy_statements
www.who.int/tb/laboratory/policy_statements
67
TABLE 6.1 Laboratory capacity, 2011a

SMEAR MICROSCOPY
HIGH TB
BURDEN
HIGH
MDR-TB
BURDEN
Afghanistan
YES
NO
Armenia
Azerbaijan
LABORATORIES
PER 100 000
POPULATION
PERCENTAGE OF
LABORATORIES
USING LED
MICROSCOPES
600
1.9
30
1.0
NUMBER
OF LABORATORIES
DRUG SUSCEPTIBILITY
TESTING
CULTURE
NUMBER
OF
LABORATORIES
LABORATORIES PER
5 MILLION
POPULATION
NUMBER
OF LABORATORIES
0.5
LABORATORIES PER
5 MILLION
POPULATION
LINE PROBE ASSAY

NUMBER
OF
LABORATORIES
1.6
1.6
LABORATORIES PER
5 MILLION
POPULATION
XPERT
MTB/RIF
NUMBER
OF SITES
1.6
Bangladesh
1 057
0.7
<0.1
<0.1
Belarus
196
2.1
41
21
20
10
0.5
Brazil
4 028
2.0
<1
306
Bulgaria
34
0.5
33
Cambodia
211
1.5
7.8
22
45
1.1
13
8.7
2.0
1.0
0.3
China
3 328
0.2
594
2.2
195
0.7
20
<0.1
16
DR Congo
1 508
2.2
<0.1
<0.1
Estonia
0.4
40
7.5
7.5
7.5
Ethiopia
1 947
2.3
0.1
<0.1
0.1
Georgia
29
0.7
2.3
1.2
1.2
India
13 026
1.0
37
0.1
37
0.1
17
<0.1
18
Indonesia
5 566
2.3
46
0.9
0.1
<0.1
Kazakhstan
466
2.9
100
22
6.8
10
3.1
0.1
31
Kenya
1 581
3.8
0.7
0.1
Kyrgyzstan
122
2.3
3.7
2.8
16
0.7
8.9
2.2
Latvia
Lithuania
Mozambique
430
1.8
<1
0.4
0.4
2.2
Myanmar
415
0.9
<1
0.2
0.2
0.2
Nigeria
1 229
0.8
0.2
0.1
<0.1
Pakistan
1 187
0.7
<1
12
0.3
10
0.3
<0.1
16
Philippines
1 986
2.1
10
0.5
0.1
<0.1
14
Republic of Moldova
Russian Federation
3 746
2.6
117
4.1
South Africa
244
0.5
15
1.5
15
1.5
10
1.0
55
Tajikistan
92
1.3
2.1
0.7
1.4
Thailand
1 100
1.6
<1
65
4.7
15
1.1
0.1
11
Uganda
1 081
3.1
1.0
1.2
1.2
18
Ukraine
UR Tanzania
945
2.0
0.5
0.1
0.1
Uzbekistan
320
1.2
<1
1.3
0.4
0.5
Viet Nam
800
0.9
<1
25
1.4
0.1
0.1
Zimbabwe
151
1.2
0.8
0.8
11
1.1
0.9
<1
AFR
1.5
AMR
2.4
<1
EMR
0.8
<1
1.8
EUR
1.1
<1
9.4
1.5
0.4
<0.1
1.3
0.4
0.1
0.7
0.4
0.2
0.9
0.1
0.4
<0.1
4.4
1.0
17
SEAR
1.2
0.4
0.2
<0.1
WPR
0.5
3.6
0.7
0.2
Global
1.1
3.9
0.8
0.2

a
The regional and global gures are aggregates of data reported by low- and middle-income countries and territories. Data for the variables shown in the table are not
requested from high-income countries in the WHO data collection form.
68
revised as a result of the introduction of new technologies in which culture and DST are invariably performed
together. In 2011, 19 of the 36 countries in the combined
list of 22 high TB burden countries and 27 high MDRTB burden countries did not reach the target (Table 6.1).
Of these 36 countries, 9 reported more than 1 laboratory
per 5 million population using line probe assays a highthroughput tool used at central and regional levels to rapidly detect resistance to rifampicin and, in some cases,
isoniazid. These numbers are changing quickly, as laboratory strengthening efforts including EXPAND-TB (see
Section 6.3) come to fruition.
Quality-assured DST is critical to ensure accurate
detection of drug resistance for subsequent treatment
decisions and to avoid false diagnoses. External quality
assessment schemes for DST appear to be comprehensively installed more commonly than those for microscopy.
While 42% of countries claim to have a comprehensive
scheme for microscopy (as stated above), 71% of the 115
low- and middle-income countries and territories indicating capacity for DST reported an external quality assessment scheme encompassing all DST laboratories.
The target for culture and DST capacity of 1 laboratory per 5 million population is likely to be revised
downwards in future following the introduction of the
WHO-recommended automated nucleic amplication
assay Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA).
Xpert MTB/RIF technology (see Box 6.1) can detect
rifampicin resistance-conferring mutations, has sensitivity for TB detection equivalent to that of solid culture, and
compared with culture methods it can be used at lower
levels of the laboratory network. Importantly, however,
culture will remain essential for testing of susceptibility
to drugs other than rifampicin, and is currently the only
tool available for monitoring the response to treatment of
the growing number of patients being treated for MDRTB. Ongoing evaluation of evidence on the use of Xpert
MTB/RIF and its impact on the workload of other laboratory diagnostics, including microscopy, culture and DST,
will allow for re nement of the current targets.
While a number of countries report suboptimal capacity to detect TB and drug resistance, patients in many
parts of the world still access laboratory testing by seeking care in the private sector. The quality of diagnostic
services in this sector is highly variable, and some private practitioners continue to use diagnostic tests that
are not recommended by WHO. In addition, in some settings laboratories in the public sector that are not under
the auspices of the national TB control programme also
diagnose TB without necessarily following recommended
guidelines and quality assurance procedures. Collaboration between national TB control programmes and all
laboratories offering TB diagnosis is therefore critical to
ensure that national guidelines are followed, that appropriate diagnostic tests are used, and that patients diag-
nosed with TB are notied to the national TB control

programme and receive proper care. In 2011, 15 of 36
high burden countries reported some level of collaboration with laboratories in the private sector; 17 reported
collaboration with laboratories in the public sector.
6.3
Strengthening TB laboratories globally,

regionally and nationally
One of the main prerequisites for strengthening TB laboratory capacity in countries is dynamic policy reform,
adapting WHO guidelines on TB diagnostics into national TB control programme guidelines. Table 6.2 presents
the uptake of selected WHO policy guidance at global,
regional and country levels, focusing on the 36 countries
in the combined list of 22 high TB burden countries and
27 high MDR-TB burden countries.
All reporting high MDR-TB burden countries and 85%
of reporting countries globally had incorporated into
their national guidelines the WHO policy guidance on
conventional phenotypic DST by 2011. Countries in the
African Region have the lowest uptake (69%).
Incorporation of policy guidance on liquid culture
is highly variable, ranging from as low as 45% in the
Eastern Mediterranean Region to 84% in the European
Region. Globally, uptake of policy on line probe assays is
relatively low (44%) for all countries; only 17% of countries in the Region of the Americas reported incorporation of the guidance in their national guidelines.
Although recommended by WHO only in December
2010, WHOs policy guidance on Xpert MTB/RIF has
been incorporated into national guidelines by one third
(33%) of reporting countries; two thirds (64%) of the
high TB burden countries and half (50%) of the high
MDR-TB burden countries have already incorporated the
assay in their revised diagnostic policies.
The EXPAND-TB project is a global initiative of multiple partners that aims to strengthen laboratory capacity
for detecting drug-resistant TB and establish rapid diagnostics in 27 countries. Launched in 2008, the project is
a collaboration among WHO, the Global Laboratory Initiative (GLI), FIND and the Global Drug Facility, funded
by UNITAID and other partners. As shown in Figure 6.1,
the participating countries are at various stages of project implementation: 17 were in the nal phase of routine
testing and monitoring as of July 2012, compared with
6 in July 2011. Given the time required to establish the
necessary infrastructure for central level laboratories
capable of using liquid culture and line probe assays, the
EXPAND-TB project is now coming to fruition in the routine detection and reporting of drug-resistant TB cases.
Several of the countries participating in the project have
reported considerable increases in the numbers of drugresistant cases during recent years (Figure 6.2).
The WHO/GLI TB Supranational Reference Laboratory
(SRL) Network is another driving force in strengthening
69
BOX 6.1
Rolling out Xpert MTB/RIF globally
In December 2010, WHO recommended use of the Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) assay for the rapid and simultaneous
detection of TB and rifampicin resistance using the GeneXpert platform. The test entails fewer biosafety and human resource requirements than
conventional culture or DST. Furthermore, its sensitivity for detecting TB is signicantly higher than that of microscopy, particularly in patients
with HIV infection.
By the end of June 2012, Xpert MTB/RIF had been rolled out in 67 of the 145 countries eligible to purchase instruments and cartridges at
concessional prices. 1.1 million test cartridges and 3602 GeneXpert instrument modules had been procured, with technical and nancial
assistance from many partners and donors. South Africa has led the adoption of the technology and intends to use it countrywide as a
replacement for microscopy for the diagnosis of TB; as of June 2012, the country accounted for 37% of the modules and 53% of the cartridges
procured globally. The most up-to-date data on procurement and country-specic site locations and plans, together with WHO guidance
documents on use of the test, are available on a dedicated WHO website.1
To gain evidence on Xpert MTB/RIF for the renement of its global policy guidance, WHO has been systematically collecting data from early
implementers of Xpert MTB/RIF on the tests conducted and algorithms used, the effects of introducing the technology on laboratory workload,
and operational and logistic challenges encountered.2 As of July 2012, 31 sites in 12 countries had contributed data. Systematic collection of
complementary laboratory and patient indicators is also underway by partners including TBCARE I, TB REACH, the South Africa National Health
Laboratory Services and Mdecins Sans Frontires. Operational research projects, including those inventoried by the TREAT-TB initiative,3 are
expected to yield further critical information on the impact and cost effectiveness of Xpert MTB/RIF in various diagnostic algorithms.
Scaling up use of the Xpert MTB/RIF assay globally is expected to be greatly accelerated by a drop in the price per test from US$ 16.86 to
US$ 9.98, following execution of a novel nancing agreement between the manufacturer (Cepheid) and the Bill & Melinda Gates Foundation,
the United States Agency for International Development (USAID), the United States Presidents Emergency Plan for AIDS Relief (PEPFAR)
and UNITAID in August 2012. The catalytic effect of the price reduction on such global scale-up will be complemented by a US$ 25.9 million
grant from UNITAID to WHOs Stop TB Department and the Stop TB Partnership. The new three-year TBXpert project will provide the Xpert
MTB/RIF technology to 21 recipient countries by linking a broad network of implementing partners with existing initiatives for TB laboratory
strengthening, using innovative approaches to expand access to vulnerable populations in the public and private sectors.
FIGURE B6.1.1
Progress in the roll-out of Xpert MTB/RIF, by July 2012
GeneXpert
modules ordered
0
14
524
2549
5099
100
Not eligible for preferential pricing
Not applicable
www.who.int/tb/laboratory/mtbrifrollout
More detail on this initiative can be found at: www.who.int/tb/features_archive/xpert_use_web/
http://xrmt.treattb.org/
70
WHO REPORT 2012
TABLE 6.2 Incorporation of WHO policy guidance for diagnosis of TB, 2011a
YES
NO
HIGH TB
BURDEN
HIGH MDR-TB
BURDEN
CONVENTIONAL DRUG
SUSCEPTIBILITY TESTING
(DST)
LIQUID CULTURE
AND RAPID SPECIATION
TEST
LINE-PROBE ASSAY FOR

DETECTING RESISTANCE
TO RIFAMPICIN
ALGORITHM FOR THE

DIAGNOSIS OF TB IN
PEOPLE LIVING WITH HIV
XPERT MTB/
RIF ASSAY
Afghanistan
Armenia
Azerbaijan
Bangladesh
Belarus
Brazil
Bulgaria
Cambodia
China
DR Congo
Estonia
Ethiopia
Georgia
India
Indonesia
Kazakhstan
Kenya
Kyrgyzstan
Latvia
Lithuania
Mozambique
Myanmar
Nigeria
Pakistan
Philippines
Republic of Moldova
Russian Federation
South Africa
Tajikistan
Thailand

Uganda
Ukraine
UR Tanzania
Uzbekistan
Viet Nam
Zimbabwe
95%
73%
64%
86%
64%
100%
75%
74%
87%
50%
AFR
69%
69%
43%
76%
32%
AMR
96%
61%
17%
78%
13%
EMR
86%
45%
40%
52%
45%
EUR
100%
84%
63%
75%
32%
SEAR
90%
50%
40%
80%
40%
WPR
78%
72%
56%
82%
44%
Global
85%
67%
44%
74%
33%

a
The regional and global gures are aggregates of data reported by low- and middle-income countries and territories. Data for the variables shown in the table are not
requested from high-income countries in the WHO data collection form.
71
FIGURE 6.1
The EXPAND-TB project progress by

July 2012
Laboratory
preparedness
Technology
transfer
Laboratory
assessment
Memorandum of
understanding
Infrastructure
upgrade
Creation of SOPs
Policy reform
FIGURE 6.2
Equipment
and supplies
Procurement
Training
Quality assurance
Laboratory
validation
612 months
Bangladesh
Belarus
Mozambique
Senegal
Tajikistan
Viet Nam
1824 months
Indonesia
Kazakhstan
Peru
Rwanda
Routine testing
and monitoring
Monitoring
and evaluation
Impact
assessment
Market
dynamics
Up to year 5
Azerbaijan
Cameroon
Cte dIvoire
Djibouti
Ethiopia
Georgia
Haiti
India
Kenya
Kyrgyzstan
Lesotho
Myanmar
Republic of
Moldova
Swaziland
Uganda
UR Tanzania
Uzbekistan
Increase in cases of MDR-TB reported by

selected countries participating in the
EXPAND-TB project, 20082011
Percentage increase (index year = 2008)
1400
1200
1000
800
600
400
200
0
2008
2009
2010
2011
India (2008 = 308 cases; 2011 = 4237 cases)

Uzbekistan (2008 = 342 cases; 2011 = 1385 cases)
Cameroona (2009 = 26 cases; 2011 = 63 cases)
Haitib (2008 = 43 cases; 2011 = 86 cases)
a
b
laboratories globally. Created in 1994 to provide qualityassured DST within the framework of the Global Project
on Anti-TB Drug Resistance Surveillance, the network
today plays a more comprehensive role in strengthening
laboratory capacity in partner countries. Its terms of reference were revised in 2009 and, with increased funding
via the US Presidents Emergency Plan for AIDS Relief
(PEPFAR) and other sources, SRLs have been able to
formalize their relationships with partner countries and
increase the scope of their activities. The network has
grown in size and comprises 29 laboratories in all regions
(Figure 6.3). Additionally, 4 candidate SRLs are under
mentorship, including the national TB reference laboratories of Benin, Denmark and Uganda, and the Aga Khan
University of Pakistan. Pending completion of successful
mentorship and the establishment of country partners,
these new laboratories will help widen the geographical
reach of the network, in particular in the African and
Eastern Mediterranean regions.
Implementing quality management systems in TB
laboratories, especially in resource-constrained settings,
has been a particular focus of laboratory strengthening efforts during 20112012. In 2011, the GLI Stepwise
Process toward TB Laboratory Accreditation tool was
launched,1 led by the Union, the United States Centers for
Disease Control and Prevention, the Royal Tropical Institute in the Netherlands and WHO. The GLI tool provides
both guidance and an incentive for improving laboratory
quality towards meeting requirements for international
standards of accreditation. The Global Plan includes a
target that more than half of all national TB reference
laboratories should have implemented a quality management system by 2015. In 2012, eld testing of the tool was
started in Uganda and Benin; further uptake is expected
in 20122013.
Index year for Cameroon is 2009, as data were not reported for 2008.
Data were not reported for Haiti for 2009.
72
www.gliquality.org
FIGURE 6.3
The Supranational Reference Laboratory Network
Copenhagen, Denmark
Stockholm, Sweden
Riga, Latvia
Borstel, Germany
London, UK
Prague, Czech Republic
Gauting, Germany
Milan, Italy
Zagreb, Croatia
Porto, Portugal
Rome, Italy
Barcelona, Spain
Le Hamma, Algeria
Cairo, Egypt
Bilthoven, Netherlands
Antwerp, Belgium
Massachusetts, USA
Atlanta, USA
Mexico City, Mexico
Guadeloupe, France
Seoul, Republic of Korea

Karachi, Pakistan
Chennai, India
Tokyo, Japan
Hong Kong, China SAR

Bangkok, Thailand
Cotonou, Benin
Kampala, Uganda
Pretoria, South Africa

Santiago, Chile
Buenos Aires, Argentina
Brisbane, Australia
Adelaide, Australia
Supranational Reference Laboratory

Supranational Reference Laboratory Coordinating Center
Candidate Supranational Reference Laboratory
73
CHAPTER 7
Addressing the co-epidemics

of TB and HIV
In 2011, 1.1 million (13%) of the 8.7 million people who
developed TB worldwide were HIV-positive; 79% of
these HIV-positive TB cases were in the African Region.
WHOs recommended package of collaborative TB/
HIV activities to reduce the burden of TB/HIV includes
HIV testing for TB patients; CPT and early initiation of
ART for HIV-positive TB patients; and screening for TB
among people living with HIV and provision of IPT to
those eligible for it.
Substantial progress in the implementation of
collaborative TB/HIV activities has occurred since WHO
recommendations were rst issued in 2004, and further
progress was evident in 2011.
The percentage of notied TB patients with a
documented HIV test result in the African Region rose
from 60% in 2010 to 69% in 2011; 46% of those
tested in 2011 were HIV-positive, ranging from 8% in
Ethiopia to 77% in Swaziland. Worldwide, 40% of TB
patients notied in 2011 had a documented HIV test
result, up from 33% in 2010 and more than ten times
the level of 2004.
In 2011, 79% of TB patients known to be HIV-positive,
were provided with CPT, and 48% were started on
ART, similar to levels achieved in 2010. More work
remains to be done to ensure that all HIV-positive TB
patients are rapidly started on ART, in line with WHO
recommendations. Their progress on treatment should
also be closely monitored.
In 2011, 3.2 million people enrolled in HIV care were
reported to have been screened for TB, up 39% from
2.3 million in 2010. Of those without active TB disease,
0.45 million were provided with IPT, more than double
the number started on IPT in 2010 (mostly the result of
progress in South Africa).
The scale-up of collaborative TB/HIV activities saved a
total of 1.3 million lives between 2005 and the end of
2011.
People living with HIV who are also infected with TB are
much more likely to develop TB disease than those who
are HIV-negative.1 Starting in the 1980s, the HIV epidemic led to a major upsurge in TB cases and TB mortality in
many countries, which persisted throughout the 1990s
and up to around 2004, especially in southern and east
Africa (Chapter 2, Chapter 3).
In 2011, 1.1 million (13%) of the 8.7 million people
who developed TB worldwide were HIV-positive (Chapter 2, Table 2.1); 79% of these HIV-positive TB cases were
in the African Region. Globally, there were an estimated 0.4 million HIV-associated TB deaths in 2011, with
approximately equal numbers among men and women
(see Chapter 2). WHO, UNAIDS and the Stop TB Partnership have set a target of halving TB mortality rates
among people who are HIV-positive by 2015 compared
with 2004 (the year in which TB mortality among HIVpositive people is estimated to have peaked). 2
WHO recommendations on the interventions needed
to prevent, diagnose and treat TB in people living with
HIV have been available since 2004,3,4 and are collectively known as collaborative TB/HIV activities. They include
testing TB patients for HIV, providing antiretroviral therapy (ART) and co-trimoxazole preventive therapy (CPT)
to TB patients living with HIV, providing HIV prevention services for TB patients, intensifying TB case- nding
among people living with HIV, offering isoniazid preventive therapy (IPT) to people living with HIV who do not
have active TB, and controlling the spread of TB infection
in health-care and congregate settings (the latter three
activities are referred to as the Three Is for HIV/TB).
Antiretroviral therapy signicantly reduces the risk of
morbidity and mortality from TB. A meta-analysis published in 2012 found that ART reduces the individual risk
74
The probability of developing TB among people living with

HIV divided by the probability of developing TB among HIVnegative people is the incidence rate ratio (IRR). The median
value of the IRR in 155 countries for which data were available
in 2011 was 14 (inter-quartile range 1220).
Getting to zero: 20112015 strategy. Geneva, Joint United Nations
Programme on HIV/AIDS, 2010.
Policy on collaborative TB/HIV activities. Geneva, World Health
Organization, 2004 (WHO/HTM/TB/2004.330; WHO/HTM/
HIV/2004.1).
WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva, 2012 (WHO/
HTM/TB/2012.1).
7.1
HIV testing for TB patients
In 2011, the number of notied TB patients who had a

documented HIV test result reached 2.5 million (Figure
7.1), equivalent to 40% of notied TB cases (Table 7.1, Figure 7.2); this was an increase from 2.1 million and 33%
respectively in 2010, and more than 10 times the level of
3.1% reported in 2004 (Figure 7.2).
The coverage of HIV testing for TB patients was particularly high in the African Region, where 69% of TB
patients had a documented HIV test result in 2011, up
from 60% in 2010. Impressively, in 28/46 African countries, *75% of TB patients had a documented HIV test
result in 2011 (Figure 7.3), up from 22 countries in 2010.
In Kenya, Rwanda, Mozambique, Swaziland, Togo, the
United Republic of Tanzania, Zambia and Zimbabwe,
1
Suthar AB et al. Antiretroviral Therapy for Prevention of

Tuberculosis in Adults with HIV: A Systematic Review
and Meta-Analysis. PLoS Medicine, 2012, 9(7): e1001270.
(doi:10.1371/journal.pmed.1001270).
HTM/TB/2012.1).
This chapter does not discuss infection control or services
aimed at preventing HIV among TB patients. Data for infection control are limited for most countries, but available data
can be accessed at www.who.int/tb/data. Data on HIV prevention services for TB patients are collected by WHOs HIV
department and UNAIDS as part of their joint monitoring of
progress towards universal access and the global response to
AIDS.
FIGURE 7.1
2500
Number of TB patients with known

HIV status, 20042011
HIV status
Positive
Negative
TB patients (thousands)
2000
1500
1000
500
2004
FIGURE 7.2
2005
2006
2007
2008
2009
2010
2011
Percentage of TB patients with known

HIV status, 20042011
70
African region
60
Percentage of TB patients
of TB disease by 65%, irrespective of CD4 cell-count.1

IPT and ART given together can have an additive effect
and substantially reduce the risk of developing active TB
disease among people living with HIV. This evidence is
the reason why updated WHO policy guidance on collaborative TB/HIV activities (issued in 2012) includes earlier initiation of ART along with the Three Is for HIV/TB as
key interventions to prevent TB among people living with
HIV.2 ART is recommended for all TB patients living with
HIV, irrespective of their CD4 cell-count.
Testing TB patients for HIV and providing CPT to TB
patients living with HIV are typically the responsibility
of national TB control programmes (NTPs). National HIV
programmes are usually responsible for initiating intensied case- nding for TB among people living with HIV as
well as providing IPT to those without active TB. Provision of ART to TB patients living with HIV has often been
the responsibility of national HIV programmes, but can
also be done by NTPs, especially to facilitate better access
to care. When NTPs do not provide ART directly, they are
responsible for referring TB patients living with HIV to
ART services.
WHO began monitoring the implementation and
expansion of collaborative TB/HIV activities in 2004.
This chapter presents the latest status of progress, using
data for 2004 up to 2011.3
50
40
Global
30
20
Regions outside Africa
10
0
2004
2005
2006
2007
2008
2009
2010
2011
>85% of TB patients had a documented HIV result (Table

7.1). Globally, there were 80 countries in which *75% of
TB patients had a documented HIV test result.
Outside the African Region, in 2011 the percentage
of TB patients who had a documented HIV test result
exceeded 50% in the European Region and the Region
of the Americas (mostly inuenced by the numbers of TB
patients with a documented HIV test result in the Russian
Federation and Brazil, respectively). In other regions, the
percentage ranged from 11% in the Eastern Mediterranean Region to 32% in the South-East Asia Region. In
the 41 high TB/HIV burden countries identied as priorities for TB/HIV at the global level in 2002 (listed in Table
7.1), overall 45% of TB patients notied in 2011 had a
documented HIV test result; levels of HIV testing were
especially low in Indonesia and Myanmar (Table 7.1).
The highest rates of HIV coinfection were reported for
TB patients in the African Region (Table 7.1), where 46%
of those with an HIV test result were HIV-positive (compared with 44% in 2010). The percentage of TB patients
found to be HIV-positive in the 28 African countries in
the list of 41 priority countries ranged from 8% in Ethiopia to 77% in Swaziland. Besides Swaziland, *50% of
the TB patients with an HIV test result were HIV-positive
in Botswana, Lesotho, Malawi, Mozambique, Namibia,
South Africa, Uganda, Zambia and Zimbabwe.
75
TABLE 7.1 HIV testing, treatment for HIV-positive TB patients and prevention of TB among people living with HIV,
41 high TB/HIV burden countries and WHO regions, 2011. Numbers in thousands except where indicated.
ESTIMATED HIV-POSTIVE INCIDENT
TB CASES
BEST
LOW
Angola
8.5
6.2
Botswana
5.9
5.3
Brazil
16
13
HIGH
11
6.6
19
NUMBER
OF TB
PATIENTS
WITH KNOWN
HIV STATUS
% OF
NOTIFIED
TB PATIENTS
TESTED
FOR HIV
% OF
TESTED TB
PATIENTS HIVPOSITIVE
% OF
IDENTIFIED
HIV-POSITIVE
TB PATIENTS
STARTED ON
CPT
% OF
IDENTIFIED
HIV-POSITIVE
TB PATIENTS
STARTED ON
ART
5.1
10
19
80
80
5.4
80
64
82
45
58
20
49
Burkina Faso
1.6
1.4
1.9
4.6
82
17
94
2.6
2.2
2.9
4.8
71
22
95
48
Cambodia
3.1
2.6
3.6
88
79
Cameroon
19
15
22
82
5.1
20
81
38
Central African Republic
7.1
5.7
8.7
1.9
33
39
Chad
5.2
4.1
6.4
4.1
38
23
China
Congo
Cte dIvoire
Djibouti
13
4.9
10
0.6
8.6
3.9
8.7
0.5
17
6.1
12
0.7
209
2.2
18
1.3
23
12
2.3
9.3
26
80
26
80
36
34
14
16
27
41
31
27
38
28
49
65
41
8.4
54
23
62
39
28
Ghana
4.6
4.0
5.2
13
79
23
71
Haiti
4.3
3.6
5.2
10
73
19
12
17
689
45
91
59
0.6
92
42
2.8
174
India
94
72
120
Indonesia
15
11
20
Kenya
47
45
49
97
93
39
97
64
Lesotho
11
12
10
82
76
90
40
Malawi
18
19
17
83
60
89
60
297
35
21
72
69
29
Mali
1.5
9.2
16
1.3
1.7
Mozambique
83
58
110
Myanmar
18
15
22
Namibia
Nigeria
Russian Federation
8.4
50
9.3
6.6
23
7.3
10
81
26
68
43
224
97
28
97
80
25
28
390
3.6
12
10
15
13
10
15
Ukraine
UR Tanzania
8.1
30
0.8
28
6.7
28
1.2
42
6.6
10
78
323
83
8.9
65
44
100
1 256
8.4
92
77
95
51
58
74
15
75
59
41
100
22
32
553
3.0
39
80
53
29
72
20
32
54
88
38
9.6
76
15
50
9.5
8.0
93
0.4
14
1.0
4.0
3.1
373
44
95
38
72
48
Viet Nam
14
11
18
59
59
Zambia
38
35
42
42
86
64
87
53
Zimbabwe
46
36
58
35
86
60
29
67
High TB/HIV burden countries
17
76
Thailand
1.0
12
79a
Swaziland
35
29
80
11
4.6
Uganda
91
100
86
3.3
Togo
63
20
13
2.6
2.1
3.1
54
3.1
270
88
98
2.9
2.8
4.5
31
386
50
3.8
330
42
36
84
Sierra Leone
Sudan
2.0
1.1
10
Rwanda
South Africa
3.5
6.5
1.3
36
24
34
0
4.7
1.4
31
Ethiopia
0.2
3.6
20
DR Congo
NUMBER OF
HIV- POSITIVE
PEOPLE
PROVIDED
WITH IPT
92
Burundi
33
NUMBER OF
HIV- POSITIVE
PEOPLE
SCREENED
FOR TB
148
1 100
990
1 100
2 170
45
25
80
48
3 208
439
AFR
870
800
950
1 002
69
46
79
46
2 770
438
AMR
37
34
40
124
53
17
43
64
EMR
7.6
9.9
1.7
45
11
4.0
59
48
1.0
0.1
EUR
23
20
25
187
52
6.5
64
47
9.2
4.6
SEAR
140
120
170
750
32
7.2
89
59
440
0.4
WPR
36
31
42
352
25
3.9
71
47
11
1.8
1 100
1 000
1 200
2 460
40
79
48
3 234
Global
8.7
2.7
23
446

a
This number is for new TB patients only. It was not possible to calculate the percentage of all TB patients with known HIV status.
76
FIGURE 7.3
Percentage of TB patients with known HIV status by country, 2011a
Percentage of notified
TB cases with known
HIV status
014
1549
5074
75
No data
Not applicable
Data for the Russian Federation are for new TB patients only.
In the Region of the Americas, the percentage of TB

patients with a documented HIV test result who were
HIV-positive was 17%. In the Eastern Mediterranean,
European, South-East Asia and Western Pacic regions,
less than 10% of TB patients with a documented HIV test
result were HIV-positive. The global average across all
regions was 23%, and 25% among the 41 high TB/HIV
burden countries.
7.2
Co-trimoxazole preventive therapy and

antiretroviral therapy for TB patients
living with HIV
Globally, the number of TB patients living with HIV who

were enrolled on CPT increased to 0.41 million in 2011,
up from a negligible number in 2004 and 0.37 million in
2010 (Figure 7.4). The coverage of CPT among TB patients
with a documented HIV-positive test result was 79% in
2011 (Table 7.1, Figure 7.5). Further progress is needed to
reach the target of 100% that is included in the Global
Plan to Stop TB, 201120151 (see Chapter 1). The African
and South-East Asia regions achieved particularly high
levels of enrolment on CPT: 79% and 89% of TB patients
known to be living with HIV, respectively (Table 7.1).
Countries that achieved rates of enrolment on CPT of
>90% in 2011 included Burkina Faso, Burundi, India,
Indonesia, Kenya, Lesotho Mozambique, Myanmar,
Namibia, Rwanda, Swaziland, Uganda and the United
Republic of Tanzania.
The number of HIV-positive TB patients on ART has
FIGURE 7.4
Number of HIV-positive TB patients enrolled

on co-trimoxazole preventive therapy (CPT)
and antiretroviral therapy (ART), 20042011
600
Tested HIV-positive
Number of TB patients (thousands)
500
400
CPT
300
200
ART
100
0
2004
2005
2006
2007
2008
2009
2010
2011
grown from a very low level in 2004 (Figure 7.4) to reach

258 000 in 2011. Among TB patients notied in 20112
and who had a documented HIV-positive test result,
48% were on ART globally in 2011 (Table 7.1, Figure 7.5),
a small improvement from 46% in 2010. In the African
Region, 46% of the TB patients notied in 2011 who had
a documented HIV-positive test result were on ART in
1

In the annual WHO TB data collection form, countries are
asked to report the number of TB patients notied in the
most recent calendar year who were living with HIV and who
started or continued on ART.
77
FIGURE 7.5
Percentage of TB patients with known HIV status who were HIV positive, and percentage of HIV-positive TB
patients enrolled on co-trimoxazole preventive therapy (CPT) and antiretroviral therapy (ART), 20062011a
% of TB patients with known HIV status

who are HIV-positive
% of HIV-positive patients on CPT
% of HIV-positive patients on ART
100
Percentage of TB patients
80
60
40
20
0
2006
a
2007
2008
2009
2010
2011
2006
2007
2008
2009
2010
2011
2006
2007
2008
2009
2010
2011
The solid lines show values for countries that reported data. The shaded areas show upper and lower limits when countries that did not report data are considered.
FIGURE 7.6
Percentage of HIV-positive TB patients enrolled on antiretroviral therapy (ART), 2011
Percentage of
HIV-positive
TB cases on ART
024
2549
5074
75100
No data
Not applicable
2011 (up from 44% in 2010). Among the 41 high TB/HIV

burden countries, 15 reported enrolling more than 50%
of notied TB patients known to be living with HIV on
ART in 2011 (Table 7.1, Figure 7.6).
Given WHOs recommendation that all HIV-positive
TB patients are eligible for ART irrespective of their CD4
cell-count and the Global Plans target of providing ART
to all TB patients known to be living with HIV by 2015
(Chapter 1), the coverage of ART for HIV-positive TB
patients needs to be improved. This could be facilitated by
78
using TB services and infrastructure to allow decentralization of care delivery according to national guidelines
and the local context (Box 7.1).
7.3
Intensifying case-finding and

isoniazid preventive therapy among
people living with HIV
Until 2010, data on intensied screening for TB among

people living with HIV and provision of IPT to those
without active TB were requested from NTPs as part of
BOX 7.1
Accelerating progress in providing ART to TB patients living with HIV
People with HIV-associated TB have a high risk of mortality. For example, in autopsy studies of people who were HIV-positive, TB was
identied in 3079%.1,2 Expanding access to ART will have a signicant impact on mortality among HIV-positive TB patients, in addition
to reducing the risk of developing TB among people living with HIV who do not have active TB.
Since 2010, WHO has recommended ART for TB patients regardless of CD4 cell-count. Furthermore, the optimum time to start ART in
patients with HIV-associated TB has now been established in three large randomized controlled trials.3,4,5 These studies collectively
showed that ART should be given concurrently with TB treatment regardless of CD4 cell-count. The risk of AIDS and death in those with
profound immunosuppression (CD4 cell-count <50 cells/mm3) was minimized by starting ART in weeks 24 of TB treatment. WHO now
recommends initiating TB treatment rst, then starting ART as soon as possible within the rst 8 weeks of TB treatment. Those with
profound immunosuppression should be started on ART within the rst 2 weeks of TB treatment.
Despite the current policy recommendations, only 48% of TB patients known to be living with HIV were started on ART in 2011 (Figure
7.5, Table 7.1). There are several explanations for this, including the availability and allocation of resources and the attitude and capacity
of health-care providers. Delayed and inconsistent uptake and adaptation of global policies by national authorities and the relative
centralization of ART services compared with the greater decentralization of TB services to more peripheral levels of the health-care
system merit special attention.
In a recent analysis of TB and HIV policies and guidelines covering 72 countries,6 ART was recommended for all TB patients living with
HIV, irrespective of their CD4 cell-count, in 24 countries. However, in 24 countries ART was recommended for TB patients living with HIV
only if their CD4 cell-count was 350 cells/mm3. In one country, ART was
recommended for TB patients living with HIV if their CD4 cell-count was
TABLE B7.1.1
200 cells/mm3. In the remaining 23 countries, guidelines did not specify any
Distribution of facilities providing TB and
criteria for when to initiate ART in TB patients living with HIV.
ART services in ve high TB/HIV burden
countries contributing 60% of the global

burden of HIV-associated TB, 2011
COUNTRY
India
TB TREATMENT FACILITIES
ART FACILITIES
32 583
1080
Mozambiquea
1333
229
Nigeria
4387
491
South Africa
4203
3222
Zimbabwe
1548
590
The results from a study of the availability of TB and ART services in ve high
TB/HIV burden countries are shown in Table B7.1.1. In each country, there
were far more facilities providing TB services. The ratio of TB to ART facilities
ranged from 1.3 in South Africa to 30 in India.
These analyses show that to increase the coverage of ART for TB patients
living with HIV, national authorities need to adopt national policies and
programme guidelines that promote and ensure access to ART. The widely
decentralized TB services and stafng offer an opportunity to further
decentralize ART services to peripheral-level health-care facilities.
Data for 2010.
Martinson NA et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS, 2007, 21:20432050.
Lawn SD, Harries AD, Meintjes G et al. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS, 2012
(epub ahead of print).
Blanc FX et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New England Journal of Medicine, 2011,
365:14711481.
Havlir DV et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. New England Journal of Medicine, 2011, 365:14821491.
Abdool Karim SS et al. Integration of antiretroviral therapy with tuberculosis treatment. New England Journal of Medicine, 2011, 365:14921501.
Gupta SS et al. Three Is for HIV/TB and early ART to prevent HIV and TB: policy review of HIV and TB guidelines for high HIV/TB-burden African
countries (in press).
the global TB data collection form. In 2011, in an effort

to streamline efforts to collect data and improve their
quality, information about these two interventions was
collected by WHOs HIV/AIDS Department from national
HIV programmes as part of reporting on universal access.
UNAIDS the Joint United Nations Programme on HIV/
AIDS also collects data on the multisectoral response to
the HIV epidemic, including health system indicators. In
2012, information on TB screening and IPT was collected
through the UNAIDS monitoring system. This alternation
between systems for data collection may help to explain

why fewer countries reported data on TB screening and
IPT provision in 2011 compared with 2010. Recording
and reporting of TB screening among people living with
HIV and provision of IPT to those without active TB is
a particular challenge in many countries; further efforts
are needed to facilitate and improve the tracking of progress nationally and globally.
Among the 53 countries that reported data, 3.2 million
people enrolled in HIV care were screened for TB in 2011,
79
FIGURE 7.7
Intensied TB case-nding among people

living with HIV, 20052011
Number of people screened (millions)
0
2005
Number of HIV-positive people without active TB

(thousands)
FIGURE 7.8
2006
2007
2008
2009
2010
2011
Provision of isoniazid preventive therapy

(IPT) to people living with HIV without
active TB, 20052011
500
400
300
7.4
200
100
0
2005
FIGURE 7.9
2006
2007
2008
2009
2010
2011
Estimated number of lives saved globally by

the implementation of TB/HIV interventions,
20052011. The blue band represents the
uncertainty interval.
0.5
Number of lives saved (millions)
compared with 2.3 million in 71 countries in 2010 (Figure

7.7). Unfortunately, at the time this report went to press,
the total number of people enrolled in HIV care in 2011
was not available (the gure was 4.0 million in 2010).
Nonetheless, it is clear that further progress is needed to
approach the target in the Global Plan, which is to screen
all those enrolled in HIV care for TB by 2015.
Among 29 countries that reported data, IPT was provided to almost 450 000 people living with HIV in 2011,
more than double the 201 000 people provided with IPT in
2010 (Figure 7.8). Most of the increase occurred in South
Africa, where 373 000 people were reported to have been
provided with IPT in 2011, followed by Ethiopia (31 000),
Mozambique (17 000) and Namibia (14 000). Unfortunately, at the time this report went to press, the total
number of people newly enrolled in HIV care in 2011 and
potentially eligible for IPT was not available (the gure
was 1.5 million in 2010). However, as with TB screening
among people in HIV care, it is clear that further efforts
are needed to reach the Global Plans 2015 target of providing IPT to all those eligible for it estimated at approximately 50% of those newly enrolled in HIV care.
In the years between the publication of WHOs rst policy

on collaborative TB/HIV activities in 2004 and updated
guidance launched in 2012,1,2 considerable progress in
implementing the recommended package of interventions occurred, as documented in Section 7.1, Section 7.2
and Section 7.3. At the time that updated guidance was
published in March 2012, the lives saved as a result of
the implementation of collaborative TB/HIV activities
between 2005 and 2010 were estimated. Here, the analysis is extended to 2011 and methods are explained.
Four interventions were considered:
0.4
0.3
0.2
0.1
2005
2006
2007
2008
2009
2010
2011
ART provided during TB treatment for people living

with HIV;
CPT provided during TB treatment for people living
with HIV;
IPT for HIV-positive people enrolled in HIV care;
Early TB diagnosis through systematic screening for
TB among people living with HIV.
These interventions were compared with a counterfactual

scenario de ned as no ART, no CPT, no IPT and no TB
screening.
80
Lives saved by the implementation

of collaborative TB/HIV activities,
20052011
Policy on collaborative TB/HIV activities. Geneva, World Health

Organization, 2004 (WHO/HTM/TB/2004.330; WHO/HTM/
HIV/2004.1).
HTM/TB/2012.1).
TABLE 7.2 Assumptions used to estimate lives saved by ART, CPT, screening for TB among people living with HIV and IPT
INTERVENTION
MEAN EFFICACY IN PREVENTING TB DEATHS
ASSUMPTIONS
ART for TB patients
0.7
Uniform, 0.60.8
CPT for TB patientsa
0.21
Normal, standard error 0.09
CPT has no additional benet if ART is also

provided.
IPT for people living with HIV

without active TB disease
0.3
Uniform, 0.250.35
Efcacy of IPT in preventing TB 0.6; case

fatality rate of 50% among HIV-positive TB
cases.
Uniform, 0.00430.0157
The probability of detecting TB in systematic

screening, per person screened, is 0.05.
Detected cases of TB are already on CPT and
the proportion started on ART is equal to
the global ART:CPT ratio. TB screening has
no additive effect for people already on ART.
Additional impact of early TB treatment for
people not on ART but on CPT is 0.2.
Systematic screening of people

living with HIV to detect cases of
TB, followed by early initiation of
TB treatment
DISTRIBUTION
0.01
www.aidsmap.com/Cotrimoxazole-prophylaxis-cuts-risk-of-death-for-HIV-positive-patients-with-TB-in-Zambia/page/1430833/
The effectiveness of the four interventions was estimated using the parameters de ned in Table 7.2.
Between 2005 and 2011, the number of lives saved
rose from less than 50 000 in 2005 to over 0.4 million
in 2011 (Figure 7.9); the total cumulative number of lives
saved was 1.3 million (range 1.21.5 million).
Four limitations of the analysis should be noted. First,
any errors and inconsistencies in data reported by countries could not be accounted for. Second, the impact of
TB screening among people living with HIV is hard to

estimate; the frequency of TB screening determines
how early TB diagnosis will be made compared with no
screening, and no global data on the frequency of screening were available. Third, only four of the 12 collaborative
activities were considered. Fourth, the impact of collaborative TB/HIV activities on the transmission of TB and
HIV was not accounted for. For the latter two reasons,
the estimates presented here are likely to be conservative.
81
CHAPTER 8
Research and development

Conventional technologies have been constraining
progress in TB care and control, but efforts to develop
new TB diagnostics, drugs, and vaccines have intensied
during the past decade and considerable progress has
been made.
WHO has endorsed several new diagnostic tests or
methods since 2007, including Xpert MTB/RIF that has
the potential to transform TB care. Other new tests,
including point-of-care tests, are in development.
For the rst time in 40 years, a coordinated portfolio of
promising new anti-TB drugs is in development, with 11
new or repurposed anti-TB drugs in clinical trials.
Results from two Phase III trials of 4-month regimens
for the treatment of drug-susceptible TB are expected
in 2013. In addition, 2 new compounds are being
evaluated for use as an adjunct to current optimized
regimens for MDR-TB; one compound recently moved
to a Phase III trial and the other is expected to do so
before the end of 2012.
A new three-drug combination regimen that could be
used to treat both drug-sensitive TB and MDR-TB and
shorten treatment duration has been tested in a Phase
II study of early bactericidal activity, with encouraging
results.
There are 11 vaccine candidates for TB prevention in
Phase I or Phase II trials and one immunotherapeutic
vaccine in a Phase III trial. It is hoped that one or two
of the candidates in a Phase II trial will enter a Phase
III trial in the next 23 years, with the possibility of
licensing at least one new vaccine by 2020.
Funding for TB research and development has increased
in recent years, but stagnated between 2009 and 2010.
At US$ 630 million in 2010, funding falls far short of
the annual target of US$ 2 billion specied in the Global
Plan to Stop TB 20112015.
There has been major progress in TB care and control

since the mid-1990s (Chapters 27). However, achievement of the Stop TB Partnerships target of eliminating TB by 2050 (Chapter 1) requires the development of
new diagnostics, drugs and vaccines as well as better and
wider use of existing technologies. For example, modeling studies show that TB elimination by 2050 demands
a combination of improved diagnosis of drug-susceptible
and drug-resistant TB, better and shorter treatments for
all forms of TB, treatment of people with latent TB infection on a massive scale (especially in high-risk populations) and mass vaccination with a vaccine that is more
effective than BCG.1
During the past decade, efforts to develop new diagnostics, drugs and vaccines for TB have intensied. For
example, publicprivate partnerships have been created
to stimulate the development of novel tools for TB control. These include the Foundation for Innovative New
Diagnostics (in 2003), which works on the development
of novel diagnostics for TB among a range of other diseases; the TB Alliance (in 2000), for new anti-TB drugs;
and for new vaccines against TB, Aeras (in 2003) and the
TB Vaccine Initiative (in 2008). The Stop TB Partnership includes three working groups for new diagnostics,
new drugs and new vaccines, which represent important forums for exchanging information and promoting
research.
Funding for TB research and development increased
from US$ 363 million in 2005 to US$ 630 million in
20102 but stagnated between 2009 and 2010. The 2010
level of funding falls about US$ 1.4 billion per year short
of the needs described in the Global Plan to Stop TB 2011
2015.3 Major sources of existing funding include the United States National Institutes of Health/National Institute
of Allergy and Infectious Diseases (NIH/NIAID), the Bill
& Melinda Gates Foundation, the European Commission
(including the European Developing Countries Clinical
Trials Partnership, EDCTP), USAID and DFID, as well as
1
82
Abu-Raddad LJ et al. Epidemiological benets of more effective tuberculosis vaccines, drugs and diagnostics. Proceedings
of the National Academy of Sciences of the United States of America,
2009, 106(33):13980139805.
Jimnez-Levi E. 2011 Report on tuberculosis research funding
trends, 20052010, 2nd ed. New York, NY, Treatment Action
Group, 2012.
FIGURE 8.1
The development pipeline for new TB diagnostics, July 2012

Liquid culture and DST
Rapid speciation
LPA for MDR-TB
Non-commercial culture and DST
(MODS, NRA, CRI)
LPA for XDR-TB

LPA for MDR-TB 2nd generation
Rapid colorimetric DST

Xpert 2nd
generation
Manual NAAT
70
INTERMEDIATE LEVEL
Access after 5 years (%)
Distance from patients
1040
REFERENCE LEVEL
New SS+ case definition
Xpert MTB/RIF
2-specimen approaches
LED microscopy
Same-day diagnosis
VOC detection
Enzymatic detection
Ag and Ab detection
NAAT 2nd generation
95
PERIPHERAL LEVEL
2007
2008
2009
2010
2011
2012
2013
2014
Technologies or methods endorsed by WHO
Technologies commercialized, not yet endorsed by WHO
Technologies at feasability stage
Technologies at early stages of development
2015
2016
Abbreviations: DST Drug susceptibility test; NAAT Nucleic acid amplication test; LTBI Latent TB infection; Ag Antigen; Ab Antibody; MODS Microscopic observation drugsusceptibility; NRA Nitrate reductase assay; CRI Colorimetric redox indicator assay; LED Light-emitting diode; LPA Line probe assay; VOC Volatile organic compound.
several other national, bilateral and multilateral agencies,

private companies and philanthropic organizations. To
highlight the need for and catalyse further efforts in TB
research, a roadmap outlining critical priority areas for
future scientic investment across the research spectrum
was published in 2011.1
In 2011, a chapter on the latest status of progress in TB
research and development was introduced in the series of
WHO global reports on TB for the rst time. In this 2012
report, the status of progress as of July 2012 is summarized, drawing primarily on information provided by the
secretariats of the relevant working groups of the Stop TB
Partnership.
8.1
New diagnostics for TB
Sputum-smear microscopy the most commonly used

diagnostic test for TB is more than 100 years old. This
test is relatively insensitive and it cannot be used to identify paucibacillary or extrapulmonary TB. Diagnosis
using culture methods the current reference standard
requires laboratory infrastructure that is not widely
available in countries with a high burden of TB (Chapter
6), and results are only available after a few weeks. Con-
An international roadmap for tuberculosis research. Geneva, World

Health Organization, 2011 (also available at:
www.stoptb.org/assets/documents/resources/
publications/technical/tbresearchroadmap.pdf;
ventional methods used to diagnose multidrug-resistant

TB (MDR-TB) also rely on culturing of specimens followed by drug susceptibility testing (DST); results take
weeks to obtain and not all laboratories with the capacity
to perform DST of rst-line drugs have the capability to
perform DST of second-line drugs.
The status of the pipeline for new TB diagnostics in
July 2012 is shown in Figure 8.1. After decades of stagnation, accelerated development of new TB diagnostics in
the past decade presents real hope that rapid diagnosis
of TB and MDR-TB can become a reality, thus removing
longstanding barriers to TB care and control.
In the past 5 years, WHO has endorsed several new
tests and diagnostic approaches. These include:
liquid culture with rapid speciation as the reference

standards for bacteriological con rmation;
molecular line probe assays for rapid detection of
MDR-TB;
non-commercial culture and DST methods;
light-emitting diode uorescence microscopes for
improved smear microscopy; and
Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) for
the rapid diagnosis of TB and rifampicin-resistant TB.
Following WHOs endorsement of Xpert MTB/RIF in

December 2010, research on its use has proliferated. By
July 2012, more than 65 peer-reviewed publications had
been published, covering the full spectrum of research
and con rming initial ndings on the tests performance.
83
BOX 8.1
Xpert MTB/RIF operational research
projects mapped by TREAT-TB
TREAT-TB, a research programme implemented by the Union
(an international NGO that conducts work on TB and other
lung diseases) with funding from USAID, is monitoring and
mapping operational research on Xpert MTB/RIF as part of its
work. The topics for which research is being conducted and the
number of studies per topic are summarized below.
Use in target populations
People suspected of having TB: 14 studies
People suspected of having MDR-TB: 9 studies
HIV-associated TB: 7 studies
Children: 4 studies
Use at different levels of the health-care system
Point-of-care level: 14 studies
District level: 11 studies
Central level: 7 studies
Impact assessment
Health-care system costs: 13 studies
Patient costs: 12 studies
Health-care system requirements: 12 studies
Equity issues: 3 studies
Further details are available from the TREAT-TB web site at
www.treattb.org
BOX 8.2
Xpert MTB/RIF innovations, 20112012
There have been ve innovations since WHO endorsed the
Xpert MTB/RIF assay in December 2010:
renements to the Xpert MTB/RIF assay cartridge,
implemented in 2011, resulting in increased rifampicin
specicity without loss of sensitivity;
modications to the software, uidics and minor changes
to Probe B, resulting in reduced error rates compared with
those observed with the earlier cartridges;
development of a calibration kit for users, allowing users
to recalibrate the optical system, verify the functioning
of the thermal system and conduct a series of systemlevel tests to ensure full system functionality within
specications, thereby reducing the need for remote
calibration of GeneXpert modules;
better packaging of cartridges, resulting in reduced
packaging requirements, thus reducing waste and shipping
costs; and
development of validation panels, allowing end-users
to validate the expected performance of the GeneXpert
instrument following installation, to demonstrate their
ability to use the assay correctly, and to interpret and
report results. Articial sputum samples spiked with
heat-killed TB bacilli, developed by the Global Laboratory
Initiative, are now being shipped with each new GeneXpert
instrument.
84
Of particular programmatic relevance are several operational research studies addressing key research questions
identied following a WHO Global Consultation on Xpert
MTB/RIF held in Geneva in December 2010. These studies are being mapped by an interactive tool developed by
the Union-led and USAID-funded TREAT-TB initiative,1
which complements the monitoring of Xpert MTB/RIF
roll-out by WHO. 2 By July 2012, 24 operational research
projects in 16 countries had been registered, covering
multiple aspects of Xpert MTB/RIF implementation (Box
8.1).
The possibility of using Xpert MTB/RIF to improve the
diagnosis of extrapulmonary TB and the diagnosis of TB
in children is also being explored. The overall sensitivity
and specicity in studies completed to date ranges from
75% to 95%, depending on the type of specimen, with
excellent specicity of 99%100% for all types of specimens investigated. WHO plans to evaluate the evidence
in the rst half of 2013. It should be noted that specimen
collection remains problematic for extrapulmonary TB
and in young children who cannot expectorate sputum.
Developing safe and effective strategies for specimen collection and optimizing specimen processing for individuals with paucibacillary disease thus remain important
topics for research. In the meantime, ongoing innovations
to the Xpert MTB/RIF assay have already resulted in signicant improvements to the technology (Box 8.2).
In 2011, WHO issued strong policy recommendations against the use of poorly-performing yet expensive
commercial, antibody-based serological diagnostic tests,
and cautioned against the use of commercial interferongamma release assays to detect latent TB infection in
high-burden TB and HIV settings (further details about
this policy guidance are provided in Chapter 6).
In 2012, WHO evaluated two tests that were already
commercially available: a manual molecular assay to
detect TB DNA in sputum specimens (TB-LAMP, Eiken Chemical Co. Ltd., Japan); and a line probe assay for
detecting resistance to second-line anti-TB drugs (GenoType MTBDRsl, Hain Lifescience, Germany). The evidence-based process followed by WHO resulted in the
conclusion that available data for the TB-LAMP assay
were insufcient to proceed with the development of policy guidance. The same process also led to the conclusion
that the line probe assay for detecting resistance to second-line anti-TB drugs cannot be used as a replacement
test for conventional phenotypic DST, given its modest
sensitivity to detect resistance to uoroquinolones and
second-line injectable agents. While the high specicity
of the test may allow the assay to be used as a triage test to
guide initial treatment albeit limited to smear-positive
1
2
www.treattb.org
http://who.int/tb/laboratory/mtbrifrollout/en/index.
html
sputum specimens and TB isolates from culture conventional phenotypic testing remains the reference standard
for detecting extensively drug-resistant TB (XDR-TB)
until more data become available. Further details about
the evaluation of these tests is provided in Chapter 6.
Consistent challenges in developing new TB diagnostics have been the sophisticated and costly laboratory
infrastructure and specialized human resources required
for the range of tests needed to diagnose TB in its various forms, and test utility being restricted to increasingly sophisticated levels of laboratory services. Only one
DST technology based on a rapid colorimetric method
suitable for use at the intermediate laboratory level is
currently at the stage of being tested for feasibility. Second-generation Xpert assays and possible alternative
molecular technologies are in the early or conceptual
stages of development and are not expected to reach the
market before the end of 2015.
TB remains unique among the major infectious diseases in lacking accurate and rapid point-of-care (POC)
tests. Insufcient progress in biomarker research, technical difculties in transforming sophisticated laboratory
technologies into robust yet accurate POC platforms, and
a lack of interest from industry have resulted in slow and
suboptimal progress. The era of omics has seen largescale searches for biological markers of disease and the
application of emerging technologies to identify novel
markers of disease, particularly from blood and urine.
These have traditionally been directed at nding reliable
surrogates for culture to assess and/or predict treatment
prognosis and have only recently become a focus for the
development of TB diagnostics.
Non-sputum based tests remain an attractive avenue
to explore for POC development. Commercially available antigen detection assays can identify Mycobacterium
tuberculosis lipoarabinomannan (LAM) in urine; however, their accuracy in routine clinical use has been
suboptimal.1 Two recent studies evaluating a low-cost,
POC version of a commercial TB-LAM test (Determine
TBLAM, Alere Inc., Waltham, MA, USA) showed moderate sensitivity and high specicity in a subgroup of TB
patients living with HIV who had advanced immunosuppression (CD4 cell-counts <50), but the overall sensitivity
in patients with culture-con rmed TB remained low.2,3
Further research is needed to evaluate the placement of
this test in appropriate algorithms and assess its clinical
impact.
The target product pro le for an ideal POC test for TB
has been described4 and the evolving landscape of TB
diagnostics offers greater promise for developing a userfriendly, robust POC test. Nonetheless, it remains to be
seen whether a single test would meet all the requirements of accuracy, speed, robustness, ease-of-use, safety
and affordability. In the foreseeable future, therefore,
tools in the pipeline will need to be rapidly assessed and
deployed if found to be good, while implementation of

existing tools must be accelerated in dynamic diagnostic algorithms and at the appropriate levels of laboratory
services.
Policy uptake and roll-out of contemporary, rapid TB
diagnostics is encouraging (Chapter 6), but urgent expansion in their availability and use is required to achieve the
testing targets set out in the Global Plan. In addition to the
funding required for implementation and scale-up of new
technologies endorsed by WHO and appropriate laboratory services (Chapter 5), increased investment in research
and development in new TB diagnostics remains imperative. In 2010, funding represented only 8% (US$ 48 million) of the overall investment (US$ 630 million) in TB
research and development. Indeed, TB diagnostics suffers
the largest relative funding gap: US$ 48 million represents only 14% of the Global Plans target of US$ 340 million/year, compared with 31% for new anti-TB drugs and
20% for new TB vaccines.5
8.2
New drugs to treat and prevent TB
The anti-TB drugs used in rst-line treatments are around

50 years old. The regimen that is currently recommended
by WHO for new cases of drug-susceptible TB is highly
efcacious, with cure rates of around 90% in HIV-negative patients. Nonetheless, it requires 6 months of treatment with rst-line drugs (a combination of rifampicin,
isoniazid, ethambutol and pyrazinamide for 2 months,
followed by a 4-month continuation phase of rifampicin
and isoniazid). Regimens for MDR-TB treatment currently recommended by WHO entail 20 months of treatment
with second-line drugs for most patients, and are associated with multiple (and sometimes serious) side-effects
and lower cure rates (see Chapter 4). There are also interactions between anti-TB treatment and antiretroviral
therapy (ART) for people living with HIV. New drugs are
required to shorten and simplify treatment, to improve
Minion J et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. European
Respiratory Journal, 38(6):13981405, 2011.
Lawn SD et al. Screening for HIV-associated pulmonary tuberculosis prior to antiretroviral therapy: diagnostic accuracy of a
low-cost, urine antigen, point-of-care screening assay for HIVassociated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infectious Diseases [epub ahead of
print, Oct. 17, 2011].
Peter J et al. The clinical utility of urine lipoarabinomannan
and the novel point-of-care lateral ow strip test (determine
TB) for the diagnosis of tuberculosis in hospitalised patients
with HIV-related advanced immunosuppression. American
Journal of Respiratory and Critical Care Medicine, 2011, 183:A5313.
Paris meeting on TB point-of-care test speci cations. Treatment
Action Group, Mdecins Sans Frontires, 2009 (available at:
http://www.msfaccess.org/TB_POC_Parismeeting/;
Jimnez-Levi E. 2011 Report on tuberculosis research funding
trends, 20052010, 2nd ed. New York, NY, Treatment Action
Group, 2012.
85
FIGURE 8.2
The development pipeline for new TB drugs, July 2012
Discoverya
Preclinical development
Lead
optimization
Preclinical
development
Diarylquinoline
DprE Inhibitors
GyrB inhibitors
InhA Inhibitors
LeuRS Inhibitors
MGyrX1 inhibitors
Mycobacterial Gyrase
Inhibitors
Pyrazinamide Analogs
Riminophenazines
Ruthenium (II)
complexes
Spectinamides
Translocase-1 Inhibitors
CPZEN-45
DC-159a
Q-201
SQ-609
SQ-641
Clinical development
Good
Laboratory
Practice
toxicity
Phase I
BTZ-043
TBA-354
Phase II
Phase III
Bedaquiline
(TMC-207)
Linezolid
Novel Regimens
PA-824
Rifapentine
SQ-109
Sutezolid (PNU100480)
Delamanid
(OPC-67683)
Gatifloxacin
Moxifloxacin
Rifapentine
Chemical classes: uoroquinolone, rifamycin, oxazolidinone, nitroimidazole, diarylquinoline, benzothiazinone

a
Ongoing projects without a lead compound series can be viewed at www.newtbdrugs.org/pipeline-discovery
Source: Stop TB Partnership Working Group on New TB Drugs; see www.newtbdrugs.org
the efcacy and tolerability of treatment for MDR-TB

and to improve the treatment of TB among people living
with HIV. New drugs could also help to treat latent TB
infection in people without active TB disease; at present,
preventive therapy usually consists of 69 months of isoniazid monotherapy.
The status of the pipeline for new anti-TB drugs in July
2012 is shown in Figure 8.2. Of the 11 new or repurposed
TB drugs under clinical investigation (one more than in
mid-2011), 4 are in Phase III (efcacy) trials and 7 are in
Phase II (early bactericidal activity and sputum culture
conversion) trials. Two of the Phase III trials are evaluating 4-month combination regimens in which a uoroquinolone (gatioxacin or moxioxacin) is substituted
for either ethambutol or isoniazid; results are expected
in 2013. A third Phase III trial is evaluating the use of
rifapentine (a rifamycin that has a longer half-life than
rifampicin) as part of a 4-month regimen for the treatment of drug-susceptible TB. Since mid-2011, the delamanid (OPC-67683) compound, which is being tested
as an addition to optimized background therapy for the
treatment of MDR-TB, has moved from a Phase II to a
Phase III trial.
Of the seven individual compounds in Phase II trials,
bedaquiline (TMC-207) is being tested as an addition to
optimized background therapy for the treatment of MDRTB. It is expected to move to a Phase III trial before the
end of 2012. The other six compounds in Phase II trials
are linezolid, which has been tested for the treatment of
XDR-TB at a dose of 600 mg/day in the Republic of Korea;
sutezolid (PNU-100480), an oxazolidinone analogue of
linezolid; PA-824, a nitro-imidazole; SQ-109, originally
synthesized as a derivative of ethambutol; and AZD-5847,
another oxazolidinone.
Besides individual compounds, very promising results
86
on the early bactericidal activity of a novel TB regimen

(NC-001) that includes three drugs (PA-824, moxioxacin and pyrazinamide) became available in July 2012
(Box 8.3).
These major advances in drug development mean that
multiple trials will be needed in various high-burden
countries. This presents several challenges. Trials are
lengthy and costly, since patients need to be followed up
for an extended period of time after completing treatment. New drugs have to be tested in various drug combinations with current and/or newly re-purposed drugs;1
to facilitate this, novel biomarkers for treatment response
and sterilizing activity, new approaches to the design of
clinical trials2 and increased capacity (including staff and
infrastructure) to implement trials in accordance with
international standards are required.
Several research groups and institutions worldwide
are working to address and overcome these challenges.
A good example is the NIH-funded AIDS Clinical Trials
Group, whose goal is to transform TB treatment (including HIV-associated TB) by developing and optimizing regimens to treat and prevent TB more quickly and
effectively. The group is working on the identication of
biomarkers to better understand TB pathogenesis and
treatment response and to shorten future clinical trials
by using surrogate markers for clinical end-points.3 This
is closely linked to strengthening the capacity of clini-
Lienhardt C et al. New drugs for the treatment of tuberculosis:

needs, challenges, promise, and prospects for the future. Journal of Infectious Diseases, 2012; published online March 23 (doi:
10.1093/infdis/jis034).
Phillips PJ et al. Innovative trial designs are practical solutions
for improving the treatment of tuberculosis. Journal of Infectious Diseases, 2012 (doi:10.1093/infdis/JIS041).
https://actgnetwork.org/
cal trial sites and building laboratory and pharmacology

research capacity; efforts are coordinated with other
clinical trial networks to optimize efforts to develop new
combination regimens. The Critical Path to New TB Drug
Regimens initiative, whose goal is to accelerate the development of novel regimens that will shorten TB treatment,
is also an important example of a global effort to ensure
that the necessary trials can be implemented.1
8.3
New vaccines to prevent TB
The BCG (Bacille-Calmette-Gurin) vaccine for the prevention of TB is almost 100 years old. The vaccine protects
against severe forms of TB in children (TB meningitis and
miliary TB), but its efcacy in preventing pulmonary TB
in adults is highly variable. BCG is not recommended
for use in infants known to be infected with HIV, due
to the risk of disseminated BCG disease. Historic opportunities for developing new TB vaccines arose during
the 1990s, following the development of techniques for
genetic manipulation of mycobacteria and completion of
the genome sequence of M. tuberculosis.
Two different approaches are being used to develop
TB vaccines for prevention of TB.2 The rst approach is
to develop vaccines that would do better than BCG and
replace it such as an improved version of BCG or a
new attenuated live M. tuberculosis vaccine. The second
approach is to develop a prime-boost strategy in which
BCG continues to be given to neonates (as now), since it
prevents TB in infants and children, and give the new
vaccine as a booster dose at a later stage. Alternatively,
the new vaccine would be delivered to infants alongside
other vaccines at 39 months of age and as a separate
booster in young adults. The vaccine candidates currently
under development could be used to prevent either infection (pre-exposure), or to prevent primary progression to
disease or reactivation of latent TB (post-exposure). Work
is also being carried out to develop vaccines that could
be used as immunotherapeutic agents, i.e. to improve
responsiveness to chemotherapy.
The status of the pipeline for new vaccines in July 2012
is shown in Figure 8.3. Of the 12 vaccine candidates in
clinical trials, 11 are for prevention of TB and one is an
immunotherapeutic vaccine.
MVA85A is an attenuated vaccinia-vectored vaccine
candidate designed as a booster vaccine for infants, adolescents and adults. Among existing vaccine candidates
for TB prevention, it is the one that is most advanced in
terms of clinical testing. The rst Phase IIb trial of this
vaccine was conducted in South Africa from 2009 to
2011, with 2797 infants enrolled. Results are expected in
early 2013, and will provide the rst efcacy data of a
1
2
BOX 8.3
Testing the new drug regimen PaMZ
(NC-001): progress by mid-2012
Novel anti-TB drug regimens could transform therapy by
shortening and simplifying the treatment of both drugsensitive and drug-resistant TB with the same oral regimen.
Novel regimens for treatment of MDR-TB have the potential to
be much less expensive than currently recommended therapies
(since they include fewer drugs and treatment duration is
shorter), fostering expansion of treatment globally.
NC-001 also known as New Combination 1 is a trial of a
novel TB regimen that includes the drug candidate PA-824
combined with moxioxacin and the standard rst-line antiTB drug, pyrazinamide (PaMZ). The trial is being conducted
in partnership with and sponsored by the TB Alliance. The
regimen has been tested for early bactericidal activity against
pulmonary TB over a 2-week period, with encouraging results.1
The regimen had bactericidal activity at least comparable
to a standard regimen of isoniazid (H), rifampicin (R),
pyrazinamide (Z) and ethambutol (E). This study also validated
a new approach to the development of new anti-TB drug
regimens, which has the potential to reduce the time required
to complete clinical trials from decades to years. Research on
NC001 has also included testing of some novel combinations
of two drugs that may form the core of future regimens, thus
informing other clinical trials being planned during the next 18
months and beyond.
The testing of the PaMZ regimen advanced to a 2-month trial
(called NC-002) in March 2012. In this trial, carried out in
Brazil, South Africa and the United Republic of Tanzania, PaMZ
is being tested for patients with drug-sensitive TB and patients
with drug-resistant TB who are sensitive to the drugs included
in the new regimen. The NC-002 trial is a landmark trial: it is
the rst to simultaneously investigate treatment of both drugsensitive and drug-resistant disease using the same regimen.
Results are expected in the third quarter of 2013.
1
Diacon AH et al. 14-day bactericidal activity of PA-824, bedaquiline,

pyrazinamide, and moxioxacin combinations: a randomised trial.
Lancet, 2012;380(9846):986-93.
http://www.c-path.org/CPTR.cfm
Kaufmann SHE, Hussey G, Lambert PH. New vaccines for
tuberculosis. Lancet, 2010, 375:21102119.
87
FIGURE 8.3
The development pipeline for new vaccines, July 2012
Phase I
Phase II
Phase IIb
Phase III
AdAg85A
McMaster University
M72+AS01
GlaxoSmithKline (GSK),
Aeras
MVA85A/AERAS-485
Oxford-Emergent
Tuberculosis Consortium
(OETC), Aeras
Mw [M. indicus pranii

(MIP)]
Department of
Biotechnology (India),
M/s. Cadila
P B PI
Hybrid-I+CAF01
with Statens Serum
Institute (SSI),
Tuberculosis Vaccine
Initiative (TBVI)
P B PI
H56+IC31
Statens Serum Institute
(SSI), Aeras, Intercell
P B PI
Hyvac 4/AERAS404+IC31
with Statens Serum
Institute (SSI), Sanofi
Pasteur, Aeras, Intercell
ID93
Infectious Disease
Research Institute
(IDRI), Aeras
B PI
VPM 1002
Max Planck, Vakzine
Projekt Mgmt,
Tuberculosis Vaccine
Initiative (TBVI)
B PI it
it
AERAS-402/Crucell Ad35
Crucell, Aeras
P B
Hybrid-1+IC31
Statens Serum Institute
(SSI), Tuberculosis
Vaccine Initiative
(TBVI), European and
Developing Countries
Clinical Trials (EDCTP),
Intercell
P B PI
RUTI
Archivel Farma, S.L.
B PI it
B PI it
Prime
Boost
PI
Post-infection
it
Immunotherapy
TB Vaccine Types
Viral-vectored: MVA85A, AERAS-402, AdAg85A

Protein/adjuvant: M72, Hybrid-1, Hyvac 4, H56, ID93
rBCG: VPM 1002
Killed WC or Extract: Mw, RUTI
Source: Stop TB Partnership Working Group on New Vaccines
BOX 8.4
Tuberculosis vaccines: a strategic blueprint
Research into TB vaccines is at a pivotal moment as focus shifts from the discovery of novel approaches and moving new vaccine
candidates from the laboratory to early clinical trials to building on the progress that has already been made. This includes learning from
the efcacy of vaccine candidates in clinical development, establishing much-needed markers and correlates of immune protection that
will help to identify the next generation of vaccine candidates, and laying the groundwork for the licensure and distribution of new TB
vaccines.
In March 2012, the Stop TB Partnerships Working Group on New TB Vaccines published Tuberculosis vaccines: a strategic blueprint. This
charts the future course of TB vaccine research and is intended as guidance for researchers, regulators, advocates, donors, policy and
decision-makers, among other stakeholders. The blueprint outlines the major scientic challenges and priorities, critical activities and
crucial questions that need to be addressed to develop life-saving TB vaccines in ve key priority areas:
Creativity in research and discovery. The major question to be answered is why certain individuals infected with M. tuberculosis are
resistant to TB disease.
Correlates of immunity and biomarkers for TB vaccines. Here, the focus is on identifying correlates of immunity for TB vaccines.
Clinical trials: harmonization and cooperation. The main question to be addressed is whether TB vaccines can effectively reduce the
transmission of M. tuberculosis.
Rational selection of TB vaccine candidates. This priority area tackles the challenge of having all developers of vaccines agree to
standardized criteria for the selection and development of novel TB vaccines.
The critical need for advocacy, community acceptance and funding. Here, the emphasis is on innovative approaches to mobilizing
funding for TB vaccines.
The blueprint is designed to initiate a renewed, intensied and well-integrated international effort to develop TB vaccines that will have a
signicant impact on global TB control.
The complete blueprint, including relevant opinion editorials, is available at http://www.stoptb.org/wg/new_vaccines/
88
new TB vaccine candidate. A Phase IIb trial of MVA85A is

now being conducted in adults living with HIV in Senegal
and South Africa; the trial started in 2011 and up to 1400
participants will be enrolled.
AERAS-402/Crucell Ad35 is an adeno-vectored vaccine candidate designed as a booster vaccine for infants,
adolescents and adults. A Phase IIb multicentre clinical
trial in healthy infants is under way in Kenya, Mozambique and South Africa; up to 4000 participants will be
enrolled.
There are four vaccines in Phase II trials. M72 and
Hybrid-1 are two distinct protein subunit vaccines, formulated in novel adjuvants to enhance their immunogenicity. Both vaccines, which are based on a combination
of two immune-dominant antigens from M. tuberculosis,
are being tested in Phase IIa trials in Europe and Africa.
VPM 1002 is a live recombinant vaccine, derived from the
Prague strain of the BCG vaccine into which the listerolysin gene from Listeria monocytogenes has been cloned
and the urease gene deleted to improve immunogenicity.
This vaccine is currently in a Phase IIa trial in South Africa. Finally, RUTI, a non-live vaccine based on fragmented
M. tuberculosis bacteria, is in a Phase IIa trial in Spain.
Research on new TB vaccines is at a crucial juncture.
While the past decade focused on the discovery of novel
approaches and moving new vaccine candidates from the
laboratory to early clinical trials, the next decade will
focus on consolidating progress.1 This will entail learning
from the efcacy of vaccine candidates in clinical development and identifying much-needed markers and correlates of immune protection that will greatly assist in the
selection of the next generation of vaccine candidates.2
The future course of work on new TB vaccines has been
charted in a new strategic document, Tuberculosis vaccines:
a strategic blueprint, developed by the Stop TB Partnerships Working Group on New TB Vaccines and published
in March 2012 (Box 8.4).
8.4
Fundamental science is necessary to drive innovations in

new tools for improved TB care and control. Fundamental
research is required to better characterize M. tuberculosis
and to improve understanding of the interaction between
the bacillus and the human host, as a basis for maintaining the ow of new technologies into the product
pipeline. Investments in basic science for TB worldwide,
at US$ 129 million in 2010, represented 20% of global
spending on TB research and development. The largest
share of this funding (43%) was from NIH/NIAID.
Researchers supported to conduct biomedical and
fundamental research on TB through NIAID and other
major funding agencies are making great strides in rede ning the spectrum of TB disease and the transition from
latent to active TB, and developing a better understanding of the reasons why prolonged antibiotic treatment is
needed. This progress is expected to deliver better knowledge about pathogenesis, identication of biomarkers and
bio-signatures relevant to new TB diagnostics. It is also
expected to point to new targets for anti-TB drugs as well
as early indicators of protective immunity, vaccine efcacy and early response to treatment. Such developments
will facilitate the selection and testing of new interventions. To catalyze further progress and pave the way for
future research, an International Roadmap for TB Research
has been developed.3 This outlines critical priority areas
for future scientic investment.
A guide on Operational research priorities to improve TB
care and control was published in 2011.4 It de nes the
critical questions that need to be addressed to improve
current programmatic performance and to facilitate the
introduction of novel strategies and interventions that
use new tools.
Fundamental science and operational

research to stimulate innovation and
optimize the use of available tools
Ottenhoff THM, Kaufmann SHE. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathogens,
2012, 8(5):e1002607 (doi:10.1371/journal.ppat.1002607).
Barker LF et al. Tuberculosis vaccine research: the impact of
immunology. Current Opinion in Immunology, 2009, 21(3):331
338.
Stop TB Partnership and World Health Organization. An
International Roadmap for Tuberculosis Research. Geneva: World
Health Organization, 2011 (also available at:
www.stoptb.org/assets/documents/resources/
publications/technical/tbresearchroadmap.pdf;
accessed July, 2012).
Stop TB Partnership, Global Fund to Fight AIDS, Tuberculosis and Malaria. Priorities in operational research to improve
tuberculosis care and control. Geneva, World Health Organization,
2011 (also available at:
http://whqlibdoc.who.int/publications/
2011/9789241548250_eng.pdf; accessed July 2012).
89
ANNEX 1
Methods used to estimate

the global burden of disease
caused by TB
91
This annex explains the methods that were used to produce estimates of the global burden of disease caused by
TB (measured in terms of incidence, prevalence and mortality). It has nine major sections:
1.
General approach. This section provides some background information about the methods used to produce estimates of disease burden.
De nitions. This section de nes TB incidence, prevalence and mortality, the case fatality rate (CFR) and
the case notication rate. It also explains the regions
for which estimates of disease burden are produced
and sources of information on population estimates.
Estimates of TB mortality, 19902011. This section
explains the three methods used to estimate TB mortality, and the countries for which they were applied.
Methods for estimating the number of HIV-associated
TB deaths and for disaggregation of TB mortality by
age and sex are also described.
Estimates of TB incidence, 19902011. This section
explains the main methods used to estimate TB incidence, and the countries for which they were applied.
Methods to estimate the prevalence of HIV among
incident TB cases are described.
Estimates of TB prevalence, 19902011. This section explains the two methods used to estimate TB
prevalence, and the countries for which they were
applied.
Estimates of the number of cases of multidrugresistant TB (MDR-TB). This section explains how
estimates of the proportion of notied cases of TB that
had MDR-TB in 2011 were produced and used to assess
the number of prevalent cases of MDR-TB in 2011.
Projections of TB incidence, prevalence and mortality. This section explains how projections up to
2015 were produced.
Uncertainty framework. This section explains the
general approach to including uncertainty in all estimates.
General approach
Estimates of the burden of disease caused by TB (measured in terms of incidence, prevalence and mortality)
are produced annually by WHO using information gathered through surveillance systems (case notications and
death registrations), special studies (including surveys of
the prevalence of disease, mortality surveys and in-depth
analyses of surveillance data), expert opinion and consultations with countries. Two recent publications provide
up-to-date guidance about how TB incidence, prevalence
and mortality should be measured,1 based on the work
of the WHO Global Task Force on TB Impact Measurement.2 The methods used to estimate the burden of disease were updated in 2009 following 18 months of work
by an expert group convened by the Task Force. Improvements to methods included systematic documentation of
expert opinion and how this has been used to produce

estimates of disease burden, simplication of models,3
updates to parameter values based on the results of systematic reviews, much greater use of mortality data from
VR systems and systematic documentation of uncertainty
(hence the uncertainty intervals shown on all of the estimates of disease burden in this report).
2.
Definitions
2.1
Incidence, prevalence, mortality, case fatality

rate, case notification rate
Incidence is de ned as the number of new and recurrent

(relapse) episodes of TB (all forms) occurring in a given
year. Recurrent episodes are de ned as a new episode of
TB in people who have had TB in the past and for whom
there was bacteriological con rmation of cure and/or
documentation that treatment was completed (Box 3.1,
Chapter 3). In the remainder of this Annex, relapse cases
are referred to as recurrent cases because the term is more
useful when explaining the estimation of TB incidence.
Recurrent cases may be true relapses or a new episode
of TB caused by reinfection. In current case de nitions,
both relapse cases and patients who require a change in
treatment are called retreatment cases. However, people
with a continuing episode of TB that requires a treatment
change are prevalent cases, not incident cases.
Prevalence is de ned as the number of TB cases (all
forms) at a given point in time.
Mortality from TB is de ned as the number of deaths
caused by TB in HIV-negative people, according to the latest revision of the international classication of diseases
(ICD-10). TB deaths among HIV-positive people are classied as HIV deaths in ICD-10. For this reason, estimates
of deaths from TB in HIV-positive people are presented
separately from those in HIV-negative people.
The case fatality rate is the risk of death from TB among
people with active TB disease.4
The case notication rate refers to new and recurrent
episodes of TB notied to WHO for a given year, expressed
per 100 000 population. The case notication rate for new
and recurrent TB is important in the estimation of TB
1

paper, no. 2; WHO/HTM/TB/2009.416). The policy paper is
available on the Task Forces web site
For further details, see the Task Force web site at:
For example, some parameter values are now estimated only
at global level or for regions, rather than for each country individually.
Straetemans M et al. Assessing tuberculosis case fatality ratio:
a meta-analysis. PLoS One. 2011, 6(6):e20755.
93
incidence. In some countries, however, information on

treatment history may be missing for some cases. When
data on treatment history are not available, recurrent
cases cannot be distinguished from cases whose treatment was changed, since both are registered and reported
in the category retreatment. Data for patients reported
in the unknown history category are assessed with
national TB control programmes (NTPs) to determine the
proportion of such patients included in the category of
recurrent cases.
2.2 Regions
Regional analyses are generally undertaken for the six
WHO regions (that is, the African Region, the Region
of the Americas, the Eastern Mediterranean Region, the
European Region, the South-East Asia Region and the
Western Pacic Region). For analyses related to MDR-TB
and for an ecological model used to estimate TB mortality in some countries, nine epidemiological regions were
de ned. These were African countries with high HIV
prevalence, African countries with low HIV prevalence,
Central Europe, Eastern Europe, high-income countries,1 Latin America, the Eastern Mediterranean Region
(excluding high-income countries), the South-East Asia
Region (excluding high-income countries) and the Western Pacic Region (excluding high-income countries). The
countries in these nine regions are listed in Appendix 1.
2.3 Population estimates

Where population sizes are needed to calculate TB indicators, the 2012 revision of estimates provided by the
United Nations Population Division (UNPD) was used.2
The UNPD estimates sometimes differ from those made
by countries.
3.
Estimates of TB mortality, 19902011
The best sources of data about deaths from TB (excluding

TB deaths among HIV-positive people) are VR systems
in which causes of death are coded according to ICD-10
(although the older ICD-9 and ICD-8 classication are
still in use in several countries). Deaths from TB in HIVpositive people are coded under HIV-associated codes.
Three methods were used to estimate TB mortality:
direct measurements of mortality from vital registration (VR) systems or mortality surveys.
indirect estimates based on an ecological model.
indirect estimates derived from multiplying estimates
of TB incidence by estimates of the CFR.
Each method is described in more detail below. The source

of data used for each country is available from tbdata@
who.int upon request.
3.1
Data from VR systems are reported to WHO by Member

States and territories every year. In countries with functioning VR systems in which causes of death are coded
according to the two latest revisions of the international classication of diseases (underlying cause of death:
ICD-10 A15-A19, equivalent to ICD-9: 010-018), VR data
are the best source of information about deaths from TB
among people not infected with HIV. When people with
AIDS die from TB, HIV is registered as the underlying
cause of death and TB is recorded as a contributory cause.
Since one third of countries with VR systems report to
WHO only the underlying causes of death and not contributory causes, VR data usually cannot be used to estimate the number of TB deaths in HIV-positive people.
TB mortality data obtained from VR systems are essential to understanding trends in TB disease burden where
case notications have incomplete coverage or their coverage is not documented through an inventory study. An
updated description of the global coverage and quality of
VR data is available in World Health Statistics 2012.3
As of May 2012, 122 countries had reported mortality data to WHO (including data from sample VR systems
and mortality surveys), among 217 countries and territories from which TB data were requested. These 122
countries included 8 of the 22 high TB-burden countries
(HBCs): Brazil, China, India, the Philippines, the Russian Federation, Thailand, South Africa and Zimbabwe.
However, the VR data on TB deaths from South Africa
and Zimbabwe were not used for this report because large
numbers of HIV deaths were miscoded as TB deaths.
Improved empirical adjustment procedures have recently
been published,4 and specic post-hoc adjustments for
misclassication errors in the measurement of TB mortality will be attempted before preparing the 2013 WHO
report on global TB care and control.
Among the countries for which VR data could be used
(see Figure 2.11 in Chapter 2), there were 1928 countryyear data points 19902011. Of these data points, 30
outliers and points obtained from systems with very low
coverage were excluded for analytical purposes. Outliers
were detected visually by plotting country-specic time
series of reported TB mortality rates. As of May 2012,
only 29 data points were available for 2010 and none for
1
94
Estimating TB mortality from vital registration

data and mortality surveys
High-income countries are de ned by the World Bank as

countries with a per capita gross national income (GNI) of
*US$ 12 475 in 2011.
http://esa.un.org/unpd/wpp/unpp/panel_population.
htm; accessed May 2012.
www.who.int/gho/publications/world_health_
statistics/2012/en/; accessed July 2012 (see particularly
pages 4445).
Birnbaum JK, Murray CJL, Lozano R. Exposing misclassied
HIV/AIDS deaths in South Africa. Bulletin of the World Health
Organization, 2011, 89:278285.
2011. On average, 15 data points were retained for analysis per country (standard deviation (SD) of 6.5) from a
total of 1898 usable data points.
Reports of TB mortality were adjusted upwards to
account for incomplete coverage (estimated deaths with
no cause documented) and ill-de ned causes of death
(ICD-9 code B46, ICD-10 codes R00R99).1
It was assumed that the proportion of TB deaths among
deaths not recorded by the VR system was the same as the
proportion of TB deaths in VR-recorded deaths. For VRrecorded deaths with ill-de ned causes, it was assumed
that the proportion of deaths attributable to TB was the
same as the observed proportion in recorded deaths.
The adjusted number of TB deaths da was obtained
from the VR report d as follows:
da =
d
c(1 g)
where c denotes coverage (i.e. the number of deaths with

a documented cause divided by the total number of estimated deaths) and g denotes the proportion of ill-de ned
causes.
The uncertainty related to the adjustment was estimated with standard deviation SD = d/4[1/(c/(1 g)) 1]. The
uncertainty calculation does not account for miscoding,
such as HIV deaths miscoded as deaths due to TB.
Missing data between existing adjusted data points
were imputed using log-linear interpolation (or simple
interpolation in small countries with reports of zero
mortality). Trailing missing values were predicted using
exponential smoothing models for time-series.2 A penalized likelihood method based on the in-sample t was
used for country-specic model selection. Leading missing values were similarly predicted backwards to 1990. A
total of 813 country-year data points were thus imputed.
Results from mortality surveys were used to estimate
TB mortality in India. Further details are available in the
2011 edition of the WHO report on global TB control.
3.2 Estimating TB mortality from an

ecological model
An out-of-sample, goodness-of-t, stepwise selection
approach was used to select an ecological model that
could predict TB mortality in countries without VR data.
The model was based on the time series of VR data reported to WHO as described above, expressed as counts of TB
deaths and corrected for ill-de ned causes of deaths and
VR coverage.
A population-averaged negative binomial model, with
total population as the offset converting model outputs
to rates, was used to account for the longitudinal structure of the data as well as the observed over-dispersion of
counts of TB deaths.
Ten variables were investigated for inclusion in the
model. These were: the infant mortality rate per 1000 live
births; gross domestic product per capita; HIV prevalence
among the general population; the percentage of the total
population aged <15 and *65 years; the TB treatment success rate; the total number of newly notied TB cases per
year; whether or not a country had a high or low burden
of MDR-TB; whether a country was among the 22 HBCs
or not; and a categorical variable classifying countries in
nine groups with similar TB epidemiology (see Appendix 1).
At the univariate level, all risk factors were associated
with the outcome of TB mortality. The nal multivariate model included the infant mortality rate per 1000 live
births, HIV prevalence among the general population,
gross domestic product per capita, the percentage of the
total population aged <15 and *65 years, whether a country was in the list of 22 HBCs or not; and the categorical
variable that de ned country groups with similar TB epidemiology.
Out of a total 4686 country-year observations in the
time series for 19902011, 802 could not be predicted due
to data not being available for any of the ten variables
included in the model.
Estimates of TB mortality predicted by the model were
used for 28 countries in which VR or mortality survey
data of sufcient quality and coverage were not available
and where estimates of TB incidence were judged too
uncertain. In the remaining 64 countries lacking VR data
of the necessary coverage and quality, TB mortality was
estimated using the methods described in Section 3.3.
3.3 Estimating TB mortality from estimates of

case-fatality rates and TB incidence
For 64 countries in which VR or mortality survey data of
sufcient quality and coverage were not available (as of
May 2012), mortality was estimated as the product of TB
incidence (see Section 4) and the CFR.
CFRs were estimated separately for TB cases notied
to NTPs and non-notied cases and, within these two
groups, separate estimates were made for HIV-negative
TB cases in high-income and other countries (Table A1.1).
TABLE A1.1
Estimates of TB case-fatality rates

(HIV-negative) by case type and country
CASE TYPE AND COUNTRY GROUP
Non-notied: high-income countries

1
Mathers CD et al. Counting the dead and what they died from:
an assessment of the global status of cause of death data. Bulletin of the World Health Organization, 2005, 83:171177.
Hyndman R et al. Forecasting with exponential smoothing: the state
space approach. Springer Series in Statistics, 2008.
Non-notied: other countries
MEAN (STANDARD DEVIATION)
0.12 (0.042)
0.32 (0.13)
Notied: high income countries
0.039 (0.042)
Notied: other countries
0.074 (0.03)
95
For consistency with VR- or survey-based mortality estimates, CFRs were estimated such that they gave the best
t to the directly measured TB death rates (within their
uncertainty ranges) in the 125 countries with VR data
that were retained for analysis, in conjunction with WHO
estimates of distributions of TB incidence in those countries. This statistical tting used Bayesian linear models and was done separately for two groups of countries
(high-income and all other countries), to account for differences in the ratio of reported TB mortality to TB notication rates among these two groups (data not shown).
The models used normal errors and Gibbs sampling:
y = (I N)`1 + N`2 + , ~ N(0,m2 )
where y is TB mortality from VR, I denotes TB incidence
excluding people living with HIV, N denotes TB notications excluding people living with HIV, and parameters
1 and 2 denote the CFR in non-notied and notied
cases respectively. Semi-conjugate priors were set with an
uninformative inverse Gamma prior on the conditional
error variance:
b ~ N(b i ,B i -2 ), m2 ~ IG(5.10 -4 ,5.10 -4 )
For low- and middle-income countries, priors b and their
precision B were de ned based on literature reviews1
and the country-year CFR parameters used by WHO for
the years 19992008. For high-income countries, noninformative priors were used. Convergence of Markov
Chains was assessed graphically and using convergence
diagnostic tests. Within each case category 19902011,
mortality estimates were computed by taking the product of posterior distributions of the CFR, assumed to be
time-independent (Table A1.1), and country-year specic
distributions of estimated incidence.
3.4 Estimating HIV-associated TB mortality

No nationally representative measurements of HIVassociated TB mortality were available from VR systems
for use in this report. In the absence of direct measurements, HIV-associated TB mortality was estimated indirectly using a Bayesian model. It should be highlighted
that there was a signicant level of sensitivity to changes
in model parameters and distributions, leading to considerable and incompletely documented uncertainty surrounding estimates.
A prior belief P about the proportion of AIDS deaths
with TB as the contributory cause of death was de ned
using evidence from a literature review2 and the assumption of a beta distribution with parameters a and b. The
proportion was de ned as 37% (SD 3.8%). The number
of AIDS deaths was obtained from data published by
UNAIDS.3 The prior distributions mean of AIDS deaths
with TB as a contributory cause of death was thus 37% of
1.75 million AIDS deaths i.e. about 648 000 AIDS deaths
with TB as a contributory cause in 2011.
96
The likelihood for the estimated number of TB deaths

among AIDS cases was based on an assumed CFR of 50%
(SD 5%) in low- and middle-income countries and a CFR
of 20% (SD 2%) in high-income countries, using methods as described above and from literature reviews.4
People with TB on antiretroviral therapy (ART) were
assumed to benet from the protective effect of ART.
To a signicant extent, the protective effect depends on
the timing of ART initiation.5 While ART increases the
odds of survival when introduced early, it also shortens
the time for subclinical TB to become symptomatic, a
phenomenon often referred to as unmasking.6 In the
absence of reported data on the timing of ART initiation
and average CD4 cell-count, we estimated the overall
protective effect of ART at 50% (SD 5%). Incident cases
of HIV-positive TB were disaggregated by ART status to
calculate the likelihood for the estimated number of TB
deaths among AIDS cases, noted D.
The likelihood D is a beta density with parameters s+1
and f+1 obtained using the method of moments described
in Section 4.1.
By combining the beta prior P with D, the posterior is
also distributed beta, with parameters a+s and b+f. Posterior distributions were determined for each country-year
data point.
On average, when the number of TB deaths among
AIDS cases from D is less than in the prior distribution P,
then the posterior distribution will be pulled away from
P towards lower values of HIV-associated TB deaths. In
countries with a high coverage of ART, D will pull the
posterior distribution more strongly away from P, towards
lower values.
In the absence of country-specic direct measurements of HIV-associated TB mortality reported to WHO,
the Bayesian model described above was used to generate
estimates of HIV-associated TB mortality. Since the prior
P is based on autopsy studies in a limited number of countries in sub-Saharan Africa (where most TB cases among
HIV-positive people occur) and based on UNAIDS estimates of AIDS deaths (most of which occur in sub-Saharan Africa), country-specic estimates for other countries
Straetemans M et al. Assessing tuberculosis case fatality ratio:

a meta-analysis. PLoS One. 2011, 6(6):e20755.
Cox JA et al. Autopsy causes of deaths in HIV-positive individuals in Sub-Saharan Africa and correlation with clinical
diagnosis. AIDS, 2010, 12:183194.
www.unaids.org/en/dataanalysis/epidemiology/;
accessed 15 July 2011.
Straetemans M et al. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One, 2010,
5(12):e15241.
Piggott DA, Petros C. Karakousis PC. Timing of Antiretroviral therapy for HIV in the setting of TB treatment. Clinical and
Developmental Immunology, 2011 (doi:10.1155/2011/103917).
Lawn DS et al. Immune reconstitution and unmasking of
tuberculosis during antiretroviral therapy. American Journal of
Respiratory and Critical Care Medicine, 2008, 177:680685.
may suffer from biases. These biases are difcult to predict. However, the inuence of countries outside the
African Region on global estimates of HIV-associated TB
deaths is relatively small due to their comparatively small
numbers of HIV-positive TB cases.
It is worth noting that at the global level, the posterior
distribution is heavily inuenced by D and by the effect of
the increasing coverage of ART in recent years, leading to
an estimated 430 000 HIV-associated TB deaths in 2011
(range 400 000460 000).
In the absence of direct measurements, it was not possible to validate country-specic estimates of HIV-associated TB mortality; as such, country-specic estimates are
not included in this report.
Direct measurements of HIV-associated TB mortality
are urgently needed. This is especially the case for countries such as South Africa and Zimbabwe, where national
VR systems are already in place. In other countries, more
efforts are needed to initiate the implementation of sample VR systems as an interim measure.
3.5 TB mortality disaggregated by age and sex

For countries with VR data, it was possible to estimate TB
deaths among children (aged <15 years) and adults (aged
* 15 years) separately. It was also possible to disaggregate
TB deaths by sex. For these countries, male:female and
child:adult ratios of TB death rates per 100 000 population were calculated (after correction for ill-de ned
causes of deaths and VR coverage). Using data from the
latest available year for each of the countries with VR
data, global ratios weighted according to a countrys total
population were then applied to the global number of
estimated TB deaths among HIV-negative TB cases to produce age and sex-disaggregated estimates. An ecological
model (described in Section 3.2) was used to predict ratios
for countries with no VR data.
HIV-positive TB deaths were disaggregated by sex
based on the assumption that the male:female sex ratio
is similar to the sex ratio of AIDS deaths estimated by
UNAIDS. Further details are provided in Chapter 2.
4.
Estimates of TB incidence, 19902011
No country has ever undertaken a nationwide survey of

TB incidence because of the large sample sizes required
and associated major logistic and nancial challenges. As
a result, there are no direct measurements of the incidence of TB. Theoretically, data from TB surveillance systems that are linked to health systems of high coverage
and performance may capture all (or almost all) incident
cases of TB. The WHO Global Task Force on TB Impact
Measurement is working on the development of TB surveillance standards and benchmarks that, if met, would
allow direct measurement of TB cases and deaths from
surveillance data (Chapter 2).
In the absence of direct measurements, estimates of
TB incidence for almost all countries rely on methods

described in sections 4.14.3.
It should be emphasized that incidence estimates are
no longer derived from surveys of the prevalence of TB
infection as measured in tuberculin surveys. The WHO
Global Task Force on TB Impact Measurement has agreed
that methods for deriving incidence from the prevalence
of infection are unreliable. The Task Force has also stated
that, with a few exceptions, repeat tuberculin surveys do
not provide a reliable estimate of the trend in TB incidence.1
4.1
Estimating TB incidence from estimates of the

proportion of cases detected
Notication data for new and recurrent cases have been

analysed in combination with evidence about the coverage of the TB surveillance system and expert opinion in
six regional workshops and country missions held during the period 20092012, according to a framework
developed by the WHO Global Task Force on TB Impact
Measurement (Figure 2.2, Chapter 2). By May 2012, these
workshops and country missions had covered 96 countries (Figure 2.1, Chapter 2).
For the 96 countries covered by these regional workshops and country missions, incidence was estimated
according to the following equation:
incidence =
case notications
1 underreporting
Expert opinion about the proportion of TB cases2 that

were not reported was elicited for three reference years
(1997, 2003 and, depending on when the workshop was
held, 2008, 2009, 2010 or 2011). This was done following in-depth analysis of notication data (including data
from sub-national administrative levels), programmatic
data reecting efforts in TB control (for example, data
on infrastructure, staf ng, the performance of services
and funding) and (where available) data from inventory studies.3 In addition, data on access to health care
from Demographic and Health Surveys and the overall
performance of health systems (using indicators such as
the infant mortality rate) were used to substantiate opinion on the proportion of cases with no or very limited
access to health care (Table A1.2). Results from inventory
studies combined with capture-recapture modelling were
used to estimate the gap between notied cases and TB
1

paper, no. 2 (WHO/HTM/TB/2009.416).
De ned as cases of all forms of TB, including sputum smearpositive pulmonary cases, sputum smear-negative pulmonary
cases and extrapulmonary cases.
Measurements from inventory studies can be used to quantify the number of cases that are diagnosed but not reported to
national surveillance systems.
97
TABLE A1.2
Sources of information and data on TB

incidence used in regional workshops and
country missions
POSSIBLE CATEGORIES OF INCIDENT CASES
Do not have physical or

nancial access
to health care
Demographic and
health surveys,
KABPa surveys
Seek care, but TB not

diagnosed
Survey
TB diagnosed, but not

reported
Inventory survey
Reported cases
a
SOURCES OF DATA
Capture
recapture
modelling
TB surveillance
KABP = knowledge, attitudes, behaviour and practices.
incidence in three countries that participated in regional

workshops: Egypt, Iraq and Yemen.
A full description of the methods used in these workshops is available in a report of the workshop held for
countries in the African Region (in Harare, Zimbabwe,
December 2010).1
Distributions of the proportion of cases that were not
reported in the three reference years were assumed to
follow a Beta distribution (Table A1.3). Reasons for using
Beta distributions include the following:
They are continuous and de ned on the interval (0,
1). Since the variance of the proportions of cases that
were not reported tend to be large as a result of high
uncertainty, random draws of numbers from a normal
distribution would yield numbers outside the interval
(0, 1). The use of truncated normal distributions may
result in excess density towards one of the bounds.
They are not necessarily symmetrical.
They are de ned with two parameters that can be
estimated from available data using the method of
moments.2
The shape and scale parameters necessary to de ne the
Beta distribution were computed using the method of
moments, as follows:
First, the variance for the distribution was taken as:
ul
V=
where l and u are the lower and upper bounds of the

plausible range for the proportion of incident cases that
were reported (also referred to as the case detection rate
in Chapter 3).
Shape 1 (noted ) and 2 (noted ) follow from:
s=
4.2 Estimating TB incidence from data

on case notifications and expert opinion
for high-income countries
For high-income countries, the level of TB incidence was
assumed to be distributed between the notication rate
for new and recurrent cases combined (lower uncertainty
bound, noted l) and 1.3 times the notication rate (upper
uncertainty bound, noted u), as informed by expert opinion. The distribution of incidence was assumed to follow
a Beta distribution with shape and scale parameters computed using the method of moments, as described above.
In the absence of country-specic data on the quality
and coverage of TB surveillance systems, it was assumed
that TB surveillance systems from countries in the highincome group performed similarly well, although the
model does allow for stochastic uctuations. The excep-
E(l E)
l
V
_ = sE
` = s(l E)
where E is the expected value of the distribution.
98
Time series for the period 19902011 were built according to the characteristics of the levels of underreporting
that were estimated for the three reference years. A cubic
spline extrapolation of V and E, with knots set at the reference years, was used for countries with low-level or
concentrated HIV epidemics. In countries with a generalized HIV epidemic, the trajectory of incidence from 1990
to the rst reference year (usually 1997) was based on the
annual rate of change in HIV prevalence. Incidence trajectories were derived from the series of notied TB cases
using Monte Carlo simulations from which expected values, 2.5th and 97.5th centiles were extracted. All computations were conducted in the R statistical environment.3
In two countries, incidence rates were estimated to
be similar to those in a neighbouring country because
information from surveillance systems was insufcient:
estimates for West Bank and Gaza Strip were extrapolated from estimates for Jordan and estimates for South
Sudan were extrapolated from estimates for Sudan. The
estimates for West Bank and Gaza Strip and South Sudan
should therefore be considered as preliminary.
Trends in incidence were derived from repeat tuberculin survey results in Bhutan, India and Yemen and for 40
countries (including countries in Eastern Europe) from
trends in mortality.
If there were insufcient data to determine the factors
leading to time-changes in case notications, incidence
was assumed to follow a horizontal trend going through
the most recent estimate of incidence.
See www.who.int/tb/advisory_bodies/impact_
measurement_taskforce.
The tools (called TISAT and the Workbook) used in regional
workshops and country missions are also available on the Task
Forces web site.
Rnyi A. Probability theory. New York, Dover Publications Inc.,
2007.
R Development Core Team. R: a language and environment
for statistical computing. Vienna, R Foundation for Statistical
Computing, 2009 (www.R-project.org).
TABLE A1.3
Parameter estimates used to produce estimates of TB incidence, prevalence and mortality
MODEL PARAMETER
DISTRIBUTION
Incidence, high-income countries
Betaa
DISTRIBUTION PARAMETERSb
_=.
(1 )
V
` = (1 ) .
(1 )
V
where was set at 1.3 times the notication rate, noted N, and V is
dened by:
0.3
V=
HIV prevalence among incident TB
Beta
x (1 x )
_ = x .
` = (1 x ) .
x (1 x )
V
Where x is the expected value and V is given by:

V=
ul
Duration of disease, non-notied

HIV-negative cases of TB
Uniform
l = 1, u = 4 (years)
Duration of disease, non-notied

HIV-positive cases of TB
Uniform
l = 0.01, u = 0.2 (years)
Duration of disease, notied

HIV-negative cases of TB
Uniform
l = 0.2, u = 2 (years)
Duration of disease, notied

HIV-positive cases of TB
Uniform
l = 0.01, u = 1 (years)
The probability density function of the Beta distribution is: (x; _, `) =
u and l denote upper and lower bounds.
x _ 1 (1 x) ` 1
t _ 1 (1 t) ` 1 dt
tions were the United Kingdom of Great Britain and

Northern Ireland and the Netherlands, where the underreporting of TB cases has been measured using inventory
studies and capture-recapture modelling.1,2 For these two
countries, the results from these studies were used to
measure TB incidence directly.
4.3 Estimating TB incidence from empirical

measurements of disease prevalence
Incidence can be estimated using measurements from
national surveys of the prevalence of TB disease combined with estimates of the duration of disease. Incidence
is estimated as the prevalence of TB divided by the average duration of disease.
Tuberculosis in the UK: annual report on tuberculosis surveillance in

the UK 2010. London, Health Protection Agency Centre for Infections,
2010 (also available at:
www.hpa.org.uk/web/HPAweb&HPAwebStandard/
HPAweb_C/1287143581697; accessed July 2011).
van Hest NA et al. Completeness of notication of tuberculosis in The Netherlands: how reliable is record-linkage and
capturerecapture analysis? Epidemiology and Infection, 2007,
135(6):10211029.
In practice, the duration of disease cannot be directly

measured. For example, measurements of the duration of
symptoms in prevalent TB cases that are detected during a prevalence survey are systematically biased towards
lower values, since active case- nding truncates the natural history of undiagnosed disease. Measurements of the
duration of disease in notied cases ignore the duration of
disease among non-notied and untreated cases.
Literature reviews commissioned by the WHO Global
Task Force on TB Impact Measurement have provided
estimates of the duration of disease in untreated TB cases
from the pre-chemotherapy era (before the 1950s). The
best estimate of the mean duration of disease (for smearpositive cases and smear-negative cases combined) in
HIV-negative individuals is about three years. However,
the proportion of incident cases that remain untreated is
unknown. There are few data on the duration of disease
in HIV-positive individuals.
When measurements from two prevalence surveys
were available, trends in TB prevalence were derived
by tting a log-linear model to available measurements.
When three or more prevalence measurements were
available, the prevalence trajectory was built using cubic
99
spline interpolation. If only one prevalence survey measurement was available, time-trends were assessed using
in-depth analysis of surveillance data, as described above.
In this report, the prevalence to incidence method was
used for three countries: Ethiopia, Laos and Viet Nam.
4.4 Disaggregations of TB incidence

In this report, TB incidence is only disaggregated by HIVinfection status (see following section). The estimation of
smear-positive TB incidence was discontinued in 2010,
for reasons explained in detail in the global report published in 2010.
4.5 Estimates of HIV prevalence among incident TB

cases, 19902011
The prevalence of HIV among incident cases of TB was
directly estimated from country-specic and empirical
data wherever possible, with missing data imputed to complete time series using methods similar to those described
in Section 3.1. For the estimates published in this report,
suitable data (as de ned in Table A1.4) were available for
a total of 639 country-year data points. When data from
several data sources were available for the same countryyear, one source was retained based on knowledge about
the underlying quality of data, consistency with adjacent
time points or with expectations. In general, national
surveys of HIV prevalence in newly detected TB cases
took precedence over the other two sources unless the
reported numbers were judged not plausible (in general
due to data entry errors that could not be corrected in
time for use in this report). The least reliable data source
was considered to be HIV sentinel surveillance systems as
these do not generally provide nationally representative
data on TB cases.
TABLE A1.4
Sources of data on HIV prevalence among

incident TB cases
DIRECT MEASUREMENT OF THE PREVALENCE OF HIV IN TB PATIENTS
NUMBER OF COUNTRY-YEARS
National surveys
20
HIV sentinel surveillance
26
Provider-initiated testing and counselling with

at least 50% coverage of testing
593
Total
639
Provider-initiated testing and counselling with at least

50% HIV testing coverage is the most widely available
source of information on the prevalence of HIV in TB
patients. However, this source of data is affected by biases, particularly when coverage is closer to 50% than to
100%. In all countries with repeat data from testing, the
relationship between the prevalence of HIV in TB patients
and the coverage of HIV testing was examined graphically. In some countries, the prevalence of HIV in TB
100
patients was found to decrease with increasing HIV testing coverage while in others it increased with increasing
HIV testing coverage; in most countries, the prevalence
of HIV followed highly inconsistent patterns (with repeat
changes in direction) as HIV testing coverage increased.
Therefore, it was not possible to adjust for the effect of
incomplete coverage of HIV testing on estimates of the
prevalence of HIV among TB patients. The assumption
was thus made that TB patients with an HIV test result
were statistically representative of all TB cases. As coverage of HIV testing continues to increase globally, biases
will decrease.
For the 4047 country-year data points for which surveillance data were either not available or for which the
percentage of TB patients tested for HIV was below 50%,
the prevalence of HIV was estimated indirectly according
to the following equation:
hl
t=
l + h(l l)
In this equation, t is HIV prevalence among incident TB
cases, h is HIV prevalence among the general population
(from the latest time-series provided by UNAIDS) and
is the incidence rate ratio (IRR) (de ned as the incidence
rate of TB in HIV-positive people divided by the incidence
rate of TB in HIV-negative people). We then let logit(t) be
log(t/(1-t)) and logit(h) be log(h/(1-h)). Using data from
countries where HIV prevalence has been estimated by
UNAIDS as an independent variable, a linear model of
logit-transformed t was tted using logit-transformed h
according to the following equation, written in matrix
notation:
T = X`
where T is a vector of predicted logit(t), X is an n x 2
matrix in which the rst column holds 1s, and the second column holds logit(h). The vector holds estimated
model parameters. Models were tested with lags set for
logit(h) ranging from no lag to a lag of 8 years. The best t
was obtained with a lag of one year.
Models were run using Monte Carlo simulations in
which h was drawn randomly from a Beta distribution
with shape parameters computed as described in Section 4.1, (low and high uncertainty bounds are provided
by UNAIDS also see Table A1.3). The model was run
50 000 times using country-specic distributions for H
and T (noted in capital letters to denote vectors or matrices) based on their uncertainty intervals. The uncertainty
bounds for were chosen as the 2.5th and 97.5th centiles.
The source of data used for each country is available
upon request from tbdata@who.int.
5.
Estimates of TB prevalence, 19902011
The best way to measure the prevalence of TB is through

national population-based surveys of TB disease.1,2 Data
from such surveys are available for an increasing number of countries (Chapter 2). It should be noted, however,
that measurements of prevalence are typically con ned
to the adult population. Furthermore, prevalence surveys
exclude extrapulmonary cases and do not allow the diagnosis of cases of culture-negative pulmonary TB.
When there is no direct measurement from a national
survey of the prevalence of TB disease, prevalence is the
most uncertain of the three TB indicators used to measure disease burden. This is because prevalence is the
product of two uncertain quantities: (i) incidence and (ii)
disease duration. The duration of disease is very difcult
to quantify because it cannot be measured during surveys of the prevalence of TB disease (surveys truncate the
natural history of disease). Duration can be assessed in
self-presenting patients, but there is no practical way to
measure the duration of disease in patients who are not
notied to NTPs.
Indirect estimates of prevalence were calculated
according to the following equation:
P=
- I i,jd i,j , iD {1,2}, jD {1,2}
where the index variable i denotes HIV+ and HIV, the

index variable j denotes notied and non-notied cases,
d denotes the duration of disease in notied cases and I is
total incidence. In the absence of measurements, we did
not allow duration in notied cases to vary among countries. Given their underlying uncertainty, prevalence estimates should be used with great caution in the absence
of direct measurements from a prevalence survey. Unless
measurements were available from national programmes
(for example, Turkey), assumptions of the duration of disease were used as shown in the last four rows of Table
A1.3.
6.
Estimates of the number of cases

of MDR-TB
6.1
Proportion of notified cases of TB that have

MDR-TB, 2011
Global and regional estimates of the proportion of new

and retreatment cases of TB that had MDR-TB in 2011
were calculated using country-level information. If countries had reported data on the proportion of new and
retreatment cases of TB that have MDR-TB from routine
surveillance or a survey of drug resistance the latest available information was used. For countries that have not
reported such data, estimates of the proportion of new
and retreatment cases of TB that have MDR-TB were produced using modelling (including multiple imputation)
that was based on data from countries for which data do
exist. Estimates for countries without data were based on
countries that were considered to be similar in terms of

TB epidemiology (for country groups see Appendix 1).
The observed and imputed estimates of the proportion
of new and retreatment cases of TB that have MDR-TB
were then pooled to give a global estimate, with countries
weighted according to their share of global notications
of new and retreatment cases.
6.2 Numbers of prevalent cases of MDR-TB, 2011

The global estimate of the number of prevalent cases
of MDR-TB in 2011 was derived in two steps. First, the
weighted average of the proportion of new and retreatment notied cases that had MDR-TB was computed, to
give an estimate of the proportion of all notied cases that
had MDR-TB. This combined proportion was then multiplied by the estimated global prevalence of TB in the
general population, under the assumption that the proportion of all cases that have MDR-TB was the same as
the proportion of notied cases that have MDR-TB.
Country-specic estimates of the number of prevalent
cases of MDR-TB in 2011 were not computed because only
a few countries have directly measured the prevalence of
TB in a population-based survey, and even among these
countries data on the proportion of culture-positive pulmonary cases that had MDR-TB were not always available. To date, direct measurements of the number of
prevalent cases of MDR-TB are available only for China,
although several upcoming surveys will include assessments of drug resistance. In the absence of direct measurements at country level, country-specic estimates
of the prevalence of MDR-TB suffer from much greater
uncertainty compared with the uncertainty that surrounds global averages.
6.3 XDR-TB or fluoroquinolone resistance among

patients with MDR-TB
Using data from 67 countries, global estimates were calculated for the following proportions: (i) patients with
MDR-TB who had XDR-TB; (ii) patients with MDR-TB
who had uoroquinolone resistance; and (iii) patients
with MDR-TB who had uoroquinolone resistance but
not XDR-TB. Proportion of second-line drug and uoroquinolone resistance testing of MDR-TB cases among
these countries has a median of 1 and an interquartile
range of (0.971). The latest available national and subnational data from each country were analysed using
logistic regression models with robust standard errors to
account for the clustering effect at the level of the country
or territory.
Glaziou P et al. Tuberculosis prevalence surveys: rationale and

cost. International Journal of Tuberculosis and Lung Disease, 2008,
12(9):10031008.
101
7.
Projections of incidence, prevalence and

mortality up to 2015
Projections of TB incidence, prevalence and mortality

rates up to 2015 enable assessment of whether global targets set for 2015 are likely to be achieved at global, regional and country levels. Projections for the years 20112015
were made using exponential smoothing models tted to
data from 20052011.
8.
Estimation of uncertainty
There are many potential sources of uncertainty associated with estimates of TB incidence, prevalence and
mortality, as well as estimates of the burden of HIV-associated TB and MDR-TB. These include uncertainties in
input data, in parameter values, in extrapolations used to
impute missing data, and in the models used.
We used xed population values from the UNPD. We
did not account for any uncertainty in these values.
Notication data are of uneven quality. Cases may be
underreported (for example, missing quarterly reports
from remote administrative areas are not uncommon),
misclassied (in particular, misclassication of recurrent
cases in the category of new cases is common), or overreported as a result of duplicated entries in TB information systems. The latter two issues can only be addressed
efciently in countries with case-based nationwide TB
databases that include patient identiers. Sudden changes
in notications over time are often the result of errors or
inconsistencies in reporting, but may sometimes reect
abrupt changes in TB epidemiology (for example, resulting from a rapid inux of migrants from countries with
a high burden of TB, or from rapid improvement in case nding efforts).
Missing national aggregates of new and recurrent cases were imputed by interpolation. Notication trajectories
were smoothed using a penalized cubic splines function
with parameters based on the data. Attempts to obtain
corrections for historical data are made every year, but
only rarely do countries provide appropriate data corrections.
Mortality estimates incorporated the following sources
of uncertainty: sampling uncertainty in the underlying
measurements of TB mortality rates from data sources,
uncertainty in estimates of incidence rates and rates of
HIV prevalence among both incident and notied TB
cases, and parameter uncertainty in the Bayesian model. Time-series of TB mortality were generated for each
country through Monte Carlo simulations.
Unless otherwise specied, uncertainty bounds and
ranges were de ned as the 2.5th and 97.5th centiles of
outcome distributions. Throughout this report, ranges
with upper and lower bounds de ned by these centiles
are provided for all estimates established with the use of
simulations. When uncertainty was established with the
102
use of observed or other empirical data, 95% condence

intervals are reported.
The model used the following sequence: (1) cleaning
and adjustment of raw mortality data from VR systems,
followed by imputation of missing values in countries
with VR data; (2) cleaning and adjustment of measurements of HIV prevalence among TB patients followed by
imputation of missing values in countries with measurements of HIV prevalence in TB patients; (3) estimation
of HIV prevalence among incident cases of TB through
modelling in countries with no measurements; (4) TB
incidence estimation; (5) estimation of TB mortality in
countries with no VR data; (6) estimation of HIV-associated TB mortality; (7) estimation of prevalence.
The general approach to uncertainty analyses was to
draw values from specied distributions for every parameter (except for notications and population values) in
Monte Carlo simulations, with the number of simulation
runs set so that they were sufcient to ensure stability
in the outcome distributions. For each country, the same
random generator seed was used for every year, and errors
were assumed to be time-dependent within countries
(thus generating autocorrelation in time-series). Regional
parameters were used in some instances (for example, for
CFRs). Summaries of quantities of interest were obtained
by extracting the 2.5th, 50th and 97.5th centiles of posterior distributions. Wherever possible, uncertainty was
propagated analytically by approximating the moments
of functions of random variables using Taylor expansions
such as when taking the product or the ratio of two random variables rather than through Monte Carlo simulations.
Appendix 1. Epidemiological regions

used for analyses
Africa countries with high HIV prevalence: Botswana, Burundi, Cameroon, the Central African Republic,
the Congo, Cte dIvoire, the Democratic Republic of
the Congo, Ethiopia, Gabon, Kenya, Lesotho, Malawi,
Mozambique, Namibia, Nigeria, Rwanda, South Africa,
South Sudan, Swaziland, Uganda, the United Republic of
Tanzania, Zambia, Zimbabwe.
Africa countries with low HIV prevalence: Algeria, Angola, Benin, Burkina Faso, Cape Verde, Chad, the
Comoros, Djibouti, Eritrea, the Gambia, Ghana, Guinea,
Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania,
Mauritius, the Niger, Sao Tome and Principe, Senegal,
Seychelles, Sierra Leone, Somalia, Sudan, Togo.
Central Europe: Albania, Bosnia and Herzegovina,
Montenegro, Serbia, the former Yugoslav Republic of
Macedonia, Turkey.
Eastern Europe: Armenia, Azerbaijan, Belarus, Bulgaria, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania,
the Republic of Moldova, Romania, the Russian Federation, Tajikistan, Turkmenistan, Ukraine, Uzbekistan.
High-income countries: Andorra, Aruba, Australia,
Austria, the Bahamas, Bahrain, Barbados, Belgium, Bermuda, Brunei Darussalam, Canada, the Cayman Islands,
China, Hong Kong SAR, China Macao SAR, Croatia,
Cyprus, the Czech Republic, Denmark, Equatorial Guinea, Estonia, Finland, France, French Polynesia, Germany,
Greece, Greenland, Guam, Hungary, Iceland, Ireland,
Israel, Italy, Japan, Kuwait, Luxembourg, Malta, Monaco,
the Netherlands, the Netherlands Antilles, New Caledonia, New Zealand, Northern Mariana Islands, Norway,
Oman, Poland, Portugal, Puerto Rico, Qatar, the Republic of Korea, Saint Kitts and Nevis, San Marino, Saudi
Arabia, Singapore, Slovakia, Slovenia, Spain, Sweden,
Switzerland, Trinidad and Tobago, the Turks and Caicos Islands, US Virgin Islands, United Arab Emirates, the
United Kingdom, the United States.
Eastern Mediterranean: Afghanistan, Egypt, Iran
(Islamic Republic of), Iraq, Jordan, Lebanon, Libya,
Morocco, Pakistan, Syrian Arab Republic, Tunisia, West
Bank and the Gaza Strip, Yemen,
Latin America: Anguilla, Antigua and Barbuda, Argentina, Belize, Bolivia (Plurinational State of), Bonaire,
Saint Eustatius and Saba, Brazil, British Virgin Islands,
Chile, Colombia, Costa Rica, Cuba, Curaao, Dominica,
the Dominican Republic, Ecuador, El Salvador, Grenada,
Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico,
Montserrat, Nicaragua, Panama, Paraguay, Peru, Saint
Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Sint Maarten (Dutch part), Suriname, Uruguay,
Venezuela (Bolivarian Republic of).
South East Asia: Bangladesh, Bhutan, Democratic
Peoples Republic of Korea, India, Indonesia, Maldives,
Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste.
West Pacic: American Samoa, Cambodia, China, Cook
Islands, Fiji, Kiribati, Lao Peoples Democratic Republic,
Malaysia, Marshall Islands, Micronesia (Federated State
of), Mongolia, Nauru, Niue, Palau, Papua New Guinea,
the Philippines, Samoa, Solomon Islands, Tokelau, Tonga,
Tuvalu, Vanuatu, Viet Nam, Wallis and Futuna Islands.
103
ANNEX 2
Country profiles
AFGHANISTAN
Estimates of TB burdena 2011

NUMBER (thousands)
Mortality (excludes HIV+TB)
RATE (per 100 000 population)
13 (5.323)
39 (1671)
Prevalence (includes HIV+TB)
110 (55190)
351 (169597)
Incidence (includes HIV+TB)
61 (5173)
189 (156225)
0.30 (0.180.45)
0.93 (0.561.4)
Incidence (HIV+TB)
Case detection, all forms (%)
Mortality (excludes HIV+TB) (rate

per 100 000 population per year)
HIGH TB BURDEN
100
Prevalence
(rate per 100 000 population)
Population 2011 32 million
800
60
40
20
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
2000
2005
46 (3855)
TB case notications 2011

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
13 789 (51)
Smear-negative
4 166 (16)
Treatment after failure
Smear-unknown/not done
1 989
Treatment after default
Extrapulmonary
6 286 (23)
Other
(7)
623
Total new
Relapse
1 130 (86)
136 (10)
48
(4)
Other
(2)
26 853
Total retreatment
1 314
27 983
Total cases notied
Other (history unknown)
600
400
200
0
1990
300
28 167
Incidence (rate per 100 000

population per year)
Total new and relapse
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
Age < 15
80
0.5
EXTRAPULMONARY
1.1
669
1 753
Laboratories
1.9
Culture (per 5 million population)
0.5
200
150
100
50
0
1990
2011
Smear (per 100 000 population)
250
1995
Incidence
Incidence (HIV+TB)
2011
Notifications
Drug susceptibility testing (per 5 million population)

Yes, outside country
Is there a national reference laboratory?
Yes
Treatment success rate 2010 (%)

New smear-positive
(and/or culture-positive)
90
New smear-negative/extrapulmonary
82
Retreatment
79
Is rifampicin used throughout

treatment for new patients?
No
100
Treatment success rate (%)
Is second-line drug susceptibility testing available?
80
60
40
20
0
1996
TB/HIV 2011
TB patients with known HIV status
NUMBER
(%)
6 445
(23)
HIV-positive TB patients
(<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
(80)
HIV-positive TB patients on antiretroviral therapy (ART)
(80)
HIV-positive people provided with IPT
Estimates of MDR-TB burden 2011a
NEW
RETREATMENT
3.4 (0.1011)
29 (2.656)
700 (212 300)
380 (34730)
% of TB cases with MDR-TB

MDR-TB cases among notied
pulmonary TB cases
RETREATMENT
Cases tested for MDR-TB
19
21
Available funding (US$ millions)

% of budget funded
2013
11
11
5.9
3.7
34
% available funding from domestic sources
10
% available funding from the Global Fund
48
60
3
2
1
2004
2005 2006
2007
2008
2009
on CPT
2010
2011
on ART
20
12
8
4
0
2006
2007
Total budget
Ranges represent uncertainty intervals.
2010
Retreatment
16
2012
53
2008
268
Patients started on MDR-TB treatment
Total budget (US$ millions)
2006
TOTAL
Laboratory-conrmed MDR-TB cases
Financing TB control
2004
US$ millions
NEW
2002
2003
Reported cases of MDR-TB 2011
2000
6
Number of patients
HIV-positive people screened for TB
1998
New smear-positive (and/or culture-positive)

Data can be downloaded from www.who.int/tb/data
2008
2009
2010
2011
2012
2013
Available funding
107
BANGLADESH
HIGH TB BURDEN | HIGH MDR-TB BURDEN
NUMBER (thousands)
68 (29120)
45 (1982)
620 (3001 100)
411 (199698)
340 (280400)
225 (185268)
Incidence (HIV+TB)
0.63 (0.341.0)
0.42 (0.230.67)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
98 948 (67)
Relapse
Smear-negative
21 921 (15)
886 (12)
320
Extrapulmonary
(0)
27 329 (18)
Other
Total new
(4)
Other
3 459 (47)
Total retreatment
7 366
100
80
60
40
20
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
2000
2005
800
600
400
200
0
1990
3 459
150 899
Total cases notied
159 023

New cases
SMEAR-POSITIVE
M:F ratio
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
1.9
1.0
2.0
932
1 152
2 583
Laboratories
2011
0.7
<0.1
Yes

92
89
Retreatment
80
200
100
1995
Incidence

Yes
100
80
60
40
20
1996
NUMBER
1 900
(1)
81
(4)
81
(100)
81
(100)
69
0
NEW
RETREATMENT
1.4 (0.702.5)
29 (2434)

pulmonary TB cases
1 700 (8503 000)
2 100 (1 7002 500)

NEW
RETREATMENT
71 (<1%)
761 (10%)
856
12
437
509
1998
2000
2002
2004
2006

(%)
2008
2010
Retreatment
90
Number of patients
2011
Notifications
TB/HIV 2011
Incidence (HIV+TB)
<0.1
New smear-positive
300
0
1990
2 701 (37)
(0)
148 198
Age < 15
120
45 (3754)
Prevalence

75
60
45
30
15
0
2003
2004
2005 2006
2007
TOTAL
390
2008
2009
on CPT
2010
2011
on ART
60
2012
2013
48
50
16
16
% of budget funded
33
33
93
93
US$ millions
50
40
30
20
10
0
2006
108
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
BRAZIL
Estimates of TB burden 2011

NUMBER (thousands)
5.6 (4.66.8)
2.9 (2.33.4)
91 (36170)
46 (1887)
83 (6997)
42 (3550)
Incidence (HIV+TB)
16 (1319)
8.2 (6.89.7)
91 (77110)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
40 294 (56)
Relapse
Smear-negative
12 683 (18)
8 278 (12)
3 344 (33)
Other
2 947 (29)
Extrapulmonary
10 067 (14)
Other
3 555 (35)
199
(2)
6
5
4
3
2
1
0
1990
Prevalence
HIGH TB BURDEN | HIGH HIV BURDEN

15 (<1)
Total new
71 337
10 045
Total cases notied
84 137
2 755
New cases
SMEAR-POSITIVE
M:F ratio
Age < 15
2000
2005
2010
1995
2000
2005
2010
2000
2005
200
150
100
50
0
1990
140
74 892

SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
1.9
1.5
2.2
692
1 243
580
Laboratories
2.0
7.8
Yes
69
Retreatment
46
80
60
40
20
1995
Incidence
Yes, in country
74
100
Incidence (HIV+TB)
2011
Notifications
1.1
New smear-positive
120
0
1990
2011

Yes
90
Total retreatment
1995
75
60
45
30
15
0
1996
TB/HIV 2011
NUMBER
(%)
49 091
(58)
9 575
(20)
8 850
(92)
1998
2000
2002
2004
2006

2008
2010
Retreatment

NEW
RETREATMENT
0.91 (0.551.4)
5.4 (4.07.2)

pulmonary TB cases
560 (340870)
540 (400730)
12 000
Number of patients
10 000
8000
6000
4000
2000
0
2003

NEW
RETREATMENT
21 (<1%)
604 (6%)
625
18
548
566
TOTAL
2007
2008
2009
on CPT
2010
2011
on ART
80
2013
86
86
77
70
% of budget funded
91
82
91
60
40
20
0
2006
2007
Total budget
2005 2006
100
630
2012
2004
US$ millions
2008
2009
2010
2011
2012
2013
Available funding
109
CAMBODIA
NUMBER (thousands)
9.1 (4.216)
63 (29111)
120 (99140)
817 (690954)
61 (5270)
424 (364489)
3.1 (2.63.6)
22 (1825)
Incidence (HIV+TB)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
15 812 (41)
Smear-negative
7 686 (20)
49
(3)
30
(2)
Extrapulmonary
(0)
14 690 (38)
Other
Total new
367 (25)
Other
1 036 (70)
Total retreatment
1 482
0
38 555
Total cases notied
250
200
150
100
50
0
1990
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
EXTRAPULMONARY
1.2
73
Laboratories
1.5
1.0
2005
2010
1995
2000
2005
2010
1995
2000
2005
Yes

94
85
Retreatment
75
1000
500
0
1990
600
400
200
Incidence
New smear-positive
1500

Yes
Notifications
100
80
60
40
20
0
1996
NUMBER
(%)
32 544
(82)
1 650
(5)
1 456
(88)
1 306
(79)
4 747
1 305
NEW
RETREATMENT
1.4 (0.712.5)
11 (4.022)

pulmonary TB cases
330 (170590)
160 (60320)
1998
2000
2002
2004
2006

2008
2010
Retreatment
7000
Number of patients
TB/HIV 2011
Incidence (HIV+TB)
2011
0.3
6000
5000
4000
3000
2000
1000
0
2003

NEW
RETREATMENT
TOTAL
18 (<1%)
190 (13%)
208
56
56
57
2012
2013
25
25
10
8.8
% of budget funded
42
35
12
55
33
2004
2005 2006
2007
2008
2009
on CPT
2010
2011
on ART
45
US$ millions
30
15
0
2006
2007
Total budget
110
2000
2000
0
1990
2011
1995
800
39 670

Relapse
(0)
38 188
Age < 15
300
64 (5574)
Prevalence

2008
2009
2010
2011
2012
2013
Available funding
CHINA

NUMBER (thousands)
47 (4549)
3.5 (3.43.6)
1 400 (1 2001 600)
104 (91119)
1 000 (8901 100)
75 (6685)
Incidence (HIV+TB)
13 (8.617)
0.93 (0.631.3)
89 (79100)

NEW CASES
(%)
Smear-positive
377 005 (44)
Smear-negative
479 486 (55)
RETREATMENT CASES
(%)
Relapse
34 610 (74)
2 028 (<1)
Extrapulmonary
6 540 (<1)
Other
Other
Total new
(5)
886
(2)
8 830 (19)
(0)
865 059
Total retreatment
46 825
0
Total cases notied
911 884
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
Age < 15
20
15
10
5
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
200
150
100
50
0
1990
200
899 669
2.6
EXTRAPULMONARY
2.1
1 378
0.8
4 165
256
Laboratories
0.2
2.2
Yes
94
Retreatment
90
50
Incidence
Yes, in country
96
100
Incidence (HIV+TB)
2011
Notifications
0.7
New smear-positive
150
0
1990
2011

Yes
98

2 499
Prevalence
HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

Population 2011 1 348 million
96
94
92
90
88
86
84
1996
TB/HIV 2011
NUMBER
(%)
208 681
(23)
4 715
(2)
1 677
(36)
1998
2000
2002
2004
2006

2008
2010
Retreatment

a
Estimates of MDR-TB burden 2011
NEW
RETREATMENT
5.7 (4.67.1)
26 (2230)
49 000 (39 00061 000)
12 000 (10 00014 000)

pulmonary TB cases
5000
Number of patients
4000
3000
2000
1000
0
2003

NEW
RETREATMENT
9 940 (3%)
382
TOTAL
577
2007
1 155
400
300
2012
2013
367
341
313
286
% of budget funded
85
84
67
83
33
17
2008 2009
on CPT
2010
2011
on ART
200
100
0
2006
2007
2008
Total budget
2006
1 601
2005
13 349
US$ millions
2004
2009
2010
2011
2012
2013
Available funding
111
DEMOCRATIC REPUBLIC OF THE CONGO

NUMBER (thousands)
36 (1665)
54 (2496)
350 (180570)
512 (263842)
220 (190250)
327 (282375)
Incidence (HIV+TB)
34 (2741)
49 (4060)
50 (4358)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
71 321 (67)
Relapse
Smear-negative
13 471 (13)
573
(7)
587
(7)
Extrapulmonary
21 579 (20)
3 761 (47)
Other
2 998 (38)
106 371
Total retreatment
7 919
110 132
Total cases notied
Other
Total new
Prevalence

100
80
60
40
20
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
1000
800
600
400
200
0
1990
400
114 290
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
EXTRAPULMONARY
1.2
3 379
3 280
7 667
Laboratories
2.2
<0.1
Yes
87
Retreatment
76
100
Incidence
Yes, in country
90
200

Yes
100
80
60
40
20
1996
NUMBER
(%)
30 636
(27)
4 942
(16)
2 645
(54)
1 118
(23)

NEW
RETREATMENT
3.1 (0.107.1)
10 (2.118)

pulmonary TB cases
2 600 (856 000)
800 (1701 400)

2002
2004
2006
2008
2010
Retreatment
6000
5000
4000
3000
2000
1000
NEW
RETREATMENT
TOTAL
22 (<1%)
160 (2%)
185
111
2000
7000
0
2003
1998

Number of patients
Notifications
TB/HIV 2011
Incidence (HIV+TB)
2011
<0.1
New smear-positive
300
0
1990
2011
Age < 15
120
2004
2005
2006
2007
2008
2009
on CPT
2010 2011
on ART
121
128
70

% of budget funded
2012
2013
15
14
3.5
23
64
8.6
62
US$ millions
60
50
40
30
20
10
100
0
2006
112
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
ETHIOPIA

NUMBER (thousands)
15 (1120)
18 (1424)
200 (160240)
237 (191288)
220 (160280)
258 (191335)
Incidence (HIV+TB)
38 (2849)
45 (3358)
72 (5596)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
49 594 (32)
Relapse
Smear-negative
52 967 (34)
658 (14)
492 (11)
2 530
Extrapulmonary
(2)
49 305 (32)
Other
Total new
Other
1 328 (29)
Total retreatment
4 621
(0)
154 396
0
Total cases notied
159 017
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
Age < 15
60
40
20
0
1990
EXTRAPULMONARY
1.2
3 830
6 025
6 617
Laboratories
2000
2005
2010
1995
2000
2005
2010
2000
2005
600
500
400
300
200
100
0
1990
600
400
200
0
1990
2011
1995
2.3
Incidence
0.1
Yes, in country
Yes

New smear-positive
83
75
Retreatment
83

Yes
NUMBER
(%)
65 140
(41)
5 442
(8)
3 348
(62)
2 123
(39)

174 146
30 816
NEW
RETREATMENT
1.6 (0.862.7)
12 (5.621)
1 700 (9102 900)
550 (260980)

NEW
RETREATMENT
73 (<1%)
139 (3%)
212
35
85
212
2000
2002
2004
2006
2008
2010
Retreatment
12 000
10 000
8000
6000
4000
2000
0
2003
1998

Number of patients
2011
Notifications
90
80
70
60
50
40
30
20
10
0
1996
TB/HIV 2011
Incidence (HIV+TB)
<0.1

pulmonary TB cases
1995
800
156 539

2 143 (46)
Prevalence

TOTAL
2004
2005 2006
2007
2008
2009
on CPT
2010
2011
on ART
60
199
2012
2013
50
52
42
13
% of budget funded
83
25
20
48
100
US$ millions
50
40
30
20
10
0
2006
Total budget
2007
2008
2009
2010
2011
2012
2013
Available funding
113
INDIA

NUMBER (thousands)
300 (190430)
24 (1535)
3 100 (2 1004 300)
249 (168346)
2 200 (2 0002 500)
181 (163199)
Incidence (HIV+TB)
94 (72120)
7.6 (5.89.6)
59 (5465)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
642 321 (53)
Relapse
Smear-negative
340 203 (28)
17 304
72 787 (24)
Extrapulmonary
226 965 (19)
112 508 (37)

(6)
Other
101 832 (33)
1 211 441
Total retreatment
304 431
1 323 949
Total cases notied
Other
1 952 (<1)
Total new

50
Prevalence
500

New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
Age < 15
EXTRAPULMONARY
2.2
12 985
36 673
34 026
Laboratories
1.0
0.1
Yes, in country
Yes

88
90
Retreatment
74
10
0
1990

Yes
NUMBER
(%)
688 530
(45)
44 702
(6)
40 583
(91)
26 165
(59)

386 081

pulmonary TB cases
NEW
RETREATMENT
2.1 (1.52.7)
15 (1316)
21 000 (15 00027 000)
45 000 (40 00050 000)
1995
2000
2005
2010
1995
2000
2005
300
200
100
0
1990
200
150
100
50
Incidence (HIV+TB)
2011
Notifications
100
80
60
40
20
NEW
RETREATMENT
1998
2000
2002
2004
2006

2008
2010
Retreatment
50 000
40 000
30 000
20 000
10 000
0
2003
2010
Incidence
Number of patients
2005
400
1996
2000
TB/HIV 2011
1995
0.1
New smear-positive
20
0
1990
2011
30
250
1 515 872
40
2004
2005 2006
2007
TOTAL
2008
2009
on CPT
2010
2011
on ART

4 237
3 384
2012
2013
219
207
219
207
% of budget funded
100
100
54
58
% available funding from Global Fund
42
39
250
200
US$ millions
Conrmed MDR-TB cases
150
100
50
0
2006
Ranges represent uncertainty intervals. Estimates for India have not yet been ofcially approved by the
Ministry of Health & Family Welfare, Government of India and should therefore be considered provisional.
114
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
INDONESIA

NUMBER (thousands)
65 (29120)
27 (1248)
680 (3101 200)
281 (130489)
450 (370540)
187 (155222)
Incidence (HIV+TB)
15 (1120)
6.2 (4.48.3)
70 (5985)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
197 797 (63)
Relapse
Smear-negative
101 750 (32)
Extrapulmonary
14 054
(4)
5 348 (69)
432
(6)
933 (12)
Other
994 (13)
Prevalence

Other
Total new
313 601
Total retreatment
318 949
Total cases notied
7 707
80
60
40
20
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
2000
2005
800
600
400
200
0
1990
300
321 308
New cases
SMEAR-POSITIVE
M:F ratio
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
1.3
0.9
1.5
1 714
23 469
2 776
Laboratories
2.3
0.9
Yes

90
86
Retreatment
73
150
100
50
1995
Incidence
Yes, in country
200

Yes
100
80
60
40
20
1996
NUMBER
(%)
3 511
(1)
1 280
(36)
1 182
(92)
544
(43)

NEW
RETREATMENT
1.9 (1.42.5)
12 (8.117)

pulmonary TB cases
5 700 (4 2007 500)
920 (6201 300)
1998
2000
2002
2004
2006

2008
2010
Retreatment
1400
Number of patients
2011
Notifications
TB/HIV 2011
Incidence (HIV+TB)
0.1
New smear-positive
250
0
1990
2011
Age < 15
100
1200
1000
800
600
400
200
0
2003

NEW
RETREATMENT
TOTAL
5 (<1%)
695 (9%)
700
380
383
2004
2005 2006
2007
260
140
100
2008
2009
on CPT
2010
2011
on ART
2012
2013
104
117
49
31
% of budget funded
47
27
21
65
92
US$ millions
120
80
60
40
20
0
2006
Total budget
2007
2008
2009
2010
2011
2012
2013
Available funding
115
KENYA

NUMBER (thousands)
9.2 (4.715)
22 (1136)

120 (63200)
291 (152475)
120 (110120)
288 (276300)
Incidence (HIV+TB)
47 (4549)
113 (109118)
81 (7885)

NEW CASES
(%)
RETREATMENT CASES
Smear-positive
37 085 (39)
Relapse
Smear-negative
30 394 (32)
9 416 (10)
Extrapulmonary
17 069 (18)
Other
Total new
3 356 (34)
263
(3)

Other
6 398 (64)
(0)
93 964
Total retreatment
10 017
0
97 320
Total cases notied
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
Age < 15
1.6
EXTRAPULMONARY
1.2
985
1.2
2 008
2 795
Laboratories
3.8
0.7
Yes
85
Retreatment
79
20
10
0
1990

Yes
97 136
(93)
38 172
(39)
37 147
(97)
24 497
(64)

NEW
RETREATMENT
3.1 (0.107.1)
10 (2.118)
2 400 (775 500)
1 000 (2101 800)

1995
2000
2005
2010
1995
2000
2005
400
300
200
100
0
1990
300
200
100
Incidence (HIV+TB)
2011
Notifications
80
60
40
20
NEW
RETREATMENT
92 (<1%)
1 195 (12%)
17
149
1998
2000
2002
2004
2006

2008
2010
Retreatment
60 000
50 000
40 000
30 000
20 000
10 000
0
2003
2010
100
Number of patients
(%)

pulmonary TB cases
2005
500
1996
NUMBER
2000
TB/HIV 2011
1995
Incidence
87
30
0.1
New smear-positive
40
0
1990
2011
50
400
103 981

(%)
Prevalence

2004
2005 2006
2007
TOTAL
2008
2009
on CPT
2010
2011
on ART
1 393
166
156
70
2012
2013
53
51
21
16
% of budget funded
41
31
46
55
51
23
US$ millions
60
50
40
30
20
10
0
2006
116
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
MOZAMBIQUE

NUMBER (thousands)
11 (4.022)
47 (1791)
120 (56200)
490 (235837)
130 (91180)
548 (380747)
Incidence (HIV+TB)
83 (58110)
347 (241473)
34 (2549)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
19 537 (45)
Relapse
Smear-negative
18 159 (42)
238
(6)
242
(6)
Extrapulmonary
(0)
5 504 (13)
Other
Total new
Other
2 345 (55)
Total retreatment
4 252
(0)
43 200
0
Total cases notied
47 452
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
EXTRAPULMONARY
M:F ratio
Age < 15
250
200
150
100
50
0
1990
324
2 180
710
Laboratories
2005
2010
1995
2000
2005
2010
2000
2005
2000
1500
1000
500
0
1990
1000
800
600
400
200
1995
1.8
0.4
0.4
Yes

New smear-positive
85
Incidence
Yes, in and outside country

Yes
Retreatment
NUMBER
(%)
41 896
(88)
26 538
(63)
24 095
(91)
7 661
(29)

17 064
NEW
RETREATMENT
3.5 (2.24.8)
12 (0.025)
1 300 (8301 800)
510 (01 100)
RETREATMENT
TOTAL
206 (1%)
443 (10%)
663
76
202
283
2013
37
35
8.5
8.1
% of budget funded
23
23
29
24
42
46
2004
2006
2008
2010
Retreatment
20 000
10 000
2004
2005 2006
2007
2008
2009
on CPT
2010
2011
on ART
40
30
20
10
0
2006
2007
Total budget
2002
146
2012
2000
US$ millions
NEW
1998
30 000
2003
2011
Notifications

Number of patients
Incidence (HIV+TB)
90
80
70
60
50
40
30
20
10
0
1996
TB/HIV 2011
2000
2500
0
1990
2011

pulmonary TB cases
1995
1200
44 627

1 427 (34)
Prevalence

2008
2009
2010
2011
2012
2013
Available funding
117
MYANMAR

NUMBER (thousands)
23 (1140)
48 (2284)
240 (190310)
506 (390637)
180 (160210)
381 (326439)
Incidence (HIV+TB)
18 (1522)
38 (3145)
74 (6487)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
42 324 (32)
Relapse
4 606 (42)
Smear-negative
62 038 (47)
1 525 (14)
Extrapulmonary
27 769 (21)
542
Other
(5)
4 336 (39)
Other
Total new
132 131
Total retreatment
136 737
Total cases notied
Prevalence

11 009

New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
Age < 15
EXTRAPULMONARY
1.9
307
Laboratories
0.9
0.2
Yes
89
Retreatment
73

Yes
4 496
(3)
900
(20)
900
(100)
724
(80)
2005
2010
1995
2000
2005
2010
2000
2005
500
0
1990
400
300
200
100
1995
Incidence
Incidence (HIV+TB)
2011
Notifications
100
80
60
40
20
12 120
361
NEW
RETREATMENT
4.2 (3.15.6)
10 (6.914)
4 400 (3 2005 800)
1 100 (7601 500)
NEW
RETREATMENT
1998
2000
2002
2004
2006

2008
2010
Retreatment
6000
Number of patients
2000
1000
(%)

pulmonary TB cases
1995
1500
1996
NUMBER
0
1990
TB/HIV 2011
50
0.2
86
100
0
1990
2011
New smear-positive
150
500
143 140
200
5000
4000
3000
2000
1000
0
2003
2004
2005 2006
2007
TOTAL
2008
2009
on CPT
2010
2011
on ART

690
163
35
2012
2013
31
29
10
% of budget funded
34
79
9.3
30
89
US$ millions
30
25
20
15
10
5
0
2006
118
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
NIGERIA

NUMBER (thousands)
27 (6.164)
17 (3.740)
280 (71620)
171 (44382)
190 (90330)
118 (55204)
Incidence (HIV+TB)
50 (2386)
30 (1453)
45 (2696)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
47 436 (56)
Relapse
Smear-negative
33 034 (39)
(0)
1 587 (18)
3 793
(5)
Other
3 966 (45)
(0)
Total retreatment
8 787
Extrapulmonary
Other
Total new
84 263
719
(8)
0
Total cases notied
93 050
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
Age < 15
120
100
80
60
40
20
0
1990
EXTRAPULMONARY
1.6
1 107
Laboratories
2000
2005
2010
1995
2000
2005
2010
2000
2005
1200
1000
800
600
400
200
0
1990
0.8
0.2
Yes
77
Retreatment
82
400
300
200
100
1995
Incidence
84
500

Yes
(%)
75 772
(81)
19 553
(26)
13 301
(68)
8 410
(43)

223 933
969
NEW
RETREATMENT
3.1 (0.107.1)
10 (2.118)
2 500 (805 700)
890 (1801 600)

NEW
RETREATMENT
TOTAL
12 (<1%)
76 (<1%)
139
56
2000
2002
2004
2006
2008
2010
Retreatment
25 000
20 000
15 000
10 000
5000
0
2003
1998

Number of patients
NUMBER
2011
Notifications
90
80
70
60
50
40
30
20
10
0
1996
TB/HIV 2011
Incidence (HIV+TB)
0.1
New smear-positive
600
0
1990
2011

pulmonary TB cases
1995
700
86 778

2 515 (29)
Prevalence

2004
2005 2006
2007
2008
2009
on CPT
2010
2011
on ART
95
38
70
2012
2013
41
39
29
29
% of budget funded
71
74
28
30
48
42
US$ millions
60
50
40
30
20
10
0
2006
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
119
PAKISTAN
NUMBER (thousands)
59 (26110)
33 (1560)
620 (2801 100)
350 (158618)
410 (340490)
231 (190276)
Incidence (HIV+TB)
1.5 (0.992.1)
0.84 (0.561.2)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
105 733 (41)
Relapse
Smear-negative
103 824 (41)
1 282 (11)
Other
3 282 (29)
Extrapulmonary
(0)
45 537 (18)
Other
Total new
896
(8)
Total retreatment
11 407
50
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
2000
2005
1000
800
600
400
200
0
1990
3 893
261 041
Total cases notied
270 394

New cases
SMEAR-POSITIVE
M:F ratio
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
1.0
0.8
1.1
3 895
14 142
7 696
Laboratories
0.7
0.3
Yes, in country
Yes

91
90
Retreatment
84
200
100
1995
Incidence

Yes
100
80
60
40
20
1996
NUMBER

8 322
(3)
33
(<1)
11
(33)
28
(85)

pulmonary TB cases
NEW
RETREATMENT
3.4 (0.1011)
29 (2.656)
7 100 (21023 000)
3 300 (3006 300)
NEW
RETREATMENT
2000
2002
2004
2006
2008
2010
Retreatment
35
Number of patients
1998

(%)
2011
Notifications
TB/HIV 2011
Incidence (HIV+TB)
0.3
New smear-positive
300
0
1990
2011
5 947 (52)
(0)
255 094
Age < 15
100
64 (5478)
Prevalence

30
25
20
15
10
5
0
2003
2004
2005 2006
2007
TOTAL
2008
2009
on CPT
2010
2011
on ART

344
344
70
2012
2013
61
52
28
17
% of budget funded
46
32
95
100
US$ millions
60
50
40
30
20
10
0
2006
120
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
PHILIPPINES
NUMBER (thousands)
28 (2531)
29 (2633)
460 (400520)
484 (425546)
260 (210310)
270 (223322)
Incidence (HIV+TB)
1.1 (0.651.6)
1.1 (0.681.7)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
90 876 (48)
Relapse
Smear-negative
95 297 (51)
468
(3)
896
(7)
Extrapulmonary
2 202
(1)
(0)
Other
Total new
188 375
3 190 (23)
Other
9 104 (67)
Total retreatment
13 658
50
40
30
20
10
0
1990
1995
2000
2005
2010
Total cases notied
202 033
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
1200
1000
800
600
400
200
0
1990
1995
2000
2005
2000
2005
2010
600
191 565

EXTRAPULMONARY
2.4
953
Laboratories
2.1
0.5
Yes
88
Retreatment
69
300
200
100
1995
Incidence
Yes, in country
91
400
Incidence (HIV+TB)
2011
Notifications
0.1
New smear-positive
500
0
1990
2011

Yes
100
Age < 15
60
75 (6391)
Prevalence

80
60
40
20
0
1996
TB/HIV 2011
NUMBER

(%)
3 917
(2)
(<1)
1998
2000
2002
2004
2006

2008
2010
Retreatment

10
815
226
a
NEW
RETREATMENT
4.0 (2.95.5)
21 (1429)
7 500 (5 40010 000)
2 900 (1 9004 000)

pulmonary TB cases
Number of patients
8
6
4
2
0
2003

NEW
RETREATMENT
25 (<1%)
2 325 (17%)
1 055
TOTAL
2007
2008
2009
on CPT
2010
2011
on ART
1 148
2 397
2012
2013
79
78
50
28
% of budget funded
64
36
44
56
100
80
60
40
20
0
2006
2007
Total budget
2005 2006
2 544
2004
US$ millions
2008
2009
2010
2011
2012
2013
Available funding
121
RUSSIAN FEDERATION

NUMBER (thousands)
22 (2223)
16 (1516)
180 (72330)
124 (50229)
140 (120160)
97 (82114)
Incidence (HIV+TB)
9.3 (7.411)
6.5 (5.18.0)
81 (7096)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
29 191 (28)
Relapse
8 590 (16)
Smear-negative
63 917 (61)
9 879 (18)
1 189
Extrapulmonary
(1)
10 023 (10)
2 745
(5)
Other
33 945 (62)
104 320
Total retreatment
55 159
112 910
Total cases notied
Other
Total new
Prevalence


20
15
10
5
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
2000
2005
300
200
100
0
1990

159 479

New cases
SMEAR-POSITIVE
M:F ratio
Age < 15
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
2.2
1.3
2.7
51
593
2 901
Laboratories
2.6
4.1
100
50
0
1990
2011
150
1995
Incidence
Incidence (HIV+TB)
2011
Notifications

Yes, in country
No

New smear-positive
53
73
Retreatment
34

Yes
80
60
40
20
0
1996
TB/HIV 2011
NUMBER
TB patients with known HIV statusb
1998
2000
2002
RETREATMENT
46 (4152)
19 000 (17 00021 000)
25 000 (23 00029 000)

NEW
RETREATMENT
34 007 (78%)
13 620 (25%)
6 596
7 189

TOTAL
4000
2000
47 627
0
13 785
2003
18 902
2012
1 204
1 204
2004
2005 2006
2007
2009
on CPT
2010
2011
on ART
1400
1200
100
1000

The reported number of TB patients with known HIV status is for new TB patients only. It was not possible
to calculate the percentage of all TB patients with known HIV status.
Funding of US$ 340 million is available from the budgets of the Federal Targeted Program and National
Project Health in 2012. The remaining funding is from local (oblast) and other budgets and was
estimated using data reported to WHO in previous years. Estimates of non-federal and other sources of
funding will be reviewed in 2013.
US$ millions
100
2008
2013
% of budget funded
122
2010
Retreatment
6000
Financing TB controlc
2008
8000
Number of patients
NEW
20 (1822)
2006
4 104
2004

79 494

pulmonary TB cases
(%)
800
600
400
200
0
2006
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
SOUTH AFRICA
NUMBER (thousands)
25 (1144)
49 (2187)
390 (200630)
768 (3991 250)
500 (410600)
993 (8191 180)
Incidence (HIV+TB)
330 (270390)
650 (536774)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
129 770 (40)
Smear-negative
70 341 (22)
2 578
77 925 (24)
4 642 (10)
Extrapulmonary
47 285 (15)
Other
20 301 (44)
Total retreatment
45 915
Other
Total new
18 394 (40)
(6)
18 738
389 974

Total cases notied
New cases
SMEAR-POSITIVE
M:F ratio
Age < 15
80
60
40
20
0
1990
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
1.0
1.0
1.2
3 404
32 080
2 399
Laboratories
2005
2010
1995
2000
2005
2010
2000
2005
1000
800
600
400
200
0
1990
1200
1000
800
600
400
200
1995
0.5
1.5
1.5
Yes
Treatment success rate 2010b (%)

New smear-positive
79
37
Retreatment
35
Incidence
Yes, in country

Yes
(%)
323 440
(83)
211 800
(65)
161 298
(76)
92 376
(44)

1 256 212
372 994
NEW
RETREATMENT
1.8 (1.42.3)
6.7 (5.58.1)
5 000 (4 0006 300)
3 100 (2 5003 700)

pulmonary TB cases
RETREATMENT
33 576
10 085
% of budget funded
2013
2006
2008
2010
Retreatment
15 0000
50 000
2004
2005 2006
2007
2008
2009
on CPT
2010
2011
on ART
450
400
350
300
250
200
150
100
50
0
2006

Treatment success rates are based on incomplete data.
2004
10 0000
5 643
2012
2002
20 0000
TOTAL
2000
US$ millions
NEW
1998
25 0000
2003
2011
Notifications

Number of patients
NUMBER
Incidence (HIV+TB)
90
80
70
60
50
40
30
20
10
0
1996
TB/HIV 2011
2000
1200
0
1990
2011
1995
1400
343 715
Relapse
(0)
325 321
100
69 (5883)
Prevalence

2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
123
THAILAND

NUMBER (thousands)
9.8 (4.218)
14 (6.125)
110 (51200)
161 (73282)
86 (71100)
124 (102147)
Incidence (HIV+TB)
13 (1015)
18 (1522)
76 (6493)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
33 169 (52)
Relapse
Smear-negative
20 726 (32)
406 (11)
556 (15)
Other
890 (24)
Extrapulmonary
10 014 (16)
Other
Total new
(0)
63 909
Total retreatment
3 767
0
65 824
Total cases notied
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
Age < 15
EXTRAPULMONARY
2.4
114
Laboratories
1.6
4.7
Yes

85
79
Retreatment
66

Yes
NUMBER
(%)
49 770
(74)
7 326
(15)
5 509
(75)
4 348
(59)
41 131

pulmonary TB cases
NEW
RETREATMENT
1.7 (1.02.6)
35 (2842)
890 (5401 400)
1 300 (1 0001 600)
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
400
300
200
100
0
1990
150
100
50
Incidence
Incidence (HIV+TB)
2011
Notifications
100
80
60
40
20
NEW
RETREATMENT
1998
2000
2002
2004
2006

2008
2010
Retreatment
10 000
Number of patients
10
1996
20
TB/HIV 2011
30
1.1
New smear-positive
40
0
1990
2011
50
200
67 676

1 915 (51)
Prevalence

8000
6000
4000
2000
0
2003
2004
2005 2006
2007
TOTAL
2008
2009
on CPT
2010
2011
on ART
4 939
510
123
60
2012
2013
44
44
41
41
% of budget funded
94
94
98
98
US$ millions
50
40
30
20
10
0
2006
124
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
UGANDA

NUMBER (thousands)
5.0 (2.19.0)
14 (6.226)
63 (33100)
183 (95298)
67 (5481)
193 (156234)
Incidence (HIV+TB)
35 (2842)
102 (82123)
69 (5786)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
25 614 (57)
Relapse
Smear-negative
12 830 (29)
1 559
Extrapulmonary
5 001 (11)
(3)
1 302 (32)
306
(8)
1 206 (30)
Other
1 198 (30)
45 004
Total retreatment
4 012
46 306
Total cases notied
Prevalence

Other
Total new
60
40
20
0
1990

49 016
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
EXTRAPULMONARY
1.8
695
Laboratories
2000
2005
2010
1995
2000
2005
2010
2000
2005
800
600
400
200
0
1990
1000
800
600
400
200
0
1990
2011
1995
3.1
1.0
1.2
Yes, in country
Yes

New smear-positive
71
62
Retreatment
65
Incidence

Yes
M:F ratio
(%)
39 394
(80)
20 725
(53)
19 258
(93)
6 720
(32)

553 057
NEW
RETREATMENT
1.4 (0.602.2)
12 (6.819)

pulmonary TB cases
560 (240900)
480 (270780)
RETREATMENT
TOTAL
316 (1%)
360 (9%)
797
43
71
% of budget funded
20
6.2
31
56
2013
2004
2006
2008
2010
Retreatment
20 000
15 000
10 000
5000
2004
2005 2006
2007
2008
2009
on CPT
2010
2011
on ART
25
20
15
10
5
0
2006
2007
Total budget
2002
7
2012
2000
US$ millions
NEW
1998
25 000
2003
2011
Notifications

Number of patients
NUMBER
Incidence (HIV+TB)
90
80
70
60
50
40
30
20
10
0
1996
TB/HIV 2011
1995
1200
Age < 15
80
2008
2009
2010
2011
2012
2013
Available funding
125
UNITED REPUBLIC OF TANZANIA

NUMBER (thousands)
6.4 (3.311)
14 (7.123)
82 (43130)
177 (93286)
78 (7383)
169 (159180)
Incidence (HIV+TB)
30 (2832)
65 (6169)
76 (7181)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
24 115 (41)
Relapse
Smear-negative
20 438 (35)
144
(5)
212
(7)
Extrapulmonary
(0)
13 725 (24)
Other
Total new
Other
1 435 (50)
Total retreatment
2 870
(0)
58 278
500
0
Total cases notied
61 148
New cases
SMEAR-POSITIVE
M:F ratio
50
40
30
20
10
0
1990
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
1.3
1.1
1.8
411
2 317
2 155
Laboratories
2000
2005
2010
1995
2000
2005
2010
2000
2005
400
300
200
100
0
1990
2.0
0.5
Yes

90
89
Retreatment
84
150
100
50
1995
Incidence
200

Yes
100
80
60
40
20
1996
(%)
53 531
(88)
20 525
(38)
19 499
(95)
7 706
(38)

148 177

NEW
RETREATMENT
1.1 (0.302.8)
0.0 (0.07.3)
480 (1301 200)
0 (0210)

2002
2004
2006
2008
2010
Retreatment
20 000
15 000
10 000
5000
0
NEW
RETREATMENT
TOTAL
83 (<1%)
17 (<1%)
582
68
2000
25 000
2003
1998

Number of patients
NUMBER
2011
Notifications
TB/HIV 2011
Incidence (HIV+TB)
0.1
New smear-positive
250
0
1990
2011

pulmonary TB cases
1995
300
59 357

Age < 15
60
1 079 (38)

Prevalence
2004
2005 2006
2007
2008
2009
on CPT
2010
2011
on ART
60
68
2012
2013
43
57
16
15
% of budget funded
39
27
47
51
23
31
US$ millions
50
40
30
20
10
0
2006
Total budget
126
2007
2008
2009
2010
2011
2012
2013
Available funding
VIET NAM

NUMBER (thousands)
30 (1255)
33 (1462)
290 (130500)
323 (148563)
180 (140220)
199 (153250)
Incidence (HIV+TB)
14 (1118)
16 (1220)
56 (4473)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
50 719 (55)
Relapse
Smear-negative
20 205 (22)
621
376
(4)
Other
717
(8)
Extrapulmonary
17 934 (20)
Other
2 679
Total new
6 925 (80)
(7)
(3)
91 537
Total retreatment
98 462
Total cases notied
Prevalence

8 639

New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
Age < 15
EXTRAPULMONARY
3.0
95
Laboratories
0.9
1.4
Yes, in country
Yes

92
92
Retreatment
69
20
0
1990

No
NUMBER
(%)
59 094
(59)
4 713
(8)
3 396
(72)
2 258
(48)


pulmonary TB cases
NEW
RETREATMENT
2.7 (2.03.6)
19 (1425)
2 000 (1 5002 700)
1 700 (1 2002 200)
2010
1995
2000
2005
2010
2000
2005
400
200
0
1990
200
150
100
50
1995
Incidence
Incidence (HIV+TB)
2011
Notifications
100
80
60
40
20
NEW
RETREATMENT
1998
2000
2002
2004
2006

2008
2010
Retreatment
7000
Number of patients
2005
600
1996
2000
TB/HIV 2011
1995
0.1
New smear-positive
40
0
1990
2011
60
250
100 176
80
6000
5000
4000
3000
2000
1000
0
2003
2004
2005 2006
2007
TOTAL
2008
2009
on CPT
2010
2011
on ART

601
578
2012
2013
73
63
16
18
% of budget funded
22
29
32
68
69
80
US$ millions
60
40
20
0
2006
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
127
ZIMBABWE

NUMBER (thousands)
6.0 (2.411)
47 (1988)
70 (37110)
547 (287889)
77 (5996)
603 (466757)
Incidence (HIV+TB)
46 (3658)
360 (279452)
50 (4065)

NEW CASES
(%)
Smear-positive
12 596 (34)
Smear-negative
RETREATMENT CASES
(%)
Relapse
1 444 (33)
15 303 (41)
176
(4)
3 869 (10)
152
(3)
Extrapulmonary
5 192 (14)
Other
2 573 (59)
Total retreatment
4 345
Other
Total new
(0)
36 960
800
0
Total cases notied
41 305
New cases
SMEAR-POSITIVE
M:F ratio
60
40
20
0
1990
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
1.1
1.1
1.2
326
2 635
459
Laboratories
1.2
0.8
0.8
No
Yes

New smear-positive
81
75
Retreatment
74

Yes
2010
1995
2000
2005
2010
1995
2000
2005
200
0
1990
800
600
400
200
Incidence
(%)
35 361
(86)
21 125
(60)

6 203
(29)
14 090
(67)


NEW
RETREATMENT
1.9 (1.03.3)
8.3 (1.822)
610 (3301 000)
360 (76980)
NEW
RETREATMENT
0 (0%)
0 (0%)
Notifications
1998
2000
2002
2004
2006
2008
2010
Retreatment
35 000
30 000
25 000
20 000
15 000
10 000
5000
0
TOTAL
2004
2005 2006
2007
2008
2009
on CPT
2010
2011
on ART
1 197
118
64
2012
2013
40
38
14
14
% of budget funded
36
37
17
20
58
55
US$ millions
2011
90
80
70
60
50
40
30
20
10
0
2003
Incidence (HIV+TB)

Number of patients
NUMBER
45
40
35
30
25
20
15
10
5
0
2006
2007
Total budget
128
2005
400
1996
TB/HIV 2011
2000
600
0
1990
2011

pulmonary TB cases
1995
1000
38 404

Age < 15
80

Prevalence
2008
2009
2010
2011
2012
2013
Available funding
ANNEX 3
Regional profiles
WHO AFRICAN REGION

46
NUMBER (thousands)
220 (180270)
26 (2131)
2 500 (2 1003 000)
293 (243347)
2 300 (2 1002 400)
262 (242283)
870 (800950)
102 (93111)
Incidence (HIV+TB)

WHO MEMBER STATES
61 (5666)
60
50
40
30
20
10
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
2000
2005
NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
605 929 (46)
Relapse
Smear-negative
357 811 (27)
9 271 (7.3)
109 258 (8.3)
13 498 (11)
Extrapulmonary
240 843 (18)
Other
51 853 (41)
Other
52 283 (41)
1 069 (<1)
Total new
1 314 910
Total retreatment
126 905
Prevalence

600
500
400
300
200
100
0
1990
18 951
1 367 193
Total cases notied
1 460 766
400
New cases
SMEAR-POSITIVE
M:F ratio
age < 15
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
1.2
1.2
1.4
19 183
43 845
12 615
Laboratories 2011
NUMBER OF MEMBER STATES
Smear (per 100 000 population) 1
28 out of 43
Culture (per 5 million population) 1
15 out of 43
Drug susceptibility testing (per 5 million population) 1
10 out of 43
200
100
0
1990
64
Retreament
54
MDR-TB (2009 cohort)
45
TB/HIV 2011
NUMBER
(%) c
1 001 972
(69)
458 608
(46)
353 306
(79)
203 851
(46)

82
80
60
40
20
0
1996
RETREATMENT
2.9 (0.16.2)
11 (3.418)
31 000 (1 10067 000)
14 000 (4 30023 000)

NEW
RETREATMENT
1 311 (<1%)
3 707 (2.9%)
41 629
183
986
12 384

TOTAL
Number of patients (thousands)
NEW
2000
2002
2004
2006
2008
2010
Retreatment
500
400
300
200
100
0
2004
7 467
2013
506
500
600
277
234
500
% of budget funded
55
47
31
30
51
54
US$ millions
(constant 2012 US$)
2012

Data are not collected from all Member States.
Calculations exclude countries with missing numerators or denominators.
Financing indicators exclude funding for general healthcare services provided outside NTPs. South Africa
has been excluded due to lack of data.
2005
2006
2007
Financing TB control (low- and middle-income countries) d
1998

437 983
2011
Notifications
2 770 295
Incidence (HIV+TB)
100
1995
Incidence

pulmonary TB cases
300
2008
2009
on CPT
2010
2011
on ART
400
300
200
100
0
2006
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
131
WHO REGION OF THE AMERICAS
NUMBER (thousands)
21 (1824)
2.2 (1.92.5)
330 (250420)
35 (2644)
260 (240280)
28 (2629)
Incidence (HIV+TB)
37 (3440)
3.9 (3.64.2)
84 (7989)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
121 130 (59)
Smear-negative
36 371 (18)
1 066 (4.9)
14 254 (6.9)
6 506 (30)
Extrapulmonary
33 757 (16)
Other
4 041 (19)
Other
Relapse
10 004 (46)
1 315 (<1)
Total new
206 827
21 617
Total cases notied
New cases
SMEAR-POSITIVE
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
EXTRAPULMONARY
1.6
1.4
1.8
2 337
5 255
2 127
Laboratories 2011
22 out of 23
9 out of 23
70
Retreament
49
49
TB/HIV 2011
NUMBER
(%) c
124 035
(53)
20 828
(17)
2 738
(43)
12 130
(64)
2 653
1 705
NEW
RETREATMENT
2 (0.83.3)
11 (4.517)
3 500 (1 4005 700)
2 400 (9703 800)

pulmonary TB cases

NEW
RETREATMENT
TOTAL
13 334 (10%)
4 234 (20%)
19 277
1 065
1 468
77
2000
2005
2010
1995
2000
2005
2010
2000
2005
140
120
100
80
60
40
20
0
1990
60
40
20
1995
Incidence (HIV+TB)
2011
Notifications
80
60
40
20
0
1996
1998
2000
2002
2004
2006

2008
2010
Retreatment
25
20
15
10
5
0
2004
2005
2006
2007
2 969
2008
2009
on CPT
2010
2011
on ART
3 087
2012
2013
174
174
146
138
% of budget funded
84
79
85
88
10
11

Financing indicators exclude funding for general healthcare services provided outside NTPs.
132
1995
100
0
1990
Incidence
1990
17 out of 23
NUMBER OF MEMBER STATESb
M:F ratio
80
231 880
216 831
age < 15
3 436
200
US$ millions
(constant 2012 US$)
Total retreatment

11
Prevalence
WHO MEMBER STATES 35

OTHER COUNTRIES AND TERRITORIES
150
100
50
0
2006
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
WHO EASTERN MEDITERRANEAN REGION
NUMBER (thousands)
99 (61150)
16 (1024)
1 000 (6601 500)
170 (108246)
660 (590740)
109 (97122)
9 (810)
1.4 (1.31.6)
Incidence (HIV+TB)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
170 748 (43)
Relapse
Smear-negative
128 182 (32)
1 977 (9.3)
2 867 (13)
Other
5 258 (25)
7 206 (1.8)
Extrapulmonary
93 605 (23)
Other
11 223 (53)
623 (<1)
Total new
400 364
Total retreatment
21 325
50
40
30
20
10
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
2000
2005
400
300
200
100
0
1990
4 132
411 587
Total cases notied
425 821
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
1.2
EXTRAPULMONARY
1.2
5 763
0.9
18 251
12 153

age < 15
60
62 (5570)
Prevalence


150
100
50
Laboratories 2011
1990
8 out of 22
12 out of 22
7 out of 22
1995
Incidence
Incidence (HIV+TB)
2011
Notifications
88
87
Retreament
75
44
TB/HIV 2011
NUMBER
(%) c
44 973
(11)
1 781
(4.0)
733
(59)
678
(48)
974
52
NEW
RETREATMENT
3.4 (0.110)
30 (6.953)
10 000 (31032 000)
6 400 (1 50011 000)

pulmonary TB cases

NEW
RETREATMENT
TOTAL
2 264 (1.2%)
1 466 (6.9%)
4 019
93
375

2012
2013
131
123
90
76
% of budget funded
69
62
34
40
61
57
c
d

20
1998
2000
2002
2004
2006

2008
2010
Retreatment
2.0
1.5
1.0
0.5
0
2004
2005
2006
2007
841
40
2008
2009
on CPT
2010
2011
on ART
756
60
1996
150
US$ millions
(constant 2012 US$)
80
100
100
50
0
2006
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
133
WHO EUROPEAN REGION
1
NUMBER (thousands)
45 (4446)
5 (4.95.1)
500 (370650)
56 (4173)
380 (350400)
42 (3945)
Incidence (HIV+TB)
23 (2025)
2.5 (2.22.8)
73 (6978)

NEW CASES
(%)
Smear-positive
79 831 (31)
Smear-negative
121 362 (48)
6 896 (2.7)
Extrapulmonary
42 489 (17)
Other
RETREATMENT CASES
(%)
Relapse
22 838 (24)
12 140 (13)
4 625 (4.8)
Other
56 531 (59)
Prevalence


3 191 (1.3)
Total new
253 769
96 134
7 502
275 872
Total cases notied
356 670
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
age < 15
2.3
EXTRAPULMONARY
1.9
391
1.2
2 850
6 638
Laboratories 2011

Total retreatment
8 out of 53
30 out of 53
25 out of 53
6
4
2
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
2000
2005
150
100
50
0
1990
80
60
40
20
0
1990
1995
Incidence
Incidence (HIV+TB)
2011
Notifications
67
78
Retreament
51
48
TB/HIV 2011
NUMBER
(%) c
187 233
(52)
12 317
(6.5)
828
(64)
3 487
(47)
9 173
4 565
NEW
RETREATMENT
15 (1020)
44 (4049)
32 000 (21 00042 000)
42 000 (38 00047 000)

pulmonary TB cases

NEW
RETREATMENT
TOTAL
69 467 (56%)
25 561 (27%)
99 470
10 290
12 097
32 348

2012
1 380
1 670
1 350
1 550
98
92
96
98
3.7
1.9
b
c
d

134
20
1998
2000
2002
2004
2006

2008
2010
Retreatment
16
12
8
4
0
2004
2005
2006
2007
2008
2009
on CPT
2010
2011
on ART
2000
2013
40
34 769
% of budget funded
60
1996
US$ millions
(constant 2012 US$)
80
100
1600
1200
800
400
0
2006
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
WHO SOUTH-EAST ASIA REGION

11
NUMBER (thousands)
480 (350630)
26 (1934)
5 000 (3 8006 300)
271 (206344)
3 500 (3 2003 700)
189 (176203)
140 (120170)
7.7 (6.49.1)
Incidence (HIV+TB)
62 (5866)

WHO MEMBER STATES

60
50
40
30
20
10
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
NEW CASES
(%)
Smear-positive
1 067 367 (53)
Smear-negative
(%)
Relapse
135 650 (39)
598 800 (30)
23 252 (6.6)
76 666 (22)
Extrapulmonary
RETREATMENT CASES
(0)
333 993 (17)
Other
Other
115 636 (33)
Total retreatment
351 204
2 878 (<1)
Total new
2 003 038
Prevalence
3 885
2 138 688
Total cases notied
600
500
400
300
200
100
0
1990
2 358 127
New cases
SMEAR-POSITIVE
M:F ratio
age < 15
2.0
EXTRAPULMONARY
1.4
17 144
1.1
26 816
7 567
Laboratories 2011

250
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
200
150
100
50
9 out of 11
3 out of 11
1990
2 out of 11
Incidence
Incidence (HIV+TB)
2011
Notifications

88
89
Retreament
75
58
TB/HIV 2011
NUMBER
(%) c
750 315
(32)
54 314
(7.2)
48 270
(89)
31 883
(59)

80
60
40
20
0
1996
2000
2002
RETREATMENT
2.1 (1.82.5)
16 (1219)
35 000 (30 00042 000)
54 000 (42 00066 000)
NEW
RETREATMENT
TOTAL
1 200 (<1%)
1 925 (<1%)
8 091
22
869
6 615

NEW
2012
469
429
358
288
% of budget funded
76
67
49
48
44
50
c
d
2008
2010
Retreatment
50
40
30
20
10
0
2004
4 572
2006
60
2005
2006
2007
2004
368
1998

439 521

pulmonary TB cases
100

2008
2009
on CPT
2010
2011
on ART
2013
US$ millions
(constant 2012 US$)
500
400
300
200
100
0
2006
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
135
WHO WESTERN PACIFIC REGION
NUMBER (thousands)
130 (100150)
6.9 (5.78.3)
2 500 (2 2002 800)
138 (123154)
1 700 (1 5001 800)
92 (84100)
Incidence (HIV+TB)
36 (3142)
2 (1.72.3)
81 (7589)

NEW CASES
(%)
RETREATMENT CASES
(%)
Smear-positive
576 044 (44)
Relapse
Smear-negative
630 219 (49)
3 967 (4.7)
17 435 (1.3)
3 371 (4.0)
Extrapulmonary
68 949 (5.3)
Other
25 919 (31)
Total retreatment
84 098
Other
50 841 (60)
2 708 (<1)
Total new
1 295 355
1 346 196
Total cases notied
1 383 249
20
15
10
5
0
1990
1995
2000
2005
2010
1995
2000
2005
2010
2000
2005
300
250
200
150
100
50
0
1990
200
New cases
SMEAR-NEGATIVE/
UNKNOWN/NOT DONE
SMEAR-POSITIVE
M:F ratio
age < 15
25
3 796
2.4
EXTRAPULMONARY
2.1
2 880
1.0
5 049
979


Prevalence

150
100
50
0
Laboratories 2011
13 out of 17
11 out of 17
5 out of 17
91
Retreament
86
57
TB/HIV 2011
NUMBER
(%) c
351 901
(25)
13 794
(3.9)
5 876
(71)
6 005
(47)
80
60
40
20
1996
1 787
NEW
RETREATMENT
4.8 (3.46.1)
22 (1826)
59 000 (42 00075 000)
19 000 (15 00022 000)

NEW
RETREATMENT
TOTAL
25 284 (4.2%)
5 131 (6.1%)
44 787
572
2 112
2002
2004
2006
2008
2010
Retreatment
12
8
4
0
2004
2005
2006
2007
4 392
2008
2009
on CPT
2010
2011
on ART
4 946
2013
700
580
532
600
425
362
% of budget funded
73
68
60
80
39
19

US$ millions
(constant 2012 US$)
2012
136
2000
16
1998

11 203
2011
Notifications
93
Incidence (HIV+TB)
100
1995
Incidence

pulmonary TB cases
1990
500
400
300
200
100
0
2006
2007
Total budget
2008
2009
2010
2011
2012
2013
Available funding
ANNEX 4
Global, regional
and country-specific data
for key indicators
Summary by WHO region
139
African Region
147
Region of the Americas
171
Eastern Mediterranean Region
195
European Region
211
South-East Asia Region
239
Western Pacic Region
251
SUMMARY BY WHO REGION

Table A4.1 Estimates of the burden of disease caused by TB, 19902011
141
Table A4.2 Incidence, notication and case detection rates, all forms, 19902011
142
Table A4.3 Case notications, 19902011
143
Table A4.4 Treatment outcomes, new smear-positive cases, 19952010
144
Table A4.5 Treatment outcomes, retreatment cases, 19952010
144
Table A4.6 HIV testing and provision of CPT, ART and IPT, 20052011
145
Table A4.7 Testing for MDR-TB and number of conrmed cases of MDR-TB, 20052011
145
Table A4.8 New smear-positive case notication by age and sex, 19952011
146
Estimates of mortality, prevalence and incidence

Estimated values are shown as best estimates followed by lower and upper bounds. The lower and upper bounds are
de ned as the 2.5th and 97.5th centiles of outcome distributions produced in simulations. See Annex 1 for further
details.
Estimated numbers are shown rounded to two signicant gures. Estimated rates are shown rounded to three signicant gures unless the value is under 100, in which case rates are shown rounded to two signicant gures. Blank cells
indicate that estimates are not available.
Estimates for all years are recalculated as new information becomes available and techniques are rened, so they may
differ from those published in previous reports in this series. Estimates published in previous global TB control reports
should no longer be used.
Data source
Data shown in this annex are taken from the WHO global TB database on 25 September 2012. Data shown in the main
part of the report were taken from the database in July 2012. As a result, data in this annex may differ slightly from
those in the main part of the report.
Data can be downloaded from www.who.int/tb/data.
140
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%
Global
1990
1995
2000
2005
2009
2010
2011
Africa
1990
1995
2000
2005
2009
2010
2011
The Americas 1990
1995
2000
2005
2009
2010
2011
Eastern
1990
Mediterranean 1995
2000
2005
2009
2010
2011
Europe
1990
1995
2000
2005
2009
2010
2011
South-East
1990
Asia
1995
2000
2005
2009
2010
2011
Western
1990
Pacific
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
5 283
5 702
6 097
6 481
6 792
6 870
6 948
507
580
656
742
817
837
857
723
777
834
885
924
933
943
381
433
484
538
585
597
609
846
862
868
880
893
897
899
1 317
1 446
1 572
1 694
1 785
1 808
1 830
1 510
1 605
1 683
1 743
1 788
1 798
1 809
NUMBER
(THOUSANDS)
1 300
1 300
1 400
1 200
1 100
1 000
990
200
230
240
240
220
220
220
41
37
30
25
22
21
21
120
130
140
120
100
99
99
37
58
69
65
52
49
45
570
630
680
620
530
500
480
310
260
200
160
130
130
130
(1 1001 500)
(1 1001 600)
(1 1001 600)
(1 1001 400)
(9001 200)
(8701 200)
(8401 100)
(130290)
(150310)
(160340)
(170330)
(180270)
(180280)
(180270)
(3449)
(3342)
(2634)
(2228)
(1925)
(1824)
(1824)
(58200)
(68210)
(71230)
(67190)
(61150)
(61150)
(61150)
(3441)
(5660)
(6771)
(6366)
(5154)
(4750)
(4446)
(410750)
(460840)
(500890)
(480780)
(390690)
(370660)
(350630)
(270350)
(220300)
(160240)
(130180)
(110160)
(110150)
(100150)
RATEa
24
24
22
19
16
15
14
40
39
37
32
27
27
26
5.7
4.8
3.6
2.8
2.3
2.3
2.2
32
30
29
23
17
17
16
4.4
6.7
8
7.3
5.9
5.4
5
43
44
43
37
30
28
26
21
16
12
9
7.5
7.2
6.9
(2028)
(2028)
(1926)
(1622)
(1318)
(1317)
(1217)
(2557)
(2654)
(2551)
(2244)
(2233)
(2133)
(2131)
(4.76.8)
(4.25.5)
(3.24.0)
(2.43.1)
(2.02.7)
(1.92.6)
(1.92.5)
(1554)
(1649)
(1547)
(1236)
(1026)
(1025)
(1024)
(4.04.8)
(6.57.0)
(7.78.2)
(7.27.5)
(5.76.0)
(5.35.6)
(4.95.1)
(3157)
(3258)
(3157)
(2846)
(2239)
(2037)
(1934)
(1823)
(1419)
(9.514)
(7.710)
(6.28.9)
(5.98.6)
(5.78.3)
PREVALENCE (INCLUDING HIV)

NUMBER
(THOUSANDS)
14 000
15 000
16 000
14 000
12 000
12 000
12 000
1 900
2 200
2 500
2 600
2 500
2 500
2 500
680
540
460
410
350
340
330
1 000
1 100
1 200
1 100
1 000
1 000
1 000
580
970
1 100
860
610
560
500
6 100
6 800
7 000
6 300
5 400
5 200
5 000
3 900
3 800
3 500
3 100
2 600
2 600
2 500
(13 00016 000)

(14 00017 000)
(14 00017 000)
(13 00016 000)
(11 00014 000)
(11 00014 000)
(10 00013 000)
(1 2002 800)
(1 5002 900)
(1 7003 300)
(1 9003 400)
(2 1002 900)
(2 1003 000)
(2 1003 000)
(480910)
(420670)
(360580)
(320520)
(260440)
(260430)
(250420)
(5701 600)
(6801 700)
(7001 800)
(7001 600)
(6601 500)
(6601 500)
(6601 500)
(480690)
(7801 200)
(8401 300)
(6601 100)
(460790)
(410730)
(370650)
(5 3007 100)
(5 8007 800)
(6 0008 100)
(5 2007 400)
(4 2006 700)
(3 9006 600)
(3 8006 300)
(3 6004 200)
(3 4004 100)
(3 1003 900)
(2 7003 400)
(2 3002 900)
(2 3002 900)
(2 2002 800)
RATEa
268
269
257
221
184
177
170
372
372
374
352
304
303
293
94
69
55
46
38
36
35
269
260
245
207
177
173
170
68
112
123
98
69
63
56
465
468
445
370
301
285
271
255
236
209
176
147
143
138
(243294)
(246293)
(234282)
(199244)
(163206)
(156200)
(150192)
(231545)
(262500)
(266500)
(256462)
(255358)
(250361)
(243347)
(67126)
(5487)
(4370)
(3659)
(2948)
(2746)
(2644)
(149425)
(158388)
(145371)
(130302)
(113255)
(110249)
(108246)
(5682)
(90137)
(96153)
(75124)
(5288)
(4681)
(4173)
(400536)
(404538)
(383513)
(309436)
(235376)
(217363)
(206344)
(236276)
(214258)
(186233)
(157195)
(131163)
(127159)
(123154)
INCIDENCE (INCLUDING HIV)

NUMBER
(THOUSANDS)
7 800
8 400
9 100
9 200
8 800
8 800
8 700
1 200
1 600
2 000
2 300
2 300
2 300
2 300
430
380
340
310
270
270
260
470
530
570
610
640
650
660
360
560
640
560
440
410
380
2 900
3 100
3 400
3 600
3 500
3 500
3 500
2 400
2 200
2 000
1 800
1 700
1 700
1 700
(7 1008 400)
(7 9008 900)
(8 5009 600)
(8 7009 700)
(8 5009 200)
(8 4009 100)
(8 3009 000)
(9501 600)
(1 3001 900)
(1 7002 400)
(1 9002 700)
(2 1002 400)
(2 1002 500)
(2 1002 400)
(360490)
(350410)
(320370)
(290330)
(260290)
(250280)
(240280)
(360590)
(480590)
(510640)
(540680)
(570720)
(580730)
(590740)
(350380)
(530590)
(600680)
(520600)
(410470)
(380440)
(350400)
(2 5003 200)
(2 8003 400)
(3 2003 700)
(3 3003 900)
(3 3003 800)
(3 2003 700)
(3 2003 700)
(2 0002 800)
(1 9002 500)
(1 8002 300)
(1 7002 000)
(1 6001 900)
(1 5001 800)
(1 5001 800)
RATEa
147
148
148
142
130
128
125
245
276
311
310
276
271
262
59
49
41
34
30
29
28
123
123
118
113
109
109
109
43
65
74
64
49
46
42
217
217
218
212
197
193
189
159
137
120
106
96
94
92
(135159)
(139157)
(140157)
(135150)
(125135)
(123133)
(120130)
(188310)
(227330)
(256371)
(263361)
(256296)
(249293)
(242283)
(5068)
(4653)
(3844)
(3237)
(2832)
(2730)
(2629)
(95154)
(110137)
(104132)
(100126)
(97123)
(97122)
(97122)
(4145)
(6269)
(6978)
(6068)
(4653)
(4349)
(3945)
(191245)
(197238)
(202235)
(196228)
(182211)
(179207)
(176203)
(133187)
(119157)
(107134)
(96116)
(88105)
(86102)
(84100)
MORTALITY (EXCLUDING HIV)

YEAR
Rates are per 100 000 population.
141
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV
Global
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
142
YEAR
POPULATION
(MILLIONS)
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
5 283
5 702
6 097
6 481
6 792
6 870
6 948
507
580
656
742
817
837
857
723
777
834
885
924
933
943
381
433
484
538
585
597
609
846
862
868
880
893
897
899
1 317
1 446
1 572
1 694
1 785
1 808
1 830
1 510
1 605
1 683
1 743
1 788
1 798
1 809
NUMBER
(THOUSANDS)
7 800
8 400
9 100
9 200
8 800
8 800
8 700
1 200
1 600
2 000
2 300
2 300
2 300
2 300
430
380
340
310
270
270
260
470
530
570
610
640
650
660
360
560
640
560
440
410
380
2 900
3 100
3 400
3 600
3 500
3 500
3 500
2 400
2 200
2 000
1 800
1 700
1 700
1 700
(7 1008 400)
(7 9008 900)
(8 5009 600)
(8 7009 700)
(8 5009 200)
(8 4009 100)
(8 3009 000)
(9501 600)
(1 3001 900)
(1 7002 400)
(1 9002 700)
(2 1002 400)
(2 1002 500)
(2 1002 400)
(360490)
(350410)
(320370)
(290330)
(260290)
(250280)
(240280)
(360590)
(480590)
(510640)
(540680)
(570720)
(580730)
(590740)
(350380)
(530590)
(600680)
(520600)
(410470)
(380440)
(350400)
(2 5003 200)
(2 8003 400)
(3 2003 700)
(3 3003 900)
(3 3003 800)
(3 2003 700)
(3 2003 700)
(2 0002 800)
(1 9002 500)
(1 8002 300)
(1 7002 000)
(1 6001 900)
(1 5001 800)
(1 5001 800)
RATEa
147
148
148
142
130
128
125
245
276
311
310
276
271
262
59
49
41
34
30
29
28
123
123
118
113
109
109
109
43
65
74
64
49
46
42
217
217
218
212
197
193
189
159
137
120
106
96
94
92
(135159)
(139157)
(140157)
(135150)
(125135)
(123133)
(120130)
(188310)
(227330)
(256371)
(263361)
(256296)
(249293)
(242283)
(5068)
(4653)
(3844)
(3237)
(2832)
(2730)
(2629)
(95154)
(110137)
(104132)
(100126)
(97123)
(97122)
(97122)
(4145)
(6269)
(6978)
(6068)
(4653)
(4349)
(3945)
(191245)
(197238)
(202235)
(196228)
(182211)
(179207)
(176203)
(133187)
(119157)
(107134)
(96116)
(88105)
(86102)
(84100)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
350
710
1 100
1 200
1 100
1 100
1 100
290
560
850
960
900
880
870
30
44
45
33
34
31
37
3
4.9
6.9
8
8.6
9.1
8.7
2.7
4.6
12
21
24
19
23
25
90
160
170
150
140
140
3.3
14
23
32
33
33
36
(310410)
(640790)
(9901 200)
(1 1001 300)
(1 1001 200)
(1 0001 200)
(1 0001 200)
(240340)
(490630)
(740960)
(8501 100)
(830980)
(810960)
(800950)
(2437)
(3751)
(3852)
(3036)
(3037)
(2834)
(3440)
(2.53.5)
(4.25.8)
(5.97.9)
(6.99.2)
(7.49.9)
(7.910)
(7.69.9)
(2.62.8)
(4.25.1)
(1013)
(1924)
(2126)
(1721)
(2025)
(2228)
(72110)
(130190)
(140200)
(120180)
(120170)
(120170)
(2.73.9)
(1117)
(1927)
(2637)
(2839)
(2839)
(3142)
RATEa
6.7
12
18
19
17
16
16
57
96
129
130
110
105
102
4.2
5.6
5.3
3.8
3.7
3.3
3.9
0.8
1.1
1.4
1.5
1.5
1.5
1.4
0.3
0.5
1.3
2.4
2.6
2.1
2.5
1.9
6.2
10
10
8.4
8
7.7
0.2
0.9
1.4
1.8
1.9
1.8
2
(5.87.7)
(1114)
(1620)
(1721)
(1618)
(1517)
(1517)
(4867)
(84109)
(113147)
(115145)
(101119)
(97114)
(93111)
(3.35.2)
(4.86.5)
(4.66.2)
(3.44.1)
(3.34.0)
(3.03.6)
(3.64.2)
(0.650.93)
(0.961.3)
(1.21.6)
(1.31.7)
(1.31.7)
(1.31.7)
(1.31.6)
(0.310.34)
(0.490.59)
(1.21.5)
(2.12.7)
(2.33.0)
(1.92.3)
(2.22.8)
(1.72.1)
(5.07.5)
(8.512)
(8.412)
(7.010)
(6.79.5)
(6.49.1)
(0.180.26)
(0.691.0)
(1.11.6)
(1.52.1)
(1.52.2)
(1.52.2)
(1.72.3)
NOTIFIED NEW AND RELAPSE

NUMBER
3 740 193
3 400 234
3 746 673
5 130 170
5 803 251
5 763 310
5 772 224
418 520
504 377
792 911
1 186 801
1 380 577
1 380 294
1 367 193
231 186
258 188
238 580
228 018
201 608
214 045
218 328
234 620
121 745
141 748
287 158
411 172
409 834
411 587
242 429
289 874
372 921
364 961
328 862
309 727
285 789
1 719 365
1 401 096
1 414 228
1 789 186
2 124 371
2 123 119
2 138 688
894 073
824 954
786 285
1 274 046
1 356 661
1 326 291
1 350 639
CASE DETECTION
RATEa
PERCENT
71
60
61
79
85
84
83
83
87
121
160
169
165
159
32
33
29
26
22
23
23
62
28
29
53
70
69
68
29
34
43
41
37
35
32
131
97
90
106
119
117
117
59
51
47
73
76
74
75
48
40
41
56
66
66
67
34
31
39
52
61
61
61
54
68
70
75
73
80
84
50
23
25
47
64
63
62
67
52
58
65
75
76
76
60
45
41
50
61
61
62
37
37
39
69
79
79
81
(4552)
(3843)
(3944)
(5359)
(6368)
(6368)
(6469)
(2744)
(2638)
(3347)
(4461)
(5766)
(5666)
(5666)
(4764)
(6373)
(6575)
(7080)
(6978)
(7586)
(7990)
(4065)
(2126)
(2228)
(4254)
(5773)
(5671)
(5570)
(6470)
(4954)
(5562)
(6170)
(7080)
(7181)
(7181)
(5368)
(4149)
(3844)
(4654)
(5665)
(5766)
(5866)
(3245)
(3343)
(3543)
(6376)
(7287)
(7286)
(7589)
7$%/($&DVHQRWLILFDWLRQV
YEAR
Global
71
83
83
159
32
23
62
68
Africa
The Americas
Eastern
Mediterranean
Europe
29
32
131
117
59
75
South-East
Asia
Western
Pacific
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
3 740 193
3 400 234
3 746 673
5 130 170
5 803 251
5 763 310
5 772 224
418 520
504 377
792 911
1 186 801
1 380 577
1 380 294
1 367 193
231 186
258 188
238 580
228 018
201 608
214 045
218 328
234 620
121 745
141 748
287 158
411 172
409 834
411 587
242 429
289 874
372 921
364 961
328 862
309 727
285 789
1 719 365
1 401 096
1 414 228
1 789 186
2 124 371
2 123 119
2 138 688
894 073
824 954
786 285
1 274 046
1 356 661
1 326 291
1 350 639
NEW CASES
% SMEARSMEAR- SMEAR-NEGATIVE/
EXTRARE-TREAT EXCL. TOTAL
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
RETREAT UNKNOWN NEW PULM
30 046
1 175 290
1 540 688
2 413 708
2 662 591
2 655 557
2 627 059
24 064
212 910
367 831
550 004
607 257
601 149
605 929
1 542
138 932
131 294
124 840
110 614
116 994
121 572
1 587
46 851
60 959
113 765
168 013
168 627
170 748
0
104 444
94 442
96 121
100 493
91 324
82 641
2 769
357 882
510 053
857 371
1 028 656
1 047 013
1 067 367
84
314 271
376 109
671 607
647 558
630 450
578 802
22 393
1 811 850
1 614 748
1 722 281
2 010 641
2 002 463
2 033 911
6 137
191 477
221 715
364 785
473 217
477 516
467 069
516
72 312
60 392
56 056
45 034
52 265
51 089
12 394
51 823
34 289
102 274
143 633
137 301
135 388
0
146 592
208 147
157 237
152 468
145 140
132 474
3 241
939 945
741 471
594 185
636 755
615 463
598 800
105
409 701
348 734
447 744
559 534
574 778
649 091
4 237
262 728
399 578
686 525
831 391
806 373
815 756
2 067
72 689
141 156
208 979
244 806
247 020
240 843
723
32 991
32 037
33 285
31 422
32 240
34 235
754
33 382
40 754
64 612
87 726
92 070
93 605
0
29 866
35 081
49 747
47 202
40 951
43 912
656
76 865
120 708
242 332
329 338
328 421
333 993
37
16 935
29 842
87 570
90 897
65 671
69 168
0
5
37
8 111
9 998
12 951
11 913
0
0
0
2 941
346
642
1 069
0
5
37
3 685
4 363
2 133
1 364
0
0
0
12
76
633
623
0
0
0
0
3 393
8 008
3 272
0
0
0
1 439
1 796
1 508
2 878
0
0
0
34
24
27
2 707
734
59 240
115 314
259 937
288 630
285 966
283 585
554
15 133
19 153
60 092
54 951
53 967
52 283
180
1 723
10 834
10 152
10 175
10 413
10 068
0
2 407
5 568
6 495
11 724
11 203
11 223
0
7 927
21 607
22 248
25 306
24 304
23 490
0
5 546
27 095
93 859
127 826
130 714
135 650
0
26 504
31 057
67 091
58 648
55 365
50 871
49
0
236 074
406 355
385 232
418 071
418 016
49
0
68 085
66 449
89 377
94 506
74 624
0
0
14 344
12 481
11 317
12 133
11 694
0
0
0
5 334
6 240
8 713
10 102
0
0
19 127
64 831
41 884
60 736
72 722
0
0
80 444
158 215
203 598
208 542
215 554
0
0
54 074
99 045
32 816
33 441
33 320
783
59 240
351 388
666 292
673 862
704 037
701 601
603
15 133
87 238
126 541
144 328
148 473
126 907
180
1 723
25 178
22 633
21 492
22 546
21 762
0
2 407
5 568
11 829
17 964
19 916
21 325
0
7 927
40 734
87 079
67 190
85 040
96 212
0
5 546
107 539
252 074
331 424
339 256
351 204
0
26 504
85 131
166 136
91 464
88 806
84 191
29
44
229
18 172
36 641
28 846
39 409
0
0
0
2 075
305
317
18 951
29
44
56
2 106
3 829
885
3 165
0
0
0
20
737
3 079
4 132
0
0
173
3 663
24 937
18 527
5 501
0
0
0
202
261
1 118
3 885
0
0
0
10 106
6 572
4 920
3 775
57
39
49
58
57
57
56
80
53
62
60
56
56
56
75
66
68
69
71
69
70
11
47
64
53
54
55
56
NEW AND RELAPSE

NOTIFICATION RATEa
19902011
42
31
38
40
39
38
46
28
41
59
62
63
64
44
43
52
60
54
52
47
143
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV
% OF COHORT
TREATMENT SUCCESS (%)a
19952010
Global
57
87
60
82
50
75
79
88
67
67
33
88
80
93
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
1 175 290
1 540 688
2 413 708
2 656 276
2 662 591
2 655 557
212 910
367 831
550 004
595 394
607 257
601 149
138 932
131 294
124 840
119 863
110 614
116 994
46 851
60 959
113 765
166 558
168 013
168 627
104 444
94 442
96 121
105 160
100 493
91 324
357 882
510 053
857 371
1 007 382
1 028 656
1 047 013
314 271
376 109
671 607
661 919
647 558
630 450
SIZE OF
COHORT
1 000 581
1 452 991
2 396 387
2 648 749
2 664 704
2 694 992
177 567
364 804
563 750
590 866
605 932
634 962
128 531
110 642
118 840
109 007
122 534
126 450
46 318
63 749
113 742
166 719
167 317
169 872
33 823
41 480
81 410
114 234
105 441
96 051
318 410
512 286
855 962
1 011 353
1 022 380
1 045 179
295 932
360 030
662 683
656 570
641 100
622 478
COHORT AS
% NOTIFIED
CURED
COMPLETED
85
94
99
100
100
101
83
99
102
99
100
106
93
84
95
91
111
108
99
105
100
100
100
101
32
44
85
109
105
105
89
100
100
100
99
100
94
96
99
99
99
99
40
60
77
79
80
79
46
59
62
70
70
68
37
60
55
56
53
53
60
69
72
74
74
74
58
47
59
54
56
54
9
44
83
84
85
85
67
85
89
89
90
90
17
9
7
7
7
8
14
12
13
11
10
13
14
17
24
21
23
22
19
12
11
13
14
14
10
28
13
15
13
13
23
6
4
4
3
4
13
5
3
3
3
3
DIED
3
4
4
4
4
4
6
7
7
6
5
5
3
5
5
5
5
5
2
4
3
2
3
2
6
5
8
8
8
8
1
2
4
4
4
4
2
2
2
2
2
2
FAILED
DEFAULTED
NOT
EVALUATED
1
1
2
2
2
2
2
1
1
2
1
1
1
1
1
1
1
1
3
2
1
1
1
1
6
6
7
10
12
12
0
1
2
2
2
2
1
1
1
1
1
1
5
7
5
5
4
4
12
11
9
7
6
6
6
8
7
7
8
8
13
8
8
5
5
5
4
6
7
6
6
6
2
7
6
5
5
5
4
2
1
1
1
1
34
19
4
4
4
3
20
10
7
6
7
6
39
11
9
10
11
11
4
6
5
4
3
3
16
7
5
6
5
7
64
40
1
1
1
1
13
4
3
4
3
3
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV
% OF COHORT
TREATMENT SUCCESS (%)a
19952010
Global
86
69
69
54
72
49
75
75
40
51
68
75
90
86
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
144
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
COHORT AS
% NOTIFIED
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
59 240
351 388
666 292
776 099
673 862
704 037
15 133
87 238
126 541
136 263
144 328
148 473
1 723
25 178
22 633
23 201
21 492
22 546
2 407
5 568
11 829
16 441
17 964
19 916
7 927
40 734
87 079
135 384
67 190
85 040
5 546
107 539
252 074
332 296
331 424
339 256
26 504
85 131
166 136
132 514
91 464
88 806
71 395
188 509
546 182
594 939
594 019
603 489
5 756
44 147
114 838
98 414
94 342
113 405
1 104
15 302
18 603
15 483
19 158
17 499
1 860
4 217
12 860
14 990
16 332
18 326
480
10 739
39 497
60 077
58 966
48 292
3 271
59 337
254 378
323 436
332 286
338 748
58 924
54 767
106 006
82 539
72 935
67 219
121
54
82
77
88
86
38
51
91
72
65
76
64
61
82
67
89
78
77
76
109
91
91
92
6
26
45
44
88
57
59
55
101
97
100
100
222
64
64
62
80
76
82
60
51
50
49
47
57
47
35
48
50
41
61
47
38
29
29
26
61
51
60
57
56
54
20
39
32
30
27
26
62
57
49
47
48
47
88
83
81
80
79
79
4
10
19
22
23
22
12
11
27
21
20
13
11
8
16
23
22
23
14
11
15
19
21
21
20
19
18
18
22
24
6
14
22
28
27
28
2
3
6
6
7
7
3
6
7
7
7
6
9
9
11
9
9
6
6
5
6
8
8
7
3
6
5
4
4
4
11
9
11
11
11
10
4
6
7
7
7
7
3
2
3
3
3
3
3
4
4
5
6
4
3
3
3
3
3
3
4
3
2
2
3
2
4
7
4
3
3
3
8
14
13
20
22
15
5
5
5
4
4
4
3
2
3
2
2
2
3
11
12
11
10
10
12
16
13
10
9
7
11
12
15
20
19
20
12
15
10
11
10
10
32
11
14
12
11
10
15
15
15
12
12
12
1
1
2
2
2
2
4
10
6
5
5
10
6
14
12
9
10
31
8
25
21
17
21
21
5
11
6
6
6
8
8
8
10
9
7
14
8
3
2
2
2
2
3
9
6
7
7
7
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37
Global
40
11
69
35
53
11
40
54
32
25
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
8
28
33
40
11
56
60
69
35
50
53
53
1
11
11
11
40
71
53
54
2
14
23
32
2
12
20
25
463 027
1 736 632
2 074 510
2 468 364
140 713
816 338
888 765
1 001 512
84 032
107 980
121 421
124 576
2 582
45 408
44 596
44 973
171 248
280 985
206 391
195 306
31 847
318 237
546 350
750 315
32 605
167 684
266 987
351 682
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
5 554 697
6 225 124
6 210 227
6 229 649
1 255 325
1 470 259
1 475 117
1 460 768
242 605
216 754
227 063
233 187
292 512
418 149
421 626
425 821
433 455
395 683
388 990
364 012
1 947 603
2 328 230
2 332 779
2 358 127
1 383 197
1 396 049
1 364 652
1 387 734
NUMBER OF
HIV-POSITIVE
TB PATIENTS
% OF TESTED
TB PATIENTS
HIV-POSITIVE
103 683
463 826
493 138
562 026
73 332
370 245
394 332
458 657
14 232
18 143
19 615
20 906
330
1 625
1 360
1 781
6 543
13 496
12 810
12 583
7 025
46 089
52 519
54 314
2 221
14 228
12 502
13 785
% OF HIV% OF HIVNUMBER OF
POSITIVE TB POSITIVE TB HIV-POSITIVE
PATIENTS ON PATIENTS ON
PEOPLE
CPT
ART
PROVIDED IPT
22
27
24
23
52
45
44
46
17
17
16
17
13
4
3
4
3
5
6
6
22
14
10
7
7
8
5
4
76
77
81
79
78
77
81
79
10
36
50
43
18
41
50
59
25
54
58
59
50
86
86
89
31
64
55
71
35
39
46
48
29
36
44
46
81
61
63
64
16
41
44
48
16
60
61
44
31
50
56
59
33
16
41
47
25 938
89 083
204 802
446 598
22 211
63 290
182 524
438 121
3 727
5 390
12 906
1 705
0
464
253
52
0
17 826
6 575
4 565
0
467
581
368
0
1 646
1 963
1 787
% OF TB PATIENTS WITH
YEAR
KNOWN HIV STATUS
20052011
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%
YEAR
TOTAL
CONFIRMED
CASES OF
a
MDR-TB
Global
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
a
b
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
11988
46897
54987
61690
2445
10741
9340
12384
4427
2884
2661
3474
350
496
886
841
4347
28157
33863
33984
68
2560
3942
6615
351
2059
4295
4392
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
310 000 (220 000400 000) 170 000 (98 000240 000)
45 000 (7 90082 000)
31 000 (1 10067 000)
5 900 (3 4008 400)
3 500 (1 4005 700)
17 000 (038 000)
10 000 (31032 000)
76 000 (64 00087 000)
33 000 (22 00044 000)
89 000 (76 000100 000)
35 000 (30 00042 000)
78 000 (60 00095 000)
59 000 (42 00075 000)
NUMBER OF
% OF
BACT+VEb
TESTED FOR
MDR-TB
72870
111226
119428
127537
1826
3878
2732
1311
14568
11638
11309
13334
1442
1760
2397
2264
34527
87815
89841
84140
661
950
1073
1204
19846
5185
12076
25284
BACT+VEb
TESTED FOR
MDR-TB
2.9
4
4
4.3
0.32
0.61
0.36
0.18
11
9.2
8.6
10
1.3
0.97
1.4
1.2
27
66
69
66
<0.1
<0.1
0.1
0.1
2.9
0.76
1.7
4.1
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
140 000 (92 000180 000)
14 000 (4 30023 000)
2 400 (9803 800)
6 400 (1 50011 000)
43 000 (38 00047 000)
54 000 (42 00066 000)
19 000 (15 00022 000)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
24002
3.6
42307
6.3
47584
6.8
47568
6.8
3922
3.1
4340
3
4294
2.9
3707
2.9
11003
49
3069
14
4234
19
4234
19
94
0.79
1274
7.1
1257
6.3
1466
6.9
7024
8.1
27618
41
34491
41
31095
32
420
0.17
5069
1.5
1264
0.37
1935
0.55
1539
0.93
937
1
2044
2.3
5131
6.1
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
BACT+VE = bacteriologically-positive cases.
145
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[
MALE
Global
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
146
FEMALE
YEAR
014
1524
2534
3544
4554
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
7 491
12 387
18 415
20 239
19 689
2 910
3 625
7 635
8 393
8 551
437
3 464
1 520
1 050
1 103
2 010
1 339
1 546
2 316
1 924
553
201
299
156
152
165
2 453
5 064
6 737
6 490
1 416
1 305
2 351
1 587
1 469
48 816
115 250
242 356
268 884
265 246
16 754
29 522
54 066
57 146
59 072
2 888
18 564
16 410
11 461
12 436
6 796
8 135
13 558
19 526
19 630
3 588
4 636
6 170
7 319
6 279
3 179
30 093
94 638
114 806
114 254
15 611
24 300
57 514
58 626
53 575
76 799
172 896
329 720
345 937
349 403
28 172
47 654
94 388
98 636
105 549
3 443
21 869
16 671
14 267
15 023
8 673
9 002
14 609
19 993
20 303
7 046
8 322
9 151
13 259
13 304
6 467
45 720
120 560
136 683
136 142
22 998
40 329
74 341
63 099
59 082
65 678
156 274
312 526
336 981
333 327
20 240
34 435
71 072
78 660
81 247
3 157
19 787
14 369
11 332
11 704
5 475
6 525
10 798
14 908
14 984
10 157
9 862
9 150
12 447
13 033
6 508
47 107
122 256
142 080
141 636
20 141
38 558
84 881
77 554
70 723
49 514
121 277
261 233
298 715
300 208
12 017
17 923
40 974
48 543
49 967
2 448
15 138
12 340
10 627
11 234
3 731
4 409
8 729
13 086
13 857
7 625
8 065
8 704
12 270
12 508
5 241
38 058
107 228
132 411
135 592
18 452
37 684
83 258
81 778
77 050
65+
UNKNOWN
41 756 34 776
82 844 75 156
184 836 166 858
227 530 186 815
229 464 183 477
7 008
4 104
8 970
5 751
18 931 12 143
24 094 14 478
24 393 14 732
1 866
2 251
9 899
9 717
7 801
7 951
7 433
7 084
7 709
7 198
3 732
2 604
2 990
3 036
6 581
5 595
10 596
9 521
11 049
9 871
5 716
4 842
4 313
3 321
4 443
4 089
6 916
4 125
7 277
4 024
4 682
3 523
25 080 16 208
74 084 45 533
101 728 67 131
106 420 72 264
18 752 17 452
31 592 37 123
72 996 91 547
76 763 84 476
72 616 75 388
0
0
42
7 502
575
0
0
0
17
516
0
0
0
59
56
0
0
0
0
0
0
0
42
7 423
3
0
0
0
0
0
0
0
0
3
0
5564
4554
5564
65+
UNKNOWN
7 730 41 378 50 102 32 741 22 688

14 749 94 641 110 306 74 705 49 823
26 178 199 700 220 530 153 503 106 029
28 825 210 729 225 986 163 260 118 565
28 124 209 651 224 345 162 737 119 546
3 167 15 873 19 005 11 339
6 643
4 315 29 530 35 386 20 037
9 402
10 023 57 115 75 056 43 213 22 855
10 287 55 537 76 051 47 070 26 299
10 632 57 027 76 968 47 873 26 401
431
2 293
2 434
1 654
1 109
3 535 15 305 14 961 10 323
7 294
1 718 12 405 11 563
7 891
5 933
1 137
8 405
8 496
5 818
4 880
1 241
8 517
8 766
5 875
4 973
1 881
5 035
5 797
3 679
3 047
1 711
6 710
5 780
3 922
2 851
2 766 13 529 12 098
8 386
6 245
4 377 21 108 17 151 12 183
9 776
3 839 21 322 17 214 12 380 10 060
548
2 906
3 636
2 594
1 549
290
3 506
4 405
2 945
1 798
422
4 667
5 101
3 161
2 242
301
4 958
6 559
4 218
3 051
248
4 564
6 560
4 360
3 097
250
2 187
2 834
2 404
2 003
3 222 21 518 25 653 19 241 13 019
8 591 71 923 76 779 54 000 37 709
10 923 84 006 84 704 63 272 48 470
10 654 85 376 84 383 64 868 50 920
1 453 13 084 16 396 11 071
8 337
1 676 18 072 24 121 18 237 15 459
2 658 40 061 39 933 36 852 31 045
1 800 36 715 33 025 30 699 26 089
1 510 32 845 30 454 27 381 24 095
17 816
33 696
72 022
86 264
87 605
3 655
4 581
11 047
13 522
13 543
912
5 038
3 788
3 467
3 690
2 742
2 039
4 383
7 532
7 770
1 560
1 243
1 336
2 033
2 229
1 866
8 142
24 289
34 052
36 755
7 081
12 653
27 179
25 658
23 618
16 686
33 829
65 717
75 368
73 843
1 734
2 578
7 163
8 685
8 843
1 311
5 894
4 751
4 068
4 243
1 902
1 893
3 399
7 032
6 432
3 289
2 490
3 176
3 398
3 532
1 480
5 468
12 975
20 004
21 593
6 970
15 506
34 253
32 181
29 200
0
0
15
2 601
311
0
0
0
9
301
0
0
0
22
9
0
0
0
0
0
0
0
15
2 567
1
0
0
0
0
0
0
0
0
3
0
014
1524
2534
3544
MALE:FEMALE
RATIO
1.7
1.8
1.8
1.9
1.9
1.5
1.4
1.3
1.4
1.4
1.6
1.6
1.6
1.7
1.8
1.4
1.4
1.2
1.1
1.2
2.5
2.3
2.1
2.4
2.3
2.3
2.1
2.0
2.0
2.0
1.8
2.0
2.2
2.4
2.4
AFRICAN REGION
149
152
155
158
161
164
166
168
Table A4.9 Laboratories, NTP services, drug management and infection control, 2011
170

details.
Data source
Country notes
South Africa
Treatment outcomes in Table A4.5 for 2010 are based on incomplete data.
148
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African
Republic
Chad
Comoros
Congo
Cte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
Eritrea
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
25
28
31
33
35
35
36
10
12
14
16
19
19
20
5
6
7
8
9
9
9
1
2
2
2
2
2
2
9
11
12
14
16
16
17
6
6
6
7
8
8
9
12
14
16
18
19
20
20
<1
<1
<1
<1
<1
<1
<1
3
3
4
4
4
4
4
6
7
8
10
11
11
12
<1
<1
<1
<1
<1
<1
<1
2
3
3
4
4
4
4
13
15
17
18
19
20
20
36
44
50
57
64
66
68
<1
<1
<1
<1
<1
<1
<1
3
3
4
4
5
5
5
NUMBER
(THOUSANDS)
2.5
2.6
4
4.5
4.4
4.7
4.8
3.7
5.5
5.1
3.7
5
5.7
7.3
0.91
0.88
0.88
0.8
0.8
0.81
0.83
1.1
1.2
0.95
0.67
0.52
0.5
0.49
1.3
1.5
1.5
1.5
1.5
1.5
1.5
1.3
2.9
2.5
2
1.7
1.6
1.6
2.3
5.7
7.9
7
6.1
6.2
5.9
0.12
0.13
0.15
0.15
0.13
0.13
0.12
3.5
5.1
5.2
3.9
2.8
2.6
2.4
0.85
1.5
1.9
2.2
2.3
2.2
2.1
0.045
0.04
0.038
0.048
0.048
0.048
0.048
0.7
0.82
1.1
1.7
1.7
1.8
1.8
4.9
8.4
9.2
6.8
5.2
4.8
4.8
27
29
30
31
34
35
36
0.076
0.1
0.1
0.077
0.073
0.08
0.075
0.38
0.31
0.28
0.26
0.26
0.26
0.26
(0.9304.9)
(0.8905.2)
(1.57.8)
(1.78.8)
(1.68.7)
(1.79.2)
(1.89.3)
(1.27.6)
(2.210)
(2.29.3)
(1.37.4)
(2.09.2)
(2.510)
(3.313)
(0.3701.7)
(0.3701.6)
(0.3701.6)
(0.3501.4)
(0.3501.4)
(0.3601.4)
(0.3701.5)
(0.2102.6)
(0.4002.4)
(0.3901.8)
(0.3101.2)
(0.2500.900)
(0.2400.850)
(0.2300.830)
(0.4902.4)
(0.5602.8)
(0.6102.9)
(0.6402.8)
(0.6602.7)
(0.6502.7)
(0.6502.6)
(0.5602.2)
(1.15.4)
(1.04.6)
(0.8803.7)
(0.7602.9)
(0.7502.9)
(0.7402.8)
(0.9804.1)
(2.211)
(3.015)
(2.813)
(2.611)
(2.611)
(2.511)
(0.0400.250)
(0.0550.250)
(0.0580.270)
(0.0630.280)
(0.0550.240)
(0.0540.230)
(0.0520.220)
(1.36.9)
(1.910)
(1.910)
(1.57.6)
(1.15.2)
(1.04.8)
(0.9804.4)
(0.3701.5)
(0.6102.9)
(0.7803.6)
(0.9104.1)
(0.9604.1)
(0.9403.9)
(0.9103.7)
(0.0190.080)
(0.0180.072)
(0.0170.069)
(0.0200.088)
(0.0200.086)
(0.0200.087)
(0.0210.088)
(0.2201.4)
(0.3401.5)
(0.4902.0)
(0.7103.0)
(0.7503.1)
(0.7603.2)
(0.7703.2)
(2.09.2)
(3.316)
(3.617)
(2.912)
(2.49.3)
(2.28.4)
(2.28.5)
(1051)
(1255)
(1255)
(1355)
(1560)
(1562)
(1665)
(00.540)
(00.740)
(00.740)
(00.500)
(00.440)
(00.490)
(<0.010.430)
(0.2500.530)
(0.2100.440)
(0.1900.390)
(0.1800.370)
(0.1700.360)
(0.1700.360)
(0.1700.360)
RATEa
9.9
9.2
13
14
13
13
13
35
46
37
22
27
30
37
19
16
13
11
9.3
9.1
9.2
77
74
54
36
26
25
24
14
14
13
11
9.5
9.1
8.7
23
48
39
28
20
20
19
19
41
50
40
32
32
29
35
34
33
32
27
26
24
121
154
142
98
65
59
53
14
22
24
23
21
19
18
10
8.1
6.8
7.5
6.6
6.5
6.4
29
30
35
47
44
44
43
39
57
55
38
27
24
24
73
66
60
54
53
53
54
20
23
20
13
11
11
10
12
9.7
7.7
5.9
5
4.9
4.7
(3.719)
(3.118)
(4.826)
(5.027)
(4.525)
(4.826)
(4.926)
(1173)
(1985)
(1667)
(7.945)
(1149)
(1354)
(1766)
(7.835)
(6.529)
(5.725)
(4.619)
(4.117)
(4.016)
(4.016)
(15189)
(25149)
(22100)
(1762)
(1345)
(1242)
(1141)
(5.226)
(5.326)
(5.024)
(4.520)
(4.117)
(4.016)
(3.815)
(1040)
(1989)
(1672)
(1250)
(9.336)
(9.034)
(8.633)
(8.033)
(1679)
(1997)
(1674)
(1358)
(1358)
(1353)
(1171)
(1463)
(1362)
(1360)
(1149)
(1147)
(1044)
(45234)
(56300)
(52275)
(37189)
(26121)
(24109)
(2298)
(6.126)
(8.741)
(9.544)
(9.342)
(8.838)
(8.435)
(7.932)
(4.418)
(3.515)
(3.012)
(3.114)
(2.812)
(2.812)
(2.712)
(9.360)
(1255)
(1662)
(2084)
(1980)
(1979)
(1977)
(1673)
(23108)
(22104)
(1669)
(1248)
(1142)
(1142)
(28139)
(26125)
(25111)
(2396)
(2394)
(2395)
(2496)
(0145)
(0168)
(0143)
(082)
(065)
(070)
(060)
(7.917)
(6.414)
(5.111)
(3.98.3)
(3.47.1)
(3.26.9)
(3.16.6)

NUMBER
(THOUSANDS)
26
28
41
47
47
49
50
35
49
51
50
63
69
81
8.4
8.2
8.3
8.1
8.4
8.5
8.8
10
13
13
10
8.4
7.8
7.3
11
13
13
14
14
14
14
12
26
23
20
17
17
16
22
48
68
67
62
63
60
1.1
1.2
1.3
1.4
1.2
1.2
1.1
30
44
45
35
26
24
23
8.3
14
18
21
22
22
22
0.42
0.38
0.37
0.43
0.43
0.44
0.45
5.9
8.2
13
18
19
19
20
43
74
82
65
53
50
50
220
250
270
290
320
330
350
1.7
2.3
2.4
1.9
1.9
2
1.9
15
12
7
8.1
8.3
8.3
8.2
(1049)
(1155)
(1678)
(1988)
(1889)
(1992)
(2093)
(1270)
(2384)
(2586)
(2095)
(27110)
(31120)
(38140)
(4.214)
(4.114)
(4.214)
(4.014)
(4.114)
(4.114)
(4.315)
(2.325)
(5.723)
(6.721)
(5.617)
(4.413)
(4.213)
(4.012)
(5.319)
(6.122)
(6.523)
(7.023)
(7.424)
(7.324)
(7.424)
(6.620)
(1343)
(1238)
(1032)
(8.927)
(8.727)
(8.627)
(1137)
(2284)
(32120)
(34110)
(32100)
(33100)
(3198)
(0.4002.1)
(0.5702.0)
(0.6102.2)
(0.6502.3)
(0.6002.0)
(0.5902.0)
(0.5601.9)
(1452)
(2077)
(2179)
(1659)
(1343)
(1241)
(1238)
(4.214)
(6.623)
(8.830)
(1034)
(1137)
(1137)
(1136)
(0.2000.710)
(0.1800.660)
(0.1800.630)
(0.2100.740)
(0.2100.740)
(0.2100.750)
(0.2200.760)
(2.311)
(4.214)
(6.421)
(9.030)
(9.532)
(9.633)
(9.733)
(2172)
(37130)
(41140)
(34110)
(2886)
(2682)
(2682)
(100390)
(120440)
(130450)
(150480)
(170530)
(170550)
(180570)
(0.8502.9)
(1.14.0)
(1.24.1)
(0.9703.1)
(0.9803.0)
(1.13.3)
(1.03.1)
(5.928)
(3.825)
(2.015)
(3.016)
(3.216)
(3.216)
(3.116)
RATEa
102
100
136
143
134
138
139
342
404
366
305
340
361
413
176
146
128
106
97
96
96
757
813
724
560
422
389
360
117
118
109
98
90
87
85
223
422
368
271
206
199
192
178
345
433
381
323
321
299
313
302
291
286
247
241
230
1 020
1 330
1 220
859
601
553
510
138
194
216
211
204
198
191
95
78
66
67
61
60
60
246
299
403
513
484
480
473
345
506
493
359
276
253
250
616
576
543
507
503
506
512
463
527
465
307
272
288
267
478
375
190
182
164
159
151
(41192)
(37193)
(54254)
(57268)
(53254)
(55259)
(55260)
(119680)
(194690)
(180617)
(120574)
(147613)
(165632)
(195712)
(89293)
(73244)
(64214)
(52178)
(48165)
(46163)
(47163)
(1681 780)
(3571 450)
(3821 170)
(298901)
(224681)
(209624)
(196574)
(56200)
(57201)
(53186)
(49164)
(46149)
(44144)
(43141)
(119359)
(209710)
(190604)
(143439)
(109334)
(104323)
(100313)
(88300)
(159602)
(202749)
(193633)
(169527)
(168522)
(155490)
(114609)
(145513)
(139498)
(137489)
(121416)
(119405)
(113387)
(4721 780)
(6102 320)
(5662 130)
(4081 480)
(3001 010)
(277922)
(259844)
(69229)
(95329)
(107363)
(106353)
(104338)
(100327)
(97316)
(46161)
(37133)
(31112)
(33115)
(29104)
(29102)
(29101)
(95469)
(152495)
(205665)
(256858)
(242809)
(238806)
(235794)
(170579)
(249853)
(244828)
(187585)
(146447)
(131414)
(131407)
(2811 080)
(274987)
(267914)
(259838)
(258828)
(259834)
(263842)
(227780)
(257893)
(231780)
(160502)
(144440)
(152466)
(140435)
(188902)
(117781)
(54410)
(68351)
(62313)
(60304)
(57291)

NUMBER
(THOUSANDS)
17
19
27
30
31
32
32
21
27
35
45
55
58
61
6.1
5.6
5.6
5.6
6
6.1
6.3
7.4
14
16
14
11
10
9.2
8.1
8.8
8.8
8.9
9.5
9.5
9.7
9.1
20
18
14
12
12
12
14
29
49
55
51
54
49
0.61
0.66
0.7
0.72
0.73
0.73
0.73
25
40
40
28
20
19
18
5.7
9
12
15
17
17
17
0.24
0.23
0.22
0.23
0.24
0.25
0.26
4
6.7
11
15
16
16
16
30
56
61
48
41
38
38
120
140
160
190
210
220
220
0.9
1.2
1.4
1.3
1.4
1.5
1.5
7.7
6.4
5.8
5.4
5.3
5.3
5.2
(1222)
(1425)
(1935)
(2240)
(2341)
(2342)
(2442)
(1331)
(2233)
(2842)
(3754)
(4665)
(4968)
(5171)
(5.17.3)
(4.76.7)
(4.66.7)
(4.66.7)
(5.07.1)
(5.07.2)
(5.27.5)
(2.914)
(8.819)
(1320)
(1315)
(9.612)
(9.011)
(8.310)
(6.99.4)
(7.510)
(7.410)
(7.510)
(8.111)
(8.111)
(8.211)
(8.010)
(1722)
(1621)
(1316)
(1114)
(1114)
(1013)
(1116)
(2434)
(4058)
(4565)
(4261)
(4464)
(4058)
(0.3800.900)
(0.5400.800)
(0.5700.840)
(0.5900.870)
(0.6000.870)
(0.6000.870)
(0.6000.870)
(2130)
(3348)
(3347)
(2333)
(1724)
(1623)
(1521)
(4.76.8)
(7.411)
(1015)
(1217)
(1420)
(1420)
(1421)
(0.1900.280)
(0.1900.270)
(0.1800.260)
(0.1900.280)
(0.2000.290)
(0.2000.290)
(0.2100.310)
(2.56.0)
(5.58.0)
(9.313)
(1218)
(1319)
(1319)
(1319)
(2634)
(4864)
(5370)
(4255)
(3647)
(3343)
(3344)
(95150)
(120170)
(140190)
(160220)
(180240)
(190250)
(190250)
(0.7901.0)
(1.11.4)
(1.21.6)
(1.11.4)
(1.21.6)
(1.31.7)
(1.31.6)
(5.111)
(4.28.9)
(3.88.1)
(3.67.6)
(3.57.4)
(3.57.4)
(3.57.4)
AFRICAN REGION

YEAR
RATEa
66
68
87
93
89
90
90
205
226
250
276
298
304
310
128
100
86
74
70
69
70
533
855
918
733
545
503
455
87
82
71
63
59
58
57
162
323
289
198
150
144
139
112
206
310
313
268
274
243
175
168
160
153
148
147
145
864
1 200
1 070
690
469
433
400
94
128
151
150
151
151
151
54
46
39
36
33
33
34
169
245
353
425
395
391
387
238
380
370
268
212
190
191
327
327
327
327
327
327
327
241
279
268
206
202
215
202
243
198
157
121
103
100
97
(4886)
(5089)
(64114)
(68121)
(65116)
(66118)
(66117)
(127303)
(185272)
(204300)
(227329)
(250349)
(256355)
(261362)
(106153)
(82119)
(71102)
(6188)
(5883)
(5782)
(5883)
(212997)
(5531 220)
(7361 120)
(667802)
(486608)
(449560)
(406507)
(74101)
(7096)
(6083)
(5373)
(5069)
(4967)
(4866)
(143183)
(284364)
(255326)
(174223)
(132169)
(127163)
(122157)
(92133)
(170246)
(255369)
(258373)
(221319)
(226327)
(200290)
(108259)
(137201)
(131193)
(125184)
(121177)
(121175)
(120173)
(7121 030)
(9901 430)
(8851 280)
(569823)
(387559)
(357516)
(330477)
(78112)
(106153)
(125180)
(124178)
(125180)
(125179)
(125179)
(4464)
(3855)
(3246)
(3043)
(2840)
(2840)
(2841)
(104250)
(200294)
(298412)
(347510)
(323474)
(320470)
(317465)
(206272)
(329434)
(321423)
(232306)
(184242)
(165217)
(165218)
(262398)
(268392)
(273385)
(279379)
(283374)
(282375)
(282375)
(211273)
(245316)
(235304)
(181234)
(177229)
(189244)
(177229)
(162341)
(132278)
(104220)
(80169)
(69145)
(67140)
(64136)
149
YEAR
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
150
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
48
57
66
74
81
83
85
<1
1
1
1
1
2
2
<1
1
1
2
2
2
2
15
17
19
22
24
24
25
6
8
8
9
10
10
10
1
1
1
1
1
2
2
23
27
31
36
39
41
42
2
2
2
2
2
2
2
2
2
3
3
4
4
4
11
13
15
18
20
21
21
9
10
11
13
14
15
15
9
10
11
13
15
15
16
2
2
3
3
3
3
4
1
1
1
1
1
1
1
14
16
18
21
23
23
24
1
2
2
2
2
2
2
NUMBER
(THOUSANDS)
24
27
27
21
17
16
15
0.37
0.62
0.99
1.1
0.86
0.76
0.69
0.35
0.44
0.48
0.61
0.77
0.82
0.88
4.8
4.6
4.5
3.6
2.7
2.2
1.9
3.5
4.1
3.7
3.1
2.6
2.5
2.4
0.21
0.25
0.39
0.37
0.42
0.45
0.38
6.5
3.9
6
8.5
7.7
8.2
9.2
0.35
0.27
0.3
0.3
0.32
0.34
0.38
0.75
1
1.5
1.5
1.8
1.9
1.9
13
11
10
10
9.9
9.9
9.9
3.3
3.5
3.3
2.5
2
1.9
1.9
1.2
1.3
1.3
1.4
1.4
1.4
1.4
0.29
0.83
1.4
2.1
2.6
2.8
2.9
0.028
0.016
0.01
0.012
0.013
0.013
0.013
11
13
11
9.8
9.9
12
11
0.074
0.15
0.46
0.47
0.37
0.35
0.33
(1436)
(1641)
(1641)
(1332)
(1224)
(1222)
(1120)
(0.1600.680)
(0.2501.2)
(0.3901.9)
(0.4302.0)
(0.3601.6)
(0.3301.4)
(0.3001.3)
(0.1100.710)
(0.1800.790)
(0.2100.860)
(0.2601.1)
(0.3301.4)
(0.3501.5)
(0.3701.6)
(1.111)
(1.49.9)
(1.59.0)
(1.46.8)
(1.34.7)
(1.13.8)
(0.8803.2)
(1.36.8)
(1.67.7)
(1.46.9)
(1.35.7)
(1.14.6)
(1.14.5)
(1.04.3)
(0.0610.450)
(0.1100.460)
(0.1700.700)
(0.1600.660)
(0.1800.760)
(0.2000.810)
(0.1600.680)
(2.712)
(1.86.7)
(2.910)
(4.214)
(4.013)
(4.213)
(4.715)
(0.1100.730)
(0.0980.530)
(0.1000.590)
(0.0750.690)
(0.1300.590)
(0.1400.610)
(0.1700.670)
(0.2401.6)
(0.4101.9)
(0.5902.8)
(0.6502.8)
(0.7903.3)
(0.8303.4)
(0.8203.4)
(4.825)
(4.320)
(4.219)
(4.218)
(4.218)
(4.218)
(4.218)
(1.26.3)
(1.46.5)
(1.36.1)
(1.04.6)
(0.9803.4)
(0.9403.3)
(0.9103.2)
(0.5402.2)
(0.5802.3)
(0.6102.3)
(0.6502.5)
(0.6702.4)
(0.6702.4)
(0.6802.4)
(<0.011.3)
(0.3601.5)
(0.5802.5)
(0.8203.9)
(1.05.0)
(1.15.3)
(1.15.6)
(0.0270.029)
(0.0160.017)
(0.0100.011)
(0.0120.012)
(0.0130.013)
(0.0130.013)
(0.0130.013)
(0.68037)
(2.233)
(2.625)
(2.921)
(3.619)
(4.223)
(4.022)
(0.0580.091)
(0.1100.180)
(0.3600.580)
(0.3600.590)
(0.2900.460)
(0.2800.430)
(0.2600.410)
RATEa
49
48
41
29
21
20
18
40
57
80
77
58
51
45
36
39
37
40
46
48
49
32
27
23
17
11
9.1
7.5
62
54
44
34
26
25
23
21
22
31
27
29
30
24
28
14
19
24
20
20
22
21
15
15
15
15
16
17
35
49
53
49
48
48
45
113
82
68
56
49
48
46
35
35
29
19
14
13
12
14
13
12
11
9.4
9.2
9
15
36
52
67
78
80
83
2.6
1.4
0.87
0.95
1
1
0.98
84
80
60
47
43
50
47
5.2
8.8
24
23
17
15
14
(2973)
(2872)
(2563)
(1744)
(1429)
(1426)
(1424)
(1774)
(23106)
(32151)
(31144)
(25106)
(2292)
(2082)
(1273)
(1670)
(1666)
(1773)
(1984)
(2087)
(2190)
(7.874)
(8.158)
(7.947)
(6.531)
(5.320)
(4.316)
(3.513)
(23118)
(21102)
(1783)
(1463)
(1147)
(1145)
(1042)
(6.044)
(9.540)
(1357)
(1248)
(1251)
(1354)
(1144)
(1151)
(6.624)
(9.233)
(1241)
(1032)
(1033)
(1136)
(6.644)
(5.529)
(5.330)
(3.633)
(6.028)
(6.628)
(7.731)
(1173)
(1992)
(2199)
(2089)
(2186)
(2185)
(2081)
(42218)
(33153)
(28126)
(23102)
(2189)
(2087)
(2084)
(1367)
(1466)
(1254)
(7.936)
(6.824)
(6.322)
(5.921)
(6.326)
(5.924)
(5.421)
(4.919)
(4.516)
(4.416)
(4.315)
(<0.167)
(1665)
(2296)
(27126)
(30148)
(31153)
(32159)
(2.52.7)
(1.41.5)
(0.850.88)
(0.940.96)
(1.01.0)
(1.01.0)
(0.961.0)
(5.0273)
(14205)
(14138)
(14100)
(1684)
(1897)
(1791)
(4.16.4)
(6.911)
(1931)
(1728)
(1320)
(1219)
(1118)

NUMBER
(THOUSANDS)
210
270
280
250
220
210
200
3.4
5.5
8.9
10
8.9
8.2
7.8
3.2
4
4.6
5.8
7.2
7.6
8.1
42
43
42
35
29
25
23
29
34
32
28
26
25
25
2.3
2.7
3.7
3.9
4.5
4.7
4.1
57
46
82
120
110
120
120
4.1
4.8
7
8.5
8.8
8.9
9
7.3
8.8
13
14
18
19
19
100
91
90
89
90
91
91
33
39
40
34
28
27
25
11
12
13
14
14
14
14
5
8.6
13
18
22
23
24
0.55
0.55
0.52
0.54
0.51
0.51
0.5
110
120
100
100
110
120
120
9.6
11
26
27
20
19
17
(140290)
(200370)
(210370)
(190320)
(170270)
(170250)
(160240)
(1.75.8)
(2.79.3)
(4.415)
(5.117)
(4.615)
(4.213)
(4.013)
(1.16.4)
(2.06.8)
(2.27.9)
(2.89.9)
(3.612)
(3.813)
(4.014)
(1195)
(1488)
(1779)
(1662)
(1547)
(1342)
(1139)
(1351)
(1659)
(1555)
(1448)
(1343)
(1342)
(1241)
(0.7904.7)
(1.24.9)
(1.86.3)
(1.96.6)
(2.27.6)
(2.37.9)
(2.26.8)
(2896)
(2573)
(44130)
(62200)
(57190)
(59190)
(63200)
(1.58.0)
(2.28.5)
(3.112)
(3.516)
(3.816)
(3.916)
(4.216)
(2.514)
(4.215)
(6.022)
(6.924)
(8.630)
(9.031)
(9.132)
(45180)
(43160)
(43150)
(43150)
(43150)
(44150)
(44160)
(1658)
(2163)
(2165)
(1856)
(1644)
(1542)
(1439)
(5.918)
(6.520)
(7.021)
(7.322)
(7.522)
(7.623)
(7.623)
(0.79013)
(4.015)
(6.222)
(8.431)
(1038)
(1140)
(1143)
(0.2001.1)
(0.2600.930)
(0.2500.880)
(0.2600.920)
(0.2500.880)
(0.2500.870)
(0.2400.850)
(5.9360)
(21290)
(30220)
(39190)
(50180)
(57210)
(56200)
(4.517)
(5.519)
(1343)
(1444)
(1133)
(9.830)
(8.728)
RATEa
425
480
430
333
265
251
237
370
502
722
732
602
545
505
335
358
357
388
430
442
455
286
256
219
163
121
104
92
503
450
383
315
262
255
242
229
244
300
285
303
312
268
243
168
261
340
291
288
291
249
268
357
412
410
408
411
341
421
449
447
462
465
453
911
695
587
498
448
439
428
354
395
357
268
195
180
164
129
125
114
103
93
92
90
252
375
481
582
653
668
686
52
48
43
43
40
39
38
816
728
564
483
460
513
490
675
681
1 380
1 280
905
820
729
(285593)
(342642)
(318560)
(251425)
(208329)
(200307)
(191288)
(182623)
(244851)
(3541 220)
(3691 220)
(311987)
(282893)
(259831)
(117664)
(173607)
(173608)
(189656)
(212722)
(218743)
(225764)
(74641)
(85518)
(86412)
(75285)
(63197)
(53172)
(44158)
(226887)
(208784)
(183654)
(156530)
(132438)
(129424)
(121404)
(78459)
(109432)
(147506)
(137485)
(149510)
(155523)
(139437)
(120408)
(92266)
(140420)
(174559)
(145486)
(146477)
(152475)
(90487)
(121473)
(160632)
(169761)
(178737)
(180727)
(190716)
(118680)
(199725)
(211774)
(218756)
(225781)
(226788)
(222766)
(4021 620)
(3271 200)
(2801 010)
(240847)
(216762)
(212745)
(207729)
(166613)
(210638)
(191575)
(140436)
(110304)
(101281)
(93255)
(67211)
(66201)
(62183)
(56165)
(50150)
(49147)
(48145)
(40656)
(174651)
(233816)
(2751 000)
(3001 140)
(3071 160)
(3121 200)
(18102)
(2382)
(2173)
(2173)
(1968)
(1967)
(1865)
(442 670)
(1331 810)
(1651 200)
(190910)
(221786)
(244881)
(235837)
(3151 170)
(3341 150)
(7092 260)
(6622 100)
(4771 460)
(4291 340)
(3741 200)

NUMBER
(THOUSANDS)
180
240
280
250
230
220
220
2
3.4
6.5
8
7.5
7.2
6.9
1.8
2.3
2.9
3.7
4.5
4.7
4.9
23
28
29
26
22
21
20
14
19
20
19
18
19
19
1.6
2
2.4
2.9
3.4
3.5
3.7
33
46
89
130
120
120
120
3
5.8
11
13
14
14
14
4.2
4.6
6.9
8.5
11
12
12
44
44
45
47
49
50
51
31
46
52
45
35
33
29
6.6
7.9
8.7
9.1
9.5
9.6
9.8
4.5
5.8
7.3
9.3
11
12
12
0.29
0.3
0.29
0.29
0.28
0.28
0.28
54
76
93
110
120
130
130
5.4
9.5
27
29
22
20
17
(110270)
(140360)
(160420)
(150380)
(160310)
(160300)
(160280)
(1.72.4)
(2.84.1)
(5.47.7)
(6.69.6)
(6.29.0)
(5.98.5)
(5.78.2)
(1.12.6)
(1.92.8)
(2.43.5)
(3.14.5)
(3.75.4)
(3.95.6)
(4.15.9)
(1041)
(1645)
(1942)
(1933)
(1925)
(1824)
(1722)
(1217)
(1622)
(1623)
(1623)
(1522)
(1522)
(1522)
(1.12.2)
(1.62.3)
(1.92.9)
(2.43.5)
(2.84.1)
(2.94.2)
(3.04.4)
(2837)
(4350)
(8495)
(120140)
(120130)
(120130)
(110120)
(2.23.9)
(5.16.6)
(9.512)
(1116)
(1215)
(1216)
(1216)
(2.66.2)
(3.85.5)
(5.68.3)
(6.910)
(9.113)
(9.714)
(1015)
(3653)
(3652)
(3754)
(3956)
(4159)
(4160)
(4261)
(2241)
(3854)
(4362)
(3754)
(3338)
(3035)
(2732)
(6.36.9)
(7.58.3)
(8.39.2)
(8.79.6)
(9.010)
(9.210)
(9.310)
(2.86.7)
(4.76.9)
(6.08.8)
(7.611)
(9.213)
(9.614)
(1015)
(0.1800.430)
(0.2400.360)
(0.2400.350)
(0.2400.350)
(0.2300.340)
(0.2300.330)
(0.2300.330)
(8.4140)
(24160)
(41170)
(62170)
(85170)
(88170)
(91180)
(4.26.6)
(7.512)
(2133)
(2336)
(1827)
(1624)
(1321)
RATEa
367
419
421
342
280
269
258
220
314
527
586
511
475
450
185
204
225
248
269
273
279
155
167
152
119
92
86
79
247
249
234
211
187
188
183
158
174
192
211
229
233
238
139
169
286
359
312
298
288
184
323
553
639
634
633
632
199
219
242
266
288
293
299
391
335
293
262
245
242
238
326
462
467
354
243
219
191
76
80
77
69
64
63
62
228
251
277
305
330
337
344
28
26
24
23
22
22
21
401
478
513
524
539
544
548
379
575
1 410
1 390
989
867
723
(218553)
(249633)
(251636)
(203516)
(191385)
(191359)
(191335)
(182262)
(259374)
(435627)
(484698)
(422609)
(392566)
(372536)
(114273)
(167245)
(184271)
(203298)
(221321)
(226325)
(230331)
(69275)
(93263)
(97220)
(88154)
(81103)
(7597)
(6989)
(204295)
(205297)
(193279)
(173251)
(154223)
(155224)
(151219)
(108217)
(142209)
(157230)
(173254)
(188274)
(192278)
(196283)
(121159)
(155184)
(267305)
(339380)
(299325)
(286311)
(276300)
(135240)
(283367)
(484626)
(535752)
(553721)
(553719)
(551717)
(123293)
(179263)
(197290)
(218320)
(237344)
(242349)
(247356)
(322466)
(276400)
(241349)
(216313)
(202293)
(199288)
(196284)
(230438)
(383548)
(387554)
(292421)
(227260)
(203236)
(177206)
(7280)
(7684)
(7481)
(6673)
(6167)
(6066)
(5965)
(140336)
(205302)
(226333)
(250367)
(271395)
(277402)
(283410)
(1741)
(2131)
(2029)
(1928)
(1826)
(1826)
(1825)
(621 050)
(153985)
(227914)
(298811)
(371738)
(377741)
(380747)
(300467)
(455708)
(1 1101 730)
(1 1001 720)
(7831 220)
(6861 070)
(573891)
Niger
Nigeria
Rwanda
Sao Tome and

Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
8
9
11
13
15
16
16
98
110
124
140
154
158
162
7
6
8
9
10
11
11
<1
<1
<1
<1
<1
<1
<1
7
8
10
11
12
12
13
<1
<1
<1
<1
<1
<1
<1
4
4
4
5
6
6
6
37
41
45
48
50
50
50
<1
<1
1
1
1
1
1
4
4
5
5
6
6
6
18
21
24
28
32
33
35
25
30
34
39
44
45
46
8
9
10
11
13
13
13
10
12
13
13
12
13
13
NUMBER
(THOUSANDS)
7.7
6.7
4.9
3.6
2.9
2.8
2.7
28
37
42
42
31
33
27
2.6
4.3
3.9
2
1.3
1.3
1.2
0.03
0.032
0.018
<0.01
0.019
0.023
0.027
1.7
2.1
2.5
2.3
2.3
2.4
2.5
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.4
2.8
3.8
6
8
8.7
9.5
15
13
19
29
27
28
25
0.27
0.23
0.34
0.36
0.41
0.47
0.64
0.25
0.39
0.62
0.62
0.53
0.57
0.55
8
9.4
10
8.2
5.8
5.3
5
8.9
6.4
6.5
6.6
6.4
6.6
6.4
4.4
4
3.5
2.5
2.7
3
3.2
2.5
1.1
1.2
2.9
3.5
3.5
6
(2.915)
(2.513)
(1.99.3)
(1.56.6)
(1.35.3)
(1.25.0)
(1.24.8)
(0.063130)
(0.830140)
(1.3150)
(2.2140)
(1065)
(8.174)
(6.164)
(1.14.9)
(1.68.2)
(1.67.3)
(0.8403.5)
(0.6102.3)
(0.5902.2)
(0.5602.0)
(<0.010.062)
(0.0130.058)
(<0.010.033)
(<0.010.027)
(<0.010.035)
(<0.010.041)
(0.0110.048)
(0.7603.1)
(0.9303.8)
(1.14.5)
(1.04.2)
(1.04.1)
(1.14.3)
(1.14.4)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.7605.0)
(1.15.3)
(1.57.2)
(2.411)
(3.215)
(3.516)
(3.818)
(4.431)
(5.524)
(8.135)
(1253)
(1150)
(1250)
(1144)
(0.0730.600)
(0.0970.430)
(0.1300.640)
(0.1300.720)
(0.1800.740)
(0.2100.850)
(0.2801.2)
(0.1100.440)
(0.1700.700)
(0.2601.2)
(0.2601.1)
(0.2300.960)
(0.2401.0)
(0.2400.990)
(2.217)
(2.720)
(3.321)
(3.116)
(2.510)
(2.39.5)
(2.19.0)
(3.716)
(2.811)
(3.011)
(3.211)
(3.311)
(3.311)
(3.311)
(1.88.2)
(1.77.3)
(1.56.2)
(1.14.7)
(1.34.6)
(1.55.1)
(1.55.4)
(0.7205.4)
(0.2602.6)
(0.2203.0)
(0.9605.9)
(1.46.5)
(1.46.5)
(2.411)
RATEa
98
73
45
28
20
18
17
29
34
34
30
20
21
17
37
77
48
21
13
12
11
26
25
13
5.9
12
14
16
24
25
26
22
19
19
19
1.6
1.5
1.6
1
1.4
1.6
1.9
60
71
92
116
139
149
159
40
32
43
60
55
55
49
31
24
32
33
35
40
53
6.7
9.5
13
11
9.1
9.4
9
45
45
43
29
18
16
14
35
21
19
17
15
15
14
56
45
34
22
21
23
24
24
9.5
9.7
23
28
28
47
(37189)
(27141)
(1886)
(1151)
(8.535)
(7.832)
(7.330)
(<0.1135)
(0.75126)
(1.0122)
(1.698)
(6.542)
(5.147)
(3.740)
(1569)
(29147)
(1991)
(9.238)
(5.922)
(5.621)
(5.119)
(8.453)
(1046)
(5.023)
(0.4718)
(4.922)
(5.925)
(6.728)
(1143)
(1145)
(1147)
(9.538)
(8.334)
(8.535)
(8.535)
(1.61.7)
(1.51.5)
(1.61.7)
(0.981.0)
(1.41.5)
(1.61.6)
(1.81.9)
(19124)
(28135)
(36174)
(46220)
(55261)
(60279)
(64297)
(1285)
(1358)
(1878)
(25110)
(23101)
(2499)
(2187)
(8.569)
(1044)
(1260)
(1265)
(1563)
(1771)
(2396)
(3.012)
(4.117)
(5.424)
(4.921)
(4.016)
(4.017)
(3.916)
(1398)
(1397)
(1489)
(1155)
(7.632)
(6.829)
(6.226)
(1564)
(9.438)
(8.733)
(8.329)
(7.525)
(7.424)
(7.123)
(23104)
(1982)
(1560)
(9.241)
(1036)
(1139)
(1140)
(6.951)
(2.222)
(1.724)
(7.647)
(1152)
(1151)
(1988)

NUMBER
(THOUSANDS)
62
54
41
32
28
27
27
280
310
380
410
300
320
280
24
37
35
19
14
14
13
0.28
0.29
0.21
0.18
0.21
0.23
0.25
17
21
24
24
24
25
25
0.034
0.06
0.044
0.051
0.04
0.042
0.034
19
23
32
51
69
75
82
160
160
240
380
400
410
390
3
3
5.7
7.5
8.4
9
10
2.6
3.8
5.7
6.1
5.7
6
5.9
79
94
100
89
69
66
63
82
72
81
85
83
83
82
46
53
54
47
46
47
47
25
28
41
53
52
51
70
(28110)
(2497)
(1972)
(1655)
(1448)
(1346)
(1345)
(0.4901 300)
(7.21 200)
(111 400)
(211 400)
(110580)
(88690)
(71620)
(1240)
(1763)
(1758)
(1131)
(7.723)
(7.322)
(6.821)
(0.0990.560)
(0.1400.490)
(0.0860.380)
(0.0560.380)
(0.0950.380)
(0.1100.400)
(0.1200.430)
(8.129)
(9.935)
(1241)
(1140)
(1141)
(1243)
(1244)
(<0.010.093)
(0.0280.100)
(0.0200.077)
(0.0240.087)
(0.0170.073)
(0.0190.074)
(0.0140.064)
(7.038)
(1140)
(1556)
(2488)
(33120)
(36130)
(39140)
(55320)
(72270)
(130390)
(200620)
(200660)
(210670)
(200630)
(1.06.1)
(1.54.9)
(2.89.5)
(3.513)
(4.114)
(4.515)
(5.517)
(1.24.5)
(1.96.3)
(2.89.6)
(3.110)
(2.89.8)
(2.910)
(2.910)
(31150)
(36180)
(43190)
(42150)
(37110)
(35110)
(33100)
(42140)
(38120)
(43130)
(44140)
(43130)
(44130)
(43130)
(2673)
(2984)
(2887)
(2380)
(2474)
(2575)
(2675)
(1048)
(1250)
(1678)
(2592)
(2884)
(2782)
(37110)
RATEa
795
591
379
249
189
176
166
282
286
306
293
194
200
171
337
658
430
211
137
129
117
243
223
148
119
131
140
151
231
248
253
217
196
201
200
49
81
56
60
47
49
39
485
594
773
987
1 200
1 280
1 370
439
376
534
795
808
815
768
349
309
534
680
721
756
854
71
92
119
113
97
100
96
446
449
431
314
215
196
183
323
241
239
218
190
186
177
590
593
528
411
359
358
352
242
237
328
425
417
406
547
(3541 410)
(2611 050)
(177656)
(121423)
(93319)
(86298)
(81281)
(0.511 350)
(6.51 070)
(8.81 110)
(15968)
(70378)
(55436)
(44382)
(172556)
(3121 130)
(214721)
(115336)
(74219)
(69207)
(62189)
(85483)
(107381)
(61271)
(37250)
(58233)
(66241)
(73256)
(111394)
(119423)
(123430)
(104371)
(92340)
(95344)
(95341)
(6.6131)
(38139)
(2598)
(29104)
(1985)
(2286)
(1673)
(176948)
(2731 040)
(3571 340)
(4611 710)
(5702 060)
(6112 200)
(6502 350)
(150878)
(174654)
(279869)
(4171 290)
(4121 330)
(4241 330)
(3991 250)
(119701)
(159507)
(267892)
(3181 180)
(3551 210)
(3831 250)
(4561 370)
(33121)
(46155)
(59200)
(57189)
(47166)
(49169)
(47162)
(174844)
(172856)
(176799)
(149539)
(113348)
(103318)
(95298)
(165534)
(128388)
(125388)
(114355)
(99309)
(98301)
(93286)
(326931)
(325938)
(278856)
(200697)
(190581)
(192573)
(193558)
(95457)
(100432)
(127623)
(202729)
(222673)
(217652)
(287889)

NUMBER
(THOUSANDS)
28
25
21
19
18
18
17
130
150
210
240
200
210
190
21
29
26
17
12
11
10
0.16
0.16
0.16
0.16
0.16
0.16
0.16
10
13
15
15
16
17
17
0.031
0.03
0.029
0.028
0.027
0.027
0.026
8.2
11
16
26
37
40
43
110
130
260
440
480
490
500
2.3
3.2
8.5
13
15
15
16
1.8
2.5
3.7
4.4
4.3
4.6
4.5
110
110
100
87
73
70
67
58
68
80
83
79
79
78
56
70
73
65
61
61
60
31
56
91
100
83
80
77
(2333)
(2029)
(1725)
(1522)
(1521)
(1521)
(1421)
(1.3510)
(8.1500)
(15660)
(33670)
(120300)
(100360)
(90330)
(1823)
(2632)
(2429)
(1519)
(1113)
(1012)
(9.211)
(0.0970.230)
(0.1300.190)
(0.1300.190)
(0.1300.190)
(0.1300.190)
(0.1300.190)
(0.1300.190)
(8.212)
(1115)
(1218)
(1318)
(1319)
(1420)
(1421)
(0.0190.045)
(0.0240.036)
(0.0230.034)
(0.0230.034)
(0.0220.032)
(0.0220.032)
(0.0220.031)
(5.112)
(8.913)
(1319)
(2131)
(3044)
(3348)
(3652)
(76150)
(110160)
(210310)
(360530)
(400580)
(410590)
(410600)
(1.43.4)
(2.73.9)
(7.010)
(1015)
(1218)
(1318)
(1319)
(1.52.2)
(2.13.0)
(3.04.4)
(3.65.2)
(3.55.2)
(3.85.5)
(3.75.4)
(58180)
(62180)
(63150)
(62110)
(5989)
(5684)
(5481)
(4967)
(5878)
(7091)
(7689)
(7585)
(7585)
(7383)
(4963)
(6477)
(6778)
(5971)
(5568)
(5567)
(5466)
(1750)
(3977)
(72110)
(80120)
(64110)
(61100)
(5996)
AFRICAN REGION

YEAR
RATEa
358
270
191
142
119
113
108
128
139
172
175
130
133
118
291
514
326
181
114
106
94
135
124
114
105
98
96
94
138
153
155
142
133
137
136
43
40
37
33
31
31
30
207
279
377
509
644
682
723
301
317
576
925
971
981
993
267
337
803
1 150
1 260
1 290
1 320
50
61
76
81
73
77
73
624
542
427
304
226
209
193
226
226
236
213
183
177
169
710
788
713
566
482
462
444
296
483
726
799
668
633
603
(295426)
(223321)
(157227)
(118170)
(98142)
(94135)
(90129)
(1.3526)
(7.4456)
(12536)
(23476)
(78196)
(64225)
(55204)
(260324)
(459573)
(291363)
(162202)
(102127)
(94118)
(84105)
(83199)
(102149)
(93137)
(88123)
(80117)
(79115)
(78113)
(114164)
(126183)
(128184)
(117169)
(110158)
(113163)
(112162)
(2764)
(3348)
(3044)
(2740)
(2637)
(2537)
(2536)
(128305)
(228335)
(308453)
(416611)
(529771)
(563813)
(596861)
(206413)
(259381)
(471691)
(7561 110)
(7981 160)
(8091 170)
(8191 180)
(165394)
(275405)
(657964)
(9381 380)
(1 0301 500)
(1 0601 530)
(1 0901 570)
(4159)
(5173)
(6391)
(6797)
(6087)
(6392)
(6087)
(3281 010)
(297860)
(259636)
(220402)
(182274)
(169253)
(156234)
(193261)
(193261)
(207268)
(197229)
(171194)
(166189)
(159180)
(624801)
(719861)
(661767)
(519615)
(434532)
(418509)
(401489)
(159476)
(335658)
(573897)
(634984)
(514842)
(489795)
(466757)
151
YEAR
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African
Republic
Chad
Comoros
Congo
Cte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
Eritrea
152
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
25
28
31
33
35
35
36
10
12
14
16
19
19
20
5
6
7
8
9
9
9
1
2
2
2
2
2
2
9
11
12
14
16
16
17
6
6
6
7
8
8
9
12
14
16
18
19
20
20
<1
<1
<1
<1
<1
<1
<1
3
3
4
4
4
4
4
6
7
8
10
11
11
12
<1
<1
<1
<1
<1
<1
<1
2
3
3
4
4
4
4
13
15
17
18
19
20
20
36
44
50
57
64
66
68
<1
<1
<1
<1
<1
<1
<1
3
3
4
4
5
5
5
NUMBER
(THOUSANDS)
17
19
27
30
31
32
32
21
27
35
45
55
58
61
6.1
5.6
5.6
5.6
6
6.1
6.3
7.4
14
16
14
11
10
9.2
8.1
8.8
8.8
8.9
9.5
9.5
9.7
9.1
20
18
14
12
12
12
14
29
49
55
51
54
49
0.61
0.66
0.7
0.72
0.73
0.73
0.73
25
40
40
28
20
19
18
5.7
9
12
15
17
17
17
0.24
0.23
0.22
0.23
0.24
0.25
0.26
4
6.7
11
15
16
16
16
30
56
61
48
41
38
38
120
140
160
190
210
220
220
0.9
1.2
1.4
1.3
1.4
1.5
1.5
7.7
6.4
5.8
5.4
5.3
5.3
5.2
(1222)
(1425)
(1935)
(2240)
(2341)
(2342)
(2442)
(1331)
(2233)
(2842)
(3754)
(4665)
(4968)
(5171)
(5.17.3)
(4.76.7)
(4.66.7)
(4.66.7)
(5.07.1)
(5.07.2)
(5.27.5)
(2.914)
(8.819)
(1320)
(1315)
(9.612)
(9.011)
(8.310)
(6.99.4)
(7.510)
(7.410)
(7.510)
(8.111)
(8.111)
(8.211)
(8.010)
(1722)
(1621)
(1316)
(1114)
(1114)
(1013)
(1116)
(2434)
(4058)
(4565)
(4261)
(4464)
(4058)
(0.3800.900)
(0.5400.800)
(0.5700.840)
(0.5900.870)
(0.6000.870)
(0.6000.870)
(0.6000.870)
(2130)
(3348)
(3347)
(2333)
(1724)
(1623)
(1521)
(4.76.8)
(7.411)
(1015)
(1217)
(1420)
(1420)
(1421)
(0.1900.280)
(0.1900.270)
(0.1800.260)
(0.1900.280)
(0.2000.290)
(0.2000.290)
(0.2100.310)
(2.56.0)
(5.58.0)
(9.313)
(1218)
(1319)
(1319)
(1319)
(2634)
(4864)
(5370)
(4255)
(3647)
(3343)
(3344)
(95150)
(120170)
(140190)
(160220)
(180240)
(190250)
(190250)
(0.7901.0)
(1.11.4)
(1.21.6)
(1.11.4)
(1.21.6)
(1.31.7)
(1.31.6)
(5.111)
(4.28.9)
(3.88.1)
(3.67.6)
(3.57.4)
(3.57.4)
(3.57.4)
RATEa
66
68
87
93
89
90
90
205
226
250
276
298
304
310
128
100
86
74
70
69
70
533
855
918
733
545
503
455
87
82
71
63
59
58
57
162
323
289
198
150
144
139
112
206
310
313
268
274
243
175
168
160
153
148
147
145
864
1 200
1 070
690
469
433
400
94
128
151
150
151
151
151
54
46
39
36
33
33
34
169
245
353
425
395
391
387
238
380
370
268
212
190
191
327
327
327
327
327
327
327
241
279
268
206
202
215
202
243
198
157
121
103
100
97
(4886)
(5089)
(64114)
(68121)
(65116)
(66118)
(66117)
(127303)
(185272)
(204300)
(227329)
(250349)
(256355)
(261362)
(106153)
(82119)
(71102)
(6188)
(5883)
(5782)
(5883)
(212997)
(5531 220)
(7361 120)
(667802)
(486608)
(449560)
(406507)
(74101)
(7096)
(6083)
(5373)
(5069)
(4967)
(4866)
(143183)
(284364)
(255326)
(174223)
(132169)
(127163)
(122157)
(92133)
(170246)
(255369)
(258373)
(221319)
(226327)
(200290)
(108259)
(137201)
(131193)
(125184)
(121177)
(121175)
(120173)
(7121 030)
(9901 430)
(8851 280)
(569823)
(387559)
(357516)
(330477)
(78112)
(106153)
(125180)
(124178)
(125180)
(125179)
(125179)
(4464)
(3855)
(3246)
(3043)
(2840)
(2840)
(2841)
(104250)
(200294)
(298412)
(347510)
(323474)
(320470)
(317465)
(206272)
(329434)
(321423)
(232306)
(184242)
(165217)
(165218)
(262398)
(268392)
(273385)
(279379)
(283374)
(282375)
(282375)
(211273)
(245316)
(235304)
(181234)
(177229)
(189244)
(177229)
(162341)
(132278)
(104220)
(80169)
(69145)
(67140)
(64136)
NUMBER
(THOUSANDS)
0.012
0.028
0.1
0.23
0.32
0.35
0.36
1.5
3.5
6.1
9.4
12
13
8.5
2.2
1.6
1.3
1
0.99
0.96
1.1
2.3
7.9
11
9.2
7
6.6
5.9
3.5
3.4
2.7
2.1
1.9
1.7
1.6
2.5
8.6
7.7
4.5
3
2.8
2.6
1.4
8.2
20
24
21
23
19
0.058
0.074
0.084
0.034
0.088
0.087
0.097
14
23
22
13
8.6
7.8
7.1
1.3
2.7
4.2
4.7
5
5.1
5.2
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.011
1.6
2.7
3.9
4.8
4.8
4.8
4.9
11
24
26
17
12
9.1
10
18
24
28
32
33
33
34
0.072
0.15
0.25
0.29
0.38
0.43
0.37
0.13
0.45
0.75
0.61
0.48
0.46
0.44
(<0.010.016)
(0.0140.047)
(0.0560.160)
(0.1400.350)
(0.1900.480)
(0.2100.520)
(0.2200.540)
(0.9502.3)
(2.74.4)
(4.77.6)
(7.412)
(9.615)
(1015)
(6.211)
(1.82.6)
(1.21.9)
(1.01.6)
(0.7901.3)
(0.8101.2)
(0.7801.2)
(0.8701.3)
(0.9204.3)
(5.111)
(8.513)
(8.210)
(6.27.8)
(5.97.4)
(5.36.6)
(3.04.1)
(2.84.1)
(2.23.3)
(1.72.6)
(1.62.2)
(1.42.0)
(1.41.9)
(2.22.8)
(7.310)
(6.59.0)
(3.85.3)
(2.53.6)
(2.43.1)
(2.22.9)
(1.11.7)
(6.510)
(1625)
(1930)
(1725)
(1928)
(1522)
(0.0360.086)
(0.0560.094)
(0.0640.110)
(0.0170.056)
(0.0670.110)
(0.0670.110)
(0.0680.130)
(1116)
(1828)
(1827)
(1116)
(6.910)
(6.29.5)
(5.78.7)
(1.01.5)
(2.23.4)
(3.35.1)
(3.85.8)
(4.06.2)
(4.16.3)
(4.16.4)
(<0.01<0.01)
(0<0.01)
(0<0.01)
(<0.010.014)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.025)
(1.02.4)
(2.13.3)
(3.24.7)
(3.85.9)
(3.85.9)
(3.86.0)
(3.96.1)
(9.412)
(2028)
(2130)
(1420)
(1114)
(7.910)
(8.712)
(1522)
(1931)
(2235)
(2639)
(2740)
(2740)
(2741)
(0.0630.082)
(0.1300.190)
(0.2000.290)
(0.2400.340)
(0.3200.450)
(0.3600.510)
(0.3100.440)
(0.0870.190)
(0.2800.660)
(0.4801.1)
(0.3900.880)
(0.3100.700)
(0.2900.670)
(0.2800.640)
RATEa
<0.1
0.1
0.3
0.7
0.9
1
1
15
29
44
57
65
66
43
46
28
20
13
12
11
12
167
500
611
488
354
329
292
38
32
22
15
12
10
9.5
44
142
121
62
37
33
30
11
59
130
138
109
119
93
17
19
19
7.2
18
18
19
463
681
591
336
199
177
159
21
39
51
48
46
45
45
0
0
0
0.7
<0.1
<0.1
1.4
68
99
126
136
121
120
119
86
163
155
94
64
46
50
51
55
57
56
52
50
49
19
35
47
48
56
62
52
4.2
14
20
14
9.5
8.8
8.2
(<0.1<0.1)
(<0.10.17)
(0.180.53)
(0.411.1)
(0.551.4)
(0.591.5)
(0.611.5)
(9.222)
(2236)
(3455)
(4571)
(5279)
(5381)
(3157)
(3855)
(2234)
(1625)
(1017)
(9.414)
(8.813)
(9.614)
(66313)
(321717)
(486749)
(437541)
(315396)
(293366)
(260325)
(3244)
(2638)
(1827)
(1218)
(9.814)
(8.512)
(8.011)
(3950)
(120166)
(102141)
(5273)
(3044)
(2938)
(2634)
(9.414)
(4773)
(104159)
(110169)
(89130)
(98142)
(76111)
(1025)
(1424)
(1524)
(3.712)
(1422)
(1422)
(1426)
(382552)
(549827)
(476718)
(269409)
(159243)
(142217)
(127194)
(1725)
(3148)
(4062)
(3859)
(3756)
(3656)
(3656)
(00)
(00)
(00)
(<0.12.1)
(0<0.1)
(<0.10.13)
(0.313.3)
(42100)
(78122)
(102151)
(107168)
(95150)
(94148)
(94147)
(7599)
(137192)
(130182)
(78111)
(5573)
(4053)
(4357)
(4162)
(4369)
(4571)
(4568)
(4263)
(4161)
(4060)
(1722)
(2842)
(3956)
(4056)
(4665)
(5272)
(4461)
(2.85.9)
(8.820)
(1330)
(8.620)
(6.014)
(5.613)
(5.212)
CASE DETECTION
NUMBER
RATEa
PERCENT
11 607
13 507
18 572
21 336
21 701
22 336
21 429
10 271
5 143
16 062
37 175
41 221
44 655
47 240
2 074
2 400
2 697
3 270
3 878
3 756
4 212
2 938
5 665
9 292
10 058
8 362
7 013
6 603
1 497
2 572
2 331
3 478
4 716
4 800
5 286
4 575
3 326
6 421
6 585
7 277
7 611
6 742
5 892
3 292
5 251
21 499
24 662
24 073
24 533
221
303
46
48
61
65
62
63
60
99
42
115
225
222
234
241
43
42
41
43
45
42
46
213
357
529
536
422
349
325
16
24
19
24
30
29
31
82
55
101
91
89
91
79
48
24
33
122
129
123
122
63
77
70
70
70
70
70
70
67
48
19
46
82
75
77
78
34
43
48
58
65
62
67
40
42
58
73
77
70
71
18
29
27
39
50
51
55
50
17
35
46
59
63
57
43
11
11
39
48
45
50
36
46
(5495)
(5495)
(5495)
(5495)
(5495)
(5495)
(5191)
(3378)
(1623)
(3856)
(6999)
(6489)
(6691)
(6692)
(2841)
(3651)
(4058)
(4970)
(5478)
(5275)
(5680)
(21100)
(2965)
(4772)
(6780)
(6987)
(6278)
(6480)
(1622)
(2534)
(2331)
(3446)
(4359)
(4360)
(4765)
(4557)
(1519)
(3140)
(4152)
(5367)
(5671)
(5064)
(3652)
(9.614)
(9.113)
(3348)
(4058)
(3854)
(4261)
(2559)
(3856)
292
332
356
380
2 124
3 339
62
68
72
76
72
100
40
46
49
52
8.4
8.4
(3449)
(3856)
(4159)
(4463)
(7.010)
(7.010)
3 210
8 743
6 643
5 611
2 591
3 186
80
202
151
125
43
46
12
43
35
31
46
35
(9.714)
(3652)
(2942)
(2638)
(3855)
(3043)
6 311
8 411
9 452
10 505
140
123
120
111
120
64
77
84
91
32
25
21
17
17
43
51
56
60
59
54
55
48
50
(3652)
(4361)
(4767)
(5173)
(5072)
(4666)
(4666)
(4058)
(4261)
117
591
3 615
9 239
9 853
9 765
10 150
10 975
7 841
11 988
15 094
19 681
22 571
22 708
22 476
21 131
42 819
61 024
97 075
111 709
114 170
110 132
260
306
16
25
132
295
279
248
251
265
63
82
91
109
117
115
112
58
97
123
169
174
173
163
70
69
45
15
54
83
66
63
64
68
26
21
25
41
55
60
59
18
30
38
52
53
53
50
29
25
(3855)
(9.924)
(4566)
(7199)
(5580)
(5277)
(5379)
(5784)
(2330)
(1925)
(2228)
(3647)
(4863)
(5370)
(5168)
(1522)
(2536)
(3245)
(4561)
(4761)
(4661)
(4358)
(2533)
(2228)
707
820
883
3 699
21 453
6 652
3 549
2 904
2 870
3 049
104
117
123
117
668
181
79
57
55
56
51
54
61
48
340
120
65
55
55
58
(4559)
(4862)
(5469)
(3472)
(240510)
(82170)
(4798)
(3983)
(3982)
(4187)
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
48
57
66
74
81
83
85
<1
1
1
1
1
2
2
<1
1
1
2
2
2
2
15
17
19
22
24
24
25
6
8
8
9
10
10
10
1
1
1
1
1
2
2
23
27
31
36
39
41
42
2
2
2
2
2
2
2
2
2
3
3
4
4
4
11
13
15
18
20
21
21
9
10
11
13
14
15
15
9
10
11
13
15
15
16
2
2
3
3
3
3
4
1
1
1
1
1
1
1
14
16
18
21
23
23
24
1
2
2
2
2
2
2
NUMBER
(THOUSANDS)
180
240
280
250
230
220
220
2
3.4
6.5
8
7.5
7.2
6.9
1.8
2.3
2.9
3.7
4.5
4.7
4.9
23
28
29
26
22
21
20
14
19
20
19
18
19
19
1.6
2
2.4
2.9
3.4
3.5
3.7
33
46
89
130
120
120
120
3
5.8
11
13
14
14
14
4.2
4.6
6.9
8.5
11
12
12
44
44
45
47
49
50
51
31
46
52
45
35
33
29
6.6
7.9
8.7
9.1
9.5
9.6
9.8
4.5
5.8
7.3
9.3
11
12
12
0.29
0.3
0.29
0.29
0.28
0.28
0.28
54
76
93
110
120
130
130
5.4
9.5
27
29
22
20
17
(110270)
(140360)
(160420)
(150380)
(160310)
(160300)
(160280)
(1.72.4)
(2.84.1)
(5.47.7)
(6.69.6)
(6.29.0)
(5.98.5)
(5.78.2)
(1.12.6)
(1.92.8)
(2.43.5)
(3.14.5)
(3.75.4)
(3.95.6)
(4.15.9)
(1041)
(1645)
(1942)
(1933)
(1925)
(1824)
(1722)
(1217)
(1622)
(1623)
(1623)
(1522)
(1522)
(1522)
(1.12.2)
(1.62.3)
(1.92.9)
(2.43.5)
(2.84.1)
(2.94.2)
(3.04.4)
(2837)
(4350)
(8495)
(120140)
(120130)
(120130)
(110120)
(2.23.9)
(5.16.6)
(9.512)
(1116)
(1215)
(1216)
(1216)
(2.66.2)
(3.85.5)
(5.68.3)
(6.910)
(9.113)
(9.714)
(1015)
(3653)
(3652)
(3754)
(3956)
(4159)
(4160)
(4261)
(2241)
(3854)
(4362)
(3754)
(3338)
(3035)
(2732)
(6.36.9)
(7.58.3)
(8.39.2)
(8.79.6)
(9.010)
(9.210)
(9.310)
(2.86.7)
(4.76.9)
(6.08.8)
(7.611)
(9.213)
(9.614)
(1015)
(0.1800.430)
(0.2400.360)
(0.2400.350)
(0.2400.350)
(0.2300.340)
(0.2300.330)
(0.2300.330)
(8.4140)
(24160)
(41170)
(62170)
(85170)
(88170)
(91180)
(4.26.6)
(7.512)
(2133)
(2336)
(1827)
(1624)
(1321)
RATEa
367
419
421
342
280
269
258
220
314
527
586
511
475
450
185
204
225
248
269
273
279
155
167
152
119
92
86
79
247
249
234
211
187
188
183
158
174
192
211
229
233
238
139
169
286
359
312
298
288
184
323
553
639
634
633
632
199
219
242
266
288
293
299
391
335
293
262
245
242
238
326
462
467
354
243
219
191
76
80
77
69
64
63
62
228
251
277
305
330
337
344
28
26
24
23
22
22
21
401
478
513
524
539
544
548
379
575
1 410
1 390
989
867
723
(218553)
(249633)
(251636)
(203516)
(191385)
(191359)
(191335)
(182262)
(259374)
(435627)
(484698)
(422609)
(392566)
(372536)
(114273)
(167245)
(184271)
(203298)
(221321)
(226325)
(230331)
(69275)
(93263)
(97220)
(88154)
(81103)
(7597)
(6989)
(204295)
(205297)
(193279)
(173251)
(154223)
(155224)
(151219)
(108217)
(142209)
(157230)
(173254)
(188274)
(192278)
(196283)
(121159)
(155184)
(267305)
(339380)
(299325)
(286311)
(276300)
(135240)
(283367)
(484626)
(535752)
(553721)
(553719)
(551717)
(123293)
(179263)
(197290)
(218320)
(237344)
(242349)
(247356)
(322466)
(276400)
(241349)
(216313)
(202293)
(199288)
(196284)
(230438)
(383548)
(387554)
(292421)
(227260)
(203236)
(177206)
(7280)
(7684)
(7481)
(6673)
(6167)
(6066)
(5965)
(140336)
(205302)
(226333)
(250367)
(271395)
(277402)
(283410)
(1741)
(2131)
(2029)
(1928)
(1826)
(1826)
(1825)
(621 050)
(153985)
(227914)
(298811)
(371738)
(377741)
(380747)
(300467)
(455708)
(1 1101 730)
(1 1001 720)
(7831 220)
(6861 070)
(573891)
NUMBER
(THOUSANDS)
22
65
93
72
47
42
38
0.24
0.86
2.5
3.5
3.2
3
2.8
0.03
0.089
0.23
0.5
0.72
0.75
0.8
3.4
7.3
9
7.6
4.9
5.5
4.6
1.8
3.8
4.9
5
4.3
4.8
4.8
0.05
0.14
0.31
0.55
0.78
0.84
1.5
5.5
23
47
59
54
50
47
0.16
3.1
8.3
10
10
11
11
0.16
0.43
0.94
1.1
0.98
0.94
1.3
0.062
0.097
0.12
0.13
0.12
0.12
0.13
16
29
36
31
23
21
18
0.88
1.6
1.8
1.7
1.5
1.5
1.5
0.18
0.35
0.55
0.83
1.2
1.4
1.5
<0.01
<0.01
0.013
<0.01
0.018
0.019
0.021
1.6
25
51
68
81
77
83
0.7
3.4
15
17
13
11
8.4
(1334)
(38100)
(54140)
(42110)
(3166)
(2958)
(2849)
(0.2000.290)
(0.6801.1)
(2.03.1)
(2.84.2)
(2.53.9)
(2.43.6)
(2.33.5)
(0.0180.044)
(0.0640.120)
(0.1700.300)
(0.3800.630)
(0.5800.880)
(0.5900.940)
(0.6200.990)
(1.56.0)
(4.012)
(5.613)
(5.510)
(4.35.5)
(4.86.3)
(4.05.2)
(1.42.1)
(2.94.7)
(3.86.1)
(3.96.2)
(3.55.2)
(3.95.8)
(3.95.7)
(0.0340.070)
(0.1000.180)
(0.2400.390)
(0.4300.690)
(0.6100.960)
(0.6601.0)
(1.21.9)
(4.86.4)
(2026)
(4252)
(5266)
(5256)
(4852)
(4549)
(0.1200.210)
(2.63.6)
(7.29.5)
(8.412)
(9.112)
(9.212)
(9.212)
(0.0980.240)
(0.3300.540)
(0.7401.2)
(0.8301.3)
(0.7601.2)
(0.7501.1)
(1.01.6)
(0.0510.074)
(0.0710.130)
(0.0920.160)
(0.0970.170)
(0.0900.160)
(0.0790.170)
(0.0870.180)
(1121)
(2436)
(3044)
(2538)
(2124)
(1922)
(1619)
(0.8300.920)
(1.31.8)
(1.62.1)
(1.41.9)
(1.31.6)
(1.31.8)
(1.31.7)
(0.1100.260)
(0.2500.450)
(0.4100.710)
(0.6301.1)
(0.9401.6)
(1.11.7)
(1.21.9)
(<0.01<0.01)
(<0.01<0.01)
(0.0100.017)
(<0.010.016)
(<0.010.035)
(<0.010.036)
(<0.010.038)
(0.2404.1)
(7.952)
(2291)
(38110)
(56110)
(53110)
(58110)
(0.5500.860)
(2.64.2)
(1219)
(1321)
(1016)
(8.613)
(6.610)
RATEa
46
114
141
97
58
51
45
26
79
203
252
214
197
185
3.1
7.9
18
33
43
44
45
23
43
47
35
21
23
18
31
50
58
55
44
48
47
5
12
25
41
52
56
99
24
84
149
165
136
123
113
9.8
172
425
490
485
487
481
7.5
20
33
33
25
23
31
0.6
0.7
0.8
0.7
0.6
0.6
0.6
166
298
324
244
157
138
114
10
16
16
13
9.9
9.8
9.4
9
15
21
27
37
40
43
<0.1
0.4
1.1
0.4
1.4
1.5
1.6
12
158
279
327
355
330
347
49
204
787
821
570
477
359
(2770)
(66175)
(82215)
(56148)
(3881)
(3570)
(3358)
(2131)
(6398)
(162249)
(202307)
(172262)
(158241)
(148226)
(1.94.5)
(5.610)
(1323)
(2642)
(3452)
(3454)
(3556)
(1041)
(2369)
(2969)
(2547)
(1823)
(2026)
(1621)
(2536)
(3863)
(4573)
(4369)
(3653)
(4058)
(3856)
(3.46.8)
(9.016)
(1931)
(3251)
(4165)
(4469)
(81120)
(2027)
(7495)
(133166)
(147184)
(131142)
(118129)
(109118)
(7.113)
(146201)
(367486)
(406581)
(423552)
(425553)
(420547)
(4.611)
(1626)
(2641)
(2641)
(2032)
(1929)
(2538)
(0.450.66)
(0.540.97)
(0.601.0)
(0.540.95)
(0.450.79)
(0.380.80)
(0.410.86)
(117223)
(242360)
(264390)
(198295)
(146168)
(128149)
(105123)
(9.611)
(1418)
(1419)
(1115)
(9.011)
(8.311)
(7.911)
(5.513)
(1120)
(1627)
(2135)
(2846)
(3150)
(3355)
(<0.10.13)
(0.260.51)
(0.841.4)
(<0.11.3)
(0.512.7)
(0.592.8)
(0.632.9)
(1.830)
(50328)
(122500)
(184509)
(244486)
(228449)
(241473)
(3961)
(157257)
(614981)
(6421 020)
(451703)
(377588)
(284443)
CASE DETECTION
RATEa
PERCENT
88 634
26 034
91 101
124 262
148 936
154 694
156 539
917
1 115
183
46
139
167
183
186
185
99
103
50
11
33
49
66
69
72
45
33
(3384)
(7.218)
(2255)
(3282)
(4896)
(5297)
(5596)
(3854)
(2740)
2 512
3 073
3 473
4 404
183
208
231
287
31
41
49
64
(2638)
(3449)
(4159)
(5477)
NUMBER
1 023
91
2 031
2 145
2 070
2 248
6 407
8 636
10 933
12 124
14 892
14 607
15 389
1 988
3 523
5 440
6 863
8 357
11 038
11 359
1 163
1 613
1 273
1 774
2 171
2 183
2 063
11 788
28 142
64 159
102 680
102 997
99 272
97 320
2 525
5 181
9 746
10 802
12 213
11 674
11 432
135
128
120
127
43
51
57
56
63
60
62
35
47
65
76
86
111
111
114
143
103
130
146
144
133
50
103
205
288
261
245
234
154
289
496
523
568
538
521
54
48
44
45
28
30
37
47
68
70
78
14
19
28
36
46
59
61
73
82
54
61
64
62
56
36
61
72
80
84
82
81
84
89
90
82
90
85
82
(4567)
(4058)
(3753)
(3855)
(1663)
(1955)
(2659)
(3663)
(6177)
(6279)
(6989)
(1217)
(1623)
(2334)
(3044)
(3856)
(4971)
(5174)
(53110)
(69100)
(4565)
(5175)
(5378)
(5275)
(4768)
(3241)
(5666)
(6777)
(7685)
(8087)
(7986)
(7885)
(64110)
(79100)
(79100)
(7098)
(79100)
(7597)
(7394)
1 393
1 500
3 432
5 918
6 597
7 906
6 261
21 616
67
53
108
154
165
191
56
165
30
22
40
54
56
64
14
49
(2537)
(1827)
(3450)
(4565)
(4768)
(5478)
(1217)
(4160)
18 993
22 758
24 432
26 019
12 395
19 155
23 604
25 491
22 674
21 092
19 361
2 933
3 087
4 216
4 704
6 611
5 291
5 428
5 284
3 849
3 067
2 162
2 640
2 461
1 776
119
131
160
125
115
122
114
15 899
17 882
21 158
33 231
43 221
43 558
44 627
2 671
1 540
10 799
14 920
11 980
11 281
10 806
106
113
118
122
132
194
210
199
157
142
126
34
31
37
36
44
34
34
265
168
116
71
78
71
50
11
12
13
9.9
8.9
9.4
8.7
117
112
116
160
189
186
186
189
93
570
717
534
494
465
41
46
49
51
41
42
45
56
65
65
66
45
39
48
52
70
55
56
120
67
42
23
24
21
15
41
44
55
43
41
44
41
29
23
23
31
35
34
34
50
16
40
52
54
57
64
(3449)
(3956)
(4159)
(4362)
(3057)
(3551)
(3854)
(4768)
(6069)
(6070)
(6171)
(4247)
(3741)
(4651)
(4954)
(6673)
(5258)
(5358)
(79190)
(5682)
(3551)
(1928)
(2029)
(1826)
(1218)
(2866)
(3754)
(4667)
(3653)
(3450)
(3753)
(3450)
(11190)
(1173)
(1351)
(2054)
(2651)
(2549)
(2549)
(4063)
(1320)
(3351)
(4265)
(4468)
(4672)
(5281)
AFRICAN REGION

YEAR
44 (3754)
153
YEAR
Niger
Nigeria
Rwanda
Sao Tome and

Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
154
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
8
9
11
13
15
16
16
98
110
124
140
154
158
162
7
6
8
9
10
11
11
<1
<1
<1
<1
<1
<1
<1
7
8
10
11
12
12
13
<1
<1
<1
<1
<1
<1
<1
4
4
4
5
6
6
6
37
41
45
48
50
50
50
<1
<1
1
1
1
1
1
4
4
5
5
6
6
6
18
21
24
28
32
33
35
25
30
34
39
44
45
46
8
9
10
11
13
13
13
10
12
13
13
12
13
13
28
25
21
19
18
18
17
130
150
210
240
200
210
190
21
29
26
17
12
11
10
0.16
0.16
0.16
0.16
0.16
0.16
0.16
10
13
15
15
16
17
17
0.031
0.03
0.029
0.028
0.027
0.027
0.026
8.2
11
16
26
37
40
43
110
130
260
440
480
490
500
2.3
3.2
8.5
13
15
15
16
1.8
2.5
3.7
4.4
4.3
4.6
4.5
110
110
100
87
73
70
67
58
68
80
83
79
79
78
56
70
73
65
61
61
60
31
56
91
100
83
80
77
(2333)
(2029)
(1725)
(1522)
(1521)
(1521)
(1421)
(1.3510)
(8.1500)
(15660)
(33670)
(120300)
(100360)
(90330)
(1823)
(2632)
(2429)
(1519)
(1113)
(1012)
(9.211)
(0.0970.230)
(0.1300.190)
(0.1300.190)
(0.1300.190)
(0.1300.190)
(0.1300.190)
(0.1300.190)
(8.212)
(1115)
(1218)
(1318)
(1319)
(1420)
(1421)
(0.0190.045)
(0.0240.036)
(0.0230.034)
(0.0230.034)
(0.0220.032)
(0.0220.032)
(0.0220.031)
(5.112)
(8.913)
(1319)
(2131)
(3044)
(3348)
(3652)
(76150)
(110160)
(210310)
(360530)
(400580)
(410590)
(410600)
(1.43.4)
(2.73.9)
(7.010)
(1015)
(1218)
(1318)
(1319)
(1.52.2)
(2.13.0)
(3.04.4)
(3.65.2)
(3.55.2)
(3.85.5)
(3.75.4)
(58180)
(62180)
(63150)
(62110)
(5989)
(5684)
(5481)
(4967)
(5878)
(7091)
(7689)
(7585)
(7585)
(7383)
(4963)
(6477)
(6778)
(5971)
(5568)
(5567)
(5466)
(1750)
(3977)
(72110)
(80120)
(64110)
(61100)
(5996)
RATEa
358
270
191
142
119
113
108
128
139
172
175
130
133
118
291
514
326
181
114
106
94
135
124
114
105
98
96
94
138
153
155
142
133
137
136
43
40
37
33
31
31
30
207
279
377
509
644
682
723
301
317
576
925
971
981
993
267
337
803
1 150
1 260
1 290
1 320
50
61
76
81
73
77
73
624
542
427
304
226
209
193
226
226
236
213
183
177
169
710
788
713
566
482
462
444
296
483
726
799
668
633
603
(295426)
(223321)
(157227)
(118170)
(98142)
(94135)
(90129)
(1.3526)
(7.4456)
(12536)
(23476)
(78196)
(64225)
(55204)
(260324)
(459573)
(291363)
(162202)
(102127)
(94118)
(84105)
(83199)
(102149)
(93137)
(88123)
(80117)
(79115)
(78113)
(114164)
(126183)
(128184)
(117169)
(110158)
(113163)
(112162)
(2764)
(3348)
(3044)
(2740)
(2637)
(2537)
(2536)
(128305)
(228335)
(308453)
(416611)
(529771)
(563813)
(596861)
(206413)
(259381)
(471691)
(7561 110)
(7981 160)
(8091 170)
(8191 180)
(165394)
(275405)
(657964)
(9381 380)
(1 0301 500)
(1 0601 530)
(1 0901 570)
(4159)
(5173)
(6391)
(6797)
(6087)
(6392)
(6087)
(3281 010)
(297860)
(259636)
(220402)
(182274)
(169253)
(156234)
(193261)
(193261)
(207268)
(197229)
(171194)
(166189)
(159180)
(624801)
(719861)
(661767)
(519615)
(434532)
(418509)
(401489)
(159476)
(335658)
(573897)
(634984)
(514842)
(489795)
(466757)
NUMBER
(THOUSANDS)
RATEa
1.3
1.8
2
1.9
1.8
1.8
1.7
2.7
23
52
60
51
52
50
11
14
11
7.6
4
3.6
2.9
<0.01
<0.01
0.014
<0.01
0.02
0.018
0.015
0.18
0.4
0.75
1.1
1.1
1.6
1.7
(1.01.5)
16 (1319)
(1.32.3)
19 (1525)
(1.52.5)
18 (1423)
(1.52.4)
15 (1119)
(1.32.4)
12 (8.516)
(1.32.2)
11 (8.714)
(1.32.2)
11 (8.214)
(0.02911)
2.8 (<0.112)
(1.274)
20 (1.168)
(3.7160)
42 (3.0132)
(8.0160)
43 (5.7118)
(3177)
33 (2050)
(2588)
33 (1656)
(2386)
30 (1453)
(9.612)
151 (134168)
(1216)
248 (212288)
(9.713)
141 (120164)
(6.78.5)
82 (7392)
(3.64.5)
39 (3443)
(3.24.0)
34 (3038)
(2.63.3)
27 (2430)
(<0.01<0.01) 3.8 (2.45.6)
(<0.010.011) 6.6 (4.98.7)
(0.0100.018) 9.7 (7.312)
(<0.010.011) 3.4 (0.947.5)
(<0.010.035) 12 (5.722)
(<0.010.030) 11 (5.718)
(<0.010.025)
9 (4.715)
(0.1500.210) 2.4 (2.02.9)
(0.2900.520) 4.7 (3.46.2)
(0.5600.970) 7.9 (5.910)
(0.8501.4)
10 (7.813)
(0.8601.3)
8.8 (7.111)
(1.32.0)
13 (1116)
(1.42.1)
14 (1116)
<0.01
<0.01
<0.01
0.018
0.17
0.81
2.4
4.2
4
3.8
3.9
34
140
270
290
300
330
0.54
1.8
6.5
10
12
12
12
0.21
0.44
0.84
1.1
0.85
1.2
1
82
77
59
45
39
38
35
18
31
36
33
30
30
30
37
49
50
45
41
40
38
21
50
83
85
65
62
46
(<0.010.013) 6.3
(<0.01<0.01) 1.8
(<0.010.011) 5.8
(0.0110.027) 0.5
(0.1200.230) 4.4
(0.6101.0)
20
(1.93.1)
47
(3.45.1)
74
(3.34.8)
69
(3.14.6)
64
(2.75.4)
11
(2742)
81
(110170)
317
(220320)
558
(240350)
586
(240350)
592
(270390)
650
(0.3300.800) 63
(1.42.2)
186
(5.27.8)
607
(8.412)
934
1 040
(1015)
(1015)
1 050
(1015)
1 010
(0.1700.250) 5.8
(0.3500.550) 11
(0.6701.0)
18
(0.8501.3)
20
(0.6801.0)
14
(0.8301.5)
19
(0.8101.2)
16
(43130)
463
(42120)
369
(3589)
244
(3260)
158
(3248)
122
(3046)
113
(2842)
102
(1521)
71
(2637)
103
(3142)
106
(2938)
86
(2832)
70
(2832)
68
(2832)
65
(3342)
476
(4455)
551
(4556)
493
(4050)
389
(3746)
325
(3644)
302
(3542)
285
(1134)
203
(3468)
427
(65100)
666
(67110)
678
(5083)
525
(4878)
491
(3658)
360
(1.415)
(<0.18.0)
(1.612)
(0.280.67)
(3.05.9)
(1525)
(3760)
(6089)
(5682)
(5277)
(7.315)
(64101)
(255386)
(450678)
(475708)
(488705)
(536774)
(3993)
(149228)
(491736)
(7571 130)
(8551 240)
(8681 250)
(8361 210)
(4.76.9)
(8.613)
(1422)
(1624)
(1218)
(1426)
(1320)
(243752)
(200588)
(146367)
(112212)
(98148)
(91136)
(82123)
(6082)
(86122)
(90124)
(7597)
(6574)
(6372)
(6169)
(418537)
(489617)
(443547)
(346434)
(292358)
(273333)
(257314)
(109327)
(294585)
(522827)
(532842)
(403662)
(379617)
(279452)

NUMBER
RATEa
CASE DETECTION
PERCENT
5 200
1 980
4 701
7 873
9 904
10 130
10 325
20 122
13 423
25 821
62 598
88 589
84 121
86 778
6 387
3 054
6 093
7 220
7 251
6 703
6 623
17
67
22
43
61
66
65
64
21
12
21
45
57
53
53
90
55
75
78
70
63
61
15
19
8
23
43
56
58
59
16
8.8
12
26
44
40
45
31
11
23
43
62
60
64
11
(1623)
(6.79.7)
(1927)
(3652)
(4767)
(4870)
(5072)
(3.91 500)
(2.7160)
(3.9170)
(9.4190)
(2974)
(2483)
(2696)
(2835)
(9.612)
(2126)
(3949)
(5569)
(5467)
(5872)
(7.318)
97
136
78
121
136
4 977
7 561
8 508
9 765
11 139
11 061
11 022
41
8
20
14
15
17
21
632
1 955
3 760
6 737
11 524
12 859
12 734
80 400
73 917
151 239
270 178
360 183
354 786
343 715
69
89
48
73
81
69
90
90
90
92
89
86
58
11
25
17
17
20
24
16
50
91
131
201
219
212
219
179
338
565
724
708
681
60
85
49
76
86
50
59
58
63
69
65
63
130
27
70
50
56
64
80
7.7
18
24
26
31
32
29
73
56
59
61
75
72
69
(5074)
(73100)
(4160)
(6493)
(72100)
(4261)
(4971)
(4970)
(5377)
(5884)
(5579)
(5377)
(90220)
(2233)
(5885)
(4261)
(4768)
(5478)
(6797)
(5.212)
(1522)
(2029)
(2131)
(2638)
(2739)
(2536)
(53110)
(4769)
(4972)
(5175)
(6291)
(6187)
(5883)
2 050
5 877
8 062
10 038
10 101
8 337
1 324
1 520
1 409
2 537
2 986
2 791
2 888
14 740
25 316
30 372
41 040
41 703
42 885
46 306
22 249
39 847
54 442
61 022
61 537
61 098
59 357
16 863
35 958
49 806
49 576
44 879
44 154
43 583
9 132
30 831
50 855
50 454
42 971
44 209
38 404
213
552
730
859
852
693
36
37
29
47
51
46
47
83
122
125
144
129
128
134
87
133
160
157
141
136
128
215
403
488
433
353
337
323
87
264
407
401
344
352
301
63
69
64
68
66
53
73
61
38
58
69
60
64
13
22
29
47
57
61
69
39
59
68
74
77
77
76
30
51
68
76
73
73
73
29
55
56
50
52
56
50
(5377)
(5784)
(5378)
(5783)
(5680)
(4464)
(6188)
(5174)
(3247)
(4970)
(5884)
(5073)
(5478)
(8.225)
(1441)
(2048)
(3666)
(4771)
(5176)
(5786)
(3345)
(5169)
(6077)
(6980)
(7383)
(7282)
(7181)
(2734)
(4756)
(6474)
(7083)
(6681)
(6681)
(6681)
(1855)
(4079)
(4571)
(4163)
(4167)
(4472)
(4065)
YEAR
Algeria
46
60
Angola
99
241
Benin
43
46
Botswana
213
325
Burkina Faso
16
31
Burundi
82
79
Cameroon
48
122
Cape Verde
63
76
Central African
Republic
72
125
Chad
43
91
Comoros
32
16
Congo
25
265
Cte d'Ivoire
63
112
Democratic
Republic
of the Congo
58
163
Equatorial
Guinea
70
123
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
11 607
13 507
18 572
21 336
21 701
22 336
21 429
10 271
5 143
16 062
37 175
41 221
44 655
47 240
2 074
2 400
2 697
3 270
3 878
3 756
4 212
2 938
5 665
9 292
10 058
8 362
7 013
6 603
1 497
2 572
2 331
3 478
4 716
4 800
5 286
4 575
3 326
6 421
6 585
7 277
7 611
6 742
5 892
3 292
5 251
21 499
24 662
24 073
24 533
221
303
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
5 735
8 328
8 654
8 402
8 299
7 790
2 256
2 019
1 651
1 691
1 770
1 753
5 065
7 758
10 216
10 888
11 770
11 444
3 804
9 053
20 410
22 488
21 146
21 703
1 410
1 839
2 277
2 739
2 960
2 973
3 331
1 631
5 367
12 467
13 755
17 285
18 380
310
281
130
96
338
296
329
266
1 102
2 569
2 580
3 780
4 399
182
212
199
285
418
367
398
1 903
3 091
3 170
3 144
3 295
2 669
2 885
4 789
5 166
3 393
2 055
1 983
1 028
1 545
2 290
3 061
3 041
3 450
267
230
0
0
451
467
548
490
497
442
0
0
0
147
181
502
396
453
738
1 058
46
726
619
130
147
1 239
548
1 122
1 072
868
0
0
0
195
502
571
671
729
742
90
92
77
175
45
88
160
213
217
227
90
167
395
335
257
45
178
327
608
552
484
0
0
0
0
0
908
1 489
1 160
1 207
963
799
1 116
1 568
2 089
1 880
1 826
1 649
0
0
24
8
5
181
205
74
192
224
229
20
42
46
108
86
181
225
116
238
332
315
0
0
0
0
0
2 896
3 960
13 001
14 635
14 464
14 927
142
625
5 021
5 780
5 437
4 941
18
415
2 461
3 190
3 157
3 597
0
0
0
0
236
251
1 016
1 057
1 015
1 068
574
512
479
593
236
251
1 590
1 569
1 494
1 661
0
0
0
0
111
150
12
135
172
186
182
93
94
98
127
43
53
54
54
1 794
964
393
3 210
8 743
6 643
5 611
2 591
3 186
2 153
5 132
3 638
3 479
608
1 841
1 598
964
286
1 394
1 079
876
2 002
518
6 311
8 411
9 452
10 505
140
123
120
111
120
2 516
3 820
3 833
4 434
2 419
2 949
3 746
4 211
103
87
79
76
10
14
14
15
707
820
883
195
196
367
679
736
692
1 121
3 159
3 262
3 974
4 590
4 060
0
0
0
189
187
109
85
108
117
591
3 615
9 239
9 853
9 765
10 150
10 975
7 841
11 988
15 094
19 681
22 571
22 708
22 476
21 131
42 819
61 024
97 075
111 709
114 170
110 132
260
306
720
1 231
1 220
1 429
1 210
1 213
451
547
713
612
691
610
134
540
2 871
3 863
7 776
4 444
221
68
280
337
271
205
262
292
332
356
380
2 124
3 339
0
0
0
134
540
1 729
2 398
2 444
2 758
172
68
91
150
162
120
154
80
165
122
194
168
0
0
1 142
1 465
5 332
1 686
49
30
0
0
0
21
13
18
17
0
0
0
30
13
20
9
10
188
34
33
27
27
0
0
0
188
24
60
163
376
304
232
463
203
1 055
1 206
1 217
1 033
0
193
249
321
436
463
578
194
240
245
269
515
676
708
847
0
0
0
7
15
16
24
0
0
7
4
2
5
1
1
1
7
5
3
6
0
8
11
650
108
170
171
168
78
819
407
451
516
507
62
13
28
2 013
4 218
3 640
3 433
3 568
3 716
849
2 016
3 249
3 398
3 545
3 930
675
2 810
2 665
2 653
2 692
2 990
8 254
10 276
12 496
14 300
14 131
14 416
1 508
1 616
2 315
2 321
2 381
2 316
1 577
2 756
4 235
4 952
5 179
4 729
20 914
36 513
65 040
73 078
73 653
71 321
7 953
8 089
9 959
12 968
14 039
13 471
9 112
13 785
18 494
21 313
22 340
21 579
219
45
41
490
579
611
109
98
118
77
109
131
128
253
117
113
291
629
421
345
0
0
0
0
0
649
446
635
998
1 017
1 015
447
345
438
502
444
649
893
980
1 436
1 519
1 459
2 891
2 637
3 582
4 350
4 138
3 761
2 483
4 316
4 466
4 158
2 891
2 637
6 065
8 666
8 604
7 919
0
0
0
31
34
23
0
0
203
78
169
299
281
345
339
0
0
0
0
0
0
0
13
33
30
44
67
53
0
0
0
AFRICAN REGION
NEW AND RELAPSE

NOTIFICATION RATE
19902011
72
80
84
83
82
82
70
63
62
62
55
54
82
87
95
97
90
91
91
40
39
38
48
62
57
84
89
86
82
81
83
55
68
74
77
83
84
95
86
72
72
73
75
43
59
65
65
59
65
78
74
69
78
79
51
56
51
51
91
86
85
84
83
70
68
53
50
50
49
85
86
84
86
86
86
72
82
87
85
84
84
83
82
86
84
155
NEW AND RELAPSE

a
NOTIFICATION RATE
19902011
YEAR
Eritrea
117
56
Ethiopia
183
185
Gabon
99
287
Gambia
127
Ghana
43
62
Guinea
35
111
Guinea-Bissau
114
133
Kenya
50
234
Lesotho
154
521
Liberia
191
Madagascar
56
122
Malawi
132
126
Mali
34
34
Mauritania
265
50
Mauritius
11
156
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
3 699
21 453
6 652
3 549
2 904
2 870
3 049
88 634
26 034
91 101
124 262
148 936
154 694
156 539
917
1 115
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
590
687
802
832
835
18 205
5 332
1 764
1 123
1 115
1 163
3 248
683
1 001
890
836
888
9 040
30 510
38 525
44 396
46 634
49 594
8 888
30 565
39 816
52 053
54 979
55 497
7 763
28 907
43 675
50 228
50 417
49 305
486
517
68
1 042
1 244
1 560
1 740
1 071
1 414
1 366
1 959
241
246
379
384
1 023
778
171
68
2 031
2 145
2 070
2 248
6 407
8 636
10 933
12 124
14 892
14 607
15 389
1 988
3 523
5 440
6 863
8 357
11 038
11 359
1 163
1 613
1 273
1 774
2 171
2 183
2 063
11 788
28 142
64 159
102 680
102 997
99 272
97 320
2 525
5 181
9 746
10 802
12 213
11 674
11 432
1 127
1 316
1 344
1 375
749
622
462
673
78
141
143
199
2 638
7 316
7 505
8 255
7 656
7 616
1 225
2 500
3 068
4 734
5 068
5 875
109
615
1 019
1 437
1 400
1 471
2 263
3 920
5 479
5 377
7 041
6 934
527
430
524
1 021
1 472
1 446
620
938
629
1 611
2 077
2 284
956
526
1 132
1 310
1 409
1 230
6 800
13 934
28 773
40 389
37 402
36 260
37 085
714
600
522
786
636
644
19
57
24
16
22
63
9 676
24 143
43 772
44 514
41 962
39 810
3 468
9 118
15 265
17 438
17 382
17 069
1 361
3 041
4 280
3 976
3 600
3 510
2 685
2 838
4 063
5 083
5 331
5 343
653
2 520
2 020
2 486
2 222
2 099
1 154
1 021
2 167
3 796
3 750
4 261
119
285
575
1 022
1 385
1 967
120
187
657
1 023
1 363
1 612
2 512
3 073
3 473
4 404
1 393
1 500
3 432
5 918
6 597
7 906
6 261
21 616
18 993
22 758
24 432
26 019
12 395
19 155
23 604
25 491
22 674
21 092
19 361
2 933
3 087
4 216
4 704
6 611
5 291
5 428
5 284
3 849
3 067
2 162
2 640
2 461
1 776
119
131
160
125
115
122
114
8 026
987
2 219
13 056
15 729
16 795
17 927
4 301
6 285
8 260
8 443
7 623
7 240
7 003
1 287
1 639
1 657
1 726
5 827
7 054
8 846
10 132
9 297
8 245
6 612
3 634
3 990
4 545
4 851
1 885
5 257
5 734
5 823
4 966
4 857
5 076
1 866
2 527
3 530
5 163
3 686
3 777
609
797
482
429
481
491
459
653
492
818
926
984
2 074
1 583
1 155
1 555
1 422
1 009
800
687
454
444
390
222
455
580
403
483
524
458
113
115
110
98
105
100
8
14
4
7
5
3
12
23
8
6
6
8
0
0
60
47
97
89
87
103
20
27
118
121
44
67
124
207
208
147
36
0
0
0
0
0
343
1 119
2 246
2 259
2 664
2 143
1 658
873
1 285
2 234
2 478
343
2 777
3 119
3 544
4 898
4 621
44
99
486
390
512
257
655
558
833
89
41
41
138
166
107
81
139
159
502
532
466
483
427
394
538
451
159
502
532
860
1 021
878
0
86
273
55
152
231
348
362
422
294
227
241
286
247
55
446
458
589
648
669
0
0
0
0
59
90
96
59
116
126
42
17
76
7
59
90
138
76
192
133
0
0
0
0
0
0
1 064
1 773
3 254
3 643
3 668
3 356
704
5 721
7 068
6 811
6 661
1 064
2 477
8 975
10 711
10 479
10 017
0
0
147
385
439
668
521
480
1 096
602
1 302
1 464
1 196
147
1 481
1 041
1 970
1 985
1 676
7
33
77
99
66
25
24
46
71
59
32
57
123
170
125
482
689
674
703
0
0
0
158
169
168
321
44
6
0
0
81
0
0
0
0
0
77
66
40
1
596
0
0
0
0
317
0
0
0
0
0
0
16
0
0
0
0
596
1 016
1 400
1 435
1 515
382
551
764
1 093
788
750
670
0
2 119
1 682
1 444
1 493
1 498
2 089
2 109
2 218
382
551
764
3 212
2 470
2 194
2 163
153
239
200
201
198
176
180
224
157
145
153
239
380
425
355
321
0
0
0
0
520
580
150
158
125
87
358
56
24
28
16
520
938
206
182
153
103
28
0
0
0
2
8
3
4
6
3
4
2
1
1
2
2
12
5
5
7
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
28
42
43
42
50
50
49
46
46
47
48
49
47
53
47
82
60
68
74
67
68
75
71
64
60
56
81
90
91
84
83
83
57
47
68
62
69
66
100
59
54
48
46
46
48
34
52
51
44
40
40
91
78
79
79
73
68
89
91
91
91
91
42
47
48
45
45
47
51
75
76
88
92
88
88
72
70
72
78
78
82
93
89
96
93
95
97
YEAR
Mozambique
117
186
Namibia
189
465
Niger
67
64
Nigeria
21
53
Rwanda
90
61
Sao Tome and

Principe
15
81
Senegal
69
86
Seychelles
58
24
Sierra Leone
16
212
South Africa
219
681
Swaziland
693
Togo
36
47
Uganda
83
134
United Republic
of Tanzania
87
128
Zambia
215
323
Zimbabwe
87
a
301
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
15 899
17 882
21 158
33 231
43 221
43 558
44 627
2 671
1 540
10 799
14 920
11 980
11 281
10 806
5 200
1 980
4 701
7 873
9 904
10 130
10 325
20 122
13 423
25 821
62 598
88 589
84 121
86 778
6 387
3 054
6 093
7 220
7 251
6 703
6 623
17
97
136
78
121
136
4 977
7 561
8 508
9 765
11 139
11 061
11 022
41
8
20
14
15
17
21
632
1 955
3 760
6 737
11 524
12 859
12 734
80 400
73 917
151 239
270 178
360 183
354 786
343 715
2 050
5 877
8 062
10 038
10 101
8 337
1 324
1 520
1 409
2 537
2 986
2 791
2 888
14 740
25 316
30 372
41 040
41 703
42 885
46 306
22 249
39 847
54 442
61 022
61 537
61 098
59 357
16 863
35 958
49 806
49 576
44 879
44 154
43 583
9 132
30 831
50 855
50 454
42 971
44 209
38 404
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
10 566
13 257
17 877
19 579
20 097
19 537
5 054
4 037
9 184
17 019
16 408
18 159
1 363
2 262
4 771
5 301
5 621
5 504
697
4 012
5 222
4 608
4 464
4 503
507
4 724
4 455
3 628
3 309
3 034
248
1 459
1 907
2 538
2 330
2 039
1 492
3 045
5 050
6 347
6 283
6 604
116
699
1 193
1 689
1 730
1 856
372
702
1 227
1 385
1 492
1 489
9 476
17 423
35 048
44 863
45 416
47 436
3 364
6 613
22 705
37 540
32 616
33 034
280
1 069
2 836
3 560
3 422
3 793
1 840
3 681
4 166
4 184
3 785
3 811
676
845
859
1 239
1 072
1 017
338
1 289
1 727
1 582
1 577
1 300
30
49
52
47
53
56
75
20
63
49
7
1
4
10
28
5 421
5 823
6 722
7 883
7 688
7 765
1 073
1 370
1 557
1 504
1 470
1 389
504
800
921
1 233
1 404
1 315
6
11
8
11
9
2
2
7
3
2
8
13
1
2
1
2
0
6
1 454
2 472
4 370
6 092
6 898
7 435
339
821
1 679
4 491
4 919
4 358
121
400
551
776
831
775
23 112
75 967
125 460
139 468
132 107
129 770
74 399
16 392
76 680
147 187
151 772
148 266
10 636
17 486
39 739
53 411
52 095
47 285
660
1 823
2 187
3 498
3 011
2 408
687
3 198
4 106
4 157
5 064
4 228
219
583
1 458
1 903
1 631
1 395
887
984
1 798
2 267
2 096
2 087
304
91
170
235
164
205
236
287
484
377
397
475
13 631
17 246
20 559
23 113
23 456
25 614
11 553
19 955
24 049
25 264
24 895
24 769
24 115
5 912
9 003
15 040
12 315
13 567
14 389
2 070
2 618
3 780
4 893
4 571
5 001
12 362
17 624
20 810
21 750
21 184
20 438
6 195
10 997
13 094
13 405
13 715
13 725
10 038
12 927
14 857
12 995
12 639
12 046
3 268
25 222
24 327
20 825
20 412
20 004
656
10 202
8 587
9 246
9 255
9 908
8 965
14 392
13 155
10 195
11 654
12 596
10 934
27 626
29 074
24 890
25 157
19 172
5 040
8 837
6 721
6 683
6 061
5 192
899
917
1 399
1 322
1 432
1 427
546
487
2 308
2 616
2 825
899
1 463
1 886
3 630
4 048
4 252
88
604
849
1 206
1 178
1 230
930
974
1 352
1 344
1 132
88
1 534
1 823
2 558
2 522
2 362
255
403
483
452
376
351
207
215
204
255
754
690
667
580
0
117
0
185
303
716
2 009
2 626
2 667
2 515
1 640
2 858
5 525
6 326
6 272
303
2 356
4 867
8 151
8 993
8 787
1 392
0
0
0
242
200
278
371
246
269
253
96
460
229
362
161
200
374
831
475
631
414
0
0
0
0
4
11
2
1
6
16
1
1
10
4
27
3
2
16
0
0
0
0
0
0
563
515
565
519
499
553
541
355
593
530
566
563
1 056
920
1 112
1 029
1 119
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
41
67
137
165
211
166
374
193
302
336
209
41
441
330
467
547
375
28 299
20 117
18 812
18 394
56 202
32 289
45 799
41 768
27 521
179
56 202
60 588
65 916
60 580
45 915
489
273
311
480
395
306
976
159
994
1 045
843
489
1 249
470
1 474
1 440
1 149
0
0
0
93
47
85
107
134
121
86
94
107
106
92
93
133
179
214
240
213
955
1 505
1 661
1 382
1 291
1 302
0
769
2 632
2 661
2 712
955
1 505
2 430
4 014
3 952
4 014
1 335
1 772
1 854
1 487
1 430
1 079
3 178
2 730
2 355
1 791
1 335
1 772
5 032
4 217
3 785
2 870
3 691
672
4 462
5 011
243
1 455
5 496
2 485
6 310
6 636
4 437
3 482
3 348
2 901
5 941
4 685
4 685
4 345
0
0
0
2 487
0
0
0
173
0
0
0
0
97
0
179
0
0
0
0
0
0
0
0
0
243
1 455
1 805
1 813
1 848
1 625
737
0
0
0
0
1 504
1 203
1 337
1 444
0
0
0
0
0
164
0
0
0
0
18 738
643
0
0
4
0
0
0
0
0
737
0
0
AFRICAN REGION
NEW AND RELAPSE

NOTIFICATION RATE
19902011
68
77
66
53
55
52
58
46
54
56
57
60
93
81
81
79
78
78
74
72
61
54
58
59
73
81
83
77
78
79
35
40
72
43
52
83
81
81
84
84
85
75
61
73
85
53
13
81
75
72
58
58
63
24
82
62
49
47
47
49
36
35
46
37
36
74
92
91
91
93
91
70
66
58
65
63
64
100
62
58
55
53
54
54
75
34
38
38
38
38
45
34
31
29
32
40
157
% OF COHORT
a
TREATMENT SUCCESS (%)

19952010
Algeria
89
Angola
48
71
91
67
81
25
77
45
92
53
78
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African
Republic
37
68
Chad
47
68
90
91
Comoros
Congo
77
68
77
74
90
89
70
Cte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
Eritrea
84
61
83
Ethiopia
Gabon
86
a
158
63
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
5 735
8 328
8 654
8 643
8 402
8 299
3 804
9 053
20 410
22 562
22 488
21 146
1 839
2 277
2 739
2 966
2 960
2 973
1 903
3 091
3 170
3 217
3 144
3 295
1 028
1 545
2 290
2 757
3 061
3 041
1 121
3 159
3 262
3 610
3 974
4 590
2 896
3 960
13 001
14 232
14 635
14 464
111
135
197
172
186
1 794
2 153
4 232
5 132
3 638
2 002
2 516
3 309
3 820
3 833
103
87
79
77
76
SIZE OF
COHORT
8 328
8 379
8 190
8 438
7 894
6 392
20 113
22 562
21 627
21 145
1 839
2 277
2 766
2 979
2 963
2 987
2 060
3 991
3 335
3 289
3 492
3 314
1 200
1 574
2 290
2 757
3 061
3 057
1 798
3 465
3 424
3 635
3 974
4 590
2 740
3 164
13 169
14 091
14 428
14 464
14
135
197
692
1 366
3 217
3 571
5 132
3 569
529
3 820
3 780
113
85
70
77
87
2 013
4 218
3 640
3 371
3 433
3 568
8 254
10 276
12 496
15 294
14 300
14 131
20 914
36 513
65 040
69 720
73 078
73 653
219
3 114
4 121
3 263
3 634
3 447
7 221
10 631
12 496
15 294
14 300
14 131
16 247
36 123
65 066
65 962
72 367
73 448
219
541
490
579
541
490
590
590
687
839
802
832
9 040
30 510
38 525
40 794
44 396
46 634
486
765
688
839
804
804
5 087
29 662
39 430
40 794
44 807
46 634
249
1 042
1 502
1 244
1 560
1 165
1 502
1 163
1 671
COHORT AS
% NOTIFIED
100
97
95
100
95
71
99
100
96
100
100
100
101
100
100
100
108
129
105
102
111
101
117
102
100
100
100
101
160
110
105
101
100
100
95
80
101
99
99
100
100
100
39
149
84
100
98
26
100
99
110
98
89
100
74
113
97
106
97
87
103
100
100
100
100
78
99
100
95
99
100
100
100
100
102
130
100
100
100
97
56
97
102
100
101
100
51
112
100
93
107
DIED
FAILED
DEFAULTED
NOT
EVALUATED
CURED
COMPLETED
80
74
80
81
79
7
13
10
10
10
1
2
2
2
2
2
0
0
1
1
5
3
3
3
4
5
8
4
3
4
68
45
45
47
30
50
57
74
81
82
84
13
22
37
46
57
50
22
53
66
73
72
74
25
42
52
76
83
87
45
67
66
62
65
64
28
24
25
18
21
20
13
8
9
7
54
55
33
18
22
32
2
7
5
3
4
3
20
39
27
14
7
4
8
10
7
15
13
14
3
3
4
4
8
6
6
7
6
5
5
5
6
7
5
5
5
5
13
14
11
10
9
3
4
4
4
3
4
7
7
6
6
6
6
2
3
2
2
1
1
2
2
2
2
2
1
0
1
2
3
2
1
2
7
8
9
7
0
0
0
0
1
1
1
2
1
1
1
1
26
19
18
18
8
17
11
3
2
1
1
12
7
8
4
4
3
3
16
6
4
4
6
14
13
17
6
5
3
35
13
14
10
10
10
2
3
6
5
35
5
3
1
1
0
1
15
10
15
24
9
8
67
9
1
1
2
1
38
1
1
0
0
0
4
1
5
5
5
5
64
56
57
0
8
17
7
3
4
0
2
2
0
19
11
29
12
11
16
36
38
43
33
45
17
21
21
28
29
20
23
30
7
0
6
7
3
6
6
0
3
2
2
1
1
1
53
34
8
12
13
19
43
3
5
19
9
30
7
3
55
39
90
91
91
90
22
28
0
2
0
0
4
4
4
4
3
4
2
2
0
4
4
0
15
21
6
0
0
4
3
5
0
0
1
3
91
57
24
63
66
63
63
47
62
67
69
66
55
69
80
83
85
86
89
12
4
13
12
13
6
10
11
9
10
12
20
8
5
4
3
4
0
4
0
1
1
2
4
5
8
9
8
7
5
6
6
4
4
4
3
0
1
0
0
1
1
2
2
2
3
2
1
1
1
1
1
1
0
22
13
21
13
12
17
16
10
9
7
8
10
8
4
3
3
3
8
5
58
1
7
8
9
20
6
4
4
5
9
7
4
4
4
3
0
42
47
50
14
19
20
4
3
5
1
1
1
31
16
17
7
14
7
64
83
72
83
81
56
63
64
67
65
66
63
12
5
3
2
4
5
17
14
17
19
17
22
8
7
4
5
7
5
6
5
3
3
3
1
1
1
1
3
3
2
1
1
1
1
1
2
9
2
1
2
1
13
9
4
3
3
3
9
6
1
18
5
5
19
4
12
10
10
10
2
35
30
37
34
12
24
18
29
10
1
1
2
1
0
1
3
42
19
25
26
1
27
18
6
Gambia
76
88
54
86
78
80
Ghana
Guinea
Guinea-Bissau
65
73
75
87
Kenya
Lesotho
47
69
Liberia
79
Madagascar
55
82
71
87
Malawi
Mali
59
76
Mauritania
69
Mauritius
90
39
85
Mozambique
Namibia
85
Niger
82
49
84
Nigeria
Rwanda
88
Sao Tome and

Principe
0
a
78
YEAR
NUMBER
NOTIFIED
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
SIZE OF
COHORT
COHORT AS
% NOTIFIED
778
686
1 127
1 300
1 316
1 344
2 638
7 316
7 505
7 904
8 255
7 656
2 263
3 920
5 479
6 561
5 377
7 041
956
526
1 132
1 223
1 310
1 409
13 934
28 773
40 389
36 811
37 402
36 260
1 361
3 041
4 280
3 862
3 976
3 600
1 154
1 021
2 167
3 038
3 796
3 750
8 026
1 127
1 318
1 296
1 344
361
7 316
7 584
7 904
8 255
7 656
2 263
3 920
5 811
4 984
5 597
7 250
959
88
100
101
98
100
14
100
101
100
100
100
100
100
106
76
104
103
100
103
102
114
90
46
99
100
100
100
100
131
129
100
102
107
138
90
100
100
100
113
117
100
100
100
100
100
100
100
100
100
69
100
100
86
102
152
100
101
100
139
100
100
100
100
100
100
100
100
100
100
100
100
100
102
102
105
100
100
99
100
100
94
100
100
100
100
103
100
100
100
101
323
100
100
96
96
13 056
15 391
15 729
16 795
6 285
8 260
8 443
7 627
7 623
7 240
1 866
2 527
3 530
4 734
5 163
3 686
2 074
1 583
1 155
1 605
1 555
1 422
113
115
110
85
98
105
10 566
13 257
17 877
18 824
19 579
20 097
697
4 012
5 222
4 928
4 608
4 464
1 492
3 045
5 050
5 853
6 347
6 283
9 476
17 423
35 048
46 026
44 863
45 416
1 840
3 681
4 166
4 173
4 184
3 785
30
49
52
52
47
1 167
1 242
1 498
1 271
6 470
28 376
40 436
36 811
37 402
36 260
1 788
5 542
3 858
4 070
3 852
1 595
924
2 167
3 042
3 796
9 101
10 506
15 298
15 376
15 709
16 789
6 293
8 296
8 443
7 632
7 624
7 240
1 290
3 530
4 734
4 454
3 778
1 761
1 605
1 563
1 422
160
110
85
98
105
10 566
13 296
17 877
18 824
19 579
20 097
4 012
5 222
4 928
4 702
4 538
3 193
5 050
5 860
6 313
6 266
9 476
16 372
35 080
46 026
44 863
45 416
3 776
4 175
4 173
4 165
3 806
97
49
52
50
45
CURED
COMPLETED
DIED
FAILED
DEFAULTED
AFRICAN REGION
% OF COHORT
a

19952010
NOT
EVALUATED
69
13
81
80
88
86
41
45
68
78
79
76
62
59
65
70
72
76
42
6
4
1
2
13
5
5
8
8
10
17
9
7
8
6
4
23
7
9
6
5
11
6
9
8
7
7
6
7
6
5
5
4
6
1
2
1
1
2
3
2
1
1
1
2
1
2
2
2
2
0
3
2
2
3
11
14
11
2
3
3
9
15
10
7
7
6
23
2
3
1
3
22
27
5
3
3
3
5
9
10
8
8
9
6
51
59
51
54
60
66
71
76
78
81
32
18
11
17
18
14
14
11
9
8
6
14
12
4
6
6
9
5
5
4
4
3
7
1
0
1
0
1
0
0
0
1
1
0
11
17
21
14
9
9
8
7
6
5
9
7
9
5
7
7
6
5
4
4
4
36
73
9
11
10
1
2
2
2
5
6
0
2
1
4
4
5
8
12
10
12
10
9
14
9
12
12
0
3
8
5
3
64
59
58
79
71
60
64
57
9
16
15
26
8
11
11
10
5
2
3
4
5
47
61
67
77
78
78
65
70
72
85
87
86
41
8
9
7
4
3
4
6
3
2
2
2
2
18
6
7
6
5
4
4
19
19
15
8
7
7
5
2
1
1
1
1
1
1
1
1
1
1
1
0
16
17
13
9
9
9
0
4
3
2
2
2
22
20
5
5
5
5
4
10
3
7
2
1
2
14
69
75
66
76
6
6
12
0
11
9
10
8
4
4
4
3
7
4
7
9
3
2
2
4
44
54
51
55
11
14
12
14
2
2
3
2
1
1
1
1
19
12
10
13
24
17
23
15
0
86
87
88
90
34
73
78
83
84
83
92
2
3
6
4
4
3
10
12
10
9
8
0
0
0
5
2
1
1
1
2
0
0
1
1
1
1
1
1
1
3
6
5
4
5
9
11
5
4
3
4
0
5
2
4
0
48
3
2
1
2
1
41
59
72
74
74
15
16
10
11
11
6
7
6
5
5
2
2
4
4
4
15
10
4
4
3
21
7
4
2
2
42
49
71
66
69
34
65
50
68
73
73
22
25
10
13
13
15
14
25
11
10
10
8
5
6
7
7
5
6
9
2
5
5
4
2
2
2
2
2
2
4
5
1
1
12
14
7
7
6
9
11
11
9
8
8
11
5
4
5
3
35
2
1
6
4
2
52
73
79
77
80
9
10
8
8
8
6
6
5
5
5
1
2
4
4
4
4
3
2
3
2
28
6
3
3
1
52
98
94
98
20
27
0
0
0
58
9
2
4
0
9
5
0
2
2
0
7
0
0
0
13
0
0
0
0
0
159
% OF COHORT
a

19952010
Senegal
44
85
89
100
69
86
58
79
Seychelles
Sierra Leone
South Africa
Swaziland
73
Togo
60
84
44
71
73
90
70
86
53
81
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
160
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
5 421
5 823
6 722
7 584
7 883
7 688
6
11
8
4
11
9
1 454
2 472
4 370
5 826
6 092
6 898
23 112
75 967
125 460
138 803
139 468
132 107
660
1 823
2 187
3 105
3 498
3 011
887
984
1 798
2 234
2 267
2 096
13 631
17 246
20 559
22 766
23 113
23 456
19 955
24 049
25 264
24 171
24 895
24 769
10 038
12 927
14 857
13 211
12 995
12 639
8 965
14 392
13 155
9 830
10 195
11 654
SIZE OF
COHORT
COHORT AS
% NOTIFIED
5 421
5 823
6 722
7 584
7 883
7 855
9
11
100
100
100
100
100
102
150
100
150
100
78
90
93
100
100
100
100
122
114
107
103
100
102
100
103
100
100
97
100
100
100
100
112
80
100
100
100
100
100
99
100
100
100
98
59
54
100
100
100
385
108
100
98
105
100
100
6
11
7
1 315
2 296
4 370
5 847
6 083
6 897
28 209
86 276
134 782
143 510
139 458
134 250
2 187
3 213
3 498
3 011
856
1 796
2 229
2 267
2 096
15 301
13 874
20 559
22 766
23 113
23 456
19 955
23 923
25 324
24 171
24 895
24 373
5 957
7 014
14 857
13 173
12 995
48 616
9 702
14 392
12 860
10 370
10 195
11 654
DEFAULTED
NOT
EVALUATED
35
43
70
79
81
81
89
82
9
9
6
5
3
4
0
0
4
3
4
4
4
4
11
0
6
1
2
2
2
2
0
0
16
21
11
7
5
6
0
9
31
22
8
4
5
4
0
9
33
55
100
55
70
77
73
68
77
40
54
58
67
67
73
67
9
0
15
7
8
13
10
9
18
9
13
9
6
6
0
18
0
5
6
6
4
6
4
4
6
7
8
7
6
0
0
0
7
2
1
1
1
1
4
1
2
2
2
2
0
0
0
16
13
6
7
11
6
15
13
10
8
7
7
0
18
0
2
2
2
2
4
3
19
17
10
7
12
6
22
50
51
51
42
20
18
19
22
18
6
10
10
11
9
2
7
7
9
3
5
8
7
6
17
45
7
7
2
11
66
76
77
81
26
33
32
28
30
35
69
72
79
84
82
84
47
48
76
83
85
25
32
61
59
67
70
72
5
3
4
3
18
30
41
42
38
36
5
6
4
5
6
6
23
19
8
5
6
61
21
8
9
7
9
10
12
11
10
8
7
7
6
5
5
5
9
10
9
5
5
5
7
7
8
5
6
6
10
12
12
9
8
8
4
3
4
3
1
0
0
1
1
1
1
0
0
0
0
0
2
6
1
1
1
0
0
0
2
0
1
1
11
3
3
4
13
17
16
11
12
11
6
6
4
2
2
2
14
6
2
3
3
4
10
7
7
7
7
5
2
3
2
1
36
12
5
14
16
13
11
5
4
4
5
3
8
14
5
4
0
4
26
13
12
9
6
5
CURED
COMPLETED
DIED
FAILED
Algeria
83
Angola
64
67
85
Benin
Botswana
66
77
76
46
82
Burkina Faso
Burundi
Cameroon
71
Cape Verde
Central African
Republic
58
Chad
48
73
43
80
Comoros
Congo
57
Cte d'Ivoire
65
Democratic
Republic
of the Congo
72
76
83
46
Equatorial
Guinea
Eritrea
88
79
83
Ethiopia
Gabon
0
a
65
YEAR
NUMBER
NOTIFIED
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
451
547
713
651
612
691
134
540
2 871
3 584
3 863
7 776
68
280
337
236
271
205
147
1 239
548
1 095
1 122
1 072
45
178
327
500
608
552
181
225
116
205
238
332
236
251
1 590
1 420
1 569
1 494
30
34
31
33
27
188
291
373
629
421
203
515
631
676
708
7
5
3
6
6
SIZE OF
COHORT
512
713
620
553
598
1 613
3 584
3 044
2 272
139
282
341
230
270
203
395
219
1 067
1 126
1 027
26
166
272
427
509
475
265
92
205
238
332
347
1 611
1 431
1 516
1 489
34
31
353
291
1 139
629
284
92
676
704
7
5
5
6
5
78
819
407
473
451
516
649
893
980
1 429
1 436
1 519
2 891
2 637
6 065
7 738
8 666
8 604
1
50
44
67
67
124
145
207
208
343
2 777
3 119
2 949
3 544
4 898
44
257
296
655
558
187
477
524
418
235
507
980
1 429
1 436
1 519
1 202
5 448
5 399
7 193
5 583
6
50
44
41
145
157
120
193
1 556
3 116
2 949
2 942
3 934
150
158
611
147
COHORT AS
% NOTIFIED
94
100
95
90
87
56
100
79
29
204
101
101
97
100
99
32
40
97
100
96
58
93
83
85
84
86
146
41
100
100
100
138
101
101
97
100
100
100
100
305
100
67
45
100
99
100
100
167
100
23
117
111
93
46
57
100
100
100
100
42
90
70
83
65
600
100
100
61
100
76
58
56
56
100
100
83
80
58
53
93
26
DIED
FAILED
DEFAULTED
AFRICAN REGION
% OF COHORT
a

19952010
NOT
EVALUATED
CURED
COMPLETED
61
48
72
72
69
16
24
11
12
14
5
2
4
4
4
4
1
2
2
2
5
6
6
5
5
10
19
6
5
6
23
39
45
42
48
61
60
65
70
76
24
18
21
23
19
21
21
12
11
9
5
4
5
8
9
5
10
13
11
6
17
4
4
4
4
1
3
7
6
6
26
18
21
16
19
11
6
3
1
1
4
18
3
7
1
0
1
0
1
1
21
33
15
22
20
65
57
71
72
70
72
25
50
54
28
30
43
46
12
4
4
5
5
4
21
13
8
11
11
13
14
8
13
6
10
9
9
6
15
1
5
3
4
3
12
5
10
9
8
8
2
3
11
12
11
8
7
0
15
6
4
5
6
28
17
6
11
30
10
10
4
7
4
1
3
1
18
1
67
81
78
9
3
4
7
6
7
1
3
5
10
4
6
5
2
0
50
49
51
51
55
10
7
16
18
16
9
6
9
9
9
5
3
2
2
3
26
16
15
13
12
2
19
8
7
6
41
32
15
16
0
6
0
3
24
29
21
13
33
53
41
19
35
29
16
30
41
12
24
18
1
9
3
5
7
5
4
0
3
2
4
2
39
8
6
8
25
40
8
1
6
53
6
4
49
38
43
100
100
100
21
35
0
0
0
0
4
4
29
0
0
0
3
2
0
0
0
0
15
18
29
0
0
0
8
3
0
0
0
0
80
20
49
12
49
59
40
13
2
22
22
17
3
0
3
2
3
3
0
4
1
2
28
3
21
14
21
4
83
0
2
18
45
43
55
50
51
56
10
14
12
14
14
16
8
8
7
13
12
8
9
7
12
11
8
2
21
13
9
9
11
12
7
15
4
3
3
6
71
70
54
72
83
4
5
23
5
0
10
9
8
7
0
4
3
2
3
17
6
5
4
6
0
5
8
8
8
0
26
36
32
10
14
15
14
14
22
4
2
0
38
16
27
8
18
5
66
70
81
71
60
41
46
47
56
2
12
8
8
11
15
29
21
27
7
7
9
3
10
9
6
5
4
7
6
2
5
4
2
2
2
3
1
2
1
8
8
5
4
3
5
17
3
0
5
7
28
13
23
6
18
10
12
32
12
21
67
33
5
18
2
3
3
2
1
3
60
11
17
26
3
39
1
2
161
% OF COHORT
a

19952010
Gambia
69
36
Ghana
74
77
67
68
Guinea
Guinea-Bissau
54
72
79
Kenya
Lesotho
58
Liberia
Madagascar
74
69
77
Malawi
Mali
99
59
Mauritania
Mauritius
86
Mozambique
Namibia
78
Niger
75
Nigeria
82
Rwanda
74
Sao Tome and

Principe
0
a
162
50
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
6
166
143
107
81
159
502
532
764
860
1 021
55
446
458
671
589
648
59
90
138
82
76
192
1 064
2 477
8 975
10 444
10 711
10 479
147
1 481
1 041
1 786
1 970
1 985
SIZE OF
COHORT
45
118
100
81
47
540
764
717
1 021
112
299
458
414
111
146
92
89
140
879
1 964
3 794
10 444
4 859
4 333
597
1 746
1 931
2 091
32
57
132
123
170
596
41
57
112
123
1 498
1 962
2 089
2 109
551
764
3 212
2 533
2 470
2 194
153
239
380
411
425
355
520
938
206
194
182
153
2
12
5
4
5
7
899
1 463
1 886
1 782
3 630
4 048
88
1 534
1 823
1 439
2 558
2 522
1 825
1 676
2 073
1 800
492
797
1 093
779
788
750
255
754
617
690
667
303
2 356
4 867
7 048
8 151
8 993
200
374
831
397
475
631
4
27
6
3
2
379
407
390
345
216
182
153
2
5
4
5
7
1 594
1 855
1 782
604
2 009
1 439
1 546
2 548
616
667
661
1 848
3 662
5 488
8 151
8 993
296
506
397
448
446
0
3
3
12
COHORT AS
% NOTIFIED
750
83
93
100
30
102
100
83
100
204
67
100
62
17
106
112
117
73
83
79
42
100
45
41
57
98
98
105
128
100
85
100
122
85
99
85
89
104
34
31
32
34
100
99
92
97
111
100
100
17
100
100
100
100
109
98
100
39
110
100
60
101
100
97
99
78
75
78
100
100
79
61
100
94
71
0
50
100
600
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
69
11
11
68
67
30
68
6
5
6
6
15
17
6
6
3
2
1
9
3
7
0
9
6
2
57
2
40
40
50
38
44
63
45
60
8
27
26
39
23
8
16
11
6
8
10
12
3
5
10
7
3
2
2
2
9
3
7
4
11
2
3
2
13
8
13
10
32
21
10
7
8
13
11
8
55
14
13
44
53
30
23
61
65
68
25
70
73
34
13
34
31
11
11
9
47
8
6
8
9
2
10
9
2
10
7
8
6
0
0
0
0
1
8
1
0
4
3
8
13
29
27
10
10
7
7
7
8
7
12
4
9
8
4
5
14
4
4
23
20
16
71
39
42
42
11
18
17
16
2
2
2
2
2
3
4
8
14
14
15
16
39
75
72
70
22
9
15
15
12
2
8
8
7
2
4
20
9
3
2
0
5
0
0
65
74
62
71
65
61
74
80
83
77
7
3
11
3
4
5
1
4
2
1
7
6
7
8
22
23
19
10
9
10
2
1
2
2
2
1
1
1
2
3
12
10
8
9
1
6
3
1
2
1
6
7
10
8
6
3
3
4
1
9
67
69
67
87
6
5
8
12
10
12
9
1
5
7
6
0
10
5
7
0
3
2
3
0
44
48
46
13
13
13
3
3
5
1
1
2
22
20
15
15
14
20
0
60
50
60
86
0
20
0
0
0
50
50
25
20
0
0
0
0
0
20
25
20
14
0
0
0
0
0
69
69
63
3
1
2
11
15
10
4
2
6
11
10
5
2
3
14
41
24
58
58
63
14
29
15
15
15
8
11
9
9
6
6
3
10
9
10
13
13
5
6
5
17
22
2
3
2
67
64
64
12
12
11
8
9
10
5
4
3
6
5
5
3
6
7
58
48
61
48
43
13
18
15
33
39
7
2
3
6
4
7
11
7
2
4
11
20
8
7
7
4
1
6
4
3
49
56
64
62
65
5
9
9
10
9
14
15
7
11
9
1
3
7
7
6
5
4
5
4
4
25
13
8
6
6
67
33
0
0
33
50
0
0
8
33
33
17
0
0
8
0
0
17
Senegal
56
60
Seychelles
Sierra Leone
87
75
South Africa
35
Swaziland
50
Togo
33
82
Uganda
65
76
84
United Republic
of Tanzania
Zambia
Zimbabwe
74
YEAR
NUMBER
NOTIFIED
SIZE OF
COHORT
COHORT AS
% NOTIFIED
563
1 056
920
1 144
1 112
1 029
0
0
2
0
0
0
41
441
330
389
467
547
179
56 202
60 588
64 470
65 916
60 580
489
1 249
470
1 319
1 474
1 440
93
133
179
196
214
240
955
1 505
2 430
3 177
4 014
3 952
1 335
1 772
5 032
4 474
4 217
3 785
243
1 455
5 496
5 236
2 485
6 310
737
634
931
920
972
889
1 029
113
88
100
85
80
100
168
99
39
100
99
44
107
60
52
100
237
108
100
31
100
72
99
111
100
80
78
71
70
109
189
101
100
100
98
61
100
56
219
79
31
26
35
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
5 941
3 631
4 685
4 685
0
0
0
69
328
153
466
543
24 847
64 923
38 754
34 122
60 580
1 113
1 418
1 474
446
93
128
194
237
240
1 209
2 491
2 856
2 764
1 455
3 356
5 067
4 474
4 217
3 714
894
5 496
2 958
5 444
1 063
4 667
1 109
1 203
1 629
CURED
COMPLETED
FAILED
DEFAULTED
NOT
EVALUATED
45
40
58
70
67
56
11
8
5
5
4
4
5
4
8
7
7
6
10
3
5
4
5
3
25
23
13
10
10
7
4
23
11
5
8
24
72
14
68
78
56
65
7
7
13
11
6
5
10
5
3
1
3
2
15
6
15
15
1
3
4
2
43
29
53
53
31
8
29
11
8
4
8
11
11
10
5
3
2
3
3
2
19
16
13
12
7
19
13
9
15
52
7
14
14
32
16
21
34
41
18
17
11
15
17
17
5
3
11
9
21
4
5
9
10
7
19
54
17
8
6
38
73
73
68
78
2
2
3
4
14
14
18
6
4
4
3
4
7
7
4
8
0
0
5
1
DIED
34
30
13
13
10
31
31
31
66
49
37
34
34
37
48
39
34
10
24
39
47
49
47
8
7
8
11
14
13
10
8
9
1
1
1
1
1
1
1
1
1
12
15
12
8
6
4
3
3
3
0
7
13
4
6
6
4
5
4
52
24
0
33
15
60
80
53
11
9
9
9
4
1
0
1
5
3
4
4
12
4
6
0
51
13
63
72
63
14
46
10
8
11
17
16
12
11
13
1
0
1
0
3
8
13
7
5
5
9
11
7
4
5
AFRICAN REGION
% OF COHORT
a

19952010
163
YEAR
KNOWN HIV STATUS
20052011
Algeria
Angola
10
15
99
Benin
Botswana
23
80
33
82
Burkina Faso
Burundi
71
81
Cameroon
Cape Verde
98
90
33
38
Central African
Republic
Chad
Comoros
100
82
20
20
80
27
Congo
Cte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
100
Eritrea
Ethiopia
41
46
Gabon
Gambia
72
Ghana
79
56
Guinea
Guinea-Bissau
11
51
Kenya
14
93
82
55
58
Lesotho
Liberia
Madagascar
164
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
5
5
10
15
96
98
99
23
75
81
80
33
90
93
82
2 023
2 434
5 107
503
3 845
3 774
4 259
2 291
6 795
6 147
5 369
1 213
4 602
4 761
4 572
50
71
71
0
72
78
81
98
80
3 625
5 511
4 817
0
18 218
19 117
20 280
298
282
90
352
42
39
33
3 749
2 638
1 890
39
38
100
91
82
3 801
4 124
112
117
119
98
24
40
20
20
75
73
80
2
27
24
27
2 357
4 106
2 247
4 079
17 253
16 991
18 297
1 885
31 312
28 997
30 636
46
92
100
331
786
911
3
37
43
41
7
32
27
46
3 211
56 040
66 955
65 140
185
1 130
1 130
2 252
94
93
72
7
65
67
79
2 045
1 962
1 726
844
9 870
10 147
12 587
63
51
56
11
30
46
51
14
88
91
93
1
78
84
82
3
100
53
55
9
9
65
58
5 444
5 776
6 548
200
664
1 046
1 053
15 658
96 676
96 930
97 136
156
10 563
11 005
10 380
114
5 964
3 533
4 355
1 759
2 176
16 439
15 532
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
21 501
21 823
22 530
21 597
38 317
42 686
49 987
48 926
3 457
3 987
3 841
4 320
10 104
9 088
7 632
6 733
3 645
5 111
5 135
5 543
6 627
7 323
7 719
6 828
22 073
25 174
24 552
25 126
305
352
365
390
3 338
8 996
6 760
5 724
6 505
8 651
9 697
10 774
112
129
119
9 961
9 935
10 321
11 143
20 026
23 009
23 210
22 920
99 558
116 025
118 636
114 290
720
853
913
3 612
3 022
2 991
3 093
125 135
150 221
156 928
159 017
2 611
3 559
4 180
4 916
2 120
2 186
2 111
2 386
12 124
15 286
15 145
15 840
7 090
8 614
11 324
11 606
1 816
2 188
2 259
2 070
108 401
110 065
106 083
103 981
11 404
13 515
13 138
12 628
3 456
5 964
6 668
7 965
19 475
23 447
25 106
26 722
NUMBER OF
HIV-POSITIVE
TB PATIENTS
% OF TESTED
TB PATIENTS
HIV-POSITIVE
306
1 620
987
57
633
592
721
1 829
4 415
4 018
3 441
559
903
839
765
15
67
19
11
16
16
17
80
65
65
64
46
20
18
17
1 305
1 260
1 036
0
7 383
8 314
7 731
14
57
47
13
1 230
862
733
33
33
39
663
959
2
0
0
4
17
23
2
0
0
4
99
757
687
1 551
5 207
4 112
4 820
386
6 126
5 273
4 942
PEOPLE
CPT
ART
PROVIDED IPT
14
43
80
9
43
80
98
97
44
57
31
79
82
68
97
98
94
36
43
45
32
53
60
36
23
22
47
95
95
32
40
48
41
43
38
5
20
86
81
50
51
0
617
0
0
674
1 373
100
0
66
0
12
35
62
9
53
45
100
100
25
25
4
18
31
38
30
24
26
20
20
18
16
2
3
24
38
71
80
80
74
45
24
54
2
3
26
14
31
27
36
1
21
9
23
121
225
234
37
29
26
14
85
55
31
21
1 321
11 098
9 809
5 442
185
667
667
578
41
20
15
8
100
59
59
26
88
68
69
62
100
52
52
29
41
39
39
52
52
326
224
16
11
93
11
46
340
2 218
2 676
2 919
40
22
26
23
100
72
77
71
37
24
18
28
1 288
1 483
1 670
110
268
396
439
8 954
42 294
40 069
38 172
127
8 084
8 459
7 909
14
72
283
454
16
7
39
40
24
26
26
55
40
38
42
57
44
41
39
81
77
77
76
12
1
8
10
1
0
0
0
40
87
72
100
7
41
63
30
44
92
100
97
79
94
96
90
0
42
8
55
17
34
48
64
339
18 762
11 732
738
0
0
0
1 983
2 403
6 636
30 816
0
28
27
40
49
0
100
71
36
Malawi
44
83
35
Mali
Mauritania
Mauritius
91
93
88
Mozambique
Namibia
16
84
44
10
81
65
97
Niger
Nigeria
Rwanda
Sao Tome and

Principe
100
100
Senegal
76
100
78
Seychelles
Sierra Leone
South Africa
22
83
92
Swaziland
Togo
84
25
80
88
86
86
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
44
86
88
83
12 243
21 041
19 855
17 339
55
42
35
0
11
24
1
91
95
95
93
3 760
2 303
1 963
10
281
608
12
115
110
117
108
84
88
88
16
74
76
84
38 087
40 554
41 896
2 547
9 849
9 534
10 042
24
48
44
10
75
79
81
65
97
98
97
100
100
92
100
2 424
4 925
4 710
6 897
70 693
71 844
75 772
5 003
7 448
6 914
6 560
152
79
112
146
59
69
76
6 906
8 018
8 757
100
100
100
15
17
21
73
74
78
22
49
54
83
8 625
9 718
10 159
67 988
197 448
213 006
323 440
97
86
92
0
56
77
84
25
71
81
80
3
88
90
88
2
77
84
86
0
62
86
86
10 730
9 536
8 419
0
1 734
2 242
2 513
10 555
31 695
36 742
39 394
1 613
56 388
56 849
53 531
1 082
34 992
40 704
41 701
0
28 952
41 062
35 361
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
27 610
24 356
22 536
20 854
4 884
6 835
5 448
5 573
2 218
2 664
2 489
1 820
127
116
123
116
33 718
45 529
46 174
47 452
15 894
13 332
12 625
11 938
8 224
10 228
10 345
10 714
66 848
94 114
90 447
93 050
7 680
7 644
7 065
6 784
152
79
122
146
10 120
11 732
11 591
11 588
14
15
17
21
6 930
11 826
13 195
12 943
302 467
405 982
396 554
389 974
8 864
11 032
11 146
9 180
2 635
3 093
2 897
2 980
41 809
44 335
45 546
49 018
64 200
64 267
63 453
61 148
53 267
45 551
48 616
48 594
54 891
46 453
47 557
41 305
NUMBER OF
HIV-POSITIVE
TB PATIENTS
% OF TESTED
TB PATIENTS
HIV-POSITIVE
PEOPLE
CPT
ART
PROVIDED IPT
8 447
13 558
12 476
10 341
69
64
63
60
92
94
94
89
49
45
46
60
585
416
440
0
27
90
12
2
7
8
8
16
18
22
0
10
15
100
2
6
7
7
100
75
66
10
52
63
0
0
61
100
50
71
75
62
100
100
100
100
25 056
24 574
26 538
1 465
5 676
5 227
4 990
152
403
405
334
1 241
18 087
17 736
19 553
2 276
2 529
2 199
1 855
5
10
13
14
66
61
63
58
58
55
50
89
97
91
22
25
29
2 429
13 164
17 064
78
93
98
43
24
37
35
44
54
34
0
0
17 737
13 989
14 428
48
59
68
15
92
97
97
0
100
92
100
39
33
43
13
63
72
80
0
30
54
100
1 853
1 750
1 107
27
37
48
100
100
100
100
17
8
7
18
26
25
26
45
34
32
28
3
13
12
10
455
776
877
2
3
1
4
7
10
10
20
6
19
85
85
85
100
100
100
100
987
976
902
35 299
114 523
128 457
211 800
11
10
9
52
58
60
65
7
6
25
100
71
74
76
13
19
28
33
42
54
44
8 889
7 788
6 480
0
342
632
667
7 523
17 131
19 836
20 725
841
21 541
21 662
20 525
614
23 584
26 571
26 737
0
22 745
31 849
21 125
83
82
77
94
93
95
26
35
51
20
28
27
71
54
54
53
52
38
38
38
57
67
65
64
74
72
37
25
86
90
93
61
89
92
95
64
75
87
36
49
30
10
22
24
32
22
31
35
38
68
42
48
53
79
78
60
92
88
29
38
45
67
AFRICAN REGION
YEAR
KNOWN HIV STATUS
20052011
2
0
0
0
0
1 466
23 583
146 247
372 994
2 107
0
0
153
165
YEAR
TOTAL
CONFIRMED
CASES OF
a
MDR-TB
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African
Republic
Chad
Comoros
Congo
Cte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
74
% OF
BACT+VEb
TESTED FOR
MDR-TB
809
BACT+VE
TESTED FOR
MDR-TB
9.1
0.13
1.1
3.5
0
6.5
11
4.5
<0.1
<0.1
<0.1
0
0.48
0
0
0
4.4
0.25
0
0
0
0
0
0
<0.1
<0.1
<0.1
<0.1
0.15
0.62
0
3.9
<0.1
<0.1
0.12
0
0
0.25
0.27
0.36
<0.1
56
190 (71310)
3
40
28
14
15
20
101
106
46
3
19
31
42
0
24
6
26
35
63
0
0
0
1 600 (8002 400)
53 (2481)
170 (110230)
170 (86250)
180 (0370)
130 (58260)
720 (2001 200)
18 (2.273)
103
0
120 (70160)
268
488
151
78 (22130)
3
1
1
150 (4.9350)
0
22
0
620 (201 400)

0
11 (5.416)
7
9
15
83 (23140)
3
0
320 (160480)
5.6 (1.59.6)
20 (0.51110)
160 (44280)
0
0
29
31
0
0
780 (01 600)
0
225
9
0
0
0
0
3.6 (1.85.3)
1.4 (0.402.5)
290 (0590)
240 (7.6540)
47
43
50
30
570 (260870)
420 (180810)
0
0
0
1
91
87
121
3 400 (446 800)
2 600 (856 000)
22
0
3
20 (1426)
13 (7.318)
11
65 (3299)
37 (1064)
233
140
212
2 200 (1 3003 200)
1 700 (9102 900)
16
42
73
0
200 (39360)
0
0
0
1
4
7
20
69
31
78
110 (3.7260)
0
9.8 (029)
9.8 (0.2554)
50
410 (200630)
240 (67420)
240 (120350)
48 (9.9140)
59 (2990)
34 (9.458)
2
44
150
112
166
3 400 (2806 500)
2 400 (775 500)
117
64
180 (37310)
80 (17230)
140 (49220)
110 (31190)
3
3
9
0
215
6
5
8
0
0
92
180 (32340)
97 (26250)
NUMBER OF
44
60
9
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
55 (6.8180)
850 (2901 400)
34 (2251)
57 (2193)
93 (32150)
32 (6.658)
170 (35300)
5.2 (1.88.6)
63 (24120)
160 (56270)
2.1 (0.733.5)
51 (1193)
150 (31270)
800 (1701 400)
6.6 (5.37.8)
28 (9.747)
550 (260980)
84 (17150)
0 (030)
170 (58280)
190 (92310)
26 (8.842)
1 000 (2101 800)
95 (20260)
24 (8.340)
87 (11300)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
164
23
107
32
94
35
6
2.9
152
58
251
22
286
27
90
10
126
39
52
8.6
117
21
68
14
0
0
2
0.60
6
1.9
216
14
35
2.3
0
0
0
0
21
3.3
0
0
56
16
0
0
0
0
0
0
0
0
309
22
72
4.7
29
2.0
111
1.3
100
1.2
160
2.0
0
0
298
8.4
510
10
139
3.0
0
0
2
0.38
21
2.1
61
6.9
34
7.4
63
11
26
4.0
26
3.9
1829
20
1971
18
706
6.7
1195
12
0
0
22
1.1
24
1.1
64
2.9
b
166
MDR-TB
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and

Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
a
b
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
9
6
40
26
2
22
12
10
11
35
8
0
1
2
1
115
140
165
283
301
214
192
24
39
18
28
21
95
35
78
90
76
0
4
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
160 (99220)
57 (19130)
140 (68210)
77 (21130)
22 (6.238)
1.0 (03.0)
1.0 (<0.15.6)
1 800 (1 2002 500)
670 (550800)
260 (130400)
1 300 (8301 800)
150 (42260)
3 400 (1506 600)
2 500 (805 700)
280 (200360)
200 (130290)
4.9 (2.57.3)
1.8 (0.513.2)
380 (170590)
0
0
0
0.27 (<0.10.47)
0.27 (<0.10.47)
190 (0400)
100 (2.6550)
190
326
332
4
2
4
46
57
93
71
10
24
34
68
8 100 (6 9009 400)
190 (63440)
BACT+VE
TESTED FOR
MDR-TB
0
10
1.5
0
0.27
0
12
0.30
100
100
100
100
0.63
0.37
0.39
1.1
0
0
<0.1
<0.1
<0.1
<0.1
1.4
1.8
4.0
1.9
0.72
0.53
0.18
63
2.9
4.1
1.6
1.5
1.2
0.60
0.75
0.44
0.34
0.46
0
871
102
0
14
0
3
114
98
105
100
113
73
80
206
0
0
1
17
27
12
57
77
171
2
57
41
14
5 000 (4 0006 300)

2200
148
900 (7001 100)
510 (320700)
0
82 (41120)
1 000 (6901 400)
480 (12950)
41 (1171)
560 (240900)
480 (1301 200)
29
17
118
BACT+VEb
TESTED FOR
MDR-TB
290 (210390)
11
38
50
8
2000
9070
7386
10085
% OF
161
42 (2163)
86
369
358
316
276
348
201
83
63
730 (2401 200)
580 (2501 100)
970 (4601 500)
610 (3301 000)
NUMBER OF
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
100 (70150)
62 (21100)
20 (6.833)
0 (02.6)
510 (01 100)
390 (300490)
110 (38180)
890 (1801 600)
79 (6495)
3.1 (1.15.1)
190 (78350)
0 (00)
87 (19200)
3 100 (2 5003 700)
390 (330450)
41 (1468)
480 (270780)
0 (0210)
150 (3.8800)
360 (76980)
AFRICAN REGION
YEAR
TOTAL
CONFIRMED
CASES OF
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
917
29
34
1.4
449
20
552
26
0
0
14
3.3
12
3.4
30
15
4
3.9
3
60
5
100
7
100
5
100
305
16
213
5.9
251
6.2
443
10
33
4.8
47
7.0
21
3.6
25
0.31
19
0.21
76
0.86
0
0
138
29
431
68
2
12
31
2.8
66
6.4
97
8.7
505
35
4
1.9
83
39
228
5.7
356
9.0
360
9.0
405
8.0
177
4.2
246
6.5
17
0.59
30
1.2
0
0
167
MALE
YEAR
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African
Republic
Chad
Comoros
Congo
Cte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
168
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
FEMALE
014
1524
2534
3544
4554
5564
65+
59
53
52
42
386
186
520
448
501
14
19
21
18
21
927
1 309
1 203
1 147
724
999
2 549
2 900
3 000
186
277
306
314
320
1 516
1 841
1 669
1 513
562
1 003
2 797
3 584
3 792
352
428
595
631
650
610
919
825
881
346
912
1 918
2 415
2 386
306
327
396
443
497
491
473
513
483
224
482
1 255
1 424
1 395
176
213
270
267
353
234
314
392
345
155
312
665
691
680
101
103
135
164
210
299
426
397
347
14
194
461
355
455
92
74
87
85
107
25
27
45
36
4
12
18
20
22
5
185
260
256
220
67
91
181
231
265
128
605
563
590
464
133
274
430
620
708
238
488
506
477
354
124
252
370
493
582
224
267
272
239
206
62
133
273
328
375
73
135
135
137
110
48
68
144
224
262
32
96
97
107
94
29
65
113
173
196
19
34
56
37
20
41
134
106
114
352
481
484
208
518
1 472
1 497
1 580
591
773
743
569
842
2 482
2 750
2 931
525
651
620
323
584
1 766
1 996
2 139
372
570
504
287
284
1 035
1 314
1 283
111
270
235
204
130
463
559
625
55
157
98
164
75
289
329
361
22
23
26
0
38
17
162
43
356
35
206
31
120
3
40
3
18
29
78
70
40
379
362
1 136
633
576
160
468
467
26
251
269
35
135
119
15
63
59
25
76
92
0
0
0
194
382
469
18
18
12
535
850
951
13
7
9
409
666
764
9
14
6
229
379
418
7
9
4
123
173
184
8
3
2
82
99
121
4
4
4
0
16
10
265
13
409
9
221
5
73
2
44
5
15
41
58
41
435
453
989
672
705
2 092
424
462
1 344
203
222
759
77
80
283
55
76
130
128
159
189
373
485
1 321
1 707
1 579
8
1 346
1 751
1 743
1 572
4 048
6 675
6 859
6 640
15
2 449
2 858
3 043
2 382
5 833
9 808
10 412
9 872
45
1 606
1 882
1 852
1 890
4 151
7 577
9 134
8 932
37
888
1 010
1 072
1 184
2 549
5 022
6 464
6 415
15
422
505
601
634
1 295
2 637
3 641
3 584
11
385
375
348
289
602
1 499
1 907
1 911
7
10
11
71
77
80
90
59
89
35
59
16
22
10
12
9
9
10
0
247
915
1 109
1 582
1 847
3
70
68
93
75
73
109
57
50
81
32
45
51
25
51
37
20
39
60
1 221
5 095
6 726
7 400
7 835
45
1 017
5 187
6 181
7 785
9 246
74
541
3 082
3 454
4 451
3 881
80
276
1 495
1 985
2 746
2 771
54
142
610
1 027
1 473
1 218
30
51
397
475
822
771
15
13
15
34
3
123
145
240
68
199
223
269
181
140
208
229
88
70
130
144
72
38
89
86
29
25
91
66
24
13
9
14
42
73
49
63
50
18
39
51
61
45
133
194
183
223
550
592
570
550
244
551
749
679
1 051
292
314
271
397
1 266
1 201
1 146
1 127
538
860
1 165
877
1 537
206
184
181
398
1 115
1 311
1 301
1 328
357
570
778
982
955
62
141
136
302
811
944
1 030
955
189
282
463
876
541
53
68
87
190
495
462
540
491
98
203
195
565
293
44
39
56
112
426
414
447
456
61
103
130
289
197
2
14
18
6
154
264
359
357
356
52
116
164
140
2 072
3 739
4 790
4 698
4 773
92
167
219
230
3 073
6 653
8 832
7 945
8 376
80
153
183
181
1 675
3 548
5 069
5 077
5 201
64
130
141
104
920
1 630
2 521
2 509
2 660
39
72
80
65
485
630
1 031
994
1 045
19
42
43
36
296
414
590
658
665
UNKNOWN
0
0
0
0
0
0
0
0
014
1524
2534
3544
4554
5564
65+
36
102
79
58
371
247
704
558
708
26
36
25
29
41
1 005
1 044
1 086
1 050
707
1 142
2 926
2 763
2 731
148
239
249
265
288
1 293
820
826
787
443
1 091
2 682
2 594
2 563
197
275
331
382
385
746
389
417
383
264
844
1 797
1 688
1 683
118
149
145
200
246
314
270
251
211
248
417
1 138
958
1 006
69
76
89
98
119
208
229
222
202
130
200
581
482
457
32
45
51
42
42
312
465
367
341
18
120
417
286
346
22
25
39
35
52
37
45
68
65
7
7
15
33
31
19
335
321
338
286
76
59
125
158
163
109
469
491
509
421
53
128
248
259
277
124
262
253
301
211
39
101
174
198
221
89
98
97
119
105
26
45
109
124
146
33
57
55
56
48
11
38
54
97
110
12
36
48
53
49
10
14
40
83
92
4
46
78
56
9
63
226
172
178
298
390
345
185
368
1 467
1 474
1 461
399
421
374
313
530
1 788
2 031
2 022
288
332
263
223
293
1 028
1 121
1 177
122
225
180
153
139
503
642
581
36
99
81
106
60
205
290
281
33
87
40
93
33
143
183
194
UNKNOWN
0
0
0
0
0
0
0
0
16
4
39
14
233
15
350
4
145
6
57
3
21
4
9
30
88
96
32
367
382
420
576
530
145
319
289
30
155
162
40
73
62
15
44
26
28
59
84
1
1
2
148
274
296
13
9
10
298
413
438
9
6
7
211
263
298
8
12
4
148
158
166
6
1
8
59
79
109
5
2
3
27
44
44
2
1
8
2
17
8
296
4
353
2
167
1
61
0
38
1
11
49
72
99
409
408
810
510
463
813
296
332
497
152
200
273
70
88
105
56
97
19
193
246
244
331
718
1 695
1 987
1 800
2
1 280
1 431
1 358
1 223
4 422
7 570
7 199
6 802
18
1 756
1 819
1 838
1 532
5 146
8 501
9 120
8 742
28
989
1 051
1 044
1 232
3 309
5 832
6 721
6 541
20
528
531
560
863
1 724
3 898
4 579
4 537
4
232
304
301
427
855
2 054
2 612
2 671
7
201
209
223
137
351
951
1 311
1 295
1
0
0
13
15
80
76
57
81
45
46
26
21
9
9
6
3
0
0
10
8
3
100
67
88
87
127
111
71
72
79
21
39
43
12
21
31
8
18
36
283
1 037
1 326
1 608
1 983
9
908
4 699
5 885
5 708
6 570
47
781
4 424
5 663
6 480
7 917
54
382
2 105
2 730
3 439
3 069
28
152
976
1 296
1 950
1 564
25
64
366
513
855
719
19
15
122
155
335
303
3
19
13
25
4
128
110
177
39
123
164
188
61
88
122
125
44
29
100
74
25
29
86
44
12
18
64
39
8
2
6
16
40
74
68
64
52
28
66
65
51
85
84
104
103
199
456
450
446
470
202
314
594
549
709
87
121
112
272
791
693
667
699
255
446
583
739
688
64
71
88
205
566
527
560
614
153
245
354
751
432
38
35
63
122
338
366
369
390
64
114
203
405
219
22
40
32
88
179
207
204
174
37
82
94
145
109
27
18
33
48
176
221
249
260
19
45
55
72
73
4
13
30
12
187
416
577
549
629
30
78
100
119
1 802
3 916
5 144
4 044
4 183
46
110
161
122
1 759
4 363
6 521
5 112
4 917
47
92
133
90
741
1 874
2 781
2 372
2 434
24
82
80
56
411
831
1 266
1 056
1 025
15
44
38
44
242
347
593
544
477
12
19
19
25
117
148
315
345
344
1
4
0
0
0
0
0
0
0
0
8
6
0
0
0
0
0
0
0
0
MALE:FEMALE
RATIO
1.1
1.6
1.6
1.6
1.1
1.0
0.99
1.3
1.3
2.0
1.7
1.9
1.8
1.8
1.4
1.4
1.3
1.3
2.1
2.3
2.0
2.2
2.3
1.8
1.7
1.8
2.0
1.6
1.7
1.4
1.4
1.5
2.0
2.6
1.1
2.0
1.2
1.2
1.7
2.0
2.1
1.3
1.7
0.88
2.4
1.1
1.2
1.2
2.2
1.4
1.5
1.6
1.4
1.1
1.1
1.2
1.2
1.7
1.2
1.4
0.93
0.95
1.1
1.4
1.2
1.2
1.3
1.2
1.6
1.4
1.4
1.6
2.4
2.5
2.4
2.1
1.7
1.8
2.0
2.0
1.9
2.0
2.0
1.8
1.6
2.0
2.0
1.6
1.5
1.6
1.6
1.4
1.3
1.6
1.6
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and

Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
FEMALE
014
1524
2534
3544
4554
5564
65+
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
9
8
32
16
19
108
165
395
222
179
214
458
695
607
584
256
517
397
497
493
189
395
148
364
329
96
198
82
244
245
88
76
37
133
121
12
26
90
67
79
133
240
338
382
791
196
352
621
595
1 289
127
333
510
727
1 173
52
155
295
440
630
17
74
114
194
423
26
65
21
87
242
98
204
146
25
50
58
50
70
27
23
26
94
25
1 159
1 721
1 807
493
653
622
565
519
72
206
350
381
370
1 867
1 621
2 764
1 195
1 476
1 653
1 509
1 486
357
430
628
707
772
1 732
2 525
2 495
833
1 113
1 031
985
1 050
294
396
539
526
515
1 349
1 782
1 938
519
585
549
485
440
181
297
365
354
352
582
960
1 044
215
245
279
275
238
138
235
263
227
267
333
485
522
89
114
157
187
201
102
144
193
207
230
17
36
2
2
0
0
187
192
165
17
6
10
9
10
1 136
295
185
13
9
15
9
13
1 475
206
131
22
18
21
13
9
1 338
137
106
27
19
20
23
17
1 022
99
58
13
14
10
15
10
664
76
55
8
8
6
7
8
320
0
18
98
36
48
68
269
355
359
337
235
874
1 027
852
844
113
665
874
680
660
55
300
365
287
361
21
147
146
146
152
29
35
44
50
450
157
325
521
529
270
557
669
709
845
2 173
3 824
4 457
4 549
174
1 204
1 587
1 673
921
3 164
6 758
9 186
9 520
441
819
988
1 025
937
1 836
4 544
6 218
6 550
252
497
615
646
557
1 091
2 863
3 804
4 230
155
45
48
42
466
494
430
423
974
713
741
795
824
592
526
500
1
2
0
0
94
60
71
81
75
0
5
5
10
5
717
772
1 050
1 351
1 264
2
0
0
0
10
18
45
64
75
2
0
0
184
287
490
718
825
11
7
14
9
1 219
1 297
1 561
1 793
1 835
0
2
1
0
1
305
486
792
1 176
1 224
116
2 035
1 496
1 472
4
11
9
30
16
7
4
11
21
15
370
283
257
268
295
183
200
190
232
190
91
349
135
723
10 422
9 925
9 772
59
130
162
207
161
95
101
177
150
169
1 193
1 511
1 598
2 055
2 075
2 108
2 357
2 062
1 975
1 975
659
2 175
1 240
105
210
150
152
UNKNOWN
014
1524
2534
3544
4554
5564
65+
14
11
19
27
23
106
222
226
283
311
125
336
721
597
572
71
195
616
329
307
49
83
494
169
185
17
36
297
64
84
19
29
121
48
58
21
37
254
67
100
140
232
339
329
799
149
297
488
433
1 108
88
171
259
517
744
28
108
171
285
340
16
52
151
88
230
16
25
99
50
78
150
323
252
65
66
84
103
79
31
14
33
31
42
1 012
1 621
1 726
802
1 038
913
610
601
132
174
208
265
255
1 451
1 943
2 031
1 028
1 481
1 598
1 196
1 119
184
232
348
337
393
1 047
1 376
1 503
573
831
859
661
660
128
152
245
247
223
614
946
978
294
401
386
314
283
107
106
152
144
147
248
397
462
108
148
180
198
161
61
75
101
96
118
129
192
188
45
64
74
102
96
52
43
72
70
68
14
28
2
1
0
0
226
90
68
4
5
4
7
7
994
104
72
12
8
5
9
12
1 314
82
47
10
8
5
4
2
1 016
52
36
8
6
11
4
3
551
29
19
4
7
2
3
6
234
29
20
4
4
1
2
3
89
6
81
120
126
138
5
16
105
67
78
49
352
399
429
427
78
654
809
685
653
50
348
525
382
410
16
161
213
206
185
1
76
95
122
100
0
52
91
87
110
151
350
415
436
611
566
1 464
1 974
2 248
78
198
342
347
515
463
950
1 363
1 443
0
0
31
34
39
50
404
239
482
595
578
123
214
272
285
842
2 934
3 996
4 182
4 198
206
388
418
449
795
2 434
4 884
6 117
6 168
168
330
347
323
770
1 110
2 448
3 431
3 574
151
223
238
278
724
676
1 350
1 846
2 014
63
131
174
189
654
344
745
1 040
1 112
9
70
135
147
451
231
415
682
724
393
408
325
376
129
142
202
210
56
71
126
124
105
73
48
50
396
483
399
358
473
442
448
398
309
262
261
235
109
157
128
146
52
60
65
87
14
29
38
67
4
6
7
8
813
857
904
972
981
1
4
2
6
0
201
361
651
1 076
1 099
7
4
1
7
408
470
533
590
582
1
1
1
0
0
99
190
397
663
781
3
5
0
1
300
279
274
329
335
2
1
0
0
0
47
113
226
320
334
10
2
1
4
213
189
236
221
214
1
3
1
0
2
84
77
83
81
88
0
7
4
5
2
428
521
709
835
807
0
0
0
0
18
27
54
77
115
0
2
1
165
249
393
648
678
5
3
3
4
283
376
351
332
362
0
0
1
0
0
110
225
312
556
543
7
2
2
1
203
217
185
217
208
0
1
0
0
0
65
92
207
293
343
4
3
0
0
126
107
116
136
144
0
1
0
0
0
24
49
114
180
219
15
0
0
0
72
61
81
105
74
1
0
1
0
22
47
124
254
287
15
5
4
10
461
540
568
643
664
1
1
1
0
0
193
298
518
742
796
0
0
0
11
30
47
131
116
1 999
20 576
20 855
20 487
117
352
406
537
459
151
168
320
350
340
2 491
3 497
4 075
4 735
5 044
4 091
4 836
4 939
4 493
4 405
1 668
2 610
3 166
2 135
19 465
19 842
19 360
130
249
285
369
318
123
144
283
358
350
1 797
2 479
3 209
4 133
4 613
2 916
3 430
4 025
4 141
4 073
1 124
3 045
2 160
1 146
11 143
12 386
12 111
98
138
139
192
158
82
109
125
217
234
1 115
1 279
1 576
2 214
2 466
1 754
2 022
2 310
2 427
2 402
487
435
917
435
4 124
5 155
5 220
40
37
57
109
69
64
48
79
116
123
602
607
725
905
994
1 007
1 202
1 279
1 309
1 211
231
261
358
212
1 705
2 211
2 164
16
17
27
50
46
49
39
69
80
85
323
395
539
613
604
640
834
1 054
1 161
1 127
130
174
321
122
2 561
1 933
1 932
5
10
14
51
35
9
13
23
39
11
402
400
371
401
400
201
257
271
248
221
129
150
168
1 283
13 632
13 023
12 751
52
198
318
354
281
80
107
157
163
167
1 376
1 649
1 811
1 964
2 092
1 904
2 106
1 852
1 689
1 660
1 125
932
1 507
1 716
19 343
20 205
19 250
57
298
453
662
495
96
124
236
285
277
1 845
2 782
3 099
2 923
2 853
2 532
3 426
3 521
2 988
2 896
1 779
1 118
2 463
933
11 338
12 910
12 807
39
62
207
276
220
45
50
146
148
146
1 104
1 510
1 800
1 691
1 809
1 324
1 738
1 892
2 013
2 140
717
1 305
1 433
423
5 416
6 873
6 955
29
62
73
104
86
38
36
67
78
89
635
671
818
924
973
735
868
968
1 044
944
257
186
569
167
2 352
3 165
3 266
8
24
21
54
40
23
24
41
62
50
312
316
389
365
409
380
494
547
578
490
117
112
235
80
1 348
2 128
2 223
6
5
8
16
24
15
15
32
29
38
113
163
257
248
313
179
269
354
471
381
63
75
185
1 033
2 897
2 194
810
280
207
151
940
1 683
1 063
422
162
99
837
710
784
2 264
2 208
2 467
1 855
1 682
2 071
762
761
780
295
350
377
656
252
278
269
173
174
1 136
974
1 084
2 242
2 185
2 161
1 255
1 283
1 386
578
490
448
193
265
274
603
171
160
0
0
0
0
0
0
0
0
0
89
0
0
0
0
16
423
0
0
UNKNOWN
0
0
0
0
0
0
0
0
0
0
0
43
0
0
0
0
1
252
0
0
AFRICAN REGION
MALE
YEAR
MALE:FEMALE
RATIO
2.4
2.0
0.72
1.4
1.3
1.2
1.4
1.1
1.4
1.4
1.5
1.4
1.5
1.2
1.1
1.1
1.3
1.3
1.7
2.2
2.0
2.1
2.0
2.6
2.5
2.3
1.9
2.9
2.6
2.0
1.4
2.5
1.4
1.3
1.3
1.3
1.9
2.6
2.9
2.8
1.0
1.2
1.4
1.5
1.6
2.1
1.6
1.7
1.8
0.73
1.7
2.4
1.8
2.3
2.1
2.2
2.3
2.2
3.5
2.7
3.0
3.5
1.0
1.5
1.5
1.7
1.6
1.6
1.4
1.2
1.2
1.2
2.4
1.4
0.99
0.98
1.0
1.9
1.7
1.5
1.6
1.7
1.4
1.3
1.4
1.8
1.8
1.8
1.6
1.7
1.7
1.8
1.0
2.3
1.3
1.7
1.1
1.1
1.2
169
7$%/($/DERUDWRULHV173VHUYLFHVGUXJPDQDJHPHQWDQGLQIHFWLRQFRQWURO
LABORATORIES
FREE THROUGH NTP
SECONDNUMBER OF
SMEAR LABS % OF SMEAR
CULTURE
DST b LABS
LPAc LABS
LABS USING LABS PER 5M
LINE DST
LABS USING
PER 100K
PER 5M
PER 5M
POPULATION
POPULATION POPULATION POPULATION XPERT MTB/RIF AVAILABLE
LEDa
Algeria
0.7
4.0
0.4
0.1
Angola
0.7
0.8
0.8
Benin
0.6
12
0.5
0.5
0.5
Botswana
2.6
2.5
2.5
Burkina Faso
0.7
0.3
0.3
Burundi
2.0
0.6
Cameroon
1.1
1.0
0.5
0.2
Cape Verde
3.2
Central African Republic

Chad
Comoros
1.6
0.5
0
0
1.1
0
1.1
0
1.1
0
0
0
Congo
0.7
Cte d'Ivoire
Democratic Republic
of the Congo
Equatorial Guinea
0.6
0.5
0.5
2.2
<0.1
<0.1
0
0
yes
yes
Yes
yes
No
yes
Yes
Yes (all suspects)
yes
Yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
No
yes
Yes
yes
No
Yes
No
yes
yes
Yes
Yes
Yes
No
yes
No
yes
0.1
3.3
2.8
0.6
0.5
3.2
<0.1
3.3
2.8
0.6
0.5
0.1
0
0.2
0
0
1
Kenya
3.8
0.7
0.1
0.1
Lesotho
Liberia
Madagascar
0.8
3.7
1.0
22
0
2
2.3
0
0.2
2.3
0
0.2
2.3
0
0.2
3
0
Malawi
1.5
13
1.0
0.3
0.3
Mali
Mauritania
0.4
1.8
0
100
0.6
1.4
0.6
1.4
0.3
Mozambique
1.8
0.4
0.4
Namibia
1.3
100
2.2
2.2
Niger
1.1
0.3
0.3
Nigeria
0.8
0.2
0.1
<0.1
Rwanda
Sao Tome and Principe
1.8
2.4
5
0
0.9
0
0.5
0
0.5
0
Senegal
0.8
1.2
0.4
Sierra Leone
South Africa
Swaziland
Togo
Uganda
2.6
0.5
1.4
1.9
3.1
35
1
1
0
1.5
4.2
0.8
1.0
0
1.5
4.2
0.8
1.2
0
1
4.2
0
1.2
0
55
4
0
18
United Republic of Tanzania
2.0
0.5
0.1
0.1
1.2
yes
Yes (all suspects)
31
0
2
0
0.8
Yes (all suspects)

Yes (for smearpositive TB)
Yes (if TB is
confirmed)
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
Yes (if TB is
confirmed)
Yes (all suspects)
Yes (if TB is
confirmed)
Yes (all suspects)
Yes (if TB is
confirmed)
Yes (all suspects)
No
Yes (all suspects)
Yes (all suspects)
Yes (all suspects)
No
1.4
0.8
yes
yes
yes
2.3
1.0
1.8
1.1
0.5
1.3
Zambia
Zimbabwe
Out of
country
Out of
country
Out of
country
In and out
of country
Out of
country
TB DIAGNOSIS
yes
yes
yes
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Seychelles
In country
NRLd
TB NOTIF.
RIFAMPICIN
RATE PER
USED
100 000
THROUGHOUT
HEALTH-CARE
TREATMENT
WORKERS
No
No
Eritrea
Mauritius
In country
Out of
country
FIRSTLINE
DRUGS
11
yes
No
No
No
yes
In country
No
In country
No
No
No
Out of
country
No
No
In country
Out of
country
No
No
Out of
country
In and out
of country
Out of
country
In and out
of country
Out of
country
yes
No
yes
yes
yes
yes
No
No
In country
In and out
of country
No
Yes
Yes
yes
Yes
yes
Yes
yes
Yes
yes
No
yes
yes
yes
yes
Yes
Yes
Yes
Yes
Yes
Yes
yes
Yes (all suspects)
yes
Yes
115
yes
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
yes
yes
yes
Yes
Yes
No
111
yes
Yes (all suspects)
yes
Yes
yes
yes
Yes (all suspects)

Yes (all suspects)
yes
yes
Yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (if TB is
confirmed)
yes
yes
Yes
Yes
yes
Yes
yes
Out of
country
No
yes
yes
1 429
No
Yes (all suspects)
yes
Yes
yes
yes
yes
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
Yes (all suspects)
Yes (all suspects)
yes
yes
yes
yes
yes
Yes
Yes
Yes
Yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)

Yes (all suspects)
yes
yes
Yes
Yes
329
14
LED = Light emitting diode microscopes

DST = Drug susceptibility testing
LPA = Line probe assay
d
NRL = National Reference Laboratory
b
c
170

173
176
179
182
185
188
190
192
194

details.
Data source
Country notes
Caribbean Islands
Data from the territories of Anguilla; Bermuda; Bonaire, Saint Eustatius and Saba; British Virgin Islands; Cayman
Islands; Curaao; Montserrat; Sint Maarten (Dutch part); Turks and Caicos Islands; and US Virgin Islands have been
re-introduced with support from the Caribbean Epidemiology Centre (CAREC/PAHO/WHO).
USA
In addition to the 51 reporting areas, the USA includes territories that report separately to WHO. The data for these territories are not included in the data reported by the USA.
De nitions of case types and outcomes do not exactly match those used by WHO.
172
Anguilla
1990
1995
2000
2005
2009
2010
2011
Antigua and
1990
Barbuda
1995
2000
2005
2009
2010
2011
Argentina
1990
1995
2000
2005
2009
2010
2011
Aruba
1990
1995
2000
2005
2009
2010
2011
Bahamas
1990
1995
2000
2005
2009
2010
2011
Barbados
1990
1995
2000
2005
2009
2010
2011
Belize
1990
1995
2000
2005
2009
2010
2011
Bermuda
1990
1995
2000
2005
2009
2010
2011
Bolivia
1990
(Plurinational
1995
State of)
2000
2005
2009
2010
2011
Bonaire, Saint
2010
Eustatius and Saba 2011
Brazil
1990
1995
2000
2005
2009
2010
2011
British Virgin
1990
Islands
1995
2000
2005
2009
2010
2011
Canada
1990
1995
2000
2005
2009
2010
2011
Cayman Islands
1990
1995
2000
2005
2009
2010
2011
Chile
1990
1995
2000
2005
2009
2010
2011
Colombia
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
33
35
37
39
40
40
41
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
7
7
8
9
10
10
10
<1
<1
150
162
174
186
193
195
197
<1
<1
<1
<1
<1
<1
<1
28
29
31
32
34
34
34
<1
<1
<1
<1
<1
<1
<1
13
14
15
16
17
17
17
33
36
40
43
46
46
47
NUMBER
(THOUSANDS)
RATEa
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
1.3
1.1
0.88
0.74
0.64
0.61
0.59
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.012
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.012
0.016
0.011
0.012
0.013
0.014
<0.01
<0.01
0
0
0
0
0
2.4
2.4
2.2
2.1
2.1
2.1
2.1
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0<0.01)
(<0.01<0.01)
(1.31.3)
(1.11.1)
(0.8500.910)
(0.6900.790)
(0.6100.680)
(0.5900.630)
(0.5700.600)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0120.012)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.010)
(0.0110.013)
(0.0160.017)
(0.0110.012)
(0.0120.012)
(0.0120.014)
(0.0130.015)
(<0.01<0.01)
(<0.01<0.01)
(00)
(00)
(00)
(00)
(00)
(0.7605.0)
(1.14.2)
(0.9704.0)
(0.9203.8)
(0.9203.8)
(0.9203.7)
(0.9103.7)
0.14
0.55
1.6
0.1
1.2
<0.1
0.99
4
3.2
2.4
1.9
1.6
1.5
1.4
0.67
0.67
0.67
0.67
0.67
0.67
0.67
0.56
4.3
2
1.1
0.77
0.7
0.64
<0.1
<0.1
0.56
0.49
0.53
<0.1
0.55
4.1
5.6
6.6
4.1
4
4.1
4.3
0.16
<0.1
0
0
0
0
0
36
32
27
23
22
21
21
(0.130.16)
(0.480.64)
(1.31.9)
(<0.10.19)
(1.11.3)
(00.18)
(0.881.1)
(3.94.0)
(3.13.2)
(2.32.5)
(1.82.1)
(1.51.7)
(1.51.6)
(1.41.5)
(0.291.2)
(0.291.2)
(0.291.2)
(0.291.2)
(0.291.2)
(0.291.2)
(0.291.2)
(0.490.63)
(4.34.4)
(1.92.1)
(1.11.1)
(0.750.79)
(0.680.72)
(0.620.65)
(<0.1<0.1)
(<0.1<0.1)
(0.550.57)
(0.480.49)
(0.510.54)
(<0.1<0.1)
(0.540.56)
(3.15.2)
(5.06.1)
(6.56.7)
(4.14.1)
(3.94.0)
(3.84.4)
(4.04.6)
(0.160.16)
(<0.1<0.1)
(00)
(00)
(00)
(00)
(00)
(1176)
(1556)
(1248)
(1042)
(9.439)
(9.238)
(9.037)
8
8.5
7.8
6.2
5.7
5.6
5.6
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.15
0.12
0.1
0.08
0.066
0.063
0.061
<0.01
0
0
0
<0.01
<0.01
<0.01
0.9
0.5
0.35
0.28
0.24
0.23
0.23
2.1
1.9
1.3
1.2
1
0.94
0.88
(6.010)
(6.710)
(6.49.3)
(5.47.1)
(5.16.3)
(4.66.8)
(4.66.8)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.1500.150)
(0.1200.120)
(0.1000.100)
(0.0790.080)
(0.0650.067)
(0.0630.064)
(0.0600.062)
(<0.01<0.01)
(00)
(00)
(00)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.8300.970)
(0.4600.530)
(0.3400.360)
(0.2700.290)
(0.2300.250)
(0.2200.250)
(0.2200.240)
(1.82.5)
(1.72.2)
(1.31.4)
(1.21.2)
(0.9001.1)
(0.8401.0)
(0.7900.970)
5.3
5.2
4.5
3.3
2.9
2.9
2.9
0.32
2.2
0.44
0.15
<0.1
<0.1
0.11
0.54
0.4
0.33
0.25
0.2
0.19
0.18
1.2
0
0
<0.1
<0.1
<0.1
<0.1
6.8
3.4
2.3
1.7
1.4
1.4
1.3
6.4
5.3
3.4
2.8
2.2
2
1.9
(4.06.9)
(4.26.5)
(3.75.3)
(2.93.8)
(2.63.3)
(2.33.5)
(2.33.4)
(0.310.33)
(2.22.2)
(0.390.50)
(0.130.17)
(<0.10.10)
(<0.10.11)
(0.100.12)
(0.520.55)
(0.400.40)
(0.330.33)
(0.240.25)
(0.190.20)
(0.180.19)
(0.180.18)
(1.21.2)
(00)
(00)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(6.37.4)
(3.23.7)
(2.22.4)
(1.61.7)
(1.41.5)
(1.31.5)
(1.31.4)
(5.47.6)
(4.85.9)
(3.23.6)
(2.72.9)
(2.02.4)
(1.82.2)
(1.72.1)

NUMBER
(THOUSANDS)
RATEa

NUMBER
(THOUSANDS)
RATEa
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
31
24
20
18
16
15
15
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.048
0.07
0.068
0.05
0.049
0.041
0.047
<0.01
<0.01
<0.01
0.015
<0.01
<0.01
(<0.01<0.01)
(<0.01<0.01)
(<0.010.011)
(<0.010.013)
(<0.010.013)
(<0.010.013)
(<0.010.013)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.014)
(<0.010.010)
(<0.010.013)
(1162)
(1043)
(8.437)
(7.432)
(6.828)
(6.627)
(6.326)
(<0.01<0.01)
(<0.010.013)
(<0.010.014)
(<0.010.016)
(<0.010.017)
(<0.010.017)
(<0.010.017)
(0.0230.083)
(0.0320.120)
(0.0310.120)
(0.0230.088)
(0.0190.094)
(0.0140.083)
(0.0180.091)
(<0.010.015)
(<0.010.010)
(<0.010.014)
(<0.010.027)
(<0.010.021)
(<0.01<0.01)
60
46
56
54
50
49
48
3.7
6.5
5.8
3.6
6.9
3.6
5.3
95
68
55
45
39
38
36
8.3
8.3
8.2
8.2
8.3
8.2
8.2
19
25
23
16
14
12
14
3.1
2.1
2.7
5.5
3.1
1.2
(21118)
(2279)
(24103)
(2399)
(2290)
(2287)
(2284)
(1.46.9)
(2.612)
(2.311)
(0.4210)
(1.815)
(0.2112)
(0.6415)
(33191)
(29124)
(23101)
(1983)
(1771)
(1668)
(1565)
(3.216)
(3.216)
(3.216)
(3.216)
(3.216)
(3.215)
(3.216)
(8.833)
(1144)
(1040)
(7.128)
(5.528)
(4.124)
(5.126)
(1.25.9)
(0.853.9)
(1.15.1)
(2.310)
(0.557.8)
(0.213.0)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
19
17
15
13
11
11
11
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.054
0.082
0.078
0.055
0.048
0.047
0.046
<0.01
<0.01
<0.01
0.013
<0.01
<0.01
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1328)
(1421)
(1218)
(1115)
(9.414)
(9.113)
(8.913)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0470.061)
(0.0720.093)
(0.0680.088)
(0.0480.062)
(0.0420.055)
(0.0410.053)
(0.0400.052)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0110.015)
(<0.01<0.01)
(<0.01<0.01)
24
23
23
22
21
21
21
2.9
5.1
4.6
4.1
5.4
6
6.9
60
49
40
33
28
27
26
6.4
6.4
6.4
6.4
6.4
6.4
6.4
21
29
26
17
14
14
13
2.5
1.7
2.3
4.8
2.4
1.2
0.095
0.091
0.12
0.12
0.15
0.15
0.13
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
25
24
23
22
21
21
21
<0.01
<0.01
180
140
130
110
97
95
91
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.9
2.8
2.5
2.2
2
2
1.9
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
12
7.7
5.5
4.7
4.4
4.3
4.1
26
28
25
24
23
22
20
(0.0280.200)
(0.0300.190)
(0.0410.240)
(0.0520.230)
(0.0660.270)
(0.0660.270)
(0.0530.240)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(9.050)
(1241)
(1140)
(1038)
(9.937)
(9.936)
(9.936)
(<0.01<0.01)
(<0.01<0.01)
(64370)
(65250)
(56220)
(48210)
(39180)
(37180)
(36170)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1.25.5)
(1.15.3)
(0.9804.6)
(0.8604.0)
(0.8003.7)
(0.7803.7)
(0.7703.6)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.014)
(5.222)
(3.214)
(2.310)
(2.18.4)
(1.98.0)
(1.87.9)
(1.77.7)
(8.752)
(1448)
(1244)
(1143)
(1040)
(1039)
(9.435)
50
41
47
44
50
49
41
4.5
6.7
0.87
7.6
4.7
2.8
0.34
380
324
276
239
217
210
205
1.7
6
123
89
72
61
50
49
46
21
22
11
3.8
2.3
2.4
2.8
11
9.7
8
6.7
6
5.8
5.6
15
8
7
1.5
5.3
7.2
9.6
91
54
36
29
26
25
24
78
78
64
57
50
48
43
(15105)
(1484)
(1695)
(1981)
(2290)
(2187)
(1775)
(1.88.4)
(2.613)
(0.341.6)
(3.014)
(1.98.9)
(0.407.4)
(<0.10.89)
(135749)
(160545)
(130477)
(111414)
(102374)
(100362)
(98352)
(0.733.2)
(1.813)
(42246)
(40156)
(32129)
(26112)
(2094)
(1992)
(1887)
(8.440)
(8.642)
(4.421)
(1.57.2)
(0.904.3)
(0.954.6)
(1.15.3)
(4.220)
(3.818)
(3.215)
(2.713)
(2.411)
(2.311)
(2.211)
(6.029)
(3.115)
(2.713)
(0.602.9)
(2.110)
(1.617)
(1.724)
(39164)
(2298)
(1565)
(1352)
(1147)
(1146)
(9.744)
(26157)
(38132)
(30110)
(2699)
(2387)
(2284)
(2074)
0.076
0.088
0.1
0.11
0.12
0.12
0.13
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
17
16
15
14
14
13
13
<0.01
<0.01
130
110
110
95
87
85
83
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.3
2.3
2
1.7
1.6
1.6
1.6
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
8.2
5.5
4
3.3
3.2
3.2
3.1
18
18
17
17
16
16
16
(0.0530.100)
(0.0720.110)
(0.0820.120)
(0.0970.130)
(0.0990.150)
(0.1000.150)
(0.1000.150)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1124)
(1419)
(1318)
(1217)
(1116)
(1116)
(1116)
(<0.01<0.01)
(<0.01<0.01)
(79180)
(94140)
(86130)
(80110)
(72100)
(71100)
(6997)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(2.02.6)
(2.02.6)
(1.72.2)
(1.52.0)
(1.41.8)
(1.41.8)
(1.41.8)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(6.69.9)
(4.56.7)
(3.34.9)
(2.74.0)
(2.63.9)
(2.63.8)
(2.53.8)
(1225)
(1421)
(1421)
(1420)
(1319)
(1319)
(1319)
40
40
40
40
40
40
40
3.5
5.2
0.68
5.9
3.7
2.2
0.26
251
215
184
158
140
135
131
0.69
0.69
84
71
60
51
45
43
42
17
17
8.8
3
1.8
1.9
2.2
8.4
7.7
6.4
5.4
4.8
4.7
4.5
12
6.2
5.5
1.2
4.1
5.7
7.5
62
38
26
20
19
19
18
54
48
43
38
35
34
34
(1535)
(2027)
(1827)
(1826)
(1826)
(1825)
(1725)
(2.53.2)
(4.55.8)
(4.05.2)
(3.64.7)
(4.76.1)
(5.36.8)
(6.07.8)
(3985)
(4059)
(3349)
(2740)
(2334)
(2332)
(2231)
(5.67.3)
(5.67.3)
(5.67.3)
(5.67.3)
(5.67.3)
(5.67.3)
(5.67.3)
(1824)
(2633)
(2330)
(1519)
(1316)
(1215)
(1115)
(2.22.8)
(1.51.9)
(2.02.6)
(4.25.4)
(2.12.7)
(1.01.3)

YEAR
(2854)
(3348)
(3348)
(3446)
(3348)
(3348)
(3348)
(3.03.9)
(4.55.9)
(0.590.77)
(5.26.7)
(3.24.2)
(1.92.4)
(0.230.30)
(166354)
(185248)
(151221)
(129190)
(114167)
(111161)
(108156)
(0.570.84)
(0.570.84)
(53121)
(5885)
(4972)
(4360)
(3753)
(3651)
(3550)
(1519)
(1519)
(7.710)
(2.63.4)
(1.62.0)
(1.72.1)
(1.92.5)
(7.39.5)
(6.88.7)
(5.67.2)
(4.76.1)
(4.25.4)
(4.15.3)
(4.05.1)
(1013)
(5.57.1)
(4.86.2)
(1.11.4)
(3.64.7)
(5.06.4)
(6.68.5)
(5075)
(3146)
(2132)
(1725)
(1523)
(1522)
(1522)
(3675)
(3958)
(3552)
(3146)
(2942)
(2841)
(2840)
173
YEAR
Costa Rica
Cuba
Curaao
Dominica
Dominican
Republic
Ecuador
El Salvador
Grenada
Guatemala
Guyana
Haiti
Honduras
Jamaica
Mexico
Montserrat
Netherlands
Antilles
Nicaragua
174
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
3
3
4
4
5
5
5
11
11
11
11
11
11
11
<1
<1
<1
<1
<1
<1
<1
<1
<1
7
8
9
9
10
10
10
10
11
12
13
14
14
15
5
6
6
6
6
6
6
<1
<1
<1
<1
<1
<1
<1
9
10
11
13
14
14
15
<1
<1
<1
<1
<1
<1
<1
7
8
9
9
10
10
10
5
6
6
7
7
8
8
2
2
3
3
3
3
3
84
92
100
106
112
113
115
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
4
5
5
5
6
6
6
NUMBER
(THOUSANDS)
0.087
0.089
0.081
0.06
0.043
0.039
0.035
0.066
0.088
0.052
0.034
0.03
0.03
0.03
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.98
0.9
0.79
0.73
0.66
0.64
0.62
2.3
2
1.6
1.2
0.83
0.75
0.68
0.31
0.26
0.17
0.11
0.08
0.073
0.066
<0.01
0
<0.01
<0.01
<0.01
<0.01
<0.01
0.97
0.8
0.57
0.42
0.37
0.36
0.36
0.067
0.084
0.15
0.16
0.18
0.19
0.2
2.2
3
3.6
3.6
3.1
3
3
0.32
0.35
0.31
0.27
0.24
0.24
0.24
0.025
0.023
0.016
0.011
<0.01
<0.01
<0.01
7.3
5.2
3.7
2.7
2.2
2.1
2
0
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.46
0.42
0.34
0.26
0.21
0.2
0.19
(0.0810.093)
(0.0860.092)
(0.0790.084)
(0.0570.062)
(0.0390.047)
(0.0370.041)
(0.0330.037)
(0.0620.069)
(0.0870.090)
(0.0510.053)
(0.0330.035)
(0.0290.030)
(0.0290.030)
(0.0290.031)
(0<0.01)
(0<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.5401.6)
(0.4601.5)
(0.4201.3)
(0.4101.1)
(0.3401.1)
(0.3301.0)
(0.3201.0)
(1.63.0)
(1.42.7)
(1.22.1)
(0.8701.5)
(0.7200.960)
(0.5401.0)
(0.4800.900)
(0.1800.470)
(0.1800.360)
(0.1300.220)
(0.0820.140)
(0.0600.100)
(0.0480.100)
(0.0430.093)
(<0.01<0.01)
(00)
(0<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.9001.0)
(0.7100.890)
(0.5100.630)
(0.3800.460)
(0.3200.430)
(0.3200.410)
(0.3200.400)
(0.0450.093)
(0.0620.110)
(0.0990.200)
(0.1100.220)
(0.1200.240)
(0.1300.260)
(0.1400.270)
(0.6504.7)
(1.25.6)
(1.56.5)
(1.56.4)
(1.45.6)
(1.35.4)
(1.35.4)
(0.1400.570)
(0.1500.650)
(0.1300.580)
(0.1100.490)
(0.1000.450)
(0.1000.440)
(0.0990.440)
(0.0200.031)
(0.0160.030)
(0.0120.021)
(<0.010.015)
(<0.010.010)
(<0.01<0.01)
(<0.01<0.01)
(7.07.6)
(4.85.5)
(3.63.8)
(2.62.8)
(2.12.2)
(2.02.2)
(1.92.1)
(00)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.2700.690)
(0.2900.580)
(0.2400.470)
(0.2000.330)
(0.1700.250)
(0.1600.230)
(0.1300.260)
RATEa
2.8
2.6
2.1
1.4
0.93
0.83
0.74
0.62
0.81
0.47
0.3
0.26
0.26
0.27
0.2
<0.1
6.7
3.5
2.7
1.8
3
3.6
4.2
14
11
9.2
7.9
6.7
6.4
6.1
22
18
13
8.8
5.9
5.2
4.6
5.7
4.6
2.9
1.8
1.3
1.2
1.1
0.3
0
<0.1
1.3
1.4
1.3
1.1
11
8
5
3.3
2.7
2.5
2.4
9.2
12
20
22
24
25
27
31
39
41
38
31
30
30
6.4
6.3
5
3.9
3.3
3.2
3.1
1.1
0.92
0.61
0.42
0.29
0.26
0.24
8.7
5.6
3.7
2.5
1.9
1.8
1.7
<0.1
0.43
0.64
0.68
0.58
0.41
0.17
0.58
0.56
0.58
0.55
0.5
11
9.1
6.8
4.8
3.6
3.4
3.2
(2.63.0)
(2.52.6)
(2.02.2)
(1.31.4)
(0.851.0)
(0.790.88)
(0.700.78)
(0.590.65)
(0.800.82)
(0.460.48)
(0.300.31)
(0.260.27)
(0.260.27)
(0.260.27)
(00.78)
(00.15)
(6.47.0)
(3.23.7)
(2.53.0)
(1.81.8)
(3.03.1)
(3.53.6)
(4.04.4)
(7.522)
(5.819)
(4.815)
(4.512)
(3.511)
(3.310)
(3.210)
(1630)
(1224)
(9.817)
(6.511)
(5.16.7)
(3.76.9)
(3.36.1)
(3.48.7)
(3.16.2)
(2.23.8)
(1.42.3)
(0.981.7)
(0.771.7)
(0.691.5)
(0.230.39)
(00)
(00.15)
(1.21.4)
(1.41.4)
(1.21.4)
(0.971.2)
(1012)
(7.18.8)
(4.55.6)
(3.03.6)
(2.33.1)
(2.22.8)
(2.12.7)
(6.213)
(8.515)
(1327)
(1530)
(1732)
(1734)
(1836)
(9.165)
(1671)
(1776)
(1669)
(1457)
(1354)
(1353)
(2.812)
(2.612)
(2.19.3)
(1.67.1)
(1.46.1)
(1.35.8)
(1.35.7)
(0.831.3)
(0.671.2)
(0.450.81)
(0.300.55)
(0.210.38)
(0.190.35)
(0.170.31)
(8.39.0)
(5.26.0)
(3.63.8)
(2.42.6)
(1.92.0)
(1.71.9)
(1.71.8)
(<0.1<0.1)
(0.370.48)
(0.560.73)
(0.600.77)
(0.510.66)
(0.360.46)
(0.150.20)
(0.550.61)
(0.530.60)
(0.560.60)
(0.530.57)
(0.480.52)
(6.617)
(6.213)
(4.89.2)
(3.66.1)
(2.94.4)
(2.84.0)
(2.24.4)

NUMBER
(THOUSANDS)
3.4
2.8
2.3
1.5
1
0.86
0.73
6.1
3.2
2.1
1.5
1.4
1.5
1.4
<0.01
<0.01
0.012
0.013
0.02
0.012
0.01
0.014
0.017
22
14
11
12
9.8
9
8.4
33
26
22
19
16
16
14
4.8
2.8
3.3
3.4
2
1.8
1.9
0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
12
13
14
15
15
16
16
1.3
0.95
0.87
1.1
0.91
0.89
0.92
23
28
34
36
32
32
31
8.5
8.1
8.6
8.8
6.1
5
3.8
0.2
0.19
0.19
0.21
0.22
0.23
0.24
110
75
50
36
22
21
20
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.013
0.012
0.012
0.014
0.011
7
5.9
5.1
4.2
3
2.7
2.9
(1.56.1)
(1.44.8)
(1.23.8)
(0.7902.6)
(0.5001.7)
(0.4101.5)
(0.3101.3)
(2.212)
(1.55.6)
(0.8503.8)
(0.6502.7)
(0.6302.5)
(0.6202.7)
(0.5502.5)
(<0.010.014)
(<0.01<0.01)
(<0.010.032)
(<0.010.026)
(<0.010.035)
(<0.010.023)
(<0.010.025)
(<0.010.024)
(<0.010.034)
(8.042)
(7.024)
(5.719)
(5.720)
(4.817)
(4.515)
(4.214)
(1266)
(1344)
(1137)
(9.333)
(8.028)
(7.726)
(7.024)
(1.59.9)
(0.9005.8)
(1.55.7)
(1.65.8)
(0.6704.0)
(0.6003.8)
(0.6203.9)
(<0.010.021)
(<0.010.014)
(<0.010.015)
(<0.010.014)
(<0.010.012)
(<0.010.012)
(<0.010.014)
(4.323)
(6.323)
(6.724)
(7.125)
(7.426)
(7.727)
(7.928)
(0.4702.4)
(0.4701.6)
(0.4401.5)
(0.4901.9)
(0.3901.7)
(0.3801.6)
(0.3801.7)
(8.446)
(1447)
(1757)
(1860)
(1654)
(1653)
(1552)
(2.917)
(4.113)
(4.314)
(4.315)
(2.910)
(2.38.9)
(1.37.6)
(0.0710.400)
(0.0910.320)
(0.0920.320)
(0.0990.360)
(0.1100.380)
(0.1100.400)
(0.1100.420)
(39210)
(36130)
(2486)
(1663)
(7.046)
(6.444)
(6.940)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.024)
(<0.010.023)
(<0.010.022)
(<0.010.026)
(<0.010.022)
(2.414)
(2.610)
(2.29.0)
(1.97.5)
(1.06.0)
(0.8305.6)
(0.8806.2)
RATEa
112
82
59
36
22
19
15
58
30
19
13
13
13
12
5.1
1
17
18
29
17
15
21
25
302
179
133
128
100
91
83
325
228
179
143
115
108
98
90
49
55
56
32
30
31
11
8.1
8.6
7.9
5
4.5
5.1
134
132
125
116
109
111
111
174
130
119
146
121
118
121
329
359
391
382
327
316
307
174
145
138
128
82
66
49
8.5
7.7
7.4
7.8
8.1
8.5
8.8
127
81
50
33
20
19
18
8.1
11
16
17
15
10
4.5
6.7
6.3
6.6
7.3
5.8
171
127
100
78
52
46
50
(50198)
(40137)
(3097)
(1859)
(1137)
(8.732)
(6.628)
(21114)
(1452)
(7.634)
(5.824)
(5.623)
(5.524)
(4.922)
(2.09.7)
(0.401.9)
(2.845)
(6.736)
(1450)
(5.634)
(2.537)
(9.736)
(8.651)
(112586)
(89300)
(66224)
(62218)
(49169)
(45152)
(42140)
(116639)
(110389)
(87303)
(70242)
(56194)
(53182)
(48165)
(29186)
(16102)
(2695)
(2696)
(1165)
(9.761)
(9.963)
(4.021)
(4.014)
(4.115)
(3.814)
(1.212)
(0.7612)
(0.8013)
(48263)
(63226)
(60214)
(56197)
(53186)
(53188)
(53188)
(65337)
(64219)
(60198)
(66258)
(52220)
(50215)
(50224)
(118646)
(179601)
(195655)
(189642)
(161552)
(156532)
(152516)
(60348)
(73242)
(69229)
(63215)
(39141)
(30117)
(1798)
(3.017)
(3.713)
(3.513)
(3.713)
(3.914)
(4.015)
(4.115)
(47248)
(39138)
(2486)
(1559)
(6.241)
(5.739)
(6.035)
(3.115)
(4.321)
(6.431)
(6.833)
(5.828)
(4.120)
(1.88.4)
(2.613)
(2.512)
(2.612)
(2.914)
(2.311)
(59341)
(56225)
(44177)
(35139)
(18104)
(1497)
(15105)

NUMBER
(THOUSANDS)
1.5
1.5
1.4
1
0.72
0.65
0.58
2.6
2
1.4
1
1
1
1
<0.01
<0.01
0.01
0.01
<0.01
<0.01
<0.01
<0.01
<0.01
11
9.6
8.6
7.6
6.9
6.7
6.5
18
16
13
11
9.7
9.4
9.1
3.4
2.6
2.2
2.4
1.8
1.8
1.7
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
6.6
7.1
7.6
8.2
8.7
8.9
9
0.65
0.65
0.76
0.86
0.84
0.84
0.83
18
19
23
25
24
23
22
6.1
7
7.2
6.1
4.3
3.9
3.4
0.15
0.16
0.17
0.18
0.18
0.18
0.18
52
41
32
24
20
18
17
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.01
<0.01
<0.01
0.011
<0.01
4.4
4
3.4
2.9
2.5
2.4
2.4
(1.31.7)
(1.31.7)
(1.21.5)
(0.8801.1)
(0.6300.810)
(0.5700.740)
(0.5100.660)
(1.63.9)
(1.62.5)
(1.11.8)
(0.8501.3)
(0.8501.2)
(0.8301.3)
(0.8301.3)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.015)
(<0.010.012)
(<0.010.012)
(<0.010.011)
(<0.010.011)
(<0.010.011)
(<0.010.011)
(6.616)
(7.912)
(7.010)
(6.29.1)
(5.68.2)
(5.58.0)
(5.47.7)
(1126)
(1319)
(1116)
(9.113)
(8.012)
(7.711)
(7.511)
(2.34.7)
(2.32.9)
(1.82.6)
(1.92.8)
(1.62.1)
(1.52.0)
(1.41.9)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(4.29.7)
(5.88.5)
(6.29.1)
(6.79.9)
(7.210)
(7.311)
(7.411)
(0.4000.960)
(0.5300.780)
(0.6200.920)
(0.7001.0)
(0.6901.0)
(0.6901.0)
(0.6800.990)
(1126)
(1623)
(1928)
(2130)
(1928)
(1927)
(1827)
(3.98.9)
(5.78.4)
(6.28.3)
(5.07.3)
(3.55.1)
(3.24.6)
(2.84.0)
(0.1100.210)
(0.1300.190)
(0.1400.200)
(0.1400.210)
(0.1500.210)
(0.1500.210)
(0.1500.210)
(3276)
(3349)
(2638)
(2029)
(1722)
(1621)
(1520)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.011)
(<0.010.011)
(<0.010.010)
(<0.010.012)
(<0.010.010)
(2.96.3)
(3.24.7)
(2.84.1)
(2.43.5)
(2.22.9)
(2.12.8)
(2.02.7)
RATEa
48
43
35
23
16
14
12
25
19
13
9.2
9.1
9.3
9.3
4
0.79
15
14
14
13
13
13
13
148
121
100
82
70
67
65
174
136
107
83
68
65
62
63
45
37
39
30
28
27
4.6
4.5
4.4
4.2
4.1
4.1
4.1
74
71
68
65
62
62
61
89
89
104
115
112
111
110
247
247
271
272
238
230
222
125
125
116
89
58
51
43
6.5
6.5
6.5
6.5
6.6
6.6
6.6
61
44
32
23
17
16
15
6.3
8.5
13
14
12
8.2
3.5
5.3
4.9
5.2
5.7
4.5
108
85
68
53
44
42
40
(4254)
(3748)
(3139)
(2026)
(1418)
(1216)
(1114)
(1537)
(1523)
(1016)
(7.511)
(7.511)
(7.411)
(7.411)
(3.54.5)
(0.690.89)
(9.321)
(1217)
(1117)
(1116)
(1116)
(1116)
(1116)
(91218)
(99146)
(82120)
(6798)
(5784)
(5580)
(5377)
(108257)
(111164)
(87128)
(68100)
(5682)
(5477)
(5174)
(4388)
(3950)
(3044)
(3247)
(2534)
(2433)
(2331)
(2.96.8)
(3.85.2)
(3.65.2)
(3.55.1)
(3.45.0)
(3.44.9)
(3.44.9)
(47109)
(5885)
(5581)
(5378)
(5174)
(5173)
(5073)
(55132)
(73107)
(85125)
(94138)
(92134)
(91132)
(91131)
(153365)
(202297)
(221325)
(222326)
(196285)
(190275)
(183265)
(79182)
(102150)
(99134)
(73107)
(4769)
(4261)
(3652)
(4.78.8)
(5.47.9)
(5.47.9)
(5.47.9)
(5.47.8)
(5.47.8)
(5.47.8)
(3890)
(3653)
(2638)
(1927)
(1520)
(1419)
(1318)
(5.57.1)
(7.59.7)
(1115)
(1215)
(1013)
(7.19.2)
(3.03.9)
(4.65.9)
(4.35.6)
(4.55.8)
(5.06.5)
(4.05.1)
(71152)
(70102)
(5581)
(4464)
(3851)
(3649)
(3546)
Panama
Paraguay
Peru
Puerto Rico
Saint Kitts and

Nevis
Saint Lucia
Saint Vincent and

the Grenadines
Sint Maarten
(Dutch part)
Suriname
Trinidad and
Tobago
Turks and Caicos

Islands
United States
of America
Uruguay
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
2
3
3
3
3
4
4
4
5
5
6
6
6
7
22
24
26
28
29
29
29
4
4
4
4
4
4
4
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1
1
1
1
1
1
1
<1
<1
<1
<1
<1
<1
<1
253
266
282
297
308
310
313
3
3
3
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
20
22
24
27
29
29
29
NUMBER
(THOUSANDS)
0.2
0.22
0.21
0.2
0.21
0.21
0.22
0.16
0.23
0.24
0.24
0.2
0.19
0.17
7.7
6.4
3.6
2.5
2.2
2.2
2.2
0.062
0.063
0.026
0.017
0.017
0.017
0.018
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.014
0.014
<0.01
<0.01
0.012
0.013
0.015
0.028
0.033
0.029
0.023
0.027
0.028
0.029
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
1.8
1.6
0.93
0.66
0.51
0.46
0.42
0.082
0.083
0.071
0.065
0.058
0.056
0.054
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
1.1
0.8
0.74
0.69
0.68
0.68
0.68
(0.1800.230)
(0.1900.240)
(0.1900.230)
(0.1900.210)
(0.2000.220)
(0.1900.240)
(0.2000.240)
(0.1200.200)
(0.1700.290)
(0.1700.330)
(0.1800.300)
(0.1700.240)
(0.1400.250)
(0.1300.220)
(2.516)
(3.410)
(2.25.2)
(1.93.1)
(1.13.7)
(1.13.7)
(1.13.7)
(0.0620.062)
(0.0630.063)
(0.0260.027)
(0.0170.017)
(0.0170.017)
(0.0170.017)
(0.0180.018)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0<0.01)
(0<0.01)
(<0.010.019)
(<0.010.023)
(<0.010.011)
(<0.010.010)
(0.0110.014)
(0.0100.017)
(0.0110.019)
(0.0270.029)
(0.0320.033)
(0.0290.029)
(0.0220.023)
(0.0270.028)
(0.0280.029)
(0.0290.030)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1.81.8)
(1.61.6)
(0.9100.950)
(0.6400.680)
(0.5000.520)
(0.4600.470)
(0.4100.430)
(0.0750.089)
(0.0800.086)
(0.0690.074)
(0.0620.068)
(0.0520.063)
(0.0530.059)
(0.0510.057)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1.11.1)
(0.7800.820)
(0.7200.770)
(0.6700.710)
(0.6600.700)
(0.6600.700)
(0.6700.700)
RATEa
8.4
8.1
7.1
6.1
6
6.1
6.1
3.7
4.7
4.6
4
3.2
2.9
2.6
35
27
14
9.1
7.7
7.5
7.4
1.8
1.7
0.69
0.44
0.44
0.46
0.48
<0.1
2.6
2.7
0.2
2.8
2.8
2.7
3.7
4.6
1.2
2
2.2
2.1
1.9
1.2
2.7
1.9
2.8
2
1.8
1.6
0.45
0.28
3.5
3.2
1.8
1.8
2.4
2.5
2.7
2.3
2.6
2.2
1.7
2
2.1
2.2
<0.1
0.58
6.5
3.6
2.8
2.7
2.6
0.7
0.61
0.33
0.22
0.16
0.15
0.13
2.6
2.6
2.2
2
1.7
1.7
1.6
0.22
3
1.8
0.71
0.26
0.18
0.12
5.5
3.6
3.1
2.6
2.4
2.3
2.3
(7.59.4)
(7.29.0)
(6.37.9)
(5.76.5)
(5.76.4)
(5.46.8)
(5.56.8)
(2.84.8)
(3.66.0)
(3.26.1)
(3.15.1)
(2.73.8)
(2.23.8)
(2.03.4)
(1272)
(1443)
(8.720)
(7.011)
(3.813)
(3.713)
(3.612)
(1.81.8)
(1.71.7)
(0.690.70)
(0.440.45)
(0.440.44)
(0.450.46)
(0.480.48)
(<0.1<0.1)
(2.62.7)
(2.62.9)
(0.180.23)
(2.62.9)
(2.62.9)
(2.62.9)
(3.53.9)
(3.55.8)
(1.01.4)
(1.92.1)
(1.92.5)
(1.82.4)
(1.62.2)
(1.21.3)
(2.62.7)
(1.82.1)
(2.82.9)
(1.92.1)
(1.71.8)
(1.51.6)
(<0.11.8)
(01.6)
(2.44.8)
(1.55.4)
(1.52.3)
(1.62.0)
(2.02.7)
(1.93.3)
(2.13.5)
(2.22.4)
(2.62.6)
(2.22.3)
(1.71.8)
(2.02.1)
(2.12.2)
(2.12.2)
(<0.1<0.1)
(0.550.61)
(6.07.0)
(3.53.7)
(2.62.9)
(2.52.8)
(2.52.8)
(0.690.72)
(0.610.62)
(0.320.33)
(0.220.23)
(0.160.17)
(0.150.15)
(0.130.14)
(2.42.9)
(2.52.7)
(2.12.2)
(1.92.1)
(1.61.9)
(1.61.7)
(1.51.7)
(0.200.25)
(3.03.1)
(1.71.8)
(0.700.71)
(0.260.26)
(0.180.19)
(0.120.12)
(5.45.7)
(3.53.7)
(2.93.2)
(2.52.7)
(2.32.4)
(2.32.4)
(2.32.4)

NUMBER
(THOUSANDS)
RATEa
1.6
1.3
1.4
1.7
1.8
1.9
2
3.9
3.5
3.7
4
4.1
4.1
3.9
110
78
64
50
36
34
34
0.28
0.38
0.25
0.13
0.1
0.088
0.075
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.027
0.034
0.023
0.023
0.014
0.015
0.011
0.071
0.062
0.055
0.047
0.02
0.035
0.033
<0.01
<0.01
0.38
0.33
0.33
0.35
0.33
0.29
0.27
0.16
0.24
0.23
0.22
0.28
0.31
0.29
(0.6203.1)
(0.4702.6)
(0.5002.8)
(0.5503.4)
(0.6303.4)
(0.7503.5)
(0.8603.6)
(1.86.8)
(1.76.1)
(1.76.3)
(1.97.0)
(1.97.1)
(1.97.1)
(1.86.6)
(37230)
(31140)
(26120)
(1995)
(1176)
(1072)
(1072)
(0.1100.530)
(0.1500.710)
(0.0960.470)
(0.0520.240)
(0.0400.190)
(0.0360.160)
(0.0290.140)
(<0.01<0.01)
(<0.010.015)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.010)
(0.0110.051)
(0.0140.065)
(<0.010.044)
(<0.010.043)
(<0.010.033)
(<0.010.031)
(<0.010.023)
(0.0260.140)
(0.0280.110)
(0.0260.093)
(0.0180.088)
(<0.010.053)
(0.0120.070)
(0.0130.063)
(<0.01<0.01)
(<0.01<0.01)
(0.1500.710)
(0.1400.610)
(0.1400.600)
(0.1500.650)
(0.1300.630)
(0.1100.550)
(0.1100.500)
(0.0620.300)
(0.0980.440)
(0.1000.420)
(0.0930.400)
(0.1200.500)
(0.1300.560)
(0.1300.520)
67
49
48
52
51
53
56
92
74
69
68
64
63
59
522
325
247
181
126
118
117
8
10
6.4
3.4
2.7
2.4
2
0.29
18
10
5.2
7.3
7.3
7.1
20
23
15
14
8.2
8.9
6
66
57
51
43
18
32
30
12
7.7
94
76
70
71
63
56
51
13
19
18
17
21
23
22
<0.01
0.015
<0.01
<0.01
<0.01
0.013
38
31
23
19
16
16
15
0.98
1.1
1
0.94
0.77
0.74
0.79
<0.01
0.011
0.011
0.011
0.011
0.011
0.011
9.7
11
11
12
14
14
14
(<0.010.019)
(<0.010.028)
(<0.010.014)
(<0.010.018)
(<0.010.024)
(<0.010.026)
(1570)
(1359)
(9.443)
(7.835)
(6.730)
(6.429)
(6.028)
(0.1502.6)
(0.4502.0)
(0.4201.8)
(0.3901.7)
(0.2601.5)
(0.2501.5)
(0.2601.6)
(<0.010.011)
(<0.010.020)
(<0.010.020)
(<0.010.020)
(<0.010.020)
(<0.010.020)
(<0.010.020)
(3.419)
(4.819)
(4.820)
(5.522)
(6.423)
(6.724)
(6.924)
64
80
24
26
26
34
15
12
8.2
6.4
5.3
5.1
4.7
31
34
30
28
23
22
23
5.8
9.9
9.9
9.9
9.9
9.9
9.9
49
50
46
47
48
49
48

NUMBER
(THOUSANDS)
RATEa
(26129)
(1895)
(1793)
(17106)
(1899)
(21100)
(24100)
(42159)
(35127)
(33119)
(32118)
(30112)
(30109)
(28101)
(1691 070)
(130608)
(100460)
(71343)
(38266)
(36249)
(35246)
(3.115)
(4.019)
(2.512)
(1.46.2)
(1.15.1)
(0.954.4)
(0.773.8)
(0.110.54)
(7.134)
(4.120)
(2.09.9)
(1.916)
(1.318)
(1.019)
(7.637)
(9.244)
(5.828)
(5.526)
(1.919)
(3.018)
(1.613)
(24129)
(26100)
(2487)
(1781)
(2.449)
(1164)
(1158)
(4.522)
(1.419)
(38175)
(31141)
(30129)
(30130)
(24121)
(22105)
(2194)
(5.124)
(7.835)
(7.733)
(7.130)
(9.037)
(9.642)
(9.339)
1.1
1.3
1.4
1.5
1.6
1.7
1.7
2.8
2.5
2.6
2.9
3
3
3
69
58
48
39
32
31
30
0.22
0.29
0.19
0.12
0.088
0.078
0.068
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.021
0.027
0.018
0.018
0.014
0.012
<0.01
0.029
0.029
0.028
0.027
0.027
0.027
0.026
<0.01
<0.01
0.26
0.4
0.4
0.31
0.26
0.24
0.23
0.13
0.2
0.21
0.22
0.27
0.28
0.29
(0.7901.6)
(1.01.5)
(1.21.7)
(1.31.8)
(1.51.8)
(1.51.9)
(1.51.9)
(2.63.0)
(2.32.7)
(2.42.8)
(2.73.1)
(2.73.2)
(2.73.2)
(2.83.2)
(42100)
(4769)
(3957)
(3345)
(2837)
(2735)
(2633)
(0.1900.250)
(0.2600.330)
(0.1700.220)
(0.1100.140)
(0.0770.100)
(0.0680.088)
(0.0590.077)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0190.024)
(0.0230.030)
(0.0160.021)
(0.0160.020)
(0.0130.016)
(0.0110.014)
(<0.010.010)
(0.0180.043)
(0.0230.034)
(0.0230.033)
(0.0220.033)
(0.0220.032)
(0.0220.032)
(0.0220.032)
(<0.01<0.01)
(<0.01<0.01)
(0.1700.360)
(0.2600.570)
(0.2600.580)
(0.2000.450)
(0.1700.370)
(0.1600.340)
(0.1700.310)
(0.1100.140)
(0.1800.230)
(0.1900.240)
(0.1900.250)
(0.2400.310)
(0.2400.320)
(0.2500.330)
47
47
47
47
48
48
48
66
52
49
49
47
46
45
317
242
184
140
113
106
101
6.2
7.9
5
3.3
2.3
2.1
1.8
0.22
14
8.1
4.1
5.7
5.7
5.5
15
18
12
11
8.4
6.9
5.1
27
27
26
25
24
24
24
9.1
6
63
92
86
63
49
46
44
10
16
17
17
20
21
21
(25121)
(31150)
(9.245)
(1049)
(5.163)
(1365)
(6.028)
(4.822)
(3.315)
(2.612)
(2.29.9)
(2.19.4)
(1.98.8)
(5.082)
(1462)
(1355)
(1252)
(7.946)
(7.444)
(7.747)
(2.311)
(3.919)
(3.819)
(3.919)
(3.919)
(3.919)
(3.819)
(1799)
(2288)
(2084)
(2183)
(2382)
(2384)
(2382)
<0.01
0.012
<0.01
<0.01
<0.01
0.011
31
26
19
16
14
13
12
0.86
0.84
0.81
0.76
0.73
0.72
0.72
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
7
7.7
8.3
9
9.5
9.7
9.8
(<0.01<0.01)
(0.0100.013)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.010)
(<0.010.012)
(2735)
(2329)
(1722)
(1418)
(1215)
(1115)
(1114)
(0.5301.3)
(0.6901.0)
(0.6600.970)
(0.6300.910)
(0.6300.830)
(0.6200.830)
(0.6200.830)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(4.99.3)
(6.39.2)
(6.810)
(7.411)
(7.811)
(8.012)
(8.112)
50
62
19
20
23
27
12
9.7
6.7
5.4
4.4
4.2
3.9
28
26
24
23
22
21
21
4.5
7.7
7.7
7.7
7.7
7.7
7.7
35
35
34
34
33
33
33
(3365)
(3957)
(3956)
(3957)
(4253)
(4254)
(4254)
(6172)
(4856)
(4553)
(4553)
(4351)
(4250)
(4249)
(196468)
(198290)
(151221)
(118164)
(98128)
(93120)
(88114)
(5.57.1)
(6.99.0)
(4.45.7)
(2.93.7)
(2.12.7)
(1.82.4)
(1.62.0)
(0.200.25)
(1216)
(7.19.2)
(3.64.6)
(5.06.4)
(5.06.4)
(4.86.2)
(1317)
(1621)
(1013)
(9.512)
(7.39.5)
(6.17.8)
(4.55.8)
(1740)
(2232)
(2131)
(2030)
(2029)
(2029)
(2029)
(8.010)
(5.26.8)
(4190)
(59131)
(56124)
(4190)
(3270)
(3165)
(3258)
(9.112)
(1418)
(1519)
(1519)
(1823)
(1824)
(1924)

YEAR
(4456)
(5470)
(1621)
(1823)
(2026)
(2430)
(1114)
(8.511)
(5.97.6)
(4.76.1)
(3.95.0)
(3.74.7)
(3.44.4)
(1741)
(2131)
(2029)
(1927)
(1925)
(1825)
(1824)
(3.95.1)
(6.78.7)
(6.88.7)
(6.88.7)
(6.88.7)
(6.88.7)
(6.88.7)
(2547)
(2842)
(2841)
(2841)
(2740)
(2740)
(2740)
175
YEAR
Anguilla
1990
1995
2000
2005
2009
2010
2011
Antigua and
1990
Barbuda
1995
2000
2005
2009
2010
2011
Argentina
1990
1995
2000
2005
2009
2010
2011
Aruba
1990
1995
2000
2005
2009
2010
2011
Bahamas
1990
1995
2000
2005
2009
2010
2011
Barbados
1990
1995
2000
2005
2009
2010
2011
Belize
1990
1995
2000
2005
2009
2010
2011
Bermuda
1990
1995
2000
2005
2009
2010
2011
Bolivia
1990
(Plurinational
1995
State of)
2000
2005
2009
2010
2011
Bonaire, Saint
2010
Brazil
1990
1995
2000
2005
2009
2010
2011
British Virgin
1990
Islands
1995
2000
2005
2009
2010
2011
Canada
1990
1995
2000
2005
2009
2010
2011
Cayman Islands
1990
1995
2000
2005
2009
2010
2011
Chile
1990
1995
2000
2005
2009
2010
2011
Colombia
1990
1995
2000
2005
2009
2010
2011
176
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
33
35
37
39
40
40
41
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
7
7
8
9
10
10
10
<1
<1
150
162
174
186
193
195
197
<1
<1
<1
<1
<1
<1
<1
28
29
31
32
34
34
34
<1
<1
<1
<1
<1
<1
<1
13
14
15
16
17
17
17
33
36
40
43
46
46
47
RATEa
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
19
17
15
13
11
11
11
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.054
0.082
0.078
0.055
0.048
0.047
0.046
<0.01
<0.01
<0.01
0.013
<0.01
<0.01
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1328)
(1421)
(1218)
(1115)
(9.414)
(9.113)
(8.913)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0470.061)
(0.0720.093)
(0.0680.088)
(0.0480.062)
(0.0420.055)
(0.0410.053)
(0.0400.052)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0110.015)
(<0.01<0.01)
(<0.01<0.01)
24
23
23
22
21
21
21
2.9
5.1
4.6
4.1
5.4
6
6.9
60
49
40
33
28
27
26
6.4
6.4
6.4
6.4
6.4
6.4
6.4
21
29
26
17
14
14
13
2.5
1.7
2.3
4.8
2.4
1.2
0.076
0.088
0.1
0.11
0.12
0.12
0.13
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
17
16
15
14
14
13
13
<0.01
<0.01
130
110
110
95
87
85
83
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.3
2.3
2
1.7
1.6
1.6
1.6
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
8.2
5.5
4
3.3
3.2
3.2
3.1
18
18
17
17
16
16
16
(0.0530.100)
(0.0720.110)
(0.0820.120)
(0.0970.130)
(0.0990.150)
(0.1000.150)
(0.1000.150)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1124)
(1419)
(1318)
(1217)
(1116)
(1116)
(1116)
(<0.01<0.01)
(<0.01<0.01)
(79180)
(94140)
(86130)
(80110)
(72100)
(71100)
(6997)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(2.02.6)
(2.02.6)
(1.72.2)
(1.52.0)
(1.41.8)
(1.41.8)
(1.41.8)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(6.69.9)
(4.56.7)
(3.34.9)
(2.74.0)
(2.63.9)
(2.63.8)
(2.53.8)
(1225)
(1421)
(1421)
(1420)
(1319)
(1319)
(1319)
40
40
40
40
40
40
40
3.5
5.2
0.68
5.9
3.7
2.2
0.26
251
215
184
158
140
135
131
0.69
0.69
84
71
60
51
45
43
42
17
17
8.8
3
1.8
1.9
2.2
8.4
7.7
6.4
5.4
4.8
4.7
4.5
12
6.2
5.5
1.2
4.1
5.7
7.5
62
38
26
20
19
19
18
54
48
43
38
35
34
34
(1535)
(2027)
(1827)
(1826)
(1826)
(1825)
(1725)
(2.53.2)
(4.55.8)
(4.05.2)
(3.64.7)
(4.76.1)
(5.36.8)
(6.07.8)
(3985)
(4059)
(3349)
(2740)
(2334)
(2332)
(2231)
(5.67.3)
(5.67.3)
(5.67.3)
(5.67.3)
(5.67.3)
(5.67.3)
(5.67.3)
(1824)
(2633)
(2330)
(1519)
(1316)
(1215)
(1115)
(2.22.8)
(1.51.9)
(2.02.6)
(4.25.4)
(2.12.7)
(1.01.3)
(2854)
(3348)
(3348)
(3446)
(3348)
(3348)
(3348)
(3.03.9)
(4.55.9)
(0.590.77)
(5.26.7)
(3.24.2)
(1.92.4)
(0.230.30)
(166354)
(185248)
(151221)
(129190)
(114167)
(111161)
(108156)
(0.570.84)
(0.570.84)
(53121)
(5885)
(4972)
(4360)
(3753)
(3651)
(3550)
(1519)
(1519)
(7.710)
(2.63.4)
(1.62.0)
(1.72.1)
(1.92.5)
(7.39.5)
(6.88.7)
(5.67.2)
(4.76.1)
(4.25.4)
(4.15.3)
(4.05.1)
(1013)
(5.57.1)
(4.86.2)
(1.11.4)
(3.64.7)
(5.06.4)
(6.68.5)
(5075)
(3146)
(2132)
(1725)
(1523)
(1522)
(1522)
(3675)
(3958)
(3552)
(3146)
(2942)
(2841)
(2840)
NUMBER
(THOUSANDS)
RATEa
<0.01 (<0.01<0.01)
2.1 (0.803.9)
<0.01
<0.01
0.4
0.57
0.64
0.59
0.55
0.54
0.53
(<0.01<0.01)
(<0.01<0.01)
(0.2600.570)
(0.4100.770)
(0.4600.840)
(0.4300.780)
(0.4000.720)
(0.4000.710)
(0.3900.690)
5
4.3
1.2
1.6
1.7
1.5
1.4
1.3
1.3
0.025
0.042
0.038
0.024
0.016
0.023
0.013
<0.01
<0.01
<0.01
<0.01
(0.0220.028) 9.8 (8.511)

(0.0350.050) 15 (1318)
(0.0320.045) 13 (1115)
(0.0200.029) 7.6 (6.39.0)
(<0.010.024) 4.7 (2.87.0)
(0.0150.032) 6.6 (4.39.4)
(<0.010.020) 3.7 (2.15.9)
(<0.01<0.01) <0.1 (<0.1<0.1)
(<0.01<0.01) 0.1 (<0.10.14)
(<0.01<0.01) 0.3 (0.200.31)
(<0.01<0.01) 0.7 (0.580.89)
(3.27.2)
(2.36.9)
(0.801.8)
(1.22.2)
(1.22.3)
(1.12.0)
(1.01.8)
(0.991.8)
(0.961.7)
<0.01 (<0.01<0.01)
0.4 (<0.10.93)
<0.01
0.013
0.019
0.026
0.023
0.025
0.048
3.6
5.9
7.4
9.4
7.6
8.2
15
1.3
1.1
1
0.81
0.58
0.53
0.5
15
23
23
15
17
15
16
0.076
0.076
0.075
0.074
0.073
0.072
0.072
0.067
0.14
0.22
0.21
0.2
0.2
0.19
0.71
1.4
1.6
1.1
1.5
1.5
3.1
(<0.01<0.01)
(0.0100.016)
(0.0150.023)
(0.0170.037)
(0.0130.036)
(0.0170.036)
(0.0310.067)
(2.54.9)
(4.67.4)
(5.89.2)
(6.213)
(4.412)
(5.312)
(9.921)
(0.8801.9)
(0.8201.3)
(0.7401.3)
(0.5901.1)
(0.4200.770)
(0.3900.710)
(0.3600.660)
20
14
12
8.8
5.9
5.4
4.9
(1328)
(1118)
(8.916)
(6.512)
(4.37.8)
(3.97.1)
(3.66.5)
(9.522)
(1630)
(1730)
(1318)
(1421)
(1318)
(1319)
10
14
13
8.2
9
7.8
8.2
(6.314)
(1018)
(9.617)
(6.89.7)
(7.511)
(6.59.2)
(6.89.7)
(0.0670.086)
(0.0560.098)
(0.0560.097)
(0.0560.095)
(0.0550.093)
(0.0550.092)
(0.0540.091)
(0.0540.081)
(0.1000.200)
(0.1600.290)
(0.1600.280)
(0.1500.260)
(0.1400.260)
(0.1400.250)
(0.4800.990)
(1.11.9)
(1.22.1)
(0.8401.3)
(0.9602.2)
(1.11.9)
(2.53.7)
0.3
0.3
0.2
0.2
0.2
0.2
0.2
0.5
1
1.5
1.3
1.2
1.2
1.1
2.1
4
4.1
2.5
3.3
3.3
6.6
(0.240.31)
(0.190.34)
(0.180.32)
(0.170.29)
(0.160.28)
(0.160.27)
(0.160.27)
(0.410.61)
(0.691.4)
(1.11.9)
(0.961.7)
(0.871.5)
(0.851.5)
(0.821.5)
(1.43.0)
(2.95.2)
(3.15.3)
(2.03.0)
(2.14.9)
(2.54.2)
(5.47.9)

NUMBER
RATEa
CASE DETECTION
PERCENT
0
2
0
20
0
88 (75100)
1
0
1
0
4
6
3
6
6
12 309
13 450
11 767
9 770
7 701
7 287
9 610
6.5
0
1.6
0
5.2
7.2
3.4
6.8
6.7
38
39
32
25
19
18
24
31
0
56
0
110
170
64
110
97
63
79
79
76
68
66
90
(100130)
(150200)
(5673)
(99130)
(86110)
(4497)
(6596)
(6696)
(6393)
(5782)
(5580)
(75110)
6
8
46
57
82
48
45
31
41
5
3
3
5.6
7.4
18
20
28
15
13
9
12
1.9
1.1
1.1
87
120
86
69
110
88
93
66
90
77
67
49
(7799)
(100130)
(7698)
(6179)
(93120)
(78100)
(82110)
(5875)
(80100)
(6888)
(5976)
(4356)
2
6
0
57
95
106
102
88
145
74
0
4
0
0.73
2.2
0
30
43
42
36
29
47
23
0
6.5
0
75
110
110
91
72
120
58
0
130
0
(55110)
(90130)
(88130)
(79110)
(6089)
(97140)
(4971)
1
1
11 166
14 422
10 127
9 748
8 847
8 345
8 521
0
1
74 570
91 013
77 899
80 209
75 040
74 395
74 892
1.5
1.5
168
193
122
107
91
84
84
0
5.4
50
56
45
43
39
38
38
71
590
67
90
66
67
65
62
64
0
780
60
79
74
84
86
88
91
(6381)
(520670)
(47100)
(78100)
(5581)
(5683)
(5479)
(5275)
(5478)
1
0
4.9
0
1
0
1 968
1 921
1 667
1 484
1 505
1 322
1 391
2
2
5
4.3
0
7.1
6.6
5.4
4.6
4.5
3.9
4
7.7
6.1
12
230
0
85
85
85
86
93
83
89
64
98
230
(7597)
(7597)
(7597)
(7698)
(83110)
(7495)
(79100)
(5774)
(86110)
(200260)
2
4
2
6 151
4 150
3 021
2 505
2 398
2 376
2 450
12 447
9 912
11 630
10 360
11 324
11 420
11 523
3.6
7.1
3.5
47
29
20
15
14
14
14
37
27
29
24
25
25
25
87
130
47
75
75
75
75
75
75
79
70
57
68
63
70
72
73
(7799)
(110140)
(4254)
(6293)
(6293)
(6293)
(6293)
(6293)
(6293)
(6597)
(50100)
(4769)
(5783)
(5277)
(5986)
(6087)
(6188)
(2637)
(5064)
31 (2735)
180 (160210)
(110140)
(650960)
(4194)
(6697)
(6291)
(71100)
(73100)
(75110)
(77110)
55 (4963)
0
(200260)
Costa Rica
Cuba
Curaao
Dominica
Dominican
Republic
Ecuador
El Salvador
Grenada
Guatemala
Guyana
Haiti
Honduras
Jamaica
Mexico
Montserrat
Netherlands
Antilles
Nicaragua
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
1990
1995
2000
2005
2009
2010
2011
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
3
3
4
4
5
5
5
11
11
11
11
11
11
11
<1
<1
<1
<1
<1
<1
<1
<1
<1
7
8
9
9
10
10
10
10
11
12
13
14
14
15
5
6
6
6
6
6
6
<1
<1
<1
<1
<1
<1
<1
9
10
11
13
14
14
15
<1
<1
<1
<1
<1
<1
<1
7
8
9
9
10
10
10
5
6
6
7
7
8
8
2
2
3
3
3
3
3
84
92
100
106
112
113
115
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
4
5
5
5
6
6
6
1.5
1.5
1.4
1
0.72
0.65
0.58
2.6
2
1.4
1
1
1
1
<0.01
<0.01
0.01
0.01
<0.01
<0.01
<0.01
<0.01
<0.01
11
9.6
8.6
7.6
6.9
6.7
6.5
18
16
13
11
9.7
9.4
9.1
3.4
2.6
2.2
2.4
1.8
1.8
1.7
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
6.6
7.1
7.6
8.2
8.7
8.9
9
0.65
0.65
0.76
0.86
0.84
0.84
0.83
18
19
23
25
24
23
22
6.1
7
7.2
6.1
4.3
3.9
3.4
0.15
0.16
0.17
0.18
0.18
0.18
0.18
52
41
32
24
20
18
17
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.01
<0.01
<0.01
0.011
<0.01
4.4
4
3.4
2.9
2.5
2.4
2.4
(1.31.7)
(1.31.7)
(1.21.5)
(0.8801.1)
(0.6300.810)
(0.5700.740)
(0.5100.660)
(1.63.9)
(1.62.5)
(1.11.8)
(0.8501.3)
(0.8501.2)
(0.8301.3)
(0.8301.3)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.015)
(<0.010.012)
(<0.010.012)
(<0.010.011)
(<0.010.011)
(<0.010.011)
(<0.010.011)
(6.616)
(7.912)
(7.010)
(6.29.1)
(5.68.2)
(5.58.0)
(5.47.7)
(1126)
(1319)
(1116)
(9.113)
(8.012)
(7.711)
(7.511)
(2.34.7)
(2.32.9)
(1.82.6)
(1.92.8)
(1.62.1)
(1.52.0)
(1.41.9)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(4.29.7)
(5.88.5)
(6.29.1)
(6.79.9)
(7.210)
(7.311)
(7.411)
(0.4000.960)
(0.5300.780)
(0.6200.920)
(0.7001.0)
(0.6901.0)
(0.6901.0)
(0.6800.990)
(1126)
(1623)
(1928)
(2130)
(1928)
(1927)
(1827)
(3.98.9)
(5.78.4)
(6.28.3)
(5.07.3)
(3.55.1)
(3.24.6)
(2.84.0)
(0.1100.210)
(0.1300.190)
(0.1400.200)
(0.1400.210)
(0.1500.210)
(0.1500.210)
(0.1500.210)
(3276)
(3349)
(2638)
(2029)
(1722)
(1621)
(1520)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.011)
(<0.010.011)
(<0.010.010)
(<0.010.012)
(<0.010.010)
(2.96.3)
(3.24.7)
(2.84.1)
(2.43.5)
(2.22.9)
(2.12.8)
(2.02.7)
RATEa
48
43
35
23
16
14
12
25
19
13
9.2
9.1
9.3
9.3
4
0.79
15
14
14
13
13
13
13
148
121
100
82
70
67
65
174
136
107
83
68
65
62
63
45
37
39
30
28
27
4.6
4.5
4.4
4.2
4.1
4.1
4.1
74
71
68
65
62
62
61
89
89
104
115
112
111
110
247
247
271
272
238
230
222
125
125
116
89
58
51
43
6.5
6.5
6.5
6.5
6.6
6.6
6.6
61
44
32
23
17
16
15
6.3
8.5
13
14
12
8.2
3.5
5.3
4.9
5.2
5.7
4.5
108
85
68
53
44
42
40
(4254)
(3748)
(3139)
(2026)
(1418)
(1216)
(1114)
(1537)
(1523)
(1016)
(7.511)
(7.511)
(7.411)
(7.411)
(3.54.5)
(0.690.89)
(9.321)
(1217)
(1117)
(1116)
(1116)
(1116)
(1116)
(91218)
(99146)
(82120)
(6798)
(5784)
(5580)
(5377)
(108257)
(111164)
(87128)
(68100)
(5682)
(5477)
(5174)
(4388)
(3950)
(3044)
(3247)
(2534)
(2433)
(2331)
(2.96.8)
(3.85.2)
(3.65.2)
(3.55.1)
(3.45.0)
(3.44.9)
(3.44.9)
(47109)
(5885)
(5581)
(5378)
(5174)
(5173)
(5073)
(55132)
(73107)
(85125)
(94138)
(92134)
(91132)
(91131)
(153365)
(202297)
(221325)
(222326)
(196285)
(190275)
(183265)
(79182)
(102150)
(99134)
(73107)
(4769)
(4261)
(3652)
(4.78.8)
(5.47.9)
(5.47.9)
(5.47.9)
(5.47.8)
(5.47.8)
(5.47.8)
(3890)
(3653)
(2638)
(1927)
(1520)
(1419)
(1318)
(5.57.1)
(7.59.7)
(1115)
(1215)
(1013)
(7.19.2)
(3.03.9)
(4.65.9)
(4.35.6)
(4.55.8)
(5.06.5)
(4.05.1)
(71152)
(70102)
(5581)
(4464)
(3851)
(3649)
(3546)
NUMBER
(THOUSANDS)
0.037
0.071
0.098
0.13
0.077
0.071
0.055
0.011
0.013
0.016
(0.0330.042)
(0.0490.096)
(0.0710.130)
(0.0980.180)
(0.0580.100)
(0.0520.093)
(0.0400.073)
(<0.010.016)
(<0.010.021)
(<0.010.024)
RATEa
1.2
2
2.5
3.1
1.7
1.5
1.2
0.1
0.1
0.1
(1.11.4)
(1.42.8)
(1.83.3)
(2.34.1)
(1.32.2)
(1.12.0)
(0.841.5)
(<0.10.15)
(<0.10.19)
(<0.10.21)
0.067 (0.0460.091) 0.6 (0.410.81)

0.01 (<0.010.014) <0.1 (<0.10.13)
0.092 (0.0660.120) 0.8 (0.581.1)
<0.01 (<0.01<0.01)
3.3 (0.2510)
1
2.1
2.1
0.65
1.1
1.5
1.7
0.71
0.88
1
0.97
0.81
0.77
0.98
0.077
0.13
0.16
0.29
0.23
0.19
0.17
14
26
25
7.1
11
15
16
7
7.7
8.3
7.3
5.7
5.3
6.7
1.4
2.3
2.7
4.8
3.7
3.1
2.8
(0.6201.5)
(1.62.6)
(1.62.7)
(0.4500.890)
(0.8801.3)
(1.21.8)
(1.32.0)
(0.4401.1)
(0.6301.2)
(0.7501.3)
(0.7201.3)
(0.6001.1)
(0.6200.940)
(0.7901.2)
(0.0520.110)
(0.0960.170)
(0.1100.210)
(0.2200.360)
(0.1800.270)
(0.1500.230)
(0.1400.210)
(8.621)
(2033)
(1932)
(4.99.6)
(9.014)
(1218)
(1320)
(4.310)
(5.510)
(6.111)
(5.39.5)
(4.27.4)
(4.36.5)
(5.48.0)
(0.972.0)
(1.72.9)
(1.93.5)
(3.75.9)
(3.04.4)
(2.53.7)
(2.23.3)
<0.01 (<0.01<0.01)
<0.01 (<0.01<0.01)
0.8 (<0.12.8)
1 (<0.13.2)
0.15
0.39
0.65
0.83
1.2
1.1
1.1
0.087
0.18
0.3
0.15
0.23
0.24
0.19
4.6
5.8
6.2
5.8
4.8
4.6
4.3
1.1
2.5
2.2
1.2
0.51
0.5
0.38
0.019
0.048
0.057
0.062
0.054
0.042
0.031
1.5
1.3
1
0.82
0.67
0.63
3.3
1.7
3.9
5.8
6.5
8.4
7.4
7.5
12
25
42
20
30
32
26
64
73
72
62
48
46
43
22
45
35
17
6.8
6.6
4.9
0.8
1.9
2.2
2.3
2
1.5
1.1
1.7
1.4
1
0.8
0.6
0.6
2.9
0.035
0.046
0.059
0.077
0.096
0.1
0.024
(0.0930.220)
(0.2800.510)
(0.4800.850)
(0.6201.1)
(0.9401.5)
(0.8501.3)
(0.8801.4)
(0.0530.130)
(0.1400.230)
(0.2400.380)
(0.1100.200)
(0.1800.280)
(0.1900.290)
(0.1500.240)
(2.86.7)
(4.67.1)
(4.97.7)
(4.57.2)
(3.75.9)
(3.85.5)
(3.65.2)
(0.6801.6)
(2.03.1)
(1.82.6)
(0.9001.5)
(0.4000.630)
(0.3900.620)
(0.3000.470)
(0.0130.025)
(0.0370.059)
(0.0450.071)
(0.0420.087)
(0.0360.075)
(0.0280.059)
(0.0170.048)
(0.9102.2)
(0.9101.7)
(0.7401.4)
(0.5801.1)
(0.4900.870)
(0.4600.830)
(2.83.8)
(0.0230.050)
(0.0290.066)
(0.0390.083)
(0.0530.110)
(0.0700.130)
(0.0740.130)
(0.0130.039)
0.9
1
1.2
1.4
1.7
1.8
0.4
(1.02.4)
(2.85.1)
(4.37.6)
(4.98.5)
(6.710)
(5.99.1)
(5.99.2)
(7.418)
(2032)
(3252)
(1526)
(2438)
(2539)
(2032)
(4095)
(5891)
(5689)
(4877)
(3860)
(3855)
(3551)
(1432)
(3656)
(2842)
(1321)
(5.38.5)
(5.28.1)
(3.96.0)
(0.561.1)
(1.52.4)
(1.72.8)
(1.63.2)
(1.32.8)
(1.02.2)
(0.621.8)
(1.12.6)
(0.981.9)
(0.741.4)
(0.551.0)
(0.440.78)
(0.410.73)
(2.43.3)
(0.561.2)
(0.631.4)
(0.781.6)
(0.982.0)
(1.22.2)
(1.32.3)
(0.220.66)
CASE DETECTION
RATEa
PERCENT
230
586
585
534
443
490
514
546
1 553
1 183
770
712
827
805
5
1
6
8
7.5
17
15
12
9.6
11
11
5.2
14
11
6.8
6.3
7.3
7.2
3.5
0.69
8.5
11
16
40
43
53
62
75
88
21
76
83
74
69
79
77
87
87
57
78
(1418)
(3545)
(3849)
(4761)
(5470)
(6786)
(78100)
(1434)
(6394)
(67100)
(6191)
(5884)
(6599)
(6397)
(7799)
(7799)
(4091)
(6695)
4
8
2
2 597
4 053
5 291
5 003
4 256
3 964
4 309
8 243
7 893
6 908
4 416
4 703
4 832
5 106
2 367
2 422
1 485
1 794
1 686
1 700
1 896
0
4
0
5.9
12
3
36
51
62
54
43
40
43
80
69
56
33
33
33
35
44
42
25
30
27
27
30
0
4
0
45
90
23
24
42
62
66
62
59
66
46
51
53
39
48
51
56
70
95
68
76
92
96
110
0
89
0
(3755)
(76110)
(1928)
(1740)
(3552)
(5175)
(5581)
(5276)
(5072)
(5680)
(3175)
(4262)
(4464)
(3348)
(4059)
(4362)
(4768)
(50100)
(84110)
(5783)
(6393)
(80110)
(84110)
(99130)
5
4
2
3 813
3 119
2 913
3 365
2 902
3 322
3 040
168
296
422
639
763
712
710
4.8
3.8
1.9
43
31
26
26
21
23
21
23
41
58
86
101
94
94
120
93
47
57
44
38
41
33
37
34
26
45
55
74
91
85
85
(97140)
(78110)
(3957)
(3992)
(3654)
(3247)
(3450)
(2840)
(3145)
(2841)
(1842)
(3856)
(4668)
(6291)
(76110)
(71100)
(72100)
6 212
10 420
14 311
79
121
153
14 222
14 315
3 647
4 984
6 406
3 333
2 924
2 876
3 233
123
109
127
90
139
130
105
14 437
11 329
18 434
18 524
18 846
19 570
19 857
1
142
141
75
89
103
48
39
38
42
5.2
4.4
4.9
3.4
5.1
4.7
3.8
17
12
18
17
17
17
17
9.3
0
1
0
18
0
0
0
0
2.8
2 944
2 842
2 402
1 907
2 283
2 448
2 693
71
61
47
35
40
42
46
NUMBER

YEAR
(77100)
32 (2739)
44 (3754)
56 (4769)
62
64
60
71
89
55
68
74
96
79
68
75
51
78
72
58
28
28
58
76
96
110
110
150
(5275)
(5377)
(4194)
(5987)
(77100)
(4567)
(5783)
(6290)
(80120)
(59110)
(5683)
(6392)
(4363)
(6595)
(6188)
(4971)
(1945)
(2334)
(4871)
(6493)
(84110)
(92120)
(98130)
(130170)
0
130 (120150)
0
0
54 (4862)
66
72
70
66
90
100
110
(47100)
(6088)
(5886)
(5580)
(78110)
(87120)
(99130)
177
YEAR
Panama
Paraguay
Peru
Puerto Rico
Saint Kitts and

Nevis
Saint Lucia
Saint Vincent and

the Grenadines
Sint Maarten
(Dutch part)
Suriname
Trinidad and
Tobago
Turks and Caicos

Islands
United States
of America
Uruguay
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
178
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
RATEa
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2
3
3
3
3
4
4
4
5
5
6
6
6
7
22
24
26
28
29
29
29
4
4
4
4
4
4
4
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1.1
1.3
1.4
1.5
1.6
1.7
1.7
2.8
2.5
2.6
2.9
3
3
3
69
58
48
39
32
31
30
0.22
0.29
0.19
0.12
0.088
0.078
0.068
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.021
0.027
0.018
0.018
0.014
0.012
<0.01
0.029
0.029
0.028
0.027
0.027
(0.7901.6)
(1.01.5)
(1.21.7)
(1.31.8)
(1.51.8)
(1.51.9)
(1.51.9)
(2.63.0)
(2.32.7)
(2.42.8)
(2.73.1)
(2.73.2)
(2.73.2)
(2.83.2)
(42100)
(4769)
(3957)
(3345)
(2837)
(2735)
(2633)
(0.1900.250)
(0.2600.330)
(0.1700.220)
(0.1100.140)
(0.0770.100)
(0.0680.088)
(0.0590.077)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0190.024)
(0.0230.030)
(0.0160.021)
(0.0160.020)
(0.0130.016)
(0.0110.014)
(<0.010.010)
(0.0180.043)
(0.0230.034)
(0.0230.033)
(0.0220.033)
(0.0220.032)
47
47
47
47
48
48
48
66
52
49
49
47
46
45
317
242
184
140
113
106
101
6.2
7.9
5
3.3
2.3
2.1
1.8
0.22
14
8.1
4.1
5.7
5.7
5.5
15
18
12
11
8.4
6.9
5.1
27
27
26
25
24
(3365)
(3957)
(3956)
(3957)
(4253)
(4254)
(4254)
(6172)
(4856)
(4553)
(4553)
(4351)
(4250)
(4249)
(196468)
(198290)
(151221)
(118164)
(98128)
(93120)
(88114)
(5.57.1)
(6.99.0)
(4.45.7)
(2.93.7)
(2.12.7)
(1.82.4)
(1.62.0)
(0.200.25)
(1216)
(7.19.2)
(3.64.6)
(5.06.4)
(5.06.4)
(4.86.2)
(1317)
(1621)
(1013)
(9.512)
(7.39.5)
(6.17.8)
(4.55.8)
(1740)
(2232)
(2131)
(2030)
(2029)
2010
2011
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1
1
1
1
1
1
1
<1
<1
<1
<1
<1
<1
<1
253
266
282
297
308
310
313
3
3
3
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
20
22
24
27
29
29
29
0.027
0.026
<0.01
<0.01
0.26
0.4
0.4
0.31
0.26
0.24
0.23
0.13
0.2
0.21
0.22
0.27
0.28
0.29
(0.0220.032)
(0.0220.032)
(<0.01<0.01)
(<0.01<0.01)
(0.1700.360)
(0.2600.570)
(0.2600.580)
(0.2000.450)
(0.1700.370)
(0.1600.340)
(0.1700.310)
(0.1100.140)
(0.1800.230)
(0.1900.240)
(0.1900.250)
(0.2400.310)
(0.2400.320)
(0.2500.330)
24
24
9.1
6
63
92
86
63
49
46
44
10
16
17
17
20
21
21
(2029)
(2029)
(8.010)
(5.26.8)
(4190)
(59131)
(56124)
(4190)
(3270)
(3165)
(3258)
(9.112)
(1418)
(1519)
(1519)
(1823)
(1824)
(1924)
<0.01
0.012
<0.01
<0.01
<0.01
0.011
31
26
19
16
14
13
12
0.86
0.84
0.81
0.76
0.73
0.72
0.72
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
7
7.7
8.3
9
9.5
9.7
9.8
(<0.01<0.01)
(0.0100.013)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.010)
(<0.010.012)
(2735)
(2329)
(1722)
(1418)
(1215)
(1115)
(1114)
(0.5301.3)
(0.6901.0)
(0.6600.970)
(0.6300.910)
(0.6300.830)
(0.6200.830)
(0.6200.830)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(4.99.3)
(6.39.2)
(6.810)
(7.411)
(7.811)
(8.012)
(8.112)
50
62
19
20
23
27
12
9.7
6.7
5.4
4.4
4.2
3.9
28
26
24
23
22
21
21
4.5
7.7
7.7
7.7
7.7
7.7
7.7
35
35
34
34
33
33
33
(4456)
(5470)
(1621)
(1823)
(2026)
(2430)
(1114)
(8.511)
(5.97.6)
(4.76.1)
(3.95.0)
(3.74.7)
(3.44.4)
(1741)
(2131)
(2029)
(1927)
(1925)
(1825)
(1824)
(3.95.1)
(6.78.7)
(6.88.7)
(6.88.7)
(6.88.7)
(6.88.7)
(6.88.7)
(2547)
(2842)
(2841)
(2841)
(2740)
(2740)
(2740)
NUMBER
(THOUSANDS)
RATEa
0.14
0.31
0.36
0.2
0.26
0.26
0.27
0.028
0.037
0.05
0.071
0.1
0.11
0.34
0.67
1.4
1.3
0.88
0.65
0.62
0.59
(0.0990.200)
(0.2400.390)
(0.2800.450)
(0.1500.240)
(0.2100.300)
(0.2200.300)
(0.2300.320)
(0.0250.030)
(0.0260.050)
(0.0360.066)
(0.0520.093)
(0.0760.130)
(0.0840.140)
(0.2900.400)
(0.4100.990)
(1.01.8)
(0.9701.7)
(0.6601.1)
(0.5000.820)
(0.4600.800)
(0.4500.750)
6
12
12
6
7.4
7.3
7.6
0.7
0.8
0.9
1.2
1.6
1.7
5.2
3.1
5.8
5
3.2
2.3
2.1
2
(4.18.2)
(9.015)
(9.615)
(4.77.5)
(6.28.7)
(6.28.6)
(6.48.9)
(0.600.71)
(0.551.1)
(0.671.2)
(0.891.6)
(1.22.0)
(1.32.2)
(4.46.1)
(1.94.6)
(4.37.6)
(3.76.4)
(2.44.1)
(1.72.9)
(1.62.8)
(1.52.6)
0.037
0.013
0.014
0.014
(0.0260.051)
(<0.010.023)
(<0.010.023)
(<0.010.023)
1
0.4
0.4
0.4
(0.681.3)
(0.160.61)
(0.210.60)
(0.170.62)
<0.01 (<0.010.010)
3 (1.15.9)
<0.01 (<0.01<0.01)
0.7 (<0.12.7)
<0.01 (<0.010.015)
0.019 (0.0110.030)
3.6 (<0.113)
17 (9.927)
<0.01 (<0.010.017)
<0.01 (<0.010.016)
7.3 (2.016)
7.6 (2.914)
0.085
0.27
0.28
0.16
0.079
0.082
0.075
<0.01
0.028
0.049
0.074
0.084
0.064
0.095
21
63
60
31
15
16
14
0.4
2.2
3.8
5.7
6.3
4.8
7.1
(0.0550.120)
(0.1700.400)
(0.1800.400)
(0.0980.230)
(0.0460.120)
(0.0510.120)
(0.0480.110)
(<0.01<0.01)
(0.0220.035)
(0.0400.060)
(0.0550.097)
(0.0670.100)
(0.0480.082)
(0.0760.120)
(1330)
(4091)
(3887)
(2045)
(8.923)
(9.723)
(9.120)
(0.320.42)
(1.82.7)
(3.14.6)
(4.27.4)
(5.07.7)
(3.66.1)
(5.68.7)
CASE DETECTION
NUMBER
RATEa
846
1 300
1 169
1 637
1 539
1 496
1 553
2 167
1 745
1 950
2 075
2 346
2 277
2 372
37 905
45 310
38 661
33 421
31 844
31 073
31 241
159
262
174
113
63
80
50
0
5
0
0
4
2
1
13
11
9
14
10
9
7
2
13
16
7
9
35
49
40
51
44
43
43
51
36
36
35
37
35
36
175
190
149
121
111
107
106
4.5
7.1
4.6
3
1.7
2.1
1.3
0
12
0
0
7.7
3.8
1.9
9.4
7.5
5.7
8.5
5.8
5.2
4
1.9
12
15
6.4
8.2
74
100
83
110
94
89
91
77
70
74
72
79
77
79
55
79
81
86
98
100
110
72
89
91
92
71
100
74
0
82
0
0
140
67
34
61
41
49
78
69
75
78
6.8
45
57
26
34
(54110)
(85130)
(70100)
(89130)
(83110)
(79100)
(81100)
(7184)
(6575)
(6981)
(6677)
(7386)
(7183)
(7386)
(3789)
(6596)
(6899)
(74100)
(87110)
(89110)
(93120)
(6482)
(79100)
(80100)
(81100)
(6382)
(90120)
(6584)
15
17
3
2
82
14
16
7.9
5.2
20
56
64
87
87
32
(4768)
(5478)
(7799)
(7799)
(2250)
89
117
177
194
124
120
166
198
166
272
219
224
0
19
23
34
37
23
9.9
13
15
13
20
16
17
0
22
37
69
80
53
96
81
92
76
100
78
78
(1534)
(2658)
(48110)
(57120)
(4173)
(84110)
(7293)
(82110)
(6786)
(89110)
(6989)
(6989)
PERCENT
(7293)
(120160)
(6077)
(3039)
(5470)
(3647)
(4356)
(6989)
(6179)
(6685)
(6989)
(4.611)
(3855)
(4870)
(2131)
(2841)
<0.01 (<0.01<0.01)
4.6 (0.2215)
2.3
1.9
1.5
2
1.3
1.1
0.96
0.022
0.074
0.12
0.098
0.11
0.12
0.11
(2.12.7)
(1.52.4)
(1.21.9)
(1.72.3)
(1.21.6)
(0.9401.3)
(0.8201.1)
(0.0140.033)
(0.0530.097)
(0.0930.160)
(0.0720.130)
(0.0890.140)
(0.0910.140)
(0.0840.130)
0.9
0.7
0.5
0.7
0.4
0.4
0.3
0.7
2.3
3.7
3
3.4
3.5
3.2
(0.811.0)
(0.560.90)
(0.420.66)
(0.590.77)
(0.380.50)
(0.300.41)
(0.260.35)
(0.441.1)
(1.63.0)
(2.84.8)
(2.23.8)
(2.64.1)
(2.74.3)
(2.53.9)
6
9
25 701
22 728
16 310
14 080
11 545
11 181
10 521
886
625
645
622
704
699
817
4
4
16
23
10
8.5
5.8
4.7
3.8
3.6
3.4
28
19
19
19
21
21
24
3.9
3.7
68
86
83
88
86
88
85
86
86
100
75
80
82
96
97
110
87
49
(6078)
(7698)
(7495)
(78100)
(7698)
(77100)
(7597)
(7699)
(7699)
(70170)
(6291)
(6697)
(6999)
(85110)
(84110)
(99130)
(7699)
(4356)
0.24
0.42
0.59
0.76
0.96
0.89
1.3
(0.1700.330)
(0.3000.550)
(0.4300.780)
(0.5600.980)
(0.7701.2)
(0.7201.1)
(1.01.5)
1.2
1.9
2.4
2.8
3.4
3.1
4.3
(0.871.7)
(1.42.5)
(1.83.2)
(2.13.7)
(2.74.1)
(2.53.7)
(3.55.2)
5 457
5 578
6 466
6 847
6 474
6 335
6 282
28
25
27
26
23
22
21
79
73
77
76
68
66
64
(58110)
(6189)
(6595)
(6393)
(5783)
(5580)
(5478)
YEAR
Anguilla
Antigua and
Barbuda
Argentina
38
24
Aruba
Bahamas
18
12
Barbados
Belize
30
23
Bermuda
Bolivia
(Plurinational
State of)
168
84
Bonaire, Saint
Eustatius and Saba
Brazil
50
38
British Virgin
Islands
Canada
Cayman Islands
Chile
47
14
Colombia
37
a
25
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
0
2
1
0
1
0
4
6
3
6
6
12 309
13 450
11 767
9 770
7 701
7 287
9 610
6
8
46
57
82
48
45
31
41
5
3
3
2
6
0
57
95
106
102
88
145
74
0
4
0
1
1
11 166
14 422
10 127
9 748
8 847
8 345
8 521
0
1
74 570
91 013
77 899
80 209
75 040
74 395
74 892
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
0
0
0
1
0
0
0
3
6
1
6
6
1
0
1
0
0
5 698
4 749
4 709
4 044
3 973
5 007
0
0
0
0
0
0
0
0
0
4 668
4 110
3 357
2 165
2 011
2 629
3 067
1 773
1 561
937
854
1 613
4
7
2
0
38
56
30
26
19
23
11
23
8
10
3
12
8
4
7
5
7
5
3
3
2
6
0
0
0
0
0
0
0
36
44
59
82
97
64
34
55
29
0
47
0
1
1
3
2
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
1
0
2
0
0
2
0
2
0
217
159
0
104
143
338
290
361
1 724
666
489
426
689
1 828
809
827
716
1 050
1
0
1
0
1
0
2
4
1
1
0
2
1
1
1
1
0
4
5
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
6
11
6
1
10
0
4
6
0
2
4
6
15
12
1
12
1
0
0
1
0
0
7 010
6 458
6 278
5 937
5 613
5 746
0
0
1 408
1 565
1 250
699
630
643
0
0
1 133
1 288
1 673
1 742
1 694
1 721
0
0
45 650
41 186
42 093
39 267
37 932
40 294
29 291
23 622
23 990
22 144
23 030
20 961
1
0
1
0
1
0
1 968
1 921
1 667
1 484
1 505
1 322
1 391
2
2
5
1
0
549
436
492
433
462
358
407
2
4
2
6 151
4 150
3 021
2 505
2 398
2 376
2 450
12 447
9 912
11 630
10 360
11 324
11 420
11 523
0
0
0
0
0
0
1
0
806
49
352
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
63
451
547
469
408
411
1 630
225
263
257
226
63
2 081
772
732
665
637
0
0
13 814
10 457
11 037
10 275
10 017
10 067
14
18
15
2 634
3 089
3 340
3 398
3 555
8 700
6 548
6 478
7 551
6 490
11 334
9 637
9 818
10 949
10 045
466
3 641
0
2 755
0
0
516
656
528
446
519
472
456
0
0
723
634
482
562
466
444
469
0
0
0
0
20
4
0
0
0
0
0
180
195
145
39
58
48
59
0
0
64
36
24
22
0
0
180
195
145
103
94
72
81
0
0
29
44
56
68
58
39
39
0
5
2
0
1
0
0
0
0
0
1
2
1
1
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1 561
1 290
1 186
1 152
1 154
1 196
1 284
879
502
509
502
473
1 017
694
631
549
553
594
0
0
0
225
158
186
188
167
187
128
118
96
85
225
158
314
306
263
272
0
0
0
7 530
8 358
6 870
7 319
7 028
6 512
1 380
1 446
1 429
1 611
1 696
2 355
1 002
1 487
1 618
2 117
1 985
2 275
0
311
0
339
443
277
400
381
339
469
461
339
443
616
869
842
0
0
0
0
0
18
18
NEW AND RELAPSE

NOTIFICATION RATE
19902011
75
100
50
100
100
55
54
58
65
66
66
67
100
78
71
79
72
86
66
100
100
100
100
51
44
67
100
67
100
50
100
0
83
80
83
89
90
90
61
64
64
64
62
66
100
100
52
40
48
49
47
43
47
0
100
50
50
50
55
59
70
69
70
72
85
85
83
82
81
73
179
NEW AND RELAPSE

a
NOTIFICATION RATE
19902011
YEAR
Costa Rica
11
Cuba
Curaao
Dominica
Dominican
Republic
36
43
Ecuador
80
35
El Salvador
44
30
Grenada
Guatemala
43
21
Guyana
23
94
Haiti
141
Honduras
75
42
Jamaica
Mexico
17
17
Montserrat
Netherlands
Antilles
180
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
NEW AND
RELAPSE
230
586
585
534
443
490
514
546
1 553
1 183
770
712
827
805
5
1
6
8
4
8
2
2 597
4 053
5 291
5 003
4 256
3 964
4 309
8 243
7 893
6 908
4 416
4 703
4 832
5 106
2 367
2 422
1 485
1 794
1 686
1 700
1 896
0
4
0
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
245
349
330
271
267
285
71
184
81
66
89
128
31
98
104
89
108
85
834
675
467
418
462
437
5
0
520
257
160
150
212
219
0
1
199
201
103
91
98
86
0
0
1
0
7
10
6
0
0
0
35
19
17
25
16
26
14
7
10
0
35
45
31
32
26
2
0
54
50
40
46
45
57
122
9
5
11
16
54
172
49
51
56
73
2
0
0
0
4
8
2
0
0
0
0
0
0
2 787
2 907
2 949
2 441
2 159
2 454
1 418
1 234
1 032
822
803
809
244
540
602
615
578
655
5 890
5 064
3 048
3 317
3 373
3 521
2 237
1 338
635
369
404
380
1 008
1 059
930
972
1 079
0
0
0
0
0
0
1
0
1
1
0
1
0
0
0
112
100
49
204
610
420
266
324
342
309
186
196
163
204
610
729
452
520
505
0
0
0
420
400
330
584
655
808
0
0
106
403
433
400
397
280
392
323
263
244
386
795
756
663
641
0
0
2 241
278
402
363
338
371
181
108
255
329
328
384
1
0
0
91
78
63
62
62
180
36
50
30
21
271
114
113
92
83
0
0
0
0
2
0
4
4
1
1
0
1
0
0
0
2 368
2 052
2 420
1 609
2 121
1 961
546
518
588
170
265
309
205
202
256
207
348
243
85
119
240
328
325
323
187
231
352
301
274
282
22
34
33
78
75
78
5 887
7 340
2 930
5 292
1 367
1 484
8 242
8 011
4 335
4 553
1 307
1 374
2 306
3 404
2 069
1 881
1 842
2 060
2 214
2 396
721
520
482
616
93
90
53
77
76
35
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
828
436
415
249
141
101
88
152
112
58
40
29
48
249
141
159
128
181
160
438
0
0
0
6
0
0
0
2
38
8
56
38
27
46
17
149
124
206
2
84
25
205
162
233
0
0
0
0
236
195
110
33
346
228
0
0
338
377
43
46
381
423
232
370
362
331
382
377
0
0
0
100
236
181
192
170
180
33
25
10
100
236
181
225
195
190
14
20
31
48
46
39
2
4
6
5
6
6
0
0
0
24
2
13
0
9
2
1
5
11
17
3
2
13
5
20
19
4
0
0
0
0
9 220
11 676
11 997
11 862
12 572
12 960
1 807
1 675
421
958
2 812
2 497
302
2 081
2 657
3 193
3 464
3 529
2 831
2 114
0
0
421
618
719
722
871
914
1 408
816
544
671
1 335
2 026
1 535
1 266
1 542
111
585
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
4
2
3 813
3 119
2 913
3 365
2 902
3 322
3 040
168
296
422
639
763
712
710
6 212
10 420
14 311
14 222
14 315
3 647
4 984
6 406
3 333
2 924
2 876
3 233
123
109
127
90
139
130
105
14 437
11 329
18 434
18 524
18 846
19 570
19 857
1
0
0
0
0
78
65
80
80
75
69
62
72
74
74
69
67
100
0
100
100
100
100
66
70
74
75
73
75
72
79
83
90
89
90
78
72
72
74
74
100
80
100
50
81
80
80
90
89
86
31
34
41
52
54
53
67
58
66
64
51
59
74
78
79
77
87
82
63
62
62
47
84
87
97
93
82
84
100
40
YEAR
Nicaragua
71
46
Panama
35
43
Paraguay
51
36
Peru
175
106
Puerto Rico
Saint Kitts and

Nevis
Saint Lucia
Saint Vincent and

the Grenadines
16
Sint Maarten
(Dutch part)
Suriname
20
23
Trinidad and
Tobago
10
17
23
Turks and Caicos

Islands
United States
of America
10
Uruguay
28
24
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
28
a
21
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
2 944
2 842
2 402
1 907
2 283
2 448
2 693
846
1 300
1 169
1 637
1 539
1 496
1 553
2 167
1 745
1 950
2 075
2 346
2 277
2 372
37 905
45 310
38 661
33 421
31 844
31 073
31 241
159
262
174
113
63
80
50
0
5
0
0
4
2
1
13
11
9
14
10
9
7
2
13
16
7
9
15
17
3
2
82
89
117
177
194
124
120
166
198
166
272
219
224
0
6
9
25 701
22 728
16 310
14 080
11 545
11 181
10 521
886
625
645
622
704
699
817
4
4
5 457
5 578
6 466
6 847
6 474
6 335
6 282
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
1 568
1 471
1 253
1 329
1 440
1 552
854
541
395
541
575
653
253
231
160
261
274
335
169
130
127
129
167
159
268
282
286
282
0
0
0
0
1 066
460
860
755
707
830
993
748
900
1 260
1 498
1 318
1 371
114
589
505
452
425
433
28
74
216
287
287
235
93
191
190
134
124
108
134
247
235
211
179
0
18
870
791
665
428
499
515
127
170
150
283
269
251
96
105
127
516
273
81
109
177
28
530
273
177
214
304
41
86
108
0
75
0
32 096
22 580
18 490
17 391
17 264
17 754
7 803
6 018
5 592
5 203
5 201
5 164
5 411
5 682
5 335
5 380
5 185
5 564
809
871
647
712
4 381
3 195
2 999
2 776
2 047
1 794
1 325
1 404
1 603
4 381
4 989
4 324
4 180
3 650
128
81
60
30
37
29
111
69
37
25
35
13
23
24
16
8
4
8
0
0
0
0
0
0
4
0
0
0
0
0
0
0
4
0
0
0
0
0
4
0
0
4
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
2
0
0
0
0
0
0
11
7
11
7
9
7
1
1
0
0
0
0
0
1
0
0
0
0
0
0
1
2
2
0
0
2
0
1
0
0
3
2
3
0
0
0
0
0
5
9
6
3
8
8
3
2
7
4
1
6
7
9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
3
0
0
0
0
0
0
0
0
2
2
0
0
4
3
0
2
2
0
0
0
37
49
149
130
64
40
54
14
42
34
12
6
9
14
20
2
0
2
1
0
6
5
6
5
1
2
10
10
6
1
8
15
16
11
0
1
0
1
7
115
95
154
136
121
68
61
50
91
58
77
12
17
12
19
20
19
0
0
0
0
22
5
9
8
5
7
26
13
52
39
42
22
31
22
60
44
49
0
0
0
3
8
1
1
1
0
0
0
1
0
1
1
2
1
0
0
8 093
5 883
5 111
4 014
3 695
3 742
10 795
7 204
6 030
4 990
4 990
4 556
3 835
3 211
2 939
2 383
2 134
2 189
5
12
0
158
362
34
349
348
355
409
368
467
178
165
147
192
218
249
78
77
73
66
72
48
32
0
0
0
20
39
15
37
41
53
0
0
20
39
19
37
41
53
0
0
3 056
3 525
3 653
3 436
3 252
3 224
1 517
1 616
1 853
1 665
1 758
1 649
709
948
1 094
1 112
1 077
1 196
0
0
0
272
377
247
261
248
213
103
167
194
195
272
377
350
428
442
408
0
116
0
0
0
0
5
0
0
0
167
159
99
152
159
153
108
41
56
45
77
55
28
14
326
0
0
0
0
0
0
65
73
76
71
71
70
90
44
63
63
62
66
100
46
53
65
78
73
73
80
79
77
77
77
77
54
54
62
55
51
69
100
NEW AND RELAPSE

NOTIFICATION RATE
19902011
100
100
100
100
88
92
100
100
100
42
69
86
33
53
47
100
100
48
48
91
76
65
9
65
66
63
70
61
75
89
43
45
46
45
43
45
66
68
71
68
63
65
50
67
69
66
67
65
66
181
% OF COHORT
a

19952010
Anguilla
Antigua and
Barbuda
33
12
48
Argentina
Aruba
Bahamas
68
Barbados
100
Belize
52
62
88
Bermuda
Bolivia
(Plurinational
State of)
Bonaire, Saint
Eustatius and Saba
Brazil
17
74
British Virgin
Islands
Canada
76
Cayman Islands
50
Chile
79
71
Colombia
79
Costa Rica
87
90
89
Cuba
182
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
0
0
3
6
1
1
6
5 698
4 749
4 709
4 758
4 044
3 973
4
6
1
3
6
5 707
5 177
4 709
2 577
5 062
5 088
6
4
38
56
30
31
26
19
3
3
1
2
6
36
44
59
83
82
97
2
0
1
7 010
6 458
6 278
6 048
5 937
5 613
0
45 650
41 186
42 093
37 697
39 267
37 932
1
0
1
436
492
433
488
462
358
0
5
1
1
2
1 561
1 290
1 186
1 114
1 152
1 154
7 530
8 358
6 870
7 196
7 319
7 028
245
349
330
287
271
267
834
675
467
498
418
462
30
31
26
19
11
3
2
6
29
45
59
82
142
1
1
7 010
6 212
6 278
6 048
5 897
5 571
0
0
45 650
34 007
42 093
40 714
40 818
41 840
1
1
0
492
459
919
850
854
5
1
2
2
1 111
1 360
1 147
1 259
1 365
1 437
1 634
7 778
7 288
6 899
7 364
349
306
280
166
297
834
673
466
496
415
458
COHORT AS
% NOTIFIED
133
100
100
300
100
100
109
100
54
125
128
100
100
100
100
300
100
100
81
102
100
99
146
100
100
96
100
100
99
99
100
83
100
108
104
110
100
100
106
188
184
239
100
200
100
71
105
97
113
118
125
20
113
101
94
105
100
93
98
61
111
100
100
100
100
99
99
COMPLETED
100
50
100
67
0
5
26
19
24
19
20
0
33
0
33
33
1
5
5
4
4
4
0
0
33
7
20
34
19
26
27
0
0
0
0
0
0
0
0
0
0
0
33
3
6
5
5
7
8
0
17
0
0
0
84
43
37
47
43
40
17
32
12
16
40
42
69
53
17
6
8
16
7
3
0
5
20
10
12
11
0
6
0
0
45
100
100
100
52
78
56
83
45
0
0
0
0
0
19
0
9
0
0
0
10
9
12
17
0
0
0
3
0
2
0
0
0
0
28
2
12
0
0
0
0
0
7
11
0
0
0
0
53
73
76
82
84
86
0
0
9
6
2
2
1
2
0
0
4
4
3
4
4
4
0
0
1
1
1
1
1
1
0
0
9
9
5
5
5
5
100
100
24
7
12
7
4
3
17
49
31
33
31
37
0
22
44
38
41
37
1
4
5
5
5
5
1
0
1
1
1
0
3
9
9
9
10
11
79
16
9
14
11
10
DIED
FAILED
DEFAULTED
NOT
EVALUATED
CURED
100
100
22
8
12
10
12
13
59
65
65
65
5
9
9
7
8
0
0
0
0
1
1
1
0
0
59
22
13
17
15
0
0
40
0
0
0
0
0
0
100
60
0
50
50
79
82
83
72
61
51
0
0
11
20
0
0
7
9
9
9
9
9
0
0
0
0
0
0
0
0
0
0
8
6
6
7
7
6
50
50
5
2
2
12
12
14
70
63
67
68
69
10
9
9
9
10
5
6
6
6
7
1
1
2
2
1
8
7
8
9
9
6
14
8
6
4
43
85
86
49
75
90
91
90
88
87
89
14
4
3
4
12
0
2
2
0
3
1
10
5
5
5
7
4
4
6
8
7
7
1
2
1
1
2
3
1
1
1
2
1
12
3
2
1
2
2
1
1
2
1
2
19
1
2
39
2
2
1
1
0
0
0
Curaao
Dominica
100
64
80
Dominican
Republic
Ecuador
39
79
El Salvador
91
Grenada
75
61
83
44
71
Guatemala
Guyana
Haiti
70
82
64
85
67
47
75
87
Honduras
Jamaica
Mexico
Montserrat
Netherlands
Antilles
0
Nicaragua
80
85
69
80
51
78
83
68
Panama
Paraguay
Peru
Puerto Rico
68
a
78
YEAR
NUMBER
NOTIFIED
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
SIZE OF
COHORT
5
5
5
3
4
8
2 787
2 907
2 949
2 458
2 441
2 159
5 890
5 064
3 048
3 380
3 317
3 373
3
4
3
2 007
2 760
2 697
2 458
2 441
2 194
5 236
1 008
1 059
985
930
972
2
0
1 008
1 059
985
930
972
5
4
4
2 368
2 052
2 420
2 070
1 609
2 121
85
119
240
320
328
325
5 887
7 340
8 171
8 242
2 306
3 404
2 069
1 897
1 881
1 842
93
90
53
78
77
76
9 220
11 676
11 997
11 903
11 862
12 572
2 150
3 380
3 330
3 373
6
6
4
4
2 368
1 908
2 070
2 121
2 121
296
119
257
340
328
325
3 081
5 887
7 340
8 435
8 242
2 226
2 362
1 905
1 888
1 881
1 918
93
99
53
78
76
76
9 220
11 538
12 172
11 840
11 821
12 304
0
1
0
0
1 568
1 471
1 253
1 394
1 329
1 440
1 066
460
860
829
755
707
748
900
1 260
1 345
1 498
1 318
32 096
22 580
18 490
17 989
17 391
17 264
128
81
60
52
30
37
1 536
1 437
1 496
1 481
1 552
1 704
1 388
460
873
883
768
717
748
900
1 452
1 350
1 467
1 317
28 185
22 230
14 793
14 805
14 212
17 264
128
81
60
43
37
37
COHORT AS
% NOTIFIED
100
100
38
72
95
91
100
100
102
89
71
100
100
100
100
100
100
100
100
120
100
100
100
93
100
132
100
348
100
107
106
100
100
100
100
100
97
69
92
100
100
104
100
110
100
100
99
100
100
99
101
99
100
98
250
98
98
119
106
117
118
130
100
102
107
102
101
100
100
115
100
98
100
88
98
80
82
82
100
100
100
100
83
123
100
DEFAULTED
NOT
EVALUATED
0
0
0
2
2
2
1
2
1
8
0
0
0
13
19
7
8
7
7
14
0
0
0
16
4
3
12
2
6
37
3
4
4
3
3
4
3
3
6
8
8
7
5
7
11
8
1
0
1
1
1
7
4
5
5
4
1
1
1
4
2
5
2
3
2
2
8
1
0
0
0
0
5
11
33
67
50
25
3
5
0
1
1
0
4
7
0
0
0
0
31
1
5
6
6
11
12
7
5
8
6
4
5
6
1
1
1
1
5
57
72
4
6
6
34
13
57
55
57
41
70
14
8
2
1
1
1
1
1
9
9
9
38
24
26
16
19
18
21
13
7
2
1
1
6
3
9
8
2
4
3
10
6
67
72
39
81
81
80
79
79
2
5
4
13
55
13
69
64
71
81
82
82
12
10
25
5
7
6
6
6
65
40
53
51
14
34
6
12
6
4
4
4
5
5
7
6
5
5
6
6
10
23
13
10
14
9
4
6
5
6
6
6
1
1
0
1
0
1
1
1
1
0
0
0
0
0
3
1
1
1
1
1
8
7
4
5
4
6
6
6
17
11
26
10
11
5
12
9
6
5
5
5
7
5
25
3
3
3
2
2
5
20
4
15
5
38
6
8
11
3
2
1
CURED
COMPLETED
100
100
67
43
37
80
71
79
73
0
0
33
21
34
5
4
6
7
39
0
0
0
5
5
4
3
4
5
2
81
74
71
75
3
4
4
4
78
91
91
88
91
67
33
50
75
56
75
79
77
77
10
43
2
14
13
30
DIED
FAILED
20
66
70
73
73
69
66
10
27
68
67
65
64
8
21
46
68
75
69
75
90
91
78
70
57
75
0
81
78
14
13
12
16
16
18
60
33
12
13
16
16
43
45
33
12
5
9
9
0
4
11
12
68
64
0
63
0
0
4
5
5
3
4
5
14
7
8
7
7
7
3
5
5
5
7
8
3
2
2
3
3
2
23
31
22
33
16
14
% OF COHORT
a

19952010
80
2
1
2
1
1
2
1
2
0
0
1
1
0
0
0
0
0
2
2
2
1
1
5
0
0
0
3
10
9
6
7
7
6
13
22
10
13
12
12
17
22
8
6
5
5
6
3
4
6
6
5
8
5
3
5
0
5
4
2
3
0
3
3
3
10
1
0
0
0
29
7
7
8
7
8
6
4
1
8
9
20
2
0
0
0
3
0
183
% OF COHORT
a

19952010
Saint Kitts and

Nevis
60
100
Saint Lucia
89
Saint Vincent and

the Grenadines
Sint Maarten
(Dutch part)
Suriname
14
60
Trinidad and
Tobago
69
76
Turks and Caicos

Islands
75
United States
of America
76
64
Uruguay
68
85
50
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
74
184
83
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
4
0
0
5
4
2
11
7
11
18
7
9
5
9
6
11
3
8
3
37
49
68
149
130
7
115
95
169
154
136
SIZE OF
COHORT
5
5
2
8
13
18
7
9
13
4
1
8
3
51
37
71
143
73
78
194
106
169
154
136
2
3
3
8 093
5 883
5 111
4 742
4 014
3 695
349
348
355
424
409
368
2
4
8 116
5 901
5 136
3 709
7 460
7 034
370
344
345
422
406
368
2
3 056
3 525
3 653
3 344
3 436
3 252
3 056
3 390
3 581
3 301
3 433
3 157
COHORT AS
% NOTIFIED
125
100
125
100
114
118
100
100
100
144
36
33
100
100
100
104
96
56
1 114
169
112
100
100
100
133
100
100
100
78
186
190
106
99
97
100
99
100
100
100
96
98
99
100
97
COMPLETED
DIED
20
40
20
20
80
100
80
0
0
0
0
0
0
0
0
0
0
0
20
20
0
12
54
67
57
67
0
31
6
29
0
0
0
0
0
0
0
0
0
14
0
0
0
0
0
11
88
15
28
22
FAILED
DEFAULTED
NOT
EVALUATED
CURED
100
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
100
100
100
4
19
0
12
16
10
49
0
8
14
0
67
3
38
64
60
49
22
68
65
61
72
21
3
0
21
46
4
2
8
4
13
11
12
19
11
12
15
14
9
0
1
0
1
2
4
1
3
24
16
4
10
6
16
14
14
11
4
5
23
0
13
0
0
1
1
0
33
0
33
0
0
0
0
100
0
0
33
76
83
84
85
60
64
27
0
4
7
7
5
15
11
8
9
6
6
10
13
11
9
12
10
0
6
0
4
4
5
4
4
5
75
41
85
80
77
73
80
50
68
76
83
83
84
83
0
0
0
1
1
0
1
0
0
0
2
1
1
4
1
4
5
6
5
0
25
6
3
6
5
32
29
17
0
1
2
2
0
50
1
0
0
0
0
0
8
13
10
11
11
11
13
6
2
1
1
0
4
3
2
% OF COHORT
Anguilla
Antigua and
Barbuda
Argentina
32
Aruba
Bahamas
100
Barbados
Belize
23
Bermuda
Bolivia
(Plurinational
State of)
66
78
Bonaire, Saint
Eustatius and Saba
Brazil
46
British Virgin
Islands
Canada
71
Cayman Islands
Chile
26
Colombia
17
Costa Rica
80
82
82
Cuba
YEAR
NUMBER
NOTIFIED
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
SIZE OF
COHORT
0
0
0
0
0
2
0
0
1
0
1 828
809
1 392
827
716
1 615
374
893
1 114
1
0
4
4
5
2
4
3
5
2
0
0
0
0
4
6
15
5
12
1
0
0
0
13
14
0
1
0
63
2 081
772
590
732
665
11 334
9 637
11 164
9 818
10 949
0
0
462
804
772
590
598
589
0
0
7 859
9 479
9 494
10 664
10 721
0
195
145
103
122
94
72
0
0
0
0
145
106
126
95
94
0
0
0
0
225
158
314
219
306
263
339
443
413
616
869
0
35
45
24
31
32
54
172
49
60
51
56
0
0
150
140
231
219
336
920
69
49
32
2
35
55
58
48
56
61
55
COHORT AS
% NOTIFIED
50
200
27
108
156
100
75
100
100
325
93
0
100
733
39
100
100
82
89
69
98
85
109
98
100
103
103
101
131
95
45
105
72
128
106
197
109
133
6
109
102
34
98
93
120
98
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
100
7
10
10
9
26
16
20
23
5
6
4
4
0
1
1
1
9
9
13
15
53
59
52
49
25
0
20
0
50
33
60
100
0
33
20
0
0
0
0
0
25
0
0
0
0
33
0
0
23
23
38
57
29
14
57
49
63
72
73
72
9
11
3
4
5
5
7
12
5
8
7
5
5
2
3
2
2
3
15
8
7
7
7
10
7
16
19
7
7
5
30
26
18
15
18
10
22
32
28
28
4
7
8
8
8
0
2
2
2
2
14
19
25
23
25
41
25
15
24
19
16
8
7
4
15
16
59
71
60
56
6
7
10
7
9
1
0
0
0
0
2
3
0
1
0
60
23
11
27
20
32
69
22
15
14
26
3
8
14
8
7
6
1
1
1
2
2
18
9
10
7
9
15
3
59
60
58
9
12
11
73
23
55
56
0
37
82
78
67
64
69
67
9
12
28
0
43
0
7
10
4
3
50
11
7
10
6
18
15
4
3
2
25
24
6
0
9
5
2
2
2
7
11
30
2
6
50
0
0
0
21
0
0
0
16
5
15
0
0
5
3
4
0
5
4

19952010
185
% OF COHORT
a

19952010
Curaao
Dominica
100
Dominican
Republic
64
Ecuador
El Salvador
90
Grenada
Guatemala
73
64
Guyana
52
Haiti
75
Honduras
75
Jamaica
67
32
Mexico
63
Montserrat
Netherlands
Antilles
0
Nicaragua
78
76
Panama
56
Paraguay
60
Peru
Puerto Rico
0
a
186
50
YEAR
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
4
1
0
204
610
729
497
452
520
0
0
1
498
530
497
434
384
386
795
778
756
663
554
778
756
271
114
86
113
92
181
114
86
113
92
0
1
0
0
249
141
159
202
128
181
2
84
25
117
205
162
346
228
373
381
100
236
181
184
225
195
2
13
5
3
20
19
1 335
2 026
1 370
1 535
1 266
0
0
0
254
164
202
181
181
38
23
146
205
162
55
228
381
381
180
169
145
192
164
6
5
3
19
19
138
1 456
1 829
1 229
1 272
0
0
0
0
167
159
268
167
282
286
108
134
247
191
235
211
28
530
273
154
177
214
289
230
181
150
178
204
4 381
4 989
4 534
4 324
4 180
4 521
2 299
0
0
0
4
42
237
238
203
208
144
164
164
188
216
2 163
113
0
0
4
COHORT AS
% NOTIFIED
0
0
82
73
100
96
74
70
100
100
67
100
100
100
100
102
116
100
141
100
45
92
125
100
100
16
100
100
76
93
79
85
84
300
100
100
95
100
10
72
134
80
100
173
145
68
90
63
71
31
96
125
86
99
27
60
106
106
101
103
46
50
100
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
100
29
56
0
47
51
26
5
0
6
13
3
7
0
13
9
4
8
0
5
5
27
19
0
29
18
11
6
100
0
4
56
61
46
8
8
9
5
7
6
10
8
8
12
15
16
9
0
16
63
68
84
85
88
3
0
0
3
2
9
6
8
3
2
3
4
0
1
3
18
13
5
8
1
3
8
3
1
3
59
63
15
16
4
4
2
4
4
10
17
2
55
55
55
10
8
8
8
5
5
6
7
7
16
20
20
5
4
4
24
22
4
0
0
29
35
22
51
52
13
9
10
14
14
5
9
2
0
1
26
13
24
18
28
3
13
38
17
5
42
63
15
7
5
3
7
0
22
13
9
14
49
60
20
14
7
5
3
2
10
10
11
8
44
59
65
50
66
0
10
9
6
7
9
67
8
6
10
10
7
17
2
2
3
1
2
0
6
17
14
10
15
17
29
7
3
22
1
0
0
16
5
20
67
58
26
0
5
26
0
0
0
80
33
21
21
0
0
0
21
33
48
55
56
55
4
7
7
5
7
8
7
11
9
9
7
4
4
6
6
12
14
11
10
11
36
20
11
14
10
69
65
71
97
70
60
10
10
12
0
6
16
4
6
7
0
3
8
3
2
2
0
6
4
11
15
7
3
11
9
3
2
2
0
3
2
19
23
16
18
23
24
35
30
30
34
2
9
9
10
11
0
4
2
0
3
48
22
42
37
30
7
7
1
4
0
19
44
46
47
54
40
26
14
9
6
6
4
9
9
8
1
1
4
2
25
10
10
11
9
9
16
21
20
20
78
78
4
5
7
5
6
11
4
1
49
21
12
12
73
23
25
25
50
% OF COHORT
Saint Kitts and

Nevis
Saint Lucia
Saint Vincent and

the Grenadines
Sint Maarten
(Dutch part)
Suriname
55
Trinidad and
Tobago
64
Turks and Caicos

Islands
United States
of America
Uruguay
76
76
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
83
YEAR
NUMBER
NOTIFIED
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
0
2
0
0
0
3
2
1
3
0
4
3
0
4
2
2
SIZE OF
COHORT
2
0
0
0
1
1
3
0
3
4
1
0
0
1
8
7
15
16
22
31
22
47
60
44
3
12
11
22
21
47
60
44
20
39
19
56
37
41
25
272
377
350
432
428
442
30
57
41
41
247
227
261
248
COHORT AS
% NOTIFIED
100
33
100
100
100
100
50
0
43
80
69
71
95
100
100
100
125
158
102
111
100
71
53
61
56
CURED
COMPLETED
DIED
FAILED
DEFAULTED
50
NOT
EVALUATED

19952010
50
100
0
33
0
67
100
0
0
0
0
0
100
0
0
0
0
0
0
0
0
100
100
0
0
0
50
45
33
0
9
0
8
27
0
0
0
33
42
0
33
0
18
23
19
32
48
43
45
38
4
20
20
14
29
11
15
14
9
6
0
0
9
14
47
17
23
0
0
0
0
0
33
33
33
56
20
16
57
60
46
56
17
12
10
20
13
14
34
15
3
0
0
0
7
14
7
5
3
0
2
5
80
84
80
83
0
0
0
4
5
4
6
2
1
2
1
12
10
13
10
2
0
2
0
187
KNOWN HIV STATUS
YEAR
20052011
Anguilla
Antigua and
Barbuda
100
100
Argentina
10
100
Aruba
Bahamas
Barbados
Belize
100
84
Bermuda
100
Bolivia
(Plurinational
State of)
0
47
Bonaire, Saint
Eustatius and Saba
Brazil
59
58
British Virgin
Islands
Canada
26
36
Cayman Islands
100
10
53
55
67
95
93
95
Chile
Colombia
Costa Rica
Cuba
Curaao
Dominica
67
Dominican
Republic
1
57
100
Ecuador
El Salvador
84
98
Grenada
100
Guatemala
16
69
70
93
73
Guyana
Haiti
188
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
100
100
86
100
0
0
0
6
4
6
8
13
14
10
1 093
1 121
1 053
100
103
100
100
100
100
95
98
84
100
100
0
17
22
47
59
52
63
58
46
33
42
8
2
6
0
106
89
142
64
1
0
1
1
0
1 509
1 897
4 118
0
100
75
100
51 552
44 038
51 764
49 091
0
1
0
0
414
645
658
529
1
2
3
2
10
53
43
43
55
67
104
99
95
93
99
103
95
0
259
5 537
5 031
5 079
6 579
374
476
494
498
729
710
862
780
0
80
38
67
1
57
60
57
0
47
102
100
84
95
96
98
4
3
2
78
2 516
2 489
2 540
10
2 385
5 183
5 350
1 544
1 650
1 667
1 878
0
5
4
2
600
1 920
2 121
2 125
456
717
734
852
0
9 886
9 518
10 461
0
26
40
48
36
100
100
100
16
65
63
69
70
79
88
93
0
67
73
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
1
0
6
4
7
8
11 242
8 190
7 762
10 651
6
8
50
46
32
42
2
6
0
106
94
145
76
1
1
9 973
9 128
8 620
8 747
0
1
87 223
85 159
81 946
84 137
0
1
0
1 616
1 599
1 385
1 452
2
4
2
2 633
2 516
2 472
2 535
10 360
11 663
11 889
11 984
560
457
499
524
781
717
838
821
5
1
5
8
3
5 312
4 442
4 160
4 472
4 808
5 026
5 095
5 350
1 830
1 736
1 730
1 917
5
4
2
3 861
2 942
3 351
3 088
656
912
836
916
14 344
14 265
14 361
NUMBER OF
HIV-POSITIVE
TB PATIENTS
% OF TESTED
TB PATIENTS
HIV-POSITIVE
0
0
0
3
0
5
5
50
0
83
62
530
672
559
48
60
53
15
16
12
2
0
2
0
25
17
29
24
0
0
0
0
0
38
130
138
0
8 249
8 828
9 338
9 575
0
1
0
0
63
64
53
77
0
0
0
0
120
353
1 133
1 231
1 292
50
41
54
47
0
46
56
69
0
0
1
1
0
3
403
547
648
3
443
427
576
188
204
180
194
0
1
1
0
478
260
255
260
80
195
209
199
1 797
2 236
1 892
2 025
PEOPLE
CPT
ART
PROVIDED IPT
100
100
40
40
100
100
33
48
29
25
0
33
40
31
42
0
67
75
67
100
24
19
20
38
0
68
100
100
68
100
100
100
3
7
3
21
0
76
87
87
16
20
18
20
85
88
92
92
100
100
100
0
0
0
5
409
0
0
50
674
27
15
10
8
15
0
0
0
0
46
6
23
24
20
13
9
11
9
0
6
6
9
21
35
36
84
0
0
0
0
0
0
30
80
62
80
1 561
1 366
1 429
25
33
0
4
16
22
26
30
19
8
11
12
12
11
10
0
100
100
100
0
0
8
41
0
0
0
4
66
953
822
5 041
20
28
82
85
38
35
63
77
97
455
20
25
0
80
14
12
12
18
27
28
23
100
0
100
0
0
0
100
100
100
243
100
100
100
82
77
94
55
59
83
162
144
119
23
20
19
5
13
12
8
10
17
4 112
100
100
250
Honduras
44
70
83
81
52
Jamaica
Mexico
Montserrat
100
Netherlands
Antilles
Nicaragua
55
Panama
86
91
60
Paraguay
Peru
21
82
90
Puerto Rico
Saint Kitts and

Nevis
100
100
Saint Lucia
Saint Vincent and

the Grenadines
100
94
Sint Maarten
(Dutch part)
Suriname
73
90
Trinidad and
Tobago
69
94
10
59
81
Turks and Caicos

Islands
United States
of America
Uruguay
92
91
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
39
62
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
44
55
54
70
83
64
87
81
7
30
43
52
100
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
1 455
1 619
1 557
2 256
79
96
128
88
1 382
5 879
8 915
10 599
1
0
0
0
2
3 333
2 957
2 901
3 243
95
150
147
108
19 932
19 773
20 699
20 528
1
0
45
56
55
86
79
96
91
0
1 081
1 440
1 552
1 569
1 364
1 558
1 534
11
33
60
2
35
29
21
82
97
95
90
271
817
1 520
668
11 710
9 539
7 052
93
61
76
45
100
100
100
7
100
100
100
100
64
59
94
100
100
73
76
85
90
69
94
98
94
71
10
59
62
66
81
92
94
92
91
4
2
1
1
11
9
7
7
7
10
16
3
2
87
143
173
118
124
306
254
250
5
3
5
1
8 273
7 197
7 404
8 527
574
662
646
741
2 076
2 413
2 575
2 822
1 828
1 729
1 630
1 695
2 348
2 427
2 461
2 549
35 541
33 169
32 477
32 844
113
63
80
50
2
4
2
1
14
11
9
7
7
11
17
17
3
2
119
188
204
131
179
324
258
266
39
73
78
62
2 678
4 856
5 213
4 033
NUMBER OF
HIV-POSITIVE
TB PATIENTS
% OF TESTED
TB PATIENTS
HIV-POSITIVE
200
192
201
255
28
29
30
15
217
945
1 645
1 985
0
0
0
0
2
100
30
32
60
16
200
213
240
245
3
4
1
13
16
15
16
140
144
174
668
678
853
960
28
9
14
9
52
18
11
100
6
9
14
30
15
18
20
7
10
14 080
11 545
11 181
10 521
626
704
699
817
0
0
0
0
4
0
1
1
5
3
5
0
0
20
44
58
38
42
95
58
83
1
1
1
0
1 035
711
627
671
74
102
104
110
0
0
0
0
36
0
14
14
71
30
31
0
0
23
31
34
32
34
31
23
33
20
33
20
0
13
10
8
8
13
15
16
15
6 950
6 641
6 645
6 477
392
487
479
519
15
10
9
13
0
0
PEOPLE
CPT
ART
PROVIDED IPT
14
12
13
11
35
30
23
17
16
16
18
19
0
0
100
90
31
43
0
89
90
71
54
100
100
93
0
96
27
100
100
64
23
26
28
676
0
94
67
94
67
42
63
65
10
28
84
48
60
465
152
400
196
0
0
25
51
67
56
18
1
2
33
43
1 214
1 361
1 183
56
50
25
0
0
100
0
20
100
60
10
50
38
53
36
6
34
36
0
11
10
18
29
14
19
20
0
0
100
100
0
0
0
0
19
34
31
0
0
39
21
33
32
YEAR
KNOWN HIV STATUS
20052011
0
4
11
102
102
189
YEAR
TOTAL
CONFIRMED
CASES OF
a
MDR-TB
2005
2009
2010
2011
Antigua and
2005
Barbuda
2009
2010
2011
Argentina
2005
2009
2010
2011
Aruba
2005
2009
2010
2011
Bahamas
2005
2009
2010
2011
Barbados
2005
2009
2010
2011
Belize
2005
2009
2010
2011
Bermuda
2005
2009
2010
2011
Bolivia
2005
(Plurinational
2009
State of)
2010
2011
Bonaire, Saint
2010
Brazil
2005
2009
2010
2011
British Virgin
2005
Islands
2009
2010
2011
Canada
2005
2009
2010
2011
Cayman Islands
2005
2009
2010
2011
Chile
2005
2009
2010
2011
Colombia
2005
2009
2010
2011
Costa Rica
2005
2009
2010
2011
Cuba
2005
2009
2010
2011
Curaao
2010
2011
Dominica
2005
2009
2010
2011
Dominican
2005
Republic
2009
2010
2011
Ecuador
2005
2009
2010
2011
El Salvador
2005
2009
2010
2011
Grenada
2005
2009
2010
2011
Guatemala
2005
2009
2010
2011
Guyana
2005
2009
2010
2011
Haiti
2005
2009
2010
2011
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
% OF
BACT+VEb
TESTED FOR
MDR-TB
BACT+VE
TESTED FOR
MDR-TB
0
0
0
46
71
110
95
97
0
0
0
1.2
100
100
0
1.7
<0.1
<0.1
150
150
130
50
100
3.2
3.7
4.4
4.8
4.7
17
37
0.49
64
9.6
32
38
36
60
100
100
12
50
0
1.4
0.42
3.2
10
6.3
1.1
7.0
0
22
0.83
8.0
0
0
0.62
0.72
<0.1
Anguilla
0
0
0
0
0
276
89
109
103
0
0
0
1
0
0
0
0
1
0
0
0
0
63
60
106
83
0
1
373
449
573
566
0
0
22
18
15
19
0
0
6
23
10
9
110
131
108
3
3
0
1
3
7
10
0
0
0
0
0
108
117
253
156
176
354
14
2
2
4
0
0
40
230
18
27
0 (00)
0 (00)
0.35 (0.190.50)
0.13 (<0.10.20)
330 (220440)
170 (94270)
0.15 (<0.10.24)
1.1 (03.3)
0 (00)
1.1 (<0.15.8)
38
21
31
1.3 (0.452.2)
0 (00.98)
0 (00.98)
170 (100230)
77 (28170)
1 100 (8101 400)
0 (00)
0
0
0
2369
2.7 (1.53.9)
1.0 (<0.11.0)
0
0
0.15 (<0.10.24)
0 (00)
0
0
0
0
1
1
1
0
98
0
0 (00)
560 (340870)
0 (00)
13 (6.520)
13 (7.422)
0 (02.0)
0 (02.0)
20 (9.631)
12 (4.225)
190 (130260)
130 (75210)
7.5 (0.9714)
6.3 (1.716)
13 (4.522)
6.3 (1.318)
0 (00.98)
0 (00.98)
0 (00)
0 (02.0)
320 (220420)
220 (140330)
350 (280420)
190 (140260)
8.4 (0.6716)
4.7 (0.5817)
<0.1 (<0.1<0.1)
<0.1 (<0.1<0.1)
22
21
0
0
1130
1321
987
1
1
49
56
65
71
455
1240
2620
2
203
32
169
172
174
313
5
1
1
1
0
32
12
117
363
239
12
65
0
238
20
134
120 (86160)
80 (49120)
0
5
3
38 (2156)
13 (4.221)
41
86
310 (140490)
260 (88430)
NUMBER OF
0
0
0
2
53
2
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
0 (00)
0.22 (<0.10.35)
160 (100240)
0 (02.0)
0 (00)
1.3 (0.522.1)
0 (00)
89 (72110)
1.0 (<0.11.0)
540 (400730)
0 (00)
0 (05.7)
0 (00)
8.8 (4.117)
61 (4481)
1.2 (<0.16.2)
6.7 (2.813)
0 (00)
0 (00.98)
99 (65140)
160 (120200)
3.6 (0.7510)
0 (00)
42 (3255)
26 (1041)
47 (1875)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
1
50
0
0
0
1290
160
4
80
2
100
1
50
3
20
0
0
670
92
664
100
597
94
0
1
100
5917
61
643
5.9
604
6.0
51
71
226
72
221
72
276
100
277
100
487
79
495
57
568
67
1
2.2
16
62
19
39
19
37
31
55
76
100
1
100
0
0
106
20
77
15
502
63
584
88
284
44
14
12
85
75
2
2.2
69
83
40
25
182
140
18
9.9
27
17
0
0
55
24
39
10
b
190
MDR-TB
Honduras
Jamaica
Mexico
Montserrat
Netherlands
Antilles
Nicaragua
Panama
Paraguay
Peru
Puerto Rico
Saint Kitts and

Nevis
Saint Lucia
Saint Vincent and

the Grenadines
Sint Maarten
(Dutch part)
Suriname
Trinidad and
Tobago
Turks and Caicos

Islands
United States
of America
Uruguay
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
a
b
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
3
4
9
5
0
0
1
1
394
11
140
140
1
0
0
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
70 (35110)
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
47 (2092)
2.5 (1.13.9)
2.1 (0.693.3)
470 (340600)
370 (320430)
0 (00)
0 (00)
% OF
BACT+VEb
TESTED FOR
MDR-TB
3
27
57
30
11
67
40
28
314
1
21
6
0
BACT+VE
TESTED FOR
MDR-TB
0.13
1.4
3.1
1.5
19
87
31
64
2.1
<0.1
0.16
<0.1
0
0.64
3.5
13
3.3
8.2
2.3
4.2
8.2
15
4.4
6.5
90
100
110
0
0
0
0
29
86
22
12
0
44
0.67
0.70
0
0
0
110
110
110
99
36
75
4.3
0.57
0.78
17
0
0
50
18
13
5
8
10
7
13
6
1
6
2748
1578
1048
1663
0
0
0
3
50
200
29
0
0
0
0
0
6
0
0
0
0
1
1
0
0
3
0
0
44 (2067)
14 (1.749)
46 (2567)
27 (8.843)
58
25
6.3 (0.1635)
64
115
227
51 (1883)
966
2 100 (1 8002 400)
1 200 (1 0001 500)
1199
2.9 (0.607.8)
2.9 (0.607.8)
54
69
44
<0.1 (<0.1<0.1)
<0.1 (<0.1<0.1)
0
0
0.15 (<0.10.24)
0.15 (<0.10.24)
0.36 (0.120.58)
0.36 (0.120.58)
<0.1 (<0.1<0.1)
<0.1 (<0.1<0.1)
3.3 (1.74.8)
2.1 (0.693.4)
9.6 (7.712)
3.6 (2.05.0)
0
0
2
6
2
1
0
49
1
1
0
0
0
1
0.29 (0.210.36)
124
114
107
119
1
1
110 (92140)
1.7 (05.0)
1.7 (<0.19.4)
28
21
21
25
0.16 (<0.10.23)
110 (92140)
80 (44120)
10064
8196
7593
6899
160
422
25 (6.965)
NUMBER OF
163
20
26
565
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
23 (1142)
0.44 (0.170.71)
97 (79120)
0 (00)
30 (1847)
20 (7.732)
44 (1884)
860 (7101 000)
0 (00)
0 (00)
0 (00)
0 (00)
0 (00)
1.2 (0.471.9)
6.1 (4.97.3)
0.12 (0.100.15)
0 (04.9)
55 (3188)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
0
0
43
19
62
32
65
34
2
40
5
26
1
25
74
3.7
11
0.72
505
40
180
12
0
8
3.0
150
52
67
24
48
19
17
8.1
40
22
46
26
52
24
93
31
2336
47
803
19
598
16
4
100
0
0
0
0
0
0
0
0
0
0
3
14
0
0
505
336
345
304
22
54
38
72
15
4.3
160
37
160
36
195
48
YEAR
TOTAL
CONFIRMED
CASES OF
191
MALE
YEAR
1995
2000
2005
2010
2011
Antigua and
1995
Barbuda
2000
2005
2010
2011
1995
Argentina
2000
2005
2010
2011
Aruba
1995
2000
2005
2010
2011
Bahamas
1995
2000
2005
2010
2011
Barbados
1995
2000
2005
2010
2011
Belize
1995
2000
2005
2010
2011
Bermuda
1995
2000
2005
2010
2011
Bolivia
1995
(Plurinational
2000
State of)
2005
2010
2011
Bonaire, Saint
2010
Brazil
1995
2000
2005
2010
2011
1995
British Virgin
Islands
2000
2005
2010
2011
Canada
1995
2000
2005
2010
2011
Cayman Islands
1995
2000
2005
2010
2011
Chile
1995
2000
2005
2010
2011
Colombia
1995
2000
2005
2010
2011
Costa Rica
1995
2000
2005
2010
2011
Cuba
1995
2000
2005
2010
2011
Curaao
2010
2011
Dominica
1995
2000
2005
2010
2011
Dominican
1995
Republic
2000
2005
2010
2011
Ecuador
1995
2000
2005
2010
2011
El Salvador
1995
2000
2005
2010
2011
Grenada
1995
2000
2005
2010
2011
014
1524
2534
3544
FEMALE
4554
5564
65+
UNKNOWN
014
1524
2534
3544
4554
5564
65+
UNKNOWN
Anguilla
192
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
1
0
1
2
3
0
0
0
1
0
1
1
2
1
0
0
0
1
2
0
1
1
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
97
64
56
143
278
621
536
664
594
530
491
657
402
358
309
434
419
384
302
397
368
340
340
358
330
348
282
289
2
9
121
90
59
142
544
530
421
587
479
474
426
470
262
290
233
279
230
198
184
192
179
169
153
169
216
240
176
213
1
4
3
1
3
2
5
7
7
9
4
4
4
2
3
1
2
2
0
2
1
5
1
7
7
2
8
0
2
0
3
1
1
1
0
0
2
2
3
3
5
6
0
2
2
2
0
1
0
0
5
1
1
3
1
3
0
0
0
0
0
0
0
0
1
2
0
2
0
0
0
1
5
8
9
8
0
0
2
7
8
16
14
1
0
4
2
6
22
9
2
0
0
6
8
24
16
0
0
1
3
5
11
2
0
0
1
5
3
18
0
0
0
0
0
0
0
0
4
0
1
0
6
2
4
5
2
0
0
2
1
4
7
0
0
0
0
2
4
7
8
2
0
1
4
3
9
4
0
0
1
1
2
4
1
0
0
2
4
4
5
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
166
157
95
100
0
0
1 182
1 320
1 150
1 231
0
0
797
725
622
685
0
0
518
439
415
372
0
0
466
391
395
371
0
0
340
346
338
302
0
0
366
415
409
457
0
0
191
160
119
146
0
0
831
846
744
778
0
0
588
533
471
459
0
0
334
276
238
235
0
0
254
226
191
183
0
0
192
182
162
155
0
0
233
262
264
272
0
0
1 894
317
298
336
7 268
5 074
4 405
4 877
11 568
6 119
6 381
6 755
11 906
6 128
5 293
5 462
8 623
5 259
4 762
5 054
5 085
2 803
2 875
3 083
4 494
2 140
1 947
2 142
43
41
1 859
355
280
356
6 719
3 496
2 677
2 815
7 215
3 663
3 008
3 131
5 395
2 626
2 211
2 230
3 582
1 897
1 720
1 779
2 384
1 112
1 038
1 164
2 496
1 104
979
1 069
15
0
0
0
1
5
3
3
2
0
0
28
34
37
30
34
0
0
31
45
45
28
36
0
0
60
46
44
36
31
0
0
34
41
40
32
40
1
0
41
32
20
25
33
0
0
70
79
68
62
70
0
0
7
4
6
1
3
0
0
33
33
28
28
23
0
0
28
40
40
24
29
0
0
22
30
27
16
28
0
0
12
25
24
10
14
0
0
18
12
13
19
9
0
0
51
66
37
44
55
0
0
24
6
3
2
4
0
0
148
81
74
90
88
0
0
182
160
128
115
139
1
0
204
198
179
144
143
0
0
155
150
162
159
164
0
1
141
132
115
122
127
0
0
163
126
133
157
134
0
0
24
10
4
6
6
0
0
100
66
55
56
62
0
0
120
96
78
76
75
0
0
108
70
60
59
66
1
0
75
54
56
56
69
0
0
73
58
36
40
48
0
0
107
83
93
72
71
246
178
148
105
1
14
1
2
0
2
0
2
3
2
0
0
763
623
602
663
17
31
43
18
23
59
71
20
17
14
0
0
1 030
685
765
714
38
53
38
48
24
118
167
73
61
51
0
0
963
666
540
558
24
62
53
33
29
83
90
90
89
83
2
0
743
687
710
702
19
39
34
27
33
75
74
50
78
86
1
0
610
510
610
594
23
28
20
22
22
75
55
58
53
50
0
0
746
695
814
753
22
49
34
28
36
156
75
51
57
48
0
0
194
179
146
98
2
13
1
0
2
1
2
2
1
1
0
0
587
581
560
461
17
21
21
18
18
17
9
14
15
6
1
0
758
533
576
535
15
33
31
20
27
52
22
17
15
18
1
0
523
457
428
324
11
24
18
12
23
29
26
26
14
18
0
0
381
389
374
337
7
20
16
14
19
39
22
13
16
17
0
0
304
292
284
278
9
23
6
15
12
48
23
22
17
17
0
0
510
395
471
390
14
24
14
8
17
80
39
29
26
26
0
0
1
0
1
0
0
0
0
0
0
2
0
0
3
0
1
0
0
0
0
0
0
0
0
0
1
0
2
0
1
0
0
0
0
0
73
43
29
20
410
399
276
333
481
483
346
406
344
386
292
318
173
228
170
200
125
123
112
133
113
105
85
112
0
0
65
57
43
30
317
339
239
242
325
332
207
274
212
209
142
159
115
119
102
103
79
72
54
66
75
54
62
58
0
0
48
32
45
446
499
481
468
529
547
308
314
364
237
309
323
150
227
272
159
246
232
48
52
49
329
298
340
305
308
311
199
178
177
139
158
141
85
113
118
127
110
121
13
5
5
3
99
97
101
114
124
140
170
183
114
128
96
106
92
104
77
96
62
74
62
77
107
117
101
115
0
0
28
6
6
6
81
85
63
61
76
82
65
61
63
59
49
44
63
50
58
52
39
42
51
69
47
70
68
92
0
0
1
0
1
1
1
0
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
MALE:FEMALE
RATIO
0.33
0.50
5.0
7.0
1.2
1.3
1.4
1.4
2.5
2.4
1.0
1.7
2.3
2.0
1.0
0.83
2.1
1.8
2.5
3.3
1.5
1.5
1.6
1.6
1.7
2.0
2.2
2.2
1.5
1.3
1.5
1.5
1.5
1.0
1.7
2.0
2.1
2.2
2.0
1.6
1.4
1.5
1.7
1.9
1.7
2.1
2.0
1.4
2.1
3.7
2.8
3.4
3.2
1.5
1.0
1.4
1.5
1.5
1.6
1.5
1.8
1.8
1.5
1.7
1.7
1.8
3.0
Guatemala
Guyana
Haiti
Honduras
Jamaica
Mexico
Montserrat
Netherlands
Antilles
Nicaragua
Panama
Paraguay
Peru
Puerto Rico
Saint Kitts and

Nevis
Saint Lucia
Saint Vincent and

the Grenadines
Sint Maarten
(Dutch part)
Suriname
Trinidad and
Tobago
Turks and Caicos

Islands
United States
of America
Uruguay
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
FEMALE
014
1524
2534
3544
4554
5564
65+
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
51
36
39
60
18
7
4
12
2
8
235
220
251
187
197
8
20
48
32
26
280
236
258
245
205
5
19
130
38
54
236
216
185
207
172
6
14
116
65
61
165
177
187
172
162
9
7
81
49
54
142
112
127
143
136
6
6
41
22
19
139
140
115
165
152
7
9
20
13
13
67
69
98
102
42
30
13
15
17
2
0
0
1
0
836
1 045
1 225
1 155
280
123
238
177
194
9
6
4
7
2
898
1 035
1 357
1 342
540
371
280
246
291
14
13
6
15
6
613
701
718
670
204
246
215
207
227
9
13
6
15
3
350
451
469
442
130
277
152
165
184
11
15
10
8
4
147
222
259
206
236
214
134
113
120
8
6
6
6
4
118
156
160
132
58
43
152
157
184
9
5
7
7
3
214
100
125
128
1 079
1 095
1 081
1 124
1 387
1 376
1 375
1 440
1 162
1 314
1 380
1 503
1 235
1 238
1 392
1 532
972
1 042
1 119
1 112
0
0
0
0
0
0
0
0
1
0
0
0
0
UNKNOWN
UNKNOWN
014
1524
2534
3544
4554
5564
65+
51
41
38
29
25
3
1
14
2
2
224
199
339
194
186
5
11
41
22
17
255
167
245
190
192
7
8
62
25
19
221
175
277
179
154
6
7
41
19
17
146
135
176
139
154
5
5
30
20
17
129
87
88
108
102
2
5
11
10
7
94
111
95
103
106
4
3
9
6
9
0
0
96
116
158
148
54
25
27
28
19
2
1
0
0
1
914
1 097
1 268
1 282
208
21
219
186
181
7
8
1
5
3
857
1 099
1 223
1 250
292
269
222
163
194
6
8
5
4
4
513
633
608
595
134
258
125
106
138
5
7
4
5
0
275
414
358
363
76
270
107
103
99
5
2
0
1
3
132
170
207
196
136
160
81
69
98
2
5
1
0
1
71
132
134
128
48
38
104
107
126
2
1
3
2
1
1 126
1 288
1 303
1 299
0
0
176
125
112
136
663
771
791
776
828
733
763
765
698
710
730
698
832
784
852
889
595
637
713
734
709
784
836
824
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
18
17
22
10
86
3
5
6
10
18
16
23
18
9
147
552
371
178
194
163
157
273
155
44
76
69
96
64
112
168
163
182
1 311
5 290
3 802
172
174
159
189
235
193
78
129
127
104
71
103
185
244
238
849
2 875
2 670
175
147
116
141
156
112
61
129
80
91
96
105
136
129
135
454
1 546
1 513
126
108
106
115
108
126
37
84
62
99
74
86
117
143
151
322
1 041
1 075
96
64
61
82
61
42
27
57
61
63
57
80
87
103
124
200
801
641
92
90
79
108
94
83
26
49
49
47
61
71
99
99
103
216
796
708
24
34
23
27
4
72
6
11
7
11
13
12
31
18
14
149
633
375
176
188
135
154
61
120
43
73
51
55
65
69
89
106
110
1 005
3 686
2 674
215
173
122
149
145
111
34
81
52
64
49
86
98
99
103
660
2 472
2 111
98
98
103
92
161
75
35
62
46
58
46
41
69
39
55
373
1 156
1 046
83
76
61
75
108
57
19
33
45
44
35
41
52
50
39
259
609
699
64
46
54
50
64
16
12
30
23
40
34
30
29
46
36
162
499
333
46
61
47
79
72
40
16
41
29
48
53
46
71
45
62
152
624
472
4
0
0
0
0
3
1
4
0
1
12
4
4
3
4
20
19
7
2
3
15
9
9
4
6
9
10
7
5
6
19
14
7
8
2
0
0
1
1
0
0
0
2
4
3
1
1
6
5
2
0
1
5
3
5
2
1
7
7
4
6
0
4
1
1
2
3
9
3
7
4
1
0
0
0
0
0
0
0
0
0
0
1
0
0
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
0
2
1
0
2
0
0
1
1
1
3
2
2
2
2
0
0
0
1
0
0
1
1
0
0
0
0
0
0
1
1
1
0
0
1
0
0
1
0
1
0
0
2
1
0
0
0
0
0
0
0
1
0
0
0
0
0
1
2
1
4
2
0
2
2
1
3
2
0
0
0
0
1
2
2
0
0
0
1
0
0
0
0
0
0
0
0
1
1
1
0
0
0
0
0
1
0
1
2
0
0
1
0
0
0
0
0
0
0
1
0
0
0
2
0
0
0
1
6
7
5
4
6
7
10
11
14
6
8
21
7
15
18
11
21
27
3
12
35
15
10
27
13
17
13
2
6
19
18
12
17
21
32
15
0
3
5
3
7
7
10
20
16
4
4
10
5
4
7
3
8
7
2
0
1
0
0
0
0
0
1
3
3
4
1
6
5
4
4
6
6
2
6
1
4
7
9
7
7
3
1
10
5
2
9
3
7
3
0
2
6
2
5
5
5
5
4
1
1
2
2
3
2
4
2
2
1
2
8
1
0
4
3
2
5
0
0
19
6
14
5
12
4
0
1
1
0
0
0
2
355
365
383
246
235
28
36
42
46
58
0
0
3
876
602
535
360
403
40
48
48
70
93
0
1
2
1 417
906
666
371
374
35
45
39
35
55
1
0
0
1 121
904
767
505
557
49
41
45
46
45
1
0
1
742
577
499
403
434
38
30
34
33
36
0
0
0
1 099
738
624
466
486
50
34
36
31
37
0
0
0
0
0
26
14
11
9
15
2
2
1
3
1
0
0
280
246
241
195
160
21
28
33
24
29
0
0
579
376
348
265
254
26
22
30
36
55
1
0
499
349
276
183
199
18
21
17
12
19
1
0
285
253
242
165
150
12
13
9
10
12
0
0
202
152
161
130
138
9
12
8
5
11
0
0
591
396
322
223
269
17
16
12
16
16
35
22
28
312
320
340
395
376
353
413
333
303
402
391
363
265
253
307
332
288
241
37
26
25
351
269
252
299
306
316
267
188
178
183
145
178
146
147
150
216
188
190
0
0
0
0
11
6
0
0
0
0
5
4
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
1
0
0
MALE:FEMALE
RATIO
1.1
1.2
0.92
1.3
1.1
1.5
2.0
2.2
2.1
2.7
1.1
1.0
1.1
1.0
1.6
1.3
1.3
1.4
1.4
2.1
1.8
2.8
3.5
1.7
1.6
1.6
1.6
1.7
1.5
1.2
1.2
1.3
1.3
1.5
1.6
1.7
1.6
1.8
1.6
1.5
1.8
1.9
2.2
2.2
1.3
1.3
1.4
2.4
2.4
1.7
1.5
3.1
1.0
1.3
0.83
2.0
8.0
2.5
3.0
3.0
0.50
1.0
1.4
3.6
2.6
4.3
2.8
2.6
2.4
4.0
3.3
0.50
2.3
2.3
2.2
2.0
2.1
2.3
2.1
2.2
2.5
2.3
1.4
1.6
1.5
MALE
YEAR
193
LABORATORIES
FREE THROUGH NTP
SECONDNUMBER OF
CULTURE
DST b LABS
LPAc LABS
LINE DST
LABS USING
PER 100K
PER 5M
PER 5M
POPULATION
LEDa
Anguilla
Antigua and Barbuda
Argentina
Aruba
1.7
Bahamas
Barbados
Belize
0.6
Bermuda
Bolivia
(Plurinational State of)
Bonaire, Saint Eustatius
and Saba
Brazil
50
No
12.6
2.1
5.3
24.3
0.5
0.5
2.0
British Virgin Islands
Canada
Cayman Islands
7.8
1.1
Chile
Colombia
0.9
7.8
4
0
11.6
133.8
0.3
0.5
0.3
0.3
0
1
Costa Rica
2.3
21.2
1.1
Cuba
Curaao
Dominica
Dominican Republic
Ecuador
El Salvador
2.3
2.2
3.3
Grenada
1
0
0
5.5
5.8
17.7
0.5
0.3
0.8
0
0
0
0
5
0
Guatemala
1.8
4.1
Guyana
2.6
100
6.6
6.6
6.6
Haiti
2.2
1.0
Honduras
2.1
3.2
0.6
Jamaica
0.1
1.8
Mexico
0.6
2.8
0.7
<0.1
Montserrat
Nicaragua
3.3
2.6
0.9
Panama
Paraguay
Peru
1.5
1.8
5.2
0
0
0
8.4
6.9
11.2
1.4
0.8
1.2
1.4
0
0.2
0
0
0
Puerto Rico
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and

the Grenadines
Sint Maarten (Dutch part)
Suriname
Trinidad and Tobago
0.6
Turks and Caicos Islands
United States of America
Uruguay
US Virgin Islands
Venezuela
(Bolivarian Republic of)
<0.1
100
9.4
In country
No
Out of
country
Out of
country
Out of
country
Out of
country
Out of
country
Out of
country
1.5
1.5
1.5
3.7
0.2
Out of
country
In and out
of country
Out of
country
In country
In country
Out of
country
In country
Out of
country
In country
In country
No
Out of
country
Out of
country
In and out
of country
Out of
country
Out of
country
In and out
of country
Out of
country
Out of
country
No
In country
In country
Out of
country
No
In and out
of country
Out of
country
No
No
No
Out of
country
In country
Out of
country
TB NOTIF.
RIFAMPICIN
RATE PER
USED
100 000
THROUGHOUT
HEALTH-CARE
TREATMENT
WORKERS
NRLd
TB DIAGNOSIS
FIRSTLINE
DRUGS
No
yes
yes
yes
No
Yes (all suspects)
Yes (all suspects)
Yes (all suspects)
No
yes
yes
yes
yes
Yes (other criteria)
yes
Yes
yes
Yes (all suspects)
yes
Yes
No
Yes
Yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
No
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
No
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
No
Yes
yes
Yes (all suspects)
yes
No
yes
Yes (all suspects)
yes
Yes
yes
yes
Yes (all suspects)

Yes (all suspects)
yes
yes
Yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
Yes (all suspects)

Yes (all suspects)
yes
No
Yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
yes
yes
yes
Yes
Yes
Yes
No
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
122
143
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
95
yes
Yes (all suspects)
yes
Yes
21
yes
Yes (all suspects)
yes
Yes
37
No
Yes (if TB is
confirmed)
No
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
yes
yes
yes
Yes
Yes
Yes
yes
Yes (all suspects)
yes
Yes
No
Yes (all suspects)

Yes (if TB is
confirmed)
yes
Yes
yes
Yes
yes
Yes (all suspects)
yes
Yes
No
yes
yes
No
yes
yes
Yes
Yes
Yes
yes
Yes
yes
No
Yes (all suspects)
Yes (all suspects)
Yes (if TB is
confirmed)
Yes (all suspects)
yes
Yes
No
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
10
33
1.9
In country

d
b
c
194

197
199
201
203
205
207
208
209
210

details.
Data source
196
Afghanistan
Bahrain
Djibouti
Egypt
Iran (Islamic
Republic of)
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
Morocco
Oman
Pakistan
Qatar
Saudi Arabia
Somalia
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
13
20
23
28
31
31
32
<1
<1
<1
<1
1
1
1
<1
<1
<1
<1
<1
<1
<1
57
62
68
74
80
81
83
55
60
65
70
73
74
75
17
20
24
27
31
32
33
3
4
5
5
6
6
6
2
2
2
2
3
3
3
3
3
4
4
4
4
4
4
5
5
6
6
6
6
25
27
29
30
32
32
32
2
2
2
2
3
3
3
112
127
145
159
170
174
177
<1
<1
<1
<1
2
2
2
16
18
20
24
27
27
28
7
7
7
8
9
9
10
NUMBER
(THOUSANDS)
4.3
11
12
11
12
12
13
0.017
0.013
0.012
<0.01
<0.01
<0.01
<0.01
0.5
0.33
0.41
0.7
0.76
0.72
0.69
1.9
1.5
1.1
0.91
0.64
0.56
0.49
2.4
3
2.4
2
2
2.1
2.2
1.3
1.2
1.2
1.1
1.1
1.1
1
0.062
0.06
0.058
0.055
0.053
0.052
0.052
0.014
0.016
0.017
0.021
0.024
0.024
0.025
0.11
0.1
0.066
0.046
0.052
0.06
0.063
0.45
0.28
0.28
0.25
0.32
0.36
0.38
5.6
4.7
3.9
3.3
2.9
2.9
2.8
0.055
0.047
0.038
0.031
0.027
0.026
0.025
80
90
99
84
65
62
59
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.65
0.73
0.81
0.95
1.1
1.1
1.1
5.7
4.8
4.8
4.4
4.9
5.3
5.7
(1.39.1)
(4.020)
(4.623)
(4.721)
(4.921)
(5.122)
(5.323)
(0.0150.019)
(0.0120.015)
(0.0100.014)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.1401.1)
(0.1000.680)
(0.1700.760)
(0.3101.3)
(0.3301.4)
(0.3101.3)
(0.3001.2)
(1.62.2)
(1.31.8)
(0.8601.5)
(0.7701.1)
(0.5900.690)
(0.5200.610)
(0.4100.570)
(0.8604.9)
(1.16.0)
(0.8404.7)
(0.7003.9)
(0.7003.9)
(0.7304.1)
(0.7604.3)
(0.6902.0)
(0.6801.9)
(0.6501.8)
(0.6201.8)
(0.5901.7)
(0.5801.7)
(0.5801.6)
(0.0340.098)
(0.0330.095)
(0.0320.091)
(0.0300.087)
(0.0290.083)
(0.0290.082)
(0.0290.081)
(0.0130.014)
(0.0150.017)
(0.0170.017)
(0.0210.021)
(0.0230.024)
(0.0240.025)
(0.0240.026)
(0.0460.190)
(0.0450.190)
(0.0280.120)
(0.0200.083)
(0.0220.094)
(0.0260.110)
(0.0270.110)
(0.1800.860)
(0.1200.500)
(0.1200.510)
(0.1000.460)
(0.1300.590)
(0.1600.650)
(0.1600.680)
(0.54017)
(0.45014)
(0.37012)
(0.3109.6)
(0.2808.6)
(0.2708.4)
(0.2708.2)
(0.0380.076)
(0.0320.065)
(0.0260.053)
(0.0210.043)
(0.0150.042)
(0.0180.035)
(0.0170.035)
(25170)
(33170)
(37190)
(34160)
(28120)
(27110)
(26110)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0621.9)
(0.0702.2)
(0.0772.4)
(0.0912.8)
(0.2002.7)
(0.1103.2)
(0.1103.3)
(1.712)
(1.89.2)
(1.99.0)
(1.88.0)
(2.19.0)
(2.29.7)
(2.310)
RATEa
33
53
53
41
38
38
39
3.4
2.3
1.8
0.95
0.57
0.57
0.59
88
53
56
87
87
81
76
3.3
2.5
1.7
1.2
0.8
0.69
0.59
4.5
5.1
3.6
2.8
2.7
2.8
2.9
7.2
6
4.9
4.1
3.5
3.3
3.2
1.8
1.4
1.2
1
0.87
0.84
0.82
0.66
0.96
0.87
0.92
0.89
0.89
0.89
3.6
3
1.8
1.1
1.2
1.4
1.5
10
5.8
5.3
4.3
5.1
5.7
5.9
23
18
14
11
9.2
8.9
8.7
2.9
2.1
1.7
1.3
0.98
0.93
0.88
72
70
68
53
38
35
33
0.47
0.45
0.38
0.25
0.15
0.14
0.14
4
4
4
4
4
4
4
86
74
64
53
54
56
59
(1070)
(20103)
(20102)
(1775)
(1669)
(1669)
(1671)
(3.13.8)
(2.12.6)
(1.62.1)
(0.871.0)
(0.510.64)
(0.500.63)
(0.520.65)
(24193)
(17109)
(23104)
(38156)
(38155)
(35144)
(33136)
(2.83.9)
(2.12.9)
(1.32.2)
(1.01.4)
(0.740.86)
(0.640.75)
(0.500.69)
(1.68.8)
(1.810)
(1.37.2)
(1.05.6)
(0.955.4)
(0.985.5)
(1.05.8)
(4.011)
(3.39.5)
(2.77.7)
(2.36.4)
(1.95.5)
(1.85.3)
(1.85.0)
(1.02.9)
(0.762.2)
(0.661.9)
(0.571.6)
(0.481.4)
(0.471.3)
(0.451.3)
(0.640.68)
(0.901.0)
(0.850.88)
(0.910.93)
(0.880.90)
(0.860.92)
(0.870.92)
(1.66.5)
(1.35.4)
(0.753.2)
(0.492.1)
(0.532.2)
(0.612.6)
(0.642.7)
(4.120)
(2.510)
(2.29.7)
(1.88.0)
(2.19.4)
(2.510)
(2.611)
(2.267)
(1.752)
(1.340)
(1.032)
(0.8827)
(0.8526)
(0.8226)
(2.04.1)
(1.42.9)
(1.12.3)
(0.871.8)
(0.551.5)
(0.631.3)
(0.601.2)
(22150)
(26137)
(25132)
(2198)
(1768)
(1663)
(1560)
(0.380.58)
(0.430.47)
(0.310.47)
(0.190.31)
(0.130.18)
(0.110.18)
(0.110.17)
(0.3912)
(0.3812)
(0.3812)
(0.3812)
(0.749.9)
(0.3812)
(0.3812)
(27181)
(28142)
(25121)
(2296)
(2399)
(23104)
(24109)

NUMBER
(THOUSANDS)
42
86
99
100
110
110
110
0.22
0.1
0.24
0.39
0.44
0.39
0.3
5.3
4.5
5.3
7.2
7.9
7.7
7.6
46
36
27
24
24
23
24
26
32
25
21
21
22
23
16
16
15
19
23
23
24
0.63
0.67
0.5
0.49
0.5
0.5
0.49
0.35
0.53
0.81
0.89
1.2
1.2
1.3
1.3
1.3
0.81
0.57
0.66
0.74
0.79
3.8
2.9
3
3
3.6
3.8
3.8
54
60
43
39
40
41
42
0.68
0.44
0.42
0.43
0.48
0.49
0.49
630
710
790
730
640
630
620
0.26
0.36
0.39
0.48
0.82
0.87
0.89
3.1
4.1
4.9
5.3
5.9
6
6.2
45
39
41
41
45
48
50
(1486)
(38150)
(44180)
(48170)
(51180)
(53190)
(55190)
(0.0880.420)
(0.0390.190)
(0.0940.460)
(0.1500.740)
(0.1800.830)
(0.1500.730)
(0.1200.560)
(1.711)
(1.68.8)
(2.29.7)
(3.512)
(3.714)
(3.613)
(3.413)
(2182)
(1760)
(1246)
(1142)
(1140)
(1140)
(1240)
(9.949)
(1261)
(9.848)
(8.140)
(8.240)
(8.542)
(9.044)
(4.934)
(4.935)
(5.429)
(8.833)
(1138)
(1239)
(1240)
(0.2401.2)
(0.2601.3)
(0.2000.940)
(0.1900.930)
(0.2000.950)
(0.1900.940)
(0.1900.920)
(0.1400.660)
(0.2101.0)
(0.3201.5)
(0.3501.7)
(0.4602.2)
(0.4802.3)
(0.5102.5)
(0.5102.5)
(0.5102.4)
(0.3201.5)
(0.2301.1)
(0.2601.2)
(0.2901.4)
(0.3101.5)
(1.76.6)
(1.35.1)
(1.35.5)
(1.25.7)
(1.56.5)
(1.76.8)
(1.86.6)
(21100)
(26110)
(1781)
(1573)
(1675)
(1677)
(1780)
(0.2701.3)
(0.1700.830)
(0.1600.790)
(0.1700.800)
(0.1900.910)
(0.1900.920)
(0.1900.920)
(2301 200)
(3101 300)
(3401 400)
(3401 300)
(3001 100)
(2901 100)
(2801 100)
(0.1000.490)
(0.1400.670)
(0.1500.750)
(0.1900.900)
(0.3201.5)
(0.3401.6)
(0.3501.7)
(1.26.0)
(1.67.7)
(1.99.3)
(2.110)
(2.311)
(2.411)
(2.512)
(1688)
(1870)
(1970)
(2069)
(2276)
(2380)
(2485)
RATEa
326
434
433
361
345
346
351
46
18
38
54
38
31
22
942
713
721
892
902
865
840
81
57
39
33
30
29
28
47
54
39
30
29
30
31
94
81
62
70
75
74
74
18
15
10
9.2
8.4
8.1
7.7
17
32
42
39
44
45
46
44
37
22
14
16
17
19
87
60
58
52
57
60
60
217
224
149
128
126
128
131
37
20
18
18
18
18
17
566
559
547
459
375
361
350
55
71
67
58
51
49
47
20
22
25
22
22
22
22
678
602
549
485
496
509
523
(108660)
(194769)
(193767)
(173618)
(167586)
(167589)
(169597)
(1886)
(7.034)
(1571)
(21102)
(1571)
(1258)
(8.842)
(2961 950)
(2551 400)
(2981 330)
(4291 520)
(4261 550)
(4031 500)
(3781 480)
(36145)
(2897)
(1868)
(1556)
(1450)
(1449)
(1448)
(1890)
(21102)
(1573)
(1258)
(1155)
(1256)
(1259)
(28198)
(24171)
(23122)
(32122)
(37125)
(37124)
(37123)
(7.235)
(6.029)
(4.020)
(3.617)
(3.316)
(3.115)
(3.014)
(6.532)
(1361)
(1779)
(1574)
(1783)
(1885)
(1887)
(1784)
(1569)
(8.541)
(5.627)
(6.329)
(6.933)
(7.435)
(40152)
(27107)
(25104)
(2098)
(24104)
(27107)
(28103)
(84412)
(98401)
(58281)
(50241)
(49238)
(50242)
(51248)
(1469)
(7.737)
(7.235)
(7.033)
(7.034)
(6.933)
(6.832)
(2031 110)
(2421 010)
(238981)
(217790)
(176647)
(167628)
(158618)
(22104)
(28134)
(26126)
(23110)
(2096)
(1993)
(1990)
(7.637)
(8.842)
(9.647)
(8.642)
(8.742)
(8.641)
(8.742)
(2441 330)
(2701 060)
(258949)
(236821)
(242838)
(249861)
(251894)

NUMBER
(THOUSANDS)
25
37
43
52
58
59
61
0.18
0.078
0.19
0.31
0.35
0.31
0.24
3.5
3.9
4.5
5
5.4
5.5
5.6
20
20
17
16
15
15
14
17
21
17
14
14
15
16
9.4
11
12
13
14
14
15
0.49
0.52
0.39
0.38
0.39
0.39
0.38
0.27
0.41
0.64
0.7
0.91
0.96
1
1
1
0.65
0.46
0.54
0.59
0.64
1.7
1.9
2.1
2.3
2.5
2.5
2.6
36
41
34
30
31
32
33
0.53
0.34
0.33
0.34
0.38
0.38
0.39
260
290
330
370
390
400
410
0.2
0.28
0.31
0.37
0.63
0.68
0.69
2.5
3.2
3.9
4.1
4.6
4.8
4.9
19
19
21
24
26
27
27
(1536)
(3145)
(3552)
(4363)
(4869)
(4971)
(5173)
(0.1500.200)
(0.0680.088)
(0.1700.210)
(0.2700.350)
(0.3100.400)
(0.2700.350)
(0.2100.270)
(2.25.0)
(3.24.7)
(3.95.3)
(4.16.0)
(4.46.5)
(4.66.6)
(4.66.7)
(1723)
(1723)
(1520)
(1318)
(1317)
(1217)
(1217)
(1222)
(1528)
(1222)
(1019)
(1019)
(1119)
(1120)
(8.211)
(9.412)
(1114)
(1115)
(1216)
(1316)
(1317)
(0.4300.560)
(0.4600.590)
(0.3400.440)
(0.3400.430)
(0.3500.450)
(0.3400.440)
(0.3300.430)
(0.2400.310)
(0.3600.470)
(0.5600.720)
(0.6100.790)
(0.8001.0)
(0.8401.1)
(0.8901.1)
(0.9001.2)
(0.8801.1)
(0.5700.730)
(0.4000.520)
(0.4700.610)
(0.5100.660)
(0.5600.720)
(1.42.1)
(1.62.3)
(1.72.5)
(2.02.7)
(2.03.0)
(2.13.0)
(2.13.1)
(2747)
(3349)
(2938)
(2734)
(2735)
(2836)
(2938)
(0.4700.600)
(0.3000.390)
(0.2900.370)
(0.3000.390)
(0.3300.430)
(0.3400.430)
(0.3400.440)
(160380)
(240350)
(270400)
(300440)
(320470)
(330480)
(340490)
(0.1800.230)
(0.2400.310)
(0.2700.350)
(0.3300.420)
(0.5600.720)
(0.5900.760)
(0.6100.790)
(2.22.8)
(2.83.6)
(3.44.4)
(3.64.7)
(4.05.2)
(4.25.4)
(4.35.5)
(1228)
(1522)
(1725)
(1929)
(2131)
(2232)
(2333)
RATEa
189
189
189
189
189
189
189
36
14
30
42
30
25
18
619
619
619
619
620
620
620
34
32
26
21
19
18
17
31
35
26
20
19
20
21
54
53
50
48
46
45
45
14
12
8.1
7.2
6.5
6.3
6
13
25
33
31
34
35
36
35
29
17
11
13
14
15
40
40
40
40
40
40
40
147
152
117
100
99
100
103
29
15
14
14
14
14
14
231
231
231
231
231
231
231
43
55
52
45
40
38
37
15
17
19
17
17
17
17
285
285
285
285
285
286
286
(117279)
(155227)
(155227)
(155227)
(155226)
(156225)
(156225)
(3140)
(1216)
(2633)
(3748)
(2634)
(2228)
(1620)
(395893)
(506744)
(528718)
(506744)
(509741)
(512738)
(512738)
(2940)
(2737)
(2230)
(1825)
(1622)
(1521)
(1520)
(2341)
(2646)
(1934)
(1527)
(1425)
(1426)
(1527)
(4762)
(4660)
(4457)
(4254)
(4052)
(4052)
(3951)
(1316)
(1013)
(7.19.1)
(6.38.1)
(5.77.4)
(5.57.1)
(5.26.8)
(1115)
(2229)
(2937)
(2735)
(3039)
(3140)
(3141)
(3139)
(2633)
(1520)
(1013)
(1115)
(1216)
(1317)
(3348)
(3348)
(3348)
(3446)
(3348)
(3348)
(3348)
(110189)
(124182)
(102132)
(88113)
(87112)
(88114)
(90117)
(2532)
(1317)
(1316)
(1216)
(1216)
(1216)
(1215)
(143341)
(189278)
(189278)
(189278)
(190277)
(190276)
(190276)
(3849)
(4863)
(4659)
(4051)
(3545)
(3443)
(3342)
(1317)
(1520)
(1722)
(1520)
(1520)
(1520)
(1520)
(176421)
(233343)
(233343)
(233343)
(234341)
(236340)
(236340)

YEAR
197
South Sudan
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
West Bank
and Gaza Strip
Yemen
198
YEAR
POPULATION
(MILLIONS)
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
10
26
30
34
38
42
44
34
12
14
16
18
20
20
21
8
9
9
10
10
10
11
2
2
3
4
7
8
8
2
3
3
4
4
4
4
12
15
18
21
23
24
25
NUMBER
(THOUSANDS)
RATEa
3
12
9
9.2
8.9
9.2
9.4
7.5
0.9
0.81
0.5
0.47
0.42
0.4
0.38
0.24
0.28
0.24
0.24
0.28
0.3
0.33
0.01
(1.35.5)
(4.522)
(3.816)
(3.917)
(3.816)
(3.917)
(4.017)
(3.214)
(0.2402.0)
(0.3301.5)
(0.1701.0)
(0.1700.930)
(0.1400.850)
(0.1400.800)
(0.1200.770)
(0.1000.430)
(0.1200.500)
(0.1000.430)
(0.1000.430)
(0.1200.510)
(0.1300.550)
(0.1400.590)
(<0.010.049)
29
44
30
27
23
22
22
22
7.3
5.7
3.1
2.6
2.1
2
1.8
2.9
3.1
2.5
2.4
2.7
2.9
3.1
0.58
(1253)
(1783)
(1354)
(1149)
(1042)
(9.339)
(9.239)
(9.240)
(2.016)
(2.311)
(1.16.3)
(0.925.1)
(0.714.2)
(0.663.9)
(0.593.7)
(1.25.2)
(1.35.6)
(1.14.6)
(1.04.3)
(1.25.0)
(1.25.2)
(1.35.6)
(02.7)
0.023
<0.01
0.016
0.018
0.021
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
3.9
3.4
3.3
2.9
1.9
1.6
1.3
(<0.010.120)
(00.051)
(00.099)
(00.110)
(00.140)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1.37.8)
(1.56.2)
(1.56.0)
(1.25.2)
(0.8503.5)
(0.7002.9)
(0.5002.3)
0.74
0.2
0.22
0.23
0.27
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
32
23
19
14
8.3
6.7
5
(04.0)
(01.2)
(01.4)
(01.5)
(01.7)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(1166)
(9.941)
(8.234)
(6.025)
(3.615)
(2.912)
(2.09.4)

NUMBER
(THOUSANDS)
28
96
83
85
85
86
88
69
10
9.1
6.7
6.1
5.3
5.1
4.8
2.9
3.4
3
2.9
3.5
3.7
4
0.28
0.51
0.56
0.19
0.37
0.42
0.5
0.25
0.3
0.26
0.27
0.28
0.27
0.26
33
34
33
28
20
17
15
(1347)
(44170)
(40140)
(41140)
(41140)
(42150)
(43150)
(34120)
(3.421)
(3.717)
(2.214)
(2.212)
(1.911)
(1.810)
(1.79.7)
(1.25.5)
(1.46.4)
(1.25.6)
(1.25.5)
(1.46.6)
(1.57.0)
(1.67.6)
(0.0820.590)
(0.1501.1)
(0.2201.1)
(0.0800.340)
(0.1600.660)
(0.1800.750)
(0.2100.920)
(0.1300.420)
(0.1500.500)
(0.1300.440)
(0.1300.450)
(0.1300.470)
(0.1300.460)
(0.1300.450)
(1265)
(1659)
(1657)
(1348)
(9.234)
(7.730)
(5.927)
RATEa
267
362
275
248
220
203
202
201
85
64
42
33
27
25
23
36
38
31
30
34
36
38
15
22
18
4.6
5.3
5.5
6.4
12
11
8.1
7.5
7
6.7
6.3
280
224
186
134
85
72
59
(129455)
(166633)
(134466)
(121420)
(108372)
(100343)
(99341)
(98339)
(27174)
(26118)
(1485)
(1265)
(9.353)
(8.649)
(8.047)
(1467)
(1572)
(1259)
(1256)
(1364)
(1467)
(1571)
(4.533)
(6.546)
(7.235)
(2.08.4)
(2.39.6)
(2.410)
(2.712)
(6.120)
(5.719)
(4.014)
(3.613)
(3.312)
(3.211)
(3.011)
(102545)
(105387)
(88321)
(64230)
(40146)
(32127)
(24109)

NUMBER
(THOUSANDS)
15
45
47
49
51
52
52
40
7.5
6.5
5.6
4.9
4.2
4.1
3.9
2.3
2.7
2.4
2.3
2.8
3
3.2
0.22
0.28
0.36
0.1
0.2
0.24
0.29
0.15
0.15
0.13
0.13
0.13
0.13
0.12
16
21
20
17
13
12
11
(1218)
(3754)
(3957)
(4159)
(4261)
(4361)
(4362)
(3348)
(5.310)
(5.37.8)
(4.86.4)
(4.15.7)
(3.55.0)
(3.44.8)
(3.24.6)
(2.12.7)
(2.43.1)
(2.12.7)
(2.02.6)
(2.43.1)
(2.63.3)
(2.83.6)
(0.1600.290)
(0.2100.370)
(0.2600.480)
(0.0760.140)
(0.1500.270)
(0.1800.320)
(0.2100.380)
(0.1300.170)
(0.1300.170)
(0.1100.150)
(0.1100.140)
(0.1100.150)
(0.1100.140)
(0.1100.140)
(1024)
(1725)
(1725)
(1420)
(1015)
(9.714)
(9.013)
RATEa
146
170
158
144
133
121
119
117
61
46
35
26
21
20
19
29
31
25
23
27
28
30
12
12
12
2.6
2.9
3.2
3.7
7.2
5.9
4
3.6
3.3
3.1
3
137
137
116
81
54
49
44
(121174)
(140203)
(130188)
(119172)
(110158)
(100145)
(98142)
(96139)
(4382)
(3855)
(3040)
(2231)
(1725)
(1624)
(1622)
(2532)
(2735)
(2228)
(2127)
(2330)
(2532)
(2634)
(8.716)
(8.716)
(8.716)
(1.93.4)
(2.13.8)
(2.34.2)
(2.74.8)
(6.38.1)
(5.26.7)
(3.54.6)
(3.14.1)
(2.93.7)
(2.83.6)
(2.63.4)
(85202)
(112165)
(94139)
(6697)
(4565)
(4058)
(3652)
Afghanistan
Bahrain
Djibouti
Egypt
Iran (Islamic
Republic of)
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
Morocco
Oman
Pakistan
Qatar
Saudi Arabia
Somalia
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
13
20
23
28
31
31
32
<1
<1
<1
<1
1
1
1
<1
<1
<1
<1
<1
<1
<1
57
62
68
74
80
81
83
55
60
65
70
73
74
75
17
20
24
27
31
32
33
3
4
5
5
6
6
6
2
2
2
2
3
3
3
3
3
4
4
4
4
4
4
5
5
6
6
6
6
25
27
29
30
32
32
32
2
2
2
2
3
3
3
112
127
145
159
170
174
177
<1
<1
<1
<1
2
2
2
16
18
20
24
27
27
28
7
7
7
8
9
9
10
25
37
43
52
58
59
61
0.18
0.078
0.19
0.31
0.35
0.31
0.24
3.5
3.9
4.5
5
5.4
5.5
5.6
20
20
17
16
15
15
14
17
21
17
14
14
15
16
9.4
11
12
13
14
14
15
0.49
0.52
0.39
0.38
0.39
0.39
0.38
0.27
0.41
0.64
0.7
0.91
0.96
1
1
1
0.65
0.46
0.54
0.59
0.64
1.7
1.9
2.1
2.3
2.5
2.5
2.6
36
41
34
30
31
32
33
0.53
0.34
0.33
0.34
0.38
0.38
0.39
260
290
330
370
390
400
410
0.2
0.28
0.31
0.37
0.63
0.68
0.69
2.5
3.2
3.9
4.1
4.6
4.8
4.9
19
19
21
24
26
27
27
(1536)
(3145)
(3552)
(4363)
(4869)
(4971)
(5173)
(0.1500.200)
(0.0680.088)
(0.1700.210)
(0.2700.350)
(0.3100.400)
(0.2700.350)
(0.2100.270)
(2.25.0)
(3.24.7)
(3.95.3)
(4.16.0)
(4.46.5)
(4.66.6)
(4.66.7)
(1723)
(1723)
(1520)
(1318)
(1317)
(1217)
(1217)
(1222)
(1528)
(1222)
(1019)
(1019)
(1119)
(1120)
(8.211)
(9.412)
(1114)
(1115)
(1216)
(1316)
(1317)
(0.4300.560)
(0.4600.590)
(0.3400.440)
(0.3400.430)
(0.3500.450)
(0.3400.440)
(0.3300.430)
(0.2400.310)
(0.3600.470)
(0.5600.720)
(0.6100.790)
(0.8001.0)
(0.8401.1)
(0.8901.1)
(0.9001.2)
(0.8801.1)
(0.5700.730)
(0.4000.520)
(0.4700.610)
(0.5100.660)
(0.5600.720)
(1.42.1)
(1.62.3)
(1.72.5)
(2.02.7)
(2.03.0)
(2.13.0)
(2.13.1)
(2747)
(3349)
(2938)
(2734)
(2735)
(2836)
(2938)
(0.4700.600)
(0.3000.390)
(0.2900.370)
(0.3000.390)
(0.3300.430)
(0.3400.430)
(0.3400.440)
(160380)
(240350)
(270400)
(300440)
(320470)
(330480)
(340490)
(0.1800.230)
(0.2400.310)
(0.2700.350)
(0.3300.420)
(0.5600.720)
(0.5900.760)
(0.6100.790)
(2.22.8)
(2.83.6)
(3.44.4)
(3.64.7)
(4.05.2)
(4.25.4)
(4.35.5)
(1228)
(1522)
(1725)
(1929)
(2131)
(2232)
(2333)
RATEa
189
189
189
189
189
189
189
36
14
30
42
30
25
18
619
619
619
619
620
620
620
34
32
26
21
19
18
17
31
35
26
20
19
20
21
54
53
50
48
46
45
45
14
12
8.1
7.2
6.5
6.3
6
13
25
33
31
34
35
36
35
29
17
11
13
14
15
40
40
40
40
40
40
40
147
152
117
100
99
100
103
29
15
14
14
14
14
14
231
231
231
231
231
231
231
43
55
52
45
40
38
37
15
17
19
17
17
17
17
285
285
285
285
285
286
286
(117279)
(155227)
(155227)
(155227)
(155226)
(156225)
(156225)
(3140)
(1216)
(2633)
(3748)
(2634)
(2228)
(1620)
(395893)
(506744)
(528718)
(506744)
(509741)
(512738)
(512738)
(2940)
(2737)
(2230)
(1825)
(1622)
(1521)
(1520)
(2341)
(2646)
(1934)
(1527)
(1425)
(1426)
(1527)
(4762)
(4660)
(4457)
(4254)
(4052)
(4052)
(3951)
(1316)
(1013)
(7.19.1)
(6.38.1)
(5.77.4)
(5.57.1)
(5.26.8)
(1115)
(2229)
(2937)
(2735)
(3039)
(3140)
(3141)
(3139)
(2633)
(1520)
(1013)
(1115)
(1216)
(1317)
(3348)
(3348)
(3348)
(3446)
(3348)
(3348)
(3348)
(110189)
(124182)
(102132)
(88113)
(87112)
(88114)
(90117)
(2532)
(1317)
(1316)
(1216)
(1216)
(1216)
(1215)
(143341)
(189278)
(189278)
(189278)
(190277)
(190276)
(190276)
(3849)
(4863)
(4659)
(4051)
(3545)
(3443)
(3342)
(1317)
(1520)
(1722)
(1520)
(1520)
(1520)
(1520)
(176421)
(233343)
(233343)
(233343)
(234341)
(236340)
(236340)
NUMBER
(THOUSANDS)
RATEa
0.044
0.079
0.11
0.17
0.24
0.27
0.3
(0.0270.065)
(0.0430.120)
(0.0610.170)
(0.0960.260)
(0.1400.370)
(0.1600.410)
(0.1800.450)
0.3
0.4
0.5
0.6
0.8
0.9
0.9
(0.210.50)
(0.220.63)
(0.270.75)
(0.350.93)
(0.471.2)
(0.511.3)
(0.561.4)
0.011
0.012
0.011
0.11
0.46
0.73
0.69
0.53
0.63
0.57
<0.01
0.017
0.056
0.054
0.042
0.042
0.043
0.02
0.094
0.25
0.29
0.33
0.35
0.38
(<0.010.021)
(<0.010.024)
(<0.010.021)
(0.0700.160)
(0.3600.580)
(0.5900.880)
(0.5400.860)
(0.4200.660)
(0.5000.780)
(0.4500.710)
(<0.01<0.01)
(<0.010.028)
(0.0330.086)
(0.0310.082)
(0.0240.065)
(0.0250.065)
(0.0250.067)
(0.0140.026)
(0.0520.150)
(0.1600.370)
(0.1800.420)
(0.2100.470)
(0.2200.500)
(0.2400.540)
0.9
0.9
0.8
20
74
99
86
61
71
63
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
0.2
0.4
0.4
0.4
0.5
0.5
(0.371.8)
(0.301.9)
(0.301.6)
(1329)
(5892)
(81120)
(67107)
(4876)
(5787)
(4979)
(<0.1<0.1)
(<0.1<0.1)
(<0.10.13)
(<0.10.11)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.10.25)
(0.240.57)
(0.260.60)
(0.280.64)
(0.300.68)
(0.320.73)
<0.01 (00.011)
<0.01 (00.011)
<0.1 (0<0.1)
<0.1 (0<0.1)
<0.01
<0.01
<0.01
<0.01
(<0.010.010) 0.2 (<0.10.52)

(<0.010.011) 0.2 (<0.10.48)
(<0.01<0.01) <0.1 (<0.10.11)
(<0.01<0.01) 0.1 (<0.10.30)
0.011
0.019
0.02
0.021
0.045
0.015
0.036
(<0.010.012)
(0.0120.028)
(0.0130.029)
(0.0140.029)
(0.0290.066)
(<0.010.030)
(0.0250.050)
0.4
0.6
0.5
0.5
1.1
0.4
0.9
(0.330.42)
(0.340.80)
(0.350.76)
(0.340.71)
(0.691.6)
(0.130.71)
(0.581.2)
0.22
0.021
0.064
0.11
0.17
0.25
0.27
0.3
<0.01
<0.01
<0.01
0.013
<0.01
<0.01
<0.01
0.011
0.036
0.13
0.42
0.98
1.2
1.5
(0.1700.280)
(0.0160.027)
(0.0370.098)
(0.0740.160)
(0.1200.240)
(0.1700.330)
(0.2000.350)
(0.2100.400)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.024)
(<0.01<0.01)
(<0.010.012)
(<0.010.017)
(<0.010.016)
(0.0170.064)
(0.0680.210)
(0.2500.630)
(0.6301.4)
(0.8601.6)
(0.9902.1)
3.4
<0.1
0.2
0.4
0.6
0.8
0.9
0.9
<0.1
<0.1
<0.1
0.6
0.1
0.2
0.3
<0.1
<0.1
<0.1
0.3
0.6
0.7
0.8
(2.64.3)
(<0.10.11)
(0.140.36)
(0.260.56)
(0.390.79)
(0.551.1)
(0.631.1)
(0.661.2)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(0.250.97)
(<0.10.34)
(<0.10.42)
(0.130.61)
(<0.1<0.1)
(<0.1<0.1)
(<0.10.14)
(0.160.40)
(0.370.82)
(0.500.92)
(0.561.2)
<0.01 (<0.01<0.01) <0.1 (<0.10.14)
0.11
0.11
0.97
1.6
2
2.1
2.1
2.1
2.1
(0.0850.140)
(0.0830.140)
(0.6001.4)
(1.22.1)
(1.52.5)
(1.62.7)
(1.62.7)
(1.62.7)
(1.62.7)
0.4
0.4
15
25
27
26
23
23
22
(0.310.52)
(0.300.50)
(9.122)
(1932)
(2134)
(1933)
(1830)
(1729)
(1728)
CASE DETECTION
NUMBER
RATEa
PERCENT
4 332
33
18 (1228)
7 107
21 844
25 417
28 029
27 983
117
43
207
280
326
246
225
2 100
31
79
83
89
86
24
7.7
32
39
28
19
17
373
16
42
44
47
46
67
55
110
92
92
79
95
60
(1420)
(3551)
(3753)
(4057)
(3855)
(5976)
(4963)
(97130)
(81100)
(82110)
(7090)
(84110)
(4295)
3 971
3 109
3 783
4 172
3 686
2 142
11 145
10 762
11 446
9 685
9 260
8 974
9 255
15 936
11 850
9 192
10 097
10 362
10 980
14 735
9 697
9 697
9 454
9 385
9 707
8 837
439
498
306
367
367
338
314
277
336
513
517
933
957
672
543
385
434
469
407
3.8
18
16
15
12
11
11
17
27
18
13
14
14
15
85
48
41
35
31
31
27
13
11
6.3
6.9
6.1
5.5
5
13
21
26
23
35
35
24
88
62
70
76
66
11
57
62
73
65
64
63
54
75
71
65
71
70
71
160
91
81
72
66
67
60
90
96
79
96
93
87
83
100
82
80
74
100
99
66
(76100)
(5276)
(5985)
(6492)
(5579)
(9.313)
(4967)
(5373)
(6286)
(5677)
(5575)
(5474)
(4174)
(57100)
(5497)
(5090)
(5498)
(5397)
(5497)
(140180)
(80100)
(7192)
(6482)
(5876)
(5977)
(5369)
(79100)
(85110)
(6990)
(85110)
(82110)
(7799)
(7395)
(90120)
(7293)
(7192)
(6685)
(90120)
(88110)
(5976)
983
571
391
499
513
496
442
1 440
1 341
2 098
2 096
28
15
9.6
12
12
12
10
30
26
36
33
97
88
85
92
88
77
26
76
64
91
84
(86110)
(78100)
(7597)
(81110)
(77100)
(6888)
(2131)
(6392)
(5379)
(79110)
(70100)
1 518
27 658
29 829
28 852
26 269
27 348
28 359
28 640
482
276
321
261
332
308
337
156 759
13 142
11 050
142 017
264 248
261 199
261 041
184
304
279
325
619
580
553
2 415
24
112
111
100
86
86
89
89
26
12
14
11
12
11
12
140
10
7.6
90
155
150
148
39
61
47
40
39
33
30
15
59
76
73
86
86
88
88
86
90
81
98
76
88
80
87
61
4.5
3.3
39
67
65
64
90
110
91
88
98
86
80
98
(4972)
(59100)
(6189)
(7698)
(7699)
(77100)
(78100)
(7698)
(80100)
(7192)
(87110)
(6787)
(78100)
(7192)
(7799)
(4198)
(3.75.5)
(2.84.0)
(3247)
(5682)
(5579)
(5478)
(80100)
(97130)
(80100)
(77100)
(86110)
(7698)
(7091)
(87110)
3 452
3 539
4 043
4 422
3 932
17
15
15
16
14
89
85
87
93
80
(79100)
(7597)
(77100)
(82110)
(7192)
2 504
5 686
12 904
11 075
10 139
11 653
38
77
154
121
109
122
13
27
54
43
38
43
(1116)
(2233)
(4566)
(3652)
(3246)
(3652)

YEAR
199
YEAR
South Sudan
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
West Bank
and Gaza Strip
Yemen
200
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
10
26
30
34
38
42
44
34
12
14
16
18
20
20
21
8
9
9
10
10
10
11
2
2
3
4
7
8
8
2
3
3
4
4
4
4
12
15
18
21
23
24
25
NUMBER
(THOUSANDS)
15
45
47
49
51
52
52
40
7.5
6.5
5.6
4.9
4.2
4.1
3.9
2.3
2.7
2.4
2.3
2.8
3
3.2
0.22
0.28
0.36
0.1
0.2
0.24
0.29
0.15
0.15
0.13
0.13
0.13
0.13
0.12
16
21
20
17
13
12
11
(1218)
(3754)
(3957)
(4159)
(4261)
(4361)
(4362)
(3348)
(5.310)
(5.37.8)
(4.86.4)
(4.15.7)
(3.55.0)
(3.44.8)
(3.24.6)
(2.12.7)
(2.43.1)
(2.12.7)
(2.02.6)
(2.43.1)
(2.63.3)
(2.83.6)
(0.1600.290)
(0.2100.370)
(0.2600.480)
(0.0760.140)
(0.1500.270)
(0.1800.320)
(0.2100.380)
(0.1300.170)
(0.1300.170)
(0.1100.150)
(0.1100.140)
(0.1100.150)
(0.1100.140)
(0.1100.140)
(1024)
(1725)
(1725)
(1420)
(1015)
(9.714)
(9.013)
RATEa
146
170
158
144
133
121
119
117
61
46
35
26
21
20
19
29
31
25
23
27
28
30
12
12
12
2.6
2.9
3.2
3.7
7.2
5.9
4
3.6
3.3
3.1
3
137
137
116
81
54
49
44
(121174)
(140203)
(130188)
(119172)
(110158)
(100145)
(98142)
(96139)
(4382)
(3855)
(3040)
(2231)
(1725)
(1624)
(1622)
(2532)
(2735)
(2228)
(2127)
(2330)
(2532)
(2634)
(8.716)
(8.716)
(8.716)
(1.93.4)
(2.13.8)
(2.34.2)
(2.74.8)
(6.38.1)
(5.26.7)
(3.54.6)
(3.14.1)
(2.93.7)
(2.83.6)
(2.63.4)
(85202)
(112165)
(94139)
(6697)
(4565)
(4058)
(3652)
NUMBER
(THOUSANDS)
1.7
2.4
3.2
3.7
3.7
3.7
2.8
0.096
0.082
0.053
0.047
0.057
0.061
0.066
RATEa
(1.42.0)
(1.83.1)
(2.44.1)
(2.74.7)
(2.84.7)
(2.84.7)
(2.13.6)
6.4
7.9
9.3
9.5
8.7
8.5
8.2
(5.37.6)
(5.810)
(6.912)
(7.212)
(6.511)
(6.311)
(6.211)
(0.0840.110)
(0.0600.110)
(0.0380.071)
(0.0330.063)
(0.0400.076)
(0.0430.081)
(0.0470.088)
1.2
0.9
0.6
0.5
0.6
0.6
0.6
(1.01.3)
(0.681.2)
(0.400.75)
(0.340.64)
(0.390.73)
(0.410.78)
(0.440.83)
0.011 (<0.010.028)
0.011 (<0.010.029)
0.2 (<0.10.37)
0.1 (<0.10.37)
0.014
0.074
0.24
0.34
0.28
0.26
0.24
0.1
0.5
1.3
1.7
1.2
1.1
1
(<0.010.020)
(0.0430.110)
(0.1500.340)
(0.2300.470)
(0.1900.380)
(0.1800.350)
(0.1700.330)
(<0.10.17)
(0.280.75)
(0.871.9)
(1.12.3)
(0.821.6)
(0.741.5)
(0.671.3)

NUMBER
RATEa
CASE DETECTION
PERCENT
7 217
212
14 320
24 807
27 562
26 001
26 131
19 348
6 018
4 404
5 090
4 310
4 050
3 666
3 395
2 054
2 383
2 038
2 079
2 155
2 368
3 015
285
70
0.8
48
73
72
61
60
56
49
31
32
23
20
18
16
25
27
22
21
21
23
28
16
48
0.47
30
50
54
50
50
48
81
68
92
89
96
90
87
88
87
87
90
78
80
95
130
115
103
116
131
103
64
77
82
28
35
31
32
4 650
14 428
13 651
9 063
8 562
8 916
8 636
3.8
2.5
1.7
1.7
1.3
3.1
3
2.6
0.79
0.89
0.77
0.77
39
95
77
44
37
37
35
32
99
57
54
36
43
50
64
22
27
24
26
28
69
67
54
67
76
79
(4058)
(0.390.57)
(2537)
(4261)
(4566)
(4261)
(4261)
(4159)
(60110)
(5683)
(79110)
(76110)
(80120)
(76110)
(73110)
(77100)
(77100)
(7799)
(79100)
(6989)
(7191)
(84110)
(100180)
(2443)
(75140)
(4379)
(4175)
(2749)
(3849)
(4457)
(5673)
(1925)
(2431)
(2228)
(2329)
(1946)
(5885)
(5682)
(4567)
(5682)
(6492)
(6796)
YEAR
Afghanistan
33
86
Bahrain
24
17
Djibouti
373
407
Egypt
11
Iran (Islamic
Republic of)
17
15
Iraq
85
27
Jordan
13
Kuwait
13
24
Lebanon
12
Libyan Arab
Jamahiriya
10
24
Morocco
112
89
Oman
26
12
Pakistan
140
148
Qatar
39
30
Saudi Arabia
15
14
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
4 332
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
7 107
21 844
25 417
28 029
27 983
117
43
207
280
326
246
225
2 100
2 892
9 949
12 497
12 947
13 789
2 358
6 085
6 108
7 085
6 155
1 620
4 954
5 730
6 248
6 286
633
623
237
856
1 082
1 116
1 130
17
23
101
131
90
89
14
16
72
74
58
47
85
8
107
121
98
89
0
0
0
0
3 971
3 109
3 783
4 172
3 686
2 142
11 145
10 762
11 446
9 685
9 260
8 974
9 255
15 936
11 850
9 192
10 097
10 362
10 980
14 735
9 697
9 697
9 454
9 385
9 707
8 837
439
498
306
367
367
338
314
277
336
513
517
933
957
672
1 391
1 120
1 377
1 181
1 336
518
739
507
538
569
1 875
1 058
1 710
2 253
1 587
4 229
4 606
5 217
5 201
4 679
4 508
9 204
2 693
2 617
1 238
1 158
1 055
4 684
2 843
3 163
2 850
3 048
3 074
5 347
5 361
4 581
5 152
5 188
5 539
1 587
3 194
3 194
3 096
3 347
3 618
3 059
6 432
2 642
1 807
1 926
1 985
1 980
12 394
13 962
3 188
2 887
2 666
2 693
2 463
3 779
3 442
2 530
2 685
2 869
3 076
754
1 367
2 753
2 703
2 904
3 009
2 957
187
89
86
109
117
103
210
69
76
64
69
81
175
180
187
386
385
222
983
571
391
499
513
496
442
1 440
1 341
2 098
2 096
1 518
27 658
29 829
28 852
26 269
27 348
28 359
28 640
482
276
321
261
332
308
337
156 759
13 142
11 050
142 017
264 248
261 199
261 041
184
304
279
325
619
580
553
2 415
3 452
3 539
4 043
4 422
3 932
208
209
184
237
856
1 290
1 325
1 314
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
184
192
189
200
194
61
21
19
37
184
253
210
219
231
0
0
0
0
0
0
0
0
753
620
449
396
375
337
289
352
328
333
753
620
738
748
703
670
0
0
0
0
0
0
0
477
405
274
334
320
385
154
439
440
515
477
405
428
773
760
900
20
0
0
0
0
0
0
68
562
768
468
387
358
283
390
411
68
562
768
751
777
769
0
0
0
101
145
187
190
150
128
12
0
0
0
6
3
6
4
2
2
4
16
16
16
6
3
10
20
18
18
0
4
0
14
42
89
95
155
163
141
115
244
234
391
407
309
0
0
0
0
0
0
4
0
1
1
2
0
0
0
0
0
0
0
4
0
1
1
2
0
0
0
0
0
0
0
197
202
131
179
194
188
528
149
75
94
99
101
255
214
181
218
210
206
607
860
936
626
82
474
455
814
652
762
696
2
9
269
14
271
23
731
305
462
20
27
47
14 171
12 872
12 757
11 907
12 239
11 822
4 095
2 934
2 142
2 021
2 174
2 272
11 563
13 046
11 370
12 131
12 730
13 331
0
0
0
0
1 289
1 216
1 215
316
429
1 130
1 605
1 645
2 345
0
0
0
135
164
131
164
152
180
60
37
37
36
28
32
81
112
89
127
124
122
0
0
0
0
8
4
5
4
3
2
5
0
0
8
4
7
9
3
0
0
0
2 578
3 285
48 220
101 887
104 263
105 733
3 806
5 578
68 337
112 948
105 623
103 824
3 037
1 846
22 789
43 416
45 443
45 537
0
0
184
341
2 671
5 997
5 870
5 947
2 754
3 203
5 055
5 460
184
341
5 425
9 200
10 925
11 407
3 036
3 893
60
53
96
220
223
197
135
98
73
102
101
120
109
128
156
297
256
236
1
0
0
0
0
0
0
0
1
0
0
0
0
0
0
1 595
1 722
2 201
2 302
2 055
722
545
578
687
586
1 023
1 067
1 170
1 311
1 227
112
205
94
122
64
50
84
83
112
205
144
206
147
0
0
0
0
0
0
0
0
3
6
4
8
10
1
733
0
2
2
3
6
4
10
12
1
0
0
0
43
55
62
67
65
69
55
59
58
64
61
65
73
60
73
69
70
31
63
67
81
80
81
45
67
72
73
72
74
11
19
50
52
56
57
55
47
56
53
63
63
56
81
67
66
71
70
61
27
58
64
66
66
65
88
64
67
71
78
81
86
85
85
84
69
82
78
82
84
85
40
37
41
47
50
50
31
35
57
68
69
62
69
76
79
77
78
NEW AND RELAPSE

NOTIFICATION RATE
19902011
201
NEW AND RELAPSE

a
NOTIFICATION RATE
19902011
YEAR
Somalia
122
South Sudan
Sudan
56
Syrian Arab
Republic
49
16
Tunisia
25
28
United Arab
Emirates
16
West Bank
and Gaza Strip
Yemen
39
202
35
1990
1995
2000
2005
2009
2010
2011
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
2 504
5 686
12 904
11 075
10 139
11 653
7 217
212
14 320
24 807
27 562
26 001
26 131
19 348
6 018
4 404
5 090
4 310
4 050
3 666
3 395
2 054
2 383
2 038
2 079
2 155
2 368
3 015
285
115
103
116
131
103
64
77
82
28
35
31
32
4 650
14 428
13 651
9 063
8 562
8 916
8 636
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
1 572
3 776
7 068
6 047
5 225
5 884
2 797
692
837
3 168
2 604
2 654
3 159
2 610
318
722
2 258
1 965
1 885
2 261
1 639
8 761
12 311
12 730
10 541
9 958
7 266
2 655
6 512
9 212
8 897
9 144
6 746
1 675
3 843
5 434
5 530
6 217
4 624
1 295
1 584
1 350
1 143
1 122
1 027
1 507
1 409
796
796
544
393
1 574
2 000
2 103
2 036
1 948
1 915
1 243
1 099
915
931
1 091
1 031
407
179
239
232
151
317
733
727
874
950
1 090
1 616
73
62
71
56
46
3
12
15
28
27
41
25
30
47
30
9
37
7
10
13
11
58
10
6
9
6
5
15
15
12
13
3 681
5 565
3 379
3 576
3 584
3 135
7 390
4 176
2 780
2 108
2 313
2 400
3 082
3 470
2 553
2 564
2 715
2 880
0
0
0
0
134
351
410
459
375
349
171
474
2 141
186
957
812
712
0
0
0
0
28
97
61
75
52
60
0
76
102
196
330
368
366
134
351
512
655
705
717
537
1 616
1 036
1 110
1 037
474
2 141
1 802
1 993
1 922
1 749
83
101
161
55
28
97
144
176
213
115
0
0
225
61
51
42
36
51
0
0
0
0
61
51
42
36
51
0
0
0
0
0
4
0
0
0
2
0
1
3
0
6
0
1
3
0
0
0
0
0
0
0
1
0
3
1
0
0
2
0
3
0
0
0
0
0
0
275
440
351
314
304
221
0
134
77
275
440
351
314
438
298
0
0
0
69
82
69
70
66
65
52
77
65
58
54
52
52
46
53
63
59
67
72
75
86
79
80
88
76
96
84
83
67
63
13
100
54
53
68
69
33
57
55
63
61
57
% OF COHORT
Afghanistan
90
Bahrain
96
Djibouti
75
80
62
86
Egypt
Iran (Islamic
Republic of)
83
80
89
92
87
71
87
91
80
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
65
64
Morocco
90
85
84
97
70
91
81
67
Oman
Pakistan
Qatar
Saudi Arabia
62
86
89
Somalia
South Sudan
Sudan
79
80
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
2 892
9 949
13 136
12 497
12 947
17
23
101
141
131
90
1 391
1 120
1 375
1 377
1 181
4 229
4 606
5 217
5 102
5 201
4 679
5 347
5 361
4 581
4 722
5 152
5 188
3 194
3 194
3 096
3 150
3 347
3 618
187
89
86
104
109
117
175
180
187
345
386
385
197
202
131
158
179
194
607
860
871
936
14 171
12 872
12 757
11 825
11 907
12 239
135
164
131
171
164
152
2 578
3 285
48 220
100 102
101 887
104 263
60
53
96
201
220
223
1 595
1 722
2 108
2 201
2 302
1 572
3 776
7 068
6 520
6 047
5 225
8 761
12 311
12 730
10 800
10 541
9 958
SIZE OF
COHORT
3 136
10 013
13 136
12 497
12 947
22
15
142
192
162
1 751
1 391
1 120
1 375
1 277
1 177
2 118
4 611
5 154
5 101
5 201
4 682
5 866
4 581
4 824
5 201
5 269
11 553
3 194
3 096
3 150
3 347
3 618
193
89
86
104
109
117
175
180
187
345
386
385
200
190
131
158
179
192
626
860
872
792
14 171
12 872
12 683
11 956
11 935
12 492
93
112
104
171
334
152
802
4 074
48 205
100 103
101 809
104 434
43
53
96
201
5
219
1 285
1 722
2 104
2 201
2 302
1 278
3 776
7 059
6 520
6 047
5 225
2 114
8 326
14 599
12 730
10 766
10 883
7 729
COHORT AS
% NOTIFIED
108
101
100
100
100
96
15
101
147
180
100
100
100
93
100
50
100
99
100
100
100
109
100
102
101
102
362
100
100
100
100
100
103
100
100
100
100
100
100
100
100
100
100
100
102
94
100
100
100
99
100
100
100
100
99
101
100
102
69
68
79
100
204
100
31
124
100
100
100
100
72
100
100
100
2
98
81
100
100
100
100
81
100
100
100
100
100
95
119
100
100
103
78
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
76
83
83
83
86
9
7
5
4
3
3
2
2
2
2
3
1
1
1
1
6
2
2
2
2
2
5
7
9
5
73
93
8
98
96
60
48
71
78
72
68
38
75
66
69
72
59
0
0
0
0
0
16
14
9
6
7
12
24
12
13
20
16
27
27
7
1
2
4
3
2
1
1
1
1
2
3
3
3
3
3
0
0
0
0
0
1
1
1
0
1
1
3
2
2
3
2
3
0
0
0
0
0
20
21
16
13
17
16
19
5
3
3
4
4
0
0
90
0
0
1
14
2
2
3
2
14
3
13
3
3
4
81
78
78
77
77
60
86
76
79
80
80
91
89
71
73
54
57
40
54
53
43
41
63
35
89
81
63
65
68
65
4
5
6
6
6
20
5
10
9
10
9
1
1
12
11
21
30
31
15
10
37
44
24
56
3
11
13
17
12
0
6
7
8
7
7
0
3
3
3
2
3
3
2
5
3
6
1
3
1
1
0
0
0
0
4
2
3
6
2
1
2
3
3
3
4
5
2
2
2
1
1
1
1
7
1
7
3
0
0
0
0
0
0
0
1
1
1
1
1
1
3
3
2
2
3
10
3
7
6
6
6
2
4
6
4
11
6
1
9
7
7
4
3
10
3
6
2
2
18
33
3
4
3
5
3
5
1
3
1
1
1
3
2
0
9
0
3
25
21
29
12
11
9
0
1
0
18
10
0
0
40
52
29
17
2
3
0
1
27
24
2
4
43
75
82
76
79
77
77
84
93
90
96
49
97
51
58
71
74
74
75
81
66
74
60
80
63
21
14
7
5
7
8
8
0
0
0
1
1
1
1
2
1
1
3
31
7
7
9
10
9
9
1
0
2
49
0
20
16
13
16
17
16
0
0
9
13
0
3
2
2
3
2
2
2
2
9
4
10
2
2
3
4
4
3
2
2
2
5
8
1
1
0
0
0
0
0
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
20
17
9
5
4
4
0
0
0
0
20
0
3
1
1
7
1
2
2
5
0
0
0
0
0
4
4
4
3
2
2
14
26
16
26
0
33
62
60
54
54
52
82
81
85
78
83
87
67
44
50
64
62
62
56
11
5
6
11
10
4
2
4
3
2
2
8
35
25
18
20
19
24
7
7
6
6
5
4
4
4
3
4
3
5
2
4
3
3
3
2
0
1
2
1
1
5
2
1
2
2
2
1
7
2
1
1
1
1
13
10
8
10
14
5
3
4
3
3
3
15
11
9
9
10
10
12
6
17
24
18
18
0
9
2
11
7
4
3
1
11
5
5
6
5

19952010
203
% OF COHORT
a

19952010
Syrian Arab
Republic
61
89
Tunisia
85
United Arab
Emirates
69
West Bank
and Gaza Strip
100
83
52
87
Yemen
204
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
COHORT AS
% NOTIFIED
1 295
1 584
1 350
1 116
1 143
1 122
1 243
1 099
915
1 005
931
1 091
1 295
1 562
1 350
1 115
1 144
1 122
100
99
100
100
100
100
100
99
96
100
100
100
100
106
100
98
144
171
100
110
92
100
100
106
100
99
100
73
62
50
71
56
9
37
7
16
10
13
3 681
5 565
3 379
3 540
3 576
3 584
1 099
910
967
931
1 091
73
62
53
71
55
13
12
16
11
12
3 681
5 565
3 566
3 540
3 557
3 584
CURED
COMPLETED
45
69
76
86
76
75
16
10
13
DIED
FAILED
DEFAULTED
NOT
EVALUATED
12
14
2
4
3
3
4
3
9
3
2
2
1
2
24
11
6
6
4
4
5
4
1
2
3
2
87
83
76
72
62
4
7
10
11
24
3
2
3
3
3
2
1
1
2
1
2
2
2
3
4
2
4
8
9
6
56
42
25
21
24
100
18
31
43
52
45
7
6
9
11
7
4
0
0
1
0
5
15
23
14
24
10
6
0
0
0
0
58
38
18
8
43
59
69
75
79
77
42
56
64
75
9
13
11
9
9
9
0
0
9
0
1
3
3
3
3
3
0
0
0
17
1
1
1
1
1
1
0
6
9
0
35
14
6
5
4
4
0
0
0
0
11
10
10
7
4
7
% OF COHORT
Afghanistan
79
Bahrain
Djibouti
70
Egypt
72
Iran (Islamic
Republic of)
69
Iraq
75
Jordan
60
Kuwait
100
Lebanon
75
Libyan Arab
Jamahiriya
33
Morocco
76
64
Oman
100
70
84
67
Pakistan
Qatar
Saudi Arabia
50
Somalia
62
South Sudan
Sudan
68
YEAR
NUMBER
NOTIFIED
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2010
1995
2000
2005
2008
2009
2010
237
856
1 135
1 290
1 325
0
0
0
0
0
184
253
196
210
219
753
620
738
792
748
703
477
405
428
423
773
760
68
562
768
685
751
777
6
3
10
1
20
18
4
0
1
1
1
2
3
6
4
11
10
12
SIZE OF
COHORT
304
856
1 325
0
0
0
268
253
196
194
213
956
738
779
748
703
606
448
692
708
781
953
685
751
777
6
12
24
5
1
1
1
2
5
4
11
10
12
271
32
23
85
1 469
1 646
1 605
1 645
0
8
4
4
7
9
184
341
5 425
7 983
9 200
10 925
1
0
0
0
0
0
112
205
145
144
206
134
351
512
621
655
705
474
2 141
1 802
2 080
1 993
1 922
1 650
1 535
1 668
2 899
7
4
7
9
374
907
5 009
7 685
8 801
8 394
3
0
0
0
139
96
141
151
249
351
524
621
655
705
434
1 828
1 953
2 147
1 517
COHORT AS
% NOTIFIED
128
100
100
146
100
100
92
97
154
100
98
100
100
150
105
164
92
103
124
100
100
100
200
1 200
120
28
100
100
100
100
83
100
100
100
100
93
104
176
88
100
100
100
203
266
92
96
96
77
300
124
47
97
105
121
100
102
100
100
100
101
94
108
79
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
73
87
5
2
4
3
4
1
11
2
3
5
73
14
27
58
66
67
53
9
10
9
8
17
0
3
3
3
6
3
2
2
2
2
22
24
14
18
19
37
2
6
3
3
52
41
39
39
38
11
17
32
39
34
7
10
8
6
6
12
12
8
5
8
13
8
9
7
8
5
12
4
4
6
63
68
57
48
49
13
8
15
25
20
6
9
8
8
8
5
3
4
3
5
6
4
5
5
4
7
8
11
11
15
60
62
57
36
12
18
27
40
4
2
3
4
8
4
3
5
12
11
9
13
4
2
1
3
83
17
8
17
0
67
62
60
0
4
0
8
0
20
17
17
0
0
0
20
0
0
0
0
100
100
100
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
80
75
55
60
58
25
9
20
17
0
27
0
8
0
0
0
0
0
0
0
17
20
0
9
20
0
31
62
11
65
22
12
2
4
0
4
45
10
20
7
55
65
60
40
17
8
9
24
4
4
4
4
5
5
3
3
14
18
16
21
5
1
8
9
86
14
50
57
44
48
37
61
62
63
68
67
50
43
56
22
17
15
17
18
16
0
0
0
0
2
6
5
5
4
3
0
0
0
0
5
3
3
3
3
3
0
0
0
0
24
29
11
10
8
6
0
0
0
0
0
8
5
4
3
3
33
43
40
34
45
31
15
9
10
15
19
7
9
5
8
8
3
5
4
1
2
13
18
16
17
22
19
19
31
14
17
53
76
48
50
48
23
1
5
4
10
14
34
5
6
5
6
6
5
5
2
2
4
5
9
3
5
3
3
4
23
34
6
38
27
23
5
53
39
33
28
29
35
38
40
3
2
3
2
1
1
1
1
9
14
15
14
6
8
10
16

19952010
205
% OF COHORT
a

19952010
Syrian Arab
Republic
81
Tunisia
United Arab
Emirates
67
West Bank
and Gaza Strip
Yemen
43
206
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
28
97
144
267
176
213
61
51
38
42
36
0
6
1
0
1
1
2
0
275
440
351
411
314
438
SIZE OF
COHORT
189
144
266
176
213
42
5
1
0
3
0
0
0
14
437
351
376
291
COHORT AS
% NOTIFIED
195
100
100
100
100
69
83
100
300
0
0
5
99
100
91
93
CURED
COMPLETED
44
53
26
48
23
10
14
51
22
58
74
DIED
NOT
EVALUATED
FAILED
DEFAULTED
4
5
5
9
4
20
9
5
4
3
15
19
12
15
11
7
0
3
3
1
10
10
80
100
0
0
0
0
0
0
20
0
0
0
67
33
29
64
48
66
70
14
8
9
9
7
21
7
2
3
3
14
6
3
3
4
14
11
7
9
7
7
4
30
10
9
Afghanistan
23
46
69
Bahrain
Djibouti
34
37
11
Egypt
Iran (Islamic
Republic of)
Iraq
42
23
97
Jordan
Kuwait
100
100
Lebanon
48
Libyan Arab
Jamahiriya
97
Morocco
Oman
98
100
Pakistan
Qatar
100
Saudi Arabia
86
Somalia
34
15
16
12
South Sudan
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
76
West Bank
and Gaza Strip
0
100
Yemen
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
4
18
23
46
79
65
69
7
55
52
34
1 175
5 170
6 445
128
256
161
155
224
2 091
2 163
1 274
32
47
37
3 204
4 483
3 441
7
8
11
700
904
1 262
63
66
42
23
100
99
97
100
100
100
100
1
59
52
48
6 121
6 711
3 858
86
387
352
332
517
933
957
672
3
298
269
236
45
97
950
2 128
1 498
3
1
6
98
100
100
100
0
3
2
3
100
100
0
0
930
215
1 856
257
334
313
337
0
8 208
6 283
8 322
325
619
0
0
47
72
86
0
8
26
34
47
1
60
28
15
8
0
2
16
6
4
7
12
1 929
3 278
3 443
0
875
2 741
4 140
3 570
180
16 168
7 532
3 082
345
0
85
577
129
80
156
360
99
64
76
0
97
100
100
0
0
0
115
84
81
0
35
31
32
0
0
0
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
21 844
26 358
28 238
28 167
280
326
246
225
3 170
3 804
4 191
3 723
11 735
10 037
9 588
9 307
9 366
10 536
10 802
11 495
9 454
9 668
10 097
9 248
371
387
354
344
517
933
957
672
391
501
515
496
2 367
2 110
1 545
26 269
27 664
28 788
29 770
261
334
313
337
144 771
267 451
269 290
270 394
325
619
580
553
3 539
4 093
4 549
4 015
13 006
11 271
10 469
12 021
7 583
29 178
27 037
27 241
20 385
4 393
4 151
3 827
3 675
2 079
2 155
2 368
3 015
105
116
132
106
28
36
31
32
9 063
8 562
9 050
8 713
NUMBER OF
HIV-POSITIVE
TB PATIENTS
% OF TESTED
TB PATIENTS
HIV-POSITIVE
PEOPLE
CPT
ART
PROVIDED IPT
5
2
5
6
8
6
7
135
207
248
177
0
0
0
5
3
4
5
60
10
11
14
100
100
80
0
0
0
0
15
0
0
100
100
80
0
12
0
43
15
23
11
11
7
12
0
0
0
100
100
100
100
100
100
1
0
223
254
289
32
28
23
13
16
18
21
28
36
418
161
1
1
2
0
0
0
0
3
4
3
0
3
25
7
9
0
0
0
0
0
0
0
1
0
0
0
100
8
3
4
100
100
50
0
0
50
0
0
100
100
100
100
100
100
0
100
100
100
100
100
100
19
68
144
212
128
15
10
9
1
0
99
17
41
10
3
4
8
0
31
28
33
0
0
0
11
8
2
4
1
1
2
23
100
100
100
100
100
88
45
100
68
100
100
100
88
0
0
0
0
0
23
39
33
39
43
85
63
77
77
21
107
231
206
475
150
692
247
292
0
0
5
7
2
2
7
10
3
2
2
0
4
3
0
0
0
0
0
0
0
0
0
14
6
1
2
2
4
3
100
57
100
0
100
100
0
0
100
100
100
100
0
5
4
100
100
100
100
0
7
26
20
29
10
54
100
100
0
0
0
2
0
38
88
68
85
85
10
43
162
0
12
8
5
13
83
4
3
9
0
YEAR
KNOWN HIV STATUS
20052011
0
0
24
24
38
0
0
207
YEAR
TOTAL
CONFIRMED
CASES OF
a
MDR-TB
Afghanistan
Bahrain
Djibouti
Egypt
Iran (Islamic
Republic of)
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
Morocco
Oman
Pakistan
Qatar
Saudi Arabia
Somalia
South Sudan
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
West Bank
and Gaza Strip
Yemen
a
b
208
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
19
19
4
0
0
9
39
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
58
43
72
110
84
19
8
10
4
6
9
5
0
3
4
7
3
8
1
180
54
45
5
5
1
4
49
444
344
2
3
4
4
14
22
57
20
6
45
94
62
62
7
14
25
24
21
12
12
4
0
1
0
0
0
1
13
4
BACT+VEb
TESTED FOR
MDR-TB
BACT+VE
TESTED FOR
MDR-TB
1.8
2.0
15
70
99
0
0.95
0.70
4.5
4.7
13
0
0
97
87
63
30
280
100
100
100
37
7.8
2.1
9.6
0.47
1.4
0.38
0.50
95
74
59
100
<0.1
<0.1
190
100
100
1.6
9.3
4.4
1.2
0.29
0
1.7
12
32
0.55
0.19
2.9
0
0
0
1.1
1.5
700 (212 300)
7.9 (3.715)
7.9 (3.715)
79 (40120)
34 (9.559)
204
134
27
% OF
238
1 100 (02 600)
2
42
162
154
0
60
400 (310500)
190 (110270)
810 (640980)
370 (260520)
39
205
271
717
0
0
410 (0860)
190 (5.5620)
17 (5.928)
12 (4.324)
0 (047)
0 (047)
4.0 (08.2)
3.0 (0.3711)
49 (0120)
35 (1.0120)
98
95
74
55
516
427
437
282
48
14
4
18
4
180
350 (230480)
67 (22160)
3.9 (0.117.6)
3.9 (1.19.8)
47
61
125
248
185
219
5
9
10 000 (026 000)
7 100 (21023 000)

264
322
324
9
3.9 (1.19.9)
3.9 (1.19.9)
71 (5389)
48 (3763)
760 (600920)
200 (100300)
470 (240700)
97 (27170)
590 (300880)
250 (70430)
120 (86160)
88 (55130)
63
408
61 (0160)
46 (1.3150)
380
6
2
1.7 (1.12.3)
1.3 (0.731.8)
0.54 (<0.11.8)
0
0
0
488
261
125
1.4 (<0.12.8)
36
0
42
89
140 (93180)
95 (28170)
NUMBER OF
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
380 (34730)
0 (00)
44 (1573)
220 (160270)
430 (310560)
220 (20430)
5.1 (0.6613)
0 (00)
1.0 (<0.11.0)
14 (1.226)
290 (180420)
0 (02.1)
3 300 (3006 300)
23 (1830)
290 (170420)
100 (35170)
340 (120550)
36 (2450)
15 (1.328)
0.37 (0.300.44)
0.87 (<0.11.7)
44 (2465)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
34
2.6
0
0
775
100
497
74
41
9.6
169
22
322
36
163
22
185
24
224
29
33
330
7
35
7
39
6
33
1
100
1
100
0
0
0
4
100
10
100
14
120
1
100
403
24
229
9.8
11
280
7
100
8
89
3
100
60
0.65
306
2.8
79
11
14
2.0
8
1.5
4
0.22
207
10
82
4.7
0
0
14
8.0
12
5.6
70
61
6
17
10
20
0
0
0
0
0
0
0
30
9.6
34
7.8
Afghanistan
Bahrain
Djibouti
Egypt
Iran (Islamic
Republic of)
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
Morocco
Oman
Pakistan
Qatar
Saudi Arabia
Somalia
South Sudan
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
West Bank
and Gaza Strip
Yemen
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
FEMALE
014
1524
2534
3544
4554
5564
65+
52
151
197
204
0
0
0
0
1
228
606
986
1 010
0
0
0
10
5
183
560
819
895
1
3
0
16
19
149
472
491
613
2
2
2
11
13
129
453
490
570
3
5
3
12
14
94
470
641
700
1
3
0
4
8
80
419
622
692
3
4
4
4
2
17
18
28
35
223
21
25
9
23
118
29
16
18
13
1 125
21
13
42
35
0
0
0
2
0
0
0
0
1
0
3
5
0
1
1
2
5
2
302
220
211
212
542
641
524
358
382
751
438
352
292
289
862
627
424
370
304
19
8
8
5
9
15
10
12
16
13
26
16
12
8
14
112
101
114
347
252
243
265
665
827
606
617
611
754
467
531
487
543
1 409
317
644
482
395
37
16
17
14
10
51
44
45
67
41
32
28
19
21
18
212
239
293
139
119
151
149
460
667
421
783
596
636
387
338
354
398
1 085
297
261
384
313
17
13
9
10
13
32
32
29
50
36
30
20
15
15
13
78
86
168
67
62
67
97
408
476
414
725
715
494
295
281
296
315
863
205
245
276
237
20
9
4
12
8
17
21
26
48
35
16
15
10
12
15
46
36
52
60
47
49
45
463
307
243
407
387
737
344
260
310
351
900
135
189
286
223
26
14
6
12
13
9
11
8
10
11
16
17
12
12
6
22
29
19
42
29
20
33
160
158
123
217
168
921
642
630
760
877
271
101
148
228
183
11
2
5
6
5
0
5
3
11
5
10
14
8
10
8
21
32
35
5
142
99
79
51
79
1
1
1
2
1
29
55
621
1 548
1 216
0
0
0
0
85
2 508
2 061
2 222
1 982
1 929
7
8
21
12
17
274
498
5 278
11 860
12 143
8
7
19
59
36
173
2 872
2 423
2 515
2 553
2 450
12
9
11
27
25
230
387
4 759
10 462
10 515
12
19
15
72
64
148
1 737
1 705
1 583
1 611
1 479
7
11
24
15
12
178
256
4 263
8 320
8 435
11
9
17
38
36
54
819
855
1 057
1 273
1 175
7
12
15
16
23
140
232
3 834
7 969
8 608
13
7
19
22
14
18
573
485
580
712
682
10
9
19
8
10
124
153
3 332
6 934
7 320
4
2
5
5
10
21
553
595
591
515
518
11
11
5
10
11
95
130
2 453
6 066
6 323
4
1
1
0
3
0
8
14
4
46
113
125
109
113
39
250
785
425
209
107
13
8
9
7
8
131
182
335
227
334
740
1 343
1 036
1 147
251
604
1 028
1 358
1 185
899
332
359
266
170
139
268
276
458
406
730
724
1 114
886
1 047
599
796
1 511
1 990
1 781
1 359
255
289
237
212
195
213
201
242
225
201
408
725
496
587
402
634
1 351
1 541
1 335
981
111
125
111
101
116
158
175
210
225
127
254
458
355
398
259
486
1 119
1 151
863
689
70
86
112
80
81
86
70
116
113
278
195
330
266
330
135
362
638
724
497
386
59
76
62
65
49
107
107
102
106
109
142
319
277
277
57
337
677
493
391
372
50
55
63
49
45
16
5
9
6
139
103
115
110
208
172
194
194
156
133
170
118
109
115
125
126
65
53
93
108
101
81
88
63
12
10
1
0
1
7
3
2
13
7
0
7
3
0
3
5
1
4
1
0
4
3
3
0
1
57
110
48
68
33
1
2
0
400
789
493
507
406
0
1
605
689
553
569
471
2
1
256
493
366
322
297
1
1
1
201
314
242
231
193
3
1
0
148
255
149
164
143
3
3
45
127
78
138
96
UNKNOWN
UNKNOWN
014
1524
2534
3544
4554
5564
65+
93
320
445
465
0
0
1
0
0
414
1 651
2 107
2 167
1
1
1
8
9
565
1 959
2 263
2 325
1
2
0
15
5
339
1 302
1 455
1 564
2
0
3
7
6
205
869
1 112
1 146
0
1
1
1
6
99
471
831
903
1
1
0
1
0
36
246
488
535
1
1
0
1
1
12
23
20
31
134
55
48
8
7
234
77
45
54
37
725
37
44
73
66
1
0
1
3
0
0
1
0
4
0
1
4
1
0
0
5
6
8
147
123
104
139
288
457
431
199
192
1 039
593
394
433
473
304
338
305
394
368
15
8
6
14
8
8
11
13
41
23
16
31
25
36
37
34
43
36
156
117
120
118
367
343
298
352
355
890
410
205
288
313
1 208
241
260
294
258
4
9
6
24
11
24
24
31
78
30
18
26
14
48
51
31
35
36
47
66
89
104
274
257
205
423
387
664
322
186
208
184
915
136
151
198
164
10
1
6
4
8
9
12
11
30
15
13
9
8
17
12
19
24
35
31
23
36
57
256
211
218
292
280
613
320
260
276
296
800
134
197
205
159
14
2
5
3
4
4
5
3
10
9
8
7
3
7
9
20
24
21
17
13
24
30
160
112
132
192
198
685
407
382
398
441
886
103
135
220
201
12
2
8
5
8
4
3
1
11
2
5
4
3
4
1
13
16
21
10
8
19
21
75
48
42
97
94
788
647
701
1 014
1 009
200
87
80
166
153
7
5
5
3
6
2
1
5
8
2
3
6
1
3
3
11
22
20
8
191
170
167
117
100
2
2
2
3
5
85
130
1 447
3 212
2 679
1
0
0
0
59
1 708
1 530
1 330
1 098
1 153
18
17
13
18
20
375
591
6 463
14 481
14 652
2
0
5
7
9
47
1 288
1 121
943
841
794
13
5
5
22
21
381
416
5 611
10 513
10 684
3
4
10
16
15
37
703
672
546
426
433
5
7
3
6
9
267
274
3 987
7 749
7 880
1
3
2
2
6
22
461
398
403
386
371
5
5
4
4
13
178
163
2 866
6 410
6 590
0
1
1
1
1
25
317
406
343
310
324
6
11
5
4
7
143
103
2 060
4 879
4 977
0
0
2
1
2
29
299
352
398
364
335
3
6
3
5
6
79
56
1 338
4 338
3 711
1
0
0
0
1
0
0
28
31
33
35
38
85
169
91
114
60
359
817
381
195
113
22
23
27
16
20
172
205
239
200
158
354
752
467
495
181
490
925
1 102
761
512
158
195
182
164
113
182
184
271
245
139
319
636
444
465
318
613
1 134
1 203
979
620
97
101
108
105
97
79
98
105
110
97
219
436
341
348
239
299
905
978
772
513
53
53
59
47
56
51
73
70
64
40
110
292
188
260
172
403
771
729
520
352
44
46
59
41
35
50
51
49
49
25
72
212
137
168
59
342
327
411
279
188
37
38
32
38
36
70
61
58
46
16
41
157
132
135
26
305
323
244
191
175
20
28
23
27
37
7
7
4
10
68
66
64
60
59
61
64
60
43
39
39
50
21
36
34
44
21
16
40
35
58
28
52
47
16
0
0
1
4
0
2
6
1
4
6
0
1
3
0
5
2
1
1
1
0
3
2
0
0
0
0
0
0
0
83
161
44
98
85
0
0
420
799
426
471
446
1
1
1
720
627
410
409
375
0
1
348
517
265
264
251
1
1
0
200
345
181
174
168
2
2
106
247
85
106
113
0
0
92
92
39
63
58
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
MALE:FEMALE
RATIO
0.52
0.46
0.49
0.51
1.7
2.8
1.5
1.7
2.3
2.3
2.0
1.9
1.7
1.9
2.1
1.7
2.0
1.9
0.90
0.94
1.1
0.94
1.0
1.3
1.6
1.6
1.3
1.2
2.1
2.3
1.3
1.1
1.3
2.4
2.2
1.9
1.1
1.7
2.1
1.3
1.4
0.69
0.66
3.7
3.1
3.9
2.2
1.9
1.8
2.1
2.5
2.4
1.1
1.2
2.7
1.5
1.2
0.71
0.99
1.0
1.0
1.1
6.5
5.6
3.8
7.3
4.8
1.5
1.4
1.8
1.7
3.6
2.1
1.7
1.9
2.0
1.7
1.2
1.4
1.5
1.7
1.9
2.1
2.1
1.8
1.6
1.6
2.9
2.6
2.7
2.4
1.6
2.3
0.92
3.5
2.5
2.2
1.8
0.87
1.0
1.3
1.3
1.1
MALE
YEAR
209
LABORATORIES
FREE THROUGH NTP
SECONDNUMBER OF
CULTURE
DST b LABS
LPAc LABS
LINE DST
LABS USING
PER 100K
PER 5M
PER 5M
POPULATION
LEDa
Afghanistan
1.9
0.5
Bahrain
1.4
7.6
3.8
3.8
Djibouti
Egypt
Iran (Islamic Republic of)
1.8
0.3
0.5
0
0
0
0
1.1
3.7
0
<0.1
0.4
0
0
0
0
0
0
Iraq
0.8
0.6
0.2
Jordan
Kuwait
2.4
0.4
0
0
39.5
1.8
0.8
1.8
0
0
0
0
Out of
country
Out of
country
No
In country
In country
NRLd
TB DIAGNOSIS
FIRSTLINE
DRUGS
yes
Yes (all suspects)
yes
yes
Yes (all suspects)
yes
Yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
Yes (if TB is
confirmed)
Yes (all suspects)
Yes (all suspects)
Yes (all suspects)
Yes (all suspects)
Yes (if TB is
confirmed)
Yes (all suspects)
yes
yes
yes
Yes
Yes
Yes
yes
Yes
yes
yes
Yes
Yes
yes
yes
Lebanon
3.9
3.5
1.2
2.3
Libya
Morocco
0.5
2.2
0.3
Oman
7.3
15.8
1.8
1.8
In country
yes
Pakistan
0.7
0.3
0.3
<0.1
16
In country
In and out
of country
No
No
Out of
country
yes
<0.1
2.7
2.7
2.7
Saudi Arabia
Somalia
Qatar
0.3
0.7
1
0
2.1
0
2.1
0
0.4
0
1
0
South Sudan
0.6
Sudan
Syrian Arab Republic
Tunisia
0.7
2.7
0.7
0.1
1.0
5.2
0.1
0.2
2.4
0
0.2
0
1.2
United Arab Emirates
West Bank and

Gaza Strip
1.5
Yemen
1.1
yes
yes
yes
0
No
In country
In and out
of country
No
yes
yes
yes
yes
No
No
Out of
country
TB NOTIF.
RIFAMPICIN
RATE PER
USED
100 000
THROUGHOUT
HEALTH-CARE
TREATMENT
WORKERS
0
8
yes
Yes
yes
yes
Yes
Yes
yes
Yes
33
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
No
Yes (all suspects)

Yes (all suspects)
yes
yes
Yes
Yes
No
Yes (all suspects)
yes
Yes
yes
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
yes
yes
yes
Yes
Yes
Yes
No
Yes (all suspects)
yes
Yes
No
yes
Yes (all suspects)
yes
Yes
No
yes
Yes (if TB is
confirmed)
yes
Yes
204

d
b
c
210
EUROPEAN REGION
213
217
221
225
228
231
233
235
238

details.
Data source
Country notes
EU/EEA countries
Notication and treatment outcome data for European Union and European Economic Area countries are provisional.
Denmark
Data for Denmark exclude Greenland.
Russian Federation
Reported number of TB patients with known HIV status in Table A4.6 is for new TB patients only in 2010 and 2011. It
was not possible to calculate the % of all TB patients with known HIV status.
212
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and
Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
3
3
3
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
4
3
3
3
3
3
3
8
8
8
8
8
8
8
7
8
8
9
9
9
9
10
10
10
10
10
10
10
10
10
10
10
11
11
11
4
3
4
4
4
4
4
9
8
8
8
8
7
7
5
5
5
4
4
4
4
<1
<1
<1
1
1
1
1
10
10
10
10
10
10
11
5
5
5
5
6
6
6
2
1
1
1
1
1
1
5
5
5
5
5
5
5
57
58
59
61
62
63
63
NUMBER
(THOUSANDS)
0.054
0.039
0.026
0.016
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.15
0.18
0.21
0.25
0.27
0.27
0.27
0.15
0.094
0.075
0.046
0.036
0.034
0.033
0.7
1.6
1.8
0.92
0.45
0.38
0.34
0.48
0.68
0.92
1.1
0.92
0.86
0.79
0.12
0.12
0.074
0.047
0.03
0.027
0.023
0.3
0.24
0.25
0.26
0.26
0.26
0.25
0.21
0.38
0.34
0.3
0.23
0.21
0.19
0.39
0.27
0.19
0.14
0.1
0.095
0.088
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.19
0.12
0.11
0.068
0.046
0.041
0.036
0.055
0.034
0.025
0.022
0.016
0.015
0.014
0.059
0.13
0.12
0.071
0.045
0.04
0.036
0.12
0.086
0.064
0.033
0.02
0.018
0.017
0.97
0.82
0.65
0.43
0.33
0.31
0.29
(0.0380.073)
(0.0310.048)
(0.0180.035)
(0.0120.022)
(<0.010.013)
(<0.010.011)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0<0.01)
(0<0.01)
(0<0.01)
(0.1100.200)
(0.1500.220)
(0.1800.230)
(0.2100.310)
(0.2000.360)
(0.2200.330)
(0.2200.330)
(0.1500.150)
(0.0940.094)
(0.0750.076)
(0.0460.046)
(0.0360.037)
(0.0340.035)
(0.0330.033)
(0.5200.910)
(1.22.0)
(1.42.2)
(0.6601.2)
(0.3200.590)
(0.2800.510)
(0.2400.440)
(0.4500.510)
(0.6200.740)
(0.8700.970)
(0.9901.1)
(0.8600.980)
(0.8100.920)
(0.7400.840)
(0.1200.130)
(0.1100.120)
(0.0720.077)
(0.0460.047)
(0.0300.031)
(0.0260.028)
(0.0230.024)
(0.2900.310)
(0.2200.250)
(0.2400.260)
(0.2500.270)
(0.2400.270)
(0.2400.270)
(0.2400.270)
(0.2100.220)
(0.3700.390)
(0.3300.350)
(0.3000.300)
(0.2200.230)
(0.2000.210)
(0.1900.190)
(0.3800.400)
(0.2500.280)
(0.1800.200)
(0.1300.140)
(0.1000.100)
(0.0930.096)
(0.0850.091)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.1900.190)
(0.1200.120)
(0.1100.110)
(0.0670.068)
(0.0450.046)
(0.0410.041)
(0.0360.036)
(0.0530.056)
(0.0330.035)
(0.0240.025)
(0.0210.022)
(0.0160.017)
(0.0140.016)
(0.0130.014)
(0.0580.060)
(0.1300.140)
(0.1200.120)
(0.0700.072)
(0.0450.046)
(0.0390.041)
(0.0350.037)
(0.1200.120)
(0.0860.086)
(0.0640.065)
(0.0330.033)
(0.0200.020)
(0.0180.018)
(0.0170.017)
(0.9401.0)
(0.7900.840)
(0.6300.670)
(0.4200.450)
(0.3100.340)
(0.2900.320)
(0.2800.300)
RATEa
1.6
1.3
0.83
0.52
0.3
0.26
0.21
2.5
1.6
0.83
0.6
0.41
0.35
0.29
4.3
5.6
6.7
8.3
8.8
8.8
8.8
1.9
1.2
0.94
0.56
0.43
0.41
0.39
9.7
20
22
11
4.9
4.2
3.6
4.6
6.6
9.1
11
9.5
9
8.3
1.2
1.1
0.73
0.45
0.29
0.25
0.22
6.9
7.1
6.7
6.9
6.8
6.8
6.8
2.4
4.6
4.2
3.9
3
2.8
2.5
8.6
5.7
4.2
3
2.3
2.1
2
0.21
0.21
0.15
0.2
0.15
0.13
0.11
1.9
1.1
1
0.66
0.44
0.39
0.34
1.1
0.65
0.46
0.4
0.3
0.27
0.25
3.8
9.3
8.8
5.3
3.4
3
2.7
2.5
1.7
1.2
0.64
0.38
0.34
0.31
1.7
1.4
1.1
0.71
0.52
0.49
0.45
(1.22.2)
(1.01.5)
(0.571.1)
(0.370.71)
(0.210.41)
(0.180.35)
(0.150.29)
(<0.19.8)
(<0.16.5)
(<0.13.3)
(<0.12.4)
(<0.11.6)
(01.4)
(01.1)
(3.15.7)
(4.66.7)
(6.07.5)
(6.710)
(6.412)
(7.211)
(7.211)
(1.92.0)
(1.21.2)
(0.930.95)
(0.560.56)
(0.430.44)
(0.410.42)
(0.390.39)
(7.213)
(1526)
(1727)
(7.714)
(3.66.5)
(3.05.5)
(2.64.8)
(4.44.9)
(6.07.2)
(8.79.6)
(1011)
(9.010)
(8.49.5)
(7.88.8)
(1.21.3)
(1.11.2)
(0.710.75)
(0.440.45)
(0.280.29)
(0.240.26)
(0.210.22)
(6.67.2)
(6.77.4)
(6.47.1)
(6.57.2)
(6.57.2)
(6.57.2)
(6.47.2)
(2.32.5)
(4.54.7)
(4.14.3)
(3.83.9)
(3.03.1)
(2.72.8)
(2.52.6)
(8.38.8)
(5.46.0)
(4.04.4)
(3.03.1)
(2.32.3)
(2.12.2)
(1.92.1)
(0.170.26)
(0.170.25)
(<0.10.25)
(0.180.23)
(0.130.16)
(0.100.16)
(<0.10.13)
(1.91.9)
(1.11.1)
(1.01.0)
(0.660.67)
(0.440.44)
(0.390.39)
(0.340.35)
(1.01.1)
(0.630.68)
(0.450.47)
(0.390.41)
(0.280.31)
(0.260.28)
(0.240.26)
(3.73.8)
(9.19.6)
(8.69.0)
(5.25.4)
(3.33.4)
(2.93.1)
(2.62.7)
(2.42.5)
(1.71.7)
(1.21.2)
(0.630.64)
(0.380.38)
(0.340.34)
(0.310.31)
(1.71.8)
(1.41.5)
(1.11.1)
(0.680.73)
(0.500.54)
(0.470.50)
(0.440.47)

NUMBER
(THOUSANDS)
1.1
0.94
0.85
0.77
0.57
0.52
0.46
0.034
0.027
0.014
0.012
<0.01
<0.01
<0.01
0.89
1.8
2.7
3.4
3.1
2.8
2.4
2.1
2
1.7
1.3
0.74
0.57
0.39
51
120
130
63
26
20
16
5.2
10
12
10
9.7
9.6
9.6
2.3
2
1.7
1.5
1.2
1.2
1.1
5.8
4.3
2.8
2.2
2.3
2.4
2.5
4
7.9
6.6
5.9
4.1
3.7
3.3
3.5
3.2
2.5
1.6
1.2
1.1
0.97
0.051
0.057
0.053
0.05
0.056
0.056
0.057
2.9
2.8
2.1
1.4
1
0.91
0.81
0.45
0.72
0.76
0.52
0.45
0.45
0.45
0.5
0.98
1.1
0.7
0.48
0.44
0.38
1.1
0.91
0.77
0.5
0.49
0.51
0.48
15
13
9.6
8.2
5.4
4.5
3.5
(0.3902.3)
(0.3201.9)
(0.2901.7)
(0.3001.5)
(0.1901.1)
(0.1601.1)
(0.1301.0)
(0.0130.064)
(0.0110.052)
(<0.010.026)
(<0.010.023)
(<0.010.017)
(<0.010.015)
(<0.010.012)
(0.3401.7)
(0.8303.2)
(1.34.7)
(1.65.9)
(1.45.4)
(1.34.9)
(1.14.3)
(0.8304.0)
(0.7803.7)
(0.6503.1)
(0.5002.4)
(0.3001.4)
(0.2301.1)
(0.1600.720)
(2391)
(51210)
(57230)
(29110)
(1243)
(9.835)
(7.728)
(2.19.5)
(4.618)
(5.422)
(4.119)
(4.118)
(4.117)
(4.217)
(0.8904.2)
(0.7803.7)
(0.6903.2)
(0.6002.8)
(0.4902.3)
(0.4602.2)
(0.4302.0)
(1.613)
(1.97.6)
(0.8406.0)
(0.5505.0)
(0.8404.6)
(0.9204.6)
(1.04.5)
(1.77.2)
(3.813)
(3.012)
(2.710)
(1.77.6)
(1.57.0)
(1.36.3)
(1.46.6)
(1.36.1)
(0.9604.6)
(0.6403.1)
(0.4602.2)
(0.4202.0)
(0.3801.8)
(0.0200.096)
(0.0220.110)
(0.0210.100)
(0.0190.094)
(0.0220.100)
(0.0220.110)
(0.0220.110)
(1.15.4)
(1.15.4)
(0.8404.1)
(0.5502.6)
(0.3901.9)
(0.3601.7)
(0.3201.5)
(0.1800.850)
(0.2801.4)
(0.3001.4)
(0.2100.980)
(0.1800.850)
(0.1800.840)
(0.1800.850)
(0.1900.940)
(0.3801.8)
(0.4202.0)
(0.2801.3)
(0.1900.890)
(0.1800.810)
(0.1600.710)
(0.4402.1)
(0.3601.7)
(0.3001.5)
(0.2000.940)
(0.1900.920)
(0.2000.960)
(0.1700.950)
(7.026)
(6.223)
(4.517)
(3.814)
(2.59.4)
(2.17.8)
(1.76.1)
RATEa
35
30
28
25
18
16
14
64
42
22
16
11
9.2
7.5
25
57
89
112
99
91
78
28
25
21
15
8.9
6.8
4.6
711
1 530
1 610
738
282
222
177
50
100
123
104
100
100
100
23
20
17
14
12
11
10
136
128
76
58
62
64
66
45
94
83
77
55
50
45
77
69
54
37
27
24
22
6.7
6.6
5.7
4.8
5.1
5.1
5.1
28
27
21
14
9.6
8.7
7.7
8.8
14
14
9.6
8.2
8.1
8.1
32
68
78
52
36
33
29
22
18
15
9.5
9.2
9.5
9
26
23
16
13
8.7
7.2
5.6
(1269)
(1060)
(9.555)
(9.646)
(5.936)
(5.134)
(4.031)
(25121)
(1780)
(8.541)
(6.230)
(4.220)
(3.617)
(3.014)
(9.548)
(26101)
(42153)
(53192)
(46174)
(41159)
(35139)
(1152)
(9.947)
(8.139)
(6.129)
(3.517)
(2.713)
(1.88.6)
(3161 260)
(6622 750)
(7002 880)
(3341 300)
(136478)
(107378)
(83306)
(2192)
(45176)
(54218)
(42194)
(42183)
(43181)
(44179)
(8.943)
(7.737)
(6.832)
(5.827)
(4.622)
(4.320)
(4.019)
(36300)
(57227)
(23162)
(15131)
(22122)
(24122)
(27121)
(1981)
(45162)
(38146)
(35135)
(23101)
(2093)
(1785)
(30146)
(27131)
(21103)
(1469)
(1050)
(9.546)
(8.642)
(2.613)
(2.613)
(2.211)
(1.99.1)
(2.09.6)
(2.09.6)
(2.09.6)
(1153)
(1152)
(8.240)
(5.326)
(3.818)
(3.416)
(3.015)
(3.517)
(5.426)
(5.627)
(3.818)
(3.215)
(3.215)
(3.215)
(1260)
(26128)
(31147)
(2197)
(1466)
(1361)
(1253)
(8.842)
(7.134)
(5.828)
(3.718)
(3.617)
(3.718)
(3.218)
(1245)
(1140)
(7.628)
(6.323)
(4.115)
(3.412)
(2.69.7)

NUMBER
(THOUSANDS)
0.8
0.77
0.7
0.59
0.47
0.45
0.42
0.026
0.021
0.011
<0.01
<0.01
<0.01
<0.01
0.61
1.3
1.9
2.4
2.1
1.9
1.7
1.7
1.6
1.3
1
0.6
0.46
0.31
22
49
55
29
14
12
11
3.5
7
8.4
7.1
6.8
6.7
6.7
1.8
1.6
1.4
1.2
0.98
0.93
0.87
4
2.8
2.3
2
1.9
1.9
1.8
2.9
5.2
4.6
4.1
3.1
2.9
2.6
2.7
2.5
1.9
1.3
0.92
0.84
0.76
0.04
0.044
0.042
0.039
0.043
0.044
0.044
2.2
2.2
1.7
1.1
0.78
0.71
0.64
0.36
0.57
0.6
0.42
0.36
0.36
0.36
0.39
0.76
0.85
0.57
0.4
0.37
0.33
0.87
0.72
0.6
0.39
0.38
0.4
0.4
11
10
7.4
6.3
4.2
3.5
2.7
(0.5801.1)
(0.6400.900)
(0.5900.810)
(0.5000.680)
(0.4000.540)
(0.3800.520)
(0.3600.490)
(0.0230.030)
(0.0190.024)
(<0.010.012)
(<0.010.011)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.4500.790)
(1.11.5)
(1.72.1)
(2.12.7)
(1.82.4)
(1.62.2)
(1.42.0)
(1.51.9)
(1.41.8)
(1.11.5)
(0.8801.1)
(0.5200.670)
(0.4000.520)
(0.2700.350)
(1826)
(4159)
(4666)
(2434)
(1217)
(9.914)
(8.713)
(2.84.3)
(5.98.2)
(7.010)
(5.48.9)
(5.38.4)
(5.48.2)
(5.58.1)
(1.52.0)
(1.41.8)
(1.21.6)
(1.11.4)
(0.8601.1)
(0.8101.1)
(0.7600.990)
(2.55.9)
(2.33.4)
(1.92.8)
(1.62.4)
(1.62.2)
(1.62.1)
(1.62.1)
(2.53.3)
(4.55.9)
(4.05.3)
(3.64.7)
(2.73.5)
(2.53.3)
(2.33.0)
(2.43.1)
(2.22.9)
(1.72.2)
(1.11.4)
(0.8101.0)
(0.7300.950)
(0.6600.860)
(0.0350.045)
(0.0390.050)
(0.0360.047)
(0.0340.044)
(0.0380.049)
(0.0380.050)
(0.0390.050)
(2.02.5)
(1.92.5)
(1.51.9)
(0.9601.2)
(0.6900.890)
(0.6200.800)
(0.5600.720)
(0.3100.400)
(0.5000.640)
(0.5300.680)
(0.3600.470)
(0.3200.410)
(0.3200.410)
(0.3200.410)
(0.3400.440)
(0.6700.860)
(0.7500.970)
(0.5000.650)
(0.3500.450)
(0.3200.410)
(0.2900.380)
(0.7600.980)
(0.6300.810)
(0.5300.680)
(0.3400.440)
(0.3400.440)
(0.3500.450)
(0.3500.450)
(1112)
(9.511)
(6.97.8)
(5.96.7)
(3.94.5)
(3.33.7)
(2.52.9)
RATEa
24
24
23
19
15
14
13
50
33
17
12
8.4
7.2
5.9
17
39
61
77
69
62
55
22
20
16
12
7.1
5.5
3.7
305
636
682
334
154
131
113
34
68
84
72
70
70
70
18
16
14
12
9.2
8.7
8.1
94
84
63
52
50
50
49
33
62
58
53
41
38
35
60
54
43
29
21
19
17
5.2
5.1
4.4
3.7
4
4
4
22
21
16
11
7.5
6.8
6
6.9
11
11
7.7
6.5
6.5
6.5
25
53
62
42
30
27
25
17
14
12
7.4
7.2
7.5
7.5
20
17
12
10
6.7
5.5
4.3
(1832)
(2029)
(1926)
(1622)
(1217)
(1216)
(1115)
(4457)
(2937)
(1519)
(1114)
(7.39.5)
(6.38.1)
(5.16.6)
(1322)
(3346)
(5469)
(6887)
(5979)
(5373)
(4565)
(1924)
(1722)
(1418)
(1114)
(6.28.0)
(4.86.2)
(3.24.2)
(252363)
(525758)
(563812)
(276398)
(127183)
(108155)
(93134)
(2742)
(5879)
(69100)
(5591)
(5587)
(5686)
(5784)
(1620)
(1418)
(1215)
(1013)
(8.110)
(7.69.8)
(7.19.2)
(58138)
(69101)
(5175)
(4363)
(4358)
(4357)
(4256)
(2937)
(5471)
(5066)
(4661)
(3647)
(3343)
(3040)
(5368)
(4761)
(3748)
(2532)
(1824)
(1722)
(1520)
(4.65.9)
(4.55.8)
(3.95.0)
(3.34.2)
(3.54.5)
(3.54.5)
(3.54.5)
(1925)
(1924)
(1419)
(9.412)
(6.68.5)
(5.97.6)
(5.36.8)
(6.17.8)
(9.512)
(9.913)
(6.78.7)
(5.77.4)
(5.77.3)
(5.77.4)
(2228)
(4660)
(5570)
(3748)
(2634)
(2431)
(2228)
(1520)
(1216)
(1013)
(6.58.4)
(6.38.1)
(6.58.4)
(6.58.4)
(1921)
(1619)
(1213)
(9.711)
(6.37.1)
(5.25.9)
(4.04.6)
EUROPEAN REGION

YEAR
213
YEAR
Georgia
Germany
Greece
Greenland
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Monaco
214
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
5
5
5
4
4
4
4
79
82
82
83
82
82
82
10
11
11
11
11
11
11
<1
<1
<1
<1
<1
<1
<1
10
10
10
10
10
10
10
<1
<1
<1
<1
<1
<1
<1
4
4
4
4
4
4
5
4
5
6
7
7
7
8
57
57
57
59
60
61
61
17
16
15
15
16
16
16
4
5
5
5
5
5
5
3
2
2
2
2
2
2
4
4
4
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
0.46
0.4
0.36
0.23
0.17
0.17
0.16
1
0.71
0.47
0.34
0.3
0.29
0.28
0.2
0.14
0.097
0.092
0.092
0.092
0.091
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.55
0.56
0.37
0.19
0.11
0.092
0.081
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.051
0.042
0.032
0.022
0.021
0.02
0.02
0.023
0.047
0.031
0.019
0.016
0.015
0.015
0.57
0.62
0.49
0.37
0.34
0.34
0.35
1.4
5.4
5.6
3.8
2.8
2.5
2.2
0.39
0.75
1.2
1
0.77
0.72
0.67
0.15
0.31
0.29
0.17
0.11
0.1
0.093
0.25
0.43
0.37
0.34
0.31
0.29
0.28
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(0.4000.510)
(0.3500.450)
(0.3200.410)
(0.1900.270)
(0.1500.200)
(0.1400.190)
(0.1400.190)
(0.9901.0)
(0.7100.720)
(0.4600.480)
(0.3400.350)
(0.2900.300)
(0.2800.290)
(0.2800.280)
(0.1900.210)
(0.1300.160)
(0.0930.100)
(0.0880.096)
(0.0890.096)
(0.0870.097)
(0.0860.096)
(<0.010.019)
(<0.010.019)
(<0.010.019)
(<0.010.020)
(<0.010.020)
(<0.010.020)
(<0.010.020)
(0.5500.560)
(0.5500.560)
(0.3700.370)
(0.1900.190)
(0.1100.110)
(0.0920.092)
(0.0810.081)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0510.052)
(0.0420.042)
(0.0320.033)
(0.0220.022)
(0.0200.021)
(0.0200.020)
(0.0200.020)
(0.0230.024)
(0.0460.049)
(0.0310.032)
(0.0180.019)
(0.0150.016)
(0.0150.016)
(0.0140.015)
(0.5500.590)
(0.6000.630)
(0.4700.510)
(0.3600.380)
(0.3400.350)
(0.3400.350)
(0.3400.360)
(1.21.5)
(5.05.9)
(5.06.3)
(3.54.2)
(2.33.4)
(2.03.1)
(2.02.5)
(0.3300.460)
(0.6400.860)
(1.11.3)
(0.9301.1)
(0.6600.890)
(0.6300.820)
(0.5900.760)
(0.1500.150)
(0.3000.320)
(0.2800.290)
(0.1700.180)
(0.1100.120)
(0.0990.100)
(0.0900.095)
(0.2500.250)
(0.4300.430)
(0.3600.370)
(0.3400.340)
(0.3000.320)
(0.2900.300)
(0.2700.280)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0<0.01)
(0<0.01)
(0<0.01)
(0<0.01)
(0<0.01)
(0<0.01)
(0<0.01)
RATEa
8.3
7.8
7.6
5.2
3.9
3.8
3.7
1.3
0.87
0.57
0.42
0.36
0.35
0.34
2
1.3
0.88
0.83
0.82
0.81
0.8
8.7
8.7
8.7
8.7
8.7
8.7
8.7
5.3
5.4
3.6
1.8
1.1
0.92
0.81
0.7
1
0.41
0.32
0.31
0.31
0.31
1.5
1.2
0.85
0.53
0.47
0.46
0.45
0.52
0.89
0.52
0.28
0.22
0.2
0.19
1
1.1
0.87
0.63
0.57
0.57
0.58
8.4
34
38
25
18
16
14
8.9
16
24
20
15
14
12
5.7
12
12
7.5
5
4.5
4.1
6.8
12
10
10
9.3
8.8
8.3
0.33
0.21
0.56
0.43
0.33
0.32
<0.1
0.46
0.27
0.34
0.3
0.32
0.3
0.29
0.13
0.12
<0.1
<0.1
0.11
0.13
0.15
(7.39.4)
(6.88.9)
(6.68.7)
(4.36.1)
(3.34.6)
(3.34.4)
(3.24.3)
(1.21.3)
(0.860.88)
(0.560.58)
(0.410.42)
(0.350.36)
(0.340.35)
(0.340.35)
(1.92.1)
(1.21.5)
(0.840.92)
(0.790.86)
(0.780.85)
(0.760.85)
(0.750.84)
(0.1235)
(0.1235)
(0.1235)
(0.1235)
(0.1235)
(0.1235)
(0.1235)
(5.35.3)
(5.45.5)
(3.63.6)
(1.81.8)
(1.11.1)
(0.920.93)
(0.810.82)
(0.690.71)
(1.01.0)
(0.410.42)
(0.320.32)
(0.310.31)
(0.300.31)
(0.300.31)
(1.41.5)
(1.21.2)
(0.850.86)
(0.530.53)
(0.450.48)
(0.450.46)
(0.450.45)
(0.510.54)
(0.860.92)
(0.510.53)
(0.270.29)
(0.210.22)
(0.200.21)
(0.190.20)
(0.981.0)
(1.11.1)
(0.830.90)
(0.610.64)
(0.560.57)
(0.560.58)
(0.560.59)
(7.59.4)
(3137)
(3342)
(2328)
(1521)
(1319)
(1215)
(7.510)
(1419)
(2227)
(1822)
(1317)
(1215)
(1114)
(5.65.8)
(1213)
(1212)
(7.27.7)
(4.75.3)
(4.44.7)
(4.04.2)
(6.76.8)
(1212)
(1011)
(9.910)
(9.09.5)
(8.78.9)
(8.38.4)
(0.320.34)
(0.200.21)
(0.550.56)
(0.420.44)
(0.330.34)
(0.310.32)
(<0.1<0.1)
(0.450.48)
(0.260.27)
(0.340.34)
(0.300.31)
(0.320.32)
(0.290.32)
(0.280.29)
(00.53)
(00.49)
(00.31)
(00.19)
(00.45)
(00.53)
(00.62)

NUMBER
(THOUSANDS)
37
28
23
14
8.1
7.4
6.9
21
18
13
7.8
5.4
5
4.7
1.2
1.4
1.1
0.83
0.68
0.62
0.55
0.13
0.13
0.13
0.13
0.13
0.13
0.13
5.1
6.3
4.8
2.8
2.2
2.2
2.3
0.025
0.02
0.016
0.013
0.017
0.018
0.02
0.97
0.72
0.57
0.55
0.49
0.46
0.42
0.48
0.63
0.75
0.57
0.5
0.53
0.53
5.7
7.2
6.1
5.4
3.6
2.9
2.1
18
110
96
53
36
31
27
7.2
14
22
17
11
10
9.4
2.8
5.6
4.3
2.3
1.3
1.2
1.1
1.8
3.6
4
3.3
2.8
2.6
2.5
0.065
0.052
0.057
0.049
0.024
0.014
<0.01
0.031
0.03
0.023
0.034
0.045
0.046
0.044
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(1665)
(1346)
(1238)
(7.022)
(3.714)
(3.113)
(2.813)
(8.340)
(7.334)
(5.024)
(3.015)
(2.110)
(2.09.4)
(1.88.8)
(0.4602.2)
(0.5502.6)
(0.4302.1)
(0.3301.6)
(0.2701.3)
(0.2401.2)
(0.2201.0)
(0.0500.240)
(0.0490.240)
(0.0500.240)
(0.0510.250)
(0.0510.250)
(0.0510.250)
(0.0510.250)
(2.09.6)
(2.512)
(1.99.2)
(1.15.3)
(0.8504.1)
(0.8504.1)
(0.8904.3)
(<0.010.047)
(<0.010.037)
(<0.010.030)
(<0.010.027)
(<0.010.032)
(<0.010.034)
(<0.010.037)
(0.3801.8)
(0.2901.4)
(0.2301.1)
(0.2201.0)
(0.2000.920)
(0.1800.860)
(0.1700.790)
(0.1900.910)
(0.2501.2)
(0.3001.4)
(0.2301.1)
(0.2000.940)
(0.2100.990)
(0.2101.0)
(2.311)
(2.914)
(2.411)
(2.110)
(1.56.8)
(1.25.5)
(0.8604.0)
(7.333)
(51190)
(47160)
(2492)
(1566)
(1358)
(1151)
(3.512)
(6.824)
(1137)
(8.330)
(5.021)
(4.419)
(3.917)
(1.44.7)
(2.89.3)
(2.17.3)
(0.9504.1)
(0.5302.5)
(0.4902.3)
(0.4602.1)
(0.6603.6)
(1.36.9)
(1.67.5)
(1.36.2)
(1.15.3)
(1.05.0)
(0.9504.7)
(0.0250.120)
(0.0210.098)
(0.0230.110)
(0.0200.092)
(<0.010.045)
(<0.010.027)
(<0.01<0.01)
(0.0120.059)
(0.0120.056)
(<0.010.042)
(0.0140.063)
(0.0170.087)
(0.0170.089)
(0.0160.085)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
RATEa
675
543
487
304
184
169
159
27
22
15
9.4
6.6
6.1
5.7
12
13
10
7.4
6
5.4
4.8
228
228
227
228
228
228
228
49
61
47
28
22
22
23
9.8
7.3
5.6
4.5
5.4
5.7
6
28
20
15
13
11
10
9.4
11
12
13
8.6
6.9
7.1
7.1
9.9
13
11
9.2
6
4.8
3.5
107
677
641
347
224
195
168
163
305
441
344
218
195
175
107
225
179
98
60
55
50
49
98
114
96
83
79
75
17
13
13
11
4.8
2.8
0.65
8.5
7.7
5.7
8.3
11
11
10
3.5
3.2
2.1
1.2
2.9
3.5
4.1
(3001 200)
(265917)
(246809)
(156500)
(84324)
(72307)
(64298)
(1050)
(8.942)
(6.029)
(3.718)
(2.612)
(2.411)
(2.211)
(4.522)
(5.125)
(3.919)
(2.914)
(2.411)
(2.210)
(1.99.0)
(89430)
(89431)
(89430)
(89430)
(89431)
(89431)
(89431)
(1992)
(24115)
(1990)
(1153)
(8.541)
(8.541)
(8.943)
(3.819)
(2.914)
(2.211)
(1.49.3)
(2.210)
(2.311)
(2.411)
(1152)
(7.938)
(6.028)
(5.325)
(4.421)
(4.119)
(3.718)
(4.220)
(4.722)
(5.023)
(3.416)
(2.813)
(2.813)
(2.813)
(4.019)
(5.124)
(4.320)
(3.617)
(2.411)
(1.99.0)
(1.46.6)
(44197)
(3191 170)
(3171 080)
(157609)
(92414)
(79364)
(66316)
(79277)
(148517)
(214748)
(165587)
(96390)
(83355)
(71324)
(54177)
(114373)
(87304)
(41178)
(23112)
(22102)
(2193)
(1896)
(36190)
(45215)
(37182)
(32159)
(30151)
(29143)
(6.732)
(5.024)
(5.225)
(4.320)
(1.99.1)
(1.15.4)
(0.261.2)
(3.416)
(3.114)
(2.311)
(3.415)
(4.221)
(4.021)
(3.820)
(1.46.6)
(1.36.1)
(0.813.9)
(0.492.4)
(1.15.6)
(1.46.6)
(1.67.7)

NUMBER
(THOUSANDS)
15
13
12
7.8
5.8
5.6
5.4
17
14
10
6.1
4.3
4
3.7
0.93
1.1
0.86
0.65
0.54
0.49
0.43
0.099
0.099
0.1
0.1
0.1
0.1
0.1
4
4.9
3.8
2.2
1.7
1.7
1.8
0.02
0.015
0.013
0.011
0.014
0.015
0.016
0.76
0.57
0.45
0.44
0.39
0.37
0.34
0.38
0.5
0.61
0.46
0.41
0.42
0.44
4.6
5.8
4.9
4.3
2.9
2.4
1.7
13
51
53
36
26
24
21
4
7.7
12
10
8
7.4
6.9
1.5
3.1
2.9
1.7
1.1
1
0.93
1.4
2.8
3.1
2.6
2.2
2.1
1.9
0.051
0.041
0.045
0.039
0.019
0.012
<0.01
0.025
0.024
0.019
0.029
0.038
0.038
0.038
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(1417)
(1215)
(1114)
(7.08.7)
(5.26.4)
(5.06.2)
(4.86.1)
(1519)
(1316)
(8.711)
(5.46.9)
(3.84.8)
(3.54.5)
(3.24.2)
(0.8101.0)
(0.9701.2)
(0.7600.980)
(0.5700.740)
(0.4700.610)
(0.4300.550)
(0.3800.490)
(0.0860.110)
(0.0870.110)
(0.0870.110)
(0.0890.110)
(0.0890.120)
(0.0890.120)
(0.0890.120)
(3.54.5)
(4.35.6)
(3.34.3)
(1.92.5)
(1.51.9)
(1.51.9)
(1.62.0)
(0.0170.022)
(0.0130.017)
(0.0110.014)
(<0.010.012)
(0.0120.015)
(0.0130.017)
(0.0140.018)
(0.6700.860)
(0.5000.640)
(0.4000.510)
(0.3900.500)
(0.3400.440)
(0.3200.420)
(0.3000.380)
(0.3300.430)
(0.4400.570)
(0.5400.690)
(0.4000.520)
(0.3600.470)
(0.3700.480)
(0.3800.490)
(4.05.2)
(5.16.6)
(4.35.6)
(3.84.9)
(2.63.3)
(2.12.7)
(1.52.0)
(1115)
(4359)
(4461)
(3042)
(2231)
(2028)
(1824)
(3.34.8)
(6.49.2)
(1015)
(8.612)
(6.69.5)
(6.18.8)
(5.78.2)
(1.31.7)
(2.83.5)
(2.53.3)
(1.52.0)
(1.01.3)
(0.9001.2)
(0.8201.1)
(1.21.7)
(2.43.3)
(2.83.5)
(2.22.9)
(1.92.5)
(1.82.4)
(1.72.2)
(0.0440.057)
(0.0360.047)
(0.0400.051)
(0.0340.044)
(0.0170.022)
(0.0100.013)
(<0.01<0.01)
(0.0220.028)
(0.0210.027)
(0.0160.021)
(0.0250.032)
(0.0330.043)
(0.0340.044)
(0.0330.043)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
RATEa
280
263
256
175
132
128
125
21
18
12
7.4
5.2
4.8
4.5
9.1
10
7.8
5.9
4.7
4.3
3.8
178
178
178
178
178
178
178
39
48
37
22
17
17
18
7.7
5.7
4.5
3.7
4.3
4.6
4.8
22
16
12
11
8.9
8.2
7.5
8.4
9.4
10
7
5.7
5.7
5.8
8
10
8.6
7.4
4.8
3.9
2.8
79
318
351
235
166
148
129
92
168
249
208
151
139
128
57
126
121
75
50
46
42
39
77
90
75
65
62
59
13
10
10
8.6
3.9
2.3
0.52
6.7
6.3
4.7
7
9.2
9.2
9.1
2.7
2.5
1.6
0.97
2.3
2.7
3.2
(250312)
(234293)
(228285)
(156195)
(118147)
(114142)
(112140)
(1824)
(1520)
(1114)
(6.58.4)
(4.65.9)
(4.25.4)
(3.95.1)
(8.010)
(9.112)
(6.98.9)
(5.16.6)
(4.15.3)
(3.84.9)
(3.34.3)
(156201)
(156201)
(156201)
(156201)
(156201)
(156201)
(156201)
(3444)
(4254)
(3342)
(1925)
(1519)
(1519)
(1620)
(6.78.7)
(5.06.5)
(3.95.1)
(3.34.2)
(3.84.9)
(4.05.2)
(4.25.4)
(1924)
(1418)
(1014)
(9.312)
(7.810)
(7.29.3)
(6.58.4)
(7.49.5)
(8.311)
(8.912)
(6.17.9)
(5.06.4)
(5.06.4)
(5.16.5)
(7.09.1)
(9.012)
(7.69.8)
(6.58.4)
(4.25.5)
(3.44.4)
(2.53.2)
(6692)
(269372)
(297411)
(199275)
(141195)
(125172)
(109151)
(76109)
(138200)
(205296)
(171248)
(125180)
(115166)
(106153)
(5065)
(111142)
(106137)
(6685)
(4457)
(4052)
(3647)
(3246)
(6690)
(79101)
(6586)
(5675)
(5372)
(5168)
(1215)
(8.911)
(9.112)
(7.59.7)
(3.44.4)
(2.02.6)
(0.460.59)
(5.97.6)
(5.57.1)
(4.15.3)
(6.17.9)
(8.010)
(8.110)
(8.010)
(2.43.1)
(2.22.9)
(1.41.8)
(0.851.1)
(2.02.6)
(2.43.1)
(2.83.6)
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of
Moldova
Romania
Russian
Federation
San Marino
Serbia
Serbia &
Montenegro
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2005
2009
2010
2011
1990
1995
2000
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
<1
<1
<1
<1
15
15
16
16
17
17
17
4
4
4
5
5
5
5
38
38
38
38
38
38
38
10
10
10
11
11
11
11
4
4
4
4
4
4
4
23
23
22
22
22
21
21
148
149
147
144
143
143
143
<1
<1
<1
<1
<1
<1
<1
10
10
10
10
10
11
11
5
5
5
5
5
5
5
2
2
2
2
2
2
2
39
39
40
43
46
46
46
9
9
9
9
9
9
9
7
7
7
7
8
8
8
5
6
6
6
7
7
7
NUMBER
(THOUSANDS)
RATEa
<0.01
<0.01
<0.01
<0.01
0.028
0.041
0.039
0.033
0.031
0.033
0.035
0.02
0.014
0.011
<0.01
<0.01
<0.01
<0.01
1.9
1.3
1.1
0.87
0.79
0.79
0.79
0.3
0.38
0.31
0.19
0.14
0.13
0.13
0.24
0.49
0.63
0.69
0.64
0.62
0.6
2
2.5
2.4
1.9
1.5
1.4
1.3
11
23
30
31
26
24
22
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0280.029)
(0.0400.042)
(0.0370.040)
(0.0320.033)
(0.0310.032)
(0.0320.034)
(0.0340.036)
(0.0190.020)
(0.0140.015)
(0.0110.012)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1.82.0)
(1.21.3)
(1.01.1)
(0.8400.910)
(0.7700.820)
(0.7600.820)
(0.7500.820)
(0.2800.320)
(0.3600.400)
(0.2800.330)
(0.1700.200)
(0.1300.150)
(0.1300.140)
(0.1200.140)
(0.2300.260)
(0.4600.530)
(0.5700.690)
(0.6400.730)
(0.6100.660)
(0.6100.630)
(0.5500.640)
(2.02.0)
(2.52.5)
(2.42.4)
(1.91.9)
(1.51.5)
(1.41.4)
(1.31.3)
(1111)
(2224)
(2931)
(3132)
(2527)
(2325)
(2223)
0.55
0.2
0.16
0.21
0.19
0.27
0.24
0.2
0.19
0.2
0.21
0.46
0.33
0.26
0.16
0.13
0.14
0.15
5
3.3
2.8
2.3
2.1
2.1
2.1
3
3.8
3
1.8
1.3
1.2
1.2
5.6
11
15
18
18
17
17
8.6
11
11
8.7
6.9
6.4
6
7.6
15
21
22
18
17
16
(0.490.60)
(0.180.23)
(0.140.19)
(0.180.24)
(0.190.20)
(0.260.27)
(0.240.25)
(0.200.20)
(0.190.19)
(0.190.20)
(0.200.21)
(0.460.47)
(0.320.33)
(0.250.26)
(0.160.16)
(0.130.14)
(0.130.14)
(0.140.15)
(4.95.2)
(3.13.4)
(2.72.9)
(2.22.4)
(2.02.1)
(2.02.1)
(2.02.1)
(2.83.2)
(3.54.0)
(2.83.2)
(1.61.9)
(1.21.4)
(1.21.3)
(1.11.3)
(5.26.0)
(1112)
(1417)
(1719)
(1718)
(1718)
(1618)
(8.68.6)
(1111)
(1111)
(8.78.7)
(6.86.9)
(6.46.5)
(6.06.0)
(7.57.7)
(1516)
(2021)
(2122)
(1719)
(1618)
(1516)
0.29
0.17
0.17
0.16
0.73
0.52
0.37
0.14
0.08
0.053
0.05
0.044
0.043
0.042
0.074
0.038
0.022
0.019
0.021
0.022
0.022
0.89
0.63
0.43
0.33
0.28
0.26
0.25
0.042
0.039
0.026
0.017
0.017
0.017
0.017
0.088
0.047
0.028
0.02
0.017
0.017
0.017
0.3
0.7
1.1
1.1
1.1
1.1
1.1
(0.2500.330)
(0.1500.200)
(0.1500.190)
(0.1400.180)
(0.7000.750)
(0.5000.540)
(0.3500.380)
(0.1400.140)
(0.0790.080)
(0.0530.053)
(0.0500.051)
(0.0430.044)
(0.0430.043)
(0.0420.043)
(0.0730.075)
(0.0380.039)
(0.0220.023)
(0.0190.020)
(0.0210.022)
(0.0220.022)
(0.0220.022)
(0.8800.900)
(0.6200.640)
(0.4200.440)
(0.3200.330)
(0.2700.280)
(0.2600.270)
(0.2500.260)
(0.0410.042)
(0.0390.040)
(0.0260.027)
(0.0170.017)
(0.0160.017)
(0.0160.017)
(0.0170.017)
(0.0870.089)
(0.0460.048)
(0.0270.028)
(0.0190.020)
(0.0170.018)
(0.0170.017)
(0.0160.017)
(0.2100.410)
(0.4900.940)
(0.6301.7)
(0.7801.4)
(0.7201.4)
(0.7401.5)
(0.7601.5)
2.9
1.7
1.7
1.6
7.1
4.8
3.4
2.7
1.5
0.98
0.93
0.8
0.78
0.77
3.8
1.9
1.1
0.97
1.1
1.1
1.1
2.3
1.6
1.1
0.76
0.6
0.57
0.55
0.49
0.45
0.3
0.19
0.18
0.18
0.18
1.3
0.67
0.39
0.26
0.23
0.22
0.22
5.7
12
18
16
15
16
16
(2.53.3)
(1.52.0)
(1.52.0)
(1.41.9)
(6.97.4)
(4.65.0)
(3.33.6)
(2.72.7)
(1.51.5)
(0.970.99)
(0.920.93)
(0.790.81)
(0.780.79)
(0.770.78)
(3.83.9)
(1.92.0)
(1.11.1)
(0.960.99)
(1.01.1)
(1.11.1)
(1.11.1)
(2.32.3)
(1.61.6)
(1.11.1)
(0.750.77)
(0.600.61)
(0.570.58)
(0.540.56)
(0.480.49)
(0.440.45)
(0.290.30)
(0.190.19)
(0.180.18)
(0.170.18)
(0.180.18)
(1.31.3)
(0.660.68)
(0.380.40)
(0.260.27)
(0.220.23)
(0.220.22)
(0.210.22)
(4.07.7)
(8.516)
(1028)
(1221)
(1121)
(1121)
(1122)

NUMBER
(THOUSANDS)
0.2
0.18
0.15
0.12
2
2.3
2
1.7
1.5
1.4
1.4
0.45
0.34
0.35
0.41
0.4
0.39
0.38
24
23
17
12
11
11
11
8.9
7.7
6.2
4.3
3.5
3.3
3
3.5
8.1
10
10
8.6
8.4
8.3
63
75
61
42
33
32
31
120
230
280
300
220
200
180
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
3.9
2.6
2.3
2.4
8.9
9.5
6
2.3
2.3
1.6
1.1
0.69
0.59
0.51
1
0.8
0.57
0.36
0.27
0.25
0.24
12
13
11
9.7
9.2
8.9
8.7
0.83
0.78
0.6
0.65
0.75
0.78
0.81
1.8
1.2
0.9
0.68
0.52
0.49
0.46
6.1
19
29
25
23
23
24
(0.0680.400)
(0.0720.330)
(0.0530.290)
(0.0370.260)
(0.7703.7)
(0.9204.3)
(0.7803.7)
(0.6603.1)
(0.5802.7)
(0.5702.7)
(0.5602.7)
(0.1700.840)
(0.1300.640)
(0.1400.660)
(0.1600.770)
(0.1600.740)
(0.1500.730)
(0.1500.710)
(9.445)
(9.043)
(6.531)
(4.823)
(4.321)
(4.321)
(4.421)
(3.517)
(3.114)
(2.612)
(1.97.8)
(1.46.4)
(1.46.1)
(1.35.6)
(1.56.2)
(3.914)
(5.018)
(4.518)
(3.815)
(3.815)
(3.815)
(30110)
(36130)
(28110)
(1780)
(1363)
(1359)
(1356)
(57200)
(110390)
(130490)
(140510)
(100390)
(88370)
(72330)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1.38.0)
(0.9805.0)
(0.6904.8)
(0.7405.1)
(2.918)
(4.516)
(2.511)
(0.9104.4)
(0.9004.4)
(0.6102.9)
(0.4102.0)
(0.2701.3)
(0.2301.1)
(0.2000.960)
(0.3901.9)
(0.3101.5)
(0.2201.1)
(0.1400.680)
(0.1100.510)
(0.0990.480)
(0.0950.460)
(4.722)
(5.123)
(4.420)
(3.918)
(3.717)
(3.617)
(3.516)
(0.3301.6)
(0.3101.5)
(0.2401.1)
(0.2501.2)
(0.2901.4)
(0.3101.5)
(0.3201.5)
(0.7003.3)
(0.4802.3)
(0.3601.7)
(0.2701.3)
(0.2100.980)
(0.2000.920)
(0.1800.860)
(2.910)
(8.634)
(1451)
(1242)
(1139)
(1140)
(1241)
RATEa
32
28
23
19
13
15
12
10
8.8
8.6
8.5
10
7.8
7.8
8.8
8.2
7.9
7.7
63
60
43
32
29
29
29
90
76
60
41
33
31
29
79
187
252
265
239
236
234
272
330
275
194
155
149
145
79
154
192
207
154
142
124
8.8
7.7
2
2.4
1.9
1.8
1.8
40
26
23
25
87
88
56
44
43
29
19
13
11
9.2
52
41
29
18
13
12
12
30
32
27
22
20
19
19
9.7
8.8
6.8
7.2
8
8.3
8.6
27
17
13
9.2
6.9
6.4
6
115
332
476
382
338
340
350
(1164)
(1152)
(8.445)
(5.841)
(5.225)
(5.928)
(4.923)
(4.119)
(3.516)
(3.416)
(3.416)
(4.120)
(3.115)
(3.115)
(3.517)
(3.215)
(3.115)
(3.014)
(25120)
(23113)
(1782)
(1360)
(1154)
(1154)
(1155)
(35169)
(30141)
(25112)
(1874)
(1460)
(1357)
(1253)
(35142)
(90319)
(122427)
(120466)
(107424)
(106417)
(107410)
(131463)
(159562)
(126482)
(76366)
(62291)
(62273)
(63261)
(39134)
(74262)
(89334)
(99354)
(70271)
(61257)
(50229)
(3.517)
(3.015)
(0.783.8)
(0.944.5)
(0.743.6)
(0.723.5)
(0.723.5)
(1381)
(9.951)
(7.048)
(7.652)
(28178)
(41151)
(23103)
(1783)
(1781)
(1154)
(7.637)
(4.924)
(4.221)
(3.617)
(2099)
(1677)
(1154)
(7.034)
(5.225)
(4.924)
(4.722)
(1255)
(1359)
(1150)
(9.041)
(8.237)
(7.836)
(7.635)
(3.818)
(3.517)
(2.713)
(2.813)
(3.215)
(3.316)
(3.416)
(1150)
(6.932)
(5.024)
(3.617)
(2.813)
(2.612)
(2.411)
(55197)
(150584)
(219831)
(184650)
(164574)
(164579)
(170593)

NUMBER
(THOUSANDS)
0.17
0.13
0.12
0.11
1.5
1.8
1.6
1.3
1.2
1.1
1.1
0.35
0.27
0.28
0.32
0.31
0.31
0.3
19
18
13
9.6
8.7
8.6
8.7
7.1
6.3
5.2
3.9
3
2.8
2.6
2.3
4.7
6
6.6
6.1
5.9
5.7
34
43
40
32
25
23
22
70
140
190
190
160
150
140
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
3.4
2.1
1.8
1.6
6
5.8
4.3
1.8
1.8
1.2
0.82
0.54
0.46
0.39
0.78
0.63
0.44
0.28
0.21
0.2
0.19
9.5
11
9
8.1
7.6
7.4
7.2
0.65
0.61
0.47
0.51
0.59
0.61
0.64
1.4
0.97
0.72
0.55
0.42
0.39
0.37
3.7
8.5
14
13
13
13
13
(0.1500.190)
(0.1200.150)
(0.1100.140)
(0.0940.120)
(1.41.8)
(1.62.1)
(1.41.8)
(1.21.5)
(1.01.3)
(1.01.3)
(0.9901.3)
(0.3100.390)
(0.2300.300)
(0.2400.310)
(0.2800.360)
(0.2700.350)
(0.2700.350)
(0.2600.340)
(1721)
(1620)
(1115)
(8.411)
(7.69.8)
(7.69.8)
(7.69.9)
(6.28.0)
(5.57.1)
(4.65.9)
(3.54.5)
(2.73.4)
(2.53.2)
(2.33.0)
(1.92.8)
(3.95.6)
(5.07.2)
(5.47.9)
(5.07.3)
(4.97.1)
(4.76.8)
(2840)
(3551)
(3348)
(2638)
(2130)
(1928)
(1826)
(5981)
(120170)
(160220)
(160230)
(140190)
(130180)
(120160)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(3.03.8)
(1.82.4)
(1.62.1)
(1.41.8)
(4.18.4)
(4.77.0)
(3.55.1)
(1.62.1)
(1.62.0)
(1.11.4)
(0.7200.930)
(0.4700.610)
(0.4100.530)
(0.3500.450)
(0.6900.890)
(0.5500.710)
(0.3900.500)
(0.2500.320)
(0.1800.240)
(0.1700.220)
(0.1700.210)
(8.411)
(9.212)
(7.910)
(7.19.1)
(6.78.6)
(6.58.4)
(6.38.1)
(0.5700.740)
(0.5400.700)
(0.4100.540)
(0.4500.580)
(0.5200.670)
(0.5400.700)
(0.5600.720)
(1.21.6)
(0.8501.1)
(0.6300.820)
(0.4800.620)
(0.3700.480)
(0.3500.450)
(0.3300.420)
(3.04.4)
(7.010)
(1116)
(1115)
(1115)
(1116)
(1116)
RATEa
27
21
19
17
10
12
9.9
8.1
7
6.9
6.8
8.2
6.1
6.2
6.9
6.5
6.3
6.1
50
47
34
25
23
23
23
71
62
50
37
28
26
24
54
109
147
175
170
166
161
146
189
181
147
116
109
101
47
96
127
135
113
106
97
6.9
6
1.6
1.9
1.5
1.4
1.4
34
21
18
16
59
53
40
34
34
23
15
9.8
8.5
7.2
41
32
22
14
10
9.8
9.3
25
27
22
19
17
16
15
7.6
7
5.3
5.7
6.4
6.6
6.8
21
14
10
7.4
5.5
5.2
4.8
70
148
220
200
190
191
193
(2331)
(1924)
(1721)
(1519)
(9.112)
(1013)
(8.611)
(7.19.2)
(6.17.9)
(6.07.8)
(5.97.7)
(7.29.3)
(5.36.9)
(5.47.0)
(6.17.9)
(5.77.3)
(5.57.1)
(5.36.9)
(4356)
(4153)
(3038)
(2229)
(2026)
(2026)
(2026)
(6281)
(5470)
(4457)
(3342)
(2532)
(2330)
(2128)
(4464)
(90130)
(121175)
(144209)
(140202)
(137198)
(133192)
(120174)
(155226)
(149216)
(121175)
(96139)
(89130)
(83121)
(4055)
(81112)
(108149)
(114158)
(96132)
(89123)
(82114)
(6.07.8)
(5.36.8)
(1.41.8)
(1.62.1)
(1.31.7)
(1.31.6)
(1.21.6)
(3039)
(1924)
(1621)
(1419)
(4082)
(4464)
(3248)
(3039)
(2938)
(2025)
(1317)
(8.611)
(7.59.6)
(6.38.2)
(3646)
(2836)
(2025)
(1216)
(9.112)
(8.511)
(8.111)
(2228)
(2330)
(2025)
(1621)
(1519)
(1418)
(1417)
(6.78.6)
(6.17.9)
(4.76.0)
(5.06.4)
(5.67.2)
(5.77.4)
(5.97.7)
(1924)
(1216)
(8.811)
(6.58.4)
(4.86.3)
(4.55.8)
(4.25.5)
(5883)
(122176)
(182263)
(165238)
(156226)
(157227)
(159230)
EUROPEAN REGION

YEAR
215
YEAR
The Former
1990
Yugoslav Republic 1995
of Macedonia
2000
2005
2009
2010
2011
Turkey
1990
1995
2000
2005
2009
2010
2011
Turkmenistan
1990
1995
2000
2005
2009
2010
2011
Ukraine
1990
1995
2000
2005
2009
2010
2011
United Kingdom of 1990
Great Britain and
1995
Northern Ireland
2000
2005
2009
2010
2011
Uzbekistan
1990
1995
2000
2005
2009
2010
2011
216
POPULATION
(MILLIONS)
2
2
2
2
2
2
2
54
59
64
68
72
73
74
4
4
5
5
5
5
5
52
51
49
47
46
45
45
57
58
59
60
62
62
62
21
23
25
26
27
27
28
NUMBER
(THOUSANDS)
0.13
0.13
0.1
0.07
0.039
0.032
0.025
3.2
2.3
1.7
0.96
0.63
0.58
0.53
0.49
0.83
1.3
1.1
0.7
0.6
0.5
4.6
7.5
10
11
9.6
8.9
8.1
0.45
0.61
0.44
0.4
0.36
0.35
0.35
1.5
2.8
4.3
3.6
2.4
2
1.7
(0.1200.140)
(0.1200.140)
(0.0960.110)
(0.0650.074)
(0.0360.042)
(0.0300.034)
(0.0240.027)
(0.7507.5)
(0.8404.5)
(0.7103.1)
(0.5101.5)
(0.2001.3)
(0.1801.2)
(0.1701.1)
(0.4000.590)
(0.7200.950)
(0.8201.8)
(0.7001.6)
(0.4501.0)
(0.3900.860)
(0.3300.720)
(4.34.8)
(7.27.7)
(1011)
(1111)
(9.110)
(8.49.3)
(7.88.3)
(0.4500.450)
(0.6000.620)
(0.4300.440)
(0.3900.410)
(0.3500.380)
(0.3400.370)
(0.3400.350)
(1.31.8)
(2.43.1)
(3.74.9)
(3.24.2)
(2.02.7)
(1.72.3)
(1.42.0)
RATEa
6.8
6.6
5.1
3.4
1.9
1.6
1.2
6
3.9
2.7
1.4
0.88
0.79
0.72
13
20
28
23
14
12
9.9
8.8
15
21
24
21
20
18
0.79
1.1
0.74
0.66
0.59
0.57
0.55
7.5
12
17
14
8.7
7.4
6.1
(6.37.2)
(6.27.0)
(4.85.5)
(3.23.6)
(1.82.1)
(1.51.7)
(1.11.3)
(1.414)
(1.47.7)
(1.14.9)
(0.752.3)
(0.281.8)
(0.251.6)
(0.231.5)
(1116)
(1723)
(1840)
(1533)
(9.120)
(7.717)
(6.414)
(8.49.3)
(1415)
(2122)
(2324)
(2022)
(1921)
(1718)
(0.790.79)
(1.01.1)
(0.730.75)
(0.650.68)
(0.570.61)
(0.550.59)
(0.540.56)
(6.68.5)
(1014)
(1520)
(1216)
(7.410)
(6.38.5)
(5.27.1)

NUMBER
(THOUSANDS)
3.4
1.6
1.2
0.66
0.54
0.54
0.57
27
34
29
19
18
18
17
6
12
18
16
8.6
6.7
4.9
34
61
75
75
63
54
47
8
8.5
8.6
12
9
9.6
12
51
97
150
120
71
60
49
(1.07.2)
(0.6803.0)
(0.5102.2)
(0.1901.4)
(0.1701.1)
(0.2001.1)
(0.2501.0)
(1151)
(1757)
(1449)
(8.733)
(8.431)
(8.231)
(8.130)
(2.810)
(5.720)
(8.832)
(7.527)
(4.015)
(3.012)
(1.89.6)
(1560)
(29100)
(36130)
(36130)
(28110)
(2497)
(2184)
(3.015)
(3.316)
(3.416)
(5.722)
(3.118)
(3.618)
(5.220)
(2487)
(45170)
(71270)
(58210)
(35120)
(29100)
(2484)
RATEa
178
82
60
33
26
26
27
51
58
45
28
25
24
24
165
286
411
329
173
134
96
66
119
154
161
137
120
104
14
15
15
21
15
15
19
248
423
618
467
263
219
177
(54374)
(35150)
(25109)
(9.370)
(8.554)
(9.751)
(1249)
(2095)
(2898)
(2276)
(1348)
(1243)
(1142)
(1141)
(78284)
(137488)
(196703)
(157561)
(81298)
(59239)
(34188)
(30116)
(57203)
(74264)
(76276)
(61243)
(53213)
(46187)
(5.227)
(5.728)
(5.827)
(9.536)
(5.029)
(5.830)
(8.333)
(118425)
(197734)
(2861 080)
(223800)
(128447)
(107370)
(86301)

NUMBER
(THOUSANDS)
1.5
1.1
0.83
0.6
0.46
0.43
0.41
28
28
23
21
19
19
18
3.7
6.3
9.6
8.2
5.3
4.5
3.8
23
37
52
56
48
44
40
6.6
6.9
7
9.2
7.8
8.1
8.8
26
46
71
60
39
34
28
(0.9502.3)
(0.9301.4)
(0.6801.0)
(0.5400.670)
(0.4000.530)
(0.3700.500)
(0.3500.470)
(2532)
(2431)
(2026)
(1824)
(1722)
(1621)
(1520)
(3.04.4)
(5.17.5)
(7.812)
(6.79.8)
(4.36.3)
(3.75.4)
(3.14.6)
(1927)
(3144)
(4362)
(4666)
(3956)
(3752)
(3347)
(6.27.1)
(6.57.4)
(6.57.4)
(8.69.8)
(7.38.4)
(7.68.6)
(8.29.4)
(2130)
(3854)
(5984)
(5072)
(3246)
(2840)
(2333)
RATEa
81
58
41
30
23
21
20
53
47
36
31
27
26
24
101
150
213
172
106
90
74
44
73
106
119
104
97
89
12
12
12
15
13
13
14
125
199
286
233
144
122
101
(50119)
(4769)
(3450)
(2733)
(2026)
(1824)
(1723)
(4660)
(4153)
(3241)
(2735)
(2431)
(2229)
(2127)
(82121)
(122180)
(174256)
(141207)
(87127)
(73108)
(6189)
(3652)
(6086)
(88126)
(99141)
(86123)
(80115)
(74105)
(1112)
(1113)
(1113)
(1416)
(1214)
(1214)
(1315)
(103148)
(165237)
(237341)
(192277)
(119171)
(101145)
(84121)
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and
Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
3
3
3
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
4
3
3
3
3
3
3
8
8
8
8
8
8
8
7
8
8
9
9
9
9
10
10
10
10
10
10
10
10
10
10
10
11
11
11
4
3
4
4
4
4
4
9
8
8
8
8
7
7
5
5
5
4
4
4
4
<1
<1
<1
1
1
1
1
10
10
10
10
10
10
11
5
5
5
5
6
6
6
2
1
1
1
1
1
1
5
5
5
5
5
5
5
57
58
59
61
62
63
63
0.8
0.77
0.7
0.59
0.47
0.45
0.42
0.026
0.021
0.011
<0.01
<0.01
<0.01
<0.01
0.61
1.3
1.9
2.4
2.1
1.9
1.7
1.7
1.6
1.3
1
0.6
0.46
0.31
22
49
55
29
14
12
11
3.5
7
8.4
7.1
6.8
6.7
6.7
1.8
1.6
1.4
1.2
0.98
0.93
0.87
4
2.8
2.3
2
1.9
1.9
1.8
2.9
5.2
4.6
4.1
3.1
2.9
2.6
2.7
2.5
1.9
1.3
0.92
0.84
0.76
0.04
0.044
0.042
0.039
0.043
0.044
0.044
2.2
2.2
1.7
1.1
0.78
0.71
0.64
0.36
0.57
0.6
0.42
0.36
0.36
0.36
0.39
0.76
0.85
0.57
0.4
0.37
0.33
0.87
0.72
0.6
0.39
0.38
0.4
0.4
11
10
7.4
6.3
4.2
3.5
2.7
(0.5801.1)
(0.6400.900)
(0.5900.810)
(0.5000.680)
(0.4000.540)
(0.3800.520)
(0.3600.490)
(0.0230.030)
(0.0190.024)
(<0.010.012)
(<0.010.011)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.4500.790)
(1.11.5)
(1.72.1)
(2.12.7)
(1.82.4)
(1.62.2)
(1.42.0)
(1.51.9)
(1.41.8)
(1.11.5)
(0.8801.1)
(0.5200.670)
(0.4000.520)
(0.2700.350)
(1826)
(4159)
(4666)
(2434)
(1217)
(9.914)
(8.713)
(2.84.3)
(5.98.2)
(7.010)
(5.48.9)
(5.38.4)
(5.48.2)
(5.58.1)
(1.52.0)
(1.41.8)
(1.21.6)
(1.11.4)
(0.8601.1)
(0.8101.1)
(0.7600.990)
(2.55.9)
(2.33.4)
(1.92.8)
(1.62.4)
(1.62.2)
(1.62.1)
(1.62.1)
(2.53.3)
(4.55.9)
(4.05.3)
(3.64.7)
(2.73.5)
(2.53.3)
(2.33.0)
(2.43.1)
(2.22.9)
(1.72.2)
(1.11.4)
(0.8101.0)
(0.7300.950)
(0.6600.860)
(0.0350.045)
(0.0390.050)
(0.0360.047)
(0.0340.044)
(0.0380.049)
(0.0380.050)
(0.0390.050)
(2.02.5)
(1.92.5)
(1.51.9)
(0.9601.2)
(0.6900.890)
(0.6200.800)
(0.5600.720)
(0.3100.400)
(0.5000.640)
(0.5300.680)
(0.3600.470)
(0.3200.410)
(0.3200.410)
(0.3200.410)
(0.3400.440)
(0.6700.860)
(0.7500.970)
(0.5000.650)
(0.3500.450)
(0.3200.410)
(0.2900.380)
(0.7600.980)
(0.6300.810)
(0.5300.680)
(0.3400.440)
(0.3400.440)
(0.3500.450)
(0.3500.450)
(1112)
(9.511)
(6.97.8)
(5.96.7)
(3.94.5)
(3.33.7)
(2.52.9)
RATEa
24
24
23
19
15
14
13
50
33
17
12
8.4
7.2
5.9
17
39
61
77
69
62
55
22
20
16
12
7.1
5.5
3.7
305
636
682
334
154
131
113
34
68
84
72
70
70
70
18
16
14
12
9.2
8.7
8.1
94
84
63
52
50
50
49
33
62
58
53
41
38
35
60
54
43
29
21
19
17
5.2
5.1
4.4
3.7
4
4
4
22
21
16
11
7.5
6.8
6
6.9
11
11
7.7
6.5
6.5
6.5
25
53
62
42
30
27
25
17
14
12
7.4
7.2
7.5
7.5
20
17
12
10
6.7
5.5
4.3
(1832)
(2029)
(1926)
(1622)
(1217)
(1216)
(1115)
(4457)
(2937)
(1519)
(1114)
(7.39.5)
(6.38.1)
(5.16.6)
(1322)
(3346)
(5469)
(6887)
(5979)
(5373)
(4565)
(1924)
(1722)
(1418)
(1114)
(6.28.0)
(4.86.2)
(3.24.2)
(252363)
(525758)
(563812)
(276398)
(127183)
(108155)
(93134)
(2742)
(5879)
(69100)
(5591)
(5587)
(5686)
(5784)
(1620)
(1418)
(1215)
(1013)
(8.110)
(7.69.8)
(7.19.2)
(58138)
(69101)
(5175)
(4363)
(4358)
(4357)
(4256)
(2937)
(5471)
(5066)
(4661)
(3647)
(3343)
(3040)
(5368)
(4761)
(3748)
(2532)
(1824)
(1722)
(1520)
(4.65.9)
(4.55.8)
(3.95.0)
(3.34.2)
(3.54.5)
(3.54.5)
(3.54.5)
(1925)
(1924)
(1419)
(9.412)
(6.68.5)
(5.97.6)
(5.36.8)
(6.17.8)
(9.512)
(9.913)
(6.78.7)
(5.77.4)
(5.77.3)
(5.77.4)
(2228)
(4660)
(5570)
(3748)
(2634)
(2431)
(2228)
(1520)
(1216)
(1013)
(6.58.4)
(6.38.1)
(6.58.4)
(6.58.4)
(1921)
(1619)
(1213)
(9.711)
(6.37.1)
(5.25.9)
(4.04.6)
NUMBER
(THOUSANDS)
<0.01
<0.01
0.021
0.034
0.029
0.026
0.055
<0.01
<0.01
0.017
0.027
0.024
0.02
0.015
<0.01
0.072
0.32
0.32
0.2
0.18
0.16
<0.01
<0.01
0.028
0.17
0.25
0.24
0.25
0.015
0.043
0.061
0.067
0.046
0.043
0.04
(<0.01<0.01)
(<0.01<0.01)
(0.0150.027)
(0.0250.045)
(0.0210.038)
(0.0140.042)
(0.0380.075)
(<0.01<0.01)
(<0.010.012)
(0.0120.024)
(0.0190.035)
(0.0180.031)
(0.0150.026)
(0.0110.018)
(<0.01<0.01)
(0.0380.120)
(0.2000.480)
(0.2100.460)
(0.1300.270)
(0.1200.240)
(0.1100.220)
(<0.01<0.01)
(<0.01<0.01)
(0.0170.043)
(0.1200.240)
(0.1900.320)
(0.1700.330)
(0.1800.340)
(0.0130.017)
(0.0300.058)
(0.0440.080)
(0.0490.089)
(0.0320.061)
(0.0310.056)
(0.0290.052)
RATEa
<0.1
0.2
0.7
1.1
0.9
0.9
1.8
<0.1
0.1
0.2
0.3
0.3
0.2
0.2
<0.1
0.9
4
3.8
2.2
1.9
1.7
0
<0.1
0.3
1.7
2.6
2.5
2.7
0.2
0.4
0.6
0.7
0.4
0.4
0.4
(<0.1<0.1)
(0.100.23)
(0.490.89)
(0.831.5)
(0.681.2)
(0.471.4)
(1.22.4)
(<0.1<0.1)
(<0.10.15)
(0.150.30)
(0.240.43)
(0.210.37)
(0.180.30)
(0.130.22)
(<0.1<0.1)
(0.491.5)
(2.55.9)
(2.55.4)
(1.43.0)
(1.32.7)
(1.22.4)
(00)
(0<0.1)
(0.170.42)
(1.22.4)
(1.93.3)
(1.83.4)
(1.93.5)
(0.130.17)
(0.300.57)
(0.440.78)
(0.470.85)
(0.300.58)
(0.290.52)
(0.270.49)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.011)
(<0.010.017)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.010)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
0
<0.1
<0.1
<0.1
<0.1
<0.1
0.1
<0.1
0.1
0.2
0.1
0.1
0.1
0.1
(00)
(0<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(00.14)
(<0.10.23)
(<0.1<0.1)
(<0.10.15)
(<0.10.23)
(<0.10.21)
(<0.10.18)
(<0.10.17)
(<0.10.16)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.016
0.015
0.016
0.016
0.016
<0.01
<0.01
0.03
0.038
0.042
0.038
0.05
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.81
0.66
0.55
0.5
0.34
0.29
0.22
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.013)
(0.0110.022)
(0.0110.020)
(<0.010.028)
(0.0110.021)
(0.0120.021)
(<0.01<0.01)
(<0.01<0.01)
(0.0220.038)
(0.0260.054)
(0.0300.057)
(0.0270.049)
(0.0360.066)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.7600.860)
(0.5100.830)
(0.4300.690)
(0.3900.620)
(0.2700.420)
(0.2400.340)
(0.1800.280)
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
0.2
0.3
0.3
0.3
0.3
0.3
<0.1
0.3
2.2
2.9
3.1
2.8
3.7
<0.1
<0.1
<0.1
<0.1
<0.1
0.1
0.1
1.4
1.1
0.9
0.8
0.6
0.5
0.4
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(0.120.26)
(0.200.40)
(0.200.37)
(0.120.52)
(0.200.37)
(0.210.38)
(<0.1<0.1)
(0.200.45)
(1.62.7)
(1.94.0)
(2.24.2)
(2.03.7)
(2.74.9)
(<0.1<0.1)
(<0.10.10)
(<0.10.13)
(<0.10.11)
(<0.10.12)
(<0.10.13)
(<0.10.14)
(1.31.5)
(0.881.4)
(0.731.2)
(0.651.0)
(0.430.68)
(0.380.54)
(0.280.44)

NUMBER
RATEa
CASE DETECTION
PERCENT
653
641
604
506
435
431
422
23
20
20
20
16
14
13
13
44
81
84
87
86
93
97
100
87
(61110)
(71100)
(75100)
(74100)
(80110)
(83110)
(87120)
(7799)
12
10
8
7
3
590
1 000
1 333
2 206
1 560
1 410
1 261
1 521
1 481
1 185
928
441
358
400
2 620
1 630
5 187
6 034
7 301
6 390
6 527
3 039
4 854
6 799
5 308
5 250
5 003
4 697
1 577
1 380
1 278
1 076
806
814
19
13
9.6
8.2
3.5
17
31
43
72
51
46
41
20
19
15
11
5.3
4.3
4.8
36
21
64
70
81
70
70
30
47
68
54
54
52
49
16
14
13
10
7.6
7.6
110
110
110
120
59
97
79
71
93
74
73
74
92
96
91
92
74
78
130
12
3.3
9.4
21
52
53
62
86
69
81
75
78
74
70
89
88
92
88
82
88
(97130)
(93120)
(100130)
(100130)
(5268)
(74130)
(6894)
(6381)
(83110)
(6486)
(6386)
(6390)
(81100)
(84110)
(81100)
(82110)
(6585)
(6989)
(110150)
(1014)
(2.84.0)
(7.911)
(1825)
(4463)
(4565)
(5275)
(70110)
(5982)
(6897)
(6098)
(6398)
(6193)
(5886)
(79100)
(78100)
(81100)
(78100)
(7293)
(77100)
4 073
2 132
2 476
2 111
1 725
1 321
1 360
2 256
3 245
3 349
3 225
2 683
2 412
2 172
2 576
2 114
1 630
1 050
832
688
619
29
36
33
34
43
33
95
64
67
56
46
35
36
26
39
42
42
36
32
29
57
45
36
24
19
16
14
3.8
4.2
3.5
3.3
3.9
3
100
76
110
110
91
71
74
78
62
72
78
86
84
83
95
84
85
82
90
82
82
73
82
79
88
99
75
(69160)
(6393)
(89130)
(89130)
(79110)
(6282)
(6486)
(6889)
(5571)
(6483)
(6990)
(7699)
(7497)
(7396)
(84110)
(7496)
(7597)
(7394)
(80100)
(7394)
(7293)
(6483)
(7293)
(7090)
(78100)
(88110)
(6686)
1 937
1 834
1 414
973
638
627
19
18
14
9.5
6.1
6
86
83
84
89
82
88
(7698)
(7394)
(7496)
(79100)
(7293)
(78100)
350
448
587
395
294
313
6.8
8.6
11
7.3
5.3
5.6
98
79
98
95
81
87
(87110)
(7090)
(86110)
(84110)
(7293)
(7799)
423
624
791
479
361
283
296
772
661
527
339
519
312
312
9 030
8 723
6 122
4 887
2 890
2 752
27
43
58
36
27
21
22
15
13
10
6.5
9.7
5.8
5.8
16
15
10
8
4.6
4.4
110
82
93
84
90
77
89
89
92
87
87
130
78
78
80
86
83
78
69
79
(96120)
(7293)
(82110)
(7496)
(80100)
(6888)
(79100)
(79100)
(82110)
(77100)
(7799)
(120150)
(6989)
(6989)
(7585)
(8192)
(7888)
(7383)
(6574)
(7484)
EUROPEAN REGION

YEAR
217
YEAR
Georgia
Germany
Greece
Greenland
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Monaco
218
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
5
5
5
4
4
4
4
79
82
82
83
82
82
82
10
11
11
11
11
11
11
<1
<1
<1
<1
<1
<1
<1
10
10
10
10
10
10
10
<1
<1
<1
<1
<1
<1
<1
4
4
4
4
4
4
5
4
5
6
7
7
7
8
57
57
57
59
60
61
61
17
16
15
15
16
16
16
4
5
5
5
5
5
5
3
2
2
2
2
2
2
4
4
4
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
15
13
12
7.8
5.8
5.6
5.4
17
14
10
6.1
4.3
4
3.7
0.93
1.1
0.86
0.65
0.54
0.49
0.43
0.099
0.099
0.1
0.1
0.1
0.1
0.1
4
4.9
3.8
2.2
1.7
1.7
1.8
0.02
0.015
0.013
0.011
0.014
0.015
0.016
0.76
0.57
0.45
0.44
0.39
0.37
0.34
0.38
0.5
0.61
0.46
0.41
0.42
0.44
4.6
5.8
4.9
4.3
2.9
2.4
1.7
13
51
53
36
26
24
21
4
7.7
12
10
8
7.4
6.9
1.5
3.1
2.9
1.7
1.1
1
0.93
1.4
2.8
3.1
2.6
2.2
2.1
1.9
0.051
0.041
0.045
0.039
0.019
0.012
<0.01
0.025
0.024
0.019
0.029
0.038
0.038
0.038
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(1417)
(1215)
(1114)
(7.08.7)
(5.26.4)
(5.06.2)
(4.86.1)
(1519)
(1316)
(8.711)
(5.46.9)
(3.84.8)
(3.54.5)
(3.24.2)
(0.8101.0)
(0.9701.2)
(0.7600.980)
(0.5700.740)
(0.4700.610)
(0.4300.550)
(0.3800.490)
(0.0860.110)
(0.0870.110)
(0.0870.110)
(0.0890.110)
(0.0890.120)
(0.0890.120)
(0.0890.120)
(3.54.5)
(4.35.6)
(3.34.3)
(1.92.5)
(1.51.9)
(1.51.9)
(1.62.0)
(0.0170.022)
(0.0130.017)
(0.0110.014)
(<0.010.012)
(0.0120.015)
(0.0130.017)
(0.0140.018)
(0.6700.860)
(0.5000.640)
(0.4000.510)
(0.3900.500)
(0.3400.440)
(0.3200.420)
(0.3000.380)
(0.3300.430)
(0.4400.570)
(0.5400.690)
(0.4000.520)
(0.3600.470)
(0.3700.480)
(0.3800.490)
(4.05.2)
(5.16.6)
(4.35.6)
(3.84.9)
(2.63.3)
(2.12.7)
(1.52.0)
(1115)
(4359)
(4461)
(3042)
(2231)
(2028)
(1824)
(3.34.8)
(6.49.2)
(1015)
(8.612)
(6.69.5)
(6.18.8)
(5.78.2)
(1.31.7)
(2.83.5)
(2.53.3)
(1.52.0)
(1.01.3)
(0.9001.2)
(0.8201.1)
(1.21.7)
(2.43.3)
(2.83.5)
(2.22.9)
(1.92.5)
(1.82.4)
(1.72.2)
(0.0440.057)
(0.0360.047)
(0.0400.051)
(0.0340.044)
(0.0170.022)
(0.0100.013)
(<0.01<0.01)
(0.0220.028)
(0.0210.027)
(0.0160.021)
(0.0250.032)
(0.0330.043)
(0.0340.044)
(0.0330.043)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
RATEa
280
263
256
175
132
128
125
21
18
12
7.4
5.2
4.8
4.5
9.1
10
7.8
5.9
4.7
4.3
3.8
178
178
178
178
178
178
178
39
48
37
22
17
17
18
7.7
5.7
4.5
3.7
4.3
4.6
4.8
22
16
12
11
8.9
8.2
7.5
8.4
9.4
10
7
5.7
5.7
5.8
8
10
8.6
7.4
4.8
3.9
2.8
79
318
351
235
166
148
129
92
168
249
208
151
139
128
57
126
121
75
50
46
42
39
77
90
75
65
62
59
13
10
10
8.6
3.9
2.3
0.52
6.7
6.3
4.7
7
9.2
9.2
9.1
2.7
2.5
1.6
0.97
2.3
2.7
3.2
(250312)
(234293)
(228285)
(156195)
(118147)
(114142)
(112140)
(1824)
(1520)
(1114)
(6.58.4)
(4.65.9)
(4.25.4)
(3.95.1)
(8.010)
(9.112)
(6.98.9)
(5.16.6)
(4.15.3)
(3.84.9)
(3.34.3)
(156201)
(156201)
(156201)
(156201)
(156201)
(156201)
(156201)
(3444)
(4254)
(3342)
(1925)
(1519)
(1519)
(1620)
(6.78.7)
(5.06.5)
(3.95.1)
(3.34.2)
(3.84.9)
(4.05.2)
(4.25.4)
(1924)
(1418)
(1014)
(9.312)
(7.810)
(7.29.3)
(6.58.4)
(7.49.5)
(8.311)
(8.912)
(6.17.9)
(5.06.4)
(5.06.4)
(5.16.5)
(7.09.1)
(9.012)
(7.69.8)
(6.58.4)
(4.25.5)
(3.44.4)
(2.53.2)
(6692)
(269372)
(297411)
(199275)
(141195)
(125172)
(109151)
(76109)
(138200)
(205296)
(171248)
(125180)
(115166)
(106153)
(5065)
(111142)
(106137)
(6685)
(4457)
(4052)
(3647)
(3246)
(6690)
(79101)
(6586)
(5675)
(5372)
(5168)
(1215)
(8.911)
(9.112)
(7.59.7)
(3.44.4)
(2.02.6)
(0.460.59)
(5.97.6)
(5.57.1)
(4.15.3)
(6.17.9)
(8.010)
(8.110)
(8.010)
(2.43.1)
(2.22.9)
(1.41.8)
(0.851.1)
(2.02.6)
(2.43.1)
(2.83.6)
NUMBER
(THOUSANDS)
0.01
0.019
0.035
0.047
0.063
0.071
0.08
0.22
0.2
0.15
0.1
0.082
0.079
0.076
0.014
0.017
0.015
0.013
0.012
0.011
<0.01
0.053
0.043
0.025
0.016
0.014
0.014
0.015
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.012
0.015
0.015
0.014
0.013
<0.01
0.018
0.038
0.025
0.032
0.016
0.027
0.22
0.29
0.27
0.23
0.15
0.12
0.088
<0.01
0.034
0.31
0.21
0.26
0.33
0.33
<0.01
<0.01
0.011
0.038
0.11
0.1
0.12
<0.01
0.035
0.1
0.075
0.1
0.09
0.083
<0.01
<0.01
0.014
0.018
0.019
0.018
0.017
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
RATEa
(<0.010.012) 0.2 (0.170.21)

(0.0110.029) 0.4 (0.220.58)
(0.0220.051) 0.7 (0.461.1)
(0.0310.065)
1 (0.701.5)
(0.0450.085) 1.4 (1.01.9)
(0.0580.085) 1.6 (1.31.9)
(0.0580.110) 1.8 (1.32.4)
(0.1900.250) 0.3 (0.240.31)
(0.1300.270) 0.2 (0.160.33)
(0.1000.210) 0.2 (0.130.25)
(0.0720.140) 0.1 (<0.10.17)
(0.0580.110) 0.1 (<0.10.13)
(0.0560.110) 0.1 (<0.10.13)
(0.0540.100) <0.1 (<0.10.12)
(0.0120.016) 0.1 (0.120.15)
(0.0120.024) 0.2 (0.110.22)
(0.0110.021) 0.1 (0.100.19)
(<0.010.018) 0.1 (<0.10.16)
(<0.010.015) 0.1 (<0.10.14)
(<0.010.014) <0.1 (<0.10.13)
(<0.010.013) <0.1 (<0.10.11)
(0.0470.060)
(0.0280.061)
(0.0160.037)
(0.0100.022)
(<0.010.020)
(<0.010.020)
(<0.010.021)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.011)
(<0.010.016)
(0.0110.019)
(0.0110.019)
(0.0110.018)
(<0.010.017)
(<0.01<0.01)
(0.0120.024)
(0.0240.054)
(0.0140.039)
(0.0190.047)
(0.0140.018)
(0.0170.040)
(0.1900.250)
(0.2200.370)
(0.2100.340)
(0.1800.300)
(0.1200.190)
(0.0930.150)
(0.0670.110)
(<0.01<0.01)
(0.0180.055)
(0.2100.440)
(0.1700.260)
(0.1900.350)
(0.2700.400)
(0.2700.390)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.017)
(0.0240.055)
(0.0820.140)
(0.0730.140)
(0.0870.160)
(<0.01<0.01)
(0.0240.049)
(0.0750.130)
(0.0550.099)
(0.0760.130)
(0.0720.110)
(0.0660.100)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.021)
(0.0120.027)
(0.0120.027)
(0.0120.026)
(0.0110.025)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.011)
(<0.010.013)
0.5
0.4
0.3
0.2
0.1
0.1
0.2
<0.1
<0.1
0.1
0.4
0.1
0.2
0.2
0.1
0.2
0.3
0.4
0.3
0.3
0.3
0.1
0.3
0.6
0.4
0.4
0.2
0.4
0.4
0.5
0.5
0.4
0.3
0.2
0.1
0
0.2
2.1
1.4
1.7
2.1
2
<0.1
<0.1
0.2
0.8
2.1
1.9
2.2
0.2
1.4
4.2
3.3
4.4
4
3.7
<0.1
0.2
0.4
0.5
0.6
0.6
0.5
<0.1
0.2
0.3
0.3
0.1
<0.1
<0.1
0.2
0.4
0.5
0.8
1
1.1
1.5
(0.450.58)
(0.270.59)
(0.160.36)
(0.100.22)
(<0.10.20)
(<0.10.20)
(0.100.22)
(<0.1<0.1)
(<0.10.10)
(<0.10.15)
(01.5)
(0.110.19)
(0.110.20)
(0.120.21)
(<0.10.11)
(0.150.31)
(0.230.42)
(0.260.46)
(0.250.43)
(0.240.41)
(0.220.38)
(0.100.13)
(0.230.45)
(0.400.89)
(0.210.58)
(0.270.64)
(0.190.25)
(0.220.53)
(0.340.44)
(0.390.66)
(0.360.60)
(0.310.51)
(0.190.32)
(0.150.26)
(0.110.18)
(0<0.1)
(0.110.35)
(1.43.0)
(1.11.7)
(1.22.2)
(1.72.5)
(1.62.4)
(0<0.1)
(<0.1<0.1)
(0.120.35)
(0.491.1)
(1.52.7)
(1.42.6)
(1.62.9)
(0.160.21)
(0.962.0)
(3.15.5)
(2.44.3)
(3.45.6)
(3.24.9)
(2.94.6)
(<0.1<0.1)
(<0.10.24)
(0.240.59)
(0.350.78)
(0.360.80)
(0.350.78)
(0.340.74)
(<0.10.10)
(0.140.26)
(0.240.43)
(0.230.40)
(0.110.19)
(<0.10.11)
(<0.1<0.1)
(0.140.18)
(0.260.57)
(0.300.63)
(0.511.0)
(0.242.2)
(0.202.7)
(0.503.1)
CASE DETECTION
NUMBER
RATEa
PERCENT
1 537
1 625
4 397
4 501
4 732
4 674
4 547
14 653
12 198
9 064
5 539
3 659
3 524
3 528
877
939
703
626
465
356
28
32
93
101
108
107
105
19
15
11
6.7
4.4
4.3
4.3
8.6
8.8
6.4
5.6
4.1
3.1
10
12
36
58
82
84
84
88
85
91
90
85
89
96
95
85
82
96
87
73
63
114
110
199
3 588
4 339
3 073
1 808
1 315
1 543
35
42
30
18
13
15
90
88
81
82
77
90
(79100)
(78100)
(7292)
(7294)
(6888)
(79100)
18
12
13
10
11
22
8
624
458
386
387
340
319
281
234
398
537
371
347
340
412
4 246
5 627
3 501
3 828
2 541
1 693
1 658
10 969
11 310
25 843
25 512
20 508
19 703
18 254
2 306
3 393
6 205
6 329
5 765
5 652
5 529
906
1 541
1 982
1 409
951
913
864
1 471
2 362
2 657
2 114
1 895
1 750
1 745
48
32
44
37
7.1
4.5
4.6
3.4
3.5
6.9
2.5
18
13
10
9.3
7.7
7.1
6.2
5.2
7.5
8.9
5.6
4.8
4.6
5.4
7.5
9.9
6.1
6.5
4.2
2.8
2.7
66
71
173
168
129
123
113
52
74
125
126
109
106
103
34
62
83
61
42
41
39
40
65
76
62
57
53
53
13
7.9
10
8.1
92
78
100
91
81
150
51
82
81
85
88
87
87
83
62
79
88
81
84
81
94
93
97
71
88
87
72
96
84
22
49
71
78
83
87
57
44
50
60
72
76
80
59
49
69
81
84
89
93
100
84
85
82
87
85
90
95
78
97
94
(82110)
(6989)
(91120)
(80100)
(7192)
(130170)
(4558)
(7294)
(7192)
(7597)
(77100)
(7799)
(7799)
(7495)
(5470)
(7090)
(77100)
(7192)
(7496)
(7192)
(83110)
(82110)
(85110)
(6381)
(78100)
(7799)
(6382)
(85110)
(72100)
(1926)
(4258)
(6185)
(6792)
(7199)
(75100)
(4869)
(3753)
(4261)
(5173)
(6188)
(6492)
(6797)
(5268)
(4356)
(6178)
(7292)
(7495)
(79100)
(82110)
(87130)
(7299)
(7596)
(7295)
(75100)
(7399)
(78100)
(84110)
(6989)
(86110)
(83110)
24
11
13
11
16
21
41
20
22
1
1
0
4.7
2.1
3.5
2.8
4
5.1
9.9
4.8
5.3
3.2
3
0
210
410
53
45
85
73
110
52
58
120
120
0
(180240)
(360470)
(4760)
(4052)
(7597)
(6584)
(95120)
(4659)
(5166)
(110140)
(110140)
2.8
100 (92120)
(9.011)
(1114)
(3241)
(5265)
(7392)
(7594)
(7594)
(78100)
(7597)
(80100)
(80100)
(7698)
(79100)
(84110)
(84110)
(7597)
(7293)
(85110)
(7799)
(6483)
62 (5571)
110 (99130)
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of
Moldova
Romania
Russian
Federation
San Marino
Serbia
Serbia &
Montenegro
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2005
2009
2010
2011
1990
1995
2000
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
<1
<1
<1
<1
15
15
16
16
17
17
17
4
4
4
5
5
5
5
38
38
38
38
38
38
38
10
10
10
11
11
11
11
4
4
4
4
4
4
4
23
23
22
22
22
21
21
148
149
147
144
143
143
143
<1
<1
<1
<1
<1
<1
<1
10
10
10
10
10
11
11
5
5
5
5
5
5
5
2
2
2
2
2
2
2
39
39
40
43
46
46
46
9
9
9
9
9
9
9
7
7
7
7
8
8
8
5
6
6
6
7
7
7
0.17
0.13
0.12
0.11
1.5
1.8
1.6
1.3
1.2
1.1
1.1
0.35
0.27
0.28
0.32
0.31
0.31
0.3
19
18
13
9.6
8.7
8.6
8.7
7.1
6.3
5.2
3.9
3
2.8
2.6
2.3
4.7
6
6.6
6.1
5.9
5.7
34
43
40
32
25
23
22
70
140
190
190
160
150
140
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
3.4
2.1
1.8
1.6
6
5.8
4.3
1.8
1.8
1.2
0.82
0.54
0.46
0.39
0.78
0.63
0.44
0.28
0.21
0.2
0.19
9.5
11
9
8.1
7.6
7.4
7.2
0.65
0.61
0.47
0.51
0.59
0.61
0.64
1.4
0.97
0.72
0.55
0.42
0.39
0.37
3.7
8.5
14
13
13
13
13
(0.1500.190)
(0.1200.150)
(0.1100.140)
(0.0940.120)
(1.41.8)
(1.62.1)
(1.41.8)
(1.21.5)
(1.01.3)
(1.01.3)
(0.9901.3)
(0.3100.390)
(0.2300.300)
(0.2400.310)
(0.2800.360)
(0.2700.350)
(0.2700.350)
(0.2600.340)
(1721)
(1620)
(1115)
(8.411)
(7.69.8)
(7.69.8)
(7.69.9)
(6.28.0)
(5.57.1)
(4.65.9)
(3.54.5)
(2.73.4)
(2.53.2)
(2.33.0)
(1.92.8)
(3.95.6)
(5.07.2)
(5.47.9)
(5.07.3)
(4.97.1)
(4.76.8)
(2840)
(3551)
(3348)
(2638)
(2130)
(1928)
(1826)
(5981)
(120170)
(160220)
(160230)
(140190)
(130180)
(120160)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(3.03.8)
(1.82.4)
(1.62.1)
(1.41.8)
(4.18.4)
(4.77.0)
(3.55.1)
(1.62.1)
(1.62.0)
(1.11.4)
(0.7200.930)
(0.4700.610)
(0.4100.530)
(0.3500.450)
(0.6900.890)
(0.5500.710)
(0.3900.500)
(0.2500.320)
(0.1800.240)
(0.1700.220)
(0.1700.210)
(8.411)
(9.212)
(7.910)
(7.19.1)
(6.78.6)
(6.58.4)
(6.38.1)
(0.5700.740)
(0.5400.700)
(0.4100.540)
(0.4500.580)
(0.5200.670)
(0.5400.700)
(0.5600.720)
(1.21.6)
(0.8501.1)
(0.6300.820)
(0.4800.620)
(0.3700.480)
(0.3500.450)
(0.3300.420)
(3.04.4)
(7.010)
(1116)
(1115)
(1115)
(1116)
(1116)
RATEa
27
21
19
17
10
12
9.9
8.1
7
6.9
6.8
8.2
6.1
6.2
6.9
6.5
6.3
6.1
50
47
34
25
23
23
23
71
62
50
37
28
26
24
54
109
147
175
170
166
161
146
189
181
147
116
109
101
47
96
127
135
113
106
97
6.9
6
1.6
1.9
1.5
1.4
1.4
34
21
18
16
59
53
40
34
34
23
15
9.8
8.5
7.2
41
32
22
14
10
9.8
9.3
25
27
22
19
17
16
15
7.6
7
5.3
5.7
6.4
6.6
6.8
21
14
10
7.4
5.5
5.2
4.8
70
148
220
200
190
191
193
(2331)
(1924)
(1721)
(1519)
(9.112)
(1013)
(8.611)
(7.19.2)
(6.17.9)
(6.07.8)
(5.97.7)
(7.29.3)
(5.36.9)
(5.47.0)
(6.17.9)
(5.77.3)
(5.57.1)
(5.36.9)
(4356)
(4153)
(3038)
(2229)
(2026)
(2026)
(2026)
(6281)
(5470)
(4457)
(3342)
(2532)
(2330)
(2128)
(4464)
(90130)
(121175)
(144209)
(140202)
(137198)
(133192)
(120174)
(155226)
(149216)
(121175)
(96139)
(89130)
(83121)
(4055)
(81112)
(108149)
(114158)
(96132)
(89123)
(82114)
(6.07.8)
(5.36.8)
(1.41.8)
(1.62.1)
(1.31.7)
(1.31.6)
(1.21.6)
(3039)
(1924)
(1621)
(1419)
(4082)
(4464)
(3248)
(3039)
(2938)
(2025)
(1317)
(8.611)
(7.59.6)
(6.38.2)
(3646)
(2836)
(2025)
(1216)
(9.112)
(8.511)
(8.111)
(2228)
(2330)
(2025)
(1621)
(1519)
(1418)
(1417)
(6.78.6)
(6.17.9)
(4.76.0)
(5.06.4)
(5.67.2)
(5.77.4)
(5.97.7)
(1924)
(1216)
(8.811)
(6.58.4)
(4.86.3)
(4.55.8)
(4.25.5)
(5883)
(122176)
(182263)
(165238)
(156226)
(157227)
(159230)
NUMBER
(THOUSANDS)
<0.01 (0<0.01)
RATEa
0.2 (01.1)
0.014
0.038
0.041
0.039
0.036
0.035
0.035
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.073
0.17
0.17
0.14
0.14
0.14
0.14
0.17
0.44
0.56
0.91
0.48
0.34
0.37
<0.01
0.028
0.25
<0.01
0.31
0.35
0.32
0.1
0.39
0.64
0.57
0.42
0.39
0.35
<0.01
0.033
0.43
7.8
13
6.5
9.3
(0.0120.016) 0.1 (<0.10.11)

(0.0270.051) 0.3 (0.180.33)
(0.0300.055) 0.3 (0.190.34)
(0.0280.051) 0.2 (0.170.31)
(0.0260.046) 0.2 (0.160.28)
(0.0260.046) 0.2 (0.160.28)
(0.0260.046) 0.2 (0.160.28)
(<0.01<0.01) <0.1 (<0.1<0.1)
(<0.01<0.01) <0.1 (<0.10.10)
(<0.01<0.01) 0.1 (<0.10.15)
(<0.01<0.01) 0.1 (0.100.18)
(<0.01<0.01) 0.1 (<0.10.17)
(<0.01<0.01) 0.1 (<0.10.17)
(<0.01<0.01) 0.1 (<0.10.16)
(0.0640.083) 0.2 (0.170.22)
(0.1100.240) 0.4 (0.290.62)
(0.1100.230) 0.4 (0.300.60)
(0.1000.200) 0.4 (0.260.52)
(0.0970.190) 0.4 (0.250.49)
(0.0970.190) 0.4 (0.250.50)
(0.0990.190) 0.4 (0.260.50)
(0.1500.200) 1.7 (1.52.0)
(0.3300.560) 4.3 (3.25.5)
(0.4400.710) 5.5 (4.26.8)
(0.7801.0)
8.6 (7.49.9)
(0.4100.560) 4.5 (3.95.3)
(0.2800.400) 3.2 (2.63.7)
(0.2900.460) 3.5 (2.74.3)
(<0.01<0.01) 0.2 (0.110.19)
(0.0180.042) 0.7 (0.410.96)
(0.1800.320)
6 (4.47.9)
(<0.010.017) 0.2 (0.100.45)
(0.2500.380) 8.6 (6.811)
(0.2800.430) 9.8 (7.812)
(0.2600.400) 9.1 (7.311)
(0.0830.120) 0.4 (0.360.52)
(0.2500.570) 1.7 (1.12.5)
(0.4300.900) 2.9 (1.94.0)
(0.3900.790) 2.6 (1.83.6)
(0.2900.590)
2 (1.32.7)
(0.2600.540) 1.8 (1.22.5)
(0.2400.490) 1.6 (1.12.3)
(0<0.01)
0 (00)
(0.0150.057) <0.1 (<0.1<0.1)
(0.2600.640) 0.3 (0.180.43)
(6.19.8)
5.4 (4.26.8)
(1016)
9 (7.311)
(5.57.6)
4.5 (3.85.3)
(7.411)
6.5 (5.18.0)
0.046
0.035
0.031
0.028
(0.0410.052)
(0.0240.047)
(0.0220.042)
(0.0200.038)
0.5
0.4
0.3
0.3
(0.410.53)
(0.250.48)
(0.220.43)
(0.200.39)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0<0.01)
(0<0.01)
(0<0.01)
0
<0.1
<0.1
<0.1
<0.1
<0.1
(00)
(0<0.1)
(<0.1<0.1)
(00.10)
(00.10)
(00.10)
<0.01
<0.01
<0.01
<0.01
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
<0.1
<0.1
<0.1
<0.1
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
<0.01
<0.01
0.78
1.1
0.96
0.8
0.72
0.69
0.66
<0.01
0.011
<0.01
0.011
0.013
0.013
0.013
0.036
0.038
0.031
0.025
0.021
0.02
0.019
<0.01
0.043
0.19
0.27
0.31
0.32
0.25
(0<0.01)
<0.1 (00.37)
(<0.01<0.01) <0.1 (<0.1<0.1)
(0.6800.890)
2 (1.82.3)
(0.8801.4)
2.9 (2.23.6)
(0.7401.2)
2.4 (1.83.0)
(0.6101.0)
1.8 (1.42.3)
(0.5500.910) 1.6 (1.22.0)
(0.5900.800) 1.5 (1.31.7)
(0.5600.760) 1.4 (1.21.6)
(<0.01<0.01) <0.1 (<0.1<0.1)
(<0.010.014) 0.1 (<0.10.16)
(<0.010.013) 0.1 (<0.10.15)
(<0.010.015) 0.1 (<0.10.16)
(<0.010.017) 0.1 (0.100.18)
(<0.010.017) 0.1 (0.100.19)
(<0.010.018) 0.1 (0.100.19)
(0.0320.041) 0.6 (0.480.62)
(0.0280.049) 0.5 (0.400.69)
(0.0230.039) 0.4 (0.320.55)
(0.0190.032) 0.3 (0.260.44)
(0.0160.026) 0.3 (0.210.35)
(0.0150.025) 0.3 (0.200.33)
(0.0140.024) 0.2 (0.190.31)
(<0.01<0.01) 0.1 (0.110.16)
(0.0270.063) 0.8 (0.471.1)
(0.1300.260) 3.1 (2.14.3)
(0.1900.360) 4.2 (3.05.7)
(0.2200.410) 4.5 (3.26.0)
(0.2400.420) 4.7 (3.56.1)
(0.1900.320) 3.6 (2.74.5)
CASE DETECTION
NUMBER
RATEa
156
113
110
110
1 369
1 619
1 244
1 127
1 111
1 029
970
285
236
221
269
258
274
25
18
17
17
9.2
10
7.8
6.9
6.7
6.2
5.8
6.7
5.4
4.9
5.8
5.3
5.6
93
85
92
100
88
89
80
85
96
90
86
82
89
80
84
82
89
(82110)
(7597)
(81100)
(91120)
(78100)
(78100)
(7091)
(7597)
(85110)
(80100)
(7698)
(7293)
(78100)
(7091)
(7496)
(7394)
(79100)
16 136
15 958
10 931
8 203
7 645
7 002
7 946
6 214
5 577
4 227
3 303
2 723
2 487
42
42
29
21
20
18
21
63
55
41
31
26
23
86
89
84
85
88
81
91
88
89
81
84
90
88
(7698)
(78100)
(7496)
(7597)
(78100)
(7292)
(80100)
(78100)
(79100)
(7293)
(7496)
(80100)
(78100)
1 728
2 925
2 935
5 141
4 347
4 122
4 208
16 256
23 271
27 470
26 104
20 868
18 379
16 866
50 641
84 980
140 677
127 930
126 227
118 641
112 910
1
2
1
40
67
71
136
121
115
119
70
103
124
120
97
86
79
34
57
96
89
88
83
79
4.1
7.8
3.7
74
62
49
78
71
70
74
48
54
68
82
83
79
78
73
60
75
66
78
79
81
60
130
240
(6289)
(5275)
(4159)
(6595)
(6086)
(5884)
(6289)
(4058)
(4566)
(5783)
(6899)
(70100)
(6696)
(6594)
(6286)
(5170)
(6589)
(5678)
(6792)
(6793)
(7096)
(5369)
(110150)
(210270)
3 208
1 879
2 326
2 171
4 194
2 798
2 864
1 448
1 540
1 010
710
438
386
352
722
525
368
269
186
169
181
7 600
8 764
7 993
7 281
6 687
6 377
6 044
557
564
417
539
515
552
457
1 278
830
404
381
334
322
379
2 460
2 029
2 779
5 460
6 125
6 297
6 290
33
19
24
22
41
26
27
27
29
19
13
8
7.1
6.4
37
27
19
13
9.2
8.3
8.9
20
22
20
17
15
14
13
6.5
6.4
4.7
6
5.5
5.9
4.8
19
12
5.6
5.1
4.4
4.2
4.9
46
35
45
85
90
92
90
95
89
130
130
70
48
67
80
86
83
86
82
83
89
92
84
83
95
89
85
96
80
83
88
90
88
86
84
85
92
88
110
87
90
72
91
85
56
70
79
82
100
67
24
20
42
48
48
47
(84110)
(79100)
(110150)
(120150)
(50100)
(4059)
(5682)
(7091)
(7698)
(7395)
(7699)
(7293)
(7395)
(79100)
(81110)
(7496)
(7395)
(84110)
(78100)
(7597)
(85110)
(7091)
(7395)
(78100)
(80100)
(77100)
(7698)
(7496)
(7698)
(81100)
(78100)
(93120)
(7799)
(79100)
(6382)
(80100)
(7597)
(4964)
(6179)
(7091)
(7293)
(90120)
(5681)
(2029)
(1725)
(3551)
(4058)
(4058)
(3957)
PERCENT
EUROPEAN REGION

YEAR
219
YEAR
The Former
1990
of Macedonia
2000
2005
2009
2010
2011
Turkey
1990
1995
2000
2005
2009
2010
2011
Turkmenistan
1990
1995
2000
2005
2009
2010
2011
Ukraine
1990
1995
2000
2005
2009
2010
2011
Great Britain and
1995
Northern Ireland
2000
2005
2009
2010
2011
Uzbekistan
1990
1995
2000
2005
2009
2010
2011
220
POPULATION
(MILLIONS)
2
2
2
2
2
2
2
54
59
64
68
72
73
74
4
4
5
5
5
5
5
52
51
49
47
46
45
45
57
58
59
60
62
62
62
21
23
25
26
27
27
28
NUMBER
(THOUSANDS)
1.5
1.1
0.83
0.6
0.46
0.43
0.41
28
28
23
21
19
19
18
3.7
6.3
9.6
8.2
5.3
4.5
3.8
23
37
52
56
48
44
40
6.6
6.9
7
9.2
7.8
8.1
8.8
26
46
71
60
39
34
28
(0.9502.3)
(0.9301.4)
(0.6801.0)
(0.5400.670)
(0.4000.530)
(0.3700.500)
(0.3500.470)
(2532)
(2431)
(2026)
(1824)
(1722)
(1621)
(1520)
(3.04.4)
(5.17.5)
(7.812)
(6.79.8)
(4.36.3)
(3.75.4)
(3.14.6)
(1927)
(3144)
(4362)
(4666)
(3956)
(3752)
(3347)
(6.27.1)
(6.57.4)
(6.57.4)
(8.69.8)
(7.38.4)
(7.68.6)
(8.29.4)
(2130)
(3854)
(5984)
(5072)
(3246)
(2840)
(2333)
RATEa
81
58
41
30
23
21
20
53
47
36
31
27
26
24
101
150
213
172
106
90
74
44
73
106
119
104
97
89
12
12
12
15
13
13
14
125
199
286
233
144
122
101
(50119)
(4769)
(3450)
(2733)
(2026)
(1824)
(1723)
(4660)
(4153)
(3241)
(2735)
(2431)
(2229)
(2127)
(82121)
(122180)
(174256)
(141207)
(87127)
(73108)
(6189)
(3652)
(6086)
(88126)
(99141)
(86123)
(80115)
(74105)
(1112)
(1113)
(1113)
(1416)
(1214)
(1214)
(1315)
(103148)
(165237)
(237341)
(192277)
(119171)
(101145)
(84121)
NUMBER
(THOUSANDS)
RATEa

NUMBER
<0.01
<0.01
0.012
0.02
0.027
0.027
0.027
(<0.01<0.01)
(<0.010.011)
(<0.010.021)
(0.0100.033)
(0.0140.043)
(0.0150.044)
(0.0150.044)
0
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
(00)
(0<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
(<0.1<0.1)
786
641
598
450
384
335
24 468
22 981
18 038
19 744
16 757
15 879
15 054
2 325
1 939
4 038
3 191
3 157
3 230
<0.01
0.43
5.5
8.1
5.4
7.3
8.1
0.069
0.085
0.12
0.24
0.26
0.27
0.3
0.072
0.27
0.68
0.25
0.65
0.7
0.96
(<0.01<0.01)
(0.2800.620)
(4.27.0)
(6.210)
(4.46.4)
(6.18.7)
(6.79.6)
(0.0640.075)
(0.0590.120)
(0.0850.160)
(0.1800.310)
(0.2000.330)
(0.2100.340)
(0.2200.380)
(0.0590.085)
(0.1900.380)
(0.4800.920)
(0.1900.310)
(0.5200.790)
(0.5700.860)
(0.7801.2)
0
0.9
11
17
12
16
18
0.1
0.2
0.2
0.4
0.4
0.4
0.5
0.4
1.2
2.7
1
2.4
2.6
3.5
(0<0.1)
(0.551.2)
(8.614)
(1322)
(9.714)
(1319)
(1521)
(0.110.13)
(0.100.20)
(0.150.27)
(0.300.52)
(0.320.53)
(0.330.56)
(0.360.60)
(0.290.42)
(0.811.7)
(1.93.7)
(0.741.2)
(1.92.9)
(2.13.1)
(2.84.2)
16 465
21 459
32 945
39 608
36 075
33 857
34 237
5 908
6 176
6 220
8 173
7 008
7 219
7 850
9 414
9 866
15 750
21 513
17 540
16 883
14 501
RATEa
CASE DETECTION
PERCENT
40
32
29
22
19
16
45
39
28
29
23
22
20
63
46
90
67
63
64
69
77
99
97
89
83
86
83
78
95
86
85
85
63
31
42
39
60
71
(5885)
(6494)
(90110)
(85110)
(77100)
(7296)
(7698)
(7395)
(6989)
(84110)
(7698)
(7597)
(7597)
(5277)
(2638)
(3551)
(3248)
(5073)
(5987)
32
42
67
84
79
74
76
10
11
11
14
11
12
13
46
43
64
83
65
62
52
73
58
63
71
76
77
86
89
89
89
89
89
89
89
37
22
22
36
45
50
52
(6188)
(4970)
(5476)
(6085)
(6491)
(6593)
(72100)
(8495)
(8495)
(8495)
(8495)
(8495)
(8495)
(8495)
(3145)
(1826)
(1927)
(3043)
(3854)
(4261)
(4362)
YEAR
Albania
20
13
Andorra
44
Armenia
17
41
Austria
20
Azerbaijan
36
70
Belarus
30
49
Belgium
16
Bosnia and
Herzegovina
95
36
Bulgaria
26
29
Croatia
57
14
Cyprus
Czech Republic
19
Denmark
Estonia
27
22
Finland
15
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
653
641
604
506
435
431
422
23
12
10
8
7
3
590
1 000
1 333
2 206
1 560
1 410
1 261
1 521
1 481
1 185
928
441
358
400
2 620
1 630
5 187
6 034
7 301
6 390
6 527
3 039
4 854
6 799
5 308
5 250
5 003
4 697
1 577
1 380
1 278
1 076
806
814
4 073
2 132
2 476
2 111
1 725
1 321
1 360
2 256
3 245
3 349
3 225
2 683
2 412
2 172
2 576
2 114
1 630
1 050
832
688
619
29
36
33
34
43
33
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
139
171
196
171
145
180
223
188
134
109
105
105
226
234
167
136
165
128
0
0
53
11
9
19
16
9
8
34
2
14
9
53
19
43
21
30
18
10
0
0
1
5
2
0
1
9
1
4
4
2
2
4
1
3
0
0
0
0
0
0
1
0
0
0
0
1
0
1
0
0
2
0
1
0
0
0
436
621
581
440
339
329
451
505
1 049
725
639
582
75
153
365
299
351
289
0
0
0
38
54
211
96
81
61
22
116
446
370
321
38
76
327
542
451
382
0
0
0
467
324
234
90
76
94
765
652
519
268
213
217
249
209
175
34
69
85
45
0
0
0
0
4
0
4
30
26
21
29
16
30
26
25
29
20
245
301
271
669
890
1 561
1 487
1 997
1 426
620
3 978
2 508
3 124
2 275
2 752
93
245
651
1 261
965
1 130
0
0
47
74
1 314
1 429
1 153
1 219
0
1 886
955
844
3 290
47
74
3 200
2 384
1 997
4 509
2 161
1 160
0
1 845
2 547
1 235
1 201
1 269
1 217
2 148
2 985
3 710
3 002
2 647
2 439
518
442
363
430
429
387
0
1 049
261
456
421
343
825
1 049
878
1 114
1 075
400
409
380
280
244
534
454
406
294
340
366
326
290
107
230
0
68
80
89
68
87
87
214
214
865
759
640
609
441
547
997
1 287
1 106
862
529
611
140
261
258
188
161
162
0
158
0
130
169
107
66
32
40
24
49
47
69
25
130
193
156
113
101
65
0
0
0
0
1 087
2 524
1 214
894
806
716
1 709
0
1 511
892
748
708
449
442
376
443
747
628
297
0
0
383
124
157
111
120
0
77
215
237
235
383
201
372
348
355
13
0
0
343
825
617
658
654
80
89
125
0
95
1 204
703
165
42
372
302
183
201
575
410
382
343
103
81
87
75
0
39
36
94
23
7
94
62
43
6
4
9
14
8
11
10
13
15
12
13
17
12
3
13
0
0
0
2
0
3
1
0
0
0
3
3
0
1 937
1 834
1 414
973
638
627
487
420
308
218
200
1 026
679
461
322
333
300
290
204
54
94
21
25
0
0
34
21
25
34
51
51
64
0
350
448
587
395
294
313
128
171
129
101
115
186
244
145
125
102
128
144
121
25
39
0
29
4
46
6
28
29
10
46
41
0
369
255
162
135
99
123
124
320
217
175
134
124
60
67
46
18
17
18
3
0
0
71
116
54
30
33
31
0
40
50
46
45
71
116
94
80
79
76
0
0
244
205
130
93
82
82
193
136
114
198
146
143
224
157
95
114
84
87
29
0
0
22
29
22
114
0
0
0
0
15
13
15
13
423
624
791
479
361
283
296
772
661
527
339
519
312
312
9
0
44
0
37
57
6
28
0
6
42
11
28
0
14
0
0
38
48
59
61
58
63
10
83
33
0
33
49
55
36
38
35
36
38
33
31
25
26
30
52
18
38
32
47
34
46
46
25
29
32
33
43
47
48
49
42
46
37
37
41
45
47
39
100
45
50
52
50
63
39
42
32
37
35
29
41
48
40
32
38
40
40
38
41
41
47
45
53
75
44
43
44
42
50
56
60
53
32
36
36
EUROPEAN REGION
NEW AND RELAPSE

NOTIFICATION RATE
19902011
221
NEW AND RELAPSE

a
NOTIFICATION RATE
19902011
YEAR
France
16
Georgia
28
105
Germany
19
Greece
Greenland
Hungary
35
Iceland
Ireland
18
Israel
Italy
Kazakhstan
66
113
Kyrgyzstan
52
103
Latvia
34
39
Lithuania
40
53
Luxembourg
13
222
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
9 030
8 723
6 122
4 887
2 890
2 752
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
3 449
1 815
1 941
1 019
960
2 969
1 364
1 557
1 038
1 015
2 305
1 665
1 389
439
765
221
601
1 509
2 055
2 140
2 026
1 087
2 213
1 524
1 119
1 088
1 141
121
1 324
1 261
1 283
1 155
1 056
3 852
6 473
1 873
1 379
1 025
910
942
2 801
1 765
1 713
1 768
235
197
198
178
63
114
3 588
4 339
3 073
1 808
1 315
1 543
1 537
1 625
4 397
4 501
4 732
4 674
4 547
14 653
12 198
9 064
5 539
3 659
3 524
3 528
877
939
703
626
465
356
18
12
13
10
11
22
8
624
458
386
387
340
319
281
234
398
537
371
347
340
412
4 246
5 627
3 501
3 828
2 541
1 693
1 658
10 969
11 310
25 843
25 512
20 508
19 703
18 254
2 306
3 393
6 205
6 329
5 765
5 652
5 529
906
1 541
1 982
1 409
951
913
864
1 471
2 362
2 657
2 114
1 895
1 750
1 745
48
32
44
37
24
11
0
0
371
0
371
394
12
116
315
315
2 049
0
0
0
196
259
207
275
291
324
422
1 945
291
1 118
986
196
681
2 152
566
1 409
1 310
2
955
4
0
1 211
353
789
728
402
16
17
148
114
96
73
345
138
271
223
493
252
367
296
161
635
535
513
339
322
196
129
81
107
44
49
26
0
48
0
1
0
74
2
44
48
74
3
44
67
121
89
24
38
30
59
3
7
6
10
0
2
6
12
796
412
423
363
270
3 292
2 361
1 137
800
1 147
251
221
117
51
70
16
0
79
131
85
56
292
216
126
198
371
347
211
254
7
0
2
1
2
3
6
1
3
7
3
3
12
2
7
4
5
2
4
5
2
0
0
0
1
0
1
0
0
0
1
0
0
1
0
1
1
1
0
1
1
0
0
138
130
95
84
85
150
156
119
122
110
96
99
60
112
83
59
1
3
2
2
7
20
38
9
31
28
22
40
16
31
28
36
139
77
121
216
142
119
103
135
213
168
130
162
207
100
55
89
74
66
0
0
0
0
0
8
6
9
1
4
0
1
0
3
6
8
7
9
4
10
0
0
0
0
0
1 413
687
1 275
885
586
476
2 700
891
1 506
863
779
730
1 514
522
1 047
408
328
452
269
0
356
293
625
293
385
0
0
0
0
74
69
74
69
16
1 336
1 482
1 167
3 022
8 903
6 911
5 213
4 769
4 306
5 966
11 324
14 472
9 319
8 745
8 094
1 002
2 555
920
2 278
2 127
1 996
0
0
0
1 320
3 061
3 209
3 698
4 062
3 858
2 032
11 800
5 673
5 151
4 822
1 320
5 093
15 009
9 371
9 213
8 680
3 117
4 397
3 696
0
832
1 296
1 972
1 609
1 645
1 537
1 685
2 929
2 141
2 267
2 028
2 125
749
1 683
1 805
1 558
1 635
1 518
0
0
127
297
411
331
344
349
258
436
427
643
725
127
555
847
758
987
1 074
504
637
536
367
339
293
693
793
554
377
400
410
226
285
148
47
86
85
39
0
0
118
267
171
121
88
76
108
34
26
21
21
118
375
205
147
109
97
0
0
979
776
964
742
719
681
1 049
1 051
793
702
633
664
206
503
357
158
221
187
75
0
0
128
327
0
218
177
213
182
460
186
187
156
128
509
460
404
364
369
1
3
21
14
19
20
0
3
4
0
4
0
0
4
18
4
6
3
0
0
0
1
0
1
0
0
0
166
27
5
14
54
57
55
50
49
17
21
50
65
66
64
37
33
37
35
35
41
38
50
58
44
39
19
15
27
31
19
40
12
40
50
33
33
48
45
44
41
44
50
46
48
39
39
34
44
46
51
43
39
34
44
32
36
35
35
33
31
48
42
45
42
42
45
49
49
46
42
48
42
55
51
53
51
52
41
0
50
YEAR
Malta
Monaco
Montenegro
17
Netherlands
Norway
Poland
42
21
Portugal
63
Republic of
Moldova
40
119
Romania
70
79
Russian
Federation
34
79
San Marino
Serbia
22
Serbia (without Kosovo)
Kosovo
Serbia &
Montenegro
41
Slovakia
27
Slovenia
37
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
1990
1995
2000
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
13
11
16
21
41
20
22
1
1
0
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
5
5
5
12
4
7
4
9
10
11
6
8
2
2
6
6
10
7
16 136
15 958
10 931
8 203
7 645
7 002
7 946
6 214
5 577
4 227
3 303
2 723
2 487
1 728
2 925
2 935
5 141
4 347
4 122
4 208
16 256
23 271
27 470
26 104
20 868
18 379
16 866
50 641
84 980
140 677
127 930
126 227
118 641
112 910
1
2
1
3 208
1 879
2 326
2 171
2 146
1 625
1 442
1 296
1 062
254
884
875
4 194
2 798
2 864
1 448
1 540
1 010
710
438
386
352
722
525
368
269
186
169
181
12
0
0
0
0
0
1
2
3
3
0
0
1
2
3
3
56
36
33
52
40
47
1
1
9
8
1
156
113
110
110
1 369
1 619
1 244
1 127
1 111
1 029
970
285
236
221
269
258
274
0
0
0
1
64
53
39
48
66
43
49
40
13
12
14
12
0
0
0
13
5
8
10
14
6
4
2
27
11
12
12
1
0
0
575
289
237
203
176
177
1 522
528
491
392
370
353
513
427
385
499
463
425
4
3
0
14
17
16
12
70
30
29
27
26
70
44
46
43
38
20
17
11
62
37
48
42
49
57
103
119
125
110
89
79
102
37
115
28
2
0
10
14
28
12
14
42
42
7
105
23
6 955
3 180
2 823
2 658
2 484
2 587
7 285
6 392
4 591
4 047
3 625
4 344
647
477
789
408
501
584
155
0
0
1 071
882
0
377
392
431
0
1 077
311
507
532
1 071
882
1 077
688
899
963
280
0
0
2 019
1 863
1 302
1 043
912
1 531
1 005
974
826
791
1 759
1 178
905
405
679
326
16
268
177
122
123
89
304
228
148
139
268
481
350
271
228
665
651
1 696
1 318
1 267
1 272
1 958
1 788
2 237
2 015
2 073
2 140
154
122
568
471
405
424
0
0
0
148
374
640
543
377
372
0
1 137
1 120
1 312
1 108
148
374
1 777
1 663
1 689
1 480
10 469
10 202
10 801
8 987
7 951
7 362
8 303
10 180
8 038
5 681
5 113
4 557
3 422
3 474
3 568
2 486
2 899
2 634
712
0
0
1 077
3 614
3 697
3 002
2 416
2 313
156
3 241
2 399
2 699
2 352
1 077
3 770
6 938
5 401
5 115
4 665
37 512
27 467
32 605
33 351
31 416
29 191
42 241
102 228
74 301
72 931
67 894
65 106
5 227
5 313
12 320
10 945
3 513
10 023
5 669
8 704
9 000
8 737
8 590
12 478
26 449
23 569
37 243
46 569
18 147
35 153
32 569
45 980
55 159
1 105
1 055
977
905
873
801
690
654
232
254
287
251
1 584
488
700
745
714
479
197
501
401
245
40
139
148
120
260
64
52
42
300
203
200
162
431
372
596
202
155
234
119
91
119
91
269
349
299
246
29
29
29
29
1 497
0
930
2 486
173
175
198
203
198
203
788
236
162
121
112
96
555
469
356
202
190
170
177
203
134
61
59
57
20
102
58
32
25
29
18
50
47
30
21
20
120
108
79
55
50
21
23
26
303
145
109
85
64
82
83
133
110
70
67
73
109
59
30
13
30
26
16
9
2
3
11
30
47
29
8
11
11
0
0
54
0
0
7 081
0
0
0
5
0
124
13
25
2
0
0
6 426
6 669
0
652
7
3
5
647
22
0
0
12
0
0
30
31
20
6
8
49
55
44
55
27
35
33
34
32
33
52
26
29
25
31
49
33
38
40
41
37
57
65
57
56
54
25
27
43
40
38
37
56
50
57
61
61
62
47
21
30
31
32
31
100
41
68
58
55
55
100
62
64
28
100
52
42
62
0
59
33
31
37
37
36
78
52
50
55
49
53
EUROPEAN REGION
NEW AND RELAPSE

NOTIFICATION RATE
19902011
223
NEW AND RELAPSE

a
NOTIFICATION RATE
19902011
YEAR
Spain
20
13
Sweden
Switzerland
19
Tajikistan
46
90
The Former
Yugoslav Republic
of Macedonia
16
Turkey
45
20
Turkmenistan
63
Ukraine
32
United Kingdom of
Great Britain and
Northern Ireland
10
76
13
Uzbekistan
46
224
52
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
7 600
8 764
7 993
7 281
6 687
6 377
6 044
557
564
417
539
515
552
457
1 278
830
404
381
334
322
379
2 460
2 029
2 779
5 460
6 125
6 297
6 290
786
641
598
450
384
335
24 468
22 981
18 038
19 744
16 757
15 879
15 054
2 325
1 939
4 038
3 191
3 157
3 230
16 465
21 459
32 945
39 608
36 075
33 857
34 237
5 908
6 176
6 220
8 173
7 008
7 219
7 850
9 414
9 866
15 750
21 513
17 540
16 883
14 501
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
2 605
3 423
2 511
2 236
2 076
2 186
6 159
4 446
3 880
2 879
2 621
2 242
124
890
1 572
1 680
1 616
102
118
134
107
117
99
235
147
208
180
226
182
216
152
197
228
209
173
185
86
84
74
82
90
515
216
187
163
149
170
126
102
110
97
91
119
1 042
434
1 745
1 972
2 290
2 174
617
1 918
2 175
2 208
2 038
2 148
427
1 417
1 684
1 631
1 613
319
167
178
198
141
132
376
308
236
103
135
99
4 383
4 315
7 450
6 007
5 375
4 927
0
0
0
1 078
0
1 078
0
0
324
370
324
370
11
0
0
40
30
11
40
30
0
3
52
42
52
45
112
71
87
63
49
51
40
54
5
63
49
51
40
54
173
133
169
186
145
0
0
123
261
338
355
2 066
272
647
574
2 189
533
985
929
1 085
697
745
66
150
141
116
92
76
0
0
0
25
16
43
33
16
28
0
60
23
36
27
25
16
103
56
52
55
0
0
0
17 534
8 544
5 944
4 289
4 191
3 925
1 064
4 371
5 359
5 647
5 617
5 565
0
0
0
808
991
814
696
637
1 559
631
672
625
808
2 550
1 445
1 368
1 262
14
0
0
544
1 017
995
1 370
1 153
1 327
2 709
1 498
1 223
1 248
1
241
656
564
473
67
71
42
1 894
100
67
1 965
142
8 263
10 738
9 793
17 258
1 514
1 739
13 632
9 976
10 502
15 934
17 599
14 106
3 858
3 355
3 367
365
3 213
1 204
1 821
1 256
1 201
1 204
4 162
2 037
2 752
2 462
2 551
2 827
2 014
2 478
3 600
3 262
3 443
3 783
28
24
36
2 735
3 825
5 695
4 959
4 711
4 198
5 798
10 142
7 857
6 943
6 735
5 958
1 333
1 760
6 324
4 667
4 288
3 839
0
0
0
0
370
274
0
0
905
388
348
370
82
82
1 889
3 210
1 889
3 210
2 651
2 562
3 049
2 826
2 552
7 858
5 477
5 114
10 907
0
0
0
460
0
460
576
524
576
524
2 032
688
589
324
7 378
1 480
3 447
568
347
9 015
2 451
4 596
1 074
2 433
0
844
23
1 637
971
1 149
506
581
30
43
39
44
44
49
30
45
39
37
34
35
26
28
31
31
35
35
63
18
45
47
53
50
46
35
43
66
51
57
20
34
56
58
56
56
29
27
40
53
48
46
38
46
36
43
37
40
34
32
30
32
27
42
42
41
41
% OF COHORT
Albania
91
Andorra
Armenia
55
72
82
65
Austria
Azerbaijan
65
77
66
Belarus
Belgium
Bosnia and
Herzegovina
97
Bulgaria
86
Croatia
75
Cyprus
100
Czech Republic
60
Denmark
Estonia
68
74
Finland
France
Georgia
58
76
Germany
0
a
77
YEAR
NUMBER
NOTIFIED
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
139
171
196
170
171
145
1
5
3
2
0
436
621
581
487
440
339
467
324
234
90
76
669
890
1 561
1 409
1 487
1 997
1 845
2 547
1 235
1 060
1 201
1 269
400
409
380
311
280
244
865
759
640
509
609
441
1 087
2 524
1 214
1 020
894
806
1 204
372
328
302
183
6
4
9
6
14
8
487
420
308
249
218
200
128
171
129
106
101
115
369
255
162
144
135
99
244
205
130
104
93
82
3 449
1 815
1 941
1 222
1 019
960
221
601
1 509
1 868
2 055
2 140
3 852
1 379
954
1 025
910
SIZE OF
COHORT
196
170
171
145
2
5
3
3
0
507
447
581
487
440
339
383
298
230
380
226
206
538
890
1 561
1 392
1 480
1 733
1 902
2 160
2 184
358
304
502
485
865
756
1 035
757
852
1 342
1 193
1 055
946
391
602
234
181
6
8
12
28
487
396
315
470
402
110
128
200
175
257
162
259
240
191
170
227
184
221
807
1 489
2 196
2 352
2 500
454
1 199
2 126
2 220
2 064
COHORT AS
% NOTIFIED
100
100
100
100
200
100
100
150
116
72
100
100
100
100
82
92
98
251
271
80
100
100
99
100
87
179
180
172
88
80
161
173
100
100
162
149
140
111
117
118
117
105
184
77
99
100
89
200
200
100
94
102
189
184
64
99
189
173
101
100
180
178
193
163
244
224
100
134
99
118
114
117
87
223
217
227
DIED
FAILED
DEFAULTED
NOT
EVALUATED
CURED
COMPLETED
43
52
64
49
35
39
25
42
4
4
2
3
2
1
1
0
5
2
4
3
11
4
4
3
80
33
33
50
0
67
67
0
0
0
0
0
0
50
0
0
0
0
20
0
0
52
81
59
62
60
55
2
0
17
7
8
6
58
89
48
48
47
43
2
6
13
11
12
16
81
73
58
40
59
59
7
0
11
8
15
33
8
4
3
5
7
4
10
9
7
10
9
6
1
4
3
3
3
36
3
5
6
3
15
0
0
0
13
0
0
12
2
4
2
7
4
1
7
14
10
8
8
7
6
7
9
8
6
19
3
12
10
16
11
0
0
4
7
10
1
1
11
11
21
16
23
4
4
22
29
12
5
68
64
66
3
0
0
9
10
8
7
4
22
3
1
1
10
20
2
25
21
20
14
41
45
55
62
10
10
7
8
1
0
4
0
17
0
9
11
6
24
4
4
97
77
93
87
97
1
18
3
5
2
0
1
1
4
0
1
1
0
1
0
1
2
0
1
0
1
1
2
1
0
82
79
78
84
3
5
7
2
4
6
9
8
2
2
2
2
7
6
4
3
1
1
1
1
40
46
48
58
100
7
11
15
17
0
7
18
26
14
0
0
3
0
0
0
1
2
3
4
0
45
19
7
7
0
38
33
29
25
25
0
12
8
0
0
0
0
17
0
25
17
71
57
59
62
67
66
3
11
10
1
2
0
17
6
21
21
3
1
0
3
0
2
1
2
6
7
35
11
20
2
4
37
44
16
22
49
39
25
31
5
6
1
4
0
1
1
1
0
2
1
1
9
8
56
42
67
70
59
57
65
2
2
1
1
3
11
8
15
15
10
1
1
18
2
2
6
10
6
6
4
12
10
1
18
17
46
33
48
26
34
27
16
17
9
6
0
0
1
1
2
5
14
15
41
38
60
53
57
59
18
25
13
20
19
17
8
3
3
3
3
3
3
9
5
12
12
12
29
25
13
8
7
7
2
0
7
4
3
2
61
39
33
33
32
16
32
34
44
44
16
9
12
12
12
1
0
7
0
0
2
2
2
1
2
4
18
11
9
9
EUROPEAN REGION

19952010
225
% OF COHORT
a

19952010
Greece
Greenland
Hungary
Iceland
100
88
Ireland
62
Israel
76
80
Italy
Kazakhstan
61
Kyrgyzstan
Latvia
61
76
Lithuania
68
Luxembourg
100
100
20
Malta
Monaco
Montenegro
87
Netherlands
72
78
77
Norway
Poland
226
65
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
235
197
80
198
178
24
38
796
412
423
346
363
270
2
1
2
2
3
6
651
412
602
597
2
2
2
5
4
16
138
130
123
95
84
73
107
188
188
164
216
142
95
119
103
1 413
687
1 275
938
885
586
3 022
8 903
6 911
6 193
5 213
4 769
832
1 296
1 972
1 712
1 609
1 645
504
637
536
400
367
339
979
776
964
884
742
719
336
227
178
202
99
295
223
8 781
6 884
6 167
5 355
4 919
1 233
1 897
1 640
1 543
475
637
536
1 471
592
596
776
958
1 764
1 033
959
37
21
14
0
0
5
5
5
15
12
4
14
5
4
5
20
10
5
64
65
53
39
575
289
237
189
203
176
62
37
48
53
42
49
6 955
3 180
2 823
2 650
2 658
2 484
63
65
78
39
715
301
208
467
454
469
87
37
47
105
146
214
2 823
4 228
4 391
3 998
COHORT AS
% NOTIFIED
158
97
174
164
100
200
100
250
133
267
53
82
153
198
195
156
160
187
170
96
21
32
99
100
100
103
103
95
96
96
96
94
100
100
368
161
176
100
99
200
139
133
100
80
100
133
83
125
98
100
147
100
124
104
88
247
224
266
140
100
98
198
348
7
100
160
165
161
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
28
32
32
45
36
13
21
12
10
13
11
10
3
12
20
19
12
9
7
7
11
20
9
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
100
100
80
75
88
0
6
0
0
0
0
0
0
0
20
25
6
33
3
7
5
0
51
62
69
62
62
12
9
7
9
7
0
3
0
0
4
1
2
1
0
0
22
15
23
31
65
69
78
72
69
73
37
18
15
11
14
7
6
36
15
11
10
10
11
3
1
0
0
0
0
0
2
0
0
3
1
1
0
11
9
1
2
1
3
13
4
16
76
70
64
62
61
3
1
0
0
0
5
5
4
4
3
10
12
26
30
7
3
5
4
3
2
3
8
2
2
27
73
81
80
79
9
4
5
4
3
3
3
3
4
5
6
4
5
5
5
6
6
2
2
4
61
68
72
32
72
72
0
4
1
0
3
3
9
12
11
4
9
8
3
3
1
5
1
1
21
7
7
2
5
6
7
7
8
57
11
10
73
70
51
73
68
100
0
31
0
0
0
10
11
7
10
11
0
4
3
3
2
1
0
12
11
7
9
11
0
2
6
0
6
8
0
7
0
0
0
15
0
0
0
0
0
0
0
0
0
0
0
0
0
20
100
100
60
80
20
0
0
0
0
93
0
0
0
25
20
80
10
52
49
46
17
23
9
14
11
1
43
49
62
62
45
21
32
37
41
55
53
75
71
69
76
34
22
30
22
37
5
8
5
8
6
7
7
9
7
14
14
2
6
4
0
0
0
2
4
3
5
3
1
1
3
4
8
3
4
50
65
54
48
47
22
12
20
19
18
11
5
7
5
6
6
1
0
0
0
0
80
0
0
0
0
0
0
1
3
0
4
1
70
9
3
5
15
15
8
7
8
12
0
11
2
7
13
6
9
10
10
9
5
8
9
17
20
% OF COHORT
Portugal
69
Republic of
Moldova
57
51
84
65
53
Romania
Russian
Federation
San Marino
Serbia
86
Serbia &
Montenegro
Slovakia
64
84
90
85
70
Slovenia
Spain
Sweden
85
Switzerland
Tajikistan
88
80
70
90
The Former
Yugoslav Republic
of Macedonia
Turkey
91
73
Turkmenistan
Ukraine
83
60
United Kingdom of
Great Britain and
Northern Ireland
81
78
81
Uzbekistan
YEAR
NUMBER
NOTIFIED
SIZE OF
COHORT
COHORT AS
% NOTIFIED
2 019
1 863
1 302
1 053
1 043
912
665
651
1 696
1 533
1 318
1 267
10 469
10 202
10 801
9 511
8 987
7 951
37 512
27 467
32 605
33 949
33 351
31 416
1 240
1 924
1 393
1 683
1 565
651
1 690
1 533
1 318
1 267
11 597
10 158
10 929
10 082
10 737
9 445
54
3 616
25 692
32 356
32 316
30 123
1 105
1 172
1 055
977
1 497
0
788
236
162
126
121
112
303
145
109
81
85
64
2 605
3 423
2 511
2 333
2 236
2 076
102
118
134
97
107
117
185
86
84
64
74
82
1 042
434
1 745
2 057
1 972
2 290
319
167
178
188
198
141
4 383
4 315
7 450
6 993
6 007
5 375
544
1 017
995
1 331
1 370
1 153
8 263
10 738
1 154
1 391
1 392
702
1 956
267
807
238
158
498
174
177
270
145
109
159
149
123
61
103
107
160
150
100
100
100
100
100
111
100
101
106
119
119
0
13
79
95
97
96
100
104
119
132
72
131
102
101
98
395
144
158
89
100
100
196
175
192
172
95
99
228
238
247
33
153
99
99
100
100
70
91
101
100
101
101
80
100
100
100
100
100
100
100
100
100
116
99
96
133
74
506
205
217
95
27
94
100
100
100
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
1995
2000
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
3 574
112
133
221
255
289
348
665
1 729
2 044
1 972
2 290
222
152
179
188
199
143
3 461
7 450
6 993
6 007
5 375
544
1 017
995
1 331
1 375
9 564
14 574
13 632
9 976
14 407
13 111
13 279
1 204
1 821
1 286
1 256
1 201
2 735
3 825
5 695
5 117
4 959
4 711
1 348
6 510
2 569
2 602
2 598
1 030
5 336
5 117
4 959
4 711
CURED
COMPLETED
DIED
45
9
13
11
9
23
71
76
77
75
4
6
6
1
60
54
49
52
38
28
71
72
72
70
54
64
55
54
52
50
FAILED
DEFAULTED
NOT
EVALUATED
4
0
0
3
0
4
5
4
2
3
19
9
2
7
7
62
2
7
5
5
13
42
11
13
14
14
11
4
3
3
3
3
0
9
11
10
11
6
4
5
5
4
5
15
6
13
12
11
12
0
11
8
17
5
7
8
4
4
4
4
6
13
14
18
20
23
0
11
12
14
13
6
8
6
5
6
6
11
9
11
9
8
7
37
7
8
5
13
31
9
4
2
1
2
4
4
4
4
5
5
100
72
80
80
80
34
82
64
81
66
47
82
84
64
33
47
38
24
28
13
6
6
5
18
7
1
2
1
1
3
0
0
26
46
0
0
26
51
38
42
63
57
5
7
6
7
2
4
16
14
6
5
14
12
4
8
12
15
9
11
1
0
1
0
0
2
0
0
1
1
0
5
4
4
4
10
6
4
2
1
1
2
3
1
5
1
2
1
1
4
2
2
2
33
1
16
1
1
0
2
1
3
3
3
2
3
3
39
32
23
0
0
0
70
79
74
87
85
15
11
6
6
6
5
0
1
1
0
0
2
1
1
1
1
8
18
4
8
9
69
74
74
76
75
76
61
51
62
81
85
83
18
3
9
7
6
4
9
35
22
7
5
7
7
15
4
4
4
5
13
4
2
7
4
4
3
8
6
7
8
11
9
2
0
1
2
3
2
0
7
5
5
3
9
7
14
2
5
2
0
0
0
1
1
1
0
1
0
1
0
1
0
45
59
61
63
55
79
70
83
83
73
44
33
30
29
18
2
14
1
1
3
2
3
3
3
11
9
6
6
5
0
0
1
1
1
7
6
4
6
6
6
5
3
2
3
2
3
5
5
5
19
3
2
3
2
7
1
1
1
1
83
56
52
51
6
7
9
12
13
13
12
16
17
9
8
8
5
3
3
68
78
82
81
0
53
9
6
5
5
7
4
6
5
9
3
6
6
6
6
0
0
0
7
6
6
6
5
6
1
1
5
6
4
5
7
4
5
5
24
16
7
8
3
6
1
3
3
3
0
0
78
27
72
75
77
76
EUROPEAN REGION

19952010
227
% OF COHORT
a

19952010
Albania
90
Andorra
Armenia
50
67
Austria
59
Azerbaijan
63
48
Belarus
Belgium
Bosnia and
Herzegovina
Bulgaria
64
Croatia
76
Cyprus
Czech Republic
Denmark
Estonia
40
Finland
46
France
Georgia
32
62
Germany
0
a
228
72
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
53
19
43
32
21
30
30
28
21
30
0
0
0
2
0
38
76
327
618
542
451
0
2
0
6
54
327
534
542
451
30
26
25
29
47
74
3 200
3 733
2 384
1 997
343
825
1 049
849
878
1 114
80
89
68
67
87
130
193
156
67
113
101
383
201
313
372
348
42
94
36
62
43
0
0
3
3
3
0
21
25
34
61
51
6
28
29
37
10
46
71
116
94
90
80
79
29
22
19
15
10
27
11
37
29
74
1 314
3 084
1 687
4 194
815
616
792
55
47
42
76
122
106
77
116
198
500
384
348
92
22
37
2
5
6
38
31
56
62
15
22
32
42
59
89
88
82
81
14
14
13
0
371
379
315
196
681
2 152
1 677
566
1 409
298
470
2 037
1 542
1 521
1 421
493
441
252
367
63
432
190
344
364
COHORT AS
% NOTIFIED
70
88
100
100
100
16
71
100
86
100
100
33
104
148
100
100
41
83
71
210
96
70
71
62
69
63
63
68
115
103
99
160
103
100
98
35
86
67
167
200
152
91
92
54
76
86
420
51
95
98
102
103
74
87
152
69
95
92
269
101
88
43
137
99
CURED
COMPLETED
DIED
37
39
38
43
37
36
38
47
3
14
10
3
FAILED
0
4
0
0
DEFAULTED
NOT
EVALUATED
10
4
10
7
13
4
5
0
100
50
52
13
15
9
5
0
15
28
36
54
62
0
7
7
8
8
6
17
7
12
15
4
10
33
19
37
21
15
13
0
0
4
5
10
4
0
11
9
3
14
80
56
27
38
45
0
11
9
5
0
0
0
36
0
0
0
11
30
0
20
11
18
24
41
59
28
18
39
14
7
9
32
14
49
5
6
4
6
3
11
6
6
9
4
14
13
23
19
15
4
38
17
13
15
29
38
20
30
4
28
9
13
10
8
7
36
3
1
1
20
37
5
16
17
7
11
45
21
48
57
13
19
10
9
0
0
14
0
15
0
19
12
11
43
2
12
79
85
70
52
15
8
5
32
3
4
22
5
1
1
1
3
2
2
1
3
0
1
0
5
57
16
32
32
10
7
38
31
7
4
12
13
11
3
5
6
14
5
8
12
2
65
5
5
20
13
57
27
59
23
16
36
14
5
3
5
8
0
40
17
100
20
0
0
40
83
53
16
46
34
11
39
16
34
8
3
21
18
3
0
5
0
0
3
5
2
26
39
5
13
27
27
16
12
60
64
44
40
7
5
0
0
0
5
3
0
7
0
38
43
54
21
36
34
28
2
20
10
17
11
3
3
9
15
11
0
4
23
6
2
3
26
20
9
15
37
25
1
20
32
36
29
38
21
7
8
21
0
0
0
0
0
0
21
64
54
8
23
19
20
26
26
24
31
35
29
34
35
12
10
7
6
5
5
9
8
10
23
17
17
45
29
23
14
15
11
2
0
6
7
3
4
51
30
30
21
25
21
36
29
44
47
16
9
8
12
12
3
0
9
0
1
5
7
5
5
6
5
18
18
17
10
Greece
Greenland
Hungary
Iceland
Ireland
38
Israel
80
Italy
48
Kazakhstan
47
Kyrgyzstan
Latvia
62
Lithuania
32
Luxembourg
Malta
33
Monaco
Montenegro
86
Netherlands
66
Norway
Poland
61
YEAR
NUMBER
NOTIFIED
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
SIZE OF
COHORT
48
74
84
3
44
6
12
371
347
285
211
254
0
1
1
0
1
0
122
333
126
208
22
40
41
16
31
10
14
51
52
34
8
7
4
9
4
8
7
4
9
5
31
26
625
293
292
74
1 320
5 093
15 009
9 229
9 371
9 213
127
555
847
756
758
987
118
375
205
152
147
109
128
509
460
357
404
364
1
1
1
0
2 901
4 085
8 662
9 392
8 734
278
845
897
924
205
205
293
148
110
282
455
354
404
364
4
0
0
0
0
0
1
7
2
3
0
1
1
4
2
3
27
10
11
12
10
10
11
14
70
44
49
46
43
28
12
14
27
18
28
47
49
44
42
1 071
882
1 077
1 020
688
899
3
9
28
30
56
985
720
942
899
COHORT AS
% NOTIFIED
33
96
44
99
100
100
45
35
124
325
110
100
100
100
100
125
57
27
94
100
95
50
100
119
122
55
100
193
101
101
55
99
99
100
100
100
57
100
100
37
100
100
117
26
64
96
107
102
25
64
104
6
91
71
137
100
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
16
12
29
35
20
37
14
26
15
13
10
13
9
8
28
12
11
11
9
6
30
18
10
8
100
100
100
0
0
40
7
6
4
0
0
57
45
58
38
10
7
6
8
15
10
0
0
0
40
0
2
0
3
0
29
41
31
44
12
71
0
56
80
42
31
25
14
75
11
0
6
15
62
14
0
11
20
26
4
0
0
0
0
0
10
12
0
0
25
0
0
13
8
0
0
0
22
0
3
31
62
46
24
22
23
4
1
18
27
24
10
13
10
9
9
14
14
32
34
4
5
6
7
6
5
5
19
8
3
35
59
40
36
28
15
31
34
43
8
8
6
7
8
9
10
6
6
11
9
7
4
1
4
9
39
50
28
43
60
2
1
0
1
2
19
10
7
14
6
3
1
13
0
0
8
9
2
14
12
29
29
50
28
20
45
27
40
30
31
0
2
21
25
22
24
18
8
4
18
5
4
22
22
19
22
22
5
19
1
20
25
0
0
0
0
0
0
0
0
0
0
100
100
50
50
33
0
0
0
0
0
0
0
0
50
50
67
70
45
50
20
10
27
36
20
10
9
0
0
0
0
10
0
0
60
0
18
14
28
11
6
4
5
22
68
32
67
61
6
4
6
2
9
0
0
0
0
6
7
2
4
7
39
11
53
22
18
33
44
29
33
0
33
43
47
67
22
7
13
0
0
14
0
0
0
0
0
0
7
7
64
22
43
30
28
12
31
21
32
33
14
6
7
5
8
0
0
1
0
0
4
32
16
14
10
5
9
12
18
21
0
1
EUROPEAN REGION
% OF COHORT
a

19952010
229
% OF COHORT
a

19952010
Portugal
55
Republic of
Moldova
32
Romania
55
Russian
Federation
58
34
San Marino
Serbia
75
Serbia &
Montenegro
Slovakia
84
Slovenia
64
Spain
56
Sweden
75
Switzerland
Tajikistan
72
The Former
Yugoslav Republic
of Macedonia
65
Turkey
69
Turkmenistan
Ukraine
United Kingdom of
Great Britain and
Northern Ireland
74
Uzbekistan
0
a
230
73
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
1995
2000
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
COHORT AS
% NOTIFIED
268
481
350
292
271
228
148
374
1 777
1 865
1 663
1 689
1 077
3 770
6 938
6 012
5 401
5 115
133
209
293
178
265
50
43
84
61
98
0
96
100
100
101
69
97
77
100
100
9
31
19
51
32
95
110
120
86
10
38
94
173
100
100
51
93
138
100
100
108
22
53
76
100
80
102
304
176
94
100
100
100
62
100
101
100
25
100
262
342
190
32
100
220
44
99
100
98
18 147
35 153
94 070
32 569
45 980
1
1 713
1 865
1 663
1 702
2 605
6 737
4 656
5 391
5 118
12
1 694
10 855
18 070
16 726
14 609
300
280
203
200
198
203
20
120
108
98
79
55
30
47
29
16
8
11
284
309
244
172
21
46
101
170
79
55
24
27
22
8
11
0
1 078
461
324
11
40
30
37
52
5
63
49
53
51
40
370
2 189
1 846
533
985
25
16
103
56
56
52
808
2 550
1 689
1 445
1 368
67
1 965
142
281
351
9
16
28
45
52
1 762
1 881
1 618
1 732
97
56
56
52
1 593
1 692
1 459
1 368
495
142
737
82
1 889
3 210
2 093
5 477
5 114
0
460
413
7 152
10 424
147
576
791
576
347
9 015
5 087
2 451
4 596
764
3 999
5 046
2 451
4 527
CURED
COMPLETED
DIED
38
10
8
7
7
17
66
66
69
62
6
4
10
0
22
16
15
15
FAILED
DEFAULTED
NOT
EVALUATED
6
0
1
5
0
9
7
9
7
8
24
14
6
12
16
0
19
18
20
17
0
13
18
15
14
100
16
12
26
5
0
17
20
20
17
0
13
16
4
32
24
39
40
38
37
42
25
33
33
31
31
20
13
10
19
18
17
24
4
3
3
4
9
10
10
10
11
25
10
16
13
13
12
20
10
14
12
12
8
21
26
29
32
33
17
14
17
16
17
8
9
16
14
12
12
11
14
8
4
5
0
11
5
7
9
9
46
49
61
56
26
27
13
19
10
10
9
10
2
1
0
1
12
7
12
10
3
6
5
4
67
10
10
14
78
50
28
34
44
0
38
20
48
40
11
7
5
14
15
2
0
1
1
0
4
3
1
0
0
4
3
46
3
2
29
44
5
12
18
46
41
32
75
45
4
4
9
0
36
0
0
14
0
0
12
4
0
0
8
7
41
12
0
25
31
33
0
0
0
0
4
13
2
0
0
7
0
0
11
0
0
21
78
75
75
69
54
7
0
11
25
14
11
23
29
32
29
33
47
43
43
38
9
9
11
11
8
8
10
11
6
6
6
4
1
2
1
1
24
34
39
29
33
38
39
37
7
11
7
17
2
2
2
4
32
12
11
12
2
4
2
2
24
30
29
25
46
44
44
43
5
4
3
5
2
2
2
2
12
9
9
7
11
10
13
17
66
42
63
9
26
18
7
13
7
11
10
7
6
9
5
1
0
0
31
18
10
29
16
14
21
22
13
12
8
5
57
36
0
0
79
74
7
7
0
0
5
7
9
12
20
28
24
30
25
55
41
48
39
48
8
9
10
11
10
8
7
7
7
5
9
14
9
9
9
0
1
3
5
4
Albania
15
39
Andorra
Armenia
12
95
Austria
Azerbaijan
Belarus
93
Belgium
82
Bosnia and
Herzegovina
Bulgaria
71
Croatia
Cyprus
Czech Republic
19
Denmark
Estonia
94
92
Finland
France
Georgia
10
46
Germany
Greece
Greenland
Hungary
Iceland
91
100
22
85
92
Ireland
Israel
Italy
Kazakhstan
77
97
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
15
47
42
39
81
211
186
170
0
0
0
12
26
70
95
0
0
0
270
521
1 242
1 499
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
540
447
445
431
10
9
7
4
2 322
2 006
1 780
1 582
954
707
688
687
7 920
10 417
8 394
9 817
6 357
5 511
5 554
5 118
1 144
1 020
1 115
NUMBER OF
HIV-POSITIVE
TB PATIENTS
1
6
0
2
0
0
0
6
17
17
49
% OF TESTED
TB PATIENTS
HIV-POSITIVE
1
3
0
1
67
100
100
100
3
5
2
3
1
3
83
53
47
33
35
41
80
62
41
139
190
190
217
52
43
66
44
95
93
93
82
91
87
5 227
5 153
4 747
937
930
969
845
0
0
0
1
40
67
71
0
0
0
23
1 155
1 773
1 698
19
23
26
189
161
177
1 007
702
678
2
6
5
1
4
3
61
0
207
0
424
339
359
8
9
0
94
92
91
92
1
490
380
298
313
3
1
1
3
3
33
40
34
47
3
6
3
3
100
100
24
1 233
519
411
329
341
361
533
327
325
5 374
2 890
5 116
121
10
10
22
32
46
674
1 289
1 841
2 550
6 448
5 978
5 796
5 533
6 045
4 432
4 330
4 264
767
588
489
13
33
35
50
2
3
2
2
100
63
63
116
0
0
91
58
95
100
6
26
23
22
85
83
90
92
0
1
1
10
7
21
9
28
125
98
94
316
288
308
384
2
1
1
1
0
1
0
11
11
15
19
17
22
13
24
100
100
10
0
5
0
39
9
15
20
5
8
4
6
77
97
84
97
31 187
29 597
23 854
22 480
183
325
333
352
1
1
1
2
2 160
1 772
1 390
1 385
3 302
2 911
2 649
2 407
1 144
855
695
619
37
55
61
PEOPLE
CPT
ART
PROVIDED IPT
4
4
5
6
5
7
5
257
32
0
0
0
1
2
5
0
0
0
0
0
0
0
0
0
100
100
1
4
0
EUROPEAN REGION
YEAR
KNOWN HIV STATUS
20052011
1
3
2 024
1 448
1 741
11
12
22
9
461
488
427
430
372
347
343
418
4 137
3 877
3 249
2 894
40 429
30 578
28 550
23 076
7
11
11
15
100
0
0
57
47
55
54
55
63
56
100
55
77
76
100
100
100
100
61
36
41
11
26
20
8
7
8
9
1 027
1 063
1 329
231
YEAR
KNOWN HIV STATUS
20052011
Kyrgyzstan
Latvia
85
Lithuania
Luxembourg
Malta
91
Monaco
Montenegro
82
22
46
Netherlands
Norway
Poland
Portugal
70
Republic of
Moldova
103
94
37
46
55
Romania
Russian
Federation
San Marino
Serbia
Slovakia
95
100
38
77
67
Slovenia
Spain
Sweden
Switzerland
Tajikistan
82
12
46
The Former
Yugoslav Republic
of Macedonia
Turkey
Turkmenistan
Ukraine
74
United Kingdom of
Great Britain and
Northern Ireland
Uzbekistan
124
232
100
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
100
3
2
85
85
80
6 358
183
153
1 226
830
748
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
6 765
6 358
6 295
6 254
1 443
977
934
885
2 574
2 081
1 938
1 904
37
27
29
26
23
44
32
33
NUMBER OF
HIV-POSITIVE
TB PATIENTS
% OF TESTED
TB PATIENTS
HIV-POSITIVE
88
183
1
100
53
73
71
71
7
14
19
4
9
9
0
4
3
5
0
11
12
17
0
0
1
0
61
42
48
31
0
0
1
0
24
11
12
7
PEOPLE
CPT
ART
PROVIDED IPT
100
68
22
37
41
55
60
76
66
58
4
4
86
81
91
1
38
26
30
5
76
74
82
22
33
38
46
0
8
91
84
92
252
380
413
460
0
0
0
0
70
86
65
27
22
26
2 485
2 455
1 720
9 280
8 236
7 509
8 478
3 536
2 871
2 626
27
22
26
571
392
303
100
100
100
23
16
18
103
91
95
94
37
28
37
46
55
100
6 469
5 107
5 192
5 017
10 860
6 443
7 833
8 870
85 537
156 222
84 669
79 494
6 278
5 591
5 447
5 341
29 347
23 267
21 078
19 218
154 379
156 222
162 553
159 479
9
260
308
285
160
214
241
240
3 533
7 064
3 633
4 104
0
5
6
6
1
3
3
3
4
5
0
0
1
3
95
99
100
100
38
71
76
77
3
5
16
67
720
500
439
399
107
134
130
147
3
5
12
6
1
1
1
0
0
0
1
0
100
100
75
9
0
0
0
0
0
0
1
0
47
69
67
0
3 599
4 909
4 542
0
425
456
415
12
9
9
9
50
53
82
0
9
9
12
0
0
4
46
670
3 714
4 049
6 241
2
43
39
45
0
1
581
7 241
1
49
100
115
2
0
0
0
0
1
14
29
0
1
2
2
100
0
0
0
100
2
0
100
3 230
3 468
2 595
2 385
2 216
760
506
439
399
278
188
172
192
8 359
7 592
7 089
6 762
569
627
675
586
563
554
548
578
7 526
7 482
7 641
7 609
658
473
420
362
21 303
17 402
16 551
15 679
3 291
3 157
3 230
1 526
3 771
5 752
5 893
11
17
19
0
4
86
95
74
33 424
34 621
31 776
124
100
100
100
35 801
21 453
20 330
15 913
170
120
114
112
1 157
1 160
1 073
1 007
290
363
339
39 608
38 901
36 409
42 676
8 633
9 040
8 483
8 963
28 891
21 453
20 330
15 913
0
0
100
54
21
100
100
100
100
10
31
38
41
33
82
89
88
188
133
145
77
199
10 451
433
0
0
0
0
100
400
100
100
100
100
100
100
0
0
73
70
0
0
45
54
57
100
0
0
0
0
315
0
0
0
36
48
0
57
64
93
32
39
44
4 980
5 029
378
147
357
427
546
0
2
2
3
0
25
92
96
0
10
37
32
1 056
2 630
MDR-TB
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and
Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Greenland
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
1
0
2
5
0
0
0
0
162
156
177
79
13
22
15
19
800
552
722
1342
1576
1594
11
10
19
15
11
2
2
7
47
43
56
55
6
7
0
8
1
4
0
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
7.8 (1.614)
2.9 (0.3610)
0 (00)
0 (01.8)
250 (220280)
86 (65110)
12 (3.919)
7.7 (2.518)
2 000 (1 9002 100)
1 200 (1 1001 300)
BACT+VE
TESTED FOR
MDR-TB
75
58
76
87
150
67
100
100
99
110
87
96
110
110
99
95
29
19
96
90
94
89
120
97
100
100
100
99
40
62
85
62
100
110
96
84
96
70
100
100
97
140
120
98
110
100
100
100
85
130
96
97
47
180
120
53
76
80
83
98
110
110
91
170
49
37
62
76
92
140
120
120
80
110
110
130
81
110
130
120
99
140
64
100
83
20
42
14
29
2071
1972
2084
588
621
466
3.3 (07.9)
1.9 (<0.111)
120 (90150)
28 (1646)
0.89 (<0.14.9)
0.89 (<0.14.9)
1035
854
600
704
482
716
801
588
586
476
353
16
27
14
562
413
352
5
2
2
307
209
209
100 (83120)
56 (4372)
6.7 (0.9313)
4.9 (1.312)
195
369
359
475
105
61
48
56
12
14
2
BACT+VEb
TESTED FOR
MDR-TB
161
119
186
194
9
2
4
1
576
480
361
439
570
265
203
257
453
930 (7901 100)
13
8
9
79
86
63
78
3
6
6
5
24
30
23
% OF
801
3 400 (3 2003 700)
316
245
197
210
198
295
184
237
1291
2890
1187
760 (700820)
340 (300390)
100 (60150)
68 (33120)
799
1777
1987
2197
3094
2343
2215
2357
497
140
115
1
26
20
19
30
0
0
0
0
3
0
2
3
16
6
12
11
442
486
474
0.12 (0.100.15)
2.5 (07.3)
0 (01.8)
0 (04.3)
14 (5.922)
13 (6.123)
48 (3461)
39 (2754)
87
3644
7387
7408
989
785
566
806
7
6
19
4
200
162
200
166
259
258
245
275
836
8 200 (8 0008 400)
3 800 (3 6003 900)
1 500 (1 4001 700)
970 (8301 100)
NUMBER OF
4140
5214
5293
837
677
225
451
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
4.9 (1.111)
0 (00.98)
170 (140190)
4.0 (0.879.6)
2 500 (2 3002 700)
810 (780850)
1.4 (<0.17.3)
91 (66120)
44 (3354)
1.9 (<0.17.5)
420 (370460)
36 (2354)
0.12 (0.100.15)
2.5 (<0.112)
1.3 (<0.15.3)
8.6 (6.012)
4 500 (4 3004 600)
550 (490620)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
12
28
9
43
19
63
11
61
1
50
0
1
100
182
56
200
37
99
22
90
24
16
62
23
92
15
52
11
55
366
11
960
48
1754
200
1697
150
948
88
41
60
56
52
60
106
68
66
58
47
47
41
63
691
340
128
34
165
47
145
41
61
65
41
66
40
0
0
4
130
0
20
59
39
28
55
18
62
33
330
30
65
71
76
62
78
61
77
52
68
22
100
7
7
47
8
62
112
30
106
91
29
515
24
594
100
558
40
675
52
251
51
151
60
184
50
145
49
0
0
14
470
15
34
88
25
55
26
80
31
1
100
1
100
0
0
0
10
25
12
75
22
71
14
50
6
86
8
89
2
50
9
90
279
380
4413
47
4655
51
4790
55
152
18
263
35
264
27
232
22
EUROPEAN REGION
YEAR
TOTAL
CONFIRMED
CASES OF
b
233
YEAR
TOTAL
CONFIRMED
CASES OF
a
MDR-TB
Latvia
2005
2009
2010
2011
Lithuania
2005
2009
2010
2011
Luxembourg
2005
2009
2010
2011
Malta
2005
2009
2010
2011
Monaco
2005
2009
2010
2011
Montenegro
2005
2009
2010
2011
Netherlands
2005
2009
2010
2011
Norway
2005
2009
2010
2011
Poland
2005
2009
2010
2011
Portugal
2005
2009
2010
2011
Republic of
2005
Moldova
2009
2010
2011
Romania
2005
2009
2010
2011
Russian
2005
Federation
2009
2010
2011
San Marino
2005
2009
2010
2011
Serbia
2005
2009
2010
2011
Slovakia
2005
2009
2010
2011
Slovenia
2005
2009
2010
2011
Spain
2005
2009
2010
2011
Sweden
2005
2009
2010
2011
Switzerland
2005
2009
2010
2011
Tajikistan
2005
2009
2010
2011
The Former
2005
of Macedonia
2010
2011
Turkey
2005
2009
2010
2011
Turkmenistan
2005
2009
2010
2011
Ukraine
2005
2009
2010
2011
Great Britain and 2009
Northern Ireland
2010
2011
Uzbekistan
2005
2009
2010
2011
160
131
87
105
338
322
310
296
0
0
0
2
0
0
1
0
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
120 (96140)
89 (70110)
360 (320390)
170 (140200)
0.14 (<0.10.21)
0.14 (<0.10.20)
0.64 (0.500.78)
0.27 (0.150.38)
% OF
BACT+VEb
TESTED FOR
MDR-TB
873
618
613
562
1293
1074
959
1031
36
BACT+VE
TESTED FOR
MDR-TB
100
100
100
96
100
100
100
100
110
120
100
140
130
220
89
88
100
100
100
130
160
160
99
150
150
100
120
81
80
77
87
77
32
73
49
74
13
20
39
38
76
72
78
76
67
91
82
100
100
92
110
110
100
100
33
34
24
150
170
100
100
150
130
130
98
42
7.0
7.4
51
80
110
72
38
52
64
63
12
7.0
88
66
61
100
150
150
95
0
12
60
9.5
17
7
11
17
11
17
2
1
0
1
7
20
11
15
3
8
8
4
72
0
30
38
28
22
19
1.5 (04.5)
11 (4.817)
14686
13692
13785
9.2 (4.816)
68 (4689)
35 (2153)
1 600 (1 5001 700)
660 (570760)
850 (6501 000)
340 (220500)
44 000 (40 00048 000)
56
49
41
4
13
18
17
5
9
8
319
333
604
4
1
7
1
191
222
250
262
39
38
158
3482
5336
4305
39
58
60
81
86
654
1023
1385
3238
4017
1407
1391
982
19 000 (17 00021 000)
536
1284
1381
1379
1594
2226
3338
3482
36888
35862
34007
9
12
9
8
1
1
5
1
1
0
0
82
80
61
57
709
720
741
695
193
210
139
5409
338
1069
1082
1001
530
435
502
485
1.5 (<0.18.3)
1112
20 (8.631)
8.1 (2.221)
5.3 (011)
3.6 (0.4413)
0 (00)
0 (04.6)
36 (1558)
9.9 (1.235)
18 (8.927)
8.8 (4.016)
6.3 (0.9612)
0.86 (<0.14.7)
1 000 (9101 200)
2.2 (06.4)
560 (240880)
9 300 (8 50010 000)
71 (5587)
3 000 (2 7003 400)
540 (420670)
0 (06.5)
83 (10300)
4 400 (3 8005 100)
54 (4270)
2 400 (1 8003 000)
NUMBER OF
811
863
248
191
185
147
217
167
123
171
1147
1009
1013
425
424
288
375
326
269
270
304
833
160
161
106
191
153
130
3237
3714
4342
4221
164
81
306
12007
9194
10352
3428
3957
3970
4549
0
571
2845
484
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
28 (1939)
190 (170210)
0 (00.98)
0.37 (0.300.44)
0 (03.0)
1.7 (<0.18.7)
33 (2052)
940 (890980)
510 (380680)
25 000 (23 00029 000)
11 (5.022)
1.7 (<0.18.9)
0 (03.7)
26 (1249)
9.4 (3.219)
5.4 (1.513)
500 (450550)
2.2 (<0.111)
470 (190810)
4 800 (4 4005 300)
16 (8.727)
670 (560760)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
182
89
134
91
102
94
82
85
440
96
404
100
360
99
369
100
1
100
0
0
2
67
0
0
14
52
9
82
12
100
13
110
30
68
30
65
29
67
22
58
8
57
20
21
50
468
52
521
54
172
49
148
55
94
41
652
37
1129
68
1140
67
1006
68
1300
19
1641
30
2011
39
1974
42
6798
21
13405
29
13620
25
121
40
113
56
100
62
56
52
36
46
32
58
29
58
28
97
8
100
9
82
11
100
383
110
34
96
26
17
57
35
24
46
31
69
30
61
41
80
33
82
40
74
580
110
223
23
415
45
19
18
28
50
28
54
25
45
508
20
599
41
615
45
602
48
111
63
77
156
6348
120
4840
95
4413
40
271
59
364
247
43
234
45
435
4.8
732
30
1180
26
123
11
b
234
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and
Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Greenland
Hungary
FEMALE
014
1524
2534
3544
4554
5564
65+
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
0
2
0
0
0
0
19
26
28
29
0
21
21
17
26
0
14
16
14
18
19
24
31
16
30
40
19
20
16
9
30
16
37
15
22
0
0
0
0
1
2
3
0
0
4
1
1
0
0
0
0
77
0
0
0
0
0
18
152
170
36
28
37
17
32
4
8
13
9
109
328
1
1
0
0
16
130
104
75
65
95
30
23
4
11
29
24
297
371
0
1
0
0
11
131
83
49
52
82
59
22
12
9
14
33
215
267
0
0
0
1
10
63
84
68
71
89
42
41
13
13
6
42
209
280
0
0
0
0
8
26
30
27
42
71
23
24
8
11
4
30
187
30
0
0
0
0
1
21
24
15
8
73
41
30
10
13
1
0
88
27
0
1
3
3
1
4
71
65
53
23
20
26
20
180
173
156
49
57
50
39
273
224
228
63
39
32
30
287
293
290
52
55
27
29
118
163
138
54
32
15
21
62
58
48
102
56
47
19
0
4
1
1
2
15
56
22
27
33
61
82
58
37
32
90
99
61
34
52
140
66
78
61
75
139
58
44
46
61
100
77
80
51
62
0
9
1
2
6
13
98
40
38
38
16
150
115
100
97
20
195
143
110
210
3
195
133
122
132
9
150
90
92
178
10
136
65
61
141
1
0
0
0
24
10
12
1
27
19
5
1
48
18
20
0
72
38
31
1
47
25
31
1
34
24
21
2
0
0
3
2
1
1
1
0
1
0
0
0
1
0
2
0
0
0
10
7
8
12
22
31
24
19
83
52
57
36
88
89
55
29
53
61
45
29
0
5
0
0
7
10
12
8
16
20
12
22
28
24
18
10
18
16
23
13
0
0
0
0
1
0
1
0
0
30
10
12
10
6
9
3
4
1
3
5
10
1
156
136
127
60
31
25
7
22
10
8
4
6
4
431
248
212
139
53
19
21
16
25
22
3
8
4
502
247
222
114
2
4
0
5
5
14
20
76
226
340
271
179
30
111
272
529
478
453
6
1
1
59
43
43
1
1
1
UNKNOWN
UNKNOWN
014
1524
2534
3544
4554
5564
65+
0
3
0
2
1
1
11
3
11
14
0
10
9
7
10
0
8
5
6
6
13
8
5
3
2
20
5
5
2
1
16
11
18
8
12
0
0
0
0
0
0
1
1
3
1
0
6
1
0
1
0
0
0
90
3
1
0
0
1
24
27
24
19
22
11
13
5
11
5
3
64
141
1
0
0
7
27
21
17
16
52
22
11
4
6
18
3
98
100
1
0
0
2
24
10
4
9
32
12
8
2
4
0
6
47
57
0
0
0
1
8
11
7
7
21
11
3
2
1
0
3
32
73
0
0
0
1
8
4
8
7
18
6
5
5
3
0
0
24
9
0
0
0
0
0
0
4
7
8
5
59
22
10
6
4
0
0
24
18
0
0
1
3
3
6
2
6
25
28
37
12
15
27
13
53
52
67
24
15
31
18
50
56
47
32
19
15
19
43
37
39
17
4
12
11
11
28
27
10
13
4
5
62
91
83
34
27
23
10
1
0
0
0
4
2
0
3
40
30
35
27
17
67
46
39
19
27
64
29
33
16
17
49
29
28
10
13
77
48
28
18
25
23
124
130
94
128
0
9
3
2
10
11
90
42
41
50
14
111
59
40
57
7
59
43
36
57
3
29
23
28
38
4
37
15
14
60
6
70
34
30
130
1
1
0
0
12
3
12
1
18
8
14
1
15
4
14
1
11
2
8
2
6
1
7
0
56
30
26
1
0
0
0
0
1
0
0
3
0
1
0
0
0
0
0
0
0
1
90
59
46
19
0
0
0
0
0
0
9
15
3
6
11
13
14
10
20
9
16
11
13
10
7
7
19
7
5
2
88
57
28
20
0
0
9
11
9
16
11
14
7
2
0
0
2
5
2
0
7
16
11
4
13
15
5
5
8
14
13
15
4
6
9
8
3
7
3
8
2
8
5
4
0
0
56
40
25
14
28
19
14
9
7
414
211
196
99
35
12
12
18
24
28
11
8
11
297
125
134
76
15
7
8
13
61
53
25
18
27
496
244
205
110
0
0
0
0
1
0
0
0
1
36
18
16
10
9
6
3
4
1
1
3
3
2
138
108
104
47
11
11
5
8
6
5
4
2
3
226
127
134
76
14
8
3
12
7
3
1
4
5
176
89
82
49
11
11
3
3
4
4
0
1
3
90
46
56
45
4
6
6
3
10
6
6
2
1
92
43
38
25
10
8
3
6
65
49
20
11
13
365
155
180
97
25
113
268
341
333
539
40
63
207
264
251
460
18
45
76
143
139
442
12
28
60
77
93
625
2
1
4
5
8
17
8
49
109
135
136
115
17
37
105
118
132
251
17
33
58
62
59
167
18
17
46
52
32
89
7
10
17
28
35
104
5
5
47
41
54
397
113
92
95
171
97
106
167
141
141
92
87
68
167
136
127
0
0
0
4
3
2
51
44
44
104
63
90
73
61
59
43
38
54
37
26
26
103
76
85
0
0
0
10
14
19
22
25
27
32
22
20
24
14
18
19
12
19
46
23
22
5
3
0
0
3
2
13
2
9
18
13
10
8
4
5
7
4
6
2
4
25
17
15
0
1
0
0
1
8
6
9
24
24
15
85
67
36
104
117
51
58
67
52
27
39
23
0
0
1
1
0
7
5
9
17
13
16
19
11
14
22
22
9
10
15
15
30
33
20
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
MALE:FEMALE
RATIO
1.8
2.1
3.4
2.7
2.9
0.67
5.0
5.5
6.0
3.9
4.2
2.1
2.5
3.5
2.0
2.2
2.9
9.2
3.1
3.2
4.1
3.3
3.0
2.6
2.6
1.7
2.0
1.7
1.4
1.2
1.4
1.4
1.6
2.3
2.7
2.7
2.0
2.1
2.7
1.5
1.0
7.0
0.60
2.2
2.7
3.2
2.6
2.3
1.4
1.7
1.6
3.3
2.2
3.3
2.4
1.6
2.0
1.9
2.6
1.9
2.1
2.1
1.8
1.7
2.0
2.9
2.9
3.9
3.4
2.4
1.9
1.9
1.6
2.7
1.8
2.8
2.2
2.9
3.2
2.3
EUROPEAN REGION
MALE
YEAR
235
MALE
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of
Moldova
Romania
Russian
Federation
San Marino
Serbia
Serbia &
Montenegro
Slovakia
236
FEMALE
YEAR
014
1524
2534
3544
4554
5564
65+
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
2005
2010
2011
1995
2000
1995
2000
2005
2010
2011
0
0
0
0
0
0
0
1
0
1
0
0
0
3
0
0
0
0
1
0
0
0
1
0
0
10
6
8
7
7
10
18
9
7
21
4
10
6
10
11
11
4
7
5
7
12
6
11
8
0
1
1
0
9
12
8
14
13
20
4
13
29
59
63
93
40
32
26
15
28
30
202
96
191
75
47
23
18
12
11
157
75
137
66
50
23
15
8
5
94
58
101
32
36
13
5
4
9
124
54
61
31
23
38
26
6
9
289
112
115
58
58
36
31
15
6
3
4
1
5
6
0
0
1
0
0
4
1
0
1
1
1 057
917
675
602
109
128
247
261
225
20
53
22
20
11
46
38
42
34
25
1 409
1 142
754
716
171
227
303
260
204
44
106
71
44
42
132
97
118
75
52
1 379
983
595
516
165
205
269
188
179
71
124
104
65
58
225
145
186
128
126
923
795
511
515
65
115
194
141
168
70
111
117
71
50
176
155
187
157
158
439
274
251
235
38
52
66
64
77
40
64
55
39
33
90
74
108
89
77
218
175
127
91
30
46
84
48
41
30
34
34
15
18
77
68
67
54
55
0
0
0
0
0
0
0
0
0
0
1
0
1
1
0
2
2
0
0
0
0
1
3
4
2
0
0
1
1
1
0
0
1
0
1
0
1
1
0
0
1
0
1
0
0
1
0
0
2
0
0
0
1
0
0
0
0
0
0
22
0
0
0
2
0
0
0
0
3
1
1
79
34
23
22
22
4
1
9
9
5
1
2
119
63
42
29
35
8
9
4
9
7
4
8
75
41
23
22
19
6
3
6
7
15
4
11
28
25
26
20
23
3
6
4
1
4
7
7
9
10
14
9
14
5
2
4
4
8
1
3
10
21
19
17
13
12
4
3
2
3
1
3
3
5
11
8
5
3
122
99
109
70
69
215
147
85
55
295
303
199
205
187
363
375
227
110
795
812
389
310
314
328
349
284
199
565
782
639
574
560
200
208
181
152
369
361
292
393
439
173
140
90
70
377
434
310
237
275
164
140
93
76
0
2
2
0
2
387
46
36
21
19
55
52
211
119
94
1 662
832
752
669
623
115
31
337
243
257
2 322
1 508
1 511
865
807
166
36
345
244
250
3 608
1 799
1 786
1 336
1 189
95
13
313
248
267
2 587
1 684
1 999
1 293
1 099
65
13
106
113
107
1 751
916
952
895
833
15
6
31
21
21
784
533
638
567
540
295
526
596
402
151
54
8
15
2 228
1 826
6 276
5 726
5 571
5 338
5 361
4 928
2 787
2 664
920
845
UNKNOWN
UNKNOWN
014
1524
2534
3544
4554
5564
65+
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
13
9
7
8
8
10
8
7
13
3
2
7
6
3
3
8
7
0
2
2
15
8
5
1
0
0
0
3
0
0
0
7
6
3
25
10
10
6
1
10
52
38
80
41
31
16
14
8
10
93
58
145
57
51
6
7
10
7
57
33
56
41
40
3
7
2
4
40
13
25
22
17
3
5
0
4
51
19
19
22
14
32
19
10
7
168
39
70
54
52
84
46
33
15
1
6
15
5
13
0
2
0
0
0
5
0
1
1
0
999
751
566
439
70
128
215
223
200
22
25
17
6
7
6
20
25
20
20
1 079
767
520
495
94
146
236
199
191
49
41
31
19
16
53
37
41
36
31
599
436
263
260
34
100
141
98
84
55
27
31
25
19
45
39
57
31
37
275
286
205
190
18
41
70
71
60
47
28
23
12
14
32
32
49
43
38
202
121
122
109
15
30
33
40
50
27
7
18
10
12
16
22
23
18
16
204
187
132
117
19
29
98
42
39
29
15
12
13
13
42
48
54
32
45
0
0
0
0
0
0
0
0
0
1
0
2
0
0
1
1
0
0
0
1
0
0
0
1
0
0
1
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
24
4
3
1
2
0
1
0
0
0
3
4
56
29
14
9
13
4
3
4
5
7
3
2
50
22
19
14
13
7
1
7
7
3
2
4
13
16
11
13
7
2
4
3
3
10
9
9
5
7
0
1
2
8
8
1
7
10
4
11
3
8
5
3
0
0
0
0
2
3
0
1
1
8
5
1
4
4
3
2
0
0
4
1
3
2
1
7
5
7
3
129
99
95
59
67
139
114
67
54
163
158
142
118
96
172
154
109
62
225
211
112
82
90
87
87
66
54
111
170
151
104
130
33
41
29
36
107
82
63
82
99
42
25
11
10
414
421
316
245
255
85
64
42
28
2
1
3
6
3
355
53
55
40
27
42
16
97
47
66
1 352
701
758
503
473
38
32
92
90
79
1 240
766
780
477
513
31
45
57
46
51
871
484
493
400
403
19
23
61
47
41
479
341
374
275
212
10
14
23
23
20
396
207
219
172
198
12
6
18
20
14
417
321
442
438
426
0
0
0
0
24
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
0
0
0
0
4
0
0
0
0
0
0
9
6
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
2
0
0
43
73
74
38
31
44
28
36
1 247
1 139
2 554
2 394
1 719
1 643
1 182
1 166
745
719
790
752
0
0
0
6
5
5
11
69
66
46
127
76
74
59
167
55
46
43
133
49
39
30
83
22
34
20
158
149
164
129
275
0
0
0
5
0
0
0
0
16
5
1
1
2
17
9
8
6
3
22
7
9
7
4
24
5
5
2
6
33
4
6
3
1
159
54
27
11
11
3
2
2
10
62
76
60
108
96
70
73
204
118
93
74
317
156
116
122
296
112
83
112
350
132
109
101
386
4
2
0
1
0
18
6
3
7
6
44
15
13
7
8
123
31
16
18
6
108
50
25
17
20
63
16
25
17
16
152
32
20
15
13
0
0
0
0
0
0
MALE:FEMALE
RATIO
1.0
2.0
0.74
1.8
2.1
1.6
2.0
1.4
2.3
2.2
2.0
2.3
1.8
1.2
1.2
1.6
1.7
1.6
1.6
2.3
1.6
1.4
1.4
1.4
1.2
3.4
3.1
3.0
2.6
3.8
2.9
2.8
3.0
2.6
1.6
3.0
0.25
3.0
6.0
1.9
0.86
2.0
2.0
2.0
2.4
2.1
2.6
1.6
2.1
1.8
1.9
2.2
2.4
2.2
2.6
2.5
2.6
2.8
2.9
2.7
3.3
1.1
3.8
3.5
3.6
2.6
2.5
2.5
2.4
2.3
6.7
2.8
2.7
1.6
1.3
1.6
1.8
1.9
1.8
1.8
2.7
2.6
FEMALE
UNKNOWN
014
1524
2534
3544
4554
5564
65+
1995
2000
2005
2010
2011
Spain
1995
2000
2005
2010
2011
Sweden
1995
2000
2005
2010
2011
Switzerland
1995
2000
2005
2010
2011
Tajikistan
1995
2000
2005
2010
2011
The Former
1995
of Macedonia
2005
2010
2011
Turkey
1995
2000
2005
2010
2011
Turkmenistan
1995
2000
2005
2010
2011
Ukraine
1995
2000
2005
2010
2011
Great Britain and 2000
Northern Ireland
2005
2010
2011
Uzbekistan
1995
2000
2005
2010
2011
1
0
0
0
0
22
13
3
4
4
3
132
39
11
10
7
9
337
63
36
16
10
16
242
36
22
15
9
12
150
26
14
11
6
8
112
27
17
14
12
5
228
13
6
15
1
0
0
1
1
0
0
2
0
2
166
139
135
5
9
7
10
14
12
5
8
6
8
394
306
325
12
10
21
28
15
23
17
10
12
16
367
291
292
8
12
16
8
12
26
10
11
9
10
230
286
277
5
11
10
5
8
23
7
11
6
13
140
146
162
4
4
5
5
3
13
6
2
5
7
230
184
197
27
25
16
13
8
27
6
7
8
3
2
1
2
8
12
8
2
5
2
0
3
308
398
343
15
8
14
6
17
279
366
365
42
14
20
19
11
164
214
181
45
20
23
24
19
104
129
128
33
19
20
24
21
54
93
75
29
20
18
12
10
48
74
77
24
14
13
11
6
0
0
0
33
23
22
1
16
2
1
1 148
631
550
11
103
148
130
1 295
779
693
188
185
181
212
1 028
703
608
0
144
146
183
963
778
696
79
127
97
141
534
514
482
30
31
51
51
429
407
412
0
21
13
26
0
0
0
10
21
385
693
1 076
1 552
2 064
2 385
1 515
2 007
1 087
1 062
437
532
539
1 991
2 209
1 796
881
377
8
9
7
3
86
135
132
137
130
200
169
193
96
166
135
137
87
95
108
97
75
95
60
69
6
25
8
8
351
596
487
378
749
831
574
493
510
723
529
453
346
522
479
440
213
263
293
306
Slovenia
UNKNOWN
014
1524
2534
3544
4554
5564
65+
0
0
0
0
0
23
7
3
4
1
0
90
24
9
4
5
5
129
11
3
6
2
4
64
9
4
5
4
2
39
5
3
4
1
1
34
42
20
16
3
17
98
10
14
15
0
1
1
2
0
1
1
0
0
2
142
130
142
10
9
10
9
12
13
8
6
7
6
252
251
249
13
8
15
16
9
20
11
11
15
13
151
151
161
5
10
12
11
10
9
7
8
6
2
63
54
75
5
2
5
4
2
1
2
3
4
4
24
23
30
4
2
3
2
2
2
1
1
1
2
108
76
100
14
15
13
3
3
15
5
4
3
2
2
0
0
26
23
31
2
1
2
0
1
225
320
314
32
15
17
9
14
185
272
229
30
14
13
12
9
151
111
104
20
17
10
7
6
89
109
100
11
5
7
7
3
43
87
105
17
5
5
4
1
53
82
114
17
10
13
6
11
0
0
0
50
33
25
2
19
3
2
699
485
409
15
73
100
112
474
384
385
146
140
101
112
243
193
195
0
76
72
74
175
141
117
47
31
46
46
166
101
121
25
34
27
38
213
203
212
0
17
8
25
0
0
0
21
41
314
487
380
590
327
447
182
298
185
218
280
405
7 417
0
11
348
741
603
388
230
380
2 559
0
138
124
108
100
0
0
0
9
14
15
19
95
115
110
120
114
163
131
129
60
80
81
75
31
39
42
45
31
28
40
26
67
83
58
49
1
0
0
107
313
297
253
0
0
11
40
22
11
261
538
365
335
547
597
512
418
288
375
308
233
213
288
248
245
112
217
239
293
111
367
350
332
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
MALE:FEMALE
RATIO
2.1
2.5
1.8
3.0
1.8
2.6
2.1
1.9
1.8
1.2
1.5
1.3
1.5
1.6
2.0
1.5
1.5
1.3
1.9
1.2
1.3
1.2
1.5
1.5
1.7
2.1
1.9
2.7
2.5
2.4
1.3
1.6
1.8
1.8
3.9
3.3
2.9
2.9
1.5
1.6
1.5
1.6
1.5
1.4
1.3
1.2
EUROPEAN REGION
MALE
YEAR
237
LABORATORIES
FREE THROUGH NTP
SECONDNUMBER OF
CULTURE
DST b LABS
LPAc LABS
LINE DST
LABS USING
PER 100K
PER 5M
PER 5M
POPULATION
LEDa
Albania
0.5
1.6
1.6
1.6
yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
yes
yes
yes
Yes
Yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
Yes (all suspects)

Yes (all suspects)
yes
yes
Yes
Yes
In country
yes
Yes (all suspects)
yes
Yes
In country
yes
yes
yes
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
Yes (all suspects)
Yes (all suspects)
yes
yes
yes
yes
yes
Yes
Yes
Yes
Yes
Yes
yes
Yes (all suspects)

Yes (if TB is
confirmed)
yes
Yes
yes
Yes
Yes (all suspects)
No
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
yes
yes
yes
Yes
Yes
Yes
9.3
464.2
464.2
1.0
1.6
1.6
1.6
0.7
2.1
1.1
3.2
21.4
53.0
1.1
10.5
7
1.1
0.5
3.7
1
0
6
Bosnia and Herzegovina
0.4
13
17.3
5.3
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Greenland
Hungary
0.5
0.3
22.2
15.9
8.7
6.8
2
1.1
0
1
22.8
8.1
8.1
7.5
10.2
7.5
0.9
7.5
4.6
In country
Out of
country
In country
0.1
40
6.5
3.5
Iceland
0.3
100
15.4
15.4
15.4
Ireland
0.3
14.4
3.3
3.3
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
0.3
12.6
1.3
0.7
2.9
2.3
0.7
0
0
0
In country
Out of
country
Out of
country
In country
30.9
3.7
8.9
6.8
2.8
2.2
3.1
No
2.2
Lithuania
0.4
9.1
9.1
Luxembourg
0.2
100
9.7
9.7
9.7
Malta
0.2
12.0
In country
In and out
of country
Out of
country
Out of
country
0.7
0.3
Monaco
2.3
11.5
1.2
5.1
2
3
1.2
In country
In country
yes
yes
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
No
Yes (all suspects)
yes
Yes
0.2
7.9
7.9
Netherlands
0.3
11.1
0.3
Norway
0.4
10.2
4.1
Poland
Portugal
Republic of Moldova
Romania
Russian Federation
San Marino
0.2
11.1
6.1
1.4
5.6
16.3
4.1
5.6
10
4.2
0
1.7
0.5
2.6
Out of
country
In country
In and out
of country
In country
In country
In country
Out of
country
In country
In and out
of country
yes
Yes (if TB is
confirmed)
Yes (all suspects)
yes
yes
yes
yes
No
No
Yes (all suspects)
yes
Yes
Yes (all suspects)
yes
Yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
yes
yes
yes
Yes
Yes
Yes
57
185
yes
Yes
11
yes
Yes
Yes (if TB is
confirmed)
Yes (all suspects)
14.7
0.5
80
4.6
1.8
Slovenia
0.1
7.4
2.5
2.5
<0.1
0.5
40
2.6
15.6
2.6
6.5
2.6
0
0
14
1.3
2.1
0.7
1.4
0.4
12.1
2.4
0.5
10.6
4.8
0.6
18
1.9
9.1
4.6
yes
Yes (all suspects)
0.3
10.1
1.7
16
In country
yes
Yes (all suspects)
1.2
1.3
0.4
0.5
In country
yes
Yes (all suspects)
yes
Yes
In country
In country
Out of
country
Out of
country
In country
yes
Yes
Yes
0.3
The Former Yugoslav

Republic of Macedonia
Turkey
Turkmenistan
Ukraine
United Kingdom of Great
Britain and Northern
Ireland
Uzbekistan
32
No
<0.1
Tajikistan
12
yes
Slovakia
Spain
Sweden
Switzerland
49
Montenegro
Serbia
Yes (if TB is
confirmed)
No
In and out
of country
In country
Andorra
0.4
0.4
TB DIAGNOSIS
TB NOTIF.
RIFAMPICIN
RATE PER
USED
100 000
THROUGHOUT
HEALTH-CARE
TREATMENT
WORKERS
Armenia
Austria
Azerbaijan
Belarus
Belgium
0.5
NRLd
FIRSTLINE
DRUGS
yes
yes
Yes (all suspects)
yes
Yes
yes
yes
yes
Yes (all suspects)

Yes (all suspects)
No
Yes (if TB is
confirmed)
Yes (if TB is
confirmed)
Yes (all suspects)
yes
yes
No
Yes
Yes
Yes
yes
Yes
yes
Yes
yes
Yes
27
yes
Yes
64
yes
Yes
yes
yes
yes
37
47

d
b
c
238

241
242
243
244
245
246
247
248
249

details.
Data source
Country notes
India
Estimates for India have not yet been ofcially approved by the Ministry of Health and Family Welfare, Government of
India and should therefore be considered provisional.
240
Bangladesh
Bhutan
Democratic
People's Republic
of Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2005
2009
2010
2011
POPULATION
(MILLIONS)
105
117
130
141
147
149
150
<1
<1
<1
<1
<1
<1
<1
20
22
23
24
24
24
24
874
964
1 054
1 140
1 208
1 225
1 241
184
199
213
227
237
240
242
<1
<1
<1
<1
<1
<1
<1
39
42
45
46
48
48
48
19
22
24
27
29
30
30
17
18
19
20
21
21
21
57
60
63
67
69
69
70
1
1
1
1
NUMBER
(THOUSANDS)
64
70
74
71
68
68
68
1.2
0.68
0.44
0.36
0.22
0.18
0.13
4.7
4.4
3.9
3.3
2.2
1.9
1.6
340
370
410
410
350
320
300
98
120
120
85
68
66
65
0.049
0.027
0.018
<0.01
<0.01
<0.01
<0.01
44
48
47
31
24
23
23
7.9
6.5
5.6
6
6.7
6.9
7
1.3
1.7
1.9
1.4
1.2
1.1
1.1
11
11
20
15
11
11
9.8
0.66
0.71
0.68
0.72
(21130)
(27130)
(29140)
(29130)
(28120)
(29120)
(29120)
(0.4702.3)
(0.2801.3)
(0.1900.790)
(0.1600.640)
(0.1000.390)
(0.0790.310)
(0.0470.250)
(4.45.1)
(4.14.8)
(3.64.2)
(3.03.5)
(2.12.3)
(1.72.0)
(1.41.7)
(220480)
(240530)
(260590)
(290540)
(220500)
(210470)
(190430)
(36190)
(44240)
(45230)
(36150)
(30120)
(29120)
(29120)
(0.0420.058)
(0.0230.031)
(0.0130.024)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1688)
(1794)
(1889)
(1355)
(1142)
(1141)
(1140)
(2.616)
(2.812)
(2.410)
(2.611)
(2.912)
(3.012)
(3.113)
(0.7102.0)
(1.02.6)
(1.12.8)
(0.8202.2)
(0.6701.8)
(0.6501.8)
(0.6401.8)
(4.820)
(4.720)
(7.937)
(6.628)
(4.920)
(4.619)
(4.218)
(0.2701.2)
(0.2901.3)
(0.2801.3)
(0.3001.3)
RATEa
61
60
57
51
46
45
45
219
131
78
55
31
24
17
23
20
17
14
9
7.7
6.4
38
38
39
36
29
27
24
53
61
56
37
29
28
27
23
11
6.6
2.2
1.8
2.1
2.5
113
115
104
66
50
49
48
41
30
23
22
23
23
23
7.3
9.4
9.9
7.3
5.7
5.5
5.4
19
19
31
23
16
15
14
65
64
60
63
(20124)
(23114)
(22108)
(2194)
(1984)
(1983)
(1982)
(84416)
(54241)
(34139)
(2497)
(1454)
(1143)
(6.334)
(2225)
(1922)
(1618)
(1315)
(8.59.6)
(7.18.3)
(5.96.9)
(2555)
(2555)
(2556)
(2648)
(1841)
(1738)
(1535)
(19104)
(22119)
(21107)
(1668)
(1351)
(1249)
(1248)
(1926)
(9.113)
(4.78.8)
(1.82.6)
(1.52.1)
(1.72.4)
(2.12.9)
(40223)
(41224)
(39199)
(29118)
(2387)
(2285)
(2284)
(1485)
(1355)
(9.841)
(9.440)
(9.841)
(1041)
(1041)
(4.111)
(5.614)
(5.915)
(4.111)
(3.28.9)
(3.18.6)
(3.08.3)
(8.534)
(7.934)
(1358)
(9.941)
(7.229)
(6.727)
(6.125)
(27120)
(27118)
(24112)
(26115)

NUMBER
(THOUSANDS)
530
580
620
620
610
610
620
10
5.9
4.1
3.3
2.3
2
1.7
150
160
150
140
100
92
100
4 100
4 500
4 600
4 200
3 500
3 300
3 100
820
970
970
790
700
680
680
0.66
0.38
0.3
0.22
0.16
0.15
0.14
350
370
370
300
260
250
240
67
61
59
65
71
73
74
19
21
20
20
21
21
21
110
110
170
150
120
120
110
7.3
7.8
7.7
8.1
(1901 000)
(2701 000)
(2901 100)
(3001 100)
(3001 000)
(3001 000)
(3001 100)
(4.517)
(2.89.9)
(2.06.9)
(1.75.6)
(1.14.0)
(0.8803.6)
(0.6003.4)
(56300)
(74280)
(73260)
(66240)
(38200)
(27200)
(31220)
(3 6004 500)
(4 0005 000)
(4 0005 300)
(3 4005 100)
(2 5004 700)
(2 2004 600)
(2 1004 300)
(3501 500)
(4101 800)
(4401 700)
(3801 400)
(3201 200)
(3201 200)
(3101 200)
(0.2401.3)
(0.1700.670)
(0.1300.540)
(0.0900.390)
(0.0650.300)
(0.0590.280)
(0.0560.260)
(160610)
(180630)
(190620)
(150490)
(200330)
(190320)
(190310)
(24130)
(29100)
(26110)
(28120)
(32130)
(33130)
(33130)
(6.439)
(1037)
(9.435)
(9.236)
(9.637)
(9.637)
(9.737)
(55190)
(55180)
(85300)
(75250)
(58210)
(55200)
(51200)
(3.113)
(3.314)
(3.114)
(3.315)
RATEa
501
496
481
444
416
413
411
1 780
1 130
718
505
326
279
230
768
738
669
582
431
377
422
465
465
438
365
289
269
249
445
485
457
349
293
285
281
299
152
110
73
51
47
44
894
881
831
647
544
525
506
349
284
242
237
241
242
243
110
118
107
102
101
101
101
199
182
276
226
178
169
161
719
710
688
701
(183974)
(227868)
(222838)
(211762)
(202707)
(199704)
(199698)
(8133 120)
(5471 920)
(3581 200)
(251846)
(154561)
(121502)
(81454)
(2781 500)
(3411 280)
(3181 150)
(277999)
(156842)
(111804)
(126892)
(415518)
(414519)
(382498)
(295443)
(204388)
(181374)
(168346)
(188810)
(205882)
(204809)
(165599)
(136509)
(132496)
(130489)
(107586)
(68269)
(49196)
(30133)
(2195)
(1988)
(1883)
(4141 550)
(4211 500)
(4151 390)
(3331 060)
(420685)
(404661)
(390637)
(128679)
(137485)
(107431)
(104424)
(108427)
(109427)
(110428)
(37223)
(56201)
(50185)
(46179)
(46178)
(46177)
(46176)
(96337)
(92301)
(135468)
(112380)
(85304)
(79293)
(73282)
(3041 310)
(2991 290)
(2791 280)
(2901 290)

NUMBER
(THOUSANDS)
240
260
290
320
330
330
340
4.4
2.9
2.3
1.9
1.6
1.5
1.4
69
75
79
82
84
84
84
1 900
2 100
2 300
2 400
2 300
2 300
2 200
380
410
440
450
450
450
450
0.33
0.26
0.2
0.15
0.12
0.11
0.11
150
170
190
190
180
180
180
31
35
40
45
48
49
50
11
12
12
13
14
14
14
79
78
110
100
91
89
86
5
5.5
5.6
5.7
(150350)
(220320)
(240350)
(260380)
(270400)
(270400)
(280400)
(3.85.0)
(2.53.4)
(2.02.6)
(1.62.2)
(1.31.8)
(1.31.7)
(1.21.6)
(43100)
(6190)
(6495)
(6798)
(7296)
(7297)
(7297)
(1 6002 200)
(1 8002 400)
(2 1002 500)
(2 1002 600)
(2 1002 500)
(2 1002 500)
(2 0002 500)
(270500)
(320510)
(350530)
(360550)
(370540)
(380540)
(370540)
(0.2000.480)
(0.2200.300)
(0.1600.240)
(0.1300.180)
(0.1100.140)
(0.0980.130)
(0.0930.120)
(110200)
(130210)
(150220)
(160220)
(160210)
(160210)
(160210)
(1946)
(2942)
(3348)
(3653)
(3957)
(4058)
(4159)
(7.217)
(9.914)
(1015)
(1116)
(1116)
(1116)
(1117)
(6594)
(6492)
(89130)
(85120)
(75110)
(73110)
(71100)
(4.16.1)
(4.56.6)
(4.66.7)
(4.76.9)
RATEa
225
225
225
225
225
225
225
784
561
402
287
220
206
192
344
344
344
344
345
345
345
216
216
216
209
190
185
181
206
205
204
199
191
189
187
150
105
74
52
39
36
34
393
404
412
403
388
384
381
163
163
163
163
163
163
163
66
66
66
66
66
66
66
138
130
171
154
132
128
124
498
498
498
498
(139331)
(184270)
(184270)
(184270)
(184269)
(185268)
(185268)
(673903)
(482646)
(345463)
(247331)
(189253)
(177237)
(165222)
(212508)
(282414)
(282414)
(282414)
(296398)
(296397)
(296397)
(182254)
(189245)
(195239)
(188231)
(171210)
(167204)
(163199)
(149271)
(159256)
(164249)
(160242)
(158227)
(156224)
(155222)
(92221)
(90122)
(6089)
(4262)
(3444)
(3141)
(2939)
(290512)
(314505)
(333498)
(340472)
(335445)
(329444)
(326439)
(101241)
(133196)
(133196)
(133196)
(134195)
(135194)
(135194)
(4296)
(5479)
(5479)
(5479)
(5479)
(5579)
(5579)
(114164)
(107155)
(141203)
(127184)
(109157)
(106153)
(102147)
(406601)
(407598)
(409596)
(409596)

YEAR
241
Bangladesh
Bhutan
Democratic
People's Republic
of Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
242
YEAR
POPULATION
(MILLIONS)
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2005
2009
2010
2011
105
117
130
141
147
149
150
<1
<1
<1
<1
<1
<1
<1
20
22
23
24
24
24
24
874
964
1 054
1 140
1 208
1 225
1 241
184
199
213
227
237
240
242
<1
<1
<1
<1
<1
<1
<1
39
42
45
46
48
48
48
19
22
24
27
29
30
30
17
18
19
20
21
21
21
57
60
63
67
69
69
70
1
1
1
1
NUMBER
(THOUSANDS)
240
260
290
320
330
330
340
4.4
2.9
2.3
1.9
1.6
1.5
1.4
69
75
79
82
84
84
84
1 900
2 100
2 300
2 400
2 300
2 300
2 200
380
410
440
450
450
450
450
0.33
0.26
0.2
0.15
0.12
0.11
0.11
150
170
190
190
180
180
180
31
35
40
45
48
49
50
11
12
12
13
14
14
14
79
78
110
100
91
89
86
5
5.5
5.6
5.7
(150350)
(220320)
(240350)
(260380)
(270400)
(270400)
(280400)
(3.85.0)
(2.53.4)
(2.02.6)
(1.62.2)
(1.31.8)
(1.31.7)
(1.21.6)
(43100)
(6190)
(6495)
(6798)
(7296)
(7297)
(7297)
(1 6002 200)
(1 8002 400)
(2 1002 500)
(2 1002 600)
(2 1002 500)
(2 1002 500)
(2 0002 500)
(270500)
(320510)
(350530)
(360550)
(370540)
(380540)
(370540)
(0.2000.480)
(0.2200.300)
(0.1600.240)
(0.1300.180)
(0.1100.140)
(0.0980.130)
(0.0930.120)
(110200)
(130210)
(150220)
(160220)
(160210)
(160210)
(160210)
(1946)
(2942)
(3348)
(3653)
(3957)
(4058)
(4159)
(7.217)
(9.914)
(1015)
(1116)
(1116)
(1116)
(1117)
(6594)
(6492)
(89130)
(85120)
(75110)
(73110)
(71100)
(4.16.1)
(4.56.6)
(4.66.7)
(4.76.9)
RATEa
225
225
225
225
225
225
225
784
561
402
287
220
206
192
344
344
344
344
345
345
345
216
216
216
209
190
185
181
206
205
204
199
191
189
187
150
105
74
52
39
36
34
393
404
412
403
388
384
381
163
163
163
163
163
163
163
66
66
66
66
66
66
66
138
130
171
154
132
128
124
498
498
498
498
(139331)
(184270)
(184270)
(184270)
(184269)
(185268)
(185268)
(673903)
(482646)
(345463)
(247331)
(189253)
(177237)
(165222)
(212508)
(282414)
(282414)
(282414)
(296398)
(296397)
(296397)
(182254)
(189245)
(195239)
(188231)
(171210)
(167204)
(163199)
(149271)
(159256)
(164249)
(160242)
(158227)
(156224)
(155222)
(92221)
(90122)
(6089)
(4262)
(3444)
(3141)
(2939)
(290512)
(314505)
(333498)
(340472)
(335445)
(329444)
(326439)
(101241)
(133196)
(133196)
(133196)
(134195)
(135194)
(135194)
(4296)
(5479)
(5479)
(5479)
(5479)
(5579)
(5579)
(114164)
(107155)
(141203)
(127184)
(109157)
(106153)
(102147)
(406601)
(407598)
(409596)
(409596)
NUMBER
(THOUSANDS)
0.067
0.089
0.19
0.39
0.56
0.6
0.63
<0.01
<0.01
<0.01
0.019
0.039
0.045
0.05
<0.01
0.052
0.089
0.11
0.11
0.11
0.11
11
60
120
130
100
99
94
<0.01
<0.01
0.21
5.2
12
14
15
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.8
8.2
16
19
17
16
18
<0.01
0.073
0.44
0.95
0.88
0.83
0.78
0.016
0.031
0.055
0.094
0.14
0.14
0.15
11
21
25
19
15
14
13
(0.0410.099)
(0.0390.160)
(0.0890.320)
(0.2000.640)
(0.3000.900)
(0.3200.960)
(0.3401.0)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0120.027)
(0.0280.052)
(0.0320.059)
(0.0370.066)
(<0.01<0.01)
(0.0250.089)
(0.0450.150)
(0.0540.170)
(0.0590.180)
(0.0600.180)
(0.0610.190)
(9.313)
(4378)
(94150)
(98160)
(80130)
(76120)
(72120)
(0<0.01)
(<0.010.017)
(0.0950.370)
(3.37.4)
(8.516)
(9.618)
(1120)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(2.03.6)
(5.811)
(1220)
(1524)
(1321)
(1320)
(1522)
(<0.010.011)
(0.0450.110)
(0.3100.590)
(0.7001.2)
(0.6501.2)
(0.6001.1)
(0.5701.0)
(0.0100.024)
(0.0160.051)
(0.0310.088)
(0.0540.140)
(0.0980.180)
(0.0830.210)
(0.0900.220)
(8.713)
(1726)
(2031)
(1524)
(1218)
(1217)
(1015)
RATEa
<0.1
<0.1
0.1
0.3
0.4
0.4
0.4
0.1
0.4
1.1
2.8
5.4
6.2
6.8
<0.1
0.2
0.4
0.4
0.5
0.5
0.5
1.3
6.2
11
11
8.6
8.1
7.6
0
0
0.1
2.3
5.1
5.7
6.2
0.5
0.4
0.3
0.2
0.1
<0.1
<0.1
7
20
35
41
36
34
38
<0.1
0.3
1.8
3.5
3
2.8
2.5
0.1
0.2
0.3
0.5
0.7
0.7
0.7
19
36
40
28
22
21
18
(<0.1<0.1)
(<0.10.14)
(<0.10.25)
(0.140.45)
(0.200.61)
(0.220.64)
(0.230.67)
(0.120.16)
(0.180.64)
(0.611.6)
(1.94.0)
(3.97.3)
(4.58.1)
(5.08.9)
(<0.1<0.1)
(0.110.41)
(0.200.64)
(0.230.73)
(0.240.74)
(0.250.75)
(0.250.76)
(1.11.5)
(4.58.1)
(8.914)
(8.614)
(6.611)
(6.210)
(5.89.6)
(00)
(0<0.1)
(<0.10.17)
(1.53.3)
(3.66.8)
(4.07.6)
(4.48.3)
(0.300.71)
(0.220.56)
(0.150.39)
(<0.10.24)
(<0.10.15)
(<0.10.13)
(<0.10.12)
(5.29.2)
(1426)
(2645)
(3251)
(2844)
(2743)
(3145)
(<0.1<0.1)
(0.210.50)
(1.32.4)
(2.64.5)
(2.23.9)
(2.03.7)
(1.93.3)
(<0.10.14)
(<0.10.28)
(0.160.47)
(0.270.72)
(0.470.88)
(0.400.99)
(0.431.1)
(1523)
(2944)
(3249)
(2235)
(1826)
(1725)
(1522)
CASE DETECTION
RATEa
PERCENT
48 673
56 437
75 557
123 118
160 875
153 892
150 899
1 154
1 299
1 140
1 007
1 125
1 311
1 235
46
48
58
88
109
103
100
207
250
200
153
158
181
167
21
21
26
39
49
46
45
26
45
50
53
72
88
87
(1433)
(1826)
(2232)
(3248)
(4159)
(3956)
(3754)
(2331)
(3952)
(4358)
(4662)
(6284)
(76100)
(75100)
34 131
42 722
76 336
84 648
91 433
1 519 182
1 218 183
1 115 718
1 156 248
1 351 913
1 339 866
1 323 949
74 470
35 529
84 591
254 601
292 754
300 659
318 949
152
231
132
122
100
95
87
12 416
18 229
30 840
107 009
128 343
131 590
136 737
10 142
19 804
29 519
33 448
34 888
35 114
35 434
6 666
5 956
8 413
9 249
9 314
9 547
9 755
46 510
45 428
34 187
57 895
63 975
66 397
65 824
3 767
4 748
149
180
315
348
374
174
126
106
101
112
109
107
40
18
40
112
123
125
132
69
93
48
41
32
30
27
32
43
69
231
270
274
283
53
92
121
123
119
117
116
38
33
45
47
45
46
46
81
76
54
87
93
96
95
373
432
43
52
91
100
110
80
58
49
49
59
59
59
20
8.7
19
56
65
66
70
46
88
65
80
82
83
81
8
11
17
57
69
71
74
33
56
74
75
73
72
71
58
49
68
70
68
69
70
59
59
32
56
71
75
76
75
87
(3653)
(4364)
(79110)
(88120)
(94130)
(6996)
(5167)
(4454)
(4454)
(5365)
(5465)
(5465)
(1527)
(7.011)
(1624)
(4670)
(5478)
(5680)
(5985)
(3175)
(76100)
(5580)
(6797)
(7295)
(7397)
(7094)
(6.211)
(8.614)
(1421)
(4968)
(6180)
(6283)
(6487)
(2253)
(4769)
(6291)
(6392)
(6188)
(6087)
(6086)
(4092)
(4160)
(5683)
(5986)
(5783)
(5884)
(5985)
(5071)
(4971)
(2738)
(4768)
(5985)
(6391)
(6493)
(6292)
(72110)
4 386
380
NUMBER
76 (6493)
YEAR
Bangladesh
46
100
Bhutan
207
167
Democratic
People's Republic
of Korea
374
India
174
107
Indonesia
40
132
Maldives
69
27
Myanmar
32
283
Nepal
53
116
Sri Lanka
38
46
Thailand
81
95
Timor-Leste
380
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
2005
2009
2010
2011
NEW AND
RELAPSE
48 673
56 437
75 557
123 118
160 875
153 892
150 899
1 154
1 299
1 140
1 007
1 125
1 311
1 235
34 131
42 722
76 336
84 648
91 433
1 519 182
1 218 183
1 115 718
1 156 248
1 351 913
1 339 866
1 323 949
74 470
35 529
84 591
254 601
292 754
300 659
318 949
152
231
132
122
100
95
87
12 416
18 229
30 840
107 009
128 343
131 590
136 737
10 142
19 804
29 519
33 448
34 888
35 114
35 434
6 666
5 956
8 413
9 249
9 314
9 547
9 755
46 510
45 428
34 187
57 895
63 975
66 397
65 824
3 767
4 748
4 386
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
20 524
38 484
84 848
109 402
105 772
98 948
19 297
29 396
23 076
25 375
21 625
21 921
2 060
5 914
11 318
21 999
23 506
27 329
367
347
308
434
457
382
657
430
272
285
275
225
265
363
387
355
518
573
16 440
17 796
29 366
31 240
31 279
13 801
18 123
32 491
36 285
37 457
3 787
5 381
12 232
13 715
16 828
264 515
349 374
508 890
624 617
630 165
642 321
880 589
650 345
399 066
384 113
366 381
340 203
68 979
98 006
171 838
233 026
231 121
226 965
31 768
52 338
158 640
169 213
183 366
197 797
34
15 035
85 373
108 616
101 247
101 750
0
833
6 142
11 215
11 659
14 054
114
65
66
45
41
47
89
31
23
13
20
12
18
32
29
41
33
28
8 681
17 254
36 541
41 357
42 318
42 324
7 058
8 659
35 601
50 919
56 840
62 038
653
2 304
30 252
31 509
27 976
27 769
8 591
13 683
14 617
15 442
15 569
15 000
2 769
3 049
4 314
4 868
4 764
4 635
4 490
7 938
9 074
9 474
9 794
9 718
9 662
3 241
1 677
2 261
2 198
1 996
2 145
2 405
2 489
4 955
7 013
7 054
7 210
7 484
656
982
1 561
1 917
2 358
2 548
2 612
20 273
17 754
29 762
32 810
33 450
33 169
1 035
1 206
22 606
12 439
18 837
20 058
20 927
20 726
2 142
3 095
1 419
2 953
7 501
9 143
10 135
10 014
554
406
1 610
2 401
337
0
0
729
1 763
3 876
4 099
2 989
2 701
4 806
4 665
729
1 763
3 876
4 099
7 795
7 366
0
3 459
10
36
40
51
61
55
11
25
21
15
10
36
51
76
82
70
0
0
0
0
0
0
103
1 364
2 247
3 408
5 869
7 752
12 329
11 650
7 638
103
9 116
14 576
15 058
13 507
690
17 993
75 073
108 361
110 691
112 508
80 072
148 580
181 395
182 281
191 923
690
98 065
223 653
289 756
292 972
304 431
106
1 448
4 446
3 710
4 387
5 348
1 978
2 202
2 359
106
1 448
4 446
5 688
6 589
7 707
10
4
4
1
1
0
0
1
4
2
1
10
4
5
5
3
1
1 837
2 623
4 615
4 558
4 456
4 606
982
5 159
5 813
6 403
1 837
2 623
5 597
9 717
10 269
11 009
786
1 807
2 344
2 598
2 617
2 362
629
519
495
520
786
1 807
2 973
3 117
3 112
2 882
0
0
248
277
266
196
219
248
372
244
213
161
147
248
649
510
409
380
395
202
261
387
426
1 130
1 041
1 795
1 964
1 885
1 915
36
41
1 965
1 111
1 852
16
11
1 130
1 041
1 795
3 929
2 996
3 767
52
52
38
31
69
58
0
1 381
1 796
1 508
1 952
0
0
0
0
0
0
926
0
0
0
0
0
0
0
0
0
731
0
0
0
52
57
79
81
83
82
36
45
53
60
62
63
54
50
47
46
46
23
35
56
62
63
65
100
78
65
61
64
66
56
68
74
78
67
80
55
67
51
45
43
41
52
60
61
61
62
61
46
65
66
69
70
68
65
47
59
61
62
62
62
33
28
40
NEW AND RELAPSE

NOTIFICATION RATE
19902011
243
% OF COHORT
a

19952010
Bangladesh
71
92
97
90
Bhutan
Democratic
People's Republic
of Korea
90
25
88
91
90
97
82
67
86
73
90
79
86
64
85
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
88
244
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
20 524
38 484
84 848
106 373
109 402
105 772
367
347
308
351
434
457
10 867
38 484
84 848
106 089
109 075
105 659
433
347
340
354
434
454
16 440
17 796
28 026
29 366
31 240
264 515
349 374
508 890
615 977
624 617
630 165
31 768
52 338
158 640
166 376
169 213
183 366
114
65
66
53
45
41
8 681
17 254
36 541
41 248
41 357
42 318
8 591
13 683
14 617
14 640
15 442
15 569
3 049
4 314
4 868
4 683
4 764
4 635
20 273
17 754
29 762
28 788
32 810
33 450
1 035
867
1 206
14 571
17 796
28 026
29 366
31 240
264 722
349 328
507 204
615 977
624 617
630 165
3 018
52 338
158 640
166 376
169 213
183 366
114
59
70
53
45
44
7 872
16 792
36 652
41 247
41 811
42 200
8 053
12 992
14 617
14 640
15 468
15 569
3 058
4 314
4 841
4 646
4 754
4 635
20 273
23 061
29 919
33 078
27 597
30 317
1 035
867
1 530
COHORT AS
% NOTIFIED
53
100
100
100
100
100
118
100
110
101
100
99
89
100
100
100
100
100
100
100
100
100
100
10
100
100
100
100
100
100
91
106
100
100
107
91
97
100
100
101
100
94
95
100
100
100
100
100
100
99
99
100
100
100
130
101
115
84
91
100
100
CURED
COMPLETED
DEFAULTED
NOT
EVALUATED
66
77
91
90
91
90
78
75
84
89
86
87
5
4
1
2
1
1
20
15
7
2
6
3
5
4
4
4
4
4
0
4
5
3
3
3
2
1
1
1
1
1
0
3
3
3
3
3
10
9
2
2
2
2
1
3
1
0
2
1
12
5
2
2
2
2
1
0
0
3
0
2
73
84
83
85
86
1
31
83
85
85
85
73
70
83
83
84
84
96
97
86
45
47
82
53
73
77
78
77
77
56
79
87
86
87
88
75
75
83
81
83
83
36
65
70
76
81
79
61
73
9
5
6
5
4
25
4
2
2
2
3
18
17
8
8
7
7
2
0
0
7
4
4
4
4
0
1
2
2
2
2
0
1
1
1
1
1
0
0
0
0
0
14
9
7
8
8
8
17
5
1
3
3
2
4
4
3
4
3
4
28
3
5
7
5
6
21
12
3
2
2
2
3
0
1
5
4
4
4
2
2
2
2
2
2
3
2
6
4
2
9
4
5
6
6
6
5
3
5
5
4
4
3
3
4
5
6
6
7
2
8
8
7
7
7
5
5
2
2
4
2
3
3
3
3
2
1
1
1
1
1
0
1
1
2
2
1
0
2
2
2
1
2
1
0
5
2
2
2
2
0
7
7
6
6
6
6
4
4
4
4
4
0
0
3
11
4
0
18
9
5
5
5
4
18
7
3
3
3
3
13
15
6
7
4
4
9
7
7
4
3
3
11
7
3
2
2
2
1
75
57
1
1
1
1
1
5
2
2
2
3
0
2
6
40
44
7
7
2
2
2
2
2
6
2
2
3
2
3
4
2
1
1
3
1
24
15
9
4
2
2
2
3
80
DIED
FAILED
Bangladesh
75
80
Bhutan
59
84
Democratic
People's Republic
of Korea
84
70
74
32
73
India
Indonesia
Maldives
Myanmar
64
73
Nepal
85
Sri Lanka
77
Thailand
66
Timor-Leste
86
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
729
1 763
3 876
6 991
4 099
7 795
10
36
51
70
76
82
1 179
1 815
3 876
103
9 116
14 170
14 576
15 058
690
98 065
223 653
289 285
289 756
292 972
106
1 448
4 446
5 430
5 688
6 589
10
4
5
2
5
3
1 837
2 623
5 597
9 009
9 717
10 269
786
1 807
2 973
2 954
3 117
3 112
248
649
510
394
409
380
1 130
1 041
1 795
3 956
3 929
2 996
52
35
52
1 285
9 116
14 170
14 576
15 058
551
48 133
224 143
289 285
289 756
292 972
76
2 530
4 812
5 430
5 687
6 589
6 637
7 814
22
52
70
76
81
5
5
0
1
0
1 443
3 001
6 556
8 631
9 540
10 106
2 047
2 973
1 954
3 063
3 112
521
504
393
408
380
2 285
3 468
2 542
2 580
56
35
56
COHORT AS
% NOTIFIED
162
103
100
162
100
220
102
100
100
99
1 248
100
100
100
100
80
49
100
100
100
100
72
175
108
100
100
100
125
100
0
20
0
79
114
117
96
98
98
113
100
66
98
100
80
99
100
100
100
127
88
65
86
108
100
DEFAULTED
NOT
EVALUATED
71
70
73
3
2
6
5
4
4
8
2
2
11
7
5
2
14
9
66
47
50
16
33
9
6
5
0
2
2
23
5
5
14
6
8
5
65
76
70
78
10
3
12
6
6
3
8
1
8
16
7
7
2
1
3
5
10
1
1
2
75
70
75
74
76
64
55
47
45
45
45
22
50
63
50
53
53
11
6
8
9
8
6
15
24
29
29
30
9
22
15
21
20
20
2
3
3
2
4
4
7
7
7
7
7
0
3
3
4
4
5
4
12
10
11
8
3
5
4
4
4
4
0
3
4
3
3
3
2
5
3
2
3
13
16
16
13
13
13
1
7
8
14
12
11
5
4
2
2
2
9
2
1
2
1
2
67
15
7
7
8
8
100
80
20
0
0
CURED
COMPLETED
DIED
FAILED
100
55
65
58
46
44
41
8
9
14
27
28
32
4
7
10
12
11
11
4
4
6
5
5
5
19
12
7
7
7
7
9
3
5
3
4
3
73
81
71
82
82
3
2
4
3
3
4
4
10
6
5
8
6
5
3
3
7
4
5
4
4
4
3
5
3
4
44
67
64
66
71
20
5
7
7
6
6
5
8
8
7
1
2
2
1
2
26
18
15
13
9
3
3
5
5
4
52
54
58
55
96
57
6
12
10
11
0
14
12
9
11
12
2
11
5
4
5
5
0
6
7
7
7
7
2
11
18
14
9
10
0
0
77
% OF COHORT
a

19952010
245
YEAR
KNOWN HIV STATUS
20052011
Bangladesh
Bhutan
Democratic
People's Republic
of Korea
India
45
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
18
Thailand
74
Timor-Leste
246
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
0
1
1
1
0
12
0
1 446
1 778
1 900
0
136
0
0
0
2
17
32
45
0
0
0
29 488
258 037
480 752
688 530
1
1
1
2 782
2 751
3 511
0
0
0
2
3
3
3
0
0
0
0
2 109
4 174
4 362
4 496
0
0
0
0
0
19
10
18
1 897
1 015
1 832
75
82
74
0
2
49 657
55 692
49 770
0
108
123 118
160 875
158 698
159 023
1 018
1 150
1 332
1 250
50 474
88 665
96 298
99 071
1 304 828
1 533 308
1 522 147
1 515 872
254 601
294 732
302 861
321 308
123
104
97
88
107 991
133 502
137 403
143 140
34 077
35 407
35 609
35 954
9 695
9 788
10 095
10 328
57 895
65 940
68 239
67 676
3 783
4 759
276
4 417
NUMBER OF
HIV-POSITIVE
TB PATIENTS
1
4
81
1
2
% OF TESTED
TB PATIENTS
HIV-POSITIVE
PEOPLE
CPT
ART
PROVIDED IPT
0
0
4
1
100
100
100
0
0
100
100
100
0
100
0
0
0
6 411
36 483
41 476
44 702
22
14
9
6
89
90
91
50
57
59
479
1 106
1 280
17
40
36
63
92
42
29
42
64
0
0
0
0
611
1 015
961
900
29
24
22
20
50
97
100
100
0
0
2
0
13
21
0
1
1
100
71
54
100
8 109
8 959
7 326
16
16
15
72
71
75
50
54
59
0
0
31
67
94
80
0
333
514
361
5
3
7
127
MDR-TB
Bangladesh
Bhutan
Democratic
People's Republic
of Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
a
b
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
339
509
2
8
17
21
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
3 800 (2 9004 800)
24 (2027)
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
1 700 (8503 000)
13 (1115)
37
34
1660
2967
4237
3 500 (3 0004 100)
1 400 (1 2001 700)
66 000 (58 00073 000)
21 000 (15 00027 000)
182
383
6 600 (5 0008 200)
5 700 (4 2007 500)
0
0
815
192
690
69
229
213
32
4
11
13
510
4
5
2
1.4 (1.21.6)
5 500 (4 2006 800)
1 100 (7401 400)
21 (046)
2 200 (1 7002 700)
1.2 (1.11.5)
% OF
BACT+VEb
TESTED FOR
MDR-TB
BACT+VE
TESTED FOR
MDR-TB
<0.1
0.65
1.6
24
13
0
<0.1
0
0
0.84
0.81
0
12
17
18
24
71
2
7
108
48
0
5
0
0
4 400 (3 2005 800)
730 (4601 100)
12 (0.3168)
130
126
0
659
813
839
1080
890 (5401 400)

0
95 (79110)
84 (72100)
NUMBER OF
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
2 100 (1 7002 500)
11 (8.513)
2 100 (1 6002 600)
45 000 (40 00050 000)
920 (6201 300)
0.16 (0.120.19)
1 100 (7601 500)
340 (210510)
8.7 (4.016)
1 300 (1 0001 600)
11 (8.313)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
339
4.3
761
10
3
5.9
8
11
30
37
26
37
43
0.32
3454
1.2
324
4.9
695
9.0
0
0
0
0
962
9.9
220
7.1
193
6.2
0
0
417
82
419
100
378
99
408
100
6
12
2
2.9
YEAR
TOTAL
CONFIRMED
CASES OF
247
MALE
Bangladesh
Bhutan
Democratic
People's Republic
of Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
248
FEMALE
YEAR
014
1524
2534
3544
4554
5564
65+
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
2005
2010
2011
29
256
524
365
309
2
6
1
2
505
3 640
8 170
10 460
9 606
42
65
47
108
88
983
5 643
10 443
12 535
11 616
65
41
58
50
39
1 001
5 750
11 423
11 409
10 152
36
30
26
25
26
748
4 718
11 038
12 758
11 728
35
24
23
12
14
648
3 667
8 476
11 176
10 746
24
12
14
26
20
424
2 837
7 453
11 536
11 301
11
2
12
13
19
293
167
447
314
16
1 588
3 185
4 871
4 649
6
928
1 409
2 524
2 218
334
20 963
62 620
78 278
78 096
203
1 508
2 422
4 046
4 066
391
31 090
74 678
82 757
82 762
297
2 927
2 688
4 849
5 493
287
30 829
76 870
90 440
89 706
306
2 519
2 040
4 061
4 542
216
24 230
64 843
81 210
82 921
302
1 167
1 185
2 629
2 474
123
15 308
43 038
60 766
63 625
228
651
485
1 153
1 024
68
8 534
24 726
38 442
42 443
109
846
714
787
1
0
0
0
0
42
88
132
106
120
15 215
16 501
17 406
28
9
9
8
12
713
1 459
3 401
3 043
2 923
20 906
24 645
25 429
11
10
8
6
7
1 423
2 636
5 877
6 578
6 182
18 401
21 090
22 353
10
2
5
0
3
1 401
2 781
5 888
6 688
6 319
17 847
20 977
22 885
8
5
6
4
8
977
2 161
4 585
5 607
5 680
13 509
17 329
19 404
10
5
6
5
1
677
1 235
2 557
3 632
3 954
6 390
7 910
9 089
6
3
5
6
3
298
836
1 764
2 308
2 500
170
148
165
245
10
25
9
14
12
59
27
44
55
38
8
1 904
1 946
2 110
1 914
163
266
341
268
246
1 191
859
1 344
1 506
1 546
136
1 763
1 685
1 832
1 755
361
459
520
539
459
2 936
2 570
3 814
3 695
3 650
149
1 713
1 722
1 724
1 723
519
695
724
602
585
2 948
2 380
4 393
5 253
5 139
116
1 491
1 806
1 856
1 732
521
793
918
884
828
2 434
2 117
4 003
5 042
5 140
119
1 294
1 759
1 857
1 710
365
484
657
683
653
2 607
1 908
2 831
3 625
3 734
52
772
820
1 126
1 180
261
360
424
448
479
2 346
2 213
3 407
4 189
4 080
47
14
199
177
137
114
99
146
UNKNOWN
0
0
0
0
0
0
014
1524
2534
3544
4554
5564
65+
64
495
751
653
623
12
7
9
17
2
309
3 029
6 776
9 221
8 849
43
57
45
104
92
546
3 238
6 785
8 279
7 679
44
34
38
45
40
360
2 247
5 538
6 185
5 683
25
31
13
18
19
236
1 315
3 960
5 458
4 946
12
23
11
18
12
132
778
2 281
3 484
3 457
9
3
9
10
4
38
370
1 230
2 250
2 253
8
2
2
9
5
167
166
407
227
32
2 250
6 292
8 544
8 336
16
683
1 127
1 493
1 390
179
14 495
45 136
53 415
53 958
160
1 121
1 756
2 461
2 264
169
17 287
45 629
49 425
49 227
244
2 004
1 890
2 910
3 093
80
11 768
28 577
34 035
34 698
282
1 524
1 381
2 276
2 409
49
7 516
17 042
22 719
23 977
192
591
764
1 347
1 271
30
4 594
10 513
15 527
17 182
90
357
336
637
494
11
2 697
5 408
9 735
10 731
33
946
816
927
1
0
1
1
0
58
72
147
196
187
13 916
14 800
15 840
13
11
10
2
4
535
1 040
2 376
2 452
2 401
16 393
17 838
18 703
8
4
7
3
3
729
1 592
3 047
3 454
3 317
13 022
14 629
15 900
4
5
1
4
1
729
1 397
2 563
2 752
2 760
10 927
13 142
14 533
6
4
2
1
2
450
987
2 101
2 525
2 554
7 539
9 524
10 556
6
5
2
0
1
343
592
1 218
1 838
2 010
2 783
3 451
3 985
2
2
4
1
2
154
378
885
1 139
1 407
176
195
192
247
15
23
19
15
13
52
32
57
82
76
8
1 267
1 208
1 177
1 182
207
312
295
255
270
741
624
907
1 087
1 214
127
1 078
1 111
1 036
978
206
264
261
233
217
888
1 035
1 662
1 930
1 773
90
833
797
819
752
142
176
189
171
191
782
780
1 334
1 749
1 658
76
575
658
681
624
122
202
200
183
192
936
873
1 367
1 467
1 586
60
419
532
642
604
81
144
154
186
191
1 175
1 016
1 259
1 494
1 402
18
228
230
352
354
56
113
130
154
154
1 178
1 321
1 938
2 276
2 133
29
16
176
182
113
85
77
75
UNKNOWN
0
0
0
0
0
0
MALE:FEMALE
RATIO
2.6
2.3
2.1
2.0
2.0
1.4
1.1
1.4
1.1
1.2
1.6
1.4
1.7
1.8
2.6
2.2
2.2
2.3
2.2
1.4
1.4
1.5
1.5
1.8
1.1
1.4
2.4
2.6
1.8
1.8
2.0
1.9
1.9
2.0
2.1
2.2
2.2
2.7
2.5
2.9
2.9
2.7
2.5
2.1
2.3
2.3
2.4
1.5
1.2
LABORATORIES
FREE THROUGH NTP
SECONDNUMBER OF
CULTURE
DST b LABS
LPAc LABS
LINE DST
LABS USING
PER 100K
PER 5M
PER 5M
POPULATION
LEDa
Bangladesh
0.7
<0.1
<0.1
Out of
country
Out of
country
TB NOTIF.
RIFAMPICIN
RATE PER
USED
100 000
THROUGHOUT
HEALTH-CARE
TREATMENT
WORKERS
NRLd
TB DIAGNOSIS
FIRSTLINE
DRUGS
yes
Yes (all suspects)
yes
Yes
yes
Yes (if TB is
confirmed)
yes
Yes
Yes (all suspects)
yes
No
Bhutan
4.6
6.8
6.8
Democratic People's
Republic of Korea
1.2
0.2
0.2
India
1.0
0.1
0.1
<0.1
18
In country
yes
yes
Yes
In country
yes
Yes (other criteria)
yes
Yes
No
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
Yes
Indonesia
2.3
0.9
0.1
<0.1
Maldives
21.9
15.6
Myanmar
0.9
0.2
0.2
0.2
1.7
100
0.5
0.3
1.0
0.5
0.2
Thailand
1.6
4.7
1.1
0.1
11
Timor-Leste
1.6
Out of
country
In and out
of country
Out of
country
No
Yes (all suspects)
yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
Don't
know
Yes
yes
Yes (all suspects)
yes
No
39
Nepal
Sri Lanka
Out of
country
Out of
country

d
b
c
249

253
256
259
262
264
266
268
270
272

details.
Data source
252
American Samoa
1990
1995
2000
2005
2009
2010
2011
Australia
1990
1995
2000
2005
2009
2010
2011
Brunei
1990
Darussalam
1995
2000
2005
2009
2010
2011
Cambodia
1990
1995
2000
2005
2009
2010
2011
China
1990
1995
2000
2005
2009
2010
2011
China, Hong Kong 1990
SAR
1995
2000
2005
2009
2010
2011
China, Macao
1990
SAR
1995
2000
2005
2009
2010
2011
Cook Islands
1990
1995
2000
2005
2009
2010
2011
Fiji
1990
1995
2000
2005
2009
2010
2011
French Polynesia 1990
1995
2000
2005
2009
2010
2011
Guam
1990
1995
2000
2005
2009
2010
2011
Japan
1990
1995
2000
2005
2009
2010
2011
Kiribati
1990
1995
2000
2005
2009
2010
2011
Lao People's
1990
Democratic
1995
Republic
2000
2005
2009
2010
2011
Malaysia
1990
1995
2000
2005
2009
2010
2011
Marshall Islands
1990
1995
2000
2005
2009
2010
2011
a
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
17
18
19
20
22
22
23
<1
<1
<1
<1
<1
<1
<1
10
11
12
13
14
14
14
1 145
1 214
1 269
1 308
1 335
1 341
1 348
6
6
7
7
7
7
7
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
122
124
126
126
127
127
126
<1
<1
<1
<1
<1
<1
<1
4
5
5
6
6
6
6
18
21
23
26
28
28
29
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.067
0.04
0.035
0.042
0.043
0.043
0.042
0.011
<0.01
0.01
0.012
0.011
0.01
0.01
15
15
16
12
9.8
9.3
9.1
210
160
110
74
55
51
47
0.54
0.33
0.3
0.24
0.22
0.23
0.23
0.034
0.021
0.019
0.015
0.014
0.014
0.015
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.055
0.04
0.03
0.022
0.017
0.016
0.015
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
4.2
3.1
2.7
2.4
2.2
2.2
2.2
0.031
0.026
0.016
<0.01
<0.01
<0.01
<0.01
1.7
1.4
1.1
0.9
0.77
0.74
0.71
1.5
1.4
1.6
1.6
1.6
1.6
1.7
0.01
0.014
0.032
0.027
0.035
0.035
0.041
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0660.068)
(0.0390.041)
(0.0350.035)
(0.0420.043)
(0.0430.044)
(0.0420.044)
(0.0410.043)
(0.0110.012)
(<0.01<0.01)
(0.0100.011)
(0.0110.012)
(<0.010.011)
(<0.010.011)
(<0.010.011)
(5.329)
(5.729)
(6.230)
(5.323)
(4.517)
(4.316)
(4.216)
(190240)
(130200)
(82140)
(7277)
(5357)
(4953)
(4549)
(0.5400.550)
(0.3300.330)
(0.3000.300)
(0.2400.240)
(0.2200.230)
(0.2300.230)
(0.2300.230)
(0.0330.035)
(0.0200.021)
(0.0180.019)
(0.0150.015)
(0.0140.014)
(0.0140.015)
(0.0140.015)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0<0.01)
(0.0430.067)
(0.0320.050)
(0.0240.037)
(0.0170.027)
(0.0170.018)
(0.0130.020)
(0.0120.019)
(<0.010.012)
(<0.010.020)
(<0.010.017)
(<0.010.013)
(<0.010.012)
(<0.010.012)
(<0.010.012)
(<0.010.012)
(<0.010.018)
(<0.010.012)
(<0.010.012)
(<0.010.018)
(<0.010.020)
(<0.010.023)
(4.14.3)
(3.13.2)
(2.72.8)
(2.32.4)
(2.22.3)
(2.12.2)
(2.12.2)
(0.0190.046)
(0.0180.034)
(0.0120.020)
(<0.010.014)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1.12.5)
(0.8502.0)
(0.6901.6)
(0.5601.3)
(0.4801.1)
(0.4601.1)
(0.4401.0)
(0.6702.5)
(0.6702.5)
(0.7002.9)
(0.8402.6)
(0.7602.8)
(0.7602.9)
(0.7702.9)
(<0.010.045)
(<0.010.053)
(0.0110.066)
(<0.010.100)
(<0.010.120)
(<0.010.160)
(<0.010.170)
RATEa
5
2.4
0.84
2.5
1.1
1.2
1.3
0.39
0.22
0.18
0.21
0.2
0.19
0.19
4.4
3
3.2
3.2
2.7
2.6
2.5
155
135
128
93
70
66
63
19
13
8.7
5.7
4.1
3.8
3.5
9.4
5.4
4.5
3.5
3.2
3.2
3.3
9.5
5.2
4.4
3.1
2.6
2.6
2.6
1.2
1.9
0.85
0.66
0.67
0.66
0.55
7.5
5.2
3.7
2.7
2
1.9
1.8
1.5
2.4
1.8
1.3
1.2
1.1
1.1
2.3
3
2
1.7
2.6
2.8
3.2
3.4
2.5
2.2
1.9
1.8
1.7
1.7
43
33
19
10
5.9
5
4.2
41
29
21
16
13
12
11
8
7
6.9
6.2
5.8
5.8
5.7
21
27
62
51
65
65
74
(2.19.1)
(0.994.4)
(0.331.6)
(1.14.6)
(0.332.4)
(0.342.6)
(0.422.8)
(0.390.40)
(0.210.23)
(0.180.19)
(0.200.21)
(0.200.20)
(0.190.20)
(0.180.19)
(4.24.7)
(2.93.2)
(3.13.3)
(3.03.4)
(2.52.9)
(2.52.7)
(2.42.7)
(56305)
(51259)
(50243)
(40169)
(32124)
(30115)
(29111)
(1621)
(1116)
(6.511)
(5.55.9)
(4.04.3)
(3.73.9)
(3.43.6)
(9.39.5)
(5.35.4)
(4.44.5)
(3.53.6)
(3.23.3)
(3.23.3)
(3.23.3)
(9.29.7)
(5.05.3)
(4.24.5)
(3.03.2)
(2.62.7)
(2.52.7)
(2.52.7)
(0.512.1)
(0.803.4)
(0.371.5)
(0.291.2)
(0.291.2)
(0.281.2)
(<0.12.0)
(5.99.2)
(4.16.4)
(2.94.5)
(2.13.3)
(2.02.1)
(1.52.3)
(1.42.2)
(<0.16.1)
(<0.19.4)
(<0.17.1)
(<0.15.0)
(<0.14.6)
(<0.14.5)
(<0.14.5)
(<0.19.1)
(<0.112)
(<0.18.0)
(<0.16.9)
(<0.110)
(<0.111)
(<0.113)
(3.43.5)
(2.52.5)
(2.12.2)
(1.81.9)
(1.71.8)
(1.71.8)
(1.71.7)
(2664)
(2444)
(1424)
(6.115)
(3.68.9)
(3.07.5)
(2.56.2)
(2560)
(1842)
(1331)
(9.723)
(7.819)
(7.317)
(6.917)
(3.714)
(3.212)
(3.012)
(3.210)
(2.710)
(2.710)
(2.710)
(0.1294)
(0.43104)
(20127)
(1.1192)
(2.1231)
(0.21297)
(0.59312)

NUMBER
(THOUSANDS)
0.022
0.011
<0.01
0.015
<0.01
<0.01
<0.01
1.4
1.5
1.5
1.5
1.7
1.7
1.7
0.23
0.26
0.36
0.29
0.31
0.34
0.36
160
190
200
160
130
120
120
2 500
2 400
2 200
1 800
1 500
1 500
1 400
9.4
9.6
9.6
8.3
7.5
7.3
7.1
0.41
0.64
0.68
0.52
0.5
0.51
0.52
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
1.7
1.2
0.87
0.63
0.43
0.36
0.29
0.078
0.13
0.11
0.084
0.081
0.081
0.081
0.08
0.11
0.082
0.076
0.12
0.13
0.15
76
66
57
41
34
33
33
0.18
0.59
0.42
0.7
0.54
0.47
0.47
62
59
51
43
36
35
34
41
37
32
31
31
30
29
0.12
0.16
0.28
0.32
0.41
0.46
0.51
(0.0100.037)
(<0.010.019)
(<0.010.010)
(<0.010.025)
(<0.010.016)
(<0.010.018)
(<0.010.018)
(0.5502.6)
(0.6002.9)
(0.5802.8)
(0.6102.9)
(0.6603.2)
(0.6703.2)
(0.6803.2)
(0.0890.430)
(0.1000.490)
(0.1400.670)
(0.1100.540)
(0.1200.590)
(0.1300.630)
(0.1400.680)
(100230)
(140240)
(160240)
(140190)
(110150)
(100140)
(99140)
(2 3002 600)
(2 1002 600)
(1 9002 500)
(1 6002 100)
(1 3001 700)
(1 3001 700)
(1 2001 600)
(3.718)
(3.818)
(3.718)
(3.316)
(3.014)
(2.914)
(2.813)
(0.1600.780)
(0.2501.2)
(0.2701.3)
(0.2000.980)
(0.2000.940)
(0.2000.960)
(0.2000.980)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.8102.9)
(0.6002.1)
(0.4301.5)
(0.3101.1)
(0.2100.710)
(0.1700.610)
(0.1100.540)
(0.0310.150)
(0.0520.250)
(0.0440.210)
(0.0330.160)
(0.0310.150)
(0.0320.150)
(0.0320.150)
(0.0310.150)
(0.0450.220)
(0.0320.150)
(0.0290.140)
(0.0470.230)
(0.0520.250)
(0.0600.290)
(30140)
(26120)
(22110)
(1677)
(1364)
(1363)
(1362)
(0.0830.330)
(0.2601.0)
(0.1500.810)
(0.3201.2)
(0.2101.0)
(0.1700.930)
(0.1700.910)
(31100)
(3194)
(2979)
(2663)
(2352)
(2351)
(2248)
(2168)
(1960)
(1754)
(1651)
(1552)
(1452)
(1352)
(<0.010.480)
(<0.010.540)
(0.1000.550)
(0.0191.0)
(0.0331.2)
(0.0141.7)
(0.0181.8)
RATEa
46
21
9.6
23
12
12
13
8.2
8.5
7.7
7.6
7.7
7.6
7.6
90
89
109
79
80
84
89
1 670
1 670
1 620
1 230
937
875
817
215
195
170
140
112
108
104
163
157
142
122
108
104
99
115
161
158
107
94
93
94
14
23
10
8.1
8.2
8
7.7
232
157
107
77
50
42
33
40
62
47
33
30
30
29
60
79
53
45
67
75
84
63
53
45
32
27
26
26
257
761
497
759
548
476
462
1 490
1 220
961
739
596
569
540
227
177
138
119
109
106
101
261
322
539
613
770
855
924
(2279)
(1037)
(3.818)
(1140)
(4.024)
(3.926)
(4.526)
(3.215)
(3.316)
(3.014)
(3.014)
(3.014)
(3.014)
(3.014)
(35171)
(35168)
(43206)
(31150)
(31150)
(33159)
(35168)
(1 0602 410)
(1 2202 180)
(1 3101 960)
(1 0201 460)
(7871 100)
(7371 020)
(690954)
(201230)
(176216)
(146196)
(121160)
(97128)
(94123)
(91119)
(63307)
(61297)
(55269)
(48231)
(42203)
(41196)
(39187)
(45217)
(63305)
(62299)
(42203)
(37178)
(37176)
(37177)
(5.627)
(8.843)
(4.020)
(3.115)
(3.216)
(3.115)
(1.120)
(112395)
(77265)
(53179)
(38128)
(2583)
(2071)
(1362)
(1676)
(24116)
(1889)
(1363)
(1257)
(1256)
(1256)
(24113)
(31149)
(21100)
(1785)
(26127)
(29141)
(33159)
(25118)
(21100)
(1885)
(1361)
(1051)
(1050)
(1049)
(116454)
(3361 360)
(184961)
(3431 340)
(2181 030)
(169938)
(167903)
(7392 500)
(6531 960)
(5531 480)
(4531 090)
(381858)
(367815)
(353767)
(116374)
(92290)
(71229)
(61196)
(53185)
(50183)
(45180)
(4.21 020)
(181 050)
(1951 050)
(361 970)
(622 330)
(263 060)
(323 230)

NUMBER
(THOUSANDS)
0.012
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
1.1
1.2
1.2
1.2
1.3
1.4
1.4
0.18
0.2
0.28
0.23
0.24
0.26
0.28
55
65
72
68
63
62
61
1 700
1 600
1 400
1 200
1 100
1 000
1 000
7.3
7.5
7.5
6.5
5.9
5.7
5.5
0.32
0.5
0.53
0.4
0.39
0.4
0.41
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.81
0.6
0.44
0.33
0.26
0.24
0.23
0.061
0.1
0.087
0.066
0.063
0.063
0.063
0.062
0.09
0.063
0.059
0.093
0.11
0.12
60
52
44
32
27
26
26
0.084
0.39
0.31
0.45
0.4
0.37
0.36
21
19
18
16
14
14
13
23
22
22
22
23
23
23
0.065
0.097
0.14
0.19
0.25
0.27
0.29
(<0.010.015)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.9801.3)
(1.11.4)
(1.01.3)
(1.11.4)
(1.21.5)
(1.21.5)
(1.21.5)
(0.1600.200)
(0.1800.230)
(0.2400.310)
(0.2000.260)
(0.2100.280)
(0.2300.300)
(0.2500.320)
(4073)
(5081)
(5788)
(5781)
(5473)
(5371)
(5270)
(1 4002 200)
(1 3001 900)
(1 2001 600)
(1 0001 400)
(9401 200)
(9101 200)
(8901 100)
(6.48.3)
(6.68.5)
(6.68.5)
(5.77.4)
(5.26.7)
(5.06.5)
(4.86.3)
(0.2800.360)
(0.4400.570)
(0.4700.600)
(0.3500.460)
(0.3400.440)
(0.3500.450)
(0.3600.460)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.7100.920)
(0.5300.680)
(0.3900.500)
(0.2900.370)
(0.2200.290)
(0.2100.270)
(0.2000.260)
(0.0530.069)
(0.0910.120)
(0.0760.098)
(0.0580.075)
(0.0550.071)
(0.0550.071)
(0.0550.071)
(0.0550.070)
(0.0790.100)
(0.0560.072)
(0.0520.067)
(0.0820.110)
(0.0920.120)
(0.1000.130)
(5267)
(4558)
(3950)
(2836)
(2330)
(2329)
(2329)
(0.0660.100)
(0.3200.470)
(0.2500.380)
(0.3600.540)
(0.3300.480)
(0.3000.450)
(0.2900.430)
(1330)
(1228)
(1126)
(9.623)
(8.721)
(8.520)
(8.320)
(2126)
(2025)
(2024)
(2124)
(2125)
(2125)
(2125)
(<0.010.190)
(0.0240.220)
(0.0840.200)
(0.0500.420)
(0.0760.530)
(0.0520.670)
(0.0570.720)
RATEa
26
12
6.9
13
7.9
7.8
7.8
6.5
6.7
6.1
6
6.1
6.1
6
71
69
85
62
63
66
70
580
578
577
510
451
437
424
153
129
109
92
80
78
75
127
122
111
96
84
81
78
89
126
123
84
73
73
73
11
18
8.1
6.3
6.4
6.3
6
112
77
54
40
30
28
26
31
48
37
26
24
23
23
47
62
41
35
52
59
65
49
41
35
25
21
21
20
116
505
372
488
408
370
356
492
403
330
270
230
221
213
127
108
95
86
83
82
81
137
190
263
363
471
502
536
(2131)
(9.414)
(5.68.4)
(1015)
(6.49.6)
(6.39.4)
(6.39.4)
(5.77.4)
(5.97.6)
(5.36.9)
(5.36.8)
(5.46.9)
(5.36.9)
(5.36.8)
(6280)
(6178)
(7596)
(5570)
(5571)
(5874)
(6179)
(423761)
(448724)
(458710)
(424604)
(387520)
(376503)
(364489)
(121189)
(106154)
(92126)
(80105)
(7091)
(6888)
(6685)
(111143)
(107139)
(97125)
(84108)
(7496)
(7192)
(6888)
(78101)
(110142)
(108140)
(7395)
(6483)
(6483)
(6483)
(9.913)
(1620)
(7.19.2)
(5.57.2)
(5.67.3)
(5.57.1)
(5.36.8)
(98126)
(6887)
(4862)
(3545)
(2634)
(2432)
(2329)
(2735)
(4254)
(3241)
(2329)
(2127)
(2026)
(2026)
(4153)
(5470)
(3646)
(3140)
(4659)
(5166)
(5774)
(4355)
(3647)
(3140)
(2228)
(1824)
(1823)
(1823)
(93143)
(410609)
(296456)
(396588)
(335487)
(298450)
(289430)
(304725)
(249593)
(204486)
(167398)
(142339)
(137326)
(131313)
(113142)
(97120)
(86103)
(7994)
(7690)
(7589)
(7488)
(14396)
(46432)
(161389)
(96803)
(143990)
(971 230)
(1031 320)

YEAR
253
YEAR
Micronesia
(Federated
States of)
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana
Islands
Palau
Papua New
Guinea
Philippines
Republic of Korea
Samoa
Singapore
Solomon Islands
Tokelau
Tonga
254
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
2
2
2
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
3
4
4
4
4
4
4
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
4
5
5
6
7
7
7
62
69
77
86
92
93
95
43
45
46
47
48
48
48
<1
<1
<1
<1
<1
<1
<1
3
3
4
4
5
5
5
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
RATEa
0.013
0.075
0.069
0.054
0.036
0.03
0.026
0.36
0.29
0.22
0.16
0.14
0.14
0.14
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.02
0.016
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
3.4
2.9
2.8
3.3
3.6
3.6
3.7
36
34
32
30
28
28
28
3.5
2.2
1.8
2
2.2
2.3
2.3
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.14
0.15
0.12
0.1
0.096
0.094
0.092
0.22
0.19
0.17
0.13
0.098
0.092
0.089
<0.01
<0.01
<0.01
(00.150)
(0.0230.160)
(0.0260.130)
(0.0190.110)
(<0.010.094)
(<0.010.095)
(<0.010.092)
(0.3300.390)
(0.2700.310)
(0.2000.240)
(0.1500.180)
(0.1300.160)
(0.1300.150)
(0.1300.150)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.033)
(<0.010.023)
(<0.010.017)
(<0.010.011)
(<0.010.011)
(<0.010.011)
(<0.010.012)
(0.0200.020)
(0.0160.016)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.015)
(<0.010.016)
(<0.010.011)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(1.16.8)
(1.05.9)
(0.8905.7)
(1.16.8)
(1.27.3)
(1.27.4)
(1.27.5)
(3239)
(2939)
(3034)
(2832)
(2531)
(2531)
(2531)
(0.04914)
(0.0308.8)
(0.0257.1)
(0.0288.1)
(0.0318.9)
(0.0329.1)
(0.0339.3)
(<0.010.014)
(<0.010.013)
(<0.010.011)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.1300.140)
(0.1400.160)
(0.1100.140)
(0.0880.120)
(0.0750.120)
(0.0840.100)
(0.0830.100)
(0.0710.440)
(0.0780.350)
(0.0700.320)
(0.0540.230)
(0.0430.170)
(0.0410.160)
(0.0390.160)
(<0.01<0.01)
(0<0.01)
(<0.01<0.01)
14
70
65
50
32
27
23
16
13
9
6.5
5.3
5.2
5
9.3
4.1
3.3
8.1
6.3
5
3.4
4.9
3
2
1.2
1.1
1.1
1.2
0.59
0.43
0.25
0.2
0.15
0.14
0.12
4.4
4.9
5.1
2.4
1.7
2.7
4.2
4.5
6.3
5.9
3.9
3.2
3.1
2.9
4.5
17
26
9.3
23
20
26
82
63
52
55
54
53
53
58
49
41
35
31
30
29
8.2
4.9
3.9
4.3
4.7
4.8
4.9
4.9
4
3.3
2
1.5
1.3
1.1
4.5
4.3
3.2
2.5
1.9
1.8
1.8
70
54
42
27
19
17
16
6.5
3.1
4.1
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
5.9
4.2
3.3
2.9
2.7
2.8
2.9

NUMBER
(THOUSANDS)
RATEa
(0155)
(21148)
(24125)
(1798)
(4.885)
(2.086)
(0.7783)
(1518)
(1214)
(8.39.8)
(5.97.0)
(4.95.8)
(4.75.6)
(4.65.5)
(4.017)
(1.87.3)
(1.46.0)
(3.515)
(2.711)
(2.29.0)
(1.56.2)
(<0.119)
(<0.112)
(<0.18.1)
(<0.14.7)
(<0.14.3)
(<0.14.5)
(<0.14.8)
(0.580.60)
(0.430.43)
(0.250.25)
(0.200.21)
(0.150.16)
(0.140.14)
(0.120.12)
(1.97.9)
(2.18.9)
(2.29.3)
(1.04.4)
(0.723.0)
(1.24.9)
(1.87.6)
(<0.118)
(<0.125)
(<0.124)
(<0.116)
(<0.113)
(<0.112)
(<0.112)
(1.59.2)
(6.232)
(1147)
(3.518)
(9.642)
(8.437)
(1248)
(28164)
(22124)
(17106)
(18111)
(18109)
(17108)
(17107)
(5264)
(4256)
(3844)
(3337)
(2834)
(2733)
(2633)
(0.1133)
(<0.120)
(<0.115)
(<0.117)
(<0.119)
(<0.119)
(<0.119)
(2.09.0)
(1.57.6)
(1.26.4)
(0.783.9)
(0.622.8)
(0.532.4)
(0.412.0)
(4.44.7)
(4.04.5)
(2.83.6)
(2.12.9)
(1.52.4)
(1.72.0)
(1.62.0)
(23142)
(22100)
(1777)
(1249)
(8.133)
(7.531)
(7.129)
(1.515)
(020)
(0.5811)
0.44
0.68
0.6
0.49
0.38
0.36
0.33
20
14
10
8
8.7
9.3
9.8
0.01
<0.01
<0.01
0.01
<0.01
<0.01
<0.01
0.22
0.15
0.11
0.071
0.07
0.074
0.081
0.48
0.51
0.55
0.49
0.44
0.43
0.43
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.051
0.095
0.11
0.07
0.052
0.049
0.047
<0.01
0.034
0.049
0.02
0.044
0.041
0.053
28
27
29
34
36
37
37
620
630
600
540
480
470
460
96
90
85
79
74
73
72
0.085
0.073
0.062
0.042
0.031
0.027
0.023
2.4
2.8
2.5
2
2.2
2.3
2.4
1.9
1.7
1.5
1.2
0.97
0.93
0.9
<0.01
<0.01
<0.01
(<0.011.9)
(0.2201.4)
(0.2501.1)
(0.1900.940)
(0.0750.940)
(0.0510.950)
(0.0390.920)
(9.236)
(7.124)
(5.317)
(3.714)
(4.215)
(4.616)
(4.916)
(<0.010.020)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.019)
(<0.010.015)
(<0.010.012)
(<0.01<0.01)
(0.0850.410)
(0.0580.280)
(0.0440.210)
(0.0280.130)
(0.0280.130)
(0.0290.140)
(0.0320.150)
(0.1900.910)
(0.2000.960)
(0.2101.0)
(0.1900.930)
(0.1700.830)
(0.1700.820)
(0.1700.810)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0200.097)
(0.0380.180)
(0.0410.200)
(0.0270.130)
(0.0200.099)
(0.0190.094)
(0.0180.089)
(<0.010.017)
(0.0130.065)
(0.0230.085)
(<0.010.037)
(0.0200.076)
(0.0180.072)
(0.0250.090)
(1154)
(1151)
(1056)
(1265)
(1371)
(1472)
(1473)
(470780)
(480790)
(480740)
(470620)
(420540)
(410530)
(400520)
(78110)
(74110)
(69100)
(6494)
(6189)
(6088)
(5987)
(0.0370.150)
(0.0290.140)
(0.0240.120)
(0.0160.080)
(0.0130.057)
(0.0110.051)
(<0.010.045)
(0.9404.5)
(1.15.2)
(1.04.8)
(0.7903.7)
(0.8604.0)
(0.9004.3)
(0.9504.4)
(0.6903.7)
(0.8002.9)
(0.7102.6)
(0.5702.0)
(0.4601.7)
(0.4301.6)
(0.4101.6)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
455
632
561
450
347
322
294
934
623
433
315
322
336
348
114
50
41
99
77
61
42
128
78
53
31
28
30
32
14
14
14
12
10
9.9
9.7
54
60
63
30
20
33
52
117
166
155
103
85
81
77
57
196
257
99
216
200
256
678
574
530
552
544
538
534
1 000
904
775
633
520
502
484
223
202
184
167
155
152
149
53
43
35
23
17
15
13
79
79
65
46
44
45
46
615
472
364
251
185
172
162
87
53
32
(2.610)
(1.87.5)
(1.26.6)
(1.25.5)
(1.25.0)
(1.15.2)
(1.25.4)
0.056
0.045
0.038
0.033
0.029
0.029
0.029
(0.0270.097)
(0.0190.081)
(0.0140.072)
(0.0130.060)
(0.0130.052)
(0.0130.051)
(0.0130.050)
59
46
39
32
28
28
27

NUMBER
(THOUSANDS)
RATEa
(3.01 950)
(2051 290)
(2381 020)
(172858)
(68846)
(46859)
(35821)
(4201 650)
(3071 050)
(221713)
(145548)
(154551)
(167563)
(176578)
(45216)
(1994)
(1677)
(39188)
(30145)
(24116)
(1679)
(50241)
(30147)
(21101)
(1258)
(1154)
(1256)
(1260)
(5.527)
(5.526)
(5.627)
(4.722)
(4.019)
(3.919)
(3.818)
(21102)
(23114)
(25119)
(1256)
(8.038)
(1363)
(2098)
(46221)
(65312)
(60292)
(40196)
(33161)
(31154)
(30146)
(20114)
(75375)
(120445)
(39187)
(101376)
(90353)
(122439)
(2611 290)
(2231 090)
(1931 030)
(2041 070)
(2001 060)
(1981 040)
(1961 040)
(7681 270)
(6921 140)
(616953)
(544729)
(459584)
(441566)
(425546)
(182267)
(166243)
(150221)
(136201)
(126186)
(124182)
(121179)
(2396)
(1781)
(1466)
(9.144)
(7.031)
(6.028)
(4.824)
(31150)
(31149)
(26122)
(1887)
(1782)
(1884)
(1886)
(2221 200)
(224809)
(173625)
(121429)
(87319)
(80299)
(75283)
(26185)
(2.0186)
(5.482)
0.36
0.35
0.3
0.26
0.23
0.23
0.22
8.9
7.2
6.1
5.7
6.1
6.2
6.2
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.17
0.12
0.088
0.056
0.055
0.058
0.063
0.38
0.4
0.43
0.39
0.35
0.34
0.34
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.04
0.074
0.082
0.054
0.041
0.038
0.037
<0.01
0.025
0.03
0.013
0.025
0.025
0.032
13
15
19
22
24
24
24
240
250
250
260
260
260
260
72
45
36
42
46
47
48
0.058
0.05
0.041
0.031
0.022
0.02
0.018
1.9
2.2
2
1.6
1.7
1.8
1.9
0.97
0.86
0.75
0.67
0.6
0.58
0.57
<0.01
<0.01
<0.01
(0.1000.800)
(0.2000.540)
(0.2100.400)
(0.1700.370)
(0.1100.400)
(0.0980.410)
(0.0960.400)
(7.610)
(6.38.2)
(5.56.8)
(5.36.2)
(5.66.5)
(5.76.6)
(5.86.7)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.1500.190)
(0.1000.130)
(0.0770.099)
(0.0490.063)
(0.0480.062)
(0.0510.066)
(0.0550.071)
(0.3300.430)
(0.3500.450)
(0.3800.490)
(0.3400.440)
(0.3000.390)
(0.3000.390)
(0.2900.380)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0350.045)
(0.0650.084)
(0.0720.093)
(0.0470.061)
(0.0360.046)
(0.0340.043)
(0.0320.042)
(<0.01<0.01)
(0.0210.031)
(0.0240.036)
(0.0110.016)
(0.0210.031)
(0.0210.031)
(0.0260.038)
(8.518)
(1021)
(1226)
(1431)
(1633)
(1634)
(1634)
(150360)
(200300)
(210310)
(210310)
(210310)
(210310)
(210310)
(6381)
(3951)
(3241)
(3647)
(4052)
(4153)
(4255)
(0.0470.070)
(0.0390.063)
(0.0310.054)
(0.0250.038)
(0.0180.027)
(0.0160.024)
(0.0140.021)
(1.72.1)
(1.92.5)
(1.82.3)
(1.41.8)
(1.52.0)
(1.62.1)
(1.72.2)
(0.6001.4)
(0.7001.0)
(0.6200.910)
(0.5500.800)
(0.4900.720)
(0.4800.700)
(0.4700.680)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
379
325
279
240
212
206
200
405
314
254
225
224
224
223
89
39
32
78
60
48
33
99
61
41
24
22
23
25
11
11
11
9.4
8
7.8
7.6
42
47
49
23
16
26
40
91
129
120
80
66
63
60
45
147
156
67
125
124
153
308
322
349
358
351
348
346
393
360
329
301
280
275
270
167
101
79
88
96
98
100
36
30
23
17
12
11
9.6
63
63
52
37
35
36
37
312
240
185
142
115
108
103
72
39
13
(28102)
(2084)
(1574)
(1360)
(1250)
(1249)
(1248)
0.036
0.032
0.027
0.023
0.019
0.017
0.016
(0.0300.042)
(0.0270.037)
(0.0210.034)
(0.0180.028)
(0.0160.021)
(0.0150.020)
(0.0140.019)
38
33
28
22
18
17
16
(104827)
(185505)
(200371)
(158338)
(101365)
(89371)
(86360)
(345470)
(274356)
(228281)
(207243)
(208240)
(209240)
(208239)
(78101)
(3444)
(2836)
(6888)
(5368)
(4254)
(2837)
(87112)
(5369)
(3647)
(2127)
(1925)
(2026)
(2228)
(9.713)
(9.612)
(9.713)
(8.211)
(7.09.1)
(6.88.8)
(6.78.6)
(3748)
(4153)
(4356)
(2026)
(1418)
(2329)
(3546)
(80103)
(113146)
(105136)
(7091)
(5875)
(5571)
(5368)
(3654)
(119178)
(127189)
(5481)
(101151)
(100150)
(126183)
(203435)
(212453)
(230492)
(236505)
(231495)
(229491)
(228488)
(243580)
(294432)
(269395)
(246361)
(230335)
(227328)
(223322)
(147190)
(88114)
(6989)
(78100)
(84108)
(86110)
(87113)
(2944)
(2337)
(1730)
(1421)
(9.915)
(8.913)
(7.911)
(5571)
(5571)
(4659)
(3342)
(3140)
(3140)
(3242)
(193460)
(196288)
(151222)
(116171)
(94137)
(89129)
(85123)
(5790)
(1380)
(3.528)
(3245)
(2839)
(2235)
(1827)
(1620)
(1420)
(1318)
YEAR
Tuvalu
Vanuatu
Viet Nam
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
67
74
79
83
87
88
89
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
RATEa
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.015
(<0.010.018)
(<0.010.017)
(<0.010.013)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.010.036)
97
61
67
49
38
38
37
10
(32196)
(4.9187)
(22135)
(1797)
(6.498)
(9.487)
(9.484)
(2.125)
0.028
0.029
0.018
0.024
0.022
31
32
28
29
30
30
30
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(0.0120.051)
(0.0130.052)
(<0.010.033)
(0.0100.043)
(<0.010.039)
(1259)
(1360)
(1153)
(1153)
(1255)
(1256)
(1255)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
15
14
7.7
10
8.8
46
43
36
34
34
34
33
16
7
6.4
7.2
4.2
3.2
2.1
(6.428)
(6.025)
(3.214)
(4.418)
(3.816)
(1887)
(1781)
(1467)
(1464)
(1463)
(1463)
(1462)
(6.829)
(3.013)
(2.812)
(3.113)
(1.87.5)
(1.45.8)
(0.654.4)

NUMBER
(THOUSANDS)
0.084
0.065
0.06
0.047
0.04
0.039
0.037
0.21
0.16
0.3
0.29
0.2
0.25
0.24
270
290
270
280
290
290
290
0.027
0.012
0.011
0.013
<0.01
<0.01
<0.01
(0.0300.160)
(<0.010.170)
(0.0220.120)
(0.0180.090)
(<0.010.095)
(0.0110.084)
(0.0110.081)
(0.0590.470)
(0.0470.340)
(0.1300.540)
(0.1300.490)
(0.0970.350)
(0.1100.440)
(0.1000.430)
(120480)
(130510)
(120480)
(120490)
(130500)
(130510)
(130500)
(0.0110.051)
(<0.010.023)
(<0.010.021)
(<0.010.024)
(<0.010.013)
(<0.010.010)
(<0.01<0.01)
RATEa
933
700
633
484
405
393
381
146
94
162
135
87
105
97
403
387
344
333
328
328
323
194
85
78
88
51
39
26
(3361 830)
(961 880)
(2311 230)
(181931)
(86967)
(109853)
(109819)
(40319)
(28199)
(70292)
(64233)
(42149)
(47185)
(42175)
(180714)
(174685)
(153612)
(148592)
(148579)
(149577)
(148563)
(76367)
(33161)
(31148)
(34167)
(2097)
(1574)
(8.953)

NUMBER
(THOUSANDS)
0.048
0.04
0.034
0.028
0.024
0.023
0.022
0.19
0.11
0.2
0.17
0.17
0.17
0.16
140
150
160
170
170
180
180
0.021
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(0.0310.069)
(0.0170.074)
(0.0220.048)
(0.0190.039)
(0.0120.041)
(0.0130.036)
(0.0130.035)
(0.1500.230)
(0.0850.130)
(0.1600.250)
(0.1400.210)
(0.1400.200)
(0.1400.200)
(0.1400.200)
(100170)
(110190)
(120210)
(130220)
(130220)
(130220)
(140220)
(0.0180.024)
(<0.010.011)
(<0.010.010)
(<0.010.011)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
RATEa
536
437
357
291
247
237
228
127
63
110
83
72
69
67
204
204
205
204
200
199
199
151
67
61
69
40
31
21
(347766)
(181805)
(231510)
(198402)
(121418)
(135368)
(130353)
(103154)
(5176)
(89132)
(6899)
(5986)
(5783)
(5580)
(155261)
(155261)
(156261)
(155260)
(153254)
(153251)
(153250)
(133171)
(5875)
(5369)
(6078)
(3545)
(2735)
(1823)
Wallis and Futuna

Islands
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
POPULATION
(MILLIONS)
255
YEAR
American Samoa
1990
1995
2000
2005
2009
2010
2011
Australia
1990
1995
2000
2005
2009
2010
2011
Brunei
1990
Darussalam
1995
2000
2005
2009
2010
2011
Cambodia
1990
1995
2000
2005
2009
2010
2011
China
1990
1995
2000
2005
2009
2010
2011
China, Hong Kong 1990
SAR
1995
2000
2005
2009
2010
2011
China, Macao
1990
SAR
1995
2000
2005
2009
2010
2011
Cook Islands
1990
1995
2000
2005
2009
2010
2011
Fiji
1990
1995
2000
2005
2009
2010
2011
French Polynesia 1990
1995
2000
2005
2009
2010
2011
Guam
1990
1995
2000
2005
2009
2010
2011
Japan
1990
1995
2000
2005
2009
2010
2011
Kiribati
1990
1995
2000
2005
2009
2010
2011
Lao People's
1990
Democratic
1995
Republic
2000
2005
2009
2010
2011
Malaysia
1990
1995
2000
2005
2009
2010
2011
Marshall Islands
1990
1995
2000
2005
2009
2010
2011
a
256
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
17
18
19
20
22
22
23
<1
<1
<1
<1
<1
<1
<1
10
11
12
13
14
14
14
1 145
1 214
1 269
1 308
1 335
1 341
1 348
6
6
7
7
7
7
7
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
122
124
126
126
127
127
126
<1
<1
<1
<1
<1
<1
<1
4
5
5
6
6
6
6
18
21
23
26
28
28
29
<1
<1
<1
<1
<1
<1
<1
0.012
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
1.1
1.2
1.2
1.2
1.3
1.4
1.4
0.18
0.2
0.28
0.23
0.24
0.26
0.28
55
65
72
68
63
62
61
1 700
1 600
1 400
1 200
1 100
1 000
1 000
7.3
7.5
7.5
6.5
5.9
5.7
5.5
0.32
0.5
0.53
0.4
0.39
0.4
0.41
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.81
0.6
0.44
0.33
0.26
0.24
0.23
0.061
0.1
0.087
0.066
0.063
0.063
0.063
0.062
0.09
0.063
0.059
0.093
0.11
0.12
60
52
44
32
27
26
26
0.084
0.39
0.31
0.45
0.4
0.37
0.36
21
19
18
16
14
14
13
23
22
22
22
23
23
23
0.065
0.097
0.14
0.19
0.25
0.27
0.29
(<0.010.015)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.9801.3)
(1.11.4)
(1.01.3)
(1.11.4)
(1.21.5)
(1.21.5)
(1.21.5)
(0.1600.200)
(0.1800.230)
(0.2400.310)
(0.2000.260)
(0.2100.280)
(0.2300.300)
(0.2500.320)
(4073)
(5081)
(5788)
(5781)
(5473)
(5371)
(5270)
(1 4002 200)
(1 3001 900)
(1 2001 600)
(1 0001 400)
(9401 200)
(9101 200)
(8901 100)
(6.48.3)
(6.68.5)
(6.68.5)
(5.77.4)
(5.26.7)
(5.06.5)
(4.86.3)
(0.2800.360)
(0.4400.570)
(0.4700.600)
(0.3500.460)
(0.3400.440)
(0.3500.450)
(0.3600.460)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.7100.920)
(0.5300.680)
(0.3900.500)
(0.2900.370)
(0.2200.290)
(0.2100.270)
(0.2000.260)
(0.0530.069)
(0.0910.120)
(0.0760.098)
(0.0580.075)
(0.0550.071)
(0.0550.071)
(0.0550.071)
(0.0550.070)
(0.0790.100)
(0.0560.072)
(0.0520.067)
(0.0820.110)
(0.0920.120)
(0.1000.130)
(5267)
(4558)
(3950)
(2836)
(2330)
(2329)
(2329)
(0.0660.100)
(0.3200.470)
(0.2500.380)
(0.3600.540)
(0.3300.480)
(0.3000.450)
(0.2900.430)
(1330)
(1228)
(1126)
(9.623)
(8.721)
(8.520)
(8.320)
(2126)
(2025)
(2024)
(2124)
(2125)
(2125)
(2125)
(<0.010.190)
(0.0240.220)
(0.0840.200)
(0.0500.420)
(0.0760.530)
(0.0520.670)
(0.0570.720)
RATEa
26
12
6.9
13
7.9
7.8
7.8
6.5
6.7
6.1
6
6.1
6.1
6
71
69
85
62
63
66
70
580
578
577
510
451
437
424
153
129
109
92
80
78
75
127
122
111
96
84
81
78
89
126
123
84
73
73
73
11
18
8.1
6.3
6.4
6.3
6
112
77
54
40
30
28
26
31
48
37
26
24
23
23
47
62
41
35
52
59
65
49
41
35
25
21
21
20
116
505
372
488
408
370
356
492
403
330
270
230
221
213
127
108
95
86
83
82
81
137
190
263
363
471
502
536
(2131)
(9.414)
(5.68.4)
(1015)
(6.49.6)
(6.39.4)
(6.39.4)
(5.77.4)
(5.97.6)
(5.36.9)
(5.36.8)
(5.46.9)
(5.36.9)
(5.36.8)
(6280)
(6178)
(7596)
(5570)
(5571)
(5874)
(6179)
(423761)
(448724)
(458710)
(424604)
(387520)
(376503)
(364489)
(121189)
(106154)
(92126)
(80105)
(7091)
(6888)
(6685)
(111143)
(107139)
(97125)
(84108)
(7496)
(7192)
(6888)
(78101)
(110142)
(108140)
(7395)
(6483)
(6483)
(6483)
(9.913)
(1620)
(7.19.2)
(5.57.2)
(5.67.3)
(5.57.1)
(5.36.8)
(98126)
(6887)
(4862)
(3545)
(2634)
(2432)
(2329)
(2735)
(4254)
(3241)
(2329)
(2127)
(2026)
(2026)
(4153)
(5470)
(3646)
(3140)
(4659)
(5166)
(5774)
(4355)
(3647)
(3140)
(2228)
(1824)
(1823)
(1823)
(93143)
(410609)
(296456)
(396588)
(335487)
(298450)
(289430)
(304725)
(249593)
(204486)
(167398)
(142339)
(137326)
(131313)
(113142)
(97120)
(86103)
(7994)
(7690)
(7589)
(7488)
(14396)
(46432)
(161389)
(96803)
(143990)
(971 230)
(1031 320)
NUMBER
(THOUSANDS)
RATEa
0.032
0.032
0.031
0.038
0.046
0.047
0.035
(0.0280.036)
(0.0220.044)
(0.0210.042)
(0.0270.051)
(0.0330.061)
(0.0290.070)
(0.0190.055)
<0.01
<0.01
<0.01
<0.01
1.9
7
8.4
5.8
4
4
3.1
0.32
3.8
7.1
11
13
13
13
(<0.01<0.01) 0.8 (<0.12.5)

(<0.01<0.01) 0.6 (<0.11.9)
(0<0.01)
0.3 (01.4)
(<0.010.010) 0.9 (0.132.5)
(1.42.5)
20 (1426)
(5.29.1)
63 (4682)
(6.311)
68 (5187)
(4.57.4)
44 (3455)
(2.95.2)
28 (2137)
(3.54.7)
29 (2433)
(2.63.6)
22 (1825)
(0.2100.460) <0.1 (<0.1<0.1)
(2.15.9)
0.3 (0.170.49)
(4.410)
0.6 (0.340.83)
(7.216)
0.8 (0.551.2)
(8.517)
0.9 (0.631.3)
(8.517)
0.9 (0.641.3)
(8.617)
0.9 (0.631.3)
0.054
0.057
0.036
0.05
(0.0360.076)
(0.0390.078)
(0.0220.053)
(0.0330.070)
0.8
0.8
0.5
0.7
(0.531.1)
(0.551.1)
(0.310.75)
(0.460.98)
<0.01
<0.01
<0.01
<0.01
(0<0.01)
(0<0.01)
(<0.01<0.01)
(<0.01<0.01)
0.2
0.2
0.6
0.4
(01.1)
(01.1)
(<0.11.5)
(<0.11.3)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(0.160.21)
(0.120.24)
(0.110.22)
(0.130.25)
(0.150.28)
(0.130.31)
(<0.10.24)
(<0.01<0.01) <0.1 (<0.1<0.1)

(<0.01<0.01) <0.1 (<0.10.12)
(<0.01<0.01) 0.1 (<0.10.19)
(00.012)
0.3 (01.5)
(<0.01<0.01) <0.1 (<0.10.15)
(<0.010.012) 0.5 (<0.11.4)
(<0.010.011) 0.5 (<0.11.3)
<0.01 (0<0.01)
0.19
0.18
0.17
0.13
0.11
0.11
0.11
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.9 (04.4)
(0.1700.220) 0.2 (0.140.18)

(0.0950.290) 0.1 (<0.10.23)
(0.0890.260) 0.1 (<0.10.21)
(0.0690.200) 0.1 (<0.10.16)
(0.0800.150) <0.1 (<0.10.12)
(0.0820.150) <0.1 (<0.10.12)
(0.0610.180) <0.1 (<0.10.14)
<0.01 (<0.010.017)
<0.01 (<0.01<0.01)
5.4 (0.3018)
2.5 (1.83.4)
0.011
0.065
0.21
0.36
0.44
0.46
0.47
0.39
1.4
1.9
2.8
2.5
2.2
2.1
0.3
1.4
3.9
6.2
7.2
7.3
7.4
2.2
6.5
8
11
8.9
7.6
7.2
(<0.010.016)
(0.0310.110)
(0.1100.340)
(0.2000.560)
(0.2500.690)
(0.2600.710)
(0.2600.730)
(0.3400.450)
(1.01.7)
(1.52.4)
(2.63.1)
(2.32.8)
(2.02.4)
(1.92.3)
(0.150.38)
(0.652.3)
(2.16.4)
(3.49.7)
(4.111)
(4.111)
(4.212)
(1.92.5)
(4.98.4)
(6.210)
(9.812)
(8.19.8)
(6.98.3)
(6.57.9)
<0.01 (<0.010.020)
9.6 (0.1837)
<0.01 (00.020)
6.1 (036)
CASE DETECTION
RATEa
PERCENT
19
75 (6293)
3
6
4
4
3
1 016
1 073
1 043
1 046
1 217
1 187
1 222
143
5.2
9.5
5.9
5.8
4.3
5.9
5.9
5.4
5.1
5.6
5.3
5.4
57
75
75
75
75
55
91
88
90
85
91
88
90
80
(6293)
(6293)
(6293)
(6293)
(4668)
(80100)
(78100)
(79100)
(7597)
(80100)
(77100)
(79100)
(7192)
307
163
213
237
230
6 501
14 603
18 891
35 535
39 202
40 460
38 555
375 481
515 764
454 372
894 428
965 257
908 399
899 669
6 510
6 212
6 015
5 660
5 160
4 935
4 739
343
402
449
355
308
368
341
0
2
1
1
2
0
1
226
203
144
132
144
189
208
59
94
45
54
59
57
68
131
152
266
280
286
270
33
42
36
68
72
68
67
112
101
89
83
74
70
67
95
101
104
74
58
68
61
0
11
5.6
5.2
9.9
0
4.9
31
26
18
16
17
22
24
30
110
72
87
90
81
12
23
26
52
62
65
64
21
33
33
74
90
87
89
89
83
80
87
87
86
86
110
80
84
88
79
93
84
0
62
69
81
150
0
82
28
34
33
41
56
79
92
97
(98130)
(6482)
(7799)
(80100)
(7192)
(9.016)
(1829)
(2133)
(4463)
(5473)
(5776)
(5574)
(1727)
(2840)
(2839)
(6585)
(79100)
(7799)
(79100)
(78100)
(7394)
(7192)
(7799)
(77100)
(7698)
(7698)
(94120)
(7192)
(7496)
(78100)
(7090)
(82110)
(7495)
62
63
53
41
64
26
25
20
15
23
71
96
84
65
100
(6381)
(85110)
(7496)
(5874)
(90120)
54
63
102
101
81
51 821
43 078
39 384
27 194
23 631
22 693
22 119
68
35
37
57
56
44
42
35
31
22
19
18
17
95
85
110
110
96
68
87
83
89
86
89
87
86
81
(7597)
(94120)
(97130)
(85110)
(6078)
(7799)
(7495)
(79100)
(7698)
(78100)
(7799)
(7698)
(66100)
252
332
278
286
343
1 826
830
2 227
3 699
3 848
3 999
4 306
11 702
11 778
15 057
15 342
17 341
18 517
19 808
300
361
284
287
339
44
17
42
64
63
64
68
64
57
64
59
62
65
69
81
74
70
78
95
8.8
4.3
13
24
27
29
32
51
53
68
68
75
80
85
(66100)
(6191)
(5885)
(6496)
(79120)
(6.014)
(2.96.9)
(8.621)
(1638)
(1944)
(2047)
(2252)
(4557)
(4858)
(6275)
(6375)
(6982)
(7387)
(7892)
34
111
135
190
139
65
213
253
352
254
25
59
54
70
47
(1741)
(27220)
(26180)
(29360)
(19250)
NUMBER
(5470)
(6179)
(7293)
(140180)
(7293)
(2532)
(3039)
(2937)
(3646)
(5064)
(7090)
(81110)
(86110)
Micronesia
(Federated
States of)
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana
Islands
Palau
Papua New
Guinea
Philippines
Republic of Korea
Samoa
Singapore
Solomon Islands
Tokelau
Tonga
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
2
2
2
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
3
4
4
4
4
4
4
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
4
5
5
6
7
7
7
62
69
77
86
92
93
95
43
45
46
47
48
48
48
<1
<1
<1
<1
<1
<1
<1
3
3
4
4
5
5
5
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
RATEa
0.36
0.35
0.3
0.26
0.23
0.23
0.22
8.9
7.2
6.1
5.7
6.1
6.2
6.2
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.17
0.12
0.088
0.056
0.055
0.058
0.063
0.38
0.4
0.43
0.39
0.35
0.34
0.34
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.04
0.074
0.082
0.054
0.041
0.038
0.037
<0.01
0.025
0.03
0.013
0.025
0.025
0.032
13
15
19
22
24
24
24
240
250
250
260
260
260
260
72
45
36
42
46
47
48
0.058
0.05
0.041
0.031
0.022
0.02
0.018
1.9
2.2
2
1.6
1.7
1.8
1.9
0.97
0.86
0.75
0.67
0.6
0.58
0.57
<0.01
<0.01
<0.01
(0.1000.800)
(0.2000.540)
(0.2100.400)
(0.1700.370)
(0.1100.400)
(0.0980.410)
(0.0960.400)
(7.610)
(6.38.2)
(5.56.8)
(5.36.2)
(5.66.5)
(5.76.6)
(5.86.7)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.1500.190)
(0.1000.130)
(0.0770.099)
(0.0490.063)
(0.0480.062)
(0.0510.066)
(0.0550.071)
(0.3300.430)
(0.3500.450)
(0.3800.490)
(0.3400.440)
(0.3000.390)
(0.3000.390)
(0.2900.380)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
(0.0350.045)
(0.0650.084)
(0.0720.093)
(0.0470.061)
(0.0360.046)
(0.0340.043)
(0.0320.042)
(<0.01<0.01)
(0.0210.031)
(0.0240.036)
(0.0110.016)
(0.0210.031)
(0.0210.031)
(0.0260.038)
(8.518)
(1021)
(1226)
(1431)
(1633)
(1634)
(1634)
(150360)
(200300)
(210310)
(210310)
(210310)
(210310)
(210310)
(6381)
(3951)
(3241)
(3647)
(4052)
(4153)
(4255)
(0.0470.070)
(0.0390.063)
(0.0310.054)
(0.0250.038)
(0.0180.027)
(0.0160.024)
(0.0140.021)
(1.72.1)
(1.92.5)
(1.82.3)
(1.41.8)
(1.52.0)
(1.62.1)
(1.72.2)
(0.6001.4)
(0.7001.0)
(0.6200.910)
(0.5500.800)
(0.4900.720)
(0.4800.700)
(0.4700.680)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
379
325
279
240
212
206
200
405
314
254
225
224
224
223
89
39
32
78
60
48
33
99
61
41
24
22
23
25
11
11
11
9.4
8
7.8
7.6
42
47
49
23
16
26
40
91
129
120
80
66
63
60
45
147
156
67
125
124
153
308
322
349
358
351
348
346
393
360
329
301
280
275
270
167
101
79
88
96
98
100
36
30
23
17
12
11
9.6
63
63
52
37
35
36
37
312
240
185
142
115
108
103
72
39
13
0.036
0.032
0.027
0.023
0.019
0.017
0.016
(0.0300.042)
(0.0270.037)
(0.0210.034)
(0.0180.028)
(0.0160.021)
(0.0150.020)
(0.0140.019)
38
33
28
22
18
17
16
(104827)
(185505)
(200371)
(158338)
(101365)
(89371)
(86360)
(345470)
(274356)
(228281)
(207243)
(208240)
(209240)
(208239)
(78101)
(3444)
(2836)
(6888)
(5368)
(4254)
(2837)
(87112)
(5369)
(3647)
(2127)
(1925)
(2026)
(2228)
(9.713)
(9.612)
(9.713)
(8.211)
(7.09.1)
(6.88.8)
(6.78.6)
(3748)
(4153)
(4356)
(2026)
(1418)
(2329)
(3546)
(80103)
(113146)
(105136)
(7091)
(5875)
(5571)
(5368)
(3654)
(119178)
(127189)
(5481)
(101151)
(100150)
(126183)
(203435)
(212453)
(230492)
(236505)
(231495)
(229491)
(228488)
(243580)
(294432)
(269395)
(246361)
(230335)
(227328)
(223322)
(147190)
(88114)
(6989)
(78100)
(84108)
(86110)
(87113)
(2944)
(2337)
(1730)
(1421)
(9.915)
(8.913)
(7.911)
(5571)
(5571)
(4659)
(3342)
(3140)
(3140)
(3242)
(193460)
(196288)
(151222)
(116171)
(94137)
(89129)
(85123)
(5790)
(1380)
(3.528)
(3245)
(2839)
(2235)
(1827)
(1620)
(1420)
(1318)
NUMBER
(THOUSANDS)
0
<0.01
<0.01
<0.01
(0<0.01)
0
(0<0.01)
0
(<0.01<0.01)
0
(<0.01<0.01) <0.1
<0.01 (<0.01<0.01)
<0.01 (<0.010.013)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
RATEa
(00)
(00)
(00)
(<0.1<0.1)
0.1 (<0.10.35)
0.2 (<0.10.45)
(<0.01<0.01) 0.1
(<0.01<0.01) 0.1
(<0.01<0.01) 0.1
(<0.01<0.01) 0.1
(<0.01<0.01) 0.1
(<0.010.015) 0.1
(<0.010.013) <0.1
(<0.10.12)
(<0.10.15)
(<0.10.18)
(0.100.20)
(<0.10.18)
(<0.10.34)
(00.29)
0.25
0.92
1.7
2.1
2.1
2.1
2.1
0.033
0.072
0.17
0.39
0.75
0.89
1.1
0.1
0.079
0.076
0.23
0.32
0.34
0.35
(0.1600.350) 5.9 (3.98.3)

(0.5701.4)
20 (1229)
(1.12.5)
32 (2047)
(1.33.1)
35 (2250)
(1.33.1)
31 (2046)
(1.33.1)
31 (1945)
(1.33.1)
30 (1944)
(0.0200.049) <0.1 (<0.1<0.1)
(0.0300.130) 0.1 (<0.10.19)
(0.0790.290) 0.2 (0.100.37)
(0.2000.630) 0.5 (0.240.73)
(0.4301.2)
0.8 (0.471.3)
(0.5201.4)
1 (0.551.5)
(0.6501.6)
1.1 (0.681.7)
(0.0860.120) 0.2 (0.200.29)
(0.0440.130) 0.2 (0.100.28)
(0.0430.120) 0.2 (<0.10.26)
(0.1400.340) 0.5 (0.310.71)
(0.2000.460) 0.7 (0.420.95)
(0.2200.480) 0.7 (0.451.0)
(0.2300.500) 0.7 (0.471.0)
0.019
0.077
0.092
0.07
0.08
0.077
0.086
(0.0160.022)
(0.0520.110)
(0.0640.130)
(0.0480.095)
(0.0580.110)
(0.0550.100)
(0.0630.110)
0.6
2.2
2.3
1.6
1.6
1.5
1.7
(0.550.72)
(1.53.0)
(1.63.2)
(1.12.2)
(1.22.1)
(1.12.0)
(1.22.2)

NUMBER
RATEa
CASE DETECTION
PERCENT
367
172
91
98
148
160
148
1 659
2 780
3 109
4 601
4 481
4 458
4 217
7
381
160
85
90
134
144
133
76
121
129
181
165
162
151
76
100
49
30
37
63
70
66
19
38
51
80
74
72
68
86
(46370)
(3287)
(2343)
(2657)
(37130)
(39160)
(37150)
(1622)
(3444)
(4657)
(7487)
(6979)
(6778)
(6373)
(7698)
4
11
4
3
5
143
87
94
47
54
49
52
348
391
344
332
298
301
305
0
0
0
0
0
0
1
28
48
75
57
38
32
33
40
109
39
29
49
84
46
44
20
22
20
20
10
11
8.9
8
6.9
6.9
6.9
0
0
0
0
0
0
70
64
83
110
85
62
53
54
130
140
65
61
150
85
75
110
85
99
84
83
92
97
80
85
86
88
91
0
0
0
0
0
0
170
70
65
91
110
93
83
90
(110140)
(120160)
(5875)
(5470)
(130170)
(7597)
(6786)
(95120)
(7597)
(87110)
(7596)
(7394)
(82110)
(86110)
(7192)
(7698)
(7698)
(78100)
(80100)
19
110
10
19
19
12
2 497
8 041
10 520
12 564
12 306
14 531
14 893
317 008
119 186
119 914
137 100
146 565
166 323
195 560
63 904
42 117
21 782
38 290
38 741
41 889
42 589
44
45
43
24
16
14
20
1 591
1 889
1 728
1 356
1 525
1 560
1 641
382
352
302
397
366
338
398
1
2
0
0
0
0
0
23
20
24
18
8
11
9
50
93
93
58
60
171
196
206
184
212
212
514
172
155
160
160
178
206
149
94
47
81
81
87
88
27
27
24
13
8.8
7.6
11
53
54
44
32
31
31
32
123
99
74
85
70
63
72
62
132
0
0
0
0
0
24
21
25
18
7.7
11
8.6
(150200)
(6280)
(5774)
(80100)
(93120)
(82110)
(7495)
(79100)
75 (6293)
75
75
75
38
19
53
56
58
52
61
61
130
48
47
53
57
65
76
89
94
60
92
84
89
88
76
90
100
78
73
71
110
84
86
85
86
88
86
86
40
41
40
60
61
58
70
86
340
0
64
63
88
79
43
63
55
(6293)
(6293)
(6293)
(3246)
(1430)
(3880)
(4085)
(4187)
(3779)
(4392)
(4493)
(89210)
(4059)
(3958)
(4465)
(4870)
(5479)
(6493)
(78100)
(83110)
(5369)
(81110)
(7596)
(79100)
(78100)
(6394)
(72120)
(80140)
(6497)
(6089)
(5986)
(95140)
(7496)
(7698)
(7597)
(7698)
(78100)
(7698)
(7698)
(2764)
(3450)
(3349)
(5073)
(5174)
(4970)
(5985)
(69110)
(1601 000)

YEAR
(5476)
(5475)
(70110)
(6599)
(3949)
(5475)
(4766)
257
YEAR
Tuvalu
Vanuatu
Viet Nam
Wallis and Futuna

Islands
258
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NUMBER
(THOUSANDS)
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
67
74
79
83
87
88
89
<1
<1
<1
<1
<1
<1
<1
0.048
0.04
0.034
0.028
0.024
0.023
0.022
0.19
0.11
0.2
0.17
0.17
0.17
0.16
140
150
160
170
170
180
180
0.021
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(0.0310.069)
(0.0170.074)
(0.0220.048)
(0.0190.039)
(0.0120.041)
(0.0130.036)
(0.0130.035)
(0.1500.230)
(0.0850.130)
(0.1600.250)
(0.1400.210)
(0.1400.200)
(0.1400.200)
(0.1400.200)
(100170)
(110190)
(120210)
(130220)
(130220)
(130220)
(140220)
(0.0180.024)
(<0.010.011)
(<0.010.010)
(<0.010.011)
(<0.01<0.01)
(<0.01<0.01)
(<0.01<0.01)
RATEa
536
437
357
291
247
237
228
127
63
110
83
72
69
67
204
204
205
204
200
199
199
151
67
61
69
40
31
21
(347766)
(181805)
(231510)
(198402)
(121418)
(135368)
(130353)
(103154)
(5176)
(89132)
(6899)
(5986)
(5783)
(5580)
(155261)
(155261)
(156261)
(155260)
(153254)
(153251)
(153250)
(133171)
(5875)
(5369)
(6078)
(3545)
(2735)
(1823)
NUMBER
(THOUSANDS)
0.05 (0.0360.067)
<0.01
0.12
3.2
8.5
10
10
14
RATEa
22 (1529)
(<0.010.015) <0.1 (<0.1<0.1)

(0.0580.210) 0.2 (<0.10.29)
(2.14.5)
4 (2.65.8)
(5.912)
10 (7.114)
(7.114)
12 (8.116)
(7.314)
12 (8.316)
(1118)
16 (1220)
CASE DETECTION
NUMBER
RATEa
PERCENT
23
36
16
12
18
14
12
140
79
152
76
134
116
110
50 203
55 739
89 792
94 916
95 036
94 867
98 804
255
390
170
124
184
142
122
95
47
82
36
57
48
45
75
75
114
114
109
108
111
48
89
48
43
74
60
53
75
75
75
44
80
70
67
37
37
56
56
55
54
56
42
64 (5673)
7
9
49
66
71 (6382)
160 (150190)
15
72 (6483)
(3374)
(48220)
(3374)
(3163)
(44150)
(39110)
(3594)
(6293)
(6293)
(6293)
(3653)
(6797)
(5885)
(5681)
(2948)
(2949)
(4473)
(4474)
(4371)
(4370)
(4473)
YEAR
American Samoa
19
Australia
Brunei
Darussalam
57
57
Cambodia
68
270
China
33
67
China, Hong Kong

SAR
112
67
China, Macao
SAR
95
61
Cook Islands
Fiji
31
24
French Polynesia
30
23
Guam
44
Japan
42
17
Kiribati
95
339
Lao People's
Democratic
Republic
44
68
Malaysia
64
69
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
9
3
6
4
4
3
1 016
1 073
1 043
1 046
1 217
1 187
1 222
143
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
0
0
0
0
0
1
0
0
0
0
0
0
0
7
5
2
17
16
41
41
20
27
20
24
29
17
43
61
65
49
77
70
17
6
13
13
15
5
0
5
8
0
0
0
0
15
5
0
5
8
0
0
0
0
0
0
0
605
814
718
432
466
367
588
997
1 168
1 115
605
814
1 306
1 429
1 634
1 482
0
0
0
42 845
34 169
6 325
6 540
0
0
0
18 693
19 664
49 707
42 537
39 307
34 610
53 480
90 780
17 046
14 909
12 215
18 693
73 144
140 487
59 583
54 216
46 825
5 301
0
0
0
3 115
3 179
2 673
2 352
2 244
772
701
722
792
815
0
0
0
0
188
219
321
316
300
594
500
188
197
187
782
719
509
513
487
0
0
0
0
141
160
136
116
123
148
0
2
0
1
1
0
1
84
68
62
63
83
89
106
94
180
162
130
175
126
0
0
1
0
1
0
0
105
99
42
29
21
45
58
70
50
43
45
49
46
0
0
0
0
0
0
0
37
34
40
40
38
45
41
0
0
0
0
0
0
0
0
0
0
0
49
12
14
17
21
21
0
0
0
0
0
0
0
17
28
39
2
0
0
0
0
0
0
0
49
12
31
45
60
23
0
0
0
0
0
0
0
43
35
26
39
0
0
0
0
0
0
0
2
0
0
0
2
0
0
0
0
2
10
3
0
2
5
2
12
8
0
0
0
62
63
53
41
64
29
21
17
13
22
19
25
17
18
27
10
14
14
6
13
0
0
0
1
3
5
4
2
0
0
0
0
1
3
5
4
2
0
0
0
0
54
63
102
101
81
51 821
43 078
39 384
27 194
23 631
22 693
22 119
68
43
27
31
39
28
5
26
60
51
39
6
9
10
9
11
0
0
0
0
1
1
1
2
3
1
0
0
0
1
2
1
2
3
0
0
0
1
14 367
11 853
10 931
8 853
8 237
7 937
25 172
19 118
10 056
8 591
8 630
8 231
2 803
7 046
5 340
4 975
4 632
4 826
0
0
736
1 367
867
1 212
1 194
1 125
1 125
539
568
562
736
1 367
1 992
1 751
1 762
1 687
54
124
145
118
140
47
79
70
91
109
106
126
59
71
87
0
0
0
3
3
4
6
7
7
0
8
11
3
10
4
14
18
0
0
0
478
1 526
2 801
3 034
3 119
3 271
404
457
484
368
394
516
95
180
275
292
323
349
2
64
139
154
163
170
41
30
22
27
2
64
180
184
185
197
67
52
62
54
6 688
8 156
8 446
9 981
11 135
11 862
4 021
5 517
4 862
4 596
4 338
4 501
1 069
1 384
1 702
2 344
2 545
2 888
210
0
332
420
499
557
651
761
820
858
210
0
983
1 181
1 319
1 415
73
0
0
0
307
163
213
237
230
6 501
14 603
18 891
35 535
39 202
40 460
38 555
375 481
515 764
454 372
894 428
965 257
908 399
899 669
6 510
6 212
6 015
5 660
5 160
4 935
4 739
343
402
449
355
308
368
341
0
2
1
1
2
0
1
226
203
144
132
144
189
208
59
252
332
278
286
343
1 826
830
2 227
3 699
3 848
3 999
4 306
11 702
11 778
15 057
15 342
17 341
18 517
19 808
2
3
0
0
0
0
2
2
3
3
1
0
2
1
0
0
0
0
0
0
1
0
0
0
251
241
267
274
301
362
339
391
410
436
369
450
511
457
463
84
101
140
146
109
166
30
18
30
52
42
27
49
43
48
11 101
14 822
21 001
17 863
17 454
15 812
1 465
1 108
7 057
8 378
8 301
7 686
1 428
2 147
6 759
12 529
14 239
14 690
134 488
204 765
472 719
449 152
429 899
377 005
203 088
229 943
329 157
439 399
432 868
481 514
1 940
1 561
1 444
1 475
1 380
1 560
0
0
0
0
100
60
0
0
0
41
42
41
40
41
34
77
89
83
68
88
93
75
68
68
67
40
47
59
51
50
44
38
33
35
39
38
60
47
46
47
41
54
100
0
100
50
100
44
41
60
68
80
66
65
60
46
50
42
45
90
51
34
43
42
36
38
52
51
49
49
53
61
67
56
56
54
77
85
89
89
86
62
60
63
68
72
72
NEW AND RELAPSE

NOTIFICATION RATE
19902011
259
NEW AND RELAPSE

a
NOTIFICATION RATE
19902011
YEAR
Marshall Islands
254
Micronesia
(Federated
States of)
381
133
Mongolia
76
151
Nauru
76
49
New Caledonia
84
20
New Zealand
10
Niue
70
Northern Mariana
Islands
64
54
Palau
58
Papua New
Guinea
60
212
Philippines
514
206
Republic of Korea
149
88
Samoa
27
11
Singapore
53
32
Solomon Islands
123
260
72
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
34
111
135
190
139
367
172
91
98
148
160
148
1 659
2 780
3 109
4 601
4 481
4 458
4 217
7
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
0
0
0
0
4
0
2
8
18
4
19
38
25
28
5
0
0
0
1 330
732
897
726
701
684
976
862
1 620
1 683
1 675
1 578
4
0
1
1
3
0
11
1
1
1
2
1
1
21
20
16
15
20
13
81
15
15
26
16
18
9
29
15
13
13
19
0
0
0
78
74
83
90
86
88
222
133
114
90
68
81
34
130
95
102
134
121
29
11
6
13
0
0
0
0
0
0
1
0
0
0
0
0
0
0
14
27
15
16
17
15
26
37
35
16
13
16
8
11
7
6
2
2
19
10
19
19
12
2 497
8 041
10 520
12 564
12 306
14 531
14 893
317 008
119 186
119 914
137 100
146 565
166 323
195 560
63 904
42 117
21 782
38 290
38 741
41 889
42 589
44
45
43
24
16
14
20
1 591
1 889
1 728
1 356
1 525
1 560
1 641
382
352
302
397
366
338
398
3
6
9
4
6
9
10
6
1
4
0
1
0
0
0
0
0
0
1
1 652
1 933
1 805
2 238
2 584
1 882
3 767
4 405
5 105
4 768
5 907
6 494
2 349
3 227
4 198
4 826
5 798
6 373
273
955
1 456
474
242
144
94 768
67 056
81 647
88 806
89 198
93 580
140 712
52 858
50 347
52 041
72 440
96 529
8
1 149
2 745
1 610
2 234
0
0
0
0
3 957
2 973
3 075
3 217
6 602
8 066
10 528
3 957
9 575
11 141
13 745
0
0
0
11 754
8 216
11 638
11 285
11 596
11 714
19 360
11 304
18 460
17 634
18 660
18 386
5 171
6 923
8 795
9 457
0
0
0
0
2 082
2 262
3 021
2 899
2 838
3 032
4 077
3 981
4 038
4 238
2 082
2 262
7 098
6 880
6 876
7 270
4 602
4 577
2 174
3 664
15
13
11
8
6
6
30
18
8
5
5
12
6
12
5
3
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
455
248
552
552
530
592
1 187
869
570
655
735
717
127
165
174
235
213
224
0
0
0
0
120
55
60
83
82
108
93
49
48
54
120
55
153
132
130
162
20
0
0
0
109
109
169
138
133
159
133
128
161
86
98
108
97
65
62
140
105
127
0
0
0
0
13
0
5
2
2
4
0
0
3
7
13
0
5
2
5
11
0
0
0
0
4
11
4
3
5
143
87
94
47
54
49
52
348
391
344
332
298
301
305
0
0
0
0
0
0
1
28
48
75
57
38
32
33
11
48
52
59
44
25
31
71
64
30
9
28
12
65
57
9
15
32
61
53
45
79
69
35
47
79
73
455
1 389
1 868
1 809
1 837
1 723
1
2
8
12
0
5
2
10
20
0
6
3
0
2
3
7
2
3
2
14
7
10
2
2
3
21
9
13
4
0
4
0
0
0
0
0
82
126
216
263
245
232
125
306
343
316
82
126
341
569
588
548
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
9
8
0
4
4
7
9
8
2
0
0
0
0
4
7
11
5
7
2
0
8
4
4
4
4
7
19
9
11
6
4
4
1
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
914
1 582
1 431
273
955
1 456
1 388
1 824
1 575
31
61
42
48
59
10
18
48
56
40
38
25
65
68
71
72
72
100
0
50
50
75
21
57
52
37
56
42
26
36
42
50
56
52
0
0
0
35
42
30
50
57
48
60
33
40
47
40
30
30
26
32
30
22
40
56
62
63
55
49
38
42
39
39
38
39
33
42
58
62
55
33
28
22
49
46
42
45
45
46
51
62
58
60
NEW AND RELAPSE

a
NOTIFICATION RATE
19902011
YEAR
Tokelau
62
Tonga
24
Tuvalu
255
122
Vanuatu
95
45
Viet Nam
15
Wallis and Futuna

Islands
NEW CASES
HISTORY POS AMONG
OTHER RELAPSE
POSITIVE
UNKNOWN
PULMONARY
RELAPSE
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
9
15
11
6
6
6
2
5
3
1
3
3
9
3
4
1
2
0
6
0
5
8
5
4
13
7
3
0
2
4
16
7
4
10
7
4
0
0
0
30
63
35
47
44
49
27
56
21
24
33
14
21
28
17
62
35
46
37 550
53 169
55 492
51 291
52 145
50 751
8 379
17 993
16 429
18 612
18 237
20 373
6 194
13 137
16 670
18 333
17 651
18 077
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
3
0
0
1
3
0
0
1
0
0
0
0
0
3
0
1
5
3
1
1
1
5
2
0
2
1
5
8
3
1
3
0
0
0
0
0
0
0
2 678
3 616
5 493
6 325
6 800
6 834
6 925
976
1 331
1 574
1 714
3 616
5 493
7 301
8 131
8 408
8 639
0
0
0
0
1 825
2 581
7
9
1
2
6
7
82
75
79
86
67
67
32
0
62
100
71
50
53
53
62
66
57
78
82
75
77
73
74
71
60
14
22
100
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
1990
1995
2000
2005
2009
2010
2011
NEW AND
RELAPSE
1
2
0
0
0
0
0
23
20
24
18
8
11
9
23
36
16
12
18
14
12
140
79
152
76
134
116
110
50 203
55 739
89 792
94 916
95 036
94 867
98 804
261
% OF COHORT
a

19952010
American Samoa
100
Australia
80
Brunei
Darussalam
81
91
94
Cambodia
China
93
96
China, Hong Kong

SAR
68
China, Macao
SAR
93
Cook Islands
100
Fiji
86
67
French Polynesia
67
92
Guam
84
Japan
52
Kiribati
87
93
70
91
69
80
Lao People's
Democratic
Republic
Malaysia
Marshall Islands
25
80
80
97
74
86
Micronesia
(Federated
States of)
Mongolia
262
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
2
3
0
0
0
4
2
4
0
3
0
251
241
299
267
274
238
241
587
606
629
84
101
132
140
146
11 101
14 822
21 001
19 860
17 863
17 454
134 488
204 765
472 719
462 596
449 152
429 899
84
101
164
164
176
4 363
14 775
21 001
19 811
17 863
17 454
131 413
213 766
472 719
464 151
449 039
429 790
1 940
1 561
1 459
1 444
1 475
141
160
136
139
116
123
2
0
1
2
1
0
68
62
63
78
83
89
1 940
1 561
1 448
1 441
1 487
29
21
20
17
13
43
27
31
31
39
14 367
11 853
10 931
8 995
8 853
8 237
54
124
147
145
118
478
1 526
2 801
3 075
3 034
3 119
6 688
8 156
8 446
10 441
9 981
11 135
11
48
28
52
59
9
15
32
38
61
53
455
1 389
1 868
1 838
1 809
1 837
160
136
246
115
219
2
1
2
0
0
73
62
68
82
79
89
33
62
18
28
18
13
43
27
31
47
51
10 348
10 931
8 999
8 772
8 242
31
54
123
146
144
117
343
1 588
2 802
3 075
3 034
3 119
13 398
7 915
8 446
9 757
9 981
11 135
163
11
47
35
58
71
10
14
20
59
60
59
455
1 389
1 868
1 838
1 809
1 837
COHORT AS
% NOTIFIED
100
133
95
100
196
227
230
100
100
124
117
121
39
100
100
100
100
100
98
104
100
100
100
100
100
100
99
100
101
100
100
177
99
178
100
100
100
0
107
100
108
105
95
100
214
86
140
106
100
100
100
100
152
131
87
100
100
99
100
100
99
99
99
99
72
104
100
100
100
100
200
97
100
93
100
100
100
98
125
112
120
111
93
62
155
98
111
100
100
100
100
100
100
DIED
FAILED
COMPLETED
100
0
75
0
100
0
0
0
0
0
0
0
0
25
100
27
12
7
6
8
45
68
73
73
72
9
10
6
3
3
0
1
0
0
3
2
1
1
2
16
8
12
16
15
42
66
64
63
61
83
88
89
92
92
91
72
93
92
92
93
94
21
5
23
8
20
8
4
4
3
3
3
22
2
2
2
2
17
7
8
9
7
2
4
3
2
2
2
2
1
2
1
1
1
0
0
0
0
0
1
0
0
0
0
0
1
2
1
1
1
1
4
2
1
0
0
4
4
2
1
1
1
1
1
1
1
1
0
17
20
4
20
12
2
1
2
2
1
2
3
3
3
3
2
2
55
60
58
59
57
5
3
10
11
11
5
5
17
15
15
6
9
0
0
0
4
3
4
3
4
24
20
11
12
13
81
93
89
86
93
100
8
0
0
2
0
0
6
4
5
3
3
0
0
0
0
0
0
0
4
1
1
2
1
0
1
3
4
7
3
0
100
50
0
0
0
0
0
0
0
50
0
0
78
81
71
82
89
65
67
0
92
8
5
0
9
5
2
0
97
89
96
89
0
7
5
10
6
4
6
3
2
11
4
6
8
0
0
0
0
0
0
0
2
0
0
0
0
3
8
10
1
1
24
21
0
0
0
6
0
4
2
9
2
1
3
9
0
0
0
0
0
93
85
90
96
84
0
0
0
0
0
7
11
6
2
16
0
0
0
0
0
0
0
0
0
0
0
4
3
2
0
30
38
18
21
20
45
83
62
93
84
88
62
68
85
92
91
89
69
0
69
78
78
79
3
64
85
91
71
63
80
93
75
39
65
97
66
83
82
84
84
83
15
22
30
31
32
42
7
31
3
13
5
8
9
5
1
2
3
0
78
1
1
1
1
21
27
2
6
14
17
0
0
5
8
23
0
7
4
6
3
4
3
5
11
19
19
21
13
7
7
4
3
5
6
7
5
5
4
6
6
8
9
8
9
9
7
0
2
0
9
8
10
7
10
2
3
3
8
3
3
3
2
2
4
3
1
1
1
1
1
4
4
3
2
0
0
0
2
2
0
1
0
1
0
2
0
0
0
0
0
0
0
0
1
0
0
0
19
9
3
1
2
2
8
10
5
4
4
4
67
9
2
3
3
1
10
0
0
2
0
0
10
4
3
2
2
3
44
26
28
24
24
0
0
0
0
0
0
4
7
1
0
1
0
14
4
16
11
9
7
1
0
9
0
3
10
0
0
5
49
7
0
2
3
2
1
0
0
0
0
0
0
0
5
0
2
0
6
3
5
7
7
8
DEFAULTED
NOT
EVALUATED
CURED
% OF COHORT
Nauru
67
New Caledonia
75
76
New Zealand
74
Niue
Northern Mariana
Islands
82
Palau
67
88
Papua New
Guinea
56
58
60
91
76
89
80
100
86
80
Philippines
Republic of Korea
Samoa
Singapore
Solomon Islands
65
87
Tokelau
Tonga
75
83
Tuvalu
100
Vanuatu
85
80
89
92
Viet Nam
Wallis and Futuna

Islands
0
a
100
YEAR
NUMBER
NOTIFIED
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
4
0
2
1
1
21
20
16
9
15
20
78
74
83
101
90
86
0
0
0
0
0
0
14
27
15
13
16
17
9
3
6
9
1 652
1 933
1 805
2 323
2 238
2 584
94 768
67 056
81 647
85 025
88 806
89 198
11 754
8 216
11 638
11 048
11 285
11 596
15
13
11
6
8
6
455
248
552
525
552
530
109
109
169
140
138
133
1
0
0
0
0
0
9
15
11
11
6
6
6
0
5
9
8
5
30
63
35
45
47
44
37 550
53 169
55 492
53 484
51 291
52 145
3
SIZE OF
COHORT
4
3
3
0
3
32
45
16
11
15
21
73
84
98
92
86
0
0
0
27
15
13
16
17
9
3
0
8
16
4 904
422
1 292
2 259
2 584
2 530
90 297
50 196
81 125
85 025
88 806
89 198
11 675
3 231
3 752
4 056
3 813
2 828
15
13
11
7
10
6
122
242
548
951
937
948
368
109
169
140
138
133
0
20
15
11
11
6
6
7
6
9
8
5
13
26
42
43
47
44
38 189
53 169
55 492
53 482
51 387
52 147
1
3
2
2
COHORT AS
% NOTIFIED
100
150
0
300
152
225
100
122
100
105
99
101
97
102
100
100
100
100
100
100
100
100
133
178
297
22
72
97
115
98
95
75
99
100
100
100
99
39
32
37
34
24
100
100
100
117
125
100
27
98
99
181
170
179
338
100
100
100
100
100
222
100
100
100
100
100
120
100
100
100
43
41
120
96
100
100
102
100
100
100
100
100
COMPLETED
DIED
25
0
33
67
67
33
0
0
0
0
0
75
0
0
0
75
33
88
9
0
0
67
0
12
9
6
9
0
19
56
6
73
93
76
0
3
2
0
0
7
5
33
9
0
0
0
0
0
5
0
0
25
60
73
76
74
23
6
8
7
17
0
0
1
3
1
47
33
15
16
8
81
73
0
0
77
81
82
11
0
0
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
19
27
15
19
18
22
0
0
56
FAILED
0
9
0
0
DEFAULTED
NOT
EVALUATED
CURED
100
62
75
73
56
82
67
57
12
12
56
24
14
7
13
10
6
15
7
8
7
7
2
2
2
2
2
4
67
8
0
0
0
0
15
71
83
19
17
17
65
7
30
11
22
30
25
12
4
2
4
4
4
3
1
2
2
2
2
2
2
2
1
1
1
1
20
8
9
29
10
0
2
14
14
16
15
17
6
5
8
2
4
1
0
0
0
0
1
2
2
2
1
1
1
1
1
1
3
1
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
3
0
0
15
26
19
16
16
14
5
6
4
4
4
4
5
3
4
3
3
3
0
0
0
0
0
0
11
14
2
0
1
1
4
4
4
1
3
5
0
0
25
9
5
13
6
23
34
3
3
5
4
2
14
12
11
12
12
6
0
0
0
0
0
0
0
0
1
2
2
3
26
11
2
3
3
4
75
93
73
100
83
83
0
0
0
0
0
0
10
0
18
0
17
17
5
7
0
0
0
0
0
0
0
0
0
0
10
0
9
0
0
0
86
0
11
0
0
11
0
0
0
0
14
0
11
0
46
12
17
28
15
14
5
2
2
2
2
2
15
8
10
5
4
16
3
3
3
3
3
3
0
0
7
2
0
0
2
1
1
1
1
1
0
4
2
2
0
2
4
2
1
2
2
2
0
0
0
12
0
0
0
0
0
0
2
2
2
2
2
2
2
39
57
58
58
48
54
73
82
80
82
85
74
81
81
82
81
85
13
85
91
71
90
100
71
62
65
62
100
67
88
100
38
77
64
63
81
66
84
90
90
90
90
91
100
100

19952010
263
% OF COHORT
a

19952010
American Samoa
Australia
69
Brunei
Darussalam
100
85
75
92
90
Cambodia
China
China, Hong Kong

SAR
68
China, Macao
SAR
66
Cook Islands
Fiji
67
French Polynesia
50
75
Guam
100
Japan
47
Kiribati
70
100
82
Lao People's
Democratic
Republic
Malaysia
59
Marshall Islands
50
100
30
61
80
Micronesia
(Federated
States of)
Mongolia
264
YEAR
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
NUMBER
NOTIFIED
SIZE OF
COHORT
0
1
0
0
0
1
0
0
0
17
43
43
61
65
11
43
50
65
58
15
5
12
0
5
605
814
1 306
1 435
1 429
1 634
18 693
73 144
140 487
102 079
59 583
54 216
5
12
0
5
436
827
1 306
597
1 429
1 524
54 052
43 252
89 239
64 023
59 853
54 469
782
719
561
509
513
49
12
31
38
45
60
0
0
0
0
0
0
2
0
4
2
12
1
3
2
5
4
1
2
1
1
2
736
1 367
1 992
1 836
1 751
1 762
218
716
526
481
512
37
37
38
46
35
0
0
0
0
0
0
5
12
2
4
4
5
4
2
0
1
2
1 169
1 992
1 547
1 452
1 466
3
10
17
4
14
2
64
180
179
184
185
210
0
983
1 054
1 181
1 319
9
3
17
6
20
1
64
181
153
184
184
1 056
1 171
1 181
1 319
0
5
7
2
10
2
3
21
5
9
13
82
126
341
544
569
588
20
2
8
4
9
20
9
5
16
10
23
126
443
385
380
234
COHORT AS
% NOTIFIED
100
65
100
116
107
89
100
100
100
72
102
100
42
100
93
289
59
64
63
100
100
28
100
94
94
100
308
119
100
102
58
0
250
100
133
200
100
100
100
0
100
100
86
100
84
83
83
300
30
100
150
143
50
100
101
85
100
99
107
111
100
100
400
29
400
40
450
667
43
100
178
77
28
100
130
71
67
40
CURED
COMPLETED
DIED
FAILED
DEFAULTED
100
NOT
EVALUATED
9
16
4
6
5
73
56
62
60
64
9
5
12
3
5
0
0
2
0
0
5
2
8
3
9
19
20
22
22
40
50
40
33
20
8
0
0
0
0
0
8
100
59
85
49
74
34
30
90
86
85
85
86
86
0
26
5
27
5
45
44
2
2
5
4
4
4
0
5
6
9
7
3
4
2
1
3
2
2
2
0
3
1
2
5
1
1
3
1
3
2
2
2
0
3
4
3
3
1
1
1
1
1
1
1
1
0
4
0
11
6
15
20
1
8
4
5
4
5
27
40
21
26
34
26
18
45
38
34
4
4
13
15
12
17
9
0
0
0
18
7
5
6
4
8
22
16
14
16
68
51
55
43
51
16
24
26
35
14
11
11
3
11
14
0
0
0
0
0
5
0
3
7
11
0
14
13
4
9
40
50
50
40
17
0
20
17
50
0
0
0
0
17
0
0
0
0
0
0
75
75
100
75
25
0
0
25
0
0
0
25
0
0
0
0
0
0
50
50
100
100
0
0
0
0
0
0
0
0
0
0
31
29
14
15
14
15
16
30
32
32
5
8
16
15
17
6
2
1
1
1
1
2
8
6
5
41
43
31
31
31
89
100
53
83
25
100
41
75
86
85
76
11
24
17
45
0
8
12
3
3
7
12
0
30
0
11
6
9
8
12
0
0
0
0
8
2
1
2
3
12
0
0
0
11
5
0
1
3
0
0
0
0
0
0
22
1
1
0
0
46
36
33
35
9
26
27
24
8
11
9
12
1
1
1
1
9
5
6
12
27
22
23
17
60
0
12
25
100
25
11
40
0
20
61
57
39
51
60
19
10
50
75
25
0
60
89
20
19
10
0
14
34
22
13
61
50
0
50
0
5
0
0
0
0
10
0
12
0
0
0
20
75
10
9
8
9
6
4
9
0
0
0
13
8
11
16
17
6
0
0
20
13
7
4
4
4
2
30
0
0
0
0
0
0
20
6
40
4
6
3
1
2
4
% OF COHORT
Nauru
New Caledonia
100
88
New Zealand
73
Niue
Northern Mariana
Islands
Palau
Papua New
Guinea
46
Philippines
69
40
79
Republic of Korea
Samoa
Singapore
78
Solomon Islands
80
Tokelau
Tonga
100
Tuvalu
Vanuatu
100
81
69
Viet Nam
Wallis and Futuna

Islands
YEAR
NUMBER
NOTIFIED
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
1995
2000
2005
2008
2009
2010
SIZE OF
COHORT
0
3
0
0
4
4
7
4
9
8
4
7
19
11
9
11
0
0
0
0
0
0
2
0
0
0
0
0
0
273
955
1 456
1 799
1 388
1 824
8
3 957
8 866
9 575
11 141
2 082
2 262
7 098
6 310
6 880
6 876
0
0
0
0
0
0
120
55
153
151
132
130
13
0
5
14
2
5
0
0
0
0
0
0
0
1
0
0
0
1
3
2
0
0
1
5
8
1
3
1
3 616
5 493
7 301
7 534
8 131
8 408
1
0
0
1
0
4
7
5
9
8
23
18
11
9
11
0
0
0
0
0
0
0
0
0
0
0
68
65
530
444
3 819
4 362
4 554
2 004
131
3 331
2 476
2 420
1 813
0
0
0
0
149
149
130
127
5
14
2
5
0
9
1
0
0
0
0
0
0
0
0
5
0
1
3
1
2 384
8 806
7 374
7 534
357
398
0
0
0
COHORT AS
% NOTIFIED
100
100
125
100
100
329
95
100
100
100
7
4
38
24
43
46
41
96
6
47
39
35
26
97
99
98
98
100
100
100
100
100
0
0
100
0
100
100
100
66
160
101
100
4
5
CURED
COMPLETED
DIED
FAILED
DEFAULTED
100
NOT
EVALUATED
100
86
0
0
0
0
40
89
88
14
40
0
12
0
20
0
0
0
0
0
0
0
0
0
30
67
91
67
73
4
0
0
11
18
29
42
35
14
36
35
0
0
11
0
0
0
0
0
4
15
1
6
21
20
9
3
22
11
5
5
5
5
29
18
3
27
56
48
53
39
59
72
74
69
76
15
13
15
1
2
3
2
3
4
4
4
5
1
3
2
1
2
2
4
4
5
2
3
0
1
1
0
7
5
6
3
12
6
6
5
6
14
26
16
53
21
18
16
21
12
40
37
47
79
30
39
31
15
22
20
17
0
0
0
0
5
3
1
2
1
5
3
3
20
79
50
80
40
21
50
0
20
0
0
20
20
0
0
0
0
0
0
0
0
0
0
0
100
100
0
0
65
33
9
22
9
100
0
100
100
80
74
79
80
67
61
0
0
0
2
5
4
3
6
8
100
0
0
5
6
5
5
8
8
0
0
0
8
5
6
5
2
4
0
0
0
2
3
3
3
10
12
0
0
0
4
7
3
3
7
6

19952010
265
KNOWN HIV STATUS
YEAR
20052011
American Samoa
100
Australia
42
56
Brunei
Darussalam
100
100
Cambodia
82
23
China
China, Hong Kong

SAR
68
74
China, Macao
SAR
91
94
100
Cook Islands
Fiji
100
75
French Polynesia
48
27
72
55
49
Guam
Japan
Kiribati
13
77
Lao People's
Democratic
Republic
47
73
89
77
58
73
Malaysia
Marshall Islands
Micronesia
(Federated
States of)
Mongolia
80
Nauru
New Caledonia
40
New Zealand
41
56
Niue
100
Northern Mariana
Islands
98
94
90
50
29
Palau
Papua New
Guinea
Philippines
266
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
0
100
75
100
42
49
54
56
100
100
100
100
3
70
77
82
0
4
3
3
448
648
686
709
163
213
237
230
1 044
28 264
32 236
32 544
6
16
23
68
74
75
74
91
90
92
94
0
0
100
100
48
82
75
48
23
27
27
72
63
62
55
63 227
145 919
208 681
4 209
3 953
3 833
3 656
378
335
399
358
0
0
0
1
132
69
157
160
30
12
11
17
46
64
63
45
51
52
49
13
54
54
77
12 429
12 098
11 221
44
151
159
274
17
38
47
73
84
91
89
77
69
68
58
6
46
49
73
0
83
89
80
0
0
0
0
40
0
0
0
41
46
60
56
100
98
87
100
94
90
100
95
50
686
1 533
2 058
11 661
15 192
17 577
18 472
86
98
137
88
7
72
85
110
1
3 993
4 256
3 612
0
0
0
0
21
0
0
0
140
140
183
172
0
0
0
1
56
33
32
31
9
19
18
6
7
13
29
888
2 122
4 671
1
1
2
1 136
1 634
3 917
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
6
4
4
3
1 073
1 314
1 281
1 268
163
213
237
230
36 123
40 199
41 628
39 670
990 509
982 303
923 308
911 884
6 160
5 348
5 132
4 926
415
371
433
382
1
2
0
1
132
144
191
213
63
53
41
64
64
102
101
82
28 319
24 170
23 261
22 681
339
278
294
354
3 807
3 930
4 083
4 387
16 066
18 102
19 337
20 666
112
143
201
151
112
155
174
150
4 726
4 787
4 801
4 533
11
4
3
5
53
63
57
52
340
302
305
309
0
0
0
1
57
38
32
33
10
19
19
12
12 564
13 220
16 113
16 324
137 100
153 167
174 389
206 088
NUMBER OF
HIV-POSITIVE
TB PATIENTS
% OF TESTED
TB PATIENTS
HIV-POSITIVE
0
0
0
22
23
24
17
2
2
1
3
86
3 597
2 112
1 650
0
0
0
5
4
3
2
1
1
0
1
8
13
7
5
2 511
4 542
4 715
35
38
24
33
1
1
3
2
0
0
0
0
1
0
3
3
0
0
0
1
0
0
1
0
4
3
2
1
1
1
1
0
0
1
1
0
1
0
2
2
0
0
0
6
0
0
2
0
52
53
75
2
2
0
0
0
0
1
5
1
0
0
179
182
218
1 468
1 644
1 628
1 629
0
2
0
1
0
0
0
0
1
0
2
3
0
0
0
0
0
0
0
26
12
11
13
11
9
9
0
2
0
1
0
0
0
0
100
0
0
0
8
3
3
2
0
0
0
0
0
0
0
0
0
0
0
1
6
2
2
1
0
0
0
0
0
0
0
0
17
91
222
531
10
10
11
1
2
9
0
0
0
PEOPLE
CPT
ART
PROVIDED IPT
0
0
100
100
100
0
100
100
100
2
0
30
65
88
15
45
79
66
491
1 305
87
49
29
17
43
45
36
54
26
29
0
0
33
50
100
0
33
50
78
100
100
100
0
0
0
100
100
100
100
0
100
0
0
89
100
100
10
22
48
10
22
46
100
100
0
100
100
100
100
100
100
0
0
0
0
0
0
135
256
0
0
0
0
1
16
226
YEAR
KNOWN HIV STATUS
20052011
Republic of Korea
Samoa
Singapore
79
17
Solomon Islands
Tokelau
Tonga
100
Tuvalu
50
15
59
Vanuatu
Viet Nam
Wallis and Futuna

Islands
400
0
12
21
5
0
2
3
1
71
74
79
0
0
11
17
1 121
1 184
1 331
0
0
39
70
0
0
0
0
100
73
100
0
0
0
0
0
0
8
50
15
36
43
59
8
8
9
0
0
0
0
0
0
9
56
14 128
34 907
42 356
59 176
100
9
10
8
400
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
46 969
47 299
48 101
50 491
24
16
14
20
1 469
1 574
1 608
1 695
397
366
341
405
0
0
0
0
18
8
11
9
15
18
14
13
81
136
116
112
95 892
98 192
99 022
100 518
7
9
2
NUMBER OF
HIV-POSITIVE
TB PATIENTS
96
135
129
0
0
0
0
52
50
60
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
595
5 934
3 515
4 703
0
0
0
0
% OF TESTED
TB PATIENTS
HIV-POSITIVE
PEOPLE
CPT
ART
PROVIDED IPT
0
0
0
5
4
5
0
0
0
0
0
0
0
0
0
0
4
17
8
8
0
0
0
89
62
72
6
43
48
1 500
1 317
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
% OF TB
NUMBER OF TB
KNOWN HIV
KNOWN HIV
STATUS
STATUS
267
YEAR
TOTAL
CONFIRMED
CASES OF
a
MDR-TB
American Samoa
Australia
Brunei
Darussalam
Cambodia
China
China, Hong Kong

SAR
China, Macao
SAR
Cook Islands
Fiji
French Polynesia
Guam
Japan
Kiribati
Lao People's
Democratic
Republic
Malaysia
Marshall Islands
Micronesia
(Federated
States of)
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana
Islands
Palau
Papua New
Guinea
Philippines
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
0
0
0
12
31
33
28
0
0
0
2
31
56
474
2792
1601
41
21
28
23
9
3
6
5
0
0
0
0
0
0
0
0
0
0
1
1
2
0
68
60
1
0
0
2
4
1
55
64
141
2
1
1
1
1
3
1
1
0
168
187
185
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
0.15 (0.110.18)
29 (1741)
0 (00)
490 (260720)
61 000 (54 00068 000)
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
0.15 (0.110.18)
0
0
0
4
7
4
0
0
0
2
0
0
0
0
0
0
1
15
274
1073
522
1148
0
0
1
0 (03.1)
330 (170590)
5
18
5.2 (0.689.7)
4.2 (1.211)
<0.1 (<0.1<0.1)
0 (013)
0 (00)
0 (03.7)
0 (00)
0 (05.5)
280 (210350)
110 (68180)
16 (1319)
12 (9.215)
230 (190280)
190 (140230)
9940
3271
2056
1897
1992
265
201
221
258
0
0
0
0
4
18
42
27
47
39
50
56
43
7684
7400
1
0
15010
16 (048)
16 (0.4191)
1.5 (04.4)
1.5 (<0.17.9)
6.7 (5.38.1)
5.8 (4.47.2)
200 (170230)
33 (1739)
0
0
BACT+VE
TESTED FOR
MDR-TB
160
99
100
100
130
<0.1
<0.1
2.6
96
73
61
79
190
100
89
110
0
4.5
17
110
87
110
110
110
110
110
54
51
0.81
180
110
69
96
100
110
79
70
98
0
6.7
2.2
9.1
140
62
140
150
150
100
130
100
100
100
58
100
<0.1
1.4
<0.1
<0.1
164
181
205
31 (1849)
0 (00)
BACT+VEb
TESTED FOR
MDR-TB
868
652
45 (2763)
<0.1 (<0.1<0.1)
% OF
16 (8.726)
49 000 (39 00061 000)
52
40
68
50
35
48
50
44
0
121
40
157
0
0.20 (0.150.24)
0.20 (0.150.24)
0.25 (0.200.30)
0 (04.4)
5.4 (1.59.2)
4.6 (1.79.9)
<0.1 (<0.1<0.1)
0 (05.5)
1.5 (03.8)
1.3 (<0.15.3)
780 (660890)
410 (310510)
11 000 (8 00013 000)
0
43
20
24
247
237
<0.1 (<0.1<0.1)
0 (05.5)
7 700 (5 50010 000)
NUMBER OF
24
21
17
19
3
11
8
4
1242
3
25
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
0 (00)
13 (5.723)
0 (03.0)
160 (60320)
12 000 (10 00014 000)
14 (5.230)
0.96 (<0.14.9)
0 (00)
0 (07.8)
0 (02.0)
0 (02.5)
170 (120220)
4.2 (3.54.8)
46 (3952)
0 (0290)
0 (012)
0.93 (0.791.1)
170 (140190)
0 (00)
0.25 (0.200.30)
0.75 (<0.13.2)
0 (00)
0 (00)
0.23 (0.200.27)
370 (310420)
2 900 (2 0004 000)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
48
74
26
53
13
5
100
8
100
93
5.7
190
13
163
23
234
46
211
41
207
43
19
61
27
60
39
65
24
100
2
100
4
33
0
0
3
100
4
80
4
100
1
50
0
0
1
100
2
100
2
67
694
39
670
40
0
0
1056
110
3
60
1
50
3
30
4
20
21
100
2
22
3
23
0
0
16
4.7
508
89
561
95
602
110
1
11
0
0
0
0
14
74
8
89
0
0
138
3.5
36
0.38
297
2.7
2325
17
b
268
YEAR
TOTAL
CONFIRMED
CASES OF
a
MDR-TB
Republic of Korea
Samoa
Singapore
Solomon Islands
Tokelau
Tonga
Tuvalu
Vanuatu
Viet Nam
450
516
0
0
3
3
3
6
0
0
0
1 800 (1 5002 200)
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
810 (6301 000)
8.2 (1.715)
16 (1219)
0
0
0
217
101
601
BACT+VE
TESTED FOR
MDR-TB
17
96
98
97
97
3.6
0.75
0
0
0
0
0
3431
8.2 (3.018)
895
915
923
952
13 (9.916)
5
1
0
0
0 (00)
0
0
0
BACT+VEb
TESTED FOR
MDR-TB
0.88 (0.671.1)
0
0
% OF
0
0.88 (0.671.1)
0.44 (0.330.55)
0 (00)
0.44 (0.330.55)
0
0
0
0
0.62 (0.520.72)
0.39 (0.300.49)
0
0.70 (0.600.80)
0 (07.5)
3 700 (2 9004 400)
2 000 (1 5002 700)
0.10 (<0.10.12)
0.10 (<0.10.12)
NUMBER OF
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
1 000 (7401 400)
0 (00)
0 (05.6)
2.6 (2.22.9)
0 (00)
0 (00)
0.23 (0.200.27)
0.70 (0.590.80)
1 700 (1 2002 200)
0 (00)
NUMBER OF
% OF NOTIFIED
NOTIFIED
TESTED FOR
TESTED FOR
MDR-TB
MDR-TB
968
13
105
69
85
64
79
61
104
64
15
750
1
20
0
0
0
0
0
0
Wallis and Futuna

Islands
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
2005
2009
2010
2011
NEW PULMONARY CASES

ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED
a
b
269
MALE
YEAR
American Samoa
Australia
Brunei
Darussalam
Cambodia
China
China, Hong Kong

SAR
China, Macao
SAR
Cook Islands
Fiji
French Polynesia
Guam
Japan
Kiribati
Lao People's
Democratic
Republic
Malaysia
Marshall Islands
Micronesia
(Federated
States of)
Mongolia
Nauru
New Caledonia
New Zealand
270
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
014
1524
2534
3544
FEMALE
4554
5564
65+
UNKNOWN
014
1524
2534
5564
65+
UNKNOWN
3544
4554
1
2
0
0
0
1
0
3
0
2
2
16
32
42
38
35
27
33
44
25
23
22
26
24
11
25
19
19
12
9
12
49
30
27
37
0
0
0
2
4
3
15
18
36
26
19
26
43
40
12
11
12
23
15
10
2
7
5
6
5
7
14
14
12
17
0
0
0
0
161
26
49
39
34
1 102
1 131
1 416
759
645
6
9
17
11
453
519
894
750
791
12 791
19 111
43 005
42 851
37 514
4
19
15
11
1 244
1 323
1 600
1 564
1 469
18 306
29 399
49 558
38 880
34 597
15
19
13
11
1 147
1 618
2 349
1 760
1 557
15 487
25 206
55 400
50 246
43 087
5
12
18
10
1 253
1 456
2 043
2 105
1 972
13 105
25 593
54 872
52 925
47 949
7
9
7
11
1 257
1 373
1 964
1 531
1 439
13 489
21 429
53 822
56 754
51 315
15
0
18
13
707
1 058
1 811
1 599
1 339
10 130
21 771
69 779
64 514
55 881
0
0
2
2
123
38
45
60
39
1 169
1 420
1 864
926
733
4
9
7
5
388
457
790
752
690
10 890
14 536
31 180
27 064
22 859
6
11
15
9
1 133
1 157
1 413
1 321
1 211
13 250
18 496
27 759
21 022
18 347
9
8
12
6
1 435
1 649
2 089
1 303
1 092
8 376
12 377
24 728
20 422
17 119
6
3
8
7
1 426
1 798
2 323
1 732
1 528
5 679
9 899
19 889
16 075
14 103
3
2
4
3
1 180
1 459
2 058
1 607
1 473
4 579
7 102
18 203
17 441
15 218
4
0
10
10
578
892
1 573
1 331
1 242
2 841
6 296
21 244
20 020
17 638
4
3
2
2
0
0
3
0
0
0
0
0
0
0
0
0
7
1
0
78
76
52
72
7
10
6
17
20
0
0
1
0
0
8
8
9
7
12
102
84
84
52
19
8
9
5
22
0
0
0
0
0
10
6
18
15
16
160
108
99
63
20
25
21
7
22
0
0
0
0
0
9
13
18
11
8
211
200
184
172
13
22
23
22
47
0
0
0
0
0
4
5
14
6
9
236
168
166
189
12
9
17
20
39
1
0
0
0
0
2
4
16
2
9
578
453
413
384
16
17
22
11
24
0
0
0
0
0
3
2
6
4
4
0
0
5
3
3
3
0
0
0
0
0
0
0
0
0
0
1
0
7
1
1
65
67
49
56
9
10
5
7
28
0
0
0
0
1
10
7
7
11
13
115
81
101
89
18
4
9
6
25
0
0
0
0
0
9
5
9
12
17
86
92
76
69
12
6
7
10
17
0
0
0
0
0
2
7
6
5
7
44
57
64
60
4
6
8
5
18
1
0
0
0
0
3
1
4
1
5
45
34
49
53
5
3
1
7
6
0
0
0
0
0
4
4
6
8
2
211
135
133
116
6
13
5
6
6
0
0
0
0
0
3
0
5
5
3
0
0
1
0
0
0
3
2
3
3
3
2
1
1
4
2
0
1
4
0
1
5
4
4
1
1
3
2
1
3
0
0
1
0
0
0
4
2
1
3
1
3
1
3
0
0
0
0
1
1
3
1
0
1
0
0
0
3
1
1
0
0
2
0
0
0
15
2
9
1
0
1
2
2
1
342
246
197
128
96
6
4
3
0
627
572
488
252
215
6
4
5
2
995
676
605
382
367
9
2
5
7
1 847
1 494
868
469
465
6
2
7
4
2 059
1 509
1 418
911
812
9
4
3
4
4 089
3 816
3 867
3 326
3 256
0
0
1
0
14
5
5
6
5
3
3
0
1
258
222
187
89
94
1
1
4
1
476
464
428
232
213
2
1
3
1
298
213
249
194
203
5
2
3
0
476
292
224
155
148
2
0
0
3
637
384
309
183
223
2
2
3
4
2 234
1 958
2 077
1 909
1 840
2
3
3
4
6
7
13
8
8
59
32
244
129
63
9
15
27
17
56
92
136
157
145
640
694
1 179
884
948
3
15
13
9
71
128
223
254
275
879
1 138
2 218
1 438
1 564
3
12
10
3
68
166
296
287
323
775
1 177
2 277
1 599
1 559
3
17
9
10
78
201
373
416
474
788
908
1 980
1 453
1 594
8
4
6
9
90
177
300
385
416
374
814
1 427
967
1 245
2
1
2
3
55
176
352
380
375
1 072
891
1 507
981
1 054
2
5
5
6
3
10
7
13
14
58
41
208
152
77
5
22
15
26
49
59
101
133
141
446
464
1 044
704
837
6
12
7
12
49
95
186
152
204
448
564
1 061
881
876
3
7
4
9
69
131
205
215
208
345
424
947
592
584
4
7
8
16
54
122
244
269
267
316
367
816
542
599
1
3
5
12
52
91
192
225
215
149
356
586
425
459
3
1
4
4
26
71
178
225
206
339
286
572
388
403
3
2
0
1
0
0
5
4
10
7
1
2
4
4
1
2
0
0
1
5
4
3
3
1
3
6
6
3
1
0
5
1
6
3
0
0
3
1
2
1
0
1
7
1
5
1
0
4
7
9
9
5
0
3
3
2
2
8
1
1
0
4
2
2
0
1
2
3
4
5
0
0
2
4
8
2
0
1
0
2
0
1
1
1
3
4
37
6
7
3
2
8
8
99
181
271
285
246
1
5
111
260
253
255
289
2
6
68
171
232
231
205
4
2
19
68
147
154
170
4
0
13
38
52
50
71
0
1
15
23
36
40
41
0
0
5
5
30
32
15
12
10
8
5
70
200
320
296
250
9
2
78
213
270
246
192
3
3
33
113
145
112
121
4
1
15
41
63
83
61
2
2
9
26
32
42
40
0
1
25
17
25
28
25
0
0
3
1
0
0
0
0
0
4
0
1
0
0
2
1
2
1
0
4
6
6
6
12
0
0
3
3
1
2
0
3
5
10
13
5
0
1
4
4
0
3
3
3
6
6
4
5
0
0
2
3
3
4
2
7
10
5
5
7
0
0
3
4
0
3
3
7
7
10
11
11
0
0
0
0
2
1
0
0
0
1
1
1
2
4
0
0
1
8
1
1
0
2
6
11
12
8
0
0
1
1
2
0
1
3
6
9
7
8
1
0
3
1
1
1
1
4
5
6
6
4
0
0
3
3
2
0
0
2
0
6
5
5
0
0
0
2
0
1
1
2
4
1
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
2
2
0
1
1
5
8
6
6
7
0
0
0
0
0
1
1
4
4
3
1
4
10
2
6
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
MALE:FEMALE
RATIO
2.0
2.1
1.6
1.4
1.4
1.6
2.1
1.5
1.6
0.99
0.99
1.0
1.2
1.2
1.8
2.0
2.3
2.5
2.6
2.4
2.3
2.1
2.1
1.6
2.2
2.9
2.0
1.7
1.0
1.1
1.6
2.0
1.1
1.2
3.1
1.2
1.2
1.8
2.6
2.0
1.8
1.8
2.3
2.4
2.1
2.0
1.9
1.2
1.2
1.5
0.65
1.4
1.6
1.5
1.5
1.6
2.2
2.3
2.1
2.0
2.1
1.1
0.92
0.97
0.83
2.5
0.36
0.71
1.4
1.4
1.2
1.1
1.2
1.5
0.50
2.0
1.7
0.90
0.60
2.3
2.2
1.6
1.3
1.3
1.1
1.2
Niue
Northern Mariana
Islands
Palau
Papua New
Guinea
Philippines
Republic of Korea
Samoa
Singapore
Solomon Islands
Tokelau
Tonga
Tuvalu
Vanuatu
Viet Nam
Wallis and Futuna

Islands
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
1995
2000
2005
2010
2011
FEMALE
014
1524
2534
3544
4554
5564
65+
1
1
0
0
0
0
1
4
0
2
0
2
3
8
1
0
0
3
5
9
3
0
0
0
10
9
4
3
1
2
0
0
1
0
2
2
0
1
1
8
28
37
50
2
87
183
279
278
43
70
205
260
265
56
482
511
573
27
19
22
22
13
0
0
0
7 358
9 320
9 725
1 131
821
687
537
491
1
3
4
1
1
9
8
8
11
21
14
13
14
16
15
11 275
12 224
12 804
1 613
1 085
1 171
705
712
1
1
0
1
0
40
9
25
21
21
6
4
18
18
22
0
0
1
0
0
0
2
3
4
4
3
UNKNOWN
014
1524
2534
3544
4554
5564
65+
3
3
1
3
5
1
3
2
2
0
3
0
0
0
0
0
0
0
0
10
0
2
0
0
2
17
0
0
1
0
6
7
1
1
0
0
4
3
1
3
2
1
1
1
1
2
3
0
1
1
1
1
0
0
1
0
1
2
1
1
0
1
0
0
0
1
1
1
0
0
0
0
0
0
0
30
108
196
152
61
21
94
135
122
46
12
48
87
71
47
5
12
27
18
26
6
38
64
53
1
77
200
313
302
20
45
204
292
272
32
21
124
191
146
26
15
65
97
97
20
5
35
52
55
19
1
2
9
15
11
13 253
13 716
14 474
1 425
988
1 326
1 049
1 019
1
1
1
12 531
13 651
14 002
1 207
853
1 336
1 496
1 414
0
1
1
4 279
4 742
4 845
1 225
901
1 669
1 997
2 132
2
1
0
374
454
448
46
25
27
23
37
1
0
0
3 710
4 825
5 155
908
546
590
472
446
2
2
2
5 268
5 489
5 848
863
544
842
686
688
2
1
0
0
1
1
0
1
0
3
8
9
4
3
2
8
9
5
15
11
17
15
23
19
13
1
18
8
20
21
25
11
13
21
17
27
3 274
3 329
3 501
408
295
373
368
421
1
0
1
1
0
19
5
20
21
20
13
5
9
4
16
2 029
2 070
2 236
867
795
1 729
2 216
2 244
1
0
0
0
62
51
94
105
108
7
8
15
8
7
5 565
5 301
5 521
431
393
491
509
520
0
1
2
2
0
21
7
33
26
23
7
7
12
11
15
4 603
4 643
4 880
296
220
370
487
432
0
0
0
0
60
34
61
38
44
5
8
9
16
12
7 646
8 923
9 568
1 307
731
1 005
1 029
1 145
3
2
0
1
0
70
26
96
86
119
9
10
12
3
8
0
94
64
118
120
126
3
6
11
3
6
0
1
1
0
1
1
0
1
0
1
0
0
0
0
0
1
1
2
2
0
0
0
2
0
0
0
1
1
1
1
0
1
2
5
0
3
1
0
0
1
0
2
1
4
2
1
1
6
7
4
6
3
1
1
2
5
5
3
4
5
1
5
1
6
51
54
59
61
2 367
3 408
3 205
3 099
6 147
7 105
7 036
6 677
8 209
8 738
7 851
7 763
0
0
0
0
0
0
3
0
0
0
0
0
0
0
1
22
9
29
21
23
12
7
11
5
10
1
31
16
43
44
51
0
2
1
5
2
1
1
1
0
1
1
1
1
0
0
1
0
0
0
2
0
0
1
2
0
0
1
2
1
2
0
0
1
1
1
0
0
0
0
1
0
3
10
0
5
5
1
2
1
4
5
4
2
4
0
2
1
0
2
0
0
0
5
0
3
0
5
3
5
5
5
0
15
1
3
7
6 713
8 606
8 564
8 474
5 150
4 958
5 790
6 107
7 712
7 573
6 248
5 821
0
0
64
47
53
64
1 334
1 747
1 870
1 863
2 320
2 293
2 454
2 325
0
1
0
0
UNKNOWN
0
0
0
0
0
0
3
0
0
0
0
0
0
0
2
0
2
7
2
3
5
0
1
3
3
4
5
4
0
3
1
3
2
0
1
2
1
0
0
0
2 754
2 116
1 681
1 681
2 594
2 298
1 864
1 814
2 847
2 023
1 863
1 878
4 907
4 604
3 751
3 124
0
0
MALE:FEMALE
RATIO
1.9
0.92
2.8
0.89
1.5
8.0
2.3
3.0
1.4
1.0
1.0
1.0
2.2
2.3
2.4
2.4
2.1
1.9
1.6
1.4
1.4
1.1
2.2
1.2
1.0
0.20
2.8
3.5
2.7
2.6
2.9
0.73
0.91
0.97
1.0
0.85
0.80
2.0
1.2
5.0
0.50
1.0
0.67
4.0
3.0
2.0
0.86
1.3
0.91
1.1
2.2
2.7
2.9
3.0
MALE
YEAR
271
LABORATORIES
FREE THROUGH NTP
SECONDNUMBER OF
CULTURE
DST b LABS
LPAc LABS
LINE DST
LABS USING
PER 100K
PER 5M
PER 5M
POPULATION
LEDa
American Samoa
Australia
Brunei Darussalam
0.2
12.3
12.3
12.3
Cambodia
1.5
1.0
0.3
China
China, Hong Kong SAR
China, Macao SAR
0.2
0.4
2
3
2.2
14.0
0.7
2.1
<0.1
7.7
16
9
Cook Islands
Fiji
No
In country
0.5
5.8
Out of
country
In country
In country
Out of
country
Out of
country
Out of
country
NRLd
TB DIAGNOSIS
No
yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
yes
yes
yes
Yes
Yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
No
Yes (all suspects)

Yes (all suspects)
Yes (all suspects)
Yes (if TB is
confirmed)
yes
yes
yes
Yes
Yes
Yes
yes
Yes
Yes (all suspects)
yes
Yes
yes
Yes
yes
yes
French Polynesia
Guam
In country
yes
Japan
In country
yes
Kiribati
Lao People's Democratic
Republic
Malaysia
2.0
2.5
2.4
2.5
6.2
1.2
0.3
Marshall Islands
5.5
33
91.2
91.2
91.2
Micronesia
(Federated States of)
Mongolia
3.6
100
1.3
3.6
1.8
1.8
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana Islands
Palau
4.9
100
242.6
242.6
242.6
Papua New Guinea
1.9
Philippines
Republic of Korea
2.1
1.0
0
0
0.5
51.7
0.1
0.7
<0.1
2.1
14
2
Samoa
Singapore
Solomon Islands
1.6
Tokelau
Tonga
Tuvalu
Out of
country
Out of
country
In country
Out of
country
Out of
country
In country
Out of
country
Out of
country
In country
Out of
country
Out of
country
Out of
country
Out of
country
In country
Out of
country
In country
Out of
country
No
Out of
country
yes
No
Yes (all suspects)
23
87
102
yes
Yes
No
Yes
yes
Yes
494
yes
Yes (all suspects)
yes
No
1 818
Yes (all suspects)
yes
Yes
97
No
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
No
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
Yes (all suspects)
yes
Yes
yes
yes
yes
yes
Yes
Yes
yes
Yes
yes
Yes (all suspects)

Yes (all suspects)
Yes (if TB is
confirmed)
No
No
Yes
yes
Yes (all suspects)
yes
Yes
No
Yes (all suspects)
No
No
yes
Yes (all suspects)
yes
Yes
yes
yes
4.5
No
yes
Viet Nam
0.9
1.4
0.1
0.1
In country
yes
No
yes
Yes (if TB is
confirmed)
Yes (if TB is
confirmed)
Yes (for certain
income groups)
56
yes
Vanuatu
Wallis and Futuna Islands
TB NOTIF.
RIFAMPICIN
RATE PER
USED
100 000
THROUGHOUT
HEALTH-CARE
TREATMENT
WORKERS
FIRSTLINE
DRUGS

Yes (all suspects)
Yes (if TB is
confirmed)
Yes (all suspects)
yes
Yes
yes
Yes
yes
No
yes
Yes
116
192
78
91

d
b
c
272
The World Health Organization monitors the

global tuberculosis epidemic in support of
national TB control programmes.
For further information about tuberculosis contact:

Information Resource Centre HTM/STB
World Health Organization
20 Avenue Appia, 1211Geneva27, Switzerland
Email: tbdocs@who.int
Web site: www.who.int/tb
ISBN 978 92 4 1564502

Global TB Report 2012

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Global TB Report 2012

Uploaded by

Copyright:

Available Formats

GLOBAL

WHO Library Cataloguing-in-Publication Data

(NLM classication: WF 300)

World Health Organization 2012

Chapter 2. The burden of disease caused by TB

Chapter 3. TB case notications and treatment outcomes

Chapter 5. Financing TB care and control

Chapter 6. Diagnostics and laboratory strengthening

Chapter 7. Addressing the co-epidemics of TB and HIV

Chapter 8. Research and development

2. Country pro les

4. Global, regional and country-specic data for key indicators

GLOBAL TUBERCULOSIS REPORT 2012

interferon-gamma release assay

WHO African Region

isoniazid preventive therapy

acquired immunodeciency syndrome

incidence rate ratio

WHO Region of the Americas

annual risk of infection

Millennium Development Goal

Brazil, Russian Federation, India,

case detection rate

co-trimoxazole preventive therapy

national tuberculosis control programme

directly observed treatment

US Presidents Emergency Plan for AIDS

the basic package that underpins the

WHO South-East Asia Region

drug resistance surveillance or survey

supranational reference laboratory

drug susceptibility testing

European Centre for Disease Prevention

Tuberculosis Technical Assistance

WHO Eastern Mediterranean Region

tuberculin skin test

External quality assurance

Electronic recording and reporting

Joint United Nations Programme on HIV/

WHO European Region

Foundation for Innovative New

international facility for the purchase of

United States Agency for International

World Health Assembly

World Health Organization

gross domestic product

Global Laboratory Initiative

Global Fund The Global Fund to ght AIDS,

Global Plan to Stop TB, 20112015

gross national income

high-burden country of which there are

Extensively drug-resistant TB, de ned

human immunodeciency virus

International Classication of Diseases

GLOBAL TUBERCULOSIS REPORT 2012

GLOBAL TUBERCULOSIS REPORT 2012

WHO staff in regional and country offices

WHO Region of the Americas

WHO Eastern Mediterranean Region

WHO European Region

WHO South-East Asia Region

GLOBAL TUBERCULOSIS REPORT 2012

WHO Western Pacific Region

National respondents who contributed to reporting and verification of data